european journal of pharmacology

Author and Keyword Indexes, 1994
Volumes 249–270
(EJP Molecular Pharmacology Section, Volumes 266–269, and EJP Environmental Toxicology and Pharmacology Section, Volume 270, incorporated)

ELSEVIER

AMSTERDAM — LAUSANNE — NEW YORK — OXFORD – SHANNON – TOKYO

© 1995 Elsevier Science B.V. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Science B.V., Copyright and Permissions Department, P.O. Box 521, 1000 AM Amsterdam, The Netherlands.

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, U.S.A., Tel.: (508) 750-8400; FAX: (508) 750-4744. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. The fee indicated on the first page of an article in this issue will apply retroactively to all articles published in the journal, regardless of the year of publication. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

This journal is in the ADONIS Service, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to ADONIS B.V., P.O. Box 839, 1000 AV Amsterdam, The Netherlands.

♾ The paper used in this publication meets the requirements of ANSI/NISO 239.48-1992 (Permanence of Paper).

US mailing notice - European Journal of Pharmacology (ISSN 0014-2999) is published 3 times/month by Elsevier Science B.V. (Molenwerf 1, Postbus 211, 1000 AE Amsterdam, The Netherlands). Annual subscription price in the USA is US$ 4576.00 (valid in North, Central and South America only) including air speed delivery. Second class postage rate is paid at Jamaica, NY 11431.
USA POSTMASTERS: Send address changes to *European Journal of Pharmacology*, Publications Expediting, Inc., 200 Meacham Avenue, Elmont, NY 11003.
Airfreight and mailing in the USA by Publications Expediting.

Printed in The Netherlands

ELSEVIER

European Journal of Pharmacology

ejp

Master author index to volumes 249–270 (1994)

Aanonsen, L.M., see Garry, M.G. (260) 129
Abad, F., see Maroto, R. (270) 331
Abbadie, C., Honoré, P., Fournié-Zaluski, M.-C., Roques, B.P. and Besson, J.-M.
Effects of opioids and non-opioids on c-Fos-like immunoreactivity induced in rat lumbar spinal cord neurons by noxious heat stimulation (258) 215
Abdel-Rahman, A.A., see Fahim, M. (254) 183
Abe, K. and Saito, H.
Modulation by metabotropic glutamate receptor of long-term potentiation of population spikes in the dentate gyrus in vivo (251) 295
Abe, K., see Chu, P.-j. (256) 155
Abel, E.L. and Hannigan, J.H.
The immobility response in the forced swim test: paradoxical effect of imipramine (258) 261
Abelli, L., see Manzini, S. (249) 251
Abengochea, A., see Martí-Cabrera, M. (255) 157
Abiko, Y., see Hayase, N. (260) 183
Abraham, E., see Garry, M.G. (260) 129
Abrahams, Z. and Sutter, M.C.
Effects of K^+ channel openers on the vascular actions of human gamma globulin (252) 195
Abram, T.S., see Tudhope, S.R. (264) 317
Acquas, E., Day, J.C. and Fibiger, H.C.
The potent and selective dopamine D_1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat (260) 85
Adachi-Akahane, S., see Ikeda, S. (264) 223
Adachi, H., see Chang, T.-h. (258) 77
Adachi, H., see Kodama, K. (263) 93
Adachi, M., Furuichi, Y. and Miyamoto, C.
Identification of a region of the human endothelin ET_A receptor required for interaction with bosentan (269) 225
Adachi, M., see Konno, S.-i. (259) 15
Adachi, M., see Konno, S.-i. (264) 265
Adams, G.D., see Haynes, J.M. (250) 231
Adan, R.A.H., Oosterom, J., Ludvigsdottir, G., Brakkee, J.H., Burbach, J.P.H. and Gispen, W.H.
Identification of antagonists for melanocortin MC_3, MC_4 and MC_5 receptors (269) 331
Adcock, I.M., see Shirasaki, H. (268) 263
Adipudi, V. and Reddy, V.K.
Effect of chronic lithium chloride on membrane adenosine triphosphatases in certain postural muscles of rats (259) 7
Adler-Graschinsky, E., see Lorenzo, P.S. (258) 253
Adler, M., Maxwell, D.M., Filbert, M.G. and Deshpande, S.S.
Contribution of direct actions of the oxime HI-6 in reversing soman-induced muscle weakness in the rat diaphragm (270) 9
Adner, M., Erlinge, D., Salford, L.G., Yee, F., Wahlestedt, C. and Edvinsson, L.
Human endothelin ET_A receptor antisense oligodeoxynucleotides inhibit endothelin-1 evoked vasoconstriction (261) 281
Advenier, C., Girard, V., Naline, E., Vilain, P. and Emonds-Alt, X.
Antitussive effect of SR 48968, a non-peptide tachykinin NK_2 receptor antagonist (250) 169
Advenier, C., see Dumas, J.-P. (263) 17
Advenier, C., see Iriarte, M.-C.F. (250) 295
Advenier, C., see Naline, E. (256) 301
Agabio, R., see Colombo, G. (265) 167
Agata, N., Tanaka, H. and Shigenobu, K.
Inotropic effects of ryanodine and nicardipine on fetal, neonatal and adult guinea-pig myocardium (260) 47
Agbotounou, W.K., Umezawa, K., Jacquemin-Sablon, A. and Pierre, J.
Inhibition by two lavendustins of the tyrosine kinase activity of $pp60^{F527}$ in vitro and in intact cells (269) 1
Aghajanian, G.K., see Marek, G.J. (259) 137
Agnati, L.F., see Fior, D.R. (262) 271
Aguglia, U., see De Sarro, G. (262) 11
Aguirre, J.A., see Narváez, J.A. (257) 257
Ahlborg, U.G., see Håkansson, H. (270) 279
Ahlenius, S. and Salmi, P.
Behavioral and biochemical effects of the dopamine D_3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat (260) 177
Ahlenius, S., see Salmi, P. (253) 67
Ahluwalia, A. and Perretti, M.
Calcitonin gene-related peptides modulate the acute inflammatory response induced by interleukin-1 in the mouse (264) 407
Ahrén, B., see Gregersen, S. (259) 79
Aihara, K., see Matsumoto, Y. (262) 157
Akaike, N., see Uneyama, C. (268) 455
Akaike, T., see Tsunoda, R. (262) 55
Akaoka, I., see Yamanouchi, T. (257) 39
Akera, T., see Jiang, J. (266) 155
Akera, T., see Temma, K. (252) 173
Åkerman, K.E.O., see Jansson, C.C. (266) 165
Akihito, C., see Temma, K. (252) 173
Akimoto, H., see Takeuchi, K. (254) 287
Akishita, M., see Ishikawa, M. (269) 311
Akiyama, T., see Nakazawa, K. (269) 375
Akiyama, Y., Hara, K., Tajima, T., Murota, S.-i. and Morita, I.
Effect of vitamin K_2 (menatetrenone) on osteoclast-like cell formation in mouse bone marrow cultures (263) 181
Akkermans, L.M.A., see Briejer, M.R. (250) 181
Al-Tikriti, M.S., see Laruelle, M. (263) 39
Ala-Uotila, S., see Marjamäki, A. (267) 117
Alanko, J., see Riutta, A. (262) 217
Alaranta, S., Klinge, E., Kostiainen, E. and Parkkisenniemi, U.-M.
Relaxation of the bovine retractor penis muscle by a small K^+ excess and the role of K^+ in its neurogenic relaxation (259) 203
Albin, R.L., see Kume, A. (263) 163
Albinsson, A., Björk, A., Svartengren, J., Klint, T. and Andersson, G.
Preclinical pharmacology of FG5893: a potential anxiolytic drug with high affinity for both 5-HT_{1A} and 5-HT_{2A} receptors (261) 285
Albinsson, A., Palazidou, E., Stephenson, J. and Andersson, G.

Involvement of the 5-HT_2 receptor in the 5-HT receptor-mediated stimulation of prolactin release (251) 157
Albuquerque, M.L.C. and Kurth, C.D.
Cocaine constricts immature cerebral arterioles by a local anesthetic mechanism (249) 215
Alcaraz, M.J., see Ferrándiz, M.L. (253) 75
Aldasoro, M., Martínez, C., Vila, J.M., Flor, B. and Lluch, S.
Endothelium-dependent component in the contractile responses of human omental arteries to adrenergic stimulation (250) 103
Aldasoro, M., see Martínez, C. (261) 73
Alesiani, M., see Mannaioni, G. (251) 201
Alexoff, D.A., see Pan, D. (264) 177
Alfaro, M.J., see Colado, M.I. (252) 291
Alfonso, A., Botana, M.A., Vieytes, M.R. and Botana, L.M.
Functional characterization of the Na^+-H^+ exchanger in rat mast cells: crosstalks between different kinase pathways (267) 289
Alhaider, A.A., Hamon, M. and Wilcox, G.L.
Intrathecal 5-methoxy-*N*,*N*-dimethyltryptamine in mice modulates 5-HT_1 and 5-HT_3 receptors (249) 151
Alhava, E., see Pellinen, P. (270) 35
Allcock, G.H., see Warner, T.D. (250) 447
Aller, M.I., see Fernández-López, A. (262) 283
Allescher, H.-D., see Kurjak, M. (257) 169
Allgaier, C., Pullmann, F., Schobert, A., Von Kügelgen, I. and Hertting, G.
P_2 purinoceptors modulating noradrenaline release from sympathetic neurons in culture (252) R7
Alling, C., see Larsson, C. (268) 19
Allison, K., Paetsch, P.R., Baker, G.B. and Greenshaw, A.J.
Chronic antidepressant drug treatment attenuates motor-suppressant effects of apomorphine without changing [^{3}H]GBR 12935 binding (249) 125
Allison, W., see Hasan, K. (249) 101
Almegård, B. and Bill, A.
C-terminal calcitonin gene-related peptide fragments and vasopressin but not somatostatin-28 induce miosis in monkeys (250) 31
Almeida, O.F.X., see Spanagel, R. (264) 157
Alsip, N.L., see Koch, L.G. (254) 249
Altavilla, D., Squadrito, F., Ioculano, M., Canale, P., Campo, G.M., Zingarelli, B. and Caputi, A.P.
E-selectin in the pathogenesis of experimental myocardial ischemia-reperfusion injury (270) 45
Altavilla, D., see Ioculano, M. (264) 143
Altavilla, D., see Squadrito, F. (255) 51
Altenburg, S.P., Bozza, P.T., Martins, M.A., Tibiriçá, E.V., Silva, P.M.R., Cordeiro, R.S.B. and Castro-Faria-Neto, H.C.
Adrenergic modulation of the blood neutrophilia induced by platelet activating factor in rats (256) 45
Altieri, P., see Ghiggeri, G.M. (270) 195
Alvaro, V., see Lévy, L. (268) 327
Amado, J.A., see Berrazueta, J.R. (251) 303
Amalric, M., see Ouagazzal, A.-m. (251) 229
Amano, Y., see Ikeda, S. (264) 223
Ambrosio, C., see Roscetti, G. (269) 17
Amejdki-Chab, N., see Bonnet, J.-J. (266) 87
Amenta, F., see Kobayashi, Y. (253) 201
Amenta, F., see Kobayashi, Y. (261) 229
Amico-Roxas, M., see Clementi, G. (256) R7
Amiranoff, B., see Heuillet, E. (269) 139
Amiranoff, B., see Lorinet, A.-M. (269) 59
Andersen, J.V., see Videbæk, C. (249) 43
Andersen, P.H., see Pedersen, U.B. (267) 85
Anderson, D.J. and Arneric, S.P.
Nicotinic receptor binding of [^{3}H]cytisine, [^{3}H]nicotine and [^{3}H]methylcarbamylcholine in rat brain (253) 261
Anderson, K.E., see Fitzgerald, M. (268) 275
Andersson, G. and Larsson, K.
Effects of FG 5893, a new compound with 5-HT_{1A} receptor agonistic and 5-HT_2 receptor antagonistic properties, on male rat sexual behavior (255) 131
Andersson, G., see Albinsson, A. (251) 157
Andersson, G., see Albinsson, A. (261) 285
Andersson, K.-E., see Persson, K. (268) 159
Andius, P., see Arakawa, H. (252) 313
Andreatini, R. and Leite, J.R.
Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal (260) 233
Andrews, A.M. and Murphy, D.L.
Fluoxetine and desipramine selectively attenuate 2′-NH_2-MPTP-induced depletions in serotonin and norepinephrine (250) 215
Andrews, N., Hogg, S., Gonzalez, L.E. and File, S.E.
5-HT_{1A} receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively (264) 259
Andrews, P.L.R., see Woods, A.J. (264) 125
Angel, F., see Chamouard, P. (262) 33
Angel, I., see Jonas, J.-C. (254) 27
Angel, I., see Jonas, J.-C. (264) 81
Animati, F., see Feriotto, G. (267) 143
Anthony, E.W. and Nevins, M.E.
Anxiolytic-like effects of *N*-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test (250) 317
Antkiewicz-Michaluk, L., Michaluk, J. and Vetulani, J.
Modification of effects of chronic electroconvulsive shock by voltage-dependent Ca^{2+} channel blockade with nifedipine (254) 9
Antonaccio, M.J. and Normandin, D.
Role of Ca^{2+} in the vascular contraction caused by a thrombin receptor activating peptide (256) 37
Antonaccio, M.J., Normandin, D. and Ferrer, P.
Reduced contractile function after balloon denudation of rat carotid arteries (256) 17
Antunes, E., see Giraldelo, C.M.M. (257) 87
Anwyl, R., see Manahan-Vaughan, D. (260) 149
Aoyama, T., see Hattori, R. (267) R1
Arakawa, H., Andius, P., Kawikova, I., Skoogh, B.-E., Löfdahl, C.-G. and Lötvall, J.
Treatment with cyclosporin A during sensitization with trimellitic anhydride attenuates the airway responses to allergen challenge three weeks later (252) 313
Arakawa, H., Lötvall, J., Kawikova, I., Tokuyama, K., Löfdahl, C.-G. and Skoogh, B.-E.
Effect of maturation on airway plasma exudation induced by eicosanoids in guinea pig (259) 251
Araki, H., see Ogawa, S.-i. (263) 9
Aramori, I., Morikawa, N., Zenkoh, J., O'Donnell, N., Iwami, M., Kojo, H., Notsu, Y., Okuhara, M., Ono, S. and Nakanishi, S.
Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors (269) 277
Arankowsky-Sandoval, G., see Ragozzino, M.E. (256) 31
Arbilla, S., see Faure, C. (268) 141
Arcamone, F., see Feriotto, G. (267) 143
Arcoraci, V., see Squadrito, F. (255) 51
Ardizzoni, A., see Favoni, R.E. (264) 199
Argiolas, A., see Stancampiano, R. (261) 149
Argiolas, L., see Marano, G. (261) 121
Arilla, E., see Iriarte, M.-C.F. (250) 295
Arimura, A., Asanuma, F., Matsumoto, Y., Kurosawa, A., Jyoyama, H. and Nagai, H.
Effect of the selective thromboxane A_2 receptor antagonist, S-1452, on antigen-induced sustained bronchial hyperresponsiveness (260) 201
Arletti, R., see Benelli, A. (260) 279

Armstrong, J.M., see Bellemin-Baurreau, J. (256) 115
Arnerić, S.P., see Anderson, D.J. (253) 261
Arnerić, S.P., see Decker, M.W. (261) 217
Artalejo, A.R., see Maroto, R. (270) 331
Artalejo, A.R., see Montiel, C. (268) 293
Artigas, F., see Ferré, S. (255) 203
Artigas, F., see Ferrer, A. (263) 227
Artigas, F., see Romero, L. (265) 103
Arvat, E., see Mazza, E. (254) 17
Asano, K., see Konno, S.-i. (259) 15
Asano, K., see Konno, S.-i. (264) 265
Asano, M., Masuzawa-Ito, K. and Matsuda, T.
Vasodilating actions of cromakalim in resting and contracting states of carotid arteries from spontaneously hypertensive rats (263) 121
Asano, M., see Yokota, Y. (258) 239
Asanuma, F., see Arimura, A. (260) 201
Ashino, H., see Oikawa, T. (249) 113
Aslan, A.N., see Özkutlu, U. (250) 349
Audinot, V., see Lejeune, F. (260) 79
Audinot, V., see Millan, M.J. (260) R3
Audinot, V., see Rivet, J.-M. (265) 175
Audus, K.L., see Borges, N. (269) 243
Auerbach, S.B., see Hjorth, S. (260) 251
Augenlicht, L.H., see Jarry, A. (267) 95
Aulakh, C.S., see Hulihan-Giblin, B.A. (263) 213
Avendano, C.E. and Billman, G.E.
Effect of interventions that increase cyclic AMP levels on susceptibility to ventricular fibrillation in unanesthetized dogs (255) 99
Avenet, P., see Biton, B. (257) 297
Azevedo, I., see Borges, N. (269) 243
Azzi, M., Gully, D., Heaulme, M., Bérod, A., Pélaprat, D., Kitabgi, P., Boigegrain, R., Maffrand, J.-P., LeFur, G. and Rostène, W.
Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists (255) 167

Bachernegg, M., see Stark, G. (252) 283
Badaoui, A., see Bonnet, V. (264) 69
Badia, A., see Sallés, J. (258) 229
Badia, A., see Sallés, J. (266) 35
Badia, A., see Sallés, J. (266) 301
Baeyens, J.M., see Robles, L.I. (251) 113
Bailbé, D., see Picarel-Blanchot, F. (264) 227
Baker, A.J., Palmer, J., Johnson, M. and Fuller, R.W.
Inhibitory actions of salmeterol on human airway macrophages and blood monocytes (264) 301
Baker, G.B., see Allison, K. (249) 125
Balasubramaniam, E., see Paul, V. (270) 1
Balasubramanian, N., see Schumacher, W.A. (259) 165
Baldessari, S., see Rattray, M. (268) 439
Baldessarini, R.J., Kula, N.S., Zong, R. and Neumeyer, J.L.
Receptor affinities of aporphine enantiomers in rat brain tissue (254) 199
Baldi, G., see Bevilacqua, M. (268) 415
Balduini, W., Reno, F., Costa, L.G. and Cattabeni, F.
Developmental neurotoxicity of ethanol: further evidence for an involvement of muscarinic receptor-stimulated phosphoinositide hydrolysis (266) 283
Baldwin, R.M., see Laruelle, M. (263) 39
Balfagón, G., see Ferrer, M. (252) 233
Balfagón, G., see Ferrer, M. (258) 103
Ball, D.I., see Nials, A.T. (251) 127
Ballabeni, V., see Barocelli, E. (254) 151
Balwierczak, J.L., Wong, M. and Jeng, A.Y.
A simple assay for the measurement of conversion of big endothelin-1 to endothelin-1 by smooth muscle (250) 379
Banba, N., see Takekoshi, K. (250) 465
Bannenberg, G., Kimland, M., Ryrfeldt, Å., Lundberg, J.M. and Moldéus, P.
Sensory neuropeptide-mediated bronchoconstriction of the guinea pig lung by diamide; a comparison to hydrogen peroxide (270) 175
Bara, A., see Schini-Kerth, V. (265) 83
Barajas-López, C., Barrientos, M. and Espinosa-Luna, R.
Suramin increases the efficacy of ATP to activate an inward current in myenteric neurons from guinea-pig ileum (250) 141
Barak, Y., see Shany, E. (253) 231
Baran, H., see Wlaź, P. (257) 217
Barbaccia, M.L., Roscetti, G., Trabucchi, M., Cuccheddu, T., Concas, A. and Biggio, G.
Neurosteroids in the brain of handling-habituated and naive rats: effect of CO_2 inhalation (261) 317
Barbaccia, M.L., see Roscetti, G. (269) 17
Barbier, P., see Maggio, R. (268) 459
Barbin, G., see Kwiecien, R. (249) 325
Barchi, R.L., see Krafte, D.S. (266) 245
Barden, J.A., see Potter, E.K. (267) 253
Bardo, M.T., see Crawford, C.A. (252) 225
Barjavel, M.J., Thorat, S.N. and Bhargava, H.N.
Enhancement of a κ-opioid receptor agonist-induced analgesia by L-tyrosine and L-tryptophan (258) 173
Barnes, J.C., Brown, J.D., Clarke, N.P., Clapham, J., Evans, D.J. and O'Shaughnessy, C.T.
Pharmacological activity of VUF 9153, an isothiourea histamine H_3 receptor antagonist (250) 147
Barnes, P.J., see Mak, J.C.W. (269) 35
Barnes, P.J., see Sakamoto, T. (251) 137
Barnes, P.J., see Shirasaki, H. (268) 263
Barnett, A., see Coffin, V. (256) R9
Barnfield, A.M.C., see Oluyomi, A.O. (264) 111
Barocelli, E., Ballabeni, V., Chiavarini, M., Molina, E., Lavezzo, A. and Impicciatore, M.
Muscarinic M_1 and M_3 receptor antagonist effects of a new pirenzepine analogue in isolated guinea-pig ileal longitudinal muscle-myenteric plexus (254) 151
Baron, A., Rakotoarisoa, L., Leprêtre, N. and Mironneau, J.
Inhibition of L-type Ca^{2+} channels in portal vein myocytes by the enantiomers of oxodipine (269) 105
Baron, B.M., see McClue, S.J. (267) 185
Barone, P., Millet, S., Moret, C., Prudhomme, N. and Fillion, G.
Quantitative autoradiography of 5-HT_{1E} binding sites in rodent brains: effect of lesion of serotonergic neurones (249) 221
Barrachina, D., Calatayud, S., Esplugues, J., Whittle, B.J.R., Moncada, S. and Esplugues, J.V.
Nitric oxide donors preferentially inhibit neuronally mediated rat gastric acid secretion (262) 181
Barrientos, M., see Barajas-López, C. (250) 141
Barrios, M., see Robles, L.I. (251) 113
Bartfai, T., see Bedecs, K. (259) 151
Bartfai, T., see Gregersen, S. (259) 79
Barthó, L. and Lefebvre, R.A.
Nitric oxide causes contraction in the rat isolated small intestine (259) 101
Barthó, L., Maggi, C.A., Wilhelm, M. and Patacchini, R.
Tachykinin NK_1 and NK_2 receptors mediate atropine-resistant ileal circular muscle contractions evoked by capsaicin (259) 187
Bartoszyk, G.D., see Seyfried, C.A. (257) 67
Bartus, R.T., see Von Lubitz, D.K.J.E. (249) 271
Basaglia, R., see Benelli, A. (260) 279

Baschirotto, A., see Ceci, A. (250) 461
Basham, D.A., see Meller, E. (249) R5
Basile, A.S., DeCosta, B. and Paul, I.A.
Multiple [^{3}H]DTG binding sites in guinea pig cerebellum: evidence for the presence of non-specific binding (252) 139
Basile, A.S., see Harris, B.D. (267) 269
Basilico, L., see Massi, P. (253) 269
Bast, A., see Ching, T.-L. (268) 89
Bastaki, M., Missirlis, E., Klouras, N., Karakiulakis, G. and Maragoudakis, M.E.
Suppression of angiogenesis by the antitumor agent titanocene dichloride (251) 263
Bastone, A., see Cagnotto, A. (266) 131
Battaglia, E., see Emanuelli, G. (261) 265
Battaglia, G., see Bruno, V. (256) 109
Battaini, F., see Pascale, A. (265) 1
Battistini, B., Warner, T.D., Fournier, A. and Vane, J.R.
Comparison of PD 145065 and Ro 46-2005 as antagonists of contractions of guinea-pig airways induced by endothelin-1 or IRL 1620 (252) 341
Battistini, B., see Warner, T.D. (250) 447
Baudrie, V., see Chaouloff, F. (249) 117
Baudry, M., see Marvizón, J.-C. (269) 165
Bauer, J.A., see Paik, S.H. (253) 101
Baugh, L.E., see Kudlacz, E.M. (270) 291
Baumann, R., see Chamouard, P. (262) 33
Baumgold, J., Pryzbyc, R.L. and Reba, R.C.
3-α-Chlorimperialine: an M_2-selective muscarinic receptor antagonist that penetrates into brain (251) 315
Bavinck, A., see Schiereck, P. (249) 317
Bayley, P., see Dawson, G.R. (252) 325
Bazan, A., see Fraeyman, N. (267) 63
Bazzani, C., Nardi, M.G., Ferrante, F., Bertolini, A. and Guarini, S.
Dopamine D_1 receptors are involved in the ACTH-induced reversal of hemorrhagic shock (253) 303
Beani, L., see Simonato, M. (265) 121
Beart, P.M., Ryan, M.C., Mercer, L.D., Jarrott, B. and Wong, M.G.
Heterocyclic amino alcohols related to ifenprodil as σ receptor ligands: binding and conformational analyses (269) 193
Beauchemin, V., see Dennis, T. (262) 143
Beaufort, P., see Chatelain, P. (267) 151
Beaulé, C., see Godin, D. (253) 225
Becker, D.J., Ongemba, L.-N. and Henquin, J.-C.
Comparison of the effects of various vanadium salts on glucose homeostasis in streptozotocin-diabetic rats (260) 169
Bedecs, K., Langel, Ü., Xu, X.-J., Wiesenfeld-Hallin, Z. and Bartfai, T.
Biological activities of two endogenously occurring *N*-terminally extended forms of galanin in the rat spinal cord (259) 151
Beer, M.S., see Heald, A. (264) 213
Belcourt, A., see Bricca, G. (266) 25
Belcourt, A., see Greney, H. (265) R1
Bell, N.J., see Trezise, D.J. (259) 295
Belleau, B., see Lemaire, S. (258) 111
Bellemin-Baurreau, J., Poizot, A., Hicks, P.E., Rochette, L. and Armstrong, J.M.
Effects of ATP-dependent K^+ channel modulators on an ischemia-reperfusion rabbit isolated heart model with programmed electrical stimulation (256) 115
Bellone, J., see Mazza, E. (254) 17
Belloni, P.A., see Letari, O. (266) 219
Belt, J.J., see Fedan, J.S. (256) 51
Ben-Ari, Y., see Dessi, F. (250) 325
Ben-Ari, Y., see Gozlan, H. (262) R3
Ben-Ari, Y., see Kwiecien, R. (249) 325
Benavides, J., see Rouquier, L. (261) 59
Bendele, A.M., see Stengel, P.W. (253) 253
Bendotti, C., see Cervo, L. (253) 139
Bendotti, C., see Rattray, M. (268) 439
Benedek, G., see Horváth, G. (253) 61
Benelli, A., Arletti, R., Bertolini, A., Menozzi, B., Basaglia, R. and Poggioli, R.
Galantide stimulates sexual behavior in male rats (260) 279
Bengen, J., see Galle, J. (265) 111
Beninger, R.J., see Mallet, P.E. (261) R5
Benini, L., see Galli, A. (270) 189
Benmansour, S., see Bonnet, J.-J. (266) 87
Bennai, F., see Greney, H. (265) R1
Bennett, M.R., see Karunanithi, S. (261) 17
Benoit, P.A., see Constantine, J.W. (252) 275
Benveniste, J., see Pellegrini, O. (270) 221
Benz, U., see De Vry, J. (249) 331
Berdeu, D., Gross, R., Ribes, G., Loubatières-Mariani, M.-M. and Bertrand, G.
Effects of imidazolines and derivatives on insulin secretion and vascular resistance in perfused rat pancreas (254) 119
Berendsen, H.H.G. and Broekkamp, C.L.E.
Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure (253) 83
Berendsen, H.H.G., Bourgondien, F.G.M. and Broekkamp, C.L.E.
Role of dorsal and median raphe nuclei in lower lip retraction in rats (263) 315
Beresford, I.J.M., see Stratton, S.C. (250) R11
Bergamaschi, M., see Civelli, M. (255) 17
Berger, S., see Lacour, F. (255) 249
Bergman, J., see Rosenzweig-Lipson, S. (260) 237
Bergman, O., see Larsson, C. (268) 19
Bernard, C., Merval, R., Esposito, B. and Tedgui, A.
Elevated temperature accelerates and amplifies the induction of nitric oxide synthesis in rat macrophages (270) 115
Bernardi, M., see Genedani, S. (252) 77
Bérod, A., see Azzi, M. (255) 167
Berrazueta, J.R., Salas, E., Amado, J.A., Sánchez de Vega, M.J. and Poveda, J.J.
Induction of nitric oxide synthase in human mammary arteries in vitro (251) 303
Berrino, L., see Maione, S. (250) 209
Berthelot, A., see Laurant, P. (258) 167
Bertolini, A., see Bazzani, C. (253) 303
Bertolini, A., see Benelli, A. (260) 279
Bertolini, A., see Genedani, S. (252) 77
Bertorelli, R., see De Sarro, G. (262) 11
Bertrand, C., see Ricciardolo, F.L.M. (261) 127
Bertrand, G., see Berdeu, D. (254) 119
Bertrand, P., Böhme, G.A., Durieux, C., Guyon, C., Capet, M., Jeantaud, B., Boudeau, P., Ducos, B., Pendley, C.E., Martin, G.E., Floch, A. and Doble, A.
Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCK_B/gastrin receptor antagonists (262) 233
Bespalov, A., Dumpis, M., Piotrovsky, L. and Zvartau, E.
Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine (264) 233
Besson, J.-M., see Abbadie, C. (258) 215
Beukers, M.W., Kerkhof, C.J.M., IJzerman, A.P. and Soudijn, W.
Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016 (266) 57
Beukers, M.W., see Van Rhee, A.M. (268) 1
Bevilacqua, M., Vago, T., Baldi, G., Renesto, E., Dallegri, F. and Norbiato, G.
Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV (268) 415
Bhargava, H.N., see Barjavel, M.J. (258) 173

Bhargava, H.N., see Thorat, S.N. (260) 5
Bhattacharyya, B.J., Tsen, K. and Sokoll, M.D.
Age-induced alteration of neuromuscular transmission: effect of halothane (254) 97
Bhogal, R., see Veale, P.R. (262) 133
Bianchi, C., see Simonato, M. (265) 121
Bianchi, M., Sacerdote, P. and Panerai, A.E.
Fluoxetine reduces inflammatory edema in the rat: involvement of the pituitary-adrenal axis (263) 81
Bichon, D., see Emonds-Alt, X. (250) 403
Bidlack, J.M., see Joseph, D.B. (267) 1
Bidzinski, A., see Plaznik, A. (257) 293
Biessels, G.J., see Kappelle, A.C. (250) 43
Biftu, T., see Qian, C. (250) R13
Biggio, G., see Barbaccia, M.L. (261) 317
Biggio, G., see Concas, A. (267) 207
Biggio, G., see Ghiani, C.A. (254) 299
Biggio, G., see Imperato, A. (261) 205
Biggio, G., see Serra, M. (259) 1
Biggio, G., see Serra, M. (265) 185
Bill, A., see Almegård, B. (250) 31
Billaud, G., Menard, J.-F., Marcellin, N., Kamenka, J.-M., Costentin, J. and Bonnet, J.-J.
Thermodynamics of the binding of BTCP (GK 13) and related derivatives on the dopamine neuronal carrier (268) 357
Billecocq, A., Hedlund, P.B., Bolaños-Jiménez, F. and Fillion, G.
Characterization of galanin and 5-HT_{1A} receptor coupling to adenylyl cyclase in discrete regions of the rat brain (269) 209
Billman, G.E., see Avendano, C.E. (255) 99
Bisschop, A., see Van den Berg, C. (270) 379
Biton, B., Granger, P., Carreau, A., Depoortere, H., Scatton, B. and Avenet, P.
The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca^{2+} channels in rat cultured cortical neurons (257) 297
Björk, A., see Albinsson, A. (261) 285
Blanchard, J.-C., see Heuillet, E. (269) 139
Bletz, C., see Strauss, J.D. (252) 219
Bley, K.R., Eglen, R.M. and Wong, E.H.F.
Characterization of 5-hydroxytryptamine-induced depolarizations in rat isolated vagus nerve (260) 139
Blier, P., see Mongeau, R. (256) 269
Block, F. and Schwarz, M.
The depressant effect of GYKI 52466 on spinal reflex transmission in rats is mediated via non-NMDA and benzodiazepine receptors (256) 149
Blomqvist, O., Engel, J.A., Nissbrandt, H. and Söderpalm, B.
The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine (249) 207
Bloom, S.R., see Veale, P.R. (262) 133
Blumberg, P.M., see Goso, C. (249) 185
Blumberg, P.M., see Szallasi, A. (264) 217
Boadle-Biber, M.C., see Singh, V.B. (256) 177
Bocanera, L.V., see Pisarev, M.A. (258) 33
Boccio, D., see Montier, F. (251) 9
Boddeke, H.W.G.M., see Doods, H.N. (250) 223
Bode, D.C., see Dundore, R.L. (249) 293
Bodelsson, G. and Stjernquist, M.
Characterization of endothelin receptors and localization of ^{125}I-endothelin-1 binding sites in human umbilical artery (249) 299
Boeckxstaens, G.E., De Man, J.G., De Winter, B.Y., Herman, A.G. and Pelckmans, P.A.
Pharmacological similarity between nitric oxide and the nitrergic neurotransmitter in the canine ileocolonic junction (264) 85
Boel, E., see Thomsen, C. (267) 77
Boffano, G., see Mazza, E. (254) 17
Bohmaker, K., see Meller, E. (249) R5
Böhme, G.A., see Bertrand, P. (262) 233
Bohn, H., see Martorana, P.A. (257) 267
Boigegrain, R., see Azzi, M. (255) 167
Bois, P., see Romey, G. (263) 101
Boksa, P., see Chaudieu, I. (264) 361
Bolaños-Jiménez, F., see Billecocq, A. (269) 209
Bolger, M.B., see Hawkinson, J.E. (269) 157
Bolkenius, F.N., see Petty, M.A. (255) 215
Bolognesi, M.L., see Maggio, R. (268) 459
Bolognesi, M.L., see Melchiorre, C. (265) 93
Bonanno, G., Vallebuona, F., Donadini, F., Fontana, G., Fedele, E. and Raiteri, M.
Heterocarrier-mediated reciprocal modulation of glutamate and glycine release in rat cerebral cortex and spinal cord synaptosomes (252) 61
Bonanno, G., see Fassio, A. (263) 311
Bondiolotti, G., see Cattaneo, M.G. (268) 425
Bondy, S.C. and Guo, S.X.
Effect of ethanol treatment on indices of cumulative oxidative stress (270) 349
Bongrani, S., see Civelli, M. (255) 17
Bonnekoh, B., see Sebök, B. (270) 79
Bonnet, J.-J., Benmansour, S., Amejdki-Chab, N. and Costentin, J.
Effect of CH_3HgCl and several transition metals on the dopamine neuronal carrier; peculiar behaviour of Zn^{2+} (266) 87
Bonnet, J.-J., see Billaud, G. (268) 357
Bonnet, J.-J., see Héron, C. (264) 391
Bonnet, J.-J., see Saadouni, S. (268) 187
Bonnet, V., Badaoui, A., Huchet-Cadiou, C. and Léoty, C.
Potentiation of the twitch responses by inhibitors of sarcoplasmic reticulum Ca^{2+}-ATPase in frog atrial fibres (264) 69
Boon, J., see Murk, A. (270) 253
Boon, J.P., Oostingh, I., Van der Meer, J. and Hillebrand, M.T.J.
A model for the bioaccumulation of chlorobiphenyl congeners in marine mammals (270) 237
Boot, J.R.
Differential effects of ω-conotoxin GVIA and MVIIC on nerve stimulation induced contractions of guinea-pig ileum and rat vas deferens (258) 155
Borchard, U., see Felsch, A. (263) 261
Borden, L.A., Dhar, T.G.M., Smith, K.E., Weinshank, R.L., Branchek, T.A. and Gluchowski, C.
Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1 (269) 219
Borea, P.A., Varani, K., Dalpiaz, A., Capuzzo, A., Fabbri, E. and IJzerman, A.P.
Full and partial agonistic behaviour and thermodynamic binding parameters of adenosine A_1 receptor ligands (267) 55
Borea, P.A., see Simonato, M. (265) 121
Borges, N., Shi, F., Azevedo, I. and Audus, K.L.
Changes in brain microvessel endothelial cell monolayer permeability induced by adrenergic drugs (269) 243
Borsini, F., see Ceci, A. (250) 461
Bos, E., see Du, X.Y. (259) 173
Botana, L.M., see Alfonso, A. (267) 289
Botana, M.A., see Alfonso, A. (267) 289
Bottari, S., see Macari, D. (249) 85
Bottema, T., see Damsma, G. (249) R9
Bouaiche, Z., see Heuillet, E. (269) 139
Boudeau, P., see Bertrand, P. (262) 233
Bouloumié, A., Valet, P., Daviaud, D., Prats, H., Lafontan, M. and Saulnier-Blache, J.-S.
Adipocyte α_{2A}-adrenoceptor is the only α_2-adrenoceptor regulated by testosterone (269) 95
Bountra, C., Bunce, K., Dale, T., Gardner, C., Jordan, C., Twissell,

D. and Ward, P.
Anti-emetic profile of a non-peptide neurokinin NK_1 receptor antagonist, CP-99,994, in ferrets (249) R3
Bourgondien, F.G.M., see Berendsen, H.H.G. (263) 315
Bousquet, P., see Bricca, G. (266) 25
Bousquet, P., see Greney, H. (265) R1
Bouvier, M., see Ng, G.YK. (267) 7
Bowen, W.D., see Hellewell, S.B. (268) 9
Bowen, W.D., see Jones, D.N.C. (249) 167
Bowery, N.G., see Malcangio, M. (250) 153
Bowling, N., Mais, D.E., Gerzon, K. and Watanabe, A.M.
Ryanodine and an iodinated analog: doxorubicin effects on binding and Ca^{2+} accumulation in cardiac sarcoplasmic reticulum (268) 365
Boyd, R.S., Donnelly, L.E. and MacDermot, J.
Loss of responses to bradykinin, ATP or carbachol follows depletion of a shared pool of calcium ions (267) 161
Boyet, S., see Nehlig, A. (258) 57
Bozza, P.T., Castro-Faria-Neto, H.C., Silva, A.R., Larangeira, A.P., Silva, P.M.R., Martins, M.A. and Cordeiro, R.S.B.
Lipopolysaccharide-induced pleural neutrophil accumulation depends on marrow neutrophils and platelet-activating factor (270) 143
Bozza, P.T., see Altenburg, S.P. (256) 45
Brailoiu, E., Serban, D.N., Popescu, L.M., Slatineanu, S., Filipeanu, C.M. and Branisteanu, D.D.
Effects of liposome-entrapped D-*myo*-inositol 1,4,5-trisphosphate and D-*myo*-inositol 1,3,4,5-tetrakisphosphate in the isolated rat aorta (250) 493
Brailoiu, E., Serban, D.N., Slatineanu, S., Filipeanu, C.M., Petrescu, B.C. and Branisteanu, D.D.
Effects of liposome-entrapped adenosine in the isolated rat aorta (250) 489
Brain, S.D., see Lawrence, E. (260) 103
Brakkee, J.H., see Adan, R.A.H. (269) 331
Bramante, M., see Invernizzi, R. (260) 243
Branchek, T.A., see Borden, L.A. (269) 219
Branisteanu, D.D., see Brailoiu, E. (250) 489
Branisteanu, D.D., see Brailoiu, E. (250) 493
Bredy-Dobreva, G., see Mizhorkova, Z. (265) 77
Brelière, J.-C., see Emonds-Alt, X. (250) 403
Breslow, M.J., see Clarkson, K. (263) R1
Bressie, S.M., see Corpus, V.M. (266) 197
Brian, Jr., J.E., see Kennedy, R.H. (255) 149
Bricca, G., Greney, H., Zhang, J., Dontenwill, M., Stutzmann, J., Belcourt, A. and Bousquet, P.
Human brain imidazoline receptors: further characterization with [^{3}H]clonidine (266) 25
Bridges, R.J., see Miller, S. (269) 235
Briejer, M.R., Akkermans, L.M.A., Meulemans, A.L., Lefebvre, R.A. and Schuurkes, J.A.J.
Substance P-induced contractions of the guinea-pig proximal colon through stimulation of post-junctional tachykinin NK_1 receptors (250) 181
Brioni, J.D., see Decker, M.W. (261) 217
Bristow, L.J. and Young, L.
Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK_1 receptor activation in gerbils (253) 245
Bristow, L.J., Thorn, L., Tricklebank, M.D. and Hutson, P.H.
Competitive NMDA receptor antagonists attenuate the behavioural and neurochemical effects of amphetamine in mice (264) 353
Brizzolara, A.L., Morris, D.G. and Burnstock, G.
Ethanol affects sympathetic cotransmission and endothelium-dependent relaxation in the rat (254) 175
Broccardo, M. and Improta, G.
Sauvagine-induced hypothermia: evidence for an interaction with the dopaminergic system (258) 179
Brocco, M., see Schreiber, R. (264) 99
Brodin, E., see Brodin, K. (263) 175
Brodin, K., Ögren, S.-O. and Brodin, E.
Clomipramine and clonazepam increase cholecystokinin levels in rat ventral tegmental area and limbic regions (263) 175
Brodowsky, I.D., Hamberg, M. and Oliw, E.H.
BW A4C and other hydroxamic acids are potent inhibitors of linoleic acid 8*R*-dioxygenase of the fungus *Gaeumannomyces graminis* (254) 43
Broekkamp, C.L.E., see Berendsen, H.H.G. (253) 83
Broekkamp, C.L.E., see Berendsen, H.H.G. (263) 315
Brooks, R., see Poucher, S.M. (252) 19
Broom, T., see Farmer, S.G. (259) 309
Brouard, A., Heaulme, M., Leyris, R., Pelaprat, D., Gully, D., Kitabgi, P., Le Fur, G. and Rostene, W.
SR 48692 inhibits neurotensin-induced [^{3}H]dopamine release in rat striatal slices and mesencephalic cultures (253) 289
Brouwer, A., see Lans, M.C. (270) 129
Brouwer, A., see Murk, A. (270) 253
Brown, A., see Vemulapalli, S. (257) 95
Brown, G., see Chien, C.-C. (253) R7
Brown, J.D., see Barnes, J.C. (250) 147
Brown, L.M., Lee, Y.-P. and Teyler, T.J.
Antiepileptics inhibit cortical *N*-methyl-D-aspartate-evoked [^{3}H]norepinephrine efflux (254) 307
Browne, I., Thomas, G., Gavin, K. and Docherty, J.R.
Prejunctional actions of *N*-ethyl-maleimide and phenoxybenzamine in rat vas deferens (265) 125
Browning, J.L., see Cirino, G. (252) 147
Browning, M.D., see Firestone, J.A. (269) 177
Bruce, A., see Hellewell, S.B. (268) 9
Brugger, F., see Lepre, M. (258) 23
Brüne, B., see Dimmeler, S. (267) 105
Brune, K., see Schmidt, N. (255) 245
Brunelleschi, S., see Dianzani, C. (263) 223
Brunissen, A., see Lavielle, S. (258) 273
Bruno, V., Copani, A., Battaglia, G., Raffaele, R., Shinozaki, H. and Nicoletti, F.
Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death (256) 109
Bruns, C., see Kusterer, K. (259) 265
Brzozowski, T., see Konturek, S.J. (253) 107
Buccafusco, J.J., see Feldman, D.S. (250) 483
Buchan, K.W., Magnusson, H., Rabe, K.F., Sumner, M.J. and Watts, I.S.
Characterisation of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46-2005 (260) 221
Buchanan, M., see Zhang, H. (251) 119
Buchheit, K.-H. and Buhl, T.
Stimulant effects of 5-hydroxytryptamine on guinea pig stomach preparations in vitro (262) 91
Buchheit, K.-H., see Kusterer, K. (259) 265
Buchholz, R.A., see Dundore, R.L. (249) 293
Buckett, W.R., see Heal, D.J. (249) 37
Buckner, C.K., see Kusner, E.J. (257) 285
Buczko, W., see Malinowska, B. (259) 315
Budai, G., see Sziráki, I. (251) 311
Buhl, T., see Buchheit, K.-H. (262) 91
Bunce, K., see Bountra, C. (249) R3
Burbach, J.P.H., see Adan, R.A.H. (269) 331
Burcher, E. and Stamatakos, C.
Septide but not substance P stimulates inhibitory neurons in guinea-pig ileum (258) R9
Burger, R., see Götz, M.E. (266) 291

Burghardt, R., see Fernandez, P. (270) 53
Burgin, R., see Weizman, R. (250) 289
Burleigh, D.E. and Kirkham, S.E.
Lack of effect of three putative vasoactive intestinal peptide receptor antagonists on vasoactive intestinal peptide-induced secretory responses in rat colon (249) 239
Burnett, J.P., see Sharp, R.L. (266) R1
Burnett, J.P., see Sharp, R.L. (269) R5
Burnstock, G., see Brizzolara, A.L. (254) 175
Burnstock, G., see Inoue, K. (268) 223
Burnstock, G., see Vials, A.J. (251) 299
Burrell, L.M., see Phillips, P.A. (259) 325
Busch, A.E., Herzer, T., Takumi, T., Krippeit-Drews, P., Waldegger, S. and Lang, F.
Blockade of human I_{sK} channels expressed in *Xenopus* oocytes by the novel class III antiarrhythmic NE-10064 (264) 33
Busch, A.E., see Herzer, T. (259) 335
Bush, L.G., see Midgley, L.P. (251) 191
Busse, R., see Schini-Kerth, V. (265) 83
Bussjaeger, L.J., see Varga, G. (250) 37
Bustos, G., see Ferrándiz, M.L. (253) 75
Butchers, P.R., see Nials, A.T. (251) 127
Butler, S.A., see Heal, D.J. (249) 37
Butt, E., Eigenthaler, M. and Genieser, H.-G.
(Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor (269) 265
Butta, N.V., see Lorenzo, P.S. (258) 253
Buzzard, S.L., Seifen, E., Lindemann, J.P. and Kennedy, R.H.
Effects of extracellular Cl^- on the inotropic response to α-adrenoceptor stimulation (260) 15

Cabot, P.J., Dodd, P.R., Cramond, T. and Smith, M.T.
Characterization of non-conventional opioid binding sites in rat and human lung (268) 247
Cacciarelli, N., see Galli, A. (270) 189
Cagnotto, A., Bastone, A. and Mennini, T.
[^{3}H](+)-Pentazocine binding to rat brain σ_1 receptors (266) 131
Cagnotto, A., see Cervo, L. (253) 139
Calabrò, F., see Chitano, P. (270) 167
Calapai, G., see Squadrito, F. (255) 51
Calatayud, S., see Barrachina, D. (262) 181
Calcutt, N.A., Mizisin, A.P. and Kalichman, M.W.
Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve (251) 27
Calder, J.A., Schachter, M. and Sever, P.S.
Vasorelaxant actions of 5-OH-indapamide, a major metabolite of indapamide: comparison with indapamide, hydrochlorothiazide and cicletanine (256) 185
Caldwell, M., O'Neill, M., Earley, B. and Leonard, B.
N^G-Nitro-L-arginine protects against ischaemia-induced increases in nitric oxide and hippocampal neuro-degeneration in the gerbil (260) 191
Callahan, P.M. and Cunningham, K.A.
Involvement of 5-HT_{2C} receptors in mediating the discriminative stimulus properties of *m*-chlorophenylpiperazine (mCPP) (257) 27
Camanni, F., see Mazza, E. (254) 17
Camarao, G.C., see Paik, S.H. (253) 101
Camargo, A.C.M., see Paik, S.H. (253) 101
Cameron, B.-R., see Taverna, F.A. (267) R3
Caminiti, G.N., see DeWitt, B.J. (257) 303
Campbell, D.R., see Varga, G. (250) 37
Campo, G.M., see Altavilla, D. (270) 45
Campo, G.M., see Ioculano, M. (264) 143
Campo, G.M., see Squadrito, F. (255) 51
Campos-Toimil, M., Orallo, F., Gil-Longo, J., Verde, I., Loza, I. and Fernández-Alzueta, A.
Pharmacological study of several effects of hydralazine in the bisected rat vas deferens (251) 83
Camussi, G., see Emanuelli, G. (261) 265
Canale, P., see Altavilla, D. (270) 45
Canale, P., see Ioculano, M. (264) 143
Canals, F., see Lacour, C. (264) 307
Candelas, M.A., see Fernández-López, A. (262) 283
Candenas, M.-L., see Naline, E. (256) 301
Caneira, M., see De Castro, M. (261) 199
Cannell, G.R., see Taylor, S.M. (270) 371
Cano, J., see Vizuete, M.L. (270) 183
Cao, B.-J. and Li, W.-P.
Antagonism of clonidine antinociception by buspirone and 1-(2-pyrimidinyl)-piperazine (259) 75
Capasso, A., Sorrentino, L., Di Giannuario, A., Pieretti, S. and Loizzo, A.
Effect of des-tyrosine-γ-endorphin on neocortical spike-and-wave spindling in DBA/2J mice (261) 209
Capasso, F., see Mascolo, N. (264) 21
Capet, M., see Bertrand, P. (262) 233
Caporali, M.G., see Popoli, P. (257) R5
Cappai, F., see Devoto, P. (252) 321
Caputi, A.P., see Altavilla, D. (270) 45
Caputi, A.P., see Ioculano, M. (264) 143
Caputi, A.P., see Squadrito, F. (255) 51
Capuzzo, A., see Borea, P.A. (267) 55
Carasso, R.L., see Yehuda, S. (254) 193
Cardinali, D.P., see Esquifino, A.I. (254) 1
Carlà, V., see Mannaioni, G. (251) 201
Carlsson, A., see Svensson, K. (263) 235
Carlsson, A., see Waters, N. (251) 181
Carneiro, R.C.G., Toffoleto, O., Cipolla-Neto, J. and Markus, R.P.
Modulation of sympathetic neurotransmission by melatonin (257) 73
Carnuccio, R., see Iuvone, T. (265) 89
Caron, M., see Ng, G.YK. (267) 7
Carpenter, D.O., see Lin, Y. (262) 99
Carpenter, T.G., see Gardiner, P.J. (258) 95
Carreau, A., Duval, D., Poignet, H., Scatton, B., Vigé, X. and Nowicki, J.-P.
Neuroprotective efficacy of N^{ω}-nitro-L-arginine after focal cerebral ischemia in the mouse and inhibition of cortical nitric oxide synthase (256) 241
Carreau, A., see Biton, B. (257) 297
Carruba, M.O., see Nisoli, E. (259) 181
Carruette, A., see Lavielle, S. (258) 273
Carruette, A., see Montier, F. (251) 9
Carruthers, A.M. and Fozard, J.R.
Effect of pertussis toxin treatment on the putative adenosine A_3 receptor-mediated hypotensive response in the rat (250) 185
Carta, G., see Imperato, A. (264) 55
Carter, C., see Voltz, C. (255) 197
Carter, M., see Von Lubitz, D.K.J.E. (249) 265
Carter, M., see Von Lubitz, D.K.J.E. (253) 95
Carter, M.F., see Von Lubitz, D.K.J.E. (256) 161
Carter, M.F., see Von Lubitz, D.K.J.E. (263) 59
Caruso, A., see Clementi, G. (256) R7
Caruso, P., see Civelli, M. (255) 17
Carvalho, C.M., see Santos, D.L. (267) 307
Castel, M.-N., Morino, P., Nylander, I., Terenius, L. and Hökfelt, T.
Differential dopaminergic regulation of the neurotensin striatonigral and striatopallidal pathways in the rat (262) 1
Casto, R., see Lysko, G.S. (263) 25
Castro-Faria-Neto, H.C., see Altenburg, S.P. (256) 45
Castro-Faria-Neto, H.C., see Bozza, P.T. (270) 143
Casu, M.A., see Imperato, A. (264) 55
Cataldi, M., Magnan, E., Guillaume, V., Héry, F., Dutour, A.,

Rettori, M.-C., Kamoun, A. and Oliver, C.
Effect of tianeptine on the hypothalamic somatotropic axis in the conscious sheep (253) 149
Catalioto, R.-M., Renzetti, A.-R., Criscuoli, M., Mizrahi, J. and Subissi, A.
Angiotensins induce the release of prostacyclin from rabbit vas deferens: evidence for receptor heterogeneity (256) 93
Cattabeni, F., see Balduini, W. (266) 283
Cattaneo, M.G., Palazzi, E., Bondiolotti, G. and Vicentini, L.M.
5-HT_{1D} receptor type is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma (268) 425
Cavallotti, D., see Kobayashi, Y. (261) 229
Cavanni, P., Pinnola, V., Mugnaini, M., Trist, D., Van Amsterdam, F.Th.M. and Ferraguti, F.
Pharmacological analysis of carboxyphenylglycines at metabotropic glutamate receptors (269) 9
Cavazzani, P., see Fassio, A. (263) 311
Cazaubon, C., see Herbert, J.-M. (251) 143
Cazaubon, C., see Lacour, C. (264) 307
Ceci, A., Baschirotto, A. and Borsini, F.
Effect of fluoxetine on the spontaneous electrical activity of fronto-cortical neurons (250) 461
Cederqvist, B., see Persson, M.G. (270) 273
Celada, P., see Romero, L. (265) 103
Celander, M., see Svartengren, J. (254) 73
Cervo, L., Bendotti, C., Tarizzo, G., Cagnotto, A., Skorupska, M., Mennini, T. and Samanin, R.
Potential antidepressant properties of SR 57746A, a novel compound with selectivity and high affinity for 5-HT_{1A} receptors (253) 139
Cervo, L., Rossi, C., Tatarczynska, E. and Samanin, R.
Role of 5-HT_{1A} receptors in the antinociceptive action of 8-hydroxy-2-(di-*n*-propylamino)tetralin in the rat (263) 187
Chaki, S., Tanaka, M., Muramatsu, M. and Otomo, S.
Discrimination of (+)-3-PPP sites from DTG sites by FH-510, a novel potent σ ligand, in rat brain (250) 173
Chaki, S., Tanaka, M., Muramatsu, M. and Otomo, S.
NE-100, a novel potent σ ligand, preferentially binds to σ_1 binding sites in guinea pig brain (251) R1
Challiss, R.A.J., see Simpson, P.B. (266) 309
Chamberlin, A.R., see Miller, S. (269) 235
Chamouard, P., Rohr, S., Meyer, C., Baumann, R. and Angel, F.
δ-Opioid receptor agonists inhibit neuromuscular transmission in human colon (262) 33
Chan, B., see Ricciardolo, F.L.M. (261) 127
Chan, P., see Hegde, S.S. (251) 43
Chan, W.W., see Götz, M.E. (266) 291
Chandel, B., see Deshpande, Y. (256) R1
Chandler, L.J., see Davda, R.K. (266) 237
Chang, C.C., see Hong, S.J. (265) 35
Chang, J.-K., see Lin, B. (260) 1
Chang, K., see Hasan, K. (249) 101
Chang, T.-h., Adachi, H., Mori, N., Saito, I. and Okuyama, T.
Effects of a pyranocoumarin compound isolated from a Chinese medicinal plant on ischemic myocardial dysfunction in anesthetized dogs (258) 77
Chang, Y.-M., see Su, M.-J. (254) 141
Chao, A.C., see Mochizuki, H. (252) 183
Chao, C.C.-K.
Enhanced excision repair of DNA damage due to *cis*-diammine-dichloroplatinum(II) in resistant cervix carcinoma HeLa cells (268) 347
Chaouche-Teyara, K., Fournier, B., Safar, M. and Dabiré, H.
Vascular and cardiac effects of α-methyl-5-HT and DOI are mediated by different 5-HT receptors in the pithed rat (250) 67
Chaouloff, F., Baudrie, V. and Coupry, I.
Behavioural and biochemical evidence that glucocorticoids are not involved in DOI-elicited 5-HT_2 receptor down-regulation (249) 117
Chapman, K.L., see Patel, S. (253) 237
Chapman, M.A., see See, R.E. (263) 269
Chapman, R.W., see Danko, G. (254) 283
Charleson, S., Evans, J.F., Léger, S., Perrier, H., Prasit, P., Wang, Z. and Vickers, P.J.
Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein (267) 275
Charney, D.S., see Laruelle, M. (263) 39
Charpentier, S., Sagan, S., Naim, M., Delfour, A. and Nicolas, P.
Mechanism of δ-opioid receptor selection by the address domain of dermenkephalin (266) 175
Charriaut-Marlangue, C., see Dessi, F. (250) 325
Chassaing, G., see Lavielle, S. (258) 273
Chatelain, P., Dewinkeleer, P., Beaufort, P., Meysmans, L. and Clinet, M.
Characterization of the binding of [^{3}H]SR 33805 to the slow Ca^{2+} channel in rat heart sarcolemmal membrane (267) 151
Chatelain, P., see Herbert, J.-M. (251) 143
Chatelain, P., see Vander Elst, L. (251) 163
Chaudieu, I., St-Pierre, J.A., Quirion, R. and Boksa, P.
$GABA_A$ receptor-mediated inhibition of *N*-methyl-D-aspartate-evoked [^{3}H]dopamine release from mesencephalic cell cultures (264) 361
Chazot, P.L., see Cik, M. (266) R1
Chen, C., see Gopalakrishnan, S.M. (250) 469
Chen, C.-C., see Yu, S.-M. (252) 29
Chen, C.-F., see Chiou, W.-F. (257) 59
Chen, C.-T., see Ho, C.-L. (259) 259
Chen, C.-Y., see Tao, P.-L. (256) 281
Chen, H.-W., see Huang, H.-C. (268) 73
Chen, J., see Yu, S.-M. (252) 29
Chen, J.-S., see Huang, H.-C. (268) 73
Chen, J.-S., see Wang, C.-N. (267) 33
Chen, K., Hernandez, Y.M., Dretchen, K.L. and Gillis, R.A.
Intravenous NBQX inhibits spontaneously occurring sympathetic nerve activity and reduces blood pressure in cats (252) 155
Chen, N.-H., see Reith, M.E.A. (253) 175
Chen, R., see Pan, D. (264) 177
Chen, S.-C., see Yu, S.-M. (252) 29
Chen, S.-P., see Fu, W.-M. (270) 321
Chen, S.C., see Götz, M.E. (266) 291
Chen, T.-S., see Koutsilieri, E. (269) R3
Chen, X., Nishimura, J., Hasna, J., Kobayashi, S., Shikasho, T. and Kanaide, H.
Protein kinase C and protein kinase A regulate the expression of angiotensin II receptor mRNA in smooth muscle cells (267) 175
Cheng, C.H.K., Costall, B., Kelly, M.E. and Naylor, R.J.
Actions of 5-hydroxytryptophan to inhibit and disinhibit mouse behaviour in the light/dark test (255) 39
Cheng, D.Y., DeWitt, B.J., Dent, E.L., Nossaman, B.D. and Kadowitz, P.J.
Analysis of responses to angiotensin IV in the pulmonary vascular bed of the cat (261) 223
Cheng, D.Y., see DeWitt, B.J. (257) 303
Cheng, D.Y., see Feng, C.J. (263) 133
Cheng, K.F., see Ng, P.C. (264) 1
Chester, H.A., see Pisarev, M.A. (258) 33
Chi, J.-F., see Su, M.-J. (254) 141
Chiavarini, M., see Barocelli, E. (254) 151
Chiba, K., see Hayase, N. (260) 183
Chiba, S., see Fujiwara, T. (258) 195
Chiba, S., see Iwatsuki, K. (249) 19
Chiba, S., see Sawaki, S. (250) 253

Chien, C.-C., Brown, G., Pan, Y.-X. and Pasternak, G.W.
Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a κ-opioid receptor (253) R7
Chien, C.C. and Pasternak, G.W.
Functional antagonism of morphine analgesia by (+)-pentazocine: evidence for an anti-opioid σ_1 system (250) R7
Chikahisa, L., see Oyama, Y. (270) 137
Childs, K.J., see Critchley, D.J.P. (264) 95
Chinestra, P., see Gozlan, H. (262) R3
Ching, T.-L., De Jong, J. and Bast, A.
Structural characteristics of histamine H_2 receptor antagonists that scavenge hypochlorous acid (268) 89
Chintala, M., see Sandoli, D. (259) 43
Chiou, W.-F., Chou, C.-J., Liao, J.-F., Sham, A.Y.-C. and Chen, C.-F.
The mechanism of the vasodilator effect of rutaecarpine, an alkaloid isolated from *Evodia rutaecarpa* (257) 59
Chisholm, J.C., see Hunnicutt, Jr., E.J. (261) R1
Chitano, P., Di Blasi, P., Lucchini, R.E., Calabrò, F., Saetta, M., Maestrelli, P., Fabbri, L.M. and Mapp, C.E.
The effects of toluene diisocyanate and of capsaicin on human bronchial smooth muscle in vitro (270) 167
Chiu, A.T., see Wong, P.C. (260) 261
Chiu, P.J.S., see Sandoli, D. (259) 43
Chiu, P.J.S., see Vemulapalli, S. (257) 95
Cho, C.H., Mei, Q.B. and Kaan, S.K.
The intraperitoneal effects of 5-hydroxytryptamine on haemodynamics, gastric mucosal blood flow and platelet aggregation (256) 9
Chou, C.-J., see Chiou, W.-F. (257) 59
Chrétien, L., Guillemette, G. and Regoli, D.
Non-peptide angiotensin receptor antagonists bind to tachykinin NK_3 receptors of rat and guinea pig brain (256) 73
Christensen, J.D., see Jørgensen, A. (259) 157
Chu, P.-j., Shirahata, A., Samejima, K., Saito, H. and Abe, K.
N-(3-Aminopropyl)-cyclohexylamine blocks facilitation by spermidine of *N*-methyl-DL-aspartate-induced seizure in mice in vivo (256) 155
Chuan, P., see Martínez, C. (261) 73
Chudzik, J., see Helmeste, D.M. (266) 327
Chueh, S.-C., see Yu, S.-M. (252) 29
Chulia, T., see Del Rio, M. (250) 133
Chung, F.-Z., see Pinnock, R.D. (269) 73
Chung, F.-Z., see Suman-Chauhan, N. (269) 65
Chung, K.F., see Sakamoto, T. (251) 137
Church, J., see Fletcher, E.J. (267) 249
Chwiecko, M., see Farbiszewski, R. (270) 263
Ciabattoni, G., see Montuschi, P. (252) 253
Cicala, C., see Cirino, G. (252) 147
Cicala, C., see Liu, J.T. (264) 183
Cicala, C., see Wallace, J.L. (257) 249
Cierco, M. and Israel, A.
Role of angiotensin AT_1 receptor in the cardiovascular response to footshock (251) 103
Cik, M., Chazot, P.L. and Stephenson, F.A.
Expression of NMDAR1-1a (N598Q)/NMDAR2A receptors results in decreased cell mortality (266) R1
Cipolla-Neto, J., see Carneiro, R.C.G. (257) 73
Cirino, G., Cicala, C., Sorrentino, R., Sorrentino, L., Browning, J.L. and Page, C.P.
Human recombinant phospholipase A_2 inhibits platelet aggregation in vitro and in vivo in rat and guinea pig (252) 147
Cirino, G., see Giraldelo, C.M.M. (257) 87
Cirino, G., see Wallace, J.L. (257) 249
Ciucci, A., see Feriotto, G. (267) 143
Civelli, M., Caruso, P., Giossi, M., Bergamaschi, M., Razzetti, R., Bongrani, S. and Gasco, A.
CHF 2206, a new potent vasodilating and antiaggregating drug as potential nitric oxide donor (255) 17
Clapham, J. and Kilpatrick, G.J.
Thioperamide, the selective histamine H_3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse (259) 107
Clapham, J., see Barnes, J.C. (250) 147
Clapham, J.C., Trail, B.K. and Hamilton, T.C.
K^+ channel activators, acute glucose tolerance and glibenclamide-induced hypoglycaemia in the hypertensive rat (257) 79
Clark, M.A., see West, Jr., R.E. (267) 343
Clarke, G.D., MacPherson, I.S., Petrone, G. and Spangler, R.S.
Antinociceptive effects of non-steroidal anti-inflammatory drugs in a rat model of unilateral hindpaw inflammation (257) 103
Clarke, G.D., see Zaratin, P. (264) 151
Clarke, N.P., see Barnes, J.C. (250) 147
Clarkson, K., Tobin, J.R. and Breslow, M.J.
Atypical β-adrenoceptor in bovine adrenal medulla (263) R1
Clas, D.M., see Dundore, R.L. (249) 293
Classen, M., see Kurjak, M. (257) 169
Classen, M., see Schepp, W. (269) 183
Classen, M., see Weigert, N. (264) 337
Claustre, Y., see Rouquier, L. (261) 59
Clementi, G., Caruso, A., Prato, A., De Bernardis, E., Fiore, C.E. and Amico-Roxas, M.
A role for nitric oxide in the anti-ulcer activity of calcitonin gene-related peptide (256) R7
Climent, V.J., see Martí-Cabrera, M. (255) 157
Cline, P., see Morhenn, V.B. (268) 409
Clinet, M., see Chatelain, P. (267) 151
Coates, J., see Gardner, C.J. (257) 117
Cockerham, S.L., see Stengel, P.W. (253) 253
Coffey, L.L., see Reith, M.E.A. (253) 175
Coffin, V., Cohen-Williams, M. and Barnett, A.
Selective antagonism of the anticonvulsant effects of felbamate by glycine (256) R9
Coggan, J.S., see Xian, H. (259) 21
Cohen, G., see Werner, P. (263) 157
Cohen, H., see Fayard, J.M. (251) 281
Cohen, M.L., see Cox, D.A. (258) 265
Cohen-Williams, M., see Coffin, V. (256) R9
Coimbra, C., see Plourde, V. (256) 125
Colado, M.I., Ormazabal, M.J., Goicoechea, C., Lopez, F., Alfaro, M.J. and Martin, M.I.
Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse (252) 291
Cole, J.C., see Rodgers, R.J. (261) 321
Coleman, R.A., see Nials, A.T. (251) 127
Collins, D.R., Pertwee, R.G. and Davies, S.N.
The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice (259) R7
Collins, K.A., see Tseng, L.F. (258) R1
Collis, M.G., see Poucher, S.M. (252) 19
Collu, M., see D'Aquila, P.S. (262) 107
Colombo, G., Agabio, R., Lobina, C., Reali, R., Fadda, F. and Gessa, G.L.
Blockade of ethanol discrimination by isradipine (265) 167
Colombo, G., see Devoto, P. (252) 321
Conant, A.R., see Poucher, S.M. (252) 19
Conaty, C., see Pritchard, G.A. (266) 107
Concas, A., Santoro, G., Mascia, M.P., Maciocco, E., Dazzi, L. and Biggio, G.
Effects of propofol, pentobarbital and alphaxalone on *t*-[^{35}S]butylbicyclophosphorothionate binding in rat cerebral cortex (267) 207
Concas, A., see Barbaccia, M.L. (261) 317
Conforti, L., Sumii, K. and Sperelakis, N.

Diphenylamine-2-carboxylate blocks voltage-dependent Na^+ and Ca^{2+} channels in rat ventricular cardiomyocytes (259) 215
Connelly, C.D., see Raffa, R.B. (258) R5
Connelly, S.T., see Shepard, P.D. (265) 141
Connolly, G.P. and Harrison, P.J.
Reactive blue 2 discriminates between responses mediated by UTP and those evoked by ATP or α,β-methylene-ATP on rat sympathetic ganglia (259) 95
Connor, H.E., see O'Shaughnessy, C.T. (259) 37
Connor, H.E., see O'Shaughnessy, C.T. (263) 193
Constantine, J.W., Lebel, W.S., Woody, H.A., Benoit, P.A., Wolfgang, E.A. and Knight, D.R.
Cardiovascular effects of CP-96,345, a non-peptide blocker of tachykinin NK_1 receptors (252) 275
Contesse, V., Hamel, C., Delarue, C., Lefebvre, H. and Vaudry, H.
Effect of a series of 5-HT_4 receptor agonists and antagonists on steroid secretion by the adrenal gland in vitro (265) 27
Cook, D.A., see Tsuji, T. (264) 77
Cools, A.R., see Kikuchi de Beltrán, K. (262) 49
Cools, A.R., see Prinssen, E.P.M. (262) 167
Cooper, T.B., see Klein, M. (254) 239
Copani, A., see Bruno, V. (256) 109
Coppes, R.P., Smit, J., Geurtsen, A.M.S., Roffel, A.F., Dahlöf, C., Doods, H.N. and Zaagsma, J.
Heterogeneity of prejunctional neuropeptide Y receptors inhibiting noradrenaline overflow in the portal vein of freely moving rats (261) 311
Corbett, J.A., see Hasan, K. (249) 101
Cordeiro, R.S.B., see Altenburg, S.P. (256) 45
Cordeiro, R.S.B., see Bozza, P.T. (270) 143
Cordeiro, R.S.B., see Zuany-Amorim, C. (257) 211
Corder, R., see Wellings, R.P. (256) 201
Coric, P., see Noble, F. (253) 283
Corley, K.C., see Singh, V.B. (256) 177
Corpus, V.M., Bressie, S.M., Stillwell, L.I. and Olins, G.M.
Interaction of guanidinium compounds and K^+ channel modulators with imidazoline binding sites in rabbit kidney (266) 197
Corsi, C., see Pazzagli, M. (254) 277
Corsico, N., see Pascale, A. (265) 1
Cortijo, J., see Iriarte, M.-C.F. (250) 295
Cortijo, J., see Martí-Cabrera, M. (255) 157
Costa, L.G., see Balduini, W. (266) 283
Costall, B., see Cheng, C.H.K. (255) 39
Costentin, J., see Billaud, G. (268) 357
Costentin, J., see Bonnet, J.-J. (266) 87
Costentin, J., see Dourmap, N. (253) R9
Costentin, J., see Héron, C. (264) 391
Costentin, J., see Nouel, D. (254) 263
Costentin, J., see Saadouni, S. (268) 187
Cotman, C.W., see Miller, S. (269) 235
Couch, R.C., see Komoriya, K. (250) 455
Coupry, I., see Chaouloff, F. (249) 117
Cox, D.A. and Cohen, M.L.
Age-related alterations in sensitivity of muscarinic and serotonergic responses of guinea pig trachea to removal of extracellular Ca^{2+} (258) 265
Cox, R.F., see Liu, J.-C. (264) 269
Coy, D.H., see DeWitt, B.J. (257) 303
Coy, D.H., see Lach, E. (265) 117
Craig, C.G., Temple, S.D. and White, T.D.
Is cyclic AMP involved in excitatory amino acid-evoked adenosine release from rat cortical slices? (269) 79
Cramond, T., see Cabot, P.J. (268) 247
Crankshaw, D., see Jang, E.K. (250) 477
Crawford, C.A., Rowlett, J.K., McDougall, S.A. and Bardo, M.T.
Age-dependent differences in the rate of recovery of striatal dopamine D_1 and D_2 receptors after inactivation with EEDQ (252) 225
Crespo, A., see Heuillet, E. (269) 139
Criddle, D.N., Rad-Niknam, M., Dewar, G.H. and Woodward, B.
Vasodilator action of the isopropyl ester of palmitoyl carnitine in the rat coronary circulation and mesenteric vascular bed (255) 223
Criscuoli, M., see Catalioto, R.-M. (256) 93
Cristòfol, R.M. and Rodríguez-Farré, E.
Hippocampal noradrenaline release is modulated by γ- and δ-hexachlorocyclohexane isomers: which mechanisms are involved? (252) 305
Critchley, D.J.P., Childs, K.J., Middlefell, V.C. and Dourish, C.T.
Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT_{1A} receptor antagonist WAY100635 (264) 95
Critchley, D.J.P., Middlefell, V.C., Liddle, C.W., Foden, N.D. and Dourish, C.T.
Effects of the selective 5-HT_{1A} receptor antagonist WAY100135 and its enantiomers on 8-OH-DPAT-induced hyperglycaemia in conscious rats (254) 133
Crowder, R.E., see McCarthy, H.D. (265) 99
Cruz, S.L., Fernández-Guasti, A. and Villarreal, J.E.
Cardiovascular effects of different schedules of nicotine administration on spinal rats: influence of pentobarbital (258) 39
Cuccheddu, T., see Barbaccia, M.L. (261) 317
Cuccheddu, T., see Ghiani, C.A. (254) 299
Cucinotta, D., see Squadrito, F. (255) 51
Cumin, F., see Macari, D. (259) 27
Cunningham, K.A., see Callahan, P.M. (257) 27
Curnow, R., see Dawson, G.R. (252) 325
Currie, M.G., see Kasten, T.P. (253) 35
Currò, D., see Montuschi, P. (252) 253
Curtis, D.R., see Ong, J. (264) 49
Curzon, G., see Oluyomi, A.O. (255) 175
Curzon, G., see Oluyomi, A.O. (264) 111
Curzon, P., see Decker, M.W. (261) 217
Cusson, J.R., see Lambert, C. (252) 245
Cuthbert, N.J., see Gardiner, P.J. (258) 95
Cuthbert, N.J., see Tudhope, S.R. (264) 317
Czechowska, G., see Pietrasiewicz, T. (250) 1
Czuczwar, S.J., Gąsior, M., Turski, W.A. and Kleinrok, Z.
Influence of a Ca^{2+} channel agonist, BAY k-8644, on the anticonvulsant activity of NMDA and non-NMDA receptor antagonists (264) 103
Czuczwar, S.J., see Pietrasiewicz, T. (250) 1
Czyżewska-Szafran, H., see Remiszewska, M. (250) 355

Dabiré, H., see Chaouche-Teyara, K. (250) 67
Daffonchio, L., see Hernandez, A. (270) 301
Dahlöf, C., see Coppes, R.P. (261) 311
Dailey, J.W., see Yan, Q.-S. (252) 105
Dale, T., see Bountra, C. (249) R3
Dalen, T., Vestereng, M., Wadsworth, R. and Kane, K.
Effect of hypoxia on contraction and $^{45}Ca^{2+}$ uptake induced by the thromboxane mimetic U46619 in sheep coronary artery (270) 313
Dalgaard, L., see Videbæk, C. (249) 43
Dallegri, F., see Bevilacqua, M. (268) 415
Dalpiaz, A., see Borea, P.A. (267) 55
Damase-Michel, C., Giraud, P., Portolan, G., Montastruc, J.-L., Montastruc, P. and Tran, M.-A.
Effects of insulin on the release of neuropeptide Y, [Met^5]enkephalin and catecholamines from dog adrenal medulla (258) 277
D'Amico, M., see Maione, S. (250) 209
Damsma, G., Bottema, T., Westerink, B.H.C., Tepper, P.G., Dijk-

stra, D., Pugsley, T.A., MacKenzie, R.G., Heffner, T.G. and Wikström, H.
Pharmacological aspects of *R*-(+)-7-OH-DPAT, a putative dopamine D_3 receptor ligand (249) R9
Daniel, E., see Zhang, H. (251) 119
Danilov, A.F., Gmiro, V.E. and Fedorov, D.J.
In search of new neuromuscular blocking drugs with quick onset and short duration of effect (257) 1
Danko, G., Hey, J.A., Egan, R.W., Kreutner, W. and Chapman, R.W.
Histamine H_3 receptors inhibit sympathetic modulation of airway microvascular leakage in allergic guinea pigs (254) 283
Dannals, R.F., see Villemagne, V.L. (257) 195
D'Aquila, P.S., Collu, M., Pani, L., Gessa, G.L. and Serra, G.
Antidepressant-like effect of selective dopamine D_1 receptor agonists in the behavioural despair animal model of depression (262) 107
Darius, H., Michael-Hepp, J., Thierauch, K.-H. and Fisch, A.
Inhibition of human platelets and polymorphonuclear neutrophils by the potent and metabolically stable prostaglandin D_2 analog ZK 118.182 (258) 207
Darlington, C., see Gilchrist, D. (252) R1
Da Silva, H., see Malcangio, M. (250) 153
Dassaud, M., see Diop, L. (257) 181
Datla, K.P., see Oluyomi, A.O. (255) 175
Daval, J.-L., see Nehlig, A. (258) 57
Davda, R.K., Chandler, L.J. and Guzman, N.J.
Protein kinase C modulates receptor-independent activation of endothelial nitric oxide synthase (266) 237
Davenas, E., see Pellegrini, O. (270) 221
Daviaud, D., see Bouloumié, A. (269) 95
Daviaud, D., see Larrouy, D. (267) 225
Davidson, M.M.L., see Jang, E.K. (250) 477
Davies, S.N., see Collins, D.R. (259) R7
Davis, J.N., see Hunnicutt, Jr., E.J. (261) R1
Davison, K., see Krafte, D.S. (266) 245
Dawson, D.A., McCulloch, J. and Macrae, I.M.
Cerebrovascular effects of N^G-nitro-L-arginine methylester are conserved under halothane anaesthesia (249) 7
Dawson, G.R., Curnow, R., Bayley, P., Rambridge, A. and Tricklebank, M.D.
Lack of effect of flumazenil and CGS 8216 on the anxiolytic-like properties of loreclezole (252) 325
Day, J.C., Tham, C.-S. and Fibiger, H.C.
Dopamine depletion attenuates amphetamine-induced increases of cortical acetylcholine release (263) 285
Day, J.C., see Acquas, E. (260) 85
Dazzi, L., see Concas, A. (267) 207
Dazzi, L., see Imperato, A. (251) 271
Dazzi, L., see Imperato, A. (261) 205
Dazzi, L., see Imperato, A. (264) 55
Dea, D.M., see Kusner, E.J. (257) 285
De Almeida, R.M.M. and Lucion, A.B.
Effects of intracerebroventricular administration of 5-HT receptor agonists on the maternal aggression of rats (264) 445
De Beer, E., see Schiereck, P. (249) 317
De Bernardis, E., see Clementi, G. (256) R7
DeBernardis, J.F., see Hancock, A.A. (267) 49
De Blas, A.L., see Ruano, D. (267) 121
De Boer, T., Nefkens, F. and Van Helvoirt, A.
The α_2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo (253) R5
De Boer, T., see Stam, N.J. (269) 339
De Castro, M., Mota-Filipe, H., Caneira, M., Gião-T. Rico, J.M., Scott-Burden, T. and Vanhoutte, P.M.
DL-Propranolol augments production of $NO^{\cdot}$ induced by cytokines in cultured aortic smooth muscle of the rat (261) 199
Decker, M.W., Curzon, P., Brioni, J.D. and Arnerić, S.P.
Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats (261) 217
DeCosta, B., see Basile, A.S. (252) 139
Decrinis, M., see Stark, G. (252) 283
De Cupis, A., see Favoni, R.E. (264) 199
Defer, N., see Matsuoka, I. (268) 215
De Gasparo, M., see Kalenga, M.K. (268) 231
De Gasparo, M., see Macari, D. (249) 85
De Gasparo, M., see Macari, D. (259) 27
De Giuli, P., see Emanuelli, G. (261) 265
De Groat, W.C., see Yoshiyama, M. (264) 417
DeHaas, C.J., see Kusner, E.J. (257) 285
De Hertogh, R., see Kalenga, M.K. (268) 231
Dehne, K., see Schepp, W. (269) 183
De Jonckheere, S., see McCaig, D. (249) 53
De Jong, J., see Ching, T.-L. (268) 89
De Jong, W., see Petty, M.A. (255) 215
De Kimpe, S.J., Tielemans, W., Van Heuven-Nolsen, D. and Nijkamp, F.P.
Reversal of bradykinin-induced relaxation to contraction after interferon-γ in bovine isolated mesenteric arteries (261) 111
De Kloet, E.R., see Meijer, O.C. (266) 255
De la Fuente, M.-T., see Maroto, R. (270) 331
De la Fuente, M.T., see Montiel, C. (268) 293
De La Fuente, P.G., see Savineau, J.-P. (249) 191
De la Lande, I.S., see Zhang, C.L. (252) 299
Delarue, C., see Contesse, V. (265) 27
Delbende, C., Tranchand Bunel, D., Tarozzo, G., Grino, M., Oliver, C., Mocaër, E. and Vaudry, H.
Effect of chronic treatment with the antidepressant tianeptine on the hypothalamo-pituitary-adrenal axis (251) 245
Delbro, D.S., see Gustafsson, B.I. (257) 227
Delfour, A., see Charpentier, S. (266) 175
Delisée, C., see Herbert, J.-M. (251) 143
Del Rio, M., Chulia, T., Gonzalez, P. and Tejerina, T.
Effects of indapamide on contractile responses and $^{45}Ca^{2+}$ movements in various isolated blood vessels (250) 133
De Luca, I.M.S., see Giraldelo, C.M.M. (257) 87
Del Valle, M., see Montiel, C. (268) 293
De Man, J.G., see Boeckxstaens, G.E. (264) 85
De Martino, A., see Emanuelli, G. (261) 265
Demattos, S., see MacKenzie, R.G. (266) 79
De Montigny, C., see Mongeau, R. (256) 269
De Montis, M.G., Gambarana, C. and Meloni, D.
α-Methyl-*para*-tyrosine antagonizes the effect of chronic imipramine on learned helplessness in rats (249) 179
Den Hertog, A., see Sipma, H. (268) 431
Denis-Pouxviel, C., see Devedjian, J.-C. (252) 43
Dennis, M., see Ng, G.YK. (267) 7
Dennis, T., Beauchemin, V. and Lavoie, N.
Antidepressant-induced modulation of $GABA_A$ receptors and β-adrenoceptors but not $GABA_B$ receptors in the frontal cortex of olfactory bulbectomised rats (262) 143
Dent, E.L., see Cheng, D.Y. (261) 223
De Nucci, G., see Giraldelo, C.M.M. (257) 87
Denyer, J., Gray, J., Wong, M., Stolz, M. and Tate, S.
Molecular and pharmacological characterization of the human CCK_B receptor (268) 29
De Pascual, R., see Salas, E. (258) 47
Depoortere, H., see Biton, B. (257) 297
De Rosa, S., see Ferrándiz, M.L. (253) 75
De Sarro, A., see De Sarro, G. (262) 11
De Sarro, G., Ongini, E., Bertorelli, R., Aguglia, U. and De Sarro, A.
Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice (262) 11
Descarries, L., see El Mansari, M. (261) 171

Deshpande, S.S., see Adler, M. (270) 9
Deshpande, Y., Longo, W.E., Chandel, B., Niehoff, M., Robinson, S., Polities, G., Vernava, A.M. and Kaminski, D.L.
Effect of platelet-activating factor and its antagonists on colonic dysmotility and tissue levels of colonic neuropeptides (256) R1
DeSiato, M.A., see Farmer, S.G. (259) 309
Desmonts, J.-M., see Mantz, J. (257) R7
Dessi, F., Ben-Ari, Y. and Charriaut-Marlangue, C.
Riluzole prevents anoxic injury in cultured cerebellar granule neurons (250) 325
Dethy, S., see Pauwels, T. (257) 53
Devaud, L.L. and Morrow, A.L.
Effects of chronic ethanol administration on [^{3}H]zolpidem binding in rat brain (267) 243
Devedjian, J.-C., Esclapez, F., Denis-Pouxviel, C. and Paris, H.
Further characterization of human α_2-adrenoceptor subtypes: [^{3}H]RX821002 binding and definition of additional selective drugs (252) 43
Devinsky, F., see Kacani, L. (270) 285
Devoto, P., Colombo, G., Cappai, F. and Gessa, G.L.
Naloxone antagonizes ethanol- but not γ-hydroxybutyrate-induced sleep in mice (252) 321
Devoto, P., see Portas, C.M. (270) 123
De Vries, T.J., see Tjon, G.H.K. (252) 205
De Vry, J., Benz, U., Schreiber, R. and Traber, J.
Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs (249) 331
De Vry, J., see Schreiber, R. (249) 341
De Waele, J.-P. and Gianoulakis, C.
Enhanced activity of the brain β-endorphin system by free-choice ethanol drinking in C57BL/6 but not DBA/2 mice (258) 119
Dewar, G.H., see Criddle, D.N. (255) 223
Dewey, S.L., see Pan, D. (264) 177
De Wildt, D.J., see Kappelle, A.C. (250) 43
De Wildt, D.J., see Van den Berg, C. (270) 379
De Wildt, D.J., see Vleeming, W. (250) 415
Dewinkeleer, P., see Chatelain, P. (267) 151
De Winter, B.Y., see Boeckxstaens, G.E. (264) 85
DeWitt, B.J., Cheng, D.Y., Caminiti, G.N., Nossaman, B.D., Coy, D.H., Murphy, W.A. and Kadowitz, P.J.
Comparison of responses to adrenomedullin and calcitonin gene-related peptide in the pulmonary vascular bed of the cat (257) 303
DeWitt, B.J., see Cheng, D.Y. (261) 223
Dhar, T.G.M., see Borden, L.A. (269) 219
Dhawan, K.N., see Nath, C. (263) 203
Dhein, S., see Stark, G. (252) 283
Diabira, D., see Gozlan, H. (262) R3
Diamond, J., see Langlands, J.M. (266) 229
Diana, M., see Mereu, G. (264) 449
Dianzani, C., Brunelleschi, S., Viano, I. and Fantozzi, R.
Adenosine modulation of primed human neutrophils (263) 223
Díaz-Juárez, J.L., see Iriarte, M.-C.F. (250) 295
Diaz, Z., see Narváez, J.A. (257) 257
Di Blasi, P., see Chitano, P. (270) 167
Di Carlo, G., see Mascolo, N. (264) 21
Di Chiara, G., see Morelli, M. (251) 21
Dickenson, J.M. and Hill, S.J.
Characteristics of [^{3}H]mepyramine binding in DDT$_1$MF-2 cells: Evidence for high affinity binding to a functional histamine H$_1$ receptor (268) 257
Diehl, N.L. and Shreeve, S.M.
Identification of the α_{1C}-adrenoceptor in rabbit arteries and the human saphenous vein using the polymerase chain reaction (268) 393
Dierich, M.P., see Kacani, L. (270) 285
Di Francesco, G.F.
Are the cardiovascular effects and '5-HT syndrome' induced by MDL 73,975 and flesinoxan in the dog mediated by 5-HT$_{1A}$ receptors? (262) 205
Di Giannuario, A., see Capasso, A. (261) 209
Dijkstra, D., see Damsma, G. (249) R9
Dimitriadou, V., see Pilon, C. (268) 129
Dimmeler, S., Meßmer, U.K., Tiegs, G. and Brüne, B.
Modulation of glyceraldehyde-3-phosphate dehydrogenase in *Salmonella abortus equi* lipopolysaccharide-treated mice (267) 105
Ding, Y.-S., see Pan, D. (264) 177
Dionisotti, S., see Sandoli, D. (259) 43
Diop, L., Rivière, P.J.M., Pascaud, X., Dassaud, M. and Junien, J.-L.
Role of vagal afferents in the antinociception produced by morphine and U-50,488H in the colonic pain reflex in rats (257) 181
Di Pasquale, E., see Monteau, R. (259) 71
Di Rosa, M., see Iuvone, T. (265) 89
Di Rosa, M., see Sautebin, L. (262) 193
Dirr, A., see Götz, M.E. (266) 291
Di Scala, G., see Rocha, B. (262) 125
Dixon, W.R., see Salas, E. (258) 47
Doble, A., see Bertrand, P. (262) 233
Doble, A., see Heuillet, E. (269) 139
Dobozy, A., see Kemény, L. (258) 269
Do Carmo, L.G., see Jurkiewicz, A. (256) 329
Docherty, J.R., see Browne, I. (265) 125
Dodd, P.R., see Cabot, P.J. (268) 247
Doherty, A.M., see Wellings, R.P. (256) 201
Dohi, T., see Kitayama, S. (268) 115
Dohi, Y., see Kojima, M. (254) 159
Dokita, S., Smith, S.D., Nishimoto, T., Wheeler, M.A. and Weiss, R.M.
Involvement of nitric oxide and cyclic GMP in rabbit urethral relaxation (266) 269
Dol, F., see Herbert, J.-M. (251) 143
Donadini, F., see Bonanno, G. (252) 61
Donatini, A., see Melchiorre, C. (265) 93
Donnelly, L.E., see Boyd, R.S. (267) 161
Dontenwill, M., see Bricca, G. (266) 25
Dontenwill, M., see Greney, H. (265) R1
Doods, H.N., Entzeroth, M., Ziegler, H., Mayer, N. and Holzer, P.
Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle (253) 275
Doods, H.N., Willim, K.D., Boddeke, H.W.G.M. and Entzeroth, M.
Characterization of muscarinic receptors in guinea-pig uterus (250) 223
Doods, H.N., see Coppes, R.P. (261) 311
Dos Santos Cruz, J. and Matsuda, H.
Depressive effects of arenobufagin on the delayed rectifier K$^+$ current of guinea-pig cardiac myocytes (266) 317
Douglas, S.A., Vickery-Clark, L.M. and Ohlstein, E.H.
Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction (255) 81
Dourish, C.T., see Critchley, D.J.P. (254) 133
Dourish, C.T., see Critchley, D.J.P. (264) 95
Dourmap, N. and Costentin, J.
Involvement of glutamate receptors in the striatal enkephalin-induced dopamine release (253) R9
Doutremepuich, J.-D., see Emonds-Alt, X. (250) 403
Dow, J., see Petty, M.A. (255) 215
Drapeau, G., see Godin, D. (253) 225
Drejer, J., see Olesen, S.-P. (251) 53
Drejer, J., see Verdoorn, T.A. (269) 43
Drekić, D., see Jovanović, A. (258) 185
Dretchen, K.L., see Chen, K. (252) 155
Dretchen, K.L., see McManigle, J.E. (252) 11

Drew, G.M., see Trezise, D.J. (250) 109
Droogmans, G., see Gericke, M. (269) 381
Drukarch, B., see Vermeulen, R.J. (269) 121
Dryden, S., see McCarthy, H.D. (265) 99
D'Souza, S.W., see McConnell, S.E. (262) 293
Du, X.Y., Schoemaker, R.G., Bos, E. and Saxena, P.R.
Different pharmacological responses of atrium and ventricle: studies with human cardiac tissue (259) 173
Duarte, J., Pérez-Vizcaíno, F., Zarzuelo, A., Jiménez, J. and Tamargo, J.
Inhibitory effects of quercetin and staurosporine on phasic contractions in rat vascular smooth muscle (262) 149
Dubois, H., see Heuillet, E. (269) 139
Dubray, C., see Lévy, L. (268) 327
Duckles, S.P., see Friedman, D.J. (252) 1
Ducos, B., see Bertrand, P. (262) 233
Ducoux, J.-P., see Emonds-Alt, X. (250) 403
Dugay, P., see Heuillet, E. (269) 139
Dughera, L., see Emanuelli, G. (261) 265
Dugrenier, N., see Krafte, D.S. (266) 245
Duhault, J., see Lacour, F. (255) 249
Dumas, J.-P., Dumas, M., Sgro, C., Advenier, C. and Giudicelli, J.-F.
Effects of two K^+ channel openers, aprikalim and pinacidil, on hypoxic pulmonary vasoconstriction (263) 17
Dumas, M., see Dumas, J.-P. (263) 17
Dumont, P., see Lach, E. (265) 117
Dumpis, M., see Bespalov, A. (264) 233
Duncia, J.V., see Wong, P.C. (260) 261
Dundore, R.L., Clas, D.M., Wheeler, L.T., Habeeb, P.G., Bode, D.C., Buchholz, R.A., Silver, P.J. and Pagani, E.D.
Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats (249) 293
Dunn, P.M.
Dequalinium, a selective blocker of the slow afterhyperpolarization in rat sympathetic neurones in culture (252) 189
Durham, R.A., see Manzanares, J. (249) 107
Durieux, C., see Bertrand, P. (262) 233
Dutour, A., see Cataldi, M. (253) 149
Dutta, A.K., see Madras, B.K. (267) 167
Duval, D., see Carreau, A. (256) 241
Dybdal, D.J., see Fornai, F. (254) R1
Dziki, M., see Pietrasiewicz, T. (250) 1
Dzwonczyk, S., see Sargent, C.A. (261) 25

Earley, B., see Caldwell, M. (260) 191
Ebara, T., Miura, K., Okumura, M., Matsuura, T., Kim, S., Yukimura, T. and Iwao, H.
Effect of adrenomedullin on renal hemodynamics and functions in dogs (263) 69
Eckman, J., see Qian, C. (250) R13
Eden, R.J., see Parker, S.G. (265) 17
Edvinsson, L., see Adner, M. (261) 281
Edwards, J.V., see Manzanares, J. (257) 199
Egan, M.F., see Karoum, F. (254) 127
Egan, R.W., see Danko, G. (254) 283
Egan, R.W., see West, Jr., R.E. (267) 343
Eger II, E.I., see Kendig, J.J. (264) 427
Eglen, R.M., see Bley, K.R. (260) 139
Eglen, R.M., see Hegde, S.S. (251) 43
Eigenthaler, M., see Butt, E. (269) 265
Eilbacher, B., see Spanagel, R. (262) 21
Eisenberg, E., LaCross, S. and Strassman, A.M.
The effects of the clinically tested NMDA receptor antagonist memantine on carrageenan-induced thermal hyperalgesia in rats (255) 123
Eizawa, H., see Hattori, R. (267) R1
El-Mas, M.M., see Fahim, M. (254) 183
Elger, B., Seega, J. and Raschack, M.
Oedema reduction by levemopamil in focal cerebral ischaemia of spontaneously hypertensive rats studied by magnetic resonance imaging (254) 65
Elkins, K.W., Gibb, J.W., Hanson, G.R., Wilkins, D.G. and Johnson, M.
Effects of nimodipine on the amphetamine- and methamphetamine-induced decrease in tryptophan hydroxylase activity (250) 395
Ellenbroek, B.A., see Prinssen, E.P.M. (262) 167
Elliott, J., Smart, D., Lambert, D.G. and Traynor, J.R.
Characterisation of μ-opioid receptors on SH-SY5Y cells using naloxonazine and β-funaltrexamine (268) 447
Elliott, J.M., see Pei, Q. (249) 243
Ellis, E.F., see Muir, J.K. (249) 287
El Mansari, M., Radja, F., Ferron, A., Reader, T.A., Molina-Holgado, E. and Descarries, L.
Hypersensitivity to serotonin and its agonists in serotonin-hyperinnervated neostriatum after neonatal dopamine denervation (261) 171
Eltze, M.
Characterization of the α_1-adrenoceptor subtype mediating contraction of guinea-pig spleen (260) 211
Eltze, M.
Pathways involved in muscarinic M_1 and M_2 receptor stimulation in rabbit vas deferens (263) 31
Elzinga, C.R.S., see Roffel, A.F. (249) 235
Elzinga, C.R.S., see Roffel, A.F. (250) 267
Emanuelli, G., Montrucchio, G., Dughera, L., Gaia, E., Lupia, E., Battaglia, E., De Martino, A., De Giuli, P., Gubetta, L. and Camussi, G.
Role of platelet activating factor in acute pancreatitis induced by lipopolysaccharides in rabbits (261) 265
Emerson, M., see Liu, J.T. (264) 183
Emonds-Alt, X., Doutremepuich, J.-D., Heaulme, M., Neliat, G., Santucci, V., Steinberg, R., Vilain, P., Bichon, D., Ducoux, J.-P., Proietto, V., Van Broeck, D., Soubrié, P., Le Fur, G. and Brelière, J.-C.
In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK_1 receptor antagonist (250) 403
Emonds-Alt, X., see Advenier, C. (250) 169
Emoto, H., see Yokoo, H. (256) 335
Emoto, M., see Murano, K. (254) 257
Encabo, A., see Ferrer, M. (252) 233
Encabo, A., see Ferrer, M. (258) 103
Endoh, M., see Kohi, M. (250) 95
Eng, J., see Schepp, W. (269) 183
Engel, G., see Kusterer, K. (259) 265
Engel, J.A., see Blomqvist, O. (249) 207
Enomori, T., see Miyake, A. (253) 155
Entzeroth, M., see Doods, H.N. (250) 223
Entzeroth, M., see Doods, H.N. (253) 275
Epand, R.M., see Nie, S.-Q. (266) 11
Erdő, S.L., see Urbányi, Z. (270) 375
Erkelens, D.W., see Kappelle, A.C. (250) 43
Erlinge, D., see Adner, M. (261) 281
Esclapez, F., see Devedjian, J.-C. (252) 43
Espinal, J., see Lacour, F. (255) 249
Espinosa-Luna, R., see Barajas-López, C. (250) 141
Esplugues, J., see Barrachina, D. (262) 181
Esplugues, J.V., see Barrachina, D. (262) 181
Esposito, B., see Bernard, C. (270) 115
Esquifino, A.I., Rosenstein, R.E., Stern, J.E. and Cardinali, D.P.
Cyclosporine effect on ornithine decarboxylase activity in rat submaxillary lymph nodes. Modulation by parasympathetic nerves (254) 1
Estep, K., see Krafte, D.S. (266) 245

Evangelista, S., see Goso, C. (249) 185
Evangelista, S., see Manzini, S. (249) 251
Evans, D.J., see Barnes, J.C. (250) 147
Evans, J.F., see Charleson, S. (267) 275
Evans, R.H., see Lepre, M. (258) 23
Eysselein, V.E., see Grandt, D. (269) 127
Ezrin, A.M., see Krafte, D.S. (266) 245

Fabbri, E., see Borea, P.A. (267) 55
Fabbri, L.M., see Chitano, P. (270) 167
Fadda, F., see Colombo, G. (265) 167
Fage, D., see Voltz, C. (255) 197
Fahey, J.M., see Pritchard, G.A. (266) 107
Fahim, M., El-Mas, M.M., Abdel-Rahman, A.A. and Mustafa, S.J.
Influence of aortic baroreceptor denervation on adenosine receptor-mediated relaxation of isolated rat aorta (254) 183
Fallgren, B., see Yoo, H. (268) 55
Fang, S., see Knapp, R.J. (269) 133
Fantozzi, R., see Dianzani, C. (263) 223
Farbiszewski, R., Chwiecko, M. and Ustymowicz, J.
The 21-aminosteroid U-74389G protects the antioxidant enzymes in the ischemia/reperfusion-induced rat brain damage (270) 263
Farges, R.C., see Paik, S.H. (253) 101
Farkas, B., see Kemény, L. (258) 269
Farmer, S.G., Broom, T. and DeSiato, M.A.
Effects of bradykinin receptor agonists, and captopril and thiorphan in ferret isolated trachea: evidence for bradykinin generation in vitro (259) 309
Farré, A.J., see Haj-Dahmane, S. (255) 185
Farrell, A.M., see Kudlacz, E.M. (270) 291
Farrell, C.B. and O'Boyle, K.M.
The kinetics of [^{3}H]SCH 23390 dissociation from rat striatal dopamine D_1 receptors: effect of dopamine (268) 79
Fassio, A., Bonanno, G., Cavazzani, P. and Raiteri, M.
Characterization of the GABA autoreceptor in human neocortex as a pharmacological subtype of the $GABA_B$ receptor (263) 311
Faure, C., Pimoule, C., Arbilla, S., Langer, S.Z. and Graham, D.
Expression of α_1-adrenoceptor subtypes in rat tissues: implications for α_1-adrenoceptor classification (268) 141
Favoni, R.E., Ravera, F., Pirani, P., Ardizzoni, A., Noonan, D. and De Cupis, A.
Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines (264) 199
Fayard, J.M., Tessier, C., Cohen, H., Lagarde, M., Pageaux, J.F. and Laugier, C.
Phospholipase A_2 inhibitors regulate the proliferation of normal uterine cells (251) 281
Fedan, J.S., Yuan, L.-X., Belt, J.J. and Frazer, D.G.
Polarized effects of amiloride and 4,4′-diisothiocyano-stilbene-2,2′-disulfonic acid on ATP-induced contraction of trachea (256) 51
Fedele, E., Versace, P. and Raiteri, M.
Evaluation of the mechanisms underlying the kainate-induced impairment of [^{3}H]dopamine release in the rat striatum (249) 71
Fedele, E., see Bonanno, G. (252) 61
Fedorov, D.J., see Danilov, A.F. (257) 1
Feige, B.D., see Koch, L.G. (254) 249
Feinstein, G., see Hellewell, S.B. (268) 9
Feldman, D.S. and Buccafusco, J.J.
Localization of cholinergic neurons involved in the cardiovascular response to intrathecal injection of carbachol (250) 483
Felsch, A., Stöcker, K. and Borchard, U.
Adenosine A_1 and A_2 receptor agonists alter cardiac functions and prostacyclin release in the isolated guinea-pig heart (263) 261
Feng, C.J., Cheng, D.Y., Kaye, A.D., Kadowitz, P.J. and Nossaman, B.D.
Influence of N^{ω}-nitro-L-arginine methyl ester, LY83583, glybenclamide and L158809 on pulmonary circulation (263) 133
Feng, D.-M., see Wang, Z.-Y. (260) 121
Feniuk, W. and Humphrey, P.P.A.
Somatostatin-induced inhibition of neurotransmission in the mouse isolated vas deferens is resistant to pertussis toxin (261) 333
Fenu, S., see Morelli, M. (251) 21
Ferencik, M., see Kacani, L. (270) 285
Feriotto, G., Ciucci, A., Mischiati, C., Animati, F., Lombardi, P., Giacomini, P., Arcamone, F. and Gambari, R.
Binding of Epstein-Barr virus nuclear antigen 1 to DNA: inhibition by distamycin and two novel distamycin analogues (267) 143
Fernández-Alzueta, A., see Campos-Toimil, M. (251) 83
Fernández-Guasti, A., see Cruz, S.L. (258) 39
Fernández-López, A. and Pazos, A.
Identification of α_2-adrenoceptors in rat lymph nodes and spleen: an autoradiographic study (252) 333
Fernández-López, A., Revilla, V., Candelas, M.A., Aller, M.I., Soria, C. and Pazos, A.
Identification of β-adrenoceptors in rat lymph nodes and spleen: an autoradiographic study (262) 283
Fernandez, P., Burghardt, R., Smith, R., Nodland, K. and Safe, S.
High passage T47D human breast cancer cells: altered endocrine and 2,3,7,8-tetrachlorodibenzo-*p*-dioxin responsiveness (270) 53
Fernández-Sánchez, M.T., see Novelli, A. (270) 361
Ferraguti, F., see Cavanni, P. (269) 9
Ferrándiz, M.L., Sanz, M.J., Bustos, G., Payá, M., Alcaraz, M.J. and De Rosa, S.
Avarol and avarone, two new anti-inflammatory agents of marine origin (253) 75
Ferrante, F., see Bazzani, C. (253) 303
Ferrari, F. and Giuliani, D.
Influence of idazoxan on the dopamine D_2 receptor agonist-induced behavioural effects in rats (250) 51
Ferraz, J.-G.P., Tigley, A. and Wallace, J.L.
Paradoxical effects of L-arginine on gastric mucosal integrity (260) 107
Ferré, S., Giménez-Llort, L., Artigas, F. and Martínez, E.
Motor activation in short- and long-term reserpinized mice: role of *N*-methyl-D-aspartate, dopamine D_1 and dopamine D_2 receptors (255) 203
Ferreira, S.H., see Tonussi, C.R. (251) 173
Ferrer, A. and Artigas, F.
Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain (263) 227
Ferrer, M., Encabo, A., Marín, J. and Balfagón, G.
Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta (252) 233
Ferrer, M., Encabo, A., Marín, J. and Balfagón, G.
Treatment with the anabolic steroid, nandrolone, reduces vasoconstrictor responses in rabbit arteries (258) 103
Ferrer, P., see Antonaccio, M.J. (256) 17
Ferri, S., see Melchiorre, C. (265) 93
Ferri, S., see Spampinato, S. (254) 229
Ferron, A., see El Mansari, M. (261) 171
Ferrone, R.A., see Lysko, G.S. (263) 25
Feth, F., see Grandt, D. (269) 127
Feuerstein, G.Z., see Yue, T.-L. (251) 237
Feuerstein, T.J., see Jackisch, R. (264) 207
Ffrench-Mullen, J.M.H., see Plata-Salamán, C.R. (266) 1
Fibiger, H.C., see Acquas, E. (260) 85
Fibiger, H.C., see Day, J.C. (263) 285
Filbert, M.G., see Adler, M. (270) 9
File, S.E., see Andrews, N. (264) 259
Filipeanu, C.M., see Brailoiu, E. (250) 489
Filipeanu, C.M., see Brailoiu, E. (250) 493

Filippelli, A., see Maione, S. (250) 209
Fillion, G., see Barone, P. (249) 221
Fillion, G., see Billecocq, A. (269) 209
Filloux, F.M., Fitts, R.C., Skeen, G.A. and White, H.S.
The dihydropyridine nitrendipine inhibits [^{3}H]MK 801 binding to mouse brain sections (269) 325
Fior, D.R., Yang, S.-N., Hedlund, P.B., Narváez, J.A., Agnati, L.F. and Fuxe, K.
Evidence for an antagonistic angiotensin II/α_2-adrenoceptor interaction in the nucleus tractus solitarii (262) 271
Fiore, C.E., see Clementi, G. (256) R7
Firestone, J.A., Marks, M.J., Gerhardt, G.A. and Browning, M.D.
ABT-200, a norepinephrine uptake inhibitor, blocks Ca^{2+} signals in chromaffin cells (269) 177
Fisch, A., see Darius, H. (258) 207
Fisher, A., see Gurwitz, D. (267) 21
Fitts, R.C., see Filloux, F.M. (269) 325
Fitzgerald, M., Anderson, K.E. and Woodcock, E.A.
Inositol 1,4,5-trisphosphate receptor function in neonatal cardiomyocytes (268) 275
Fitzgerald, M.F., see Gardiner, P.J. (258) 95
Fjalland, B., see Jørgensen, A. (259) 157
Fleckenstein, A.E., Lookingland, K.J. and Moore, K.E.
Effects of histamine on 5-hydroxytryptaminergic neuronal activity in the rat hypothalamus (254) 35
Fleckenstein, A.E., Lookingland, K.J. and Moore, K.E.
Histaminergic neurons mediate restraint stress-induced activation of central 5-hydroxytryptaminergic neurons in the rat (264) 163
Fleißner, S., see Schmidt, J. (260) 247
Fletcher, A., see Hartley, J.E. (252) 329
Fletcher, E.J., Church, J. and MacDonald, J.F.
Haloperidol blocks voltage-activated Ca^{2+} channels in hippocampal neurones (267) 249
Floch, A., see Bertrand, P. (262) 233
Flor, B., see Aldasoro, M. (250) 103
Florin, T.H.J., see Taylor, S.M. (270) 371
Foden, N.D., see Critchley, D.J.P. (254) 133
Foged, C., see Videbæk, C. (249) 43
Folco, G., see Letari, O. (266) 219
Folkers, K., see Wang, Z.-Y. (260) 121
Fontana, G., see Bonanno, G. (252) 61
Fornai, F., Dybdal, D.J., Proctor, M.R. and Gale, K.
Focal intracerebral elevation of L-lactate is anticonvulsant (254) R1
Foster, A.C., see Grimwood, S. (266) 43
Fournié-Zaluski, M.-C., see Abbadie, C. (258) 215
Fournié-Zaluski, M.-C., see Noble, F. (253) 283
Fournier, A., see Battistini, B. (252) 341
Fournier, B., see Chaouche-Teyara, K. (250) 67
Fowler, J.S., see Pan, D. (264) 177
Fozard, J.R. and Hannon, J.P.
BW-A522 blocks adenosine A_3 receptor-mediated hypotensive responses in the rat (252) R5
Fozard, J.R., see Carruthers, A.M. (250) 185
Fraeyman, N., Bazan, A. and Vanscheeuwijck, P.
Thermodynamic analysis of isoproterenol binding to β-adrenoceptors in rat lung membranes (267) 63
Francis, H.P., see Gardiner, P.J. (258) 95
Franklin, P.H., see Zhang, G. (255) 239
Fraser, C.M., see Gurwitz, D. (267) 21
Frazer, D.G., see Fedan, J.S. (256) 51
Freedman, J.E., see Liu, J.-C. (264) 269
Freedman, S.B., see Patel, S. (253) 237
Freedman, S.B., see Patel, S. (267) 329
Freedman, S.B., see Smith, A.J. (267) 215
French, R.J., see Light, P.E. (259) 219
Frew, R., see Lundy, P.M. (261) 79
Friberg, L., see Videbæk, C. (249) 43
Friberg, S.G., see Persson, M.G. (249) R7
Friderichs, E., see Selve, N. (256) 287
Friedman, D.J. and Duckles, S.P.
Influence of age on control of norepinephrine release: Ca^{2+} channels and dopamine D_2 receptors (252) 1
Frost, J.J., see Villemagne, V.L. (257) 195
Fu, W.-M., Chen, S.-P. and Wang, S.-M.
Pharmacological evidence for a lack of role for protein kinase C in staurosporine-induced morphological changes in embryonic *Xenopus* myocytes (270) 321
Fuentes, J.A., see Hernando, F. (261) 257
Fujibayashi, K., Sakamoto, K., Watanabe, M. and Iizuka, Y.
Pharmacological properties of R-84760, a novel κ-opioid receptor agonist (261) 133
Fujii, E., see Irie, K. (251) 75
Fujimoto, S.
Effects of pimobendan, its active metabolite UD-CG 212, and milrinone on isolated blood vessels (265) 159
Fujinami, T., see Saeki, T. (261) 249
Fujioka, H., see Shimomura, A. (252) 81
Fujita, A., see Maehara, T. (261) 163
Fujiwara, T. and Chiba, S.
Mechanisms of augmented vascular responses to histamine in atherosclerotic rabbit common carotid arteries (258) 195
Fukao, M., see Hattori, Y. (256) 215
Fukata, M., see Sudo, J.-i. (270) 229
Fukuda, H., see Shimizu, M. (268) 65
Fukuda, T., see Irifune, M. (264) 117
Fukui, H., Yamamoto, M., Sasaki, S. and Sato, S.
Emetic effects of anticancer drugs and involvement of visceral afferent fibers and 5-HT_3 receptors in dogs (250) 281
Fukui, H., Yamamoto, M., Sasaki, S. and Sato, S.
Involvement of 5-HT_3 receptors and vagal afferents in copper sulfate- and cisplatin-induced emesis in monkeys (249) 13
Fukui, H., Yamamoto, M., Sasaki, S. and Sato, S.
Possible involvement of peripheral 5-HT_4 receptors in copper sulfate-induced vomiting in dogs (257) 47
Fukumura, D., see Kurose, I. (250) 85
Fukuroda, T., see Okada, M. (259) 339
Fulcrand, P., see Lallement, J.-C. (267) 297
Fuller, R.W., see Baker, A.J. (264) 301
Funada, M., see Suzuki, T. (263) 207
Funder, J., see Jefferys, D. (253) 91
Furuhama, K., see Tabuchi, Y. (250) 197
Furuhama, K., see Tabuchi, Y. (255) 229
Furuichi, A., see Isono, T. (260) 163
Furuichi, Y., see Adachi, M. (269) 225
Furukawa, K., see Irie, K. (251) 75
Furukawa, K.-I., see Ohkura, M. (268) R1
Furukawa, T., see Soejima, O. (249) 1
Furukawa, Y., see Nitta, A. (250) 23
Furukawa, Y., see Sawaki, S. (250) 253
Fuxe, K., see Fior, D.R. (262) 271
Fuxe, K., see Morari, M. (256) 23
Fuxe, K., see Narváez, J.A. (257) 257
Fuxe, K., see Pérez de la Mora, M. (250) 423
Fyhrquist, F., see Helin, K. (264) 135

Gaginella, T.S., see Mascolo, N. (264) 21
Gaia, E., see Emanuelli, G. (261) 265
Gainetdinov, R.R., Grekhova, T.V., Sotnikova, T.D. and Rayevsky, K.S.
Dopamine D_2 and D_3 receptor preferring antagonists differentially affect striatal dopamine release and metabolism in conscious rats (261) 327
Gajdzik, L., see Thalhammer, T. (270) 213

Gale, K., see Fornai, F. (254) R1
Galindo, G., see Lacour, C. (264) 307
Galle, J., Bengen, J., Schollmeyer, P. and Wanner, C.
Oxidized lipoprotein(a) inhibits endothelium-dependent dilation: prevention by high density lipoprotein (265) 111
Galleyrand, J.-C., see Lallement, J.-C. (267) 297
Galli, A., Mori, F., Benini, L. and Cacciarelli, N.
Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020 (270) 189
Gambarana, C., see De Montis, M.G. (249) 179
Gambari, R., see Feriotto, G. (267) 143
Gan, Q., see Knuepfer, M.M. (259) 305
Gandía, L., see Montiel, C. (268) 293
Gando, S., see Hattori, Y. (256) 215
Gao, Y., see Lin, B. (260) 1
Garcha, R.S. and Hughes, A.D.
Action of heparin and ruthenium red on responses of reversibly permeabilised rat mesenteric arteries (268) 319
García, A.G., see Maroto, R. (270) 331
García, A.G., see Montiel, C. (268) 293
García, A.G., see Salas, E. (258) 47
Garcia-Barrado, M.-J., see Jonas, J.-C. (264) 81
García-Sancho, J., see Maroto, R. (270) 331
Gard, P.R., Mandy, A., Whiting, J.M., Nickels, D.P.D. and Meakin, A.J.L.S.
Reduction of responses to angiotensin II by antidepressant drugs (264) 295
Gardier, A.M., Trillat, A.-C., Malagié, I. and Jacquot, C.
8-OH-DPAT attenuates the dexfenfluramine-induced increase in extracellular serotonin: an in vivo dialysis study (265) 107
Gardiner, P.J., Cuthbert, N.J., Francis, H.P., Fitzgerald, M.F., Thompson, A.M., Carpenter, T.G., Patel, U.P., Newton, B.B., Mohrs, K., Müller-Peddinghaus, R. and Taylor, W.A.
Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005 (258) 95
Gardiner, P.J., see Tudhope, S.R. (264) 317
Gardner, C., see Bountra, C. (249) R3
Gardner, C.J., Twissell, D.J., Coates, J. and Strong, P.
The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat (257) 117
Garratt, H., see White, D.G. (257) 307
Garret, C., see Lavielle, S. (258) 273
Garret, C., see Montier, F. (251) 9
Garrett, B.E. and Holtzman, S.G.
Caffeine cross-tolerance to selective dopamine D_1 and D_2 receptor agonists but not to their synergistic interaction (262) 65
Garrison, E.A., see Santiago, J.A. (254) 207
Garry, M.G., Abraham, E., Hargreaves, K.M. and Aanonsen, L.M.
Intrathecal injection of cell-permeable analogs of cyclic 3′,5′-guanosine monophosphate produces hyperalgesia in mice (260) 129
Garzón, J., see Sánchez-Blázquez, P. (258) 159
Gasco, A., see Civelli, M. (255) 17
Gascón, S., see Sallés, J. (266) 35
Gąsior, M., see Czuczwar, S.J. (264) 103
Gaspary, H.L., Simon, R.P. and Graham, S.H.
BW1003C87 and NBQX but not CGS19755 reduce glutamate release and cerebral ischemic necrosis (262) 197
Gatley, S.J., see Pan, D. (264) 177
Gaughan, G.T., see Parker, E.M. (268) 43
Gavin, K., see Browne, I. (265) 125
Gavish, M., see Shany, E. (253) 231
Gavish, M., see Weizman, R. (250) 289
Gee, K.W., see Hawkinson, J.E. (269) 157
Geisel, J., see Sebök, B. (270) 79
Geisslinger, G., see Schmidt, N. (255) 245
Geller, E., see Shany, E. (253) 231
Genedani, S., Bernardi, M. and Bertolini, A.
Influence of ifenprodil on the ACTH-induced behavioral syndrome in rats (252) 77
Genieser, H.-G., see Butt, E. (269) 265
George, S.R., see Ng, G.YK. (267) 7
George, S.R., see Ng, G.YK. (269) 349
George, S.R., see Ng, G.YK. (269) 365
Geppetti, P., see Ricciardolo, F.L.M. (261) 127
Gerhardt, G.A., see Firestone, J.A. (269) 177
Gericke, M., Oike, M., Droogmans, G. and Nilius, B.
Inhibition of capacitative Ca^{2+} entry by a Cl^- channel blocker in human endothelial cells (269) 381
Gertner, S.B., see McLeod, R.L. (259) 211
Gerzon, K., see Bowling, N. (268) 365
Gessa, G.L., see Colombo, G. (265) 167
Gessa, G.L., see D'Aquila, P.S. (262) 107
Gessa, G.L., see Devoto, P. (252) 321
Gessa, G.L., see Imperato, A. (251) 271
Gessa, G.L., see Imperato, A. (261) 205
Gessa, G.L., see Imperato, A. (264) 55
Gessa, G.L., see Mereu, G. (264) 449
Gessa, G.L., see Portas, C.M. (270) 123
Gettinby, G., see McKellar, Q.A. (253) 191
Geurtsen, A.M.S., see Coppes, R.P. (261) 311
Ghiani, C.A., Serra, M., Motzo, C., Giusti, P., Cuccheddu, T., Porceddu, M.L. and Biggio, G.
Chronic administration of an anticonvulsant dose of imidazenil fails to induce tolerance of $GABA_A$ receptor function in mice (254) 299
Ghiani, C.A., see Serra, M. (259) 1
Ghiani, C.A., see Serra, M. (265) 185
Ghiggeri, G.M., Altieri, P., Oleggini, R., Spada, F., Ginevri, F., Perfumo, F. and Gusmano, R.
Selective enhancement by cyclosporin A of collagen expression by mesangial cells 'in culture' (270) 195
Ghigo, E., see Mazza, E. (254) 17
Giacomini, P., see Feriotto, G. (267) 143
Giagnoni, G., see Massi, P. (253) 269
Gianoulakis, C., see De Waele, J.-P. (258) 119
Gião-T. Rico, J.M., see De Castro, M. (261) 199
Gibb, J.W., see Elkins, K.W. (250) 395
Gibb, J.W., see Gygi, S.P. (250) 177
Gibb, J.W., see Midgley, L.P. (251) 191
Gibbs, L.M., see Kendig, J.J. (264) 427
Gibson, E.L., see Oluyomi, A.O. (264) 111
Gies, J.-P., see Lach, E. (265) 117
Gies, J.-P., see Lach, E. (269) 87
Gil-Longo, J., see Campos-Toimil, M. (251) 83
Gilchrist, D., Darlington, C. and Smith, P.
Org 2766 prevents disruption of vestibular compensation by an NMDA receptor antagonist (252) R1
Gillis, R.A., see Chen, K. (252) 155
Gillis, R.A., see McManigle, J.E. (252) 11
Gillis, R.A., see Travagli, R.A. (264) 385
Gillman, T.A., see Pennefather, J.N. (262) 297
Giménez-Llort, L., see Ferré, S. (255) 203
Ginevri, F., see Ghiggeri, G.M. (270) 195
Giossi, M., see Civelli, M. (255) 17
Giraldelo, C.M.M., Zappellini, A., Muscará, M.N., De Luca, I.M.S., Hyslop, S., Cirino, G., Zatz, R., De Nucci, G. and Antunes, E.
Effect of arginine analogues on rat hind paw oedema and mast cell activation in vitro (257) 87
Giraldo, J., see Sallés, J. (258) 229
Girard, V., see Advenier, C. (250) 169
Giraud, P., see Damase-Michel, C. (258) 277
Gispen, W.H., see Adan, R.A.H. (269) 331
Gispen, W.H., see Kappelle, A.C. (250) 43

Giudicelli, J.-F., see Dumas, J.-P. (263) 17
Giuliani, D., see Ferrari, F. (250) 51
Giuliani, S., see Lecci, A. (259) 129
Giusti, P., see Ghiani, C.A. (254) 299
Gluchowski, C., see Borden, L.A. (269) 219
Gmiro, V.E., see Danilov, A.F. (257) 1
Gobaille, S., see Maitre, M. (256) 211
Gobert, A., see Lejeune, F. (260) 79
Gobert, A., see Millan, M.J. (260) R3
Gobert, A., see Rivet, J.-M. (265) 175
Godfraind, T., see Morel, N. (252) R3
Godin, D., Marceau, F., Beaulé, C., Rioux, F. and Drapeau, G.
Aminopeptidase modulation of the pharmacological responses to synthetic thrombin receptor agonists (253) 225
Godlewski, G., see Malinowska, B. (259) 315
Goebell, H., see Grandt, D. (269) 127
Goettl, V.M., Xu, X.-J., Larson, A.A. and Wiesenfeld-Hallin, Z.
Substance P N-terminus inhibits C-fiber-dependent facilitation of the rat flexor reflex (259) 83
Goicoechea, C., see Colado, M.I. (252) 291
Gold, L.H., Stinus, L., Inturrisi, C.E. and Koob, G.F.
Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellet implantation in the rat (253) 45
Gold, P.E., see Ragozzino, M.E. (256) 31
Goldberg, S.R., see Yasar, S. (259) 243
Goldman, S., see Pauwels, T. (257) 53
Goldstein, M., see Meller, E. (249) R5
Gomi, Y., see Suzuki, N. (251) 221
Gonogami, Y., see Konno, S.-i. (259) 15
González-Barón, S., see Narváez, J.A. (257) 257
Gonzalez, L.E., see Andrews, N. (264) 259
Gonzalez, P., see Del Rio, M. (250) 133
Gopalakrishnan, S.M., Chen, C. and Lokhandwala, M.F.
Identification of α_1-adrenoceptor subtypes in rat renal proximal tubules (250) 469
Gordon, T.L., see Schechter, M.D. (249) 79
Gores, R.-J.J., see Santing, R.E. (257) 145
Gori, E., see Massi, P. (253) 269
Goso, C., Evangelista, S., Tramontana, M., Manzini, S., Blumberg, P.M. and Szallasi, A.
Topical capsaicin administration protects against trinitrobenzene sulfonic acid-induced colitis in the rat (249) 185
Goso, C., Potier, E., Manzini, S. and Szallasi, A.
Comparison of tachykinin NK_1 receptors in human IM9 and U373 MG cells, using antagonist (FK888, (±)-CP-96,345, and RP 67580) binding (254) 221
Goto, K., see Koyama, K. (270) 151
Goto, N., see Matsumoto, Y. (262) 157
Göttinger, W., see Kähler, C.M. (262) 261
Götz, M.E., Dirr, A., Burger, R., Janetzky, B., Weinmüller, M., Chan, W.W., Chen, S.C., Reichmann, H., Rausch, W.-D. and Riederer, P.
Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate (266) 291
Götze, K. and Jakobs, K.H.
Unoccupied β-adrenoceptor-induced adenylyl cyclase stimulation in turkey erythrocyte membranes (268) 151
Govoni, P., see Spampinato, S. (254) 229
Govoni, S., see Pascale, A. (265) 1
Gozlan, H., Chinestra, P., Diabira, D. and Ben-Ari, Y.
NMDA redox site modulates long-term potentiation of NMDA but not of AMPA receptors (262) R3
Gozlan, H., see Haj-Dahmane, S. (255) 185
Graf, J., see Thalhammer, T. (270) 213
Graham, D., see Faure, C. (268) 141
Graham, S.H., see Gaspary, H.L. (262) 197
Grahame-Smith, D.G., see Pei, Q. (249) 243
Grandordy, B., see Mak, J.C.W. (269) 35
Grandt, D., Feth, F., Rascher, W., Reeve Jr., J.R., Schlicker, E., Schimiczek, M., Layer, P., Goebell, H., Eysselein, V.E. and Michel, M.C.
[Pro^{34}]peptide YY is a Y_1-selective agonist at peptide YY/neuropeptide Y receptors (269) 127
Graneß, A. and Liebmann, C.
Affinity cross-linking of bradykinin B_2 receptors in guinea pig ileum membranes (268) 271
Granger, P., see Biton, B. (257) 297
Gray, J., see Denyer, J. (268) 29
Grbović, L., see Jovanović, A. (256) 103
Grbović, L., see Jovanović, A. (256) 131
Grbović, L., see Jovanović, A. (258) 185
Green, P.G., Luo, J., Heller, P.H. and Levine, J.D.
Effect of E-type prostaglandins on bradykinin-induced plasma extravasation in the knee joint of the rat (252) 127
Greenlees, C., see Medhurst, A.D. (256) R5
Greenshaw, A.J., see Allison, K. (249) 125
Gregersen, S., Langel, Ü., Bartfai, T. and Ahrén, B.
Galanin message-associated polypeptide (GMAP) does not affect insulin secretion from isolated islets (259) 79
Greif, G.J., see Liu, J.-C. (264) 269
Grekhova, T.V., see Gainetdinov, R.R. (261) 327
Greney, H., Bennai, F., Molines, A., Belcourt, A., Dontenwill, M. and Bousquet, P.
Isolation of a human cerebral imidazoline-specific binding protein (265) R1
Greney, H., see Bricca, G. (266) 25
Grider, J.S., see Kidwell, D.T. (270) 97
Griffin, G., see Pertwee, R. (259) 115
Griffin, T.B., see Komoriya, K. (250) 455
Griffith, K.E., see Tschanz, J.A.T. (257) 161
Griffon, N., see Pilon, C. (268) 129
Grimson, P., see Suman-Chauhan, N. (269) 65
Grimwood, S., Struthers, L. and Foster, A.C.
Polyamines modulate [^{3}H]L-689,560 binding to the glycine site of the NMDA receptor from rat brain (266) 43
Grino, M., see Delbende, C. (251) 245
Grisar, J.M., see Petty, M.A. (255) 215
Griscti, K., see Vemulapalli, S. (257) 95
Grisel, D.A., see Parker, E.M. (268) 43
Grisham, M., see Wallace, J.L. (257) 249
Grooms, S.Y., see Jones, L.S. (264) 39
Gross, R., see Berdeu, D. (254) 119
Gross, S.S., see Szabó, C. (250) 157
Grover, G.J., see Sargent, C.A. (261) 25
Gruber, C., see Klemm, P. (250) R9
Gruener, R., see Reitstetter, R. (264) 27
Gruetter, C.A., Lemke, S.M., Valentovic, M.A. and Szarek, J.L.
Evidence that histamine is involved as a mediator of endothelium-dependent contraction induced by A23187 in bovine intrapulmonary vein (257) 275
Grundemar, L., Krstenansky, J.L. and Håkanson, R.
Neuropeptide Y and truncated neuropeptide Y analogs evoke histamine release from rat peritoneal mast cells. A direct effect on G proteins? (258) 163
Grupp, L.A., see Saab, G. (256) 1
Gu, J.-L., see Yue, T.-L. (251) 237
Guard, S., see Suman-Chauhan, N. (269) 65
Guarini, S., see Bazzani, C. (253) 303
Guarneri, L., see Testa, R. (249) 307
Gubetta, L., see Emanuelli, G. (261) 265
Gudelsky, G.A., Yamamoto, B.K. and Nash, J.F.

Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT_2 receptor agonists (264) 325
Guh, J.-H., see Teng, C.-M. (265) 61
Guilbaud, G., see Lee, S.H. (264) 61
Guillaume, V., see Cataldi, M. (253) 149
Guillemette, G., see Chrétien, L. (256) 73
Guillén, J., see Luquin, M.R. (253) 215
Guiot, Y., Henquin, J.-C. and Rahier, J.
Effects of glibenclamide on pancreatic β-cell proliferation in vivo (261) 157
Gully, D., see Azzi, M. (255) 167
Gully, D., see Brouard, A. (253) 289
Guo, S.X., see Bondy, S.C. (270) 349
Gupta, A.N., see Woods, A.J. (264) 125
Gupta, M.B., see Nath, C. (263) 203
Gurwitz, D., Haring, R., Heldman, E., Fraser, C.M., Manor, D. and Fisher, A.
Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands (267) 21
Gusmano, R., see Ghiggeri, G.M. (270) 195
Gustafsson, B.I. and Delbro, D.S.
Neurogenic inhibition of duodenal and jejunal motility in the anaesthetized rat (257) 227
Gustafsson, L.E., see Persson, M.G. (249) R7
Gustafsson, L.E., see Persson, M.G. (264) 13
Gustafsson, L.E., see Persson, M.G. (270) 273
Gustavsson, L., see Larsson, C. (268) 19
Guyon, C., see Bertrand, P. (262) 233
Guzman, N.J., see Davda, R.K. (266) 237
Gygi, S.P., Gibb, J.W., Johnson, M. and Hanson, G.R.
Blockade of tachykinin NK_1 receptors by CP-96345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats (250) 177
Gyires, K.
The role of endogenous nitric oxide in the gastroprotective action of morphine (255) 33

Haaseth, R.C., see Vanderah, T. (252) 133
Habeeb, P.G., see Dundore, R.L. (249) 293
Haberny, K.A. and Young, G.A.
Interactive effects of MK-801 and morphine on EEG, EEG power spectra and behavior in rats: I. Morphine tolerance development (261) 1
Haberny, K.A. and Young, G.A.
Interactive effects of MK-801 and morphine on EEG, EEG power spectra and behavior in rats: II. Morphine dependence (261) 11
Hagan, R.M., see Stratton, S.C. (250) R11
Haj-Dahmane, S., Jolas, T., Laporte, A.-M., Gozlan, H., Farré, A.J., Hamon, M. and Lanfumey, L.
Interactions of lesopitron (E-4424) with central 5-HT_{1A} receptors: in vitro and in vivo studies in the rat (255) 185
Haj-Dahmane, S., see Lanfumey, L. (249) 25
Håkanson, R., see Grundemar, L. (258) 163
Håkanson, R., see Wang, Z.-Y. (260) 121
Håkansson, H., Johansson, L., Manzoor, E. and Ahlborg, U.G.
Effect of 2,3,7,8-tetrachlorodibenzoy-*p*-dioxin on the hepatic 7-ethoxyresorufin *O*-deethylase activity in four rodent species (270) 279
Hale, C.C., see Shannon, T.R. (267) 233
Halpern, P., see Shany, E. (253) 231
Hamada, E., see Hazama, H. (259) 143
Hamaguchi, A., see Ohta, K. (269) 115
Hamberg, M., see Brodowsky, I.D. (254) 43
Hamel, C., see Contesse, V. (265) 27
Hamilton, C.A., see Thorin-Trescases, N. (268) 199
Hamilton, T.C., see Clapham, J.C. (257) 79
Hamon, M., see Alhaider, A.A. (249) 151
Hamon, M., see Haj-Dahmane, S. (255) 185
Hamon, M., see Lanfumey, L. (249) 25
Hampson, D.L., see Taverna, F.A. (267) R3
Hampson, D.R., see Taverna, F.A. (266) 181
Han, C., see Xia, Y. (255) 67
Han, S.-z., see Ishikawa, M. (269) 311
Hancock, A.A., Surber, B.W., Rotert, G., Thomas, S., Tasker, A.S., Sorensen, B.K., Vodenlich, A.D., Opgenorth, T.J., Kerkman, D.J. and DeBernardis, J.F.
[^{3}H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT_1 receptors (267) 49
Hannigan, J.H., see Abel, E.L. (258) 261
Hannon, J.P., see Fozard, J.R. (252) R5
Hanoune, J., see Matsuoka, I. (268) 215
Hansen, A., see Pedersen, U.B. (267) 85
Hansen, P.R.
In vitro studies on responses to pentoxifylline and aminophylline of rat mesenteric resistance vessels (261) 105
Hanson, G.R., see Elkins, K.W. (250) 395
Hanson, G.R., see Gygi, S.P. (250) 177
Hanson, G.R., see Midgley, L.P. (251) 191
Hanson, P.J., see Price, K.J. (263) 199
Hansson, L., see Waters, N. (251) 181
Hanuš, L., see Pertwee, R. (259) 115
Haque, M., see Olmos, G. (262) 41
Hara, H., see Harada, Y. (256) 321
Hara, H., see Harada, Y. (261) 91
Hara, K., see Akiyama, Y. (263) 181
Haracz, J.L., see Tschanz, J.A.T. (257) 161
Harada, Y., Hara, H. and Sukamoto, T.
Binding properties of KB-5492, a novel anti-ulcer agent, at σ receptors in porcine gastric fundic mucosa (261) 91
Harada, Y., Hara, H. and Sukamoto, T.
Receptor binding profiles of KB-5492, a novel anti-ulcer agent, at σ receptors in guinea-pig brain (256) 321
Harding, S., see Saab, G. (256) 1
Hargreaves, K.M., see Garry, M.G. (260) 129
Hargreaves, R.J., see Tattersall, F.D. (250) R5
Haring, R., see Gurwitz, D. (267) 21
Hariton, C.
Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors (258) 85
Harris, B.A., see McClue, S.J. (267) 185
Harris, B.D., Moody, E.J., Basile, A.S. and Skolnick, P.
Volatile anesthetics bidirectionally and stereospecifically modulate ligand binding to GABA receptors (267) 269
Harris, P.D., see Koch, L.G. (254) 249
Harris, R.A., see Klein, R.L. (268) 237
Harris, R.A., see Mihic, S.J. (268) 209
Harrison, P.J., see Connolly, G.P. (259) 95
Hart, S.D., see Wong, P.C. (262) 185
Hart, S.L., see Oluyomi, A.O. (258) 131
Hartley, J.E. and Fletcher, A.
The effects of WAY-100135 and 8-hydroxy-2-(di-*n*-propylamino)tetralin on feeding in the rat (252) 329
Harvey, F.J., see Stratton, S.C. (250) R11
Hasan, K., Heesen, B.-J., Corbett, J.A., McDaniel, M.L., Chang, K., Allison, W., Wolffenbuttel, B.H.R., Williamson, J.R. and Tilton, R.G.
Inhibition of nitric oxide formation by guanidines (249) 101
Hasegawa, M., see Komoriya, K. (250) 455
Hasegawa, T., see Nabeshima, T. (255) 57
Hasegawa, T., see Nitta, A. (250) 23

Hasharoni, A., see Shany, E. (253) 231
Hashimoto, K., Mantione, C.R., Spada, M.R., Neumeyer, J.L. and London, E.D.
Further characterization of [^{3}H]ifenprodil binding in rat brain (266) 67
Hashimoto, K., see Hirasawa, A. (267) 71
Hashimoto, T., see Takeuchi, K. (254) 287
Hashimoto, Y., Ozaki, J., Yasuhara, M., Hori, R., Suga, S.-i., Itoh, H., Nakao, K. and Inui, K.-i.
Functional evidence for an apical ANP receptor in LLC-PK$_1$ kidney epithelial cells (268) 443
Haslam, R.J., see Jang, E.K. (250) 477
Haslam, R.J., see Tang, K.M. (268) 105
Hasna, J., see Chen, X. (267) 175
Hata, F., see Kanada, A. (250) 59
Hata, F., see Maehara, T. (261) 163
Hatake, K., see Wakabayashi, I. (255) 111
Hattori, H., see Hayakawa, T. (257) 131
Hattori, R., Inoue, R., Sase, K., Eizawa, H., Kosuga, K., Aoyama, T., Masayasu, H., Kawai, C., Sasayama, S. and Yui, Y.
Preferential inhibition of inducible nitric oxide synthase by ebselen (267) R1
Hattori, Y., Kawasaki, H., Kanno, M., Gando, S. and Fukao, M.
Attenuated contractile response of diabetic rat aorta to caffeine but not to noradrenaline in Ca^{2+}-free medium (256) 215
Hauber, W. and Waldenmeier, M.T.
The AMPA receptor antagonist GYKI 52466 reverses the anticataleptic effects of the competitive NMDA receptor antagonist CGP 37849 (256) 339
Hawkinson, J.E., Kimbrough, C.L., McCauley, L.D., Bolger, M.B., Lan, N.C. and Gee, K.W.
The neuroactive steroid 3α-hydroxy-5β-pregnan-20-one is a two-component modulator of ligand binding to the GABA$_A$ receptor (269) 157
Hayakawa, H., see Koumi, S.-i. (258) 281
Hayakawa, H., see Koumi, S.-i. (261) 213
Hayakawa, T., Higuchi, Y., Nigami, H. and Hattori, H.
Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect (257) 131
Hayase, N., Chiba, K., Abiko, Y. and Ichihara, K.
Effects of tilisolol on ischemic myocardial metabolism in dogs (260) 183
Hayashi, A., see Oyama, Y. (270) 137
Hayashi, Jr., T., see Matsuda, Y. (250) 341
Hayashi, K., see Nitta, A. (250) 23
Hayashi, T., see Sudo, J.-i. (270) 229
Haynes, J.M., Adams, G.D. and Pennefather, J.N.
α_2-Adrenoceptors in the guinea-pig uterus: heterogeneity in the circular and longitudinal smooth muscle layers (250) 231
Hazama, H., Nakajima, T., Hisada, T., Hamada, E., Omata, M. and Kurachi, Y.
Effects of azelastine on membrane currents in tracheal smooth muscle cells isolated from the guinea-pig (259) 143
He, D.S., see Reitstetter, R. (264) 27
Heal, D.J., Butler, S.A., Prow, M.R. and Buckett, W.R.
Quantification of presynaptic α_2-adrenoceptors in rat brain after short-term DSP-4 lesioning (249) 37
Heald, A., Stanton, J.A., Osborne, S.-A., Middlemiss, D.N. and Beer, M.S.
[^{3}H]L-694,247 labels the 5-HT$_{1D\beta}$ receptor in pig caudate membranes (264) 213
Heald, A., see Patel, S. (253) 237
Heaton, J., see Lin, B. (260) 1
Heaulme, M., see Azzi, M. (255) 167
Heaulme, M., see Brouard, A. (253) 289
Heaulme, M., see Emonds-Alt, X. (250) 403
Hechler, V., see Maitre, M. (256) 211
Hedlund, P.B., see Billecocq, A. (269) 209
Hedlund, P.B., see Fior, D.R. (262) 271
Hedlund, P.B., see Narváez, J.A. (257) 257
Hedqvist, P., see Persson, M.G. (249) R7
Heesen, B.-J., see Hasan, K. (249) 101
Heffner, T.G., see Damsma, G. (249) R9
Hegde, S.S., Chan, P. and Eglen, R.M.
Cardiovascular effects of *R*-α-methylhistamine, a selective histamine H$_3$ receptor agonist, in rats: lack of involvement of histamine H$_3$ receptors (251) 43
Heidari, M.-R., see Zarrindast, M.-R. (257) 13
Heimann-Weitschat, I., see Schmidt, J. (260) 247
Heldman, E., see Gurwitz, D. (267) 21
Helin, K., Tikkanen, I., Hohenthal, U. and Fyhrquist, F.
Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes (264) 135
Heller, B., see Izenwasser, S. (263) 277
Heller, P.H., see Green, P.G. (252) 127
Hellewell, S.B., Bruce, A., Feinstein, G., Orringer, J., Williams, W. and Bowen, W.D.
Rat liver and kidney contain high densities of σ_1 and σ_2 receptors: characterization by ligand binding and photoaffinity labeling (268) 9
Hellman, B., see Saha, S. (258) 145
Helmeste, D.M. and Tang, S.W.
Kinase inhibitors compete with imipramine for binding and inhibition of serotonin transport (267) 239
Helmeste, D.M., Chudzik, J. and Tang, S.W.
Interaction of lectins with human platelet serotonin transporter (266) 327
Henning, R., see Klemm, P. (250) R9
Henning, R., see Martorana, P.A. (257) 267
Henquin, J.-C., see Becker, D.J. (260) 169
Henquin, J.-C., see Guiot, Y. (261) 157
Henquin, J.-C., see Jonas, J.-C. (254) 27
Henquin, J.-C., see Jonas, J.-C. (264) 81
Henzel, D., see Mantz, J. (257) R7
Herbert, J.-M., Delisée, C., Dol, F., Schaeffer, P., Cazaubon, C., Nisato, D. and Chatelain, P.
Effect of SR 47436, a novel angiotensin II AT$_1$ receptor antagonist, on human vascular smooth muscle cells in vitro (251) 143
Herbert, M.K. and Holzer, P.
Nitric oxide mediates the amplification by interleukin-1β of neurogenic vasodilatation in the rat skin (260) 89
Herman, A.G., see Boeckxstaens, G.E. (264) 85
Herman, A.G., see Verbeuren, T.J. (270) 27
Hernandez, A., Daffonchio, L., Vigano', T., Letari, O. and Malandrino, S.
Effect of 3'-hydroxyfarrerol on airway hyperreactivity induced by acute cigarette smoke exposure in guinea pigs (270) 301
Hernandez-Gómez, A.-M., see Pérez de la Mora, M. (250) 423
Hernandez, Y.M., see Chen, K. (252) 155
Hernando, F., Fuentes, J.A., Roques, B.P. and Ruiz-Gayo, M.
The CCK$_B$ receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice (261) 257
Heron, A.E., see Taylor, S.M. (270) 371
Héron, C., Costentin, J. and Bonnet, J.-J.
Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier (264) 391
Herting, R.L., see Quartermain, D. (257) 7
Hertting, G., see Allgaier, C. (252) R7
Hertting, G., see Jackisch, R. (264) 207
Héry, F., see Cataldi, M. (253) 149
Herzer, T., Busch, A.E., Waldegger, S. and Lang, F.
Inhibition of human I$_{sK}$ channels expressed in *Xenopus* oocytes by calmodulin antagonists (259) 335
Herzer, T., see Busch, A.E. (264) 33

Herzog, H., see Potter, E.K. (267) 253
Hess, J.F., see Schneck, K.A. (266) 277
Heuillet, E., Bouaiche, Z., Ménager, J., Dugay, P., Munoz, N., Dubois, H., Amiranoff, B., Crespo, A., Lavayre, J., Blanchard, J.-C. and Doble, A.
The human galanin receptor: ligand-binding and functional characteristics in the Bowes melanoma cell line (269) 139
Hexum, T.D., see Zhu, J. (268) 279
Hey, J.A., see Danko, G. (254) 283
Hey, J.A., see McLeod, R.L. (259) 211
Heyser, C.J., see Molina, V.A. (260) 57
Hicks, K.K., see Kennedy, R.H. (255) 149
Hicks, P.E., see Bellemin-Baurreau, J. (256) 115
Hidaka, K., see Miyata, K. (250) 303
Hidaka, K., see Wanibuchi, F. (265) 151
Hidaka, T., see Ishizuka, T. (262) 113
Hietala, J., see Kuoppamäki, M. (255) 91
Hietala, J., see Kuoppamäki, M. (269) 201
Higashida, H., see Tohda, M. (268) 169
Higuchi, Y., see Hayakawa, T. (257) 131
Hilaire, G., see Monteau, R. (259) 71
Hill, D.R., see Pinnock, R.D. (269) 73
Hill, R.G., see Longmore, J. (265) 53
Hill, R.G., see Tattersall, F.D. (250) R5
Hill, S.J., see Dickenson, J.M. (268) 257
Hillebrand, M.T.J., see Boon, J.P. (270) 237
Hillefors-Berglund, M. and Von Euler, G.
Pharmacology of dopamine D_3 receptors in the islands of Calleja of the rat using quantitative receptor autoradiography (261) 179
Hirabayashi, A., Nishiwaki, K., Taki, K., Shimada, Y. and Ishikawa, N.
Effects of neuropeptide Y on lung vascular permeability in the pulmonary circulation of rats (256) 227
Hirai, H. and Okada, Y.
Adenosine facilitates glutamate release in a protein kinase-dependent manner in superior colliculus slices (256) 65
Hirakawa, Y., Kuga, T., Kanaide, H. and Takeshita, A.
Actions of a new Ca^{2+} channel antagonist, CD832, on two types of Ca^{2+} channels in smooth muscle (252) 267
Hiramatsu, M., see Pechnick, R.N. (252) 35
Hirano, K. and Kanaide, H.
Cytosolic Ca^{2+} transients in endothelium-dependent relaxation of pig coronary artery, and effects of captopril (250) 439
Hirano, Y., see Uchida, W. (264) 285
Hirasawa, A., Hashimoto, K. and Tsujimoto, G.
Distribution and developmental change of vasopressin V_{1A} and V_2 receptor mRNA in rats (267) 71
Hirasawa, A., see Horie, K. (268) 399
Hirasawa, Y., see Kita, Y. (257) 123
Hirokami, M., Togashi, H., Matsumoto, M., Yoshioka, M. and Saito, H.
The functional role of opioid receptors in acetylcholine release in the rat adrenal medulla (253) 9
Hirouchi, M., see Ichida, T. (267) 43
Hisada, T., see Hazama, H. (259) 143
Hjorth, S. and Auerbach, S.B.
Further evidence for the importance of 5-HT_{1A} autoreceptors in the action of selective serotonin reuptake inhibitors (260) 251
Ho, C.-L., Hwang, L.-L., Lin, Y.-L., Chen, C.-T., Yu, H.-M. and Wang, K.-T.
Cardiovascular effects of mastoparan B and its structural requirements (259) 259
Ho, D.D., see Ng, P.C. (264) 1
Ho, I.K., see Jaw, S.P. (257) 153
Hoang, D., see Knuepfer, M.M. (259) 305
Hochhauser, E., see Shany, E. (253) 231
Hodé, Y., see Maitre, M. (256) 211
Hoffer, P.B., see Laruelle, M. (263) 39
Hogenboom, F., see Tjon, G.H.K. (252) 205
Hogg, J.E., see Longmore, J. (265) 53
Hogg, S., see Andrews, N. (264) 259
Hohenthal, U., see Helin, K. (264) 135
Hohmann, A.G., see Leitner, M.L. (259) 65
Hökfelt, T., see Castel, M.-N. (262) 1
Hökfelt, T., see Szallasi, A. (264) 217
Hollenberg, M.D., see Shimomura, A. (252) 81
Holm, S., see Videbæk, C. (249) 43
Holman, R.B., see Thomas, D.N. (261) 53
Holst, J.J., see Schepp, W. (269) 183
Holtman, Jr., J.R. and King, K.A.
Effect of activation of 5-HT_{1A} receptors at the ventral medulla on phrenic nerve activity (253) 307
Holtzman, S.G., see Garrett, B.E. (262) 65
Holtzman, S.G., see Jones, D.N.C. (249) 167
Holzer, H., see Raybould, H.E. (250) 165
Holzer, P., see Doods, H.N. (253) 275
Holzer, P., see Herbert, M.K. (260) 89
Holzer, P., see Peskar, B.M. (250) 201
Hönack, D., see Löscher, W. (259) R3
Honda, K., see Saita, Y. (269) 249
Hong, S.J. and Chang, C.C.
Facilitation of nicotinic receptor desensitization at mouse motor endplate by a receptor-operated Ca^{2+} channel blocker, SK&F 96365 (265) 35
Honkakoski, P., see Pellinen, P. (270) 35
Honkanen, A., see Wegelius, K. (263) 141
Honma, Y., see Saita, Y. (269) 249
Honoré, P., see Abbadie, C. (258) 215
Hopfer, U., see Jarry, A. (267) 95
Horackova, M., see Murphy, M.G. (268) 121
Hori, M., see Karaki, H. (262) 255
Hori, M., see Takizawa, S. (250) 431
Hori, R., see Hashimoto, Y. (268) 443
Horie, K., Hirasawa, A. and Tsujimoto, G.
The pharmacological profile of cloned and stably expressed α_{1B}-adrenoceptor in CHO cells (268) 399
Horiuchi, A., see Iwatsuki, K. (249) 19
Horiuchi, H., see Komoriya, K. (250) 455
Horowitz, J.D., see Zhang, C.L. (252) 299
Horváth, G., Kovács, M., Szikszay, M. and Benedek, G.
Mydriatic and antinociceptive effects of intrathecal dexmedetomidine in conscious rats (253) 61
Hoskins, B., see Jaw, S.P. (257) 153
Hosokawa, M., see Kanada, A. (250) 59
Hosoki, E. and Iijima, T.
Chloride-sensitive Ca^{2+} entry by histamine and ATP in human aortic endothelial cells (266) 213
Hosoki, K., see Yamamoto, T. (250) 189
Hotta, K., see Ichikawa, T. (251) 107
Houbara, T., see Ogino, K. (270) 73
Howell, R.E., Kovalsky, M.P. and Laemont, K.D.
Methoctramine induces nonspecific airway hyperresponsiveness in vivo (265) 67
Hoyer, D., see Rocha, B. (262) 125
Hruby, V.J., see Knapp, R.J. (269) 133
Hruby, V.J., see Vanderah, T. (252) 133
Hsieh, L.-M., see Huang, H.-C. (251) 91
Hsieh, L.-M., see Huang, H.-C. (268) 73
Hu, X.-H., Tang, H.-W., Li, Q.-S. and Huang, X.-F.
Central mechanism of indomethacin analgesia (263) 53
Huang, H.-C., Hsieh, L.-M., Chen, H.-W., Lin, Y.-S. and Chen, J.-S.
Effects of baicalein and esculetin on transduction signals and growth factors expression in T-lymphoid leukemia cells (268) 73
Huang, H.-C., Wang, H.-R. and Hsieh, L.-M.

Antiproliferative effect of baicalein, a flavonoid from a Chinese herb, on vascular smooth muscle cell (251) 91
Huang, N.-Y. and Kostrzewa, R.M.
Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats (253) 163
Huang, X.-F., see Hu, X.-H. (263) 53
Huchet-Cadiou, C., see Bonnet, V. (264) 69
Huff, R.M., see Svensson, K. (263) 235
Hughes, A.D., see Garcha, R.S. (268) 319
Hughes, R., see Ong, J. (264) 49
Hulihan-Giblin, B.A., Park, Y.D. and Aulakh, C.S.
Differential effects of chronic antidepressant treatment on 5-HT_{1C} receptor binding sites in Wistar rat brain (263) 213
Humbles, A.A., see Nials, A.T. (251) 127
Humeniuk, R.E., see Kerr, D.I.B. (262) 189
Humphrey, P.P.A., see Feniuk, W. (261) 333
Humphrey, P.P.A., see Kennedy, I. (261) 273
Humphrey, P.P.A., see Khakh, B.S. (263) 301
Humphrey, P.P.A., see Trezise, D.J. (259) 295
Hunnicutt, Jr., E.J., Davis, J.N. and Chisholm, J.C.
A new glibenclamide-insensitive neuroselective hyperpolarizing agent (261) R1
Hunt, R.H., see Muller, M.J. (251) 151
Hutchins, A.-M., see Phillips, P.A. (259) 325
Hutson, P.H., see Bristow, L.J. (264) 353
Hutson, P.H., see Longmore, J. (265) 53
Hutson, P.H., see Patel, S. (255) 25
Hwang, C.-L., see Tao, P.-L. (256) 281
Hwang, L.-L., see Ho, C.-L. (259) 259
Hyman, A., see Lin, B. (260) 1
Hymel, L.J., see Ruiz-Velasco, V. (268) 311
Hyslop, S., see Giraldelo, C.M.M. (257) 87
Hyttel, J., see Sánchez, C. (264) 241

Ibba, M., see Testa, R. (249) 307
Iben, L.G., see Parker, E.M. (268) 43
Ichida, T., Hirouchi, M., Mizutani, H., Narihara, R. and Kuriyama, K.
Association and agonistic action of DN-2327, a novel isoindoline derivative, on $GABA_B$ receptor in brain (267) 43
Ichihara, K., see Hayase, N. (260) 183
Ichihara, K., see Nabeshima, T. (255) 57
Ichihara, K., see Satoh, K. (270) 365
Ichikawa, T., Ishihara, K., Saigenji, K. and Hotta, K.
Effects of acid-inhibitory antiulcer drugs on mucin biosynthesis in the rat stomach (251) 107
Ichiki, H., see Osada, S. (252) 347
Ichimura, M., see Nonaka, H. (267) 335
Idänpään-Heikkilä, J.J., see Rauhala, P. (259) 57
Iguchi, A., see Nonogaki, K. (262) 177
Iijima, T., see Hosoki, E. (266) 213
Iinuma, K., see Yokoyama, H. (260) 23
Iizuka, Y., see Fujibayashi, K. (261) 133
IJzerman, A.P., Van der Wenden, E.M., Van Galen, P.J.M. and Jacobson, K.A.
Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A_{2A} receptor (268) 95
IJzerman, A.P., see Beukers, M.W. (266) 57
IJzerman, A.P., see Borea, P.A. (267) 55
IJzerman, A.P., see Van Rhee, A.M. (268) 1
Ikawa, K., Watanabe, A., Kaneno, S. and Toru, M.
Modulation of [^{3}H]mazindol binding sites in rat striatum by dopaminergic agents (250) 261
Ikawa, K., Watanabe, A., Kaneno, S. and Toru, M.
Modulation of [^{3}H]mazindol binding sites in rat striatum by dopaminergic agents. European Journal of Pharmacology, 250 (1993) 261–266 (252) 123
Ikeda, K., see Konno, S.-i. (259) 15
Ikeda, S., Amano, Y., Adachi-Akahane, S. and Nagao, T.
Binding of [^{3}H](+)-PN200-110 to aortic membranes from normotensive and spontaneously hypertensive rats (264) 223
Ikeda, U. and Shimada, K.
Nitric oxide release from rat aortic smooth muscle cells is not attenuated by angiotensin converting enzyme inhibitors (269) 319
Ikemoto, F., see Okada, M. (259) 339
Im, W.B., see Ito, C. (257) 203
Imai, S., see Nakazawa, M. (253) 179
Imanishi, N., see Koike, H. (269) 299
Imperato, A., Dazzi, L., Serra, M., Gessa, G.L. and Biggio, G.
Differential effects of abecarnil on basal release of acetylcholine and dopamine in the rat brain (261) 205
Imperato, A., Obinu, M.C., Carta, G., Mascia, M.S., Casu, M.A., Dazzi, L. and Gessa, G.L.
Neuroleptics cause stimulation of dopamine D_1 receptors and their desensitization after chronic treatment (264) 55
Imperato, A., Obinu, M.C., Dazzi, L. and Gessa, G.L.
Does dopamine exert a tonic inhibitory control on the release of striatal acetylcholine in vivo? (251) 271
Impicciatore, M., see Barocelli, E. (254) 151
Improta, G., see Broccardo, M. (258) 179
Inada, Y., see Wada, T. (253) 27
Inaguma, K., see Ito, M. (263) 253
Inamura, N., see Yokota, Y. (258) 239
Inazu, M., see Zhang, H. (251) 119
Ingenito, A.J., see Wang, J.Q. (256) 57
Ingram, D.K., see Shimada, A. (263) 293
Innis, R.B., see Laruelle, M. (263) 39
Inoue, K., Watano, T., Koizumi, S., Nakazawa, K. and Burnstock, G.
Dual modulation by adenosine of ATP-activated channels through GTP-binding proteins in rat pheochromocytoma PC12 cells (268) 223
Inoue, K., see Nakazawa, K. (269) 375
Inoue, R., see Hattori, R. (267) R1
Inoue, Y., see Murano, K. (254) 257
Inoue, Y., see Sawaki, S. (250) 253
Inscho, E.W., see Ruiz-Velasco, V. (268) 311
Inturrisi, C.E., see Gold, L.H. (253) 45
Inui, K.-i., see Hashimoto, Y. (268) 443
Invernizzi, R., Bramante, M. and Samanin, R.
Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT_{1A} receptors (260) 243
Ioculano, M., Squadrito, F., Altavilla, D., Canale, P., Squadrito, G., Campo, G.M., Saitta, A. and Caputi, A.P.
Antibodies against intercellular adhesion molecule 1 protect against myocardial ischaemia-reperfusion injury in rat (264) 143
Ioculano, M., see Altavilla, D. (270) 45
Ionescu, P., see Kendig, J.J. (264) 427
Ip, S., see Qian, C. (250) R13
Iravani, M.M. and Zar, M.A.
Differential effects of nifedipine on nerve-mediated and noradrenaline-evoked contractions of rat anococcygeus muscle (250) 193
Iriarte, M.-C.F., Díaz-Juárez, J.L., Arilla, E., Pascual, R., Cortijo, J., Advenier, C., Prieto, J.C. and Morcillo, E.J.
Effects of sensitization on vasoactive intestinal polypeptide-induced relaxation and its concentration and binding in guinea-pig airways (250) 295
Irie, K., Furukawa, K., Nomoto, T., Fujii, E. and Muraki, T.
Developmental changes in the response of rat isolated duodenum to nicotine (251) 75
Irifune, M., Nomoto, M. and Fukuda, T.
Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-DOPA and as chronic treatment (264) 117

Ishida, M., Saitoh, T., Nakamura, Y., Kataoka, K. and Shinozaki, H.
A novel metabotropic glutamate receptor agonist: (2*S*,1′*S*,2′*R*, 3′*R*)-2-(2-carboxy-3-methoxymethylcyclopropyl)glycine (*cis*-MCG-I) (268) 267
Ishida, M., see Miyamoto, M. (260) 99
Ishiguro, K., see Osada, S. (252) 347
Ishihara, K., see Ichikawa, T. (251) 107
Ishihara, K., see Nakamura, J. (254) 83
Ishii, A., see Nakamura, J. (254) 83
Ishii, A., see Tomaru, A. (264) 91
Ishii, H., see Yokoo, H. (256) 335
Ishii, K., see Murakoshi, H. (268) 451
Ishii, R., see Takeuchi, K. (254) 287
Ishikawa, M., Ouchi, Y., Han, S.-z., Akishita, M., Kozaki, K., Toba, K., Namiki, A., Yamaguchi, T. and Orimo, H.
Parathyroid hormone-related protein reduces cytosolic free Ca^{2+} level and tension in rat aortic smooth muscle (269) 311
Ishikawa, M., see Yokoo, H. (256) 335
Ishikawa, N., see Hirabayashi, A. (256) 227
Ishiyama, H., see Ogino, K. (270) 73
Ishizaka, H., see Tsunoda, R. (262) 55
Ishizuka, T., Suzuki, K., Kawakami, M., Kawaguchi, Y., Hidaka, T., Matsuki, Y. and Nakamura, H.
DP-1904, a specific inhibitor of thromboxane A_2 synthesizing enzyme, suppresses ICAM-1 expression by stimulated vascular endothelial cells (262) 113
Isojima, Y., see Nagai, K. (260) 29
Isono, T., Sato, N., Yamamoto, T., Sawada, T., Yamazaki, S., Miura, S., Furuichi, A., Ozaki, R., Koibuchi, Y. and Ohtsuka, M.
Tolerance to the vascular effect of a novel nitric oxide-donating vasodilator, FK409 (260) 163
Israel, A., see Cierco, M. (251) 103
Ito, C., Im, W.B., Takagi, H., Takahashi, M., Tsuzuki, K., Liou, S.-Y. and Kunihara, M.
U-92032, a T-type Ca^{2+} channel blocker and antioxidant, reduces neuronal ischemic injuries (257) 203
Ito, H., see Miyata, K. (250) 303
Ito, K., see Naganobu, K. (251) 307
Ito, K.M., see Ohno, N. (249) 121
Ito, M., Segami, T., Inaguma, K. and Suzuki, Y.
Cimetidine and omeprazole accelerate gastric ulcer healing by an increase in gastrin secretion (263) 253
Ito, M., Segami, T., Tsukahara, T., Kojima, R. and Suzuki, Y.
Effect of cimetidine and omeprazole on gastric ulcer healing of rats with limited food intake time (263) 245
Ito, M., see Nagao, T. (259) 233
Ito, M., see Shimomura, A. (252) 81
Ito, S., see Kitamura, N. (256) 169
Itoh, H., see Hashimoto, Y. (268) 443
Itoh, H., see Shimomura, A. (252) 81
Itoh, S., see Nagai, K. (260) 29
Iuvone, T., Carnuccio, R. and Di Rosa, M.
Modulation of granuloma formation by endogenous nitric oxide (265) 89
Ivorra, D., see Sallés, J. (266) 35
Iwami, M., see Aramori, I. (269) 277
Iwamoto, Y., see Kamei, J. (249) 161
Iwamoto, Y., see Kamei, J. (251) 95
Iwamoto, Y., see Kamei, J. (251) 291
Iwamoto, Y., see Kamei, J. (253) 293
Iwamoto, Y., see Kamei, J. (254) 113
Iwamoto, Y., see Kamei, J. (260) 257
Iwao, H., see Ebara, T. (263) 69
Iwao, H., see Ohta, K. (269) 115
Iwao, H., see Yukimura, T. (264) 399
Iwatsuki, K., Horiuchi, A., Ren, L.-M. and Chiba, S.
Effects of KRN2391, a novel vasodilator, on pancreatic exocrine secretion in anesthetized dogs (249) 19
Izenwasser, S., Terry, P., Heller, B., Witkin, J.M. and Katz, J.L.
Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors (263) 277
Izumi, Y., see Ogino, K. (270) 73
Izzo, A.A., see Mascolo, N. (264) 21

Jackisch, R., Kruchen, A., Sauermann, W., Hertting, G. and Feuerstein, T.J.
The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists (264) 207
Jackson, A., see Rupniak, N.M.J. (262) 171
Jackson, B., see Perich, R.B. (266) 201
Jackson, B.A., see Kidwell, D.T. (270) 97
Jacobson, K.A., see IJzerman, A.P. (268) 95
Jacobson, K.A., see Von Lubitz, D.K.J.E. (249) 265
Jacobson, K.A., see Von Lubitz, D.K.J.E. (249) 271
Jacobson, K.A., see Von Lubitz, D.K.J.E. (253) 95
Jacobson, K.A., see Von Lubitz, D.K.J.E. (256) 161
Jacobson, K.A., see Von Lubitz, D.K.J.E. (263) 59
Jacobsson, G., see Meister, B. (267) 323
Jacquemin-Sablon, A., see Agbotounou, W.K. (269) 1
Jacquot, C., see Gardier, A.M. (265) 107
Jakab, I., see Lonovics, J. (255) 117
Jakobs, K.H., see Götze, K. (268) 151
Jane, D., see Kemp, M. (266) 187
Janetzky, B., see Götz, M.E. (266) 291
Jang, E.K., Davidson, M.M.L., Crankshaw, D. and Haslam, R.J.
Synergistic inhibitory effects of atriopeptin II and isoproterenol on contraction of rat aortic smooth muscle: roles of cGMP and cAMP (250) 477
Jang, E.K., see Tang, K.M. (268) 105
Janssen, P., see Schiereck, P. (249) 317
Jansson, C.C., Marjamäki, A., Luomala, K., Savola, J.-M., Scheinin, M. and Åkerman, K.E.O.
Coupling of human α_2-adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells (266) 165
Jantos, H., see Ponzoni, A. (249) 259
Jardine, E., see Thorin-Trescases, N. (268) 199
Jarrott, B., see Beart, P.M. (269) 193
Jarry, A., Merlin, D., Velcich, A., Hopfer, U., Augenlicht, L.H. and Laboisse, C.L.
Interferon-γ modulates cAMP-induced mucin exocytosis without affecting mucin gene expression in a human colonic goblet cell line (267) 95
Jastrzębski, Z., see Remiszewska, M. (250) 355
Jauzac, P., see Polastron, J. (266) 139
Javoy-Agid, F., see Lorinet, A.-M. (269) 59
Jaw, S.P., Makimura, M., Oh, K.W., Hoskins, B. and Ho, I.K.
Involvement of κ-opioid receptors in opioid dependence/withdrawal: studies using butorphanol (257) 153
Jeantaud, B., see Bertrand, P. (262) 233
Jefferys, D. and Funder, J.
The effect of water temperature on immobility in the forced swimming test in rats (253) 91
Jeng, A.Y., see Balwierczak, J.L. (250) 379
Jennekens, F., see Schiereck, P. (249) 317
Jennings, M.A., see Tudhope, S.R. (264) 317
Jensen, A.A., see Pedersen, U.B. (267) 85
Jeppsson, A.-B., Nilsson, E. and Waldeck, B.
Formoterol and salmeterol are both long acting compared to terbutaline in the isolated perfused and ventilated guinea-pig lung (257) 137
Jessa, M., see Plaznik, A. (257) 293
Ji, X.-d., see Von Lubitz, D.K.J.E. (253) 95

Ji, X.-d., see Von Lubitz, D.K.J.E. (256) 161
Jiang, J., Temma, K. and Akera, T.
Dual effects of nicardipine: evidence from intracellular Ca^{2+} transients and twitch contractions observed in single myocytes obtained from rat heart (266) 155
Jiménez, J., see Duarte, J. (262) 149
Jobe, P.C., see Yan, Q.-S. (252) 105
Joëls, M., see Karst, H. (270) 357
Johansen, T.H., see Verdoorn, T.A. (269) 43
Johansson, L., see Håkansson, H. (270) 279
Johansson, M.H. and Westlind-Danielsson, A.
Forskolin-induced up-regulation and functional supersensitivity of dopamine D_2long receptors expressed by Ltk^- cells (269) 149
Johnson, M., see Baker, A.J. (264) 301
Johnson, M., see Elkins, K.W. (250) 395
Johnson, M., see Gygi, S.P. (250) 177
Johnson, M., see Nials, A.T. (251) 127
Johnston, C.I., see Perich, R.B. (266) 201
Johnston, C.I., see Phillips, P.A. (259) 325
Johnston, M.V., see Supko, D.E. (270) 105
Jolas, T., see Haj-Dahmane, S. (255) 185
Jolicoeur, F.B., see Lemaire, S. (258) 111
Jonas, J.-C., Garcia-Barrado, M.-J., Angel, I. and Henquin, J.-C.
The imidazoline SL 84.0418 shows stereoselectivity in blocking α_2-adrenoceptors but not ATP-sensitive K^+ channels in pancreatic B-cells (264) 81
Jonas, J.-C., Plant, T.D., Angel, I., Langer, S.Z. and Henquin, J.-C.
In vitro stimulation of insulin release by SL 84.0418, a new α_2-adrenoceptor antagonist (254) 27
Jones, A., see Kemp, M. (266) 187
Jones, D.N.C., Bowen, W.D., Portoghese, P.S. and Holtzman, S.G.
δ-Opioid receptor antagonists attenuate motor activity induced by amphetamine but not cocaine (249) 167
Jones-Humble, S.A. and Morgan, P.F.
High expression of nitrobenzylthioinosine-insensitive dipyridamole binding sites in postmortem human ependymal tissue (257) 311
Jones, L.S., Grooms, S.Y., Salvadori, S. and Lazarus, L.H.
Dermorphin-induced hyperexcitability in hippocampal CA3 and CA1 in vitro (264) 39
Jones, P., see Kemp, M. (266) 187
Jones, S.B., see Zorn, S.H. (269) R1
Jongenelen, C.A.M., see Vermeulen, R.J. (269) 121
Joó, F., see Tósaki, Á. (264) 455
Jordan, C., see Bountra, C. (249) R3
Jordan, C.C., see Rudd, J.A. (262) R1
Jørgensen, A., Fjalland, B., Christensen, J.D. and Treiman, M.
Dihydropyridine ligands influence the evoked release of oxytocin and vasopressin dependent on stimulation conditions (259) 157
Josef, K., see Krafte, D.S. (266) 245
Joseph, D.B. and Bidlack, J.M.
The κ-opioid receptor expressed on the mouse lymphoma cell line R1.1 contains a sulfhydryl group at the binding site (267) 1
Joubert, D., see Lévy, L. (268) 327
Jovanović, A., Grbović, L. and Tulić, I.
L-Arginine induces relaxation of human uterine artery with both intact and denuded endothelium (256) 103
Jovanović, A., Grbović, L. and Tulić, I.
Endothelium-dependent relaxation in response to acetylcholine in the human uterine artery (256) 131
Jovanović, A., Grbović, L., Drekić, D. and Novaković, S.
Muscarinic receptor function in the guinea-pig uterine artery is not altered during pregnancy (258) 185
Junien, J.-L., see Diop, L. (257) 181
Junien, J.-L., see Lagente, V. (255) 253
Juorio, A.V., Paterson, I.A. and Zhu, M.-Y.
Dopamine metabolism in the guinea pig striatum: role of monoamine oxidase A and B (254) 213
Jurkiewicz, A., Lafayette, S.S., Nunes, S.H., Martini, L.C., Do Carmo, L.G., Wanderley, A.G. and Jurkiewicz, N.H.
Decreased density of binding sites for the Ca^{2+} channel antagonist [^{3}H]isradipine after denervation of rat vas deferens (256) 329
Jurkiewicz, N.H., see Jurkiewicz, A. (256) 329
Juvenal, G.J., see Pisarev, M.A. (258) 33
Jyoyama, H., see Arimura, A. (260) 201

Kaan, S.K., see Cho, C.H. (256) 9
Kacani, L., Ferencik, M., Devinsky, F., Möst, J. and Dierich, M.P.
Immunomodulatory effect of sodium dodecyl sulfate on human neutrophils and the human promyelocytic HL-60 cell line (270) 285
Kadowitz, P.J., see Cheng, D.Y. (261) 223
Kadowitz, P.J., see DeWitt, B.J. (257) 303
Kadowitz, P.J., see Feng, C.J. (263) 133
Kadowitz, P.J., see Santiago, J.A. (254) 207
Kagawa, M., see Onogi, T. (262) 163
Kähler, C.M., Kieselbach, G.F., Reinisch, N., Troger, J., Göttinger, W. and Wiedermann, C.J.
Fibroblast growth-promoting activity in proliferative vitreoretinopathy: antagonism by acetylsalicylic acid (262) 261
Kähler, C.M., Sitte, B.A., Reinisch, N. and Wiedermann, C.J.
Stimulation of the chemotactic migration of human fibroblasts by substance P (249) 281
Kaiser, L., see Lamb, V.L. (256) 221
Kaku, K., see Murano, K. (254) 257
Kakuno, K., see Sudo, J.-i. (270) 229
Kalenga, M.K., De Gasparo, M., Thomas, K. and De Hertogh, R.
Angiotensin II induces human placental lactogen and pregnancy-specific β_1-glycoprotein secretion via an angiotensin AT_1 receptor (268) 231
Kalichman, M.W., see Calcutt, N.A. (251) 27
Kallen, R.G., see Krafte, D.S. (266) 245
Kalso, E., see Suzuki, N. (249) 247
Kamata, K., Numazawa, T. and Kasuya, Y.
Decrease in vasodilator effects of platelet-activating factor in resistance vessels of spontaneously hypertensive rats (259) 321
Kamata, T., see Matsumoto, Y. (262) 157
Kamato, T., see Miyata, K. (250) 303
Kamei, H., Kameyama, T. and Nabeshima, T.
SKF-10,047 reverses stress-induced motor suppression: interaction with dopaminergic system (260) 39
Kamei, J., Iwamoto, Y., Misawa, M., Nagase, H. and Kasuya, Y.
Antinociceptive effect of L-arginine in diabetic mice (254) 113
Kamei, J., Iwamoto, Y., Misawa, M., Nagase, H. and Kasuya, Y.
Antitussive effect of [Met^5]enkephalin-Arg^6-Phe^7 in mice (253) 293
Kamei, J., Iwamoto, Y., Suzuki, T., Misawa, M., Kasuya, Y., Nagase, H., Okutomi, T., Soma, G.-I. and Mizuno, D.
Antinociceptive effect of lipopolysaccharide from *Pantoea agglomerans* on streptozotocin-induced diabetic mice (251) 95
Kamei, J., Iwamoto, Y., Suzuki, T., Misawa, M., Nagase, H. and Kasuya, Y.
Antitussive effect of dihydroetorphine in mice (260) 257
Kamei, J., Iwamoto, Y., Suzuki, T., Misawa, M., Nagase, H. and Kasuya, Y.
Antitussive effects of naltrindole, a selective δ-opioid receptor antagonist, in mice and rats (249) 161
Kamei, J., Iwamoto, Y., Suzuki, T., Misawa, M., Nagase, H. and Kasuya, Y.
Involvement of δ_1-opioid receptor antagonism in the antitussive effect of δ-opioid receptor antagonists (251) 291
Kamenka, J.-M., see Billaud, G. (268) 357

Kameyama, T., see Kamei, H. (260) 39
Kaminski, D.L., see Deshpande, Y. (256) R1
Kamoun, A., see Cataldi, M. (253) 149
Kampine, J.P., see Tseng, L.F. (258) R1
Kan, S., Niwa, M. and Taniyama, K.
Specific receptor for vasoactive intestinal contractor in myenteric cholinergic neurones (258) 139
Kanada, A., Hosokawa, M., Suthamnatpong, N., Maehara, T., Takeuchi, T. and Hata, F.
Neuronal pathway involved in nitric oxide-mediated descending relaxation in rat ileum (250) 59
Kanaide, H., see Chen, X. (267) 175
Kanaide, H., see Hirakawa, Y. (252) 267
Kanaide, H., see Hirano, K. (250) 439
Kanayama, T., see Murai, T. (261) 65
Kanda, T., Shiozaki, S., Shimada, J., Suzuki, F. and Nakamura, J.
KF17837: a novel selective adenosine A_{2A} receptor antagonist with anticataleptic activity (256) 263
Kanda, T., see Nakamura, J. (254) 83
Kane, K., see Dalen, T. (270) 313
Kaneko, T., see Murano, K. (254) 257
Kaneno, S., see Ikawa, K. (250) 261
Kaneno, S., see Ikawa, K. (252) 123
Kanno, M., see Hattori, Y. (256) 215
Kanno, M., see Tohse, N. (249) 231
Kappelle, A.C., Biessels, G.J., Van Buren, T., Erkelens, D.W., De Wildt, D.J. and Gispen, W.H.
Effects of nimodipine on sciatic nerve blood flow and vasa nervorum responsiveness in the diabetic rat (250) 43
Karácsony, G., see László, F. (258) 15
Karaki, H., Sudjarwo, S.A., Hori, M., Tanaka, T. and Matsuda, Y.
Endothelin ET_B receptor antagonist, RES-701-1: effects on isolated blood vessels and small intestine (262) 255
Karaki, H., see Kitajima, S. (266) 263
Karaki, H., see Takizawa, S. (250) 431
Karakiulakis, G., see Bastaki, M. (251) 263
Karasawa, A., see Tomaru, A. (264) 91
Karasawa, T., see Yamamoto, T. (250) 189
Kardos, V., see Sziráki, I. (251) 311
Karlsson, T., see Salmi, P. (253) 67
Karoum, F., Egan, M.F. and Wyatt, R.J.
Selective reduction in dopamine turnover in the rat frontal cortex and hypothalamus during withdrawal from repeated cocaine exposure (254) 127
Karppanen, H., see Mervaala, E.M.A. (255) 73
Karst, H., Joëls, M., Wadman, W.J. and Piek, T.
Philanthotoxin inhibits Ca^{2+} currents in rat hippocampal CA1 neurons (270) 357
Karunanithi, S., Lavidis, N.A. and Bennett, M.R.
Effect of yohimbine on the contractile response of the mouse vas deferens to short, low frequency trains of nerve impulses (261) 17
Kasai, K., see Takekoshi, K. (250) 465
Kase, H., see Nonaka, H. (267) 335
Kasten, T.P., Settle, S.L., Misko, T.P., Currie, M.G. and Nickols, G.A.
Manganese potentiation of nitric oxide-mediated vascular relaxation (253) 35
Kasuya, Y., see Kamata, K. (259) 321
Kasuya, Y., see Kamei, J. (249) 161
Kasuya, Y., see Kamei, J. (251) 95
Kasuya, Y., see Kamei, J. (251) 291
Kasuya, Y., see Kamei, J. (253) 293
Kasuya, Y., see Kamei, J. (254) 113
Kasuya, Y., see Kamei, J. (260) 257
Kataoka, K., see Ishida, M. (268) 267
Kataoka, Y., see Koizumi, S. (259) 195
Kataoka, Y., see Matsumoto, Y. (264) 107
Katsumata, K., see Sakurada, T. (261) 85
Katsuragi, T., see Soejima, O. (249) 1
Katz, J.L., see Izenwasser, S. (263) 277
Kawaguchi, Y., see Ishizuka, T. (262) 113
Kawai, C., see Hattori, R. (267) R1
Kawakami, M., see Ishizuka, T. (262) 113
Kawana, S., see Miyamoto, A. (266) 147
Kawarabayashi, K., see Tabuchi, Y. (250) 197
Kawasaki, H., see Hattori, Y. (256) 215
Kawasaki, H., see Naganobu, K. (251) 307
Kawashima, H., see Miyake, A. (253) 155
Kawikova, I., see Arakawa, H. (252) 313
Kawikova, I., see Arakawa, H. (259) 251
Kaye, A.D., see Feng, C.J. (263) 133
Kayser, V., see Lee, S.H. (264) 61
Kazi, M., see Paul, V. (270) 1
Keana, J.F.W., see Lutfy, K. (252) 261
Keegan, K.D., Woodruff, G.N. and Pinnock, R.D.
The pharmacology of neurotensin analogues on neurones in the rat substantia nigra, pars compacta in vitro (253) 131
Kellar, K.J., see Travagli, R.A. (264) 385
Kelly, E., see Williams, R.J. (268) 177
Kelly, M.E., see Cheng, C.H.K. (255) 39
Kemény, L., Kenderessy, A.Sz., Olasz, E., Michel, G., Ruzicka, T., Farkas, B. and Dobozy, A.
The interleukin-8 receptor: a potential target for antipsoriatic therapy? (258) 269
Kemp, M., Roberts, P., Pook, P., Jane, D., Jones, A., Jones, P., Sunter, D., Udvarhelyi, P. and Watkins, J.
Antagonism of presynaptically mediated depressant responses and cyclic AMP-coupled metabotropic glutamate receptors (266) 187
Kenderessy, A.Sz., see Kemény, L. (258) 269
Kendig, J.J., Kodde, A., Gibbs, L.M., Ionescu, P. and Eger II, E.I.
Correlates of anesthetic properties in isolated spinal cord: cyclobutanes (264) 427
Kennedy, I. and Humphrey, P.P.A.
Evidence for the presence of two types of P_2 purinoceptor in the guinea-pig ileal longitudinal smooth muscle preparation (261) 273
Kennedy, R.H., Hicks, K.K., Brian, Jr., J.E. and Seifen, E.
Nitric oxide has no chronotropic effect in right atria isolated from rat heart (255) 149
Kennedy, R.H., see Buzzard, S.L. (260) 15
Kerkhof, C.J.M., see Beukers, M.W. (266) 57
Kerkman, D.J., see Hancock, A.A. (267) 49
Kerr, D.I.B., Humeniuk, R.E. and Ong, J.
γ-Guanidinobaclofen is a peripheral $GABA_B$ receptor agonist (262) 189
Kerr, D.I.B., see Ong, J. (260) 73
Kerr, D.I.B., see Ong, J. (264) 49
Kettenbach, B., see Martorana, P.A. (257) 267
Khakh, B.S., Michel, A. and Humphrey, P.P.A.
Estimates of antagonist affinities at P_{2X} purinoceptors in rat vas deferens (263) 301
Khakh, B.S., see Trezise, D.J. (259) 295
Khan, Z., see Ruano, D. (267) 121
Kiang, J.G.
Corticotropin-releasing factor increases $[Ca^{2+}]_i$ via receptor-mediated Ca^{2+} channels in human epidermoid A-431 cells (267) 135
Kickenweiz, E., see Stark, G. (252) 283
Kidwell, D.T., McKeown, J.W., Grider, J.S., McCombs, G.B., Ott, C.E. and Jackson, B.A.
Acute effects of gentamicin on thick ascending limb function in the rat (270) 97

Kieselbach, G.F., see Kähler, C.M. (262) 261
Kikuchi de Beltrán, K., Koshikawa, N., Miwa, Y. and Kobayashi, M.
Dorsal striatal mechanisms involved in the dopamine D_2 receptor-mediated potentiation of apomorphine-induced jaw movements (252) 99
Kikuchi de Beltrán, K., Koshikawa, N., Miwa, Y., Kobayashi, M. and Cools, A.R.
Clozapine injected into the nucleus accumbens potentiates apomorphine-induced jaw movements (262) 49
Kilpatrick, G.J., see Clapham, J. (259) 107
Kim, S., see Ebara, T. (263) 69
Kim, S., see Ohta, K. (269) 115
Kim, S., see Yukimura, T. (264) 399
Kim, Y.-H., see Suh, H.-W. (263) 217
Kimbrough, C.L., see Hawkinson, J.E. (269) 157
Kimland, M., see Bannenberg, G. (270) 175
Kimura, H., see Miyamoto, A. (266) 147
Kimura, T., Takeuchi, A. and Satoh, S.
Inhibition by ω-conotoxin GVIA of adrenal catecholamine release in response to endogenous and exogenous acetylcholine (264) 169
King, K.A., see Holtman, Jr., J.R. (253) 307
Kirk, S.A., see Pons, F. (261) 237
Kirkham, S.E., see Burleigh, D.E. (249) 239
Kisara, K., see Sakurada, T. (261) 85
Kishibayashi, N., see Tomaru, A. (264) 91
Kita, Y., Hirasawa, Y., Maeda, K., Nishio, M. and Yoshida, K.
Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409 (257) 123
Kitabgi, P., see Azzi, M. (255) 167
Kitabgi, P., see Brouard, A. (253) 289
Kitajima, S., Ozaki, H. and Karaki, H.
Role of different subtypes of P_2 purinoceptor on cytosolic Ca^{2+} levels in rat aortic smooth muscle (266) 263
Kitamura, N., Ohta, T., Ito, S. and Nakazato, Y.
Effects of nifedipine and Bay K 8644 on contractile activities in single skeletal muscle fibers of the frog (256) 169
Kitamura, Y., Nagatani, T. and Watanabe, T.
Buspirone enhances head twitch behavior in mice (253) 297
Kitayama, S., Dohi, T. and Uhl, G.R.
Phorbol esters alter functions of the expressed dopamine transporter (268) 115
Klaus, W., see Stark, G. (252) 283
Klegeris, A. and McGeer, P.L.
Inhibition of respiratory burst in macrophages by complement receptor blockade (260) 273
Klein, M., Cooper, T.B. and Musacchio, J.M.
Effects of haloperidol and reduced haloperidol on binding to σ sites (254) 239
Klein, R.L., Sanna, E., McQuilkin, S.J., Whiting, P.J. and Harris, R.A.
Effects of 5-HT_3 receptor antagonists on binding and function of mouse and human $GABA_A$ receptors (268) 237
Kleinrok, Z., see Czuczwar, S.J. (264) 103
Kleinrok, Z., see Pietrasiewicz, T. (250) 1
Klemm, P., Ostrowski, J., Morath, T., Gruber, C., Martorana, P.A. and Henning, R.
N-Acetylserotonin prevents the hypotension induced by bacterial lipopolysaccharides in the rat (250) R9
Kling-Petersen, T., see Svensson, K. (263) 235
Klinge, E., see Alaranta, S. (259) 203
Klint, T., see Albinsson, A. (261) 285
Klitgaard, H. and Laudrup, P.
Metabotropic excitatory amino acid receptor agonists selectively potentiate behavioral effects induced by ionotropic excitatory amino acid receptor agonists in mice (250) 9
Klitgaard, H., see Laudrup, P. (250) 15
Klomp, J., see Stam, N.J. (269) 339
Klouras, N., see Bastaki, M. (251) 263
Knapp, R.J., Malatynska, E., Peterson, P., Zalewska, T., Fang, S., Hruby, V.J., Smith, T.L. and Yamamura, H.I.
[*N*-Methylnorleucine-(28,31)]cholecystokinin-(26-33) (SNF 8702) activity at a cloned rat CCK_B receptor (269) 133
Knight, D.R., see Constantine, J.W. (252) 275
Knoper, S.R., see Xian, H. (259) 21
Knuepfer, M.M., O'Brien, D., Hoang, D., Gan, Q. and Song, C.
Central sympathetic control of spinal endothelin release in the rat (259) 305
Ko, F.-N., see Teng, C.-M. (265) 61
Ko, F.-N., see Yu, S.-M. (252) 29
Ko, F.-N., see Yu, S.-M. (256) 85
Kobayashi, H., see Yamaguchi, Y. (254) 91
Kobayashi, M., see Kikuchi de Beltrán, K. (252) 99
Kobayashi, M., see Kikuchi de Beltrán, K. (262) 49
Kobayashi, M., see Murai, T. (261) 65
Kobayashi, S., see Chen, X. (267) 175
Kobayashi, Y., Cavallotti, D., Ricci, A. and Amenta, F.
Localisation of dopamine D_2-like receptors in pulmonary artery of the human and rabbit but not of the rat (261) 229
Kobayashi, Y., Ricci, A. and Amenta, F.
Autoradiographic localization of dopamine D_1-like receptors in the rabbit pulmonary circulation (253) 201
Koch, L.G., Alsip, N.L., Feige, B.D., Wead, W.B. and Harris, P.D.
In vivo effect of naftidrofuryl on 5-hydroxytryptamine-mediated constriction in rat peripheral microcirculation (254) 249
Kodama, K., Adachi, H., Mori, N. and Saito, I.
Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs (263) 93
Kodde, A., see Kendig, J.J. (264) 427
Koeman, J.H., see Lans, M.C. (270) 129
Koga, C., see Yokoo, H. (256) 335
Kohi, M., Yang, H.-T. and Endoh, M.
Myocardial α_{1A}-adrenoceptor subtypes in rabbit: differentiation by a selective antagonist, HV723 (250) 95
Kohno, S., see Yamamura, H. (257) 235
Kohno, S., see Yamamura, H. (265) 9
Koibuchi, Y., see Isono, T. (260) 163
Koike, H., Imanishi, N., Natsume, Y. and Morooka, S.
Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils (269) 299
Koivisto, E., see Pitkänen, M. (253) 125
Koizumi, S., Kataoka, Y., Niwa, M., Watanabe, S. and Taniyama, K.
Two distinct pathways are involved in the endothelin-3-evoked dopamine release from rat striatal slices (259) 195
Koizumi, S., see Inoue, K. (268) 223
Kojda, G., Meyer, W. and Noack, E.
Influence of endothelium and nitrovasodilators on free thiols and disulfides in porcine coronary smooth muscle (250) 385
Kojima, C., see Satoh, M. (265) 133
Kojima, I., see Mogami, H. (269) 293
Kojima, M., Dohi, Y. and Sato, K.
Ryanodine-induced contraction in femoral artery from spontaneously hypertensive rats (254) 159
Kojima, R., see Ito, M. (263) 245
Kojima, S., see Yamanouchi, T. (257) 39
Kojo, H., see Aramori, I. (269) 277
Kokubu, N., see Satoh, M. (265) 133
Komada, T., see Tabuchi, Y. (250) 197
Komoriya, K., Osada, Y., Hasegawa, M., Horiuchi, H., Kondo, S., Couch, R.C. and Griffin, T.B.
Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees (250) 455
Kondo, H., see Temma, K. (252) 173
Kondo, S., see Komoriya, K. (250) 455
Kong, Y.C., see Ng, P.C. (264) 1
Konishi, T., see Shimomura, A. (252) 81

Konno, S.-i., Adachi, M., Asano, K., Gonogami, Y., Ikeda, K., Okamoto, K.-i. and Takahashi, T.
Suppressive effects of IPD-1151T (suplatast-tosilate) on induction of mast cells from normal mouse splenocytes (259) 15
Konno, S.-i., Asano, K., Okamoto, K.-i. and Adachi, M.
Inhibition of cytokine production from human peripheral blood leukocytes by anti-allergic agents in vitro (264) 265
Konturek, S.J., Brzozowski, T., Stachura, J. and Majka, J.
Role of neutrophils and mucosal blood flow in gastric adaptation to aspirin (253) 107
Koob, G.F., see Gold, L.H. (253) 45
Korpi, E.R., see Wegelius, K. (263) 141
Kortezova, N., see Mizhorkova, Z. (265) 77
Kosakai, K., see Satake, N. (251) 1
Koshikawa, N., see Kikuchi de Beltrán, K. (252) 99
Koshikawa, N., see Kikuchi de Beltrán, K. (262) 49
Koshikawa, N., see Murai, T. (261) 65
Koshiya, K., see Wanibuchi, F. (265) 151
Koss, M.C.
Histamine H_3 receptor activation inhibits sympathetic-cholinergic responses in cats (257) 109
Kosten, T.A.
Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal (254) 59
Kostiainen, E., see Alaranta, S. (259) 203
Kostrzewa, R.M., see Huang, N.-Y. (253) 163
Kosuga, K., see Hattori, R. (267) R1
Koumi, S.-i., Sato, R. and Hayakawa, H.
Modulation of the delayed rectifier K^+ current by apamin in guinea-pig heart (261) 213
Koumi, S.-i., Sato, R. and Hayakawa, H.
Modulation of voltage-dependent inactivation of the inwardly rectifying K^+ channel by chloramine-T (258) 281
Koutsilieri, E., O'Callaghan, J.F.X., Chen, T.-S., Riederer, P. and Rausch, W.-D.
Selegiline enhances survival and neurite outgrowth of MPP^+-treated dopaminergic neurons (269) R3
Kovács, M., see Horváth, G. (253) 61
Kovalsky, M.P., see Howell, R.E. (265) 67
Koyama, K., Yamashita, M., Miyauchi, T. and Goto, K.
Mechanisms of hypotension in iminoctadine poisoning: pharmacological analysis in rats (270) 151
Koyama, S., see Matsuda, Y. (250) 341
Kozaki, K., see Ishikawa, M. (269) 311
Krafte, D.S., Davison, K., Dugrenier, N., Estep, K., Josef, K., Barchi, R.L., Kallen, R.G., Silver, P.J. and Ezrin, A.M.
Pharmacological modulation of human cardiac Na^+ channels (266) 245
Krawiec, L., see Pisarev, M.A. (258) 33
Krell, R.D., see Kusner, E.J. (257) 285
Kreulen, D.L., see Xian, H. (259) 21
Kreutner, W., see Danko, G. (254) 283
Krieg, R.J., see Singh, V.B. (256) 177
Krieglstein, J., see Lippert, K. (253) 207
Krippeit-Drews, P., see Busch, A.E. (264) 33
Krstenansky, J.L., see Grundemar, L. (258) 163
Kruchen, A., see Jackisch, R. (264) 207
Krůšek, J. and Zemková, H.
Effect of ivermectin on γ-aminobutyric acid-induced chloride currents in mouse hippocampal embryonic neurones (259) 121
Kudlacz, E.M., Shatzer, S.A., Farrell, A.M. and Baugh, L.E.
Parainfluenza virus type 3 induced alterations in tachykinin NK_1 receptors, substance P levels and respiratory functions in guinea pig airways (270) 291
Kuei-Sen Hsu, and Shoei-Yn Lin-Shiau,
Relaxation of rat thoracic aorta induced by 2,2′,2″-tripyridine (270) 89
Kuga, T., see Hirakawa, Y. (252) 267
Kühn-Velten, W.N.
Norharman (β-carboline) as a potent inhibitory ligand for steroidogenic cytochromes *P*450 (CYP11 and CYP17) (250) R1
Kula, N.S., see Baldessarini, R.J. (254) 199
Kulkarni, R.N., see Olmos, G. (262) 41
Kume, A. and Albin, R.L.
Quantitative autoradiography of 4′-ethynyl-4-*n*-[2,3-$^3H_2$]propylbicycloorthobenzoate binding to the $GABA_A$ receptor complex (263) 163
Kuneš, J., see Železná, B. (260) 95
Kung, H.F., see Laruelle, M. (263) 39
Kunihara, M., see Ito, C. (257) 203
Kunitomo, M., see Osada, S. (252) 347
Kunz, D., see Mühl, H. (249) 95
Kuoppamäki, M., Pälvimäki, E.-P., Syvälahti, E. and Hietala, J.
5-HT_{1C} receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine (255) 91
Kuoppamäki, M., Seppälä, T., Syvälahti, E. and Hietala, J.
Regulation of serotonin 5-HT_{2C} receptors in the rat choroid plexus after acute clozapine treatment (269) 201
Kupryszewski, G., see Patacchini, R. (250) 311
Kurachi, Y., see Hazama, H. (259) 143
Kuraishi, Y., see Onogi, T. (262) 163
Kurasaki, N., see Yokoo, H. (256) 335
Kuribara, H.
Early post-treatment with haloperidol retards induction of methamphetamine sensitization in mice (256) 295
Kurita, M., see Miyamoto, K.-i. (267) 317
Kuriyama, K., see Ichida, T. (267) 43
Kurjak, M., Allescher, H.-D., Schusdziarra, V. and Classen, M.
Release of bombesin-like immunoreactivity from synaptosomal membranes isolated from the rat ileum (257) 169
Kuroda, Y., Watanabe, Y. and McEwen, B.S.
Tianeptine decreases both serotonin transporter mRNA and binding sites in rat brain (268) R3
Kurosawa, A., see Arimura, A. (260) 201
Kurose, H., see Marjamäki, A. (267) 117
Kurose, I., Miura, S., Fukumura, D. and Tsuchiya, M.
Mechanisms of endothelin-induced macromolecular leakage in microvascular beds of rat mesentery (250) 85
Kuroume, T., see Mochizuki, H. (252) 183
Kurowski, S., see Vemulapalli, S. (257) 95
Kurth, C.D., see Albuquerque, M.L.C. (249) 215
Kusner, E.J., Buckner, C.K., Dea, D.M., DeHaas, C.J., Marks, R.L. and Krell, R.D.
The 5-lipoxygenase inhibitors ZD2138 and ZM230487 are potent and selective inhibitors of several antigen-induced guinea-pig pulmonary responses (257) 285
Kusterer, K., Buchheit, K.-H., Schade, A., Bruns, C., Neuberger, C., Engel, G. and Usadel, K.H.
The somatostatin analogue octreotide protects against ethanol-induced microcirculatory stasis and elevated vascular permeability in rat gastric mucosa (259) 265
Kwak, S., see Matsui, K. (254) 295
Kwak, S., see Miyamoto, M. (260) 99
Kwan, C.-Y., see Nie, S.-Q. (266) 11
Kwiecien, R., Medina, I., Barbin, G. and Ben-Ari, Y.
The hypoglycemic sulphonylurea tolbutamide increases *N*-methyl-D-aspartate- but not kainate-activated currents in hippocampal neurons in culture (249) 325
Kwok, Y.-N., see McIntosh, C. (259) 331
Kwon, I.-S., see Lutfy, K. (265) 171
Kwon, O.J., see Shirasaki, H. (268) 263

La, M. and Rand, M.J.
Endothelin-1 enhances vasoconstrictor responses to exogenously administered and neurogenically released ATP in rabbit isolated perfused arteries (249) 133

Laakso, J., see Mervaala, E.M.A. (255) 73
Laakso, M.-L., see Lindroos, O.F.C. (250) 161
Laboisse, C.L., see Jarry, A. (267) 95
Laburthe, M., see Lorinet, A.-M. (269) 59
Lacey, G., see Ong, J. (264) 49
Lach, E., Coy, D.H., Dumont, P., Landry, Y. and Gies, J.-P.
Gastrin releasing peptide-preferring bombesin binding sites in human lung (265) 117
Lach, E., Trifilieff, A., Scherrer, D. and Gies, J.-P.
Association of guinea pig lung bombesin receptors with pertussis toxin-sensitive guanine nucleotide binding proteins (269) 87
Lacour, C., Canals, F., Galindo, G., Cazaubon, C., Segondy, D. and Nisato, D.
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT_1 receptor antagonist in hypertensive rat models (264) 307
Lacour, F., Berger, S., Espinal, J. and Duhault, J.
8-OH-DPAT induces a selective increase in protein intake in ageing overweight animals (255) 249
LaCross, S., see Eisenberg, E. (255) 123
Laemont, K.D., see Howell, R.E. (265) 67
Lafayette, S.S., see Jurkiewicz, A. (256) 329
Lafontan, M., see Bouloumié, A. (269) 95
Lafontan, M., see Larrouy, D. (267) 225
Lagarde, M., see Fayard, J.M. (251) 281
Lagente, V., Moodley, I., Perrin, S., Mottin, G. and Junien, J.-L.
Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung (255) 253
Laguna, J., see Luquin, M.R. (253) 215
Lahtinen, H., see Pitkänen, M. (253) 125
Lakics, V., see Urbányi, Z. (270) 375
Lallement, J.-C., Galleyrand, J.-C., Lima-Leite, A.-C., Fulcrand, P. and Martinez, J.
$Gastrin_{13}$ and the C-terminal octapeptide of cholecystokinin are differently coupled to G-proteins in guinea-pig brain membranes (267) 297
Lamb, V.L., Schwartz, A.J., Rohn, W.R. and Kaiser, L.
Cyclooxygenase inhibitors depress norepinephrine constriction of rat abdominal, but not thoracic, aorta (256) 221
Lambert, C., Ribuot, C., Robichaud, A. and Cusson, J.R.
Negative chronotropic effect of the atrial natriuretic peptide in an anaesthetized dog model (252) 245
Lambert, D.G., see Elliott, J. (268) 447
Lambrecht, N., see Stroff, T. (260) R1
Lan, N.C., see Hawkinson, J.E. (269) 157
Landry, Y., see Lach, E. (265) 117
Lanfumey, L., Haj-Dahmane, S. and Hamon, M.
Further assessment of the antagonist properties of the novel and selective 5-HT_{1A} receptor ligands (+)-WAY 100 135 and SDZ 216-525 (249) 25
Lanfumey, L., see Haj-Dahmane, S. (255) 185
Lang, F., see Busch, A.E. (264) 33
Lang, F., see Herzer, T. (259) 335
Lang, M.A., see Pellinen, P. (270) 35
Langel, Ü., see Bedecs, K. (259) 151
Langel, Ü., see Gregersen, S. (259) 79
Langer, S.Z., see Faure, C. (268) 141
Langer, S.Z., see Jonas, J.-C. (254) 27
Langeveld, C.H., see Vermeulen, R.J. (269) 121
Langlands, J.M. and Diamond, J.
The effect of Ca^{2+} on the translocation of protein kinase C in bovine tracheal smooth muscle (266) 229
Lans, M.C., Spiertz, C., Brouwer, A. and Koeman, J.H.
Different competition of thyroxine binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBs, PCDDs and PCDFs (270) 129
Lanthorn, T.H., see Quartermain, D. (257) 7
Laporte, A.-M., see Haj-Dahmane, S. (255) 185
Larangeira, A.P., see Bozza, P.T. (270) 143
Larrouy, D., Remaury, A., Daviaud, D. and Lafontan, M.
Coupling of inhibitory receptors with G_i-proteins in hamster adipocytes: comparison between adenosine A_1 receptor and α_2-adrenoceptor (267) 225
Larson, A.A., see Goettl, V.M. (259) 83
Larsson, C., Gustavsson, L., Simonsson, P., Bergman, O. and Alling, C.
Mechanisms of muscarinic receptor-stimulated expression of c-*fos* in SH-SY5Y cells (268) 19
Larsson, K., see Andersson, G. (255) 131
Laruel, R., see Vander Elst, L. (251) 163
Laruelle, M., Al-Tikriti, M.S., Zea-Ponce, Y., Zoghbi, S.S., Baldwin, R.M., Charney, D.S., Hoffer, P.B., Kung, H.F. and Innis, R.B.
In vivo quantification of dopamine D_2 receptor parameters in nonhuman primates with [^{123}I]iodobenzofuran and single photon emission computerized tomography (263) 39
Lassen, N.A., see Videbæk, C. (249) 43
László, F. and Whittle, B.J.R.
Constitutive nitric oxide modulates the injurious actions of vasopressin on rat intestinal microcirculation in acute endotoxaemia (260) 265
László, F., Karácsony, G., Pávó, I., Varga, C., Rojik, I. and László, F.A.
Aggressive role of vasopressin in development of different gastric lesions in rats (258) 15
László, F.A., see László, F. (258) 15
Latini, S., Pedata, F. and Pepeu, G.
Effect of idebenone on adenosine outflow and adenine nucleotide level in hippocampal slices under ischemia-like conditions (249) 65
Latini, S., see Pazzagli, M. (254) 277
Laudenbach, V., see Mantz, J. (257) R7
Laudrup, P. and Klitgaard, H.
Metabotropic and ionotropic excitatory amino acid receptor agonists induce different behavioral effects in mice (250) 15
Laudrup, P., see Klitgaard, H. (250) 9
Laugier, C., see Fayard, J.M. (251) 281
Laurant, P. and Berthelot, A.
Influence of endothelium on Mg^{2+}-induced relaxation in noradrenaline-contracted aorta from DOCA-salt hypertensive rat (258) 167
Laurent, S., see Yin, Y. (261) 97
Laurie, D.J. and Seeburg, P.H.
Ligand affinities at recombinant *N*-methyl-D-aspartate receptors depend on subunit composition (268) 335
Lavayre, J., see Heuillet, E. (269) 139
Lavezzo, A., see Barocelli, E. (254) 151
Lavidis, N.A., see Karunanithi, S. (261) 17
Lavielle, S., Brunissen, A., Carruette, A., Garret, C. and Chassaing, G.
Highly potent substance P antagonists substituted with β-phenyl- or β-benzyl-proline at position 10 (258) 273
Lavoie, N., see Dennis, T. (262) 143
Lawrence, E. and Brain, S.D.
Effect of BQ-123 and Ro 47-0203 (bosentan) on endothelin-induced vasoconstriction in the rat skin (260) 103
Layer, P., see Grandt, D. (269) 127
Lazarovici, P., see Rasouly, D. (269) 255
Lazarus, L.H., see Jones, L.S. (264) 39
Lazdunski, M., see Romey, G. (263) 101
Lebel, W.S., see Constantine, J.W. (252) 275
Lecci, A., Giuliani, S., Santicioli, P. and Maggi, C.A.
Involvement of spinal tachykinin NK_1 and NK_2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats (259) 129
Lecharny, J.-B., see Mantz, J. (257) R7

Lee, J.-Y., see Yu, S.-M. (256) 85
Lee, S.-S., see Su, M.-J. (254) 141
Lee, S.H., Kayser, V. and Guilbaud, G.
Antinociceptive effect of systemic kelatorphan, in mononeuropathic rats, involves different opioid receptor types (264) 61
Lee, Y.-P., see Brown, L.M. (254) 307
Lees, P., see McKellar, Q.A. (253) 191
Lefebvre, H., see Contesse, V. (265) 27
Lefebvre, R.A., see Barthó, L. (259) 101
Lefebvre, R.A., see Briejer, M.R. (250) 181
Le Fur, G., see Brouard, A. (253) 289
Le Fur, G., see Emonds-Alt, X. (250) 403
LeFur, G., see Azzi, M. (255) 167
Léger, S., see Charleson, S. (267) 275
Lehmann, H., see Shepard, P.D. (265) 141
Leinonen, L.M., see Lindroos, O.F.C. (250) 161
Leite, J.R., see Andreatini, R. (260) 233
Leite, P.E.P., see Paik, S.H. (253) 101
Leitner, M.L., Hohmann, A.G., Patrick, S.L. and Walker, J.M.
Regional variation in the ratio of σ_1 to σ_2 binding in rat brain (259) 65
Lejeune, F., Audinot, V., Gobert, A., Rivet, J.-M., Spedding, M. and Millan, M.J.
Clozapine inhibits serotoninergic transmission by an action at α_1-adrenoceptors not at 5-HT_{1A} receptors (260) 79
Lemaire, S., Belleau, B. and Jolicoeur, F.B.
Agonist and antagonist opioid activity of axial and equatorial conformations of *S*-methyl- and *S*-allyl-morphinans (258) 111
Lemke, S.M., see Gruetter, C.A. (257) 275
Leonard, B., see Caldwell, M. (260) 191
Leonardi, A., see Testa, R. (249) 307
Leone, A.M., see Persson, M.G. (264) 13
Léoty, C., see Bonnet, V. (264) 69
Lepre, M., Olpe, H.-R., Evans, R.H. and Brugger, F.
Physiological and pharmacological characterization of the spinal tachykinin NK_2 receptor (258) 23
Leprêtre, N., see Baron, A. (269) 105
Letari, O., Miozzo, A., Folco, G., Belloni, P.A., Sala, A., Rovati, G.E. and Nicosia, S.
Effects of loratadine on cytosolic Ca^{2+} levels and leukotriene release: novel mechanisms of action independent of the antihistamine activity (266) 219
Letari, O., see Hernandez, A. (270) 301
Leurs, R., see Yokoyama, H. (260) 23
Levens, N., see Macari, D. (249) 85
Levens, N., see Macari, D. (259) 27
Lever, J.R., see Villemagne, V.L. (257) 195
Lévesque, D., see Pilon, C. (268) 129
Levi, R., see Park, K.H. (256) 99
Levine, J.D., see Green, P.G. (252) 127
Levkovitz, Y. and Segal, M.
Acetylcholine mediates the effects of fenfluramine on dentate granule cell excitability in the rat (264) 279
Lévy, L., Alvaro, V., Dubray, C. and Joubert, D.
Ca^{2+}-dependent protein kinase C isoforms in rat pituitary hyperplasia: effect of in vivo treatment with quinagolide (268) 327
Lewis, A.I., see Zuccarello, M. (259) R1
Leyris, R., see Brouard, A. (253) 289
Leyva, J., see Maione, S. (250) 209
Li, Q.-S., see Hu, X.-H. (263) 53
Li, S.-Y., see Vincens, M. (260) 157
Li, T., see Qian, C. (250) R13
Li, W.-P., see Cao, B.-J. (259) 75
Liao, J.-F., see Chiou, W.-F. (257) 59
Libertine-Garahan, L., see Qian, C. (250) R13
Liddle, C.W., see Critchley, D.J.P. (254) 133
Liebmann, C., see Graneß, A. (268) 271
Lieu, A.T. and Reid, J.J.
Changes in the responsiveness to endothelin-1 in isolated atria from diabetic rats (261) 33
Light, P.E. and French, R.J.
Glibenclamide selectively blocks ATP-sensitive K^+ channels reconstituted from skeletal muscle (259) 219
Lilliu, V., see Mereu, G. (264) 449
Lima-Leite, A.-C., see Lallement, J.-C. (267) 297
Lin, B., Gao, Y., Chang, J.-K., Heaton, J., Hyman, A. and Lippton, H.
An adrenomedullin fragment retains the systemic vasodepressor activity of rat adrenomedullin (260) 1
Lin, C.-N., see Wang, J.-P. (251) 35
Lin, R.C.-S., see Von Lubitz, D.K.J.E. (256) 161
Lin, R.C.-S., see Von Lubitz, D.K.J.E. (263) 59
Lin-Shiau, S.-Y., see Liu, S.-H. (251) 61
Lin, Y. and Carpenter, D.O.
Direct excitatory opiate effects mediated by non-synaptic actions on rat medial vestibular neurons (262) 99
Lin, Y.-L., see Ho, C.-L. (259) 259
Lin, Y.-S., see Huang, H.-C. (268) 73
Lindahl, A., see Yoo, H. (268) 55
Lindemann, J.P., see Buzzard, S.L. (260) 15
Lindroos, O.F.C., Veilahti, J., Leinonen, L.M. and Laakso, M.-L.
Characterization of melatonin binding to the anteroventral and anterodorsal thalamic nuclei of the rat (250) 161
Lindstaedt, R., see Schmidt, J. (260) 247
Liou, S.-Y., see Ito, C. (257) 203
Lippert, K., Welsch, M. and Krieglstein, J.
Over-additive protective effect of dizocilpine and NBQX against neuronal damage (253) 207
Lippton, H., see Lin, B. (260) 1
Liston, D.R., see Zorn, S.H. (269) R1
Liu, J.-C., Cox, R.F., Greif, G.J., Freedman, J.E. and Waszczak, B.L.
The putative dopamine D_3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity (264) 269
Liu, J.-X., Tanonaka, K., Yamamoto, K. and Takeo, S.
Propafenone and disopyramide enhance post-ischemic contractile and metabolic recovery of perfused hearts (250) 361
Liu, J.T., Paul, W., Emerson, M., Cicala, C. and Page, C.P.
Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature (264) 183
Liu, S.-H. and Lin-Shiau, S.-Y.
Potentiation by metal ions of ryanodine contracture of the mouse diaphragm (251) 61
Llopis, P., see Martí-Cabrera, M. (255) 157
Lloret, S. and Moreno, J.J.
Effect of nonapeptide fragments of uteroglobin and lipocortin I on oedema and mast cell degranulation (264) 379
Lluch, S., see Aldasoro, M. (250) 103
Lluch, S., see Martínez, C. (261) 73
Lobina, C., see Colombo, G. (265) 167
Löfberg, L., see Waters, N. (251) 181
Löfdahl, C.-G., see Arakawa, H. (252) 313
Löfdahl, C.-G., see Arakawa, H. (259) 251
Loizzo, A., see Capasso, A. (261) 209
Lokhandwala, M.F., see Gopalakrishnan, S.M. (250) 469
Lombardi, P., see Feriotto, G. (267) 143
Lombet, A. and Spedding, M.
Differential effects of non-peptidic tachykinin receptor antagonists on Ca^{2+} channels (267) 113
London, E.D., see Hashimoto, K. (266) 67
London, E.D., see Shimada, A. (263) 293
Long, J.B. and Skolnick, P.
1-Aminocyclopropanecarboxylic acid protects against dynorphin A-induced spinal injury (261) 295
Longmore, J., Hogg, J.E., Hutson, P.H. and Hill, R.G.

Effects of two truncated forms of human calcitonin-gene related peptide: implications for receptor classification (265) 53
Longmore, J., see Seabrook, G.R. (250) 125
Longo, W.E., see Deshpande, Y. (256) R1
Lonovics, J., Jakab, I., Szilvássy, J. and Szilvássy, Z.
Regional differences in nitric oxide-mediated relaxation of the rabbit sphincter of Oddi (255) 117
Lookingland, K.J., see Fleckenstein, A.E. (254) 35
Lookingland, K.J., see Fleckenstein, A.E. (264) 163
Lookingland, K.J., see Manzanares, J. (249) 107
Lookingland, K.J., see Manzanares, J. (257) 199
Lookingland, K.J., see Wagner, E.J. (254) 105
Lopes, M.C., see Santos, D.L. (267) 307
Lopez, F., see Colado, M.I. (252) 291
López, M.G., see Maroto, R. (270) 331
López, M.G., see Salas, E. (258) 47
López-Novoa, J.M., see Rivas-Cabañero, L. (270) 119
Lorden, J.F., see Weissman, A.D. (250) 329
Lorenzo, P.S., Butta, N.V. and Adler-Graschinsky, E.
Effects of L-glutamate on the responses to nerve stimulation in rat isolated atria (258) 253
Lorinet, A.-M., Javoy-Agid, F., Laburthe, M. and Amiranoff, B.
Galanin receptors in human hypothalamus: biochemical and structural analysis (269) 59
Löscher, W. and Hönack, D.
Over-additive anticonvulsant effect of memantine and NBQX in kindled rats (259) R3
Löscher, W. and Richter, A.
The novel selective and silent 5-HT_{1A} receptor antagonist (+)-WAY-100135 aggravates dystonic movements in a mutant hamster model (255) 235
Löscher, W., see Richter, A. (264) 345
Löscher, W., see Richter, A. (264) 371
Löscher, W., see Wlaź, P. (257) 217
Löschmann, P.-A., see Richter, A. (264) 345
Lötvall, J., see Arakawa, H. (252) 313
Lötvall, J., see Arakawa, H. (259) 251
Loubatières-Mariani, M.-M., see Berdeu, D. (254) 119
Loza, I., see Campos-Toimil, M. (251) 83
Lucchi, L., see Pascale, A. (265) 1
Lucchini, R.E., see Chitano, P. (270) 167
Lucion, A.B., see De Almeida, R.M.M. (264) 445
Lucot, J.B.
Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-*n*-propylamino)tetralin (253) 53
Ludbrook, J. and Ventura, S.
The decompensatory phase of acute hypovolaemia in rabbits involves a central δ_1-opioid receptor (252) 113
Ludvigsdottir, G., see Adan, R.A.H. (269) 331
Lukovic, L., see Petty, M.A. (255) 215
Lundberg, J.M., see Bannenberg, G. (270) 175
Lundberg, J.M., see Modin, A. (261) 185
Lundberg, J.M., see Szallasi, A. (264) 217
Lundy, P.M. and Frew, R.
Effect of ω-agatoxin-IVA on autonomic neurotransmission (261) 79
Lunn, W.H.W., see Schoepp, D.D. (270) 67
Luo, D. and Vincent, S.R.
Metalloporphyrins inhibit nitric oxide-dependent cGMP formation in vivo (267) 263
Luo, J., see Green, P.G. (252) 127
Luo, L., see Puke, M.J.C. (260) 227
Luo, L., see Wiesenfeld-Hallin, Z. (251) 99
Luomala, K., see Jansson, C.C. (266) 165
Lupia, E., see Emanuelli, G. (261) 265
Luquin, M.R., Guillén, J., Martínez-Vila, E., Laguna, J. and Martínez-Lage, J.M.
Functional interaction between dopamine D_1 and D_2 receptors in 'MPTP' monkeys (253) 215
Lutfy, K., Sadowski, B., Kwon, I.-S. and Weber, E.
Morphine analgesia and tolerance in mice selectively bred for divergent swim stress-induced analgesia (265) 171
Lutfy, K., Woodward, R.M., Keana, J.F.W. and Weber, E.
Inhibition of clonic seizure-like excitatory effects induced by intrathecal morphine using two NMDA receptor antagonists: MK-801 and ACEA-1011 (252) 261
Luxen, A., see Pauwels, T. (257) 53
Lysko, G.S., Robinson, J.L., Casto, R. and Ferrone, R.A.
The stereospecific effects of isoflurane isomers in vivo (263) 25
Lysko, K.A., see Yue, T.-L. (251) 237
Lysko, P.G., see Yue, T.-L. (251) 237

Macari, D., Bottari, S., Whitebread, S., De Gasparo, M. and Levens, N.
Renal actions of the selective angiotensin AT_2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat (249) 85
Macari, D., Whitebread, S., Cumin, F., De Gasparo, M. and Levens, N.
Renal actions of the angiotensin AT_2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system (259) 27
Maccario, M., see Mazza, E. (254) 17
MacDermot, J., see Boyd, R.S. (267) 161
MacDermot, J., see Olmos, G. (262) 41
MacDonald, E., see Unkila, M. (270) 157
MacDonald, J.F., see Fletcher, E.J. (267) 249
MacDonald, J.F., see Taverna, F.A. (267) R3
MacDonald, R.G., see Zhu, J. (268) 279
Machado, A., see Ruano, D. (267) 121
Machado, A., see Vizuete, M.L. (270) 183
Maciocco, E., see Concas, A. (267) 207
MacKenzie, R.G., VanLeeuwen, D., Pugsley, T.A., Shih, Y.-H., Demattos, S., Tang, L., Todd, R.D. and O'Malley, K.L.
Characterization of the human dopamine D_3 receptor expressed in transfected cell lines (266) 79
MacKenzie, R.G., see Damsma, G. (249) R9
MacLeod, K.M., see Ray, A. (256) 311
MacPherson, I.S., see Clarke, G.D. (257) 103
Macrae, I.M., see Dawson, D.A. (249) 7
Madden, Z., see Pinnock, R.D. (269) 73
Madden, Z., see Suman-Chauhan, N. (269) 65
Madras, B.K., Reith, M.E.A., Meltzer, P.C. and Dutta, A.K.
O-526, a piperidine analog of GBR 12909, retains high affinity for the dopamine transporter in monkey caudate-putamen (267) 167
Maeda, H., see Tsunoda, R. (262) 55
Maeda, K., see Kita, Y. (257) 123
Maehara, T., Fujita, A., Suthamnatpong, N., Takeuchi, T. and Hata, F.
Differences in relaxant effects of cyclic GMP on skinned muscle preparations from the proximal and distal colon of rats (261) 163
Maehara, T., see Kanada, A. (250) 59
Maestrelli, P., see Chitano, P. (270) 167
Maeyama, K., see Yokoyama, H. (260) 23
Maffrand, J.-P., see Azzi, M. (255) 167
Maggi, C.A., see Barthó, L. (259) 187
Maggi, C.A., see Lecci, A. (259) 129
Maggi, C.A., see Patacchini, R. (250) 311
Maggi, C.A., see Wiesenfeld-Hallin, Z. (251) 99
Maggi, C.A., see Zagorodnyuk, V. (255) 9
Maggio, R., Barbier, P., Bolognesi, M.L., Minarini, A., Tedeschi, D. and Melchiorre, C.
Binding profile of the selective muscarinic receptor antagonist tripitramine (268) 459

Magnan, E., see Cataldi, M. (253) 149
Magnusson, H., see Buchan, K.W. (260) 221
Mahle, C.D., see Parker, E.M. (268) 43
Mahrle, G., see Sebök, B. (270) 79
Mailleux, P. and Vanderhaeghen, J.-J.
δ-9-Tetrahydrocannabinol regulates substance P and enkephalin mRNAs levels in the caudate-putamen (267) R1
Mailleux, P. and Vanderhaeghen, J.-J.
Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen (266) 193
Main, M.J., see Seabrook, G.R. (250) 125
Maione, S., D'Amico, M., Berrino, L., Filippelli, A., Leyva, J. and Rossi, F.
Involvement of periaqueductal gray area NMDA receptors in endothelin-induced behavioural effects (250) 209
Mais, D.E., see Bowling, N. (268) 365
Mais, D.E., see True, T.A. (266) 51
Maitre, M., Ratomponirina, C., Gobaille, S., Hodé, Y. and Hechler, V.
Displacement of [^{3}H]γ-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics (256) 211
Majarais, I., see Nie, S.-Q. (266) 11
Majka, J., see Konturek, S.J. (253) 107
Mak, J.C., see Shirasaki, H. (268) 263
Mak, J.C.W., Grandordy, B. and Barnes, P.J.
High affinity [^{3}H]formoterol binding sites in lung: characterization and autoradiographic mapping (269) 35
Makimura, M., see Jaw, S.P. (257) 153
Malagié, I., see Gardier, A.M. (265) 107
Malandrino, S., see Hernandez, A. (270) 301
Malatynska, E., see Knapp, R.J. (269) 133
Malcangio, M., Da Silva, H. and Bowery, N.G.
Plasticity of $GABA_B$ receptor in rat spinal cord detected by autoradiography (250) 153
Maldonado, R., see Matsuoka, I. (268) 215
Malinowska, B., Godlewski, G., Buczko, W. and Schlicker, E.
EP_3 receptor-mediated inhibition of the neurogenic vasopressor response in pithed rats (259) 315
Mallet, P.E. and Beninger, R.J.
7-OH-DPAT produces place conditioning in rats (261) R5
Malmberg, A.B. and Yaksh, T.L.
Antinociception produced by spinal delivery of the *S* and *R* enantiomers of flurbiprofen in the formalin test (256) 205
Malmberg, A.B. and Yaksh, T.L.
Antinociception produced by spinal delivery of the *S* and *R* enantiomers of flurbiprofen in the formalin test. European Journal of Pharmacology, 256 (1994) 205–209 (260) 283
Manahan-Vaughan, D., Anwyl, R. and Rowan, M.J.
5-HT_{1A} receptor-mediated inhibition in the hippocampus of the alert rat – effects of repeated gepirone treatment (260) 149
Mandy, A., see Gard, P.R. (264) 295
Mannaioni, G., Alesiani, M., Carlà, V., Natalini, B., Marinozzi, M., Pellicciari, R. and Moroni, F.
Sulfate esters of hydroxy amino acids as stereospecific glutamate receptor agonists (251) 201
Manning, A.S., see Vander Elst, L. (251) 163
Männistö, P.T., see Rauhala, P. (259) 57
Männistö, P.T., see Törnwall, M. (250) 77
Manome, Y., see Sakurada, T. (261) 85
Manor, D., see Gurwitz, D. (267) 21
Mansbridge, J.N., see Morhenn, V.B. (268) 409
Mantione, C.R., see Hashimoto, K. (266) 67
Mantz, J., Laudenbach, V., Lecharny, J.-B., Henzel, D. and Desmonts, J.-M.
Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes (257) R7
Manuel, Y., see Pellegrini, O. (270) 221
Manzanares, J., Durham, R.A., Lookingland, K.J. and Moore, K.E.
δ-Opioid receptor-mediated regulation of central dopaminergic neurons in the rat (249) 107
Manzanares, J., Edwards, J.V., Lookingland, K.J. and Moore, K.E.
MDL-101,562 blocks the stimulatory effects of bombesin and gastrin-releasing peptide on hypothalamic dopaminergic neurons (257) 199
Manzini, S., Perretti, F., Abelli, L., Evangelista, S., Seeds, E.A.M. and Page, C.P.
Isbufylline, a new xanthine derivative, inhibits airway hyperresponsiveness and airway inflammation in guinea pigs (249) 251
Manzini, S., see Goso, C. (249) 185
Manzini, S., see Goso, C. (254) 221
Manzoor, E., see Håkansson, H. (270) 279
Mapp, C.E., see Chitano, P. (270) 167
Maragoudakis, M.E., see Bastaki, M. (251) 263
Maragoudakis, M.E., see Tsopanoglou, N.E. (258) 151
Marano, G. and Argiolas, L.
Postjunctional regulation by angiotensin II of α_1-adrenoceptor-mediated pressor responses in the rat (261) 121
Marceau, F., see Godin, D. (253) 225
Marceau, F., see Petitclerc, E. (259) 91
Marcellin, N., see Billaud, G. (268) 357
Marden, C., see Rattray, M. (268) 439
Marek, G.J. and Aghajanian, G.K.
Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: blockade by MDL 100,907, a highly selective 5-HT_{2A} receptor antagonist (259) 137
Marín, J., see Ferrer, M. (252) 233
Marín, J., see Ferrer, M. (258) 103
Marinozzi, M., see Mannaioni, G. (251) 201
Marjamäki, A., Pohjanoksa, K., Ala-Uotila, S., Sizmann, D., Oker-Blom, C., Kurose, H. and Scheinin, M.
Similar ligand binding in recombinant human α_2C2-adrenoceptors produced in mammalian, insect and yeast cells (267) 117
Marjamäki, A., see Jansson, C.C. (266) 165
Marks, M.J., see Firestone, J.A. (269) 177
Marks, R.L., see Kusner, E.J. (257) 285
Markus, R.P., see Carneiro, R.C.G. (257) 73
Marona-Lewicka, D. and Nichols, D.E.
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (258) 1
Maroto, R., De la Fuente, M.-T., Artalejo, A.R., Abad, F., López, M.G., García-Sancho, J. and García, A.G.
Effects of Ca^{2+} channel antagonists on chromaffin cell death and cytosolic Ca^{2+} oscillations induced by veratridine (270) 331
Martelli, E.A., see Pascale, A. (265) 1
Marthan, R., see Savineau, J.-P. (249) 191
Martí-Cabrera, M., Llopis, P., Abengochea, A., Ortiz, J.L., Climent, V.J., Cortijo, J. and Morcillo, E.J.
Effects of Ca^{2+} channel antagonists and benzodiazepine receptor ligands in normal and skinned rat urinary bladder (255) 157
Martin, D., Thompson, M.A. and Nadler, J.V.
The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1 (250) 473
Martin, D.L., see Waniewski, R.A. (260) 113
Martin, G.E., see Bertrand, P. (262) 233
Martin, J.-D., see Naline, E. (256) 301
Martín, M.-L., see Morán, A. (252) 161
Martin, M.I., see Colado, M.I. (252) 291
Martínez, C., Vila, J.M., Aldasoro, M., Medina, P., Chuan, P. and Lluch, S.
The human deferential artery: endothelium-mediated contraction in response to adrenergic stimulation (261) 73
Martínez, C., see Aldasoro, M. (250) 103
Martínez, E., see Ferré, S. (255) 203

Martinez, J., see Lallement, J.-C. (267) 297
Martínez-Lage, J.M., see Luquin, M.R. (253) 215
Martinez, R.P., see Raffa, R.B. (258) R5
Martínez-Vila, E., see Luquin, M.R. (253) 215
Martini, L.C., see Jurkiewicz, A. (256) 329
Martins, M.A., see Altenburg, S.P. (256) 45
Martins, M.A., see Bozza, P.T. (270) 143
Martorana, P.A., Kettenbach, B., Bohn, H., Schönafinger, K. and Henning, R.
Antiischemic effects of pirsidomine, a new nitric oxide donor (257) 267
Martorana, P.A., see Klemm, P. (250) R9
Martres, M.-P., see Pilon, C. (268) 129
Marvizón, J.-C. and Baudry, M.
Allosteric interactions and modulator requirement for NMDA receptor function (269) 165
Masayasu, H., see Hattori, R. (267) R1
Mascia, M.P., see Concas, A. (267) 207
Mascia, M.S., see Imperato, A. (264) 55
Mascolo, N., Gaginella, T.S., Izzo, A.A., Di Carlo, G. and Capasso, F.
Nitric oxide involvement in sodium choleate-induced fluid secretion and diarrhoea in rats (264) 21
Massi, P., Giagnoni, G., Basilico, L., Gori, E., Rubino, T. and Parolaro, D.
Intestinal effect of morphine 6-glucuronide: in vivo and in vitro characterization (253) 269
Massotti, M., see Roscetti, G. (269) 17
Masuda, N., see Uchida, W. (264) 285
Masuzawa-Ito, K., see Asano, M. (263) 121
Matsuda, H., see Dos Santos Cruz, J. (266) 317
Matsuda, T., see Asano, M. (263) 121
Matsuda, Y., Shibamoto, T., Hayashi, Jr., T., Saeki, Y., Yamaguchi, Y., Tanaka, S. and Koyama, S.
Renal vascular and sympathetic nerve responses to hypotension induced by platelet-activating factor in anesthetized dogs (250) 341
Matsuda, Y., see Karaki, H. (262) 255
Matsui, K., Wada, K. and Kwak, S.
Ataxia-ameliorating effects of YM-14673, a potent analog of thyrotropin releasing hormone, in ataxic mutant mice (254) 295
Matsui, M., see Yokoo, H. (256) 335
Matsuki, Y., see Ishizuka, T. (262) 113
Matsumoto, M., see Hirokami, M. (253) 9
Matsumoto, Y., Aihara, K., Kamata, T. and Goto, N.
Nizofenone, a neuroprotective drug, suppresses glutamate release and lactate accumulation (262) 157
Matsumoto, Y., Kataoka, Y., Watanabe, Y., Miyazaki, A. and Taniyama, K.
Antianxiety actions of Ca^{2+} channel antagonists with Vogel-type conflict test in rats (264) 107
Matsumoto, Y., see Arimura, A. (260) 201
Matsunaga, K., see Matsuno, K. (261) 43
Matsunaga, T., see Tsunoda, R. (262) 55
Matsunaga, T.O., see Vanderah, T. (252) 133
Matsuno, K., Senda, T., Matsunaga, K. and Mita, S.
Ameliorating effects of σ receptor ligands on the impairment of passive avoidance tasks in mice: involvement in the central acetylcholinergic system (261) 43
Matsuoka, I., Maldonado, R., Defer, N., Noël, F., Hanoune, J. and Roques, B.-P.
Chronic morphine administration causes region-specific increase of brain type VIII adenylyl cyclase mRNA (268) 215
Matsuura, T., see Ebara, T. (263) 69
Maurer, J.A. and McKay, D.B.
Staurosporine-induced reduction of secretory function in cultured bovine adrenal chromaffin cells (253) 115
Maxey, R.J., see Tudhope, S.R. (264) 317
Maxwell, D.M., see Adler, M. (270) 9
May, P.C., see Sharp, R.L. (266) R1
May, T., see Rommelspacher, H. (252) 51
Mayer, M.B., see Ruiz-Velasco, V. (268) 311
Mayer, N., see Doods, H.N. (253) 275
Mayne, N.G., see Sharp, R.L. (266) R1
Mayne, N.G., see Sharp, R.L. (269) R5
Mazza, E., Ghigo, E., Boffano, G., Valetto, M., Maccario, M., Arvat, E., Bellone, J., Procopio, M., Müller, E.E. and Camanni, F.
Effects of direct and indirect acetylcholine receptor agonists on growth hormone secretion in humans (254) 17
McAuley, M.A., see Patel, T.R. (260) 65
McCaig, D. and De Jonckheere, S.
Effects of two Ca^{2+} modulators in normal and albumin-sensitized guinea-pig trachea (249) 53
McCann, D.J., see Weissman, A.D. (250) 329
McCarthy, H.D., Crowder, R.E., Dryden, S. and Williams, G.
Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations (265) 99
McCauley, L.D., see Hawkinson, J.E. (269) 157
McCloskey, M.J.D., see Potter, E.K. (267) 253
McClue, S.J., Baron, B.M. and Harris, B.A.
Activation of G_i protein by peptide structures of the muscarinic M_2 receptor second intracellular loop (267) 185
McCombs, G.B., see Kidwell, D.T. (270) 97
McConnell, S.E., D'Souza, S.W. and Slater, P.
A polyamine binding site labelled with [^{3}H]spermidine in developing human cerebellum (262) 293
McCulloch, J., see Dawson, D.A. (249) 7
McCulloch, J., see Patel, T.R. (260) 65
McDaniel, M.L., see Hasan, K. (249) 101
McDonald, F., see Pons, F. (261) 237
McDonald, J.W., see Schoepp, D.D. (270) 67
McDougall, S.A., see Crawford, C.A. (252) 225
McEwen, B.S., see Kuroda, Y. (268) R3
McGeer, P.L., see Klegeris, A. (260) 273
McIntosh, C., Yago, V. and Kwok, Y.-N.
β-Funaltrexamine blockade of opioid-induced inhibition of somatostatin secretion from rat stomach (259) 331
McKay, D.B., see Maurer, J.A. (253) 115
McKellar, Q.A., Lees, P. and Gettinby, G.
Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships (253) 191
Mckenna, P.J., see Yue, T.-L. (251) 237
McKeown, J.W., see Kidwell, D.T. (270) 97
McKnight, W., see Wallace, J.L. (257) 249
McLeod, R.L., Gertner, S.B. and Hey, J.A.
Species differences in the cardiovascular responses to histamine H_3 receptor activation (259) 211
McManigle, J.E., Taveira DaSilva, A.M., Dretchen, K.L. and Gillis, R.A.
Potentiation of MK-801-induced breathing impairment by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (252) 11
McMorn, S.O., see Rana, B. (250) 247
McMurdo, L., Thiemermann, C. and Vane, J.R.
The endothelin ET_B receptor agonist, IRL 1620, causes vasodilatation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit (259) 51
McQuilkin, S.J., see Klein, R.L. (268) 237
Meakin, A.J.L.S., see Gard, P.R. (264) 295
Mechoulam, R., see Pertwee, R. (259) 115
Medhurst, A.D., Greenlees, C., Parsons, A.A. and Smith, S.J.
Nitric oxide synthase inhibitors 7- and 6-nitroindazole relax smooth muscle in vitro (256) R5
Medina, I., see Kwiecien, R. (249) 325

Medina, P., see Martínez, C. (261) 73
Meehan, S.M., see Schechter, M.D. (260) 133
Mei, Q.B., see Cho, C.H. (256) 9
Meijer, O.C. and De Kloet, E.R.
Corticosterone suppresses the expression of 5-HT_{1A} receptor mRNA in rat dentate gyrus (266) 255
Meister, B. and Jacobsson, G.
Segment-specific expression of messenger RNA encoding for a glutamate transporter by renal tubule cells (267) 323
Melchiorre, C., Romualdi, P., Bolognesi, M.L., Donatini, A. and Ferri, S.
Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas (265) 93
Melchiorre, C., see Maggio, R. (268) 459
Melis, M.R., see Stancampiano, R. (261) 149
Mellemkjær, S. and Nielsen-Kudsk, J.E.
Glibenclamide inhibits hypoxic relaxation of isolated porcine coronary arteries under conditions of impaired glycolysis (270) 307
Meller, E., Bohmaker, K., Goldstein, M. and Basham, D.A.
Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D_3 receptors (249) R5
Melman, N., see Von Lubitz, D.K.J.E. (256) 161
Meloni, D., see De Montis, M.G. (249) 179
Meltzer, P.C., see Madras, B.K. (267) 167
Ménager, J., see Heuillet, E. (269) 139
Menard, J.-F., see Billaud, G. (268) 357
Méndez-Franco, J., see Pérez de la Mora, M. (250) 423
Mennini, T., see Cagnotto, A. (266) 131
Mennini, T., see Cervo, L. (253) 139
Menozzi, B., see Benelli, A. (260) 279
Mercer, L.D., see Beart, P.M. (269) 193
Mereu, G., Lilliu, V., Vargiu, P., Muntoni, A.L., Diana, M. and Gessa, G.L.
Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats (264) 449
Merlin, D., see Jarry, A. (267) 95
Mervaala, E.M.A., Laakso, J. and Karppanen, H.
Cardiovascular effects of felodipine are not antagonized by dietary salt (255) 73
Merval, R., see Bernard, C. (270) 115
Meßmer, U.K., see Dimmeler, S. (267) 105
Meulemans, A.L., see Briejer, M.R. (250) 181
Meunier, J.-C., see Polastron, J. (266) 139
Meurs, H., see Roffel, A.F. (249) 235
Meurs, H., see Santing, R.E. (254) 49
Meurs, H., see Santing, R.E. (257) 145
Meyer, C., see Chamouard, P. (262) 33
Meyer, W., see Kojda, G. (250) 385
Meysmans, L., see Chatelain, P. (267) 151
Michael-Hepp, J., see Darius, H. (258) 207
Michaluk, J., see Antkiewicz-Michaluk, L. (254) 9
Michel, A., see Khakh, B.S. (263) 301
Michel, A.D., see Trezise, D.J. (259) 295
Michel, G., see Kemény, L. (258) 269
Michel, M.C., see Grandt, D. (269) 127
Middlefell, V.C., see Critchley, D.J.P. (254) 133
Middlefell, V.C., see Critchley, D.J.P. (264) 95
Middlemiss, D.N., see Heald, A. (264) 213
Midgley, L.P., Wagstaff, J.D., Singh, N.A., Bush, L.G., Gibb, J.W. and Hanson, G.R.
Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions (251) 191
Midtvedt, T., see Persson, M.G. (264) 13
Mihic, S.J., Whiting, P.J. and Harris, R.A.
Anaesthetic concentrations of alcohols potentiate $GABA_A$ receptor-mediated currents: lack of subunit specificity (268) 209
Milano, S., see Pascale, A. (265) 1
Millan, M.J., Audinot, V., Rivet, J.-M., Gobert, A., Vian, J., Prost, J.-F., Spedding, M. and Peglion, J.-L.
S 14297, a novel selective ligand at cloned human dopamine D_3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats (260) R3
Millan, M.J., see Lejeune, F. (260) 79
Millan, M.J., see Rivet, J.-M. (265) 175
Millan, M.J., see Schreiber, R. (264) 99
Millan, M.J., see Seguin, L. (253) R1
Miller, L.G., see Pritchard, G.A. (266) 107
Miller, S., Bridges, R.J., Chamberlin, A.R. and Cotman, C.W.
Pharmacological dissociation of glutamatergic metabotropic signal transduction pathways in cortical astrocytes (269) 235
Millet, S., see Barone, P. (249) 221
Minami, M., see Onogi, T. (262) 163
Minarini, A., see Maggio, R. (268) 459
Minocha, S.C., see Pritchard, G.A. (266) 107
Minoda, S., see Yamanouchi, T. (257) 39
Miozzo, A., see Letari, O. (266) 219
Mironneau, J., see Baron, A. (269) 105
Misawa, M., see Kamei, J. (249) 161
Misawa, M., see Kamei, J. (251) 95
Misawa, M., see Kamei, J. (251) 291
Misawa, M., see Kamei, J. (253) 293
Misawa, M., see Kamei, J. (254) 113
Misawa, M., see Kamei, J. (260) 257
Misawa, M., see Suzuki, T. (263) 207
Mischiati, C., see Feriotto, G. (267) 143
Misko, T.P., see Kasten, T.P. (253) 35
Missirlis, E., see Bastaki, M. (251) 263
Mita, S., see Matsuno, K. (261) 43
Mitchelson, F., see Pennefather, J.N. (262) 297
Mitchelson, F., see Shen, A. (252) 167
Miura, K., see Ebara, T. (263) 69
Miura, K., see Ohta, K. (269) 115
Miura, K., see Yukimura, T. (264) 399
Miura, S., see Isono, T. (260) 163
Miura, S., see Kurose, I. (250) 85
Miwa, Y., see Kikuchi de Beltrán, K. (252) 99
Miwa, Y., see Kikuchi de Beltrán, K. (262) 49
Miyake, A., Yamamoto, H., Enomori, T. and Kawashima, H.
Exogenous group II phospholipase A_2 induces prostaglandin E_2 production in mouse peritoneal macrophages (253) 155
Miyamoto, A., Kawana, S., Kimura, H. and Ohshika, H.
Impaired expression of $G_{s\alpha}$ protein mRNA in rat ventricular myocardium with aging (266) 147
Miyamoto, C., see Adachi, M. (269) 225
Miyamoto, K.-i., Kurita, M., Ohmae, S., Sakai, R., Sanae, F. and Takagi, K.
Selective tracheal relaxation and phosphodiesterase-IV inhibition by xanthine derivatives (267) 317
Miyamoto, M., Ishida, M., Kwak, S. and Shinozaki, H.
Agonists for metabotropic glutamate receptors in the rat delay recovery from halothane anesthesia (260) 99
Miyashita, H., see Yamanouchi, T. (257) 39
Miyata, K., Ito, H., Yamano, M., Hidaka, K., Kamato, T., Nishida, A. and Yuki, H.
Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT_3 receptor antagonist, on stress-induced defecation (250) 303
Miyata, K., see Saita, Y. (269) 249
Miyata, N., Yamaura, H., Tanaka, M., Takahashi, K., Tsuchida, K. and Otomo, S.
CD-832, a new dihydropyridine derivative with both nitrate-like and Ca^{2+} channel antagonist vasodilator activities (249) 141
Miyata, N., see Yamaura, H. (260) 269

Miyauchi, T., see Koyama, K. (270) 151
Miyauchi, Y. and Uchida, M.K.
Ca^{2+}-inhibition of Ca^{2+}-induced small contraction of rat uterine smooth muscle (263) 75
Miyazaki, A., see Matsumoto, Y. (264) 107
Miyazaki, J.-i., see Mogami, H. (269) 293
Mizhorkova, Z., Kortezova, N., Bredy-Dobreva, G. and Papasova, M.
Role of nitric oxide in mediating non-adrenergic non-cholinergic relaxation of the cat ileocecal sphincter (265) 77
Mizisin, A.P., see Calcutt, N.A. (251) 27
Mizoguchi, K., see Yokoo, H. (256) 335
Mizrahi, J., see Catalioto, R.-M. (256) 93
Mizuno, A., see Umemura, K. (251) 69
Mizuno, D., see Kamei, J. (251) 95
Mizuno, K., see Suzuki, N. (251) 221
Mizutani, H., see Ichida, T. (267) 43
Mocaër, E., see Delbende, C. (251) 245
Mochizuki, H., Morikawa, A., Tokuyama, K., Kuroume, T. and Chao, A.C.
The effect of non-steroidal anti-inflammatory drugs on the electrical properties of cultured dog tracheal epithelial cells (252) 183
Modin, A., Weitzberg, E. and Lundberg, J.M.
Nitric oxide regulates peptide release from parasympathetic nerves and vascular reactivity to vasoactive intestinal polypeptide in vivo (261) 185
Mogami, H., Shibata, H., Nobusawa, R., Ohnota, H., Satou, F., Miyazaki, J.-i. and Kojima, I.
Inhibition of ATP-sensitive K^+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell (269) 293
Mohrs, K., see Gardiner, P.J. (258) 95
Moldéus, P., see Bannenberg, G. (270) 175
Moldéus, P., see Nakagawa, Y. (270) 341
Moldt, P., see Olesen, S.-P. (251) 53
Molina, E., see Barocelli, E. (254) 151
Molina-Holgado, E., see El Mansari, M. (261) 171
Molina, V.A., Heyser, C.J. and Spear, L.P.
Chronic variable stress enhances the stimulatory action of a low dose of morphine: reversal by desipramine (260) 57
Molines, A., see Greney, H. (265) R1
Moncada, S., see Barrachina, D. (262) 181
Monclus, M., see Pauwels, T. (257) 53
Mongeau, R., De Montigny, C. and Blier, P.
Activation of 5-HT_3 receptors enhances the electrically evoked release of [^{3}H]noradrenaline in rat brain limbic structures (256) 269
Montastruc, J.-L., see Damase-Michel, C. (258) 277
Montastruc, P., see Damase-Michel, C. (258) 277
Monteau, R., Di Pasquale, E. and Hilaire, G.
Further evidence that various 5-HT receptor subtypes modulate central respiratory activity: in vitro studies with SR 46349B (259) 71
Montero, A., see Rivas-Cabañero, L. (270) 119
Monti, J.M., see Ponzoni, A. (249) 259
Montiel, C., De la Fuente, M.T., Vinet, R., Del Valle, M., Gandía, L., Artalejo, A.R. and García, A.G.
Interactions between Ca^{2+}, PCA50941 and Bay K 8644 in bovine chromaffin cells (268) 293
Montier, F., Carruette, A., Moussaoui, S., Boccio, D. and Garret, C.
Antagonism of substance P and related peptides by RP 67580 and CP-96,345, at tachykinin NK_1 receptor sites, in the rat urinary bladder (251) 9
Montrucchio, G., see Emanuelli, G. (261) 265
Montuschi, P., Tringali, G., Currò, D., Ciabattoni, G., Parente, L., Preziosi, P. and Navarra, P.
Evidence that interleukin-1β and tumor necrosis factor inhibit gastric fundus motility via the 5-lipoxygenase pathway (252) 253
Moodley, I., see Lagente, V. (255) 253
Moody, E.J., see Harris, B.D. (267) 269
Moore, G., see Nakagawa, Y. (270) 341
Moore, K.E., see Fleckenstein, A.E. (254) 35
Moore, K.E., see Fleckenstein, A.E. (264) 163
Moore, K.E., see Manzanares, J. (249) 107
Moore, K.E., see Manzanares, J. (257) 199
Moore, K.E., see Wagner, E.J. (254) 105
Morán, A., Velasco, C., Martín, M.-L. and San Román, L.
Pharmacological characterization of 5-HT receptors in parasympathetic innervation of rat heart (252) 161
Morari, M., O'Connor, W.T., Ungerstedt, U. and Fuxe, K.
Dopamine D_1 and D_2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by *N*-methyl-D-aspartic acid (256) 23
Morath, T., see Klemm, P. (250) R9
Morcillo, E.J., see Iriarte, M.-C.F. (250) 295
Morcillo, E.J., see Martí-Cabrera, M. (255) 157
Moreau, J., see Naline, E. (256) 301
Morel, N. and Godfraind, T.
The endothelin ET_A receptor antagonist, BQ-123, normalizes the response of SHR aorta to Ca^{2+} channel activator (252) R3
Morelli, M., Fenu, S., Pinna, A. and Di Chiara, G.
Adenosine A_2 receptors interact negatively with dopamine D_1 and D_2 receptors in unilaterally 6-hydroxydopamine-lesioned rats (251) 21
Moreno, J.J., see Lloret, S. (264) 379
Moret, C., see Barone, P. (249) 221
Morgan, D.G.A., see Veale, P.R. (262) 133
Morgan, J.P., see Paik, G.Y. (264) 437
Morgan, P.F., see Jones-Humble, S.A. (257) 311
Morhenn, V.B., Waleh, N.S., Mansbridge, J.N., Unson, D., Zolotorev, A., Cline, P. and Toll, L.
Evidence for an NMDA receptor subunit in human keratinocytes and rat cardiocytes (268) 409
Mori, F., see Galli, A. (270) 189
Mori, N., see Chang, T.-h. (258) 77
Mori, N., see Kodama, K. (263) 93
Mori, T., see Suzuki, T. (263) 207
Morii, N., see Tohda, M. (266) 19
Morikawa, A., see Mochizuki, H. (252) 183
Morikawa, N., see Aramori, I. (269) 277
Morin, L., see Pellegrini, O. (270) 221
Morino, P., see Castel, M.-N. (262) 1
Morita, I., see Akiyama, Y. (263) 181
Morita, I., see Oikawa, T. (249) 113
Moromizato, H., see Yamanouchi, T. (257) 39
Moroni, F., see Mannaioni, G. (251) 201
Morooka, S., see Koike, H. (269) 299
Morris, D.G., see Brizzolara, A.L. (254) 175
Morrow, A.L., see Devaud, L.L. (267) 243
Morse, D., see Murk, A. (270) 253
Moryl, E., see Papp, M. (263) 1
Mos, J., see Ybema, C.E. (256) 141
Mosberg, H.I., see Vanderah, T. (252) 133
Möst, J., see Kacani, L. (270) 285
Mostofsky, D.I., see Yehuda, S. (254) 193
Mota-Filipe, H., see De Castro, M. (261) 199
Mottin, G., see Lagente, V. (255) 253
Motzo, C., see Ghiani, C.A. (254) 299
Motzo, C., see Serra, M. (259) 1
Mouillac, B., see Ng, G.YK. (267) 7
Moussaoui, S., see Montier, F. (251) 9
Mower, J., see Quartermain, D. (257) 7
Mucha, I., see Riutta, A. (262) 217
Mugnaini, M., see Cavanni, P. (269) 9
Mühl, H., Kunz, D., Rob, P. and Pfeilschifter, J.

Cyclosporin derivatives inhibit interleukin 1β induction of nitric oxide synthase in renal mesangial cells (249) 95
Muir, J.K. and Ellis, E.F.
Cocaine potentiates the blood pressure and cerebral blood flow response to norepinephrine in rats (249) 287
Mulder, A.H., see Ronken, E. (263) 149
Mulder, A.H., see Tjon, G.H.K. (252) 205
Müller, E.E., see Mazza, E. (254) 17
Muller, M.J., Prior, T., Hunt, R.H. and Rangachari, P.K.
Adenosine A_1 receptors are not involved in contraction of canine gastric muscularis mucosae by adenosine analogues (251) 151
Müller-Peddinghaus, R., see Gardiner, P.J. (258) 95
Muller, R.N., see Vander Elst, L. (251) 163
Mullikin-Kilpatrick, D. and Treistman, S.N.
Ethanol inhibition of L-type Ca^{2+} channels in PC12 cells: role of permeant ions (270) 17
Mülsch, A., see Schini-Kerth, V. (265) 83
Munch, E., see Olesen, S.-P. (251) 53
Mundin, J.W., see White, D.G. (257) 307
Munoz, N., see Heuillet, E. (269) 139
Muntoni, A.L., see Mereu, G. (264) 449
Murai, T., Koshikawa, N., Kanayama, T., Takada, K., Tomiyama, K. and Kobayashi, M.
Opposite effects of midazolam and β-carboline-3-carboxylate ethyl ester on the release of dopamine from rat nucleus accumbens measured by in vivo microdialysis (261) 65
Muraki, T., see Irie, K. (251) 75
Murakoshi, H., Ishii, K., Nunoki, K. and Taira, N.
Receptor-mediated modulation of rat $K_{V1.2}$ in *Xenopus* oocytes (268) 451
Muramatsu, M., see Chaki, S. (250) 173
Muramatsu, M., see Chaki, S. (251) R1
Murano, K., Inoue, Y., Emoto, M., Kaku, K. and Kaneko, T.
CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes (254) 257
Murari, G., see Spampinato, S. (254) 229
Murase, K., see Nitta, A. (250) 23
Murk, A., Morse, D., Boon, J. and Brouwer, A.
In vitro metabolism of 3,3′,4,4′-tetrachlorobiphenyl in relation to ethoxyresorufin-*O*-deethylase activity in liver microsomes of some wildlife species and rat (270) 253
Murota, S.-i., see Akiyama, Y. (263) 181
Murota, S.-i., see Oikawa, T. (249) 113
Murphy, D.L., see Andrews, A.M. (250) 215
Murphy, M.G. and Horackova, M.
Short-term exposure of intact ventricular myocytes to isoproterenol results in desensitization of adenylate cyclase (268) 121
Murphy, W.A., see DeWitt, B.J. (257) 303
Murray, T.F., see Zhang, G. (255) 239
Musacchio, J.M., see Klein, M. (254) 239
Muscará, M.N., see Giraldelo, C.M.M. (257) 87
Muskardin, D.T., see Wallace, D.R. (258) 67
Mustafa, S.J., see Fahim, M. (254) 183
Muzzolini, A., see Simonato, M. (265) 121
Myers, J., see West, Jr., R.E. (267) 343
Mytilineou, C., see Werner, P. (263) 157

Nabe, T., see Yamamura, H. (257) 235
Nabe, T., see Yamamura, H. (265) 9
Nabeshima, T., Nakayama, S., Ichihara, K., Yamada, K., Shiotani, T. and Hasegawa, T.
Effects of nefiracetam on drug-induced impairment of latent learning in mice in a water finding task (255) 57
Nabeshima, T., see Kamei, H. (260) 39
Nabeshima, T., see Nitta, A. (250) 23
Nadel, J.A., see Ricciardolo, F.L.M. (261) 127
Nadler, J.V., see Martin, D. (250) 473
Nagai, H., see Arimura, A. (260) 201
Nagai, K., Nagai, N., Isojima, Y., Itoh, S., Okumura, N. and Nakagawa, H.
Mazindol enhances glucose uptake by rat skeletal muscle (260) 29
Nagai, N., see Nagai, K. (260) 29
Nagai, S., see Utsunomiya, I. (252) 213
Nagamatsu, T., see Nagao, T. (259) 233
Naganobu, K., Takagi, M., Kawasaki, H. and Ito, K.
Modification by cyclopiazonic acid and ryanodine of depolarization-induced constriction in rat mesenteric artery (251) 307
Nagao, T., Ito, M., Nagamatsu, T. and Suzuki, Y.
Effect of DP-1904, a thromboxane A_2 synthetase inhibitor, on crescentic nephritis in rats (259) 233
Nagao, T., see Ikeda, S. (264) 223
Nagase, H., see Kamei, J. (249) 161
Nagase, H., see Kamei, J. (251) 95
Nagase, H., see Kamei, J. (251) 291
Nagase, H., see Kamei, J. (253) 293
Nagase, H., see Kamei, J. (254) 113
Nagase, H., see Kamei, J. (260) 257
Nagase, H., see Suzuki, T. (263) 207
Nagatani, T., see Kitamura, Y. (253) 297
Nahorski, S.R., see Simpson, P.B. (266) 309
Naim, M., see Charpentier, S. (266) 175
Nakagawa, H., see Nagai, K. (260) 29
Nakagawa, Y., Nakajima, K., Moore, G. and Moldéus, P.
On the mechanisms of 3-*tert*-butyl-4-hydroxyanisole- and its metabolites-induced cytotoxicities in isolated rat hepatocytes (270) 341
Nakahara, K., see Yokota, Y. (258) 239
Nakai, T., see Satoh, K. (270) 365
Nakajima, K., see Nakagawa, Y. (270) 341
Nakajima, T., see Hazama, H. (259) 143
Nakamura, H., see Ishizuka, T. (262) 113
Nakamura, J., Tamura, S., Kanda, T., Ishii, A., Ishihara, K., Serikawa, T., Yamada, J. and Sasa, M.
Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice (254) 83
Nakamura, J., see Kanda, T. (256) 263
Nakamura, J., see Tohda, M. (266) 19
Nakamura, T., see Takekoshi, K. (250) 465
Nakamura, Y., see Ishida, M. (268) 267
Nakanishi, S., see Aramori, I. (269) 277
Nakano, T., see Shimomura, A. (252) 81
Nakao, K., see Hashimoto, Y. (268) 443
Nakashima, M., see Nishiyama, H. (264) 191
Nakashima, M., see Umemura, K. (251) 69
Nakashima, M., see Umemura, K. (262) 27
Nakayama, S., see Nabeshima, T. (255) 57
Nakazato, Y., see Kitamura, N. (256) 169
Nakazawa, K., Akiyama, T. and Inoue, K.
Block by apomorphine of acetylcholine receptor channels expressed in *Xenopus* oocytes (269) 375
Nakazawa, K., see Inoue, K. (268) 223
Nakazawa, M. and Imai, S.
Rp-8-Br-guanosine-3′,5′-cyclic monophosphorothioate inhibits relaxation elicited by nitroglycerin in rabbit aorta (253) 179
Nalepa, I., see Papp, M. (261) 141
Naline, E., Candenas, M.-L., Palette, C., Moreau, J., Norte, M., Martin, J.-D., Pays, M. and Advenier, C.
Effects of okadaic acid on the human isolated bronchus (256) 301
Naline, E., see Advenier, C. (250) 169
Namiki, A., see Ishikawa, M. (269) 311
Nardi, M.G., see Bazzani, C. (253) 303
Narihara, R., see Ichida, T. (267) 43

Narumiya, S., see Tohda, M. (266) 19
Narváez, J.A., Diaz, Z., Aguirre, J.A., González-Barón, S., Yanaihara, N., Fuxe, K. and Hedlund, P.B.
Intracisternally injected galanin-(1–15) modulates the cardiovascular responses of galanin-(1–29) and the 5-HT_{1A} receptor agonist 8-OH-DPAT (257) 257
Narváez, J.A., see Fior, D.R. (262) 271
Nash, J.F., see Gudelsky, G.A. (264) 325
Natalini, B., see Mannaioni, G. (251) 201
Natarajan, T.K., see Villemagne, V.L. (257) 195
Nath, C., Gupta, M.B., Patnaik, G.K. and Dhawan, K.N.
Morphine-induced straub tail response: mediated by central μ_2-opioid receptor (263) 203
Natsume, Y., see Koike, H. (269) 299
Navarra, P., see Montuschi, P. (252) 253
Naylor, R.J., see Cheng, C.H.K. (255) 39
Naylor, R.J., see Rudd, J.A. (262) R1
Nazar, M., see Plaznik, A. (257) 293
Nefkens, F., see De Boer, T. (253) R5
Nehlig, A., Daval, J.-L. and Boyet, S.
Effects of selective adenosine A_1 and A_2 receptor agonists and antagonists on local rates of energy metabolism in the rat brain (258) 57
Nelemans, A., see Sipma, H. (268) 431
Neliat, G., see Emonds-Alt, X. (250) 403
Neuberger, C., see Kusterer, K. (259) 265
Neumeyer, J.L., see Baldessarini, R.J. (254) 199
Neumeyer, J.L., see Hashimoto, K. (266) 67
Nevins, M.E., see Anthony, E.W. (250) 317
Newton, B.B., see Gardiner, P.J. (258) 95
Ng, G.YK. and George, S.R.
Dopamine receptor agonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse (269) 365
Ng, G.YK., Mouillac, B., George, S.R., Caron, M., Dennis, M., Bouvier, M. and O'Dowd, B.F.
Desensitization, phosphorylation and palmitoylation of the human dopamine D_1 receptor (267) 7
Ng, G.YK., O'Dowd, B.F. and George, S.R.
Genotypic differences in brain dopamine receptor function in the DBA/2J and C57BL/6J inbred mouse strains (269) 349
Ng, K.H., see Ng, P.C. (264) 1
Ng, P.C., Ho, D.D., Ng, K.H., Kong, Y.C., Cheng, K.F. and Stone, G.
Mixed estrogenic and anti-estrogenic activities of yuehchukene – a *bis*-indole alkaloid (264) 1
Nials, A.T., Ball, D.I., Butchers, P.R., Coleman, R.A., Humbles, A.A., Johnson, M. and Vardey, C.J.
Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol (251) 127
Nichols, D.E., see Marona-Lewicka, D. (258) 1
Nickel, P., see Van Rhee, A.M. (268) 1
Nickels, D.P.D., see Gard, P.R. (264) 295
Nickols, G.A., see Kasten, T.P. (253) 35
Nicolas, P., see Charpentier, S. (266) 175
Nicolas, P., see Yin, Y. (261) 97
Nicoletti, F., see Bruno, V. (256) 109
Nicosia, S., see Letari, O. (266) 219
Nie, S.-Q., Majarais, I., Kwan, C.-Y. and Epand, R.M.
Analogues of tetramethylpyrazine affect membrane fluidity of liposomes: relationship to their biological activities (266) 11
Niehoff, M., see Deshpande, Y. (256) R1
Nielsen, E.Ø., see Verdoorn, T.A. (269) 43
Nielsen-Kudsk, J.E., see Mellemkjær, S. (270) 307
Niemitz, M., see Pellinen, P. (270) 35
Nieoullon, A., see Ouagazzal, A.-m. (251) 229
Nigami, H., see Hayakawa, T. (257) 131
Nijkamp, F.P., see De Kimpe, S.J. (261) 111
Nikfar, S., see Rezayat, M. (254) 21
Niki, Y., see Shimomura, A. (252) 81
Nikolsky, E.E., see Shakiryanova, D.M. (263) 107
Nilius, B., see Gericke, M. (269) 381
Nilsson, E., see Jeppsson, A.-B. (257) 137
Nilsson, S., see Szallasi, A. (264) 217
Nilsson, S.F.E.
PACAP-27 and PACAP-38: vascular effects in the eye and some other tissues in the rabbit (253) 17
Nimura, M., see Satake, N. (251) 1
Nisato, D., see Herbert, J.-M. (251) 143
Nisato, D., see Lacour, C. (264) 307
Nishi, S., see Yamada, S. (257) 243
Nishida, A., see Miyata, K. (250) 303
Nishida, A., see Saita, Y. (269) 249
Nishida, A., see Shimizu, M. (268) 65
Nishida, T., see Wanibuchi, F. (265) 151
Nishikawa, K., see Wada, T. (253) 27
Nishikawa, M., see Shirasaki, H. (268) 263
Nishikibe, M., see Okada, M. (259) 339
Nishimoto, T., see Dokita, S. (266) 269
Nishimura, J., see Chen, X. (267) 175
Nishimura, M., see Saeki, T. (261) 249
Nishio, M., see Kita, Y. (257) 123
Nishiwaki, K., see Hirabayashi, A. (256) 227
Nishiyama, H., Umemura, K., Saniabadi, A.R., Takiguchi, Y., Uematsu, T. and Nakashima, M.
Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model (264) 191
Nisoli, E., Tonello, C. and Carruba, M.O.
SR 58611A: a novel thermogenic β-adrenoceptor agonist (259) 181
Nissbrandt, H., see Blomqvist, O. (249) 207
Nitta, A., Murase, K., Furukawa, Y., Hayashi, K., Hasegawa, T. and Nabeshima, T.
Effects of oral administration of a stimulator for nerve growth factor synthesis in basal forebrain-lesioned rats (250) 23
Niwa, M., see Kan, S. (258) 139
Niwa, M., see Koizumi, S. (259) 195
Noack, E., see Kojda, G. (250) 385
Noble, F., Coric, P., Turcaud, S., Fournié-Zaluski, M.-C. and Roques, B.P.
Assessment of physical dependence after continuous perfusion into the rat jugular vein of the mixed inhibitor of enkephalin-degrading enzymes, RB 101 (253) 283
Nobusawa, R., see Mogami, H. (269) 293
Noda, M., see Wada, T. (253) 27
Nodland, K., see Fernandez, P. (270) 53
Noël, F., see Matsuoka, I. (268) 215
Nomoto, M., see Irifune, M. (264) 117
Nomoto, T., see Irie, K. (251) 75
Nomura, Y., see Tohda, M. (266) 19
Nomura, Y., see Tohda, M. (268) 169
Nonaka, H., Ichimura, M., Takeda, M., Nonaka, Y., Shimada, J., Suzuki, F., Yamaguchi, K. and Kase, H.
KF17837 ((*E*)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A_2 receptor antagonist (267) 335
Nonaka, Y., see Nonaka, H. (267) 335
Nonogaki, K., Iguchi, A. and Sakamoto, N.
Effects of adrenoceptor antagonists on the hyperthermia and hyperglycemia induced by prostaglandin $F_{2\alpha}$ in rats (262) 177
Noonan, D., see Favoni, R.E. (264) 199
Norbiato, G., see Bevilacqua, M. (268) 415
Norby, B., see Pedersen, U.B. (267) 85
Norman, P., see Tudhope, S.R. (264) 317
Normandin, D., see Antonaccio, M.J. (256) 17

Normandin, D., see Antonaccio, M.J. (256) 37
Norte, M., see Naline, E. (256) 301
Nossaman, B.D., see Cheng, D.Y. (261) 223
Nossaman, B.D., see DeWitt, B.J. (257) 303
Nossaman, B.D., see Feng, C.J. (263) 133
Notsu, Y., see Aramori, I. (269) 277
Notsu, Y., see Yokota, Y. (258) 239
Nouel, D. and Costentin, J.
Locomotor effects of [D-Trp[11]]neurotensin and dopamine transmission in rats (254) 263
Novaković, S., see Jovanović, A. (258) 185
Novelli, A., Torreblanca, A. and Fernández-Sánchez, M.T.
Two components in neurotoxicity by L-2-amino-3-phosphonopropionate in cultured cerebellar neurons (270) 361
Nowak, H.P., see Parker, E.M. (268) 43
Nowicki, J.-P., see Carreau, A. (256) 241
Numazawa, T., see Kamata, K. (259) 321
Nunes, S.H., see Jurkiewicz, A. (256) 329
Nunoki, K., see Murakoshi, H. (268) 451
Nutt, D., see Thomas, D.N. (261) 53
Nylander, I., see Castel, M.-N. (262) 1

Obara, K. and Yabu, H.
Effect of cytochalasin B on intestinal smooth muscle cells (255) 139
Obinu, M.C., see Imperato, A. (251) 271
Obinu, M.C., see Imperato, A. (264) 55
Oblin, A. and Schoemaker, H.
Complex allosteric modulation of the binding of the NMDA receptor antagonist [^{3}H]CGP39653 (266) 103
O'Boyle, K.M., see Farrell, C.B. (268) 79
O'Brien, D., see Knuepfer, M.M. (259) 305
O'Callaghan, J.F.X., see Koutsilieri, E. (269) R3
O'Connor, W.T., see Morari, M. (256) 23
O'Donnell, N., see Aramori, I. (269) 277
O'Dowd, B.F., see Ng, G.YK. (267) 7
O'Dowd, B.F., see Ng, G.YK. (269) 349
Ogawa, S.-i., Okuyama, S., Araki, H. and Otomo, S.
Effect of NE-100, a novel σ receptor ligand, on phencyclidine-induced cognitive dysfunction (263) 9
Ogino, K., Izumi, Y., Segawa, H., Takeyama, Y., Ishiyama, H., Houbara, T., Uda, T. and Yamashita, S.
Zinc hydroxide induced respiratory burst in rat neutrophils (270) 73
Ögren, S.-O., see Brodin, K. (263) 175
Oguchi, T., see Sawaki, S. (250) 253
Oh-ishi, S., see Utsunomiya, I. (252) 213
Oh, K.W., see Jaw, S.P. (257) 153
Ohata, K., see Yamamura, H. (257) 235
Ohata, K., see Yamamura, H. (265) 9
Ohba, M., see Sakurada, T. (261) 85
Ohizumi, Y., see Ohkura, M. (268) R1
Ohkura, M., Furukawa, K.-I., Tu, A.T. and Ohizumi, Y.
Calsequestrin is a major binding protein of myotoxin α and an endogenious Ca^{2+} releaser in sarcoplasmic reticulum (268) R1
Ohlstein, E.H., see Douglas, S.A. (255) 81
Ohmae, S., see Miyamoto, K.-i. (267) 317
Ohno, M., Yamamoto, T. and Watanabe, S.
Intrahippocampal administration of a glycine site antagonist impairs working memory performance of rats (253) 183
Ohno, N., Ito, K.M., Yamamoto, Y. and Suzuki, H.
Suramin selectively inhibits the non-adrenergic non-cholinergic inhibitory junction potential in the guinea-pig stomach (249) 121
Ohnota, H., see Mogami, H. (269) 293
Ohshika, H., see Miyamoto, A. (266) 147
Ohta, K., Kim, S., Hamaguchi, A., Yukimura, T., Miura, K., Takaori, K. and Iwao, H.
Role of angiotensin II in extracellular matrix and transforming growth factor-β1 expression in hypertensive rats (269) 115
Ohta, T., see Kitamura, N. (256) 169
Ohtsuka, M., see Isono, T. (260) 163
Oikawa, T., Okayasu, I., Ashino, H., Morita, I., Murota, S.-i. and Shudo, K.
Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo (249) 113
Oike, M., see Gericke, M. (269) 381
Ojima, M., see Wada, T. (253) 27
Okada, M., Fukuroda, T., Shimamoto, K., Takahashi, R., Ikemoto, F., Yano, M. and Nishikibe, M.
Antihypertensive effects of BQ-123, a selective endothelin ET_A receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt (259) 339
Okada, T., see Yukimura, T. (264) 399
Okada, Y., see Hirai, H. (256) 65
Okamoto, K., see Sakuta, H. (255) 1
Okamoto, K., see Sakuta, H. (259) 223
Okamoto, K., see Sakuta, H. (267) 281
Okamoto, K.-i., see Konno, S.-i. (259) 15
Okamoto, K.-i., see Konno, S.-i. (264) 265
Okamura, T. and Toda, N.
Inhibition by calmodulin antagonists of the neurogenic relaxation in cerebral arteries (256) 79
Okamura, T. and Toda, N.
Mechanism underlying nicotine-induced relaxation in dog saphenous arteries (263) 85
Okayasu, I., see Oikawa, T. (249) 113
Oker-Blom, C., see Marjamäki, A. (267) 117
Oktay, Ş., see Özkutlu, U. (250) 349
Oku, H., see Osada, S. (252) 347
Okuhara, M., see Aramori, I. (269) 277
Okumura, K., see Tsunoda, R. (262) 55
Okumura, M., see Ebara, T. (263) 69
Okumura, N., see Nagai, K. (260) 29
Okutomi, T., see Kamei, J. (251) 95
Okuyama, S., see Ogawa, S.-i. (263) 9
Okuyama, T., see Chang, T.-h. (258) 77
Olasz, E., see Kemény, L. (258) 269
Oleggini, R., see Ghiggeri, G.M. (270) 195
Olesen, S.-P., Munch, E., Moldt, P. and Drejer, J.
Selective activation of Ca^{2+}-dependent K^+ channels by novel benzimidazolone (251) 53
Olijve, W., see Stam, N.J. (269) 339
Olins, G.M., see Corpus, V.M. (266) 197
Oliveira, E.S., see Paik, S.H. (253) 101
Oliver, C., see Cataldi, M. (253) 149
Oliver, C., see Delbende, C. (251) 245
Olivier, B., see Ybema, C.E. (256) 141
Oliw, E.H., see Brodowsky, I.D. (254) 43
Olmos, G., Kulkarni, R.N., Haque, M. and MacDermot, J.
Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I_1 and I_2 receptors (262) 41
Olpe, H.-R., see Lepre, M. (258) 23
Oluyomi, A.O., Datla, K.P. and Curzon, G.
Effects of *d*-fenfluramine on feeding and hypothalamic 5-hydroxytryptamine and dopamine in male and female rats (255) 175
Oluyomi, A.O., Gibson, E.L., Barnfield, A.M.C. and Curzon, G.
d-Fenfluramine and *d*-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release (264) 111
Oluyomi, A.O., Poole, S., Smith, T.W. and Hart, S.L.
Antinociceptive activity of peptides related to interleukin-1β-(193–195), Lys-Pro-Thr (258) 131
Olymulder, C.G., see Santing, R.E. (254) 49
Olymulder, C.G., see Santing, R.E. (257) 145

O'Malley, K.L., see MacKenzie, R.G. (266) 79
Omata, M., see Hazama, H. (259) 143
Onat, F., see Özkutlu, U. (250) 349
O'Neill, M., see Caldwell, M. (260) 191
Ong, J. and Kerr, D.I.B.
Suppression of $GABA_B$ receptor function in rat neocortical slices by amiloride (260) 73
Ong, J., Kerr, D.I.B., Lacey, G., Curtis, D.R., Hughes, R. and Prager, R.H.
Differing actions of nitropropane analogs of GABA and baclofen in central and peripheral preparations (264) 49
Ong, J., see Kerr, D.I.B. (262) 189
Ongemba, L.-N., see Becker, D.J. (260) 169
Ongini, E., see De Sarro, G. (262) 11
Ongini, E., see Sandoli, D. (259) 43
Ono, S., see Aramori, I. (269) 277
Ono, T., see Yokota, Y. (258) 239
Onodera, K., see Yokoyama, H. (260) 23
Onogi, T., Kagawa, M., Minami, M., Kuraishi, Y. and Satoh, M.
Intrathecal neuromedin C enhances mechanical nociception: possible involvement of NMDA receptors (262) 163
Oosterom, J., see Adan, R.A.H. (269) 331
Oostingh, I., see Boon, J.P. (270) 237
Opgenorth, T.J., see Hancock, A.A. (267) 49
Opitz, T., see Wilsch, V.W. (262) 287
Orallo, F., see Campos-Toimil, M. (251) 83
Orimo, H., see Ishikawa, M. (269) 311
Ormazabal, M.J., see Colado, M.I. (252) 291
Orringer, J., see Hellewell, S.B. (268) 9
Ortiz, J.L., see Martí-Cabrera, M. (255) 157
Osada, S., Ichiki, H., Oku, H., Ishiguro, K., Kunitomo, M. and Semma, M.
Participation of nitric oxide in mouse anaphylactic hypotension (252) 347
Osada, Y., see Komoriya, K. (250) 455
Osborne, S.-A., see Heald, A. (264) 213
O'Shaughnessy, C.T. and Connor, H.E.
Activation of sensory nerves in guinea-pig isolated basilar artery by nicotine: evidence for inhibition of trigeminal sensory neurotransmission by sumatriptan (259) 37
O'Shaughnessy, C.T. and Connor, H.E.
Investigation of the role of tachykinin NK_1, NK_2 receptors and CGRP receptors in neurogenic plasma protein extravasation in dura mater (263) 193
O'Shaughnessy, C.T., see Barnes, J.C. (250) 147
Ostrowski, J., see Klemm, P. (250) R9
Otomo, S., see Chaki, S. (250) 173
Otomo, S., see Chaki, S. (251) R1
Otomo, S., see Miyata, N. (249) 141
Otomo, S., see Ogawa, S.-i. (263) 9
Otomo, S., see Yamaura, H. (260) 269
Otsuki, M., see Watanabe, N. (264) 331
Ott, C.E., see Kidwell, D.T. (270) 97
Ouagazzal, A.-m., Nieoullon, A. and Amalric, M.
Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum (251) 229
Ouchi, Y., see Ishikawa, M. (269) 311
Oyama, Y., Ueha, T., Hayashi, A. and Chikahisa, L.
Effect of tri-*n*-butyltin on intracellular Ca^{2+} concentration of mouse thymocytes under Ca^{2+}-free condition (270) 137
Ozaki, H., see Kitajima, S. (266) 263
Ozaki, H., see Takizawa, S. (250) 431
Ozaki, J., see Hashimoto, Y. (268) 443
Ozaki, R., see Isono, T. (260) 163
Ozawa, S., see Temma, K. (252) 173
Özkutlu, U., Onat, F., Aslan, A.N. and Oktay, Ş.
Central muscarinic M_2 cholinoceptors involved in cholinergic hypertension (250) 349

Paalzow, G.H.M.
Noradrenaline but not dopamine involved in NMDA receptor-mediated hyperalgesia induced by theophylline in awake rats (252) 87
Paetsch, P.R., see Allison, K. (249) 125
Pagani, E.D., see Dundore, R.L. (249) 293
Page, C.P., see Cirino, G. (252) 147
Page, C.P., see Liu, J.T. (264) 183
Page, C.P., see Manzini, S. (249) 251
Pageaux, J.F., see Fayard, J.M. (251) 281
Paik, G.Y., Wang, J., Perreault, C.L. and Morgan, J.P.
Endothelin-1 does not alter Ca^{2+} responsiveness in saponin-skinned ferret papillary muscles (264) 437
Paik, S.H., Camarao, G.C., Bauer, J.A., Leite, P.E.P., Oliveira, E.S., Camargo, A.C.M. and Farges, R.C.
Effects of morphine withdrawal syndrome on endo-oligopeptidase (EC 3.4.22.19) activity (253) 101
Palazidou, E., see Albinsson, A. (251) 157
Palazzi, E., see Cattaneo, M.G. (268) 425
Palette, C., see Naline, E. (256) 301
Palmer, J., see Baker, A.J. (264) 301
Pälvimäki, E.-P., see Kuoppamäki, M. (255) 91
Pan, D., Gatley, S.J., Dewey, S.L., Chen, R., Alexoff, D.A., Ding, Y.-S. and Fowler, J.S.
Binding of bromine-substituted analogs of methylphenidate to monoamine transporters (264) 177
Pan, Y.-X., see Chien, C.-C. (253) R7
Panerai, A.E., see Bianchi, M. (263) 81
Pang, C.C.Y., see Wang, Y.-X. (250) 335
Pani, L., see D'Aquila, P.S. (262) 107
Papasova, M., see Mizhorkova, Z. (265) 77
Papp, M. and Moryl, E.
Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression (263) 1
Papp, M., Nalepa, I. and Vetulani, J.
Reversal by imipramine of β-adrenoceptor up-regulation induced in a chronic mild stress model of depression (261) 141
Parente, L., see Montuschi, P. (252) 253
Paris, H., see Devedjian, J.-C. (252) 43
Park, K.H. and Levi, R.
Hypoxic coronary vasodilatation and cGMP overproduction are blocked by a nitric oxide synthase inhibitor, but not by a guanylyl cyclase ANF receptor antagonist (256) 99
Park, Y.D., see Hulihan-Giblin, B.A. (263) 213
Parker, E.M., Grisel, D.A., Iben, L.G., Nowak, H.P., Mahle, C.D., Yocca, F.D. and Gaughan, G.T.
Characterization of human $5\text{-}HT_1$ receptors expressed in Sf9 insect cells (268) 43
Parker, S.G., Raval, P., Yeulet, S. and Eden, R.J.
Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D_2-like receptor agonist (265) 17
Parkkisenniemi, U.-M., see Alaranta, S. (259) 203
Parolaro, D., see Massi, P. (253) 269
Parsons, A.A., see Medhurst, A.D. (256) R5
Pasanen, M., see Pellinen, P. (270) 35
Pascale, A., Milano, S., Corsico, N., Lucchi, L., Battaini, F., Martelli, E.A., Trabucchi, M. and Govoni, S.
Protein kinase C activation and anti-amnesic effect of acetyl-L-carnitine: in vitro and in vivo studies (265) 1
Pascaud, X., see Diop, L. (257) 181
Pascual, R., see Iriarte, M.-C.F. (250) 295

Pasternak, G.W., see Chien, C.-C. (253) R7
Pasternak, G.W., see Chien, C.C. (250) R7
Patacchini, R., Quartara, L., Rolka, K., Zboinska, J., Kupryszewski, G. and Maggi, C.A.
Effect of scyliorhinin I and synthetic scyliorhinin I derivatives at mammalian tachykinin NK_1, NK_2 and NK_3 receptors (250) 311
Patacchini, R., see Barthó, L. (259) 187
Patel, S. and Freedman, S.B.
The muscarinic receptor agonist L-658,903 modulates the in vivo accumulation of inositol monophosphates in mouse brain (267) 329
Patel, S. and Hutson, P.H.
Hypothermia induced by cholinomimetic drugs is blocked by galanin: possible involvement of ATP-sensitive K^+ channels (255) 25
Patel, S., Chapman, K.L., Heald, A., Smith, A.J. and Freedman, S.B.
Measurement of central nervous system activity of systemically administered CCK_B receptor antagonists by ex vivo binding (253) 237
Patel, S., see Smith, A.J. (267) 215
Patel, T.R., McAuley, M.A. and McCulloch, J.
Effects on feline pial arterioles in situ of bosentan, a non-peptide endothelin receptor antagonist (260) 65
Patel, U.P., see Gardiner, P.J. (258) 95
Paterson, I.A., see Juorio, A.V. (254) 213
Pátfalusi, M., see Sziráki, I. (251) 311
Patnaik, G.K., see Nath, C. (263) 203
Patrick, S.L., see Leitner, M.L. (259) 65
Patthy, M., see Sziráki, I. (251) 311
Paul, I.A., see Basile, A.S. (252) 139
Paul, I.A., see Von Lubitz, D.K.J.E. (249) 265
Paul, I.A., see Von Lubitz, D.K.J.E. (249) 271
Paul, I.A., see Von Lubitz, D.K.J.E. (253) 95
Paul, V., Balasubramaniam, E. and Kazi, M.
The neurobehavioural toxicity of endosulfan in rats: a serotonergic involvement in learning impairment (270) 1
Paul, W., see Liu, J.T. (264) 183
Pauwels, T., Dethy, S., Goldman, S., Monclus, M. and Luxen, A.
Effect of catechol-*O*-methyl transferase inhibition on peripheral and central metabolism of 6-[^{18}F]fluoro-L-DOPA (257) 53
Pávó, I., see László, F. (258) 15
Payá, M., see Ferrándiz, M.L. (253) 75
Pays, M., see Naline, E. (256) 301
Pazos, A., see Fernández-López, A. (252) 333
Pazos, A., see Fernández-López, A. (262) 283
Pazzagli, M., Corsi, C., Latini, S., Pedata, F. and Pepeu, G.
In vivo regulation of extracellular adenosine levels in the cerebral cortex by NMDA and muscarinic receptors (254) 277
Pechnick, R.N. and Hiramatsu, M.
The effects of MK-801 on body temperature and behavior in the rat: cross-sensitization and cross-tolerance with phencyclidine (252) 35
Pechnick, R.N. and Poland, R.E.
Neuroendocrine responses produced by enantiomeric pairs of drugs that interact with phencyclidine and σ receptors (263) 115
Pedata, F., see Latini, S. (249) 65
Pedata, F., see Pazzagli, M. (254) 277
Pedersen, U.B., Norby, B., Jensen, A.A., Schiødt, M., Hansen, A., Suhr-Jessen, P., Scheideler, M., Thastrup, O. and Andersen, P.H.
Characteristics of stably expressed human dopamine D_{1a} and D_{1b} receptors: Atypical behavior of the dopamine D_{1b} receptor (267) 85
Peers, C., see Rana, B. (250) 247
Peglion, J.-L., see Millan, M.J. (260) R3
Peglion, J.-L., see Rivet, J.-M. (265) 175
Pei, Q., Elliott, J.M., Grahame-Smith, D.G. and Zetterström, T.
Quinine and 4-aminopyridine inhibit the stimulatory output of dopamine in nucleus accumbens and the behavioural activity produced by morphine (249) 243
Pélaprat, D., see Azzi, M. (255) 167
Pelaprat, D., see Brouard, A. (253) 289
Pelckmans, P.A., see Boeckxstaens, G.E. (264) 85
Pelkonen, O., see Pellinen, P. (270) 35
Pellegrini, O., Davenas, E., Morin, L., Tsangaris, G.T., Benveniste, J., Manuel, Y. and Thomas, Y.
Modulation of stress proteins by Cd^{2+} in a human T cell line (270) 221
Pelletier, G., see Vincens, M. (260) 157
Pellicciari, R., see Mannaioni, G. (251) 201
Pellinen, P., Honkakoski, P., Stenbäck, F., Niemitz, M., Alhava, E., Pelkonen, O., Lang, M.A. and Pasanen, M.
Cocaine *N*-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors (270) 35
Pendley, C.E., see Bertrand, P. (262) 233
Pennefather, J.N., Gillman, T.A. and Mitchelson, F.
Muscarinic receptors in rat uterus (262) 297
Pennefather, J.N., see Haynes, J.M. (250) 231
Pennefather, J.N., see Ventura, S. (254) 167
Pepeu, G., see Latini, S. (249) 65
Pepeu, G., see Pazzagli, M. (254) 277
Pérez-Vizcaíno, F., see Duarte, J. (262) 149
Pérez de la Mora, M., Hernandez-Gómez, A.-M., Méndez-Franco, J. and Fuxe, K.
Cholecystokinin-8 increases K^+-evoked [^{3}H]γ-aminobutyric acid release in slices from various brain areas (250) 423
Perfumo, F., see Ghiggeri, G.M. (270) 195
Perich, R.B., Jackson, B. and Johnston, C.I.
Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme (266) 201
Perreault, C.L., see Paik, G.Y. (264) 437
Perret, G.-Y., see Yin, Y. (261) 97
Perretti, F., see Manzini, S. (249) 251
Perretti, M., see Ahluwalia, A. (264) 407
Perrier, H., see Charleson, S. (267) 275
Perrin, S., see Lagente, V. (255) 253
Persson, K. and Andersson, K.-E.
Non-adrenergic, non-cholinergic relaxation and levels of cyclic nucleotides in rabbit lower urinary tract (268) 159
Persson, M.G., Cederqvist, B., Wiklund, C.U. and Gustafsson, L.E.
Ethanol causes decrements in airway excretion of endogenous nitric oxide in humans (270) 273
Persson, M.G., Friberg, S.G., Hedqvist, P. and Gustafsson, L.E.
Endogenous nitric oxide counteracts antigen-induced bronchoconstriction (249) R7
Persson, M.G., Midtvedt, T., Leone, A.M. and Gustafsson, L.E.
Ca^{2+}-dependent and Ca^{2+}-independent exhaled nitric oxide, presence in germ-free animals, and inhibition by arginine analogues (264) 13
Pertwee, R., Griffin, G., Hanuš, L. and Mechoulam, R.
Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia (259) 115
Pertwee, R.G., see Collins, D.R. (259) R7
Pertwee, R.G., see Wickens, A.P. (250) 205
Peskar, B.M., Wong, H.C., Walsh, J.H. and Holzer, P.
A monoclonal antibody to calcitonin gene-related peptide abolishes capsaicin-induced gastroprotection (250) 201
Peskar, B.M., see Stroff, T. (260) R1
Peterson, P., see Knapp, R.J. (269) 133
Petitclerc, E., Poubelle, P.E. and Marceau, F.
Epidermal growth factor-induced rapid relaxation of the isolated rabbit mesenteric artery (259) 91
Petrescu, B.C., see Brailoiu, E. (250) 489

Petrone, G., see Clarke, G.D. (257) 103
Petty, M.A., Lukovic, L., Grisar, J.M., Dow, J., Bolkenius, F.N. and De Jong, W.
Myocardial protection by a cardioselective free radical scavenger (255) 215
Pèzzola, A., see Popoli, P. (257) 21
Pèzzola, A., see Popoli, P. (257) R5
Pfaffendorf, M., see Zhang, J. (252) 337
Pfaffendorf, M., see Zhang, J. (262) 247
Pfeilschifter, J., see Mühl, H. (249) 95
Phan, T.-H., see Singh, V.B. (256) 177
Phillips, P.A., Hutchins, A.-M., Burrell, L.M., Risvanis, J. and Johnston, C.I.
V_1-like [Arg^8]vasopressin binding sites occur in rat hepatocyte nuclei (259) 325
Picarel-Blanchot, F., Bailbé, D. and Portha, B.
d-Fenfluramine improves hepatic insulin action in streptozotocin-diabetic rats (264) 227
Pidoplichko, V.I., see Wilsch, V.W. (262) 287
Piek, T., see Karst, H. (270) 357
Pieretti, S., see Capasso, A. (261) 209
Pierre, J., see Agbotounou, W.K. (269) 1
Piet, J.J., see Van den Berg, C. (270) 379
Pietrasiewicz, T., Czechowska, G., Dziki, M., Turski, W.A., Kleinrok, Z. and Czuczwar, S.J.
Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics (250) 1
Pilon, C., Lévesque, D., Dimitriadou, V., Griffon, N., Martres, M.-P., Schwartz, J.-C. and Sokoloff, P.
Functional coupling of the human dopamine D_3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line (268) 129
Pimoule, C., see Faure, C. (268) 141
Pinna, A., see Morelli, M. (251) 21
Pinnock, R., see Suman-Chauhan, N. (269) 65
Pinnock, R.D., Suman-Chauhan, N., Chung, F.-Z., Webdale, L., Madden, Z., Hill, D.R. and Woodruff, G.N.
Characterization of tachykinin mediated increases in $[Ca^{2+}]_i$ in Chinese hamster ovary cells expressing human tachykinin NK_3 receptors (269) 73
Pinnock, R.D., see Keegan, K.D. (253) 131
Pinnock, R.D., see Puttick, R.M. (254) 303
Pinnola, V., see Cavanni, P. (269) 9
Piotrovsky, L., see Bespalov, A. (264) 233
Pipili-Synetos, E., see Tsopanoglou, N.E. (258) 151
Pirani, P., see Favoni, R.E. (264) 199
Pisarev, M.A., Krawiec, L., Juvenal, G.J., Bocanera, L.V., Pregliasco, L.B., Sartorio, G. and Chester, H.A.
Studies on the goiter inhibiting action of iodolactones (258) 33
Pistacchio, E., see Spampinato, S. (254) 229
Pitkänen, M., Sirviö, J., Lahtinen, H., Koivisto, E. and Riekkinen, P.
d-Cycloserine, a partial agonist at the glycine site, enhances the excitability of dentate granule cells in vivo in rats (253) 125
Plant, T.D., see Jonas, J.-C. (254) 27
Plata-Salamán, C.R. and Ffrench-Mullen, J.M.H.
Interleukin-1β inhibits Ca^{2+} channel currents in hippocampal neurons through protein kinase C (266) 1
Plaznik, A., Jessa, M., Bidzinski, A. and Nazar, M.
The effect of serotonin depletion and intra-hippocampal midazolam on rat behavior in the Vogel conflict test (257) 293
Pleeth, R.M., see Poucher, S.M. (252) 19
Plourde, V., Quintero, E., Suto, G., Coimbra, C. and Taché, Y.
Delayed gastric emptying induced by inhibitors of nitric oxide synthase in rats (256) 125
Poggesi, E., see Testa, R. (249) 307
Poggioli, R., see Benelli, A. (260) 279
Pohjanoksa, K., see Marjamäki, A. (267) 117
Pohjanvirta, R., see Unkila, M. (270) 157
Poignet, H., see Carreau, A. (256) 241
Poizot, A., see Bellemin-Baurreau, J. (256) 115
Poland, R.E., see Pechnick, R.N. (263) 115
Polastron, J., Meunier, J.-C. and Jauzac, P.
Chronic morphine induces tolerance and desensitization of μ-opioid receptor but not down-regulation in rabbit (266) 139
Polities, G., see Deshpande, Y. (256) R1
Pons, F., Williams, T.J., Kirk, S.A., McDonald, F. and Rossi, A.G.
Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D_2 analogue, ZK 118.182 (261) 237
Ponzoni, A., Monti, J.M. and Jantos, H.
The effects of selective activation of the 5-HT_3 receptor with m-chlorophenylbiguanide on sleep and wakefulness in the rat (249) 259
Pook, P., see Kemp, M. (266) 187
Poole, S., see Oluyomi, A.O. (258) 131
Poon, K.S., see Wang, Y.-X. (250) 335
Popescu, L.M., see Brailoiu, E. (250) 493
Popik, P., see Von Lubitz, D.K.J.E. (263) 59
Popoli, P., Pèzzola, A. and Scotti de Carolis, A.
Modulation of striatal adenosine A_1 and A_2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats (257) 21
Popoli, P., Pèzzola, A., Reggio, R., Caporali, M.G. and Scotti de Carolis, A.
CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease (257) R5
Porceddu, M.L., see Ghiani, C.A. (254) 299
Porceddu, M.L., see Serra, M. (259) 1
Porreca, F., see Vanderah, T. (252) 133
Porsius, A.J., see Vleeming, W. (250) 415
Portas, C.M., Devoto, P. and Gessa, G.L.
Effect of ethanol on extracellular 5-hydroxytryptamine output in rat frontal cortex (270) 123
Portha, B., see Picarel-Blanchot, F. (264) 227
Portoghese, P.S., see Jones, D.N.C. (249) 167
Portoghese, P.S., see Vanderah, T. (252) 133
Portolan, G., see Damase-Michel, C. (258) 277
Poston, L., see Richards, N.T. (257) 189
Potier, E., see Goso, C. (254) 221
Potter, E.K., Barden, J.A., McCloskey, M.J.D., Selbie, L.A., Tseng, A., Herzog, H. and Shine, J.
A novel neuropeptide Y analog, *N*-acetyl [Leu^{28},Leu^{31}]neuropeptide Y-(24–36), with functional specificity for the presynaptic (Y_2) receptor (267) 253
Poubelle, P.E., see Petitclerc, E. (259) 91
Poucher, S.M., Brooks, R., Pleeth, R.M., Conant, A.R. and Collis, M.G.
Myocardial infarction and purine transport inhibition in anaesthetised ferrets (252) 19
Poveda, J.J., see Berrazueta, J.R. (251) 303
Prager, R.H., see Ong, J. (264) 49
Prasit, P., see Charleson, S. (267) 275
Prato, A., see Clementi, G. (256) R7
Prats, H., see Bouloumié, A. (269) 95
Pregliasco, L.B., see Pisarev, M.A. (258) 33
Preziosi, P., see Montuschi, P. (252) 253
Price, K.J., Hanson, P.J. and Whittle, B.J.R.
Stimulation by carbachol of mucus gel thickness in rat stomach involves nitric oxide (263) 199
Priestley, J.V., see Rattray, M. (268) 439
Prieto, J.C., see Iriarte, M.-C.F. (250) 295
Prinssen, E.P.M., Ellenbroek, B.A. and Cools, A.R.
Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine (262) 167
Prior, T., see Muller, M.J. (251) 151

Pritchard, G.A., Fahey, J.M., Minocha, S.C., Conaty, C. and Miller, L.G.
Polyamine potentiation and inhibition of NMDA-mediated increases of intracellular free Ca^{2+} in cultured chick cortical neurons (266) 107
Procopio, M., see Mazza, E. (254) 17
Proctor, M.R., see Fornai, F. (254) R1
Proietto, V., see Emonds-Alt, X. (250) 403
Prost, J.-F., see Millan, M.J. (260) R3
Prow, M.R., see Heal, D.J. (249) 37
Prudhomme, N., see Barone, P. (249) 221
Pryzbyc, R.L., see Baumgold, J. (251) 315
Przewłocki, R., see Sowa, G. (266) 125
Pugsley, M.K., Saint, D.A. and Walker, M.J.A.
An electrophysiological basis for the antiarrhythmic actions of the κ-opioid receptor agonist U-50,488H (261) 303
Pugsley, T.A., see Damsma, G. (249) R9
Pugsley, T.A., see MacKenzie, R.G. (266) 79
Puke, M.J.C., Luo, L. and Xu, X.-J.
The spinal analgesic role of α_2-adrenoceptor subtypes in rats after peripheral nerve section (260) 227
Pullmann, F., see Allgaier, C. (252) R7
Puttick, R.M., Pinnock, R.D. and Woodruff, G.N.
Galanin-induced membrane depolarization of neonatal rat cultured dorsal root ganglion cells (254) 303

Qian, C., Li, T., Shen, T.Y., Libertine-Garahan, L., Eckman, J., Biftu, T. and Ip, S.
Epibatidine is a nicotinic analgesic (250) R13
Qin, Z.-H. and Weiss, B.
Dopamine receptor blockade increases dopamine D_2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra (269) 25
Quartara, L., see Patacchini, R. (250) 311
Quartermain, D., Mower, J., Rafferty, M.F., Herting, R.L. and Lanthorn, T.H.
Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention (257) 7
Quintero, E., see Plourde, V. (256) 125
Quirion, R., see Chaudieu, I. (264) 361

Rabe, K.F., see Buchan, K.W. (260) 221
Raberger, G., see Todt, H. (265) 43
Rabkin, S.W.
Indapamide alters the cyclic AMP signal transduction pathway in cardiomyocytes in culture (266) 117
Rad-Niknam, M., see Criddle, D.N. (255) 223
Radhakrishnan, R. and Sim, M.K.
Enhanced pressor response to angiotensin III in spontaneously hypertensive rats: effects of losartan (259) 87
Radhakrishnan, R., see Sim, M.K. (253) 171
Radhakrishnan, R., see Sim, M.K. (257) R1
Radja, F., see El Mansari, M. (261) 171
Raffa, R.B., Martinez, R.P. and Connelly, C.D.
G-protein antisense oligodeoxyribonucleotides and μ-opioid supraspinal antinociception (258) R5
Raffaele, R., see Bruno, V. (256) 109
Rafferty, M.F., see Quartermain, D. (257) 7
Ragozzino, M.E., Arankowsky-Sandoval, G. and Gold, P.E.
Glucose attenuates the effect of combined muscarinic-nicotinic receptor blockade on spontaneous alternation (256) 31
Rahier, J., see Guiot, Y. (261) 157
Raiteri, M., see Bonanno, G. (252) 61
Raiteri, M., see Fassio, A. (263) 311
Raiteri, M., see Fedele, E. (249) 71
Rakotoarisoa, L., see Baron, A. (269) 105
Rambridge, A., see Dawson, G.R. (252) 325
Rana, B., McMorn, S.O., Reeve, H.L., Wyatt, C.N., Vaughan, P.F.T. and Peers, C.
Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine (250) 247
Rand, M.J., see La, M. (249) 133
Randall, D.J., see Wang, Y.-X. (250) 335
Randriantsoa, A., see Schoeffter, P. (249) 199
Rangachari, P.K., see Muller, M.J. (251) 151
Ransom, R.W., see Schneck, K.A. (266) 277
Rapoport, R.M., see Zuccarello, M. (259) R1
Raschack, M., see Elger, B. (254) 65
Rascher, W., see Grandt, D. (269) 127
Rasouly, D. and Lazarovici, P.
Staurosporine induces tyrosine phosphorylation of a 145 kDa protein but does not activate $gp140^{trk}$ in PC12 cells (269) 255
Ratomponirina, C., see Maitre, M. (256) 211
Rattray, M., Wotherspoon, G., Savery, D., Baldessari, S., Marden, C., Priestley, J.V. and Bendotti, C.
Chronic D-fenfluramine decreases serotonin transporter messenger RNA expression in dorsal raphe nucleus (268) 439
Raufman, J.-P., see Schepp, W. (269) 183
Rauhala, P., Idänpään-Heikkilä, J.J., Tuominen, R.K. and Männistö, P.T.
N-Nitro-L-arginine attenuates development of tolerance to antinociceptive but not to hormonal effects of morphine (259) 57
Raung, S.-L., see Wang, J.-P. (251) 35
Rausch, W.-D., see Götz, M.E. (266) 291
Rausch, W.-D., see Koutsilieri, E. (269) R3
Raval, P., see Parker, S.G. (265) 17
Ravera, F., see Favoni, R.E. (264) 199
Ravert, H.T., see Villemagne, V.L. (257) 195
Ray, A. and MacLeod, K.M.
Effect of carbachol in the absence and presence of phenylephrine on Rb^+ efflux and tension in rabbit left atria (256) 311
Raybould, H.E. and Holzer, H.
Secretin inhibits gastric emptying in rats via a capsaicin-sensitive vagal afferent pathway (250) 165
Rayevsky, K.S., see Gainetdinov, R.R. (261) 327
Razzaque, Z., see Seabrook, G.R. (250) 125
Razzetti, R., see Civelli, M. (255) 17
Reader, T.A., see El Mansari, M. (261) 171
Reali, R., see Colombo, G. (265) 167
Reba, R.C., see Baumgold, J. (251) 315
Rebec, G.V., see Tschanz, J.A.T. (257) 161
Rebec, G.V., see White, I.M. (253) 167
Reddy, V.K., see Adipudi, V. (259) 7
Reeve, H.L., see Rana, B. (250) 247
Reeve Jr., J.R., see Grandt, D. (269) 127
Refahi-Lyamani, F., see Saadouni, S. (268) 187
Reggio, R., see Popoli, P. (257) R5
Regoli, D., see Chrétien, L. (256) 73
Regunathan, S. and Reis, D.J.
Effects of moxonidine, an imidazoline antihypertensive agent, on second messenger systems in rat brain (269) 273
Reichmann, H., see Götz, M.E. (266) 291
Reid, A., see Sawynok, J. (264) 249
Reid, J.J., see Lieu, A.T. (261) 33
Reid, J.L., see Thorin-Trescases, N. (268) 199
Reimann, W., see Selve, N. (256) 287
Reinartz, S., see Selve, N. (256) 287
Reinisch, N., see Kähler, C.M. (249) 281
Reinisch, N., see Kähler, C.M. (262) 261
Reis, D.J., see Regunathan, S. (269) 273
Reith, M.E.A., Coffey, L.L., Xu, C. and Chen, N.-H.
GBR 12909 and 12935 block dopamine uptake into brain synaptic vesicles as well as nerve endings (253) 175

Reith, M.E.A., see Madras, B.K. (267) 167
Reitstetter, R., He, D.S. and Gruener, R.
Oxotremorine-M activates single nicotinic acetylcholine receptor channels in cultured *Xenopus* myocytes (264) 27
Remaury, A., see Larrouy, D. (267) 225
Remiszewska, M., Jastrzębski, Z., Czyżewska-Szafran, H. and Wutkiewicz, M.
Enhancement of GABAergic system activity by metoprolol in spontaneously hypertensive rats (250) 355
Ren, L.-M., see Iwatsuki, K. (249) 19
Renesto, E., see Bevilacqua, M. (268) 415
Reno, F., see Balduini, W. (266) 283
Renzetti, A.-R., see Catalioto, R.-M. (256) 93
Rettori, M.-C., see Cataldi, M. (253) 149
Reuter, B., see Wallace, J.L. (257) 249
Revilla, V., see Fernández-López, A. (262) 283
Reymann, K.G., see Wilsch, V.W. (262) 287
Rezayat, M., Nikfar, S. and Zarrindast, M.-R.
CCK receptor activation may prevent tolerance to morphine in mice (254) 21
Ribes, G., see Berdeu, D. (254) 119
Ribuot, C., see Lambert, C. (252) 245
Ricci, A., see Kobayashi, Y. (253) 201
Ricci, A., see Kobayashi, Y. (261) 229
Ricciardolo, F.L.M., Nadel, J.A., Bertrand, C., Yamawaki, I., Chan, B. and Geppetti, P.
Tachykinins and kinins in antigen-evoked plasma extravasation in guinea-pig nasal mucosa (261) 127
Richards, N.T. and Poston, L.
Effect of flosequinan on human small subcutaneous arteries (257) 189
Richter, A. and Löscher, W.
(+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters (264) 371
Richter, A., Löschmann, P.-A. and Löscher, W.
The novel antiepileptic drug, lamotrigine, exerts prodystonic effects in a mutant hamster model of generalized dystonia (264) 345
Richter, A., see Löscher, W. (255) 235
Riedel, T., see Schepp, W. (269) 183
Riederer, P., see Götz, M.E. (266) 291
Riederer, P., see Koutsilieri, E. (269) R3
Riekkinen, P., see Pitkänen, M. (253) 125
Riekkinen Jr., P.
5-HT_{1A} and muscarinic acetylcholine receptors jointly regulate passive avoidance behavior (262) 77
Riezebos, J., see Vleeming, W. (250) 415
Rigo, M., see Rocha, B. (262) 125
Rioux, F., see Godin, D. (253) 225
Risvanis, J., see Phillips, P.A. (259) 325
Riutta, A., Alanko, J., Mucha, I. and Vapaatalo, H.
Effects of Trolox C and SIN-1 on arachidonic acid metabolism and on cyclic GMP formation in leukocytes (262) 217
Rivas-Cabañero, L., Montero, A. and López-Novoa, J.M.
Increased glomerular nitric oxide synthesis in gentamicin-induced renal failure (270) 119
Rivet, J.-M., Audinot, V., Gobert, A., Peglion, J.-L. and Millan, M.J.
Modulation of mesolimbic dopamine release by the selective dopamine D_3 receptor antagonist, (+)-S 14297 (265) 175
Rivet, J.-M., see Lejeune, F. (260) 79
Rivet, J.-M., see Millan, M.J. (260) R3
Rivière, P.J.M., see Diop, L. (257) 181
Roach, A.G., see Trezise, D.J. (250) 109
Rob, P., see Mühl, H. (249) 95
Roberts, P., see Kemp, M. (266) 187
Roberts, P.J., see Toms, N.J. (266) 63
Robertson, J.M., see Saab, G. (256) 1
Robichaud, A., see Lambert, C. (252) 245
Robinson, J.L., see Lysko, G.S. (263) 25
Robinson, S., see Deshpande, Y. (256) R1
Robles, L.I., Barrios, M. and Baeyens, J.M.
ATP-sensitive K^+ channel openers inhibit morphine withdrawal (251) 113
Rocha, B., Rigo, M., Di Scala, G., Sandner, G. and Hoyer, D.
Chronic mianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5-HT_{2C} receptor levels (262) 125
Rochette, L., see Bellemin-Baurreau, J. (256) 115
Rodgers, R.J. and Cole, J.C.
Anxiolytic-like effect of (*S*)-WAY 100135, a 5-HT_{1A} receptor antagonist, in the murine elevated plus-maze test (261) 321
Rodríguez-Farré, E., see Cristòfol, R.M. (252) 305
Roeske, W.R., see Wei, H.-B. (268) 381
Roffel, A.F., Elzinga, C.R.S. and Zaagsma, J.
Cholinergic contraction of the guinea pig lung strip is mediated by muscarinic M_2-like receptors (250) 267
Roffel, A.F., Meurs, H., Elzinga, C.R.S. and Zaagsma, J.
Muscarinic M_2 receptors do not participate in the functional antagonism between methacholine and isoprenaline in guinea pig tracheal smooth muscle (249) 235
Roffel, A.F., see Coppes, R.P. (261) 311
Rohn, W.R., see Lamb, V.L. (256) 221
Rohr, S., see Chamouard, P. (262) 33
Rojik, I., see László, F. (258) 15
Rolka, K., see Patacchini, R. (250) 311
Romagnoli, C., see Spampinato, S. (254) 229
Romero, L., Celada, P. and Artigas, F.
Reduction of in vivo striatal 5-hydroxytryptamine release by 8-OH-DPAT after inactivation of G_i/G_o proteins in dorsal raphe nucleus (265) 103
Romey, G., Bois, P. and Lazdunski, M.
Effects of two chemically related new Ca^{2+} channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel (263) 101
Rommelspacher, H., May, T. and Salewski, B.
Harman (1-methyl-β-carboline) is a natural inhibitor of monoamine oxidase type A in rats (252) 51
Romualdi, P., see Melchiorre, C. (265) 93
Ronken, E., Mulder, A.H. and Schoffelmeer, A.N.M.
Glucocorticoid and mineralocorticoid receptors differentially modulate cultured dopaminergic neurons of rat ventral mesencephalon (263) 149
Ronken, E., see Tjon, G.H.K. (252) 205
Roppolo, J.R., see Yoshiyama, M. (264) 417
Roques, B.-P., see Matsuoka, I. (268) 215
Roques, B.P., see Abbadie, C. (258) 215
Roques, B.P., see Hernando, F. (261) 257
Roques, B.P., see Noble, F. (253) 283
Roscetti, G., Ambrosio, C., Trabucchi, M., Massotti, M. and Barbaccia, M.L.
Modulatory mechanisms of cyclic AMP-stimulated steroid content in rat brain cortex (269) 17
Roscetti, G., see Barbaccia, M.L. (261) 317
Rosenberg, P.H., see Suzuki, N. (249) 247
Rosenstein, R.E., see Esquifino, A.I. (254) 1
Rosenzweig-Lipson, S. and Bergman, J.
Catalepsy-associated behavior induced by dopamine D_1 receptor antagonists and partial dopamine D_1 receptor agonists in squirrel monkeys (260) 237
Rossi, A.G., see Pons, F. (261) 237
Rossi, C., see Cervo, L. (263) 187
Rossi, F., see Maione, S. (250) 209
Rostène, W., see Azzi, M. (255) 167
Rostène, W., see Brouard, A. (253) 289
Rotert, G., see Hancock, A.A. (267) 49

Rouquier, L., Claustre, Y. and Benavides, J.
α_1-Adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study (261) 59
Rovati, G.E., see Letari, O. (266) 219
Rowan, M.J., see Manahan-Vaughan, D. (260) 149
Rowlett, J.K., see Crawford, C.A. (252) 225
Ruano, D., Khan, Z., De Blas, A.L., Machado, A. and Vitorica, J.
Molecular heterogeneity of the type I $GABA_A$/benzodiazepine receptor complex (267) 121
Rubino, T., see Massi, P. (253) 269
Rudd, J.A., Jordan, C.C. and Naylor, R.J.
Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis (262) R1
Rüegg, J.C., see Strauss, J.D. (252) 219
Ruffolo, Jr., R.R., see Yue, T.-L. (251) 237
Ruiz-Gayo, M., see Hernando, F. (261) 257
Ruiz-Velasco, V., Mayer, M.B., Inscho, E.W. and Hymel, L.J.
Modulation of dihydropyridine receptors in vascular smooth muscle cells by membrane potential and cell proliferation (268) 311
Rupniak, N.M.J. and Jackson, A.
Non-specific inhibition of dopamine receptor agonist-induced behaviour by the tachykinin NK_1 receptor antagonist CP-99,994 in guinea-pigs (262) 171
Rupniak, N.M.J. and Williams, A.R.
Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK_1 receptor antagonists (265) 179
Ruskoaho, H., see Taskinen, P. (256) 251
Ruskoaho, H., see Tokola, H. (267) 195
Ruzicka, T., see Kemény, L. (258) 269
Ryan, M.C., see Beart, P.M. (269) 193
Rycroft, W., see Tattersall, F.D. (250) R5
Ryrfeldt, Å., see Bannenberg, G. (270) 175

Saab, G., Robertson, J.M., Harding, S. and Grupp, L.A.
Adrenalectomy does not modify the suppressive effect of angiotensin II on voluntary ethanol drinking in rats (256) 1
Saadouni, S., Refahi-Lyamani, F., Costentin, J. and Bonnet, J.-J.
Cocaine and GBR 12783 recognize nonidentical, overlapping binding domains on the dopamine neuronal carrier (268) 187
Sacerdote, P., see Bianchi, M. (263) 81
Sadowski, B., see Lutfy, K. (265) 171
Saeki, T., Uchida, T., Nishimura, M., Fujinami, T. and Watanabe, Y.
Block of Na^+ channel by moricizine hydrochloride in isolated feline ventricular myocytes (261) 249
Saeki, Y., see Matsuda, Y. (250) 341
Saetta, M., see Chitano, P. (270) 167
Safar, M., see Chaouche-Teyara, K. (250) 67
Safe, S., see Fernandez, P. (270) 53
Sagan, S., see Charpentier, S. (266) 175
Saha, S. and Hellman, B.
Sulfonylureas mimic glucose in stimulating the uptake of Na^+ in pancreatic islets exposed to ouabain (258) 145
Saigenji, K., see Ichikawa, T. (251) 107
Saint, D.A., see Pugsley, M.K. (261) 303
Saita, Y., Yazawa, H., Honma, Y., Nishida, A., Miyata, K. and Honda, K.
Characterization of YM022: its CCK_B/gastrin receptor binding profile and antagonism to CCK-8-induced Ca^{2+} mobilization (269) 249
Saito, H., see Abe, K. (251) 295
Saito, H., see Chu, P.-j. (256) 155
Saito, H., see Hirokami, M. (253) 9
Saito, H., see Shimizu, M. (268) 65
Saito, I., see Chang, T.-h. (258) 77
Saito, I., see Kodama, K. (263) 93
Saitoh, T., see Ishida, M. (268) 267
Saitta, A., see Ioculano, M. (264) 143
Sakai, R., see Miyamoto, K.-i. (267) 317
Sakamoto, K., see Fujibayashi, K. (261) 133
Sakamoto, K., see Wakabayashi, I. (255) 111
Sakamoto, N., see Nonogaki, K. (262) 177
Sakamoto, T., Sun, J., Barnes, P.J. and Chung, K.F.
Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig (251) 137
Sakuma, S., see Tohda, M. (268) 169
Sakurada, S., see Sakurada, T. (261) 85
Sakurada, T., Manome, Y., Katsumata, K., Tan-No, K., Sakurada, S., Ohba, M. and Kisara, K.
Comparison of antagonistic effects of sendide and CP-96,345 on a spinally mediated behavioural response in mice (261) 85
Sakurai, E., see Yokoyama, H. (260) 23
Sakuta, H. and Okamoto, K.
Effects of Ca^{2+} channel antagonists and their isomers on glibenclamide-sensitive K^+ currents in follicle-enclosed *Xenopus* oocytes (255) 1
Sakuta, H. and Okamoto, K.
Inhibition by imidazoline and imidazolidine derivatives of glibenclamide-sensitive K^+ currents in *Xenopus* oocytes (259) 223
Sakuta, H. and Yoneda, I.
Inhibition by SKF 525A and quinacrine of endogenous glibenclamide-sensitive K^+ channels in follicle-enclosed *Xenopus* oocytes (252) 117
Sakuta, H., Okamoto, K. and Tandai, M.
Atrial natriuretic factor potentiates glibenclamide-sensitive K^+ currents via the activation of receptor guanylate cyclase in follicle-enclosed *Xenopus* oocytes (267) 281
Sakuta, H.
Inhibition by histamine H_1 receptor antagonists of endogenous glibenclamide-sensitive K^+ channels in follicle-enclosed *Xenopus* oocytes (266) 99
Sakuta, H.
Potentiation by insulin and insulin-like growth factor-1 of glibenclamide-sensitive K^+currents in follicle-enclosed *Xenopus* oocytes (268) 375
Sakuta, H.
Vanadate-induced oscillatory inward Cl^- currents in *Xenopus laevis* oocytes (268) 305
Sala, A., see Letari, O. (266) 219
Salas, E., López, M.G., Villarroya, M., Sánchez-García, P., De Pascual, R., Dixon, W.R. and García, A.G.
Endothelium-independent relaxation by 17-α-estradiol of pig coronary arteries (258) 47
Salas, E., see Berrazueta, J.R. (251) 303
Salewski, B., see Rommelspacher, H. (252) 51
Salford, L.G., see Adner, M. (261) 281
Salhoff, C.R., see Schoepp, D.D. (270) 67
Sallés, J., Gascón, S., Ivorra, D. and Badia, A.
In vivo recovery of α_1-adrenoceptors in rat myocardial tissue after alkylation with phenoxybenzamine (266) 35
Sallés, J. and Badia, A.
Selective enrichment with α_{1A}- and α_{1B}-adrenoceptor subtypes in rat brain cortical membranes (266) 301
Sallés, J., Giraldo, J. and Badia, A.
Analysis of agonism at functional prejunctional α_2-adrenoceptors of rat vas deferens using operational and null approaches (258) 229
Salmi, P., Karlsson, T. and Ahlenius, S.
Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat (253) 67
Salmi, P., see Ahlenius, S. (260) 177
Salo, K., see Tokola, H. (267) 195

Salvadori, S., see Jones, L.S. (264) 39
Samanin, R., see Cervo, L. (253) 139
Samanin, R., see Cervo, L. (263) 187
Samanin, R., see Invernizzi, R. (260) 243
Samejima, K., see Chu, P.-j. (256) 155
Sanada, T., see Wada, T. (253) 27
Sanae, F., see Miyamoto, K.-i. (267) 317
Sánchez-Blázquez, P. and Garzón, J.
Mastoparan reduces the supraspinal analgesia mediated by μ/δ-opioid receptors in mice (258) 159
Sánchez, C. and Hyttel, J.
Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT_{1A} receptors (264) 241
Sánchez-García, P., see Salas, E. (258) 47
Sánchez de Vega, M.J., see Berrazueta, J.R. (251) 303
Sandner, G., see Rocha, B. (262) 125
Sandoli, D., Chiu, P.J.S., Chintala, M., Dionisotti, S. and Ongini, E.
In vivo and ex vivo effects of adenosine A_1 and A_2 receptor agonists on platelet aggregation in the rabbit (259) 43
Saniabadi, A.R., see Nishiyama, H. (264) 191
Sanna, E., see Klein, R.L. (268) 237
San Román, L., see Morán, A. (252) 161
Santella III, J.B., see Wong, P.C. (260) 261
Santiago, J.A., Garrison, E.A. and Kadowitz, P.J.
Comparative effects of N^{ω}-nitro-L-arginine and N^{ω}-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, bradykinin, and substance P (254) 207
Santicioli, P., see Lecci, A. (259) 129
Santicioli, P., see Zagorodnyuk, V. (255) 9
Santing, R.E., Schraa, E.O., Vos, B.G., Gores, R.-J.J., Olymulder, C.G., Meurs, H. and Zaagsma, J.
Dissociation between bronchial hyperreactivity in vivo and reduced β-adrenoceptor sensitivity in vitro in allergen-challenged guinea pigs (257) 145
Santing, R.E., Schraa, E.O., Wachters, A., Olymulder, C.G., Zaagsma, J. and Meurs, H.
Role of histamine in allergen-induced asthmatic reactions, bronchial hyperreactivity and inflammation in unrestrained guinea pigs (254) 49
Santoro, G., see Concas, A. (267) 207
Santos, D.L., Lopes, M.C. and Carvalho, C.M.
Calcium channel blockers inhibit the (Ca^{2+} + Mg^{2+})-ATPase activity and the ^{125}I-calmodulin binding in brain membranes (267) 307
Santucci, V., see Emonds-Alt, X. (250) 403
Sanz, M.J., see Ferrándiz, M.L. (253) 75
Sargent, C.A., Dzwonczyk, S. and Grover, G.J.
The effect of α_2-adrenoceptor antagonists in isolated globally ischemic rat hearts (261) 25
Sartorio, G., see Pisarev, M.A. (258) 33
Sasa, M., see Nakamura, J. (254) 83
Sasaki, S., see Fukui, H. (249) 13
Sasaki, S., see Fukui, H. (250) 281
Sasaki, S., see Fukui, H. (257) 47
Sasayama, S., see Hattori, R. (267) R1
Sase, K., see Hattori, R. (267) R1
Satake, N., Zhou, Q., Kosakai, K., Nimura, M. and Shibata, S.
Vasoinhibitory action of KT2-734, an antihypertensive agent, in isolated rat aorta (251) 1
Sato, K., see Kojima, M. (254) 159
Sato, K., see Tsunoda, R. (262) 55
Sato, N., see Isono, T. (260) 163
Sato, R., see Koumi, S.-i. (258) 281
Sato, R., see Koumi, S.-i. (261) 213
Sato, S., see Fukui, H. (249) 13
Sato, S., see Fukui, H. (250) 281
Sato, S., see Fukui, H. (257) 47
Satoh, K., Nakai, T. and Ichihara, K.
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in rat liver during ischemia (270) 365
Satoh, K., see Yamagishi, T. (251) 253
Satoh, M., Kojima, C., Kokubu, N. and Takayanagi, I.
α_1-Adrenoceptor subtypes mediating the regulation and modulation of Ca^{2+} sensitization in rabbit thoracic aorta (265) 133
Satoh, M., see Onogi, T. (262) 163
Satoh, N., see Uchida, W. (264) 285
Satoh, S., see Kimura, T. (264) 169
Satou, F., see Mogami, H. (269) 293
Sauermann, W., see Jackisch, R. (264) 207
Saulnier-Blache, J.-S., see Bouloumié, A. (269) 95
Sautebin, L. and Di Rosa, M.
Nitric oxide modulates prostacyclin biosynthesis in the lung of endotoxin-treated rats (262) 193
Savery, D., see Rattray, M. (268) 439
Savineau, J.-P., De La Fuente, P.G. and Marthan, R.
Effect of vascular smooth muscle relaxants on the protein kinase C-mediated contraction in the rat pulmonary artery (249) 191
Savola, J.-M., see Jansson, C.C. (266) 165
Sawada, T., see Isono, T. (260) 163
Sawaki, S., Furukawa, Y., Inoue, Y., Oguchi, T. and Chiba, S.
Selective inhibition by E4080, a novel bradycardic agent, of positive chronotropic responses to norepinephrine in isolated dog hearts (250) 253
Sawynok, J. and Reid, A.
Spinal supersensitivity to 5-HT_1, 5-HT_2 and 5-HT_3 receptor agonists following 5,7-dihydroxytryptamine (264) 249
Saxena, P.R., see Du, X.Y. (259) 173
Scatton, B., see Biton, B. (257) 297
Scatton, B., see Carreau, A. (256) 241
Schachter, M., see Calder, J.A. (256) 185
Schade, A., see Kusterer, K. (259) 265
Schaeffer, P., see Herbert, J.-M. (251) 143
Schäfer, S. and Walland, A.
Staurosporine inhibits the anaphylactic reaction of the isolated guinea-pig heart (258) 247
Schaffer, K., see Weigert, N. (264) 337
Schechter, M.D. and Gordon, T.L.
Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity (249) 79
Schechter, M.D. and Meehan, S.M.
Conditioned place aversion produced by dopamine release inhibition (260) 133
Scheideler, M., see Pedersen, U.B. (267) 85
Scheinin, M., see Jansson, C.C. (266) 165
Scheinin, M., see Marjamäki, A. (267) 117
Schepp, W., Schmidtler, J., Riedel, T., Dehne, K., Schusdziarra, V., Holst, J.J., Eng, J., Raufman, J.-P. and Classen, M.
Exendin-4 and exendin-(9–39)NH_2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH_2 (269) 183
Schepp, W., see Weigert, N. (264) 337
Scherrer, D., see Lach, E. (269) 87
Schiele, J.O. and Schwabe, U.
Characterization of the adenosine receptor in microvascular coronary endothelial cells (269) 51
Schiereck, P., De Beer, E., Van Heijst, B., Janssen, P., Van Andel, A., Jennekens, F., Sontrop, A. and Bavinck, A.
Ca^{2+} channel antagonists enhance tension in skinned skeletal and heart muscle fibres (249) 317
Schimiczek, M., see Grandt, D. (269) 127

Schindler, C.W., see Yasar, S. (259) 243
Schini-Kerth, V., Bara, A., Mülsch, A. and Busse, R.
Pyrrolidine dithiocarbamate selectively prevents the expression of the inducible nitric oxide synthase in the rat aorta (265) 83
Schiødt, M., see Pedersen, U.B. (267) 85
Schlicker, E., see Grandt, D. (269) 127
Schlicker, E., see Malinowska, B. (259) 315
Schmidt, J., Fleißner, S., Heimann-Weitschat, I., Lindstaedt, R. and Szelenyi, I.
The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine T_H2-type T cells (260) 247
Schmidt, N., Brune, K. and Geisslinger, G.
Opioid receptor agonist potencies of morphine and morphine-6-glucuronide in the guinea-pig ileum (255) 245
Schmidtler, J., see Schepp, W. (269) 183
Schneck, K.A., Hess, J.F., Stonesifer, G.Y. and Ransom, R.W.
Bradykinin B_1 receptors in rabbit aorta smooth muscle cells in culture (266) 277
Schobert, A., see Allgaier, C. (252) R7
Schoeffter, P. and Randriantsoa, A.
Differences between endothelin receptors mediating contraction of guinea-pig aorta and pig coronary artery (249) 199
Schoemaker, H., see Oblin, A. (266) 103
Schoemaker, R.G., see Du, X.Y. (259) 173
Schoepp, D.D., Lunn, W.H.W., Salhoff, C.R. and McDonald, J.W.
The NMDA receptor agonist DL-(tetrazol-5-yl)glycine is a highly potent excitotoxin (270) 67
Schoffelmeer, A.N.M., see Ronken, E. (263) 149
Schoffelmeer, A.N.M., see Tjon, G.H.K. (252) 205
Schollmeyer, P., see Galle, J. (265) 111
Schönafinger, K., see Martorana, P.A. (257) 267
Schraa, E.O., see Santing, R.E. (254) 49
Schraa, E.O., see Santing, R.E. (257) 145
Schreiber, R. and De Vry, J.
Neuronal circuits involved in the anxiolytic effects of the 5-HT_{1A} receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat (249) 341
Schreiber, R., Brocco, M. and Millan, M.J.
Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone (264) 99
Schreiber, R., see De Vry, J. (249) 331
Schumacher, W.A., Balasubramanian, N., St. Laurent, D.R. and Seiler, S.M.
Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis (259) 165
Schusdziarra, V., see Kurjak, M. (257) 169
Schusdziarra, V., see Schepp, W. (269) 183
Schusdziarra, V., see Weigert, N. (264) 337
Schütz, W., see Todt, H. (265) 43
Schuurkes, J.A.J., see Briejer, M.R. (250) 181
Schwabe, U., see Schiele, J.O. (269) 51
Schwartz, A.J., see Lamb, V.L. (256) 221
Schwartz, J.-C., see Pilon, C. (268) 129
Schwarz, M., see Block, F. (256) 149
Scott-Burden, T., see De Castro, M. (261) 199
Scotti de Carolis, A., see Popoli, P. (257) 21
Scotti de Carolis, A., see Popoli, P. (257) R5
Seabrook, G.R., Main, M.J., Razzaque, Z. and Longmore, J.
Differences in the effects of tachykinin NK_1 receptor antagonists: neuronal versus smooth muscle tissues (250) 125
Sebök, B., Bonnekoh, B., Geisel, J. and Mahrle, G.
Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures (270) 79
See, R.E. and Chapman, M.A.
Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats (263) 269
Seeburg, P.H., see Laurie, D.J. (268) 335
Seeds, E.A.M., see Manzini, S. (249) 251
Seega, J., see Elger, B. (254) 65
Segal, M., see Levkovitz, Y. (264) 279
Segami, T., see Ito, M. (263) 245
Segami, T., see Ito, M. (263) 253
Segawa, H., see Ogino, K. (270) 73
Segondy, D., see Lacour, C. (264) 307
Seguin, L. and Millan, M.J.
The glycine B receptor partial agonist, (+)-HA 966, enhances induction of antinociception by RP 67580 and CP-99,994 (253) R1
Seifen, E., see Buzzard, S.L. (260) 15
Seifen, E., see Kennedy, R.H. (255) 149
Seiler, S.M., see Schumacher, W.A. (259) 165
Sekiguchi, Y., see Takekoshi, K. (250) 465
Sekino, N., see Yamanouchi, T. (257) 39
Selbie, L.A., see Potter, E.K. (267) 253
Selve, N., Friderichs, E., Reimann, W. and Reinartz, S.
Absence of emetic effects of morphine and loperamide in *Suncus murinus* (256) 287
Semma, M., see Osada, S. (252) 347
Senda, T., see Matsuno, K. (261) 43
Seppälä, T., see Kuoppamäki, M. (269) 201
Serban, D.N., see Brailoiu, E. (250) 489
Serban, D.N., see Brailoiu, E. (250) 493
Serikawa, T., see Nakamura, J. (254) 83
Serra, G., see D'Aquila, P.S. (262) 107
Serra, M., Ghiani, C.A., Motzo, C., Porceddu, M.L. and Biggio, G.
Long-term treatment with abecarnil fails to induce tolerance in mice (259) 1
Serra, M., Ghiani, C.A., Spano, S. and Biggio, G.
Felbamate antagonizes isoniazid- and FG 7142-induced reduction of $GABA_A$ receptor function in mouse brain (265) 185
Serra, M., see Ghiani, C.A. (254) 299
Serra, M., see Imperato, A. (261) 205
Settle, S.L., see Kasten, T.P. (253) 35
Sever, P.S., see Calder, J.A. (256) 185
Seyfried, C.A. and Bartoszyk, G.D.
Sensitivity of dopamine D_2 receptors following long-term treatment with roxindole (257) 67
Sgro, C., see Dumas, J.-P. (263) 17
Shafaghi, B., see Zarrindast, M.R. (256) 233
Shakiryanova, D.M., Zefirov, A.L., Nikolsky, E.E. and Vyskočil, F.
The effect of acetylcholine and related drugs on currents at the frog motor nerve terminal (263) 107
Sham, A.Y.-C., see Chiou, W.-F. (257) 59
Shannon, T.R. and Hale, C.C.
Identification of a 65 kDa endothelin receptor in bovine cardiac sarcolemmal vesicles (267) 233
Shany, E., Hochhauser, E., Halpern, P., Vidne, B., Gavish, M., Geller, E., Hasharoni, A., Barak, Y. and Yakirevich, V.
Ro 5-4864 has a negative inotropic effect on human atrial muscle strips that is not antagonized by PK 11195 (253) 231
Sharonova, I.N., see Vorobjev, V.S. (253) 1
Sharp, R.L., May, P.C., Mayne, N.G., Snyder, Y.M. and Burnett, J.P.
Cyclothiazide potentiates agonist responses at human AMPA/kainate receptors expressed in oocytes (266) R1
Sharp, R.L., Mayne, N.G. and Burnett, J.P.
Cyclothiazide differentially modulates human metabotropic glutamate receptors linked to phosphoinositide hydrolysis stimulation in oocytes (269) R5
Shatzer, S.A., see Kudlacz, E.M. (270) 291
Shen, A. and Mitchelson, F.
Characterization of the muscarine receptor subtype on sympathetic nerve endings in the rat caudal artery (252) 167

Shen, T.Y., see Qian, C. (250) R13
Shepard, P.D., Lehmann, H. and Connelly, S.T.
Effects of NPC16377, a potent and selective σ receptor ligand, on the activity of mesencephalic dopamine-containing neurons in the rat (265) 141
Shi, F., see Borges, N. (269) 243
Shiao, M.-S., see Wang, C.-N. (267) 33
Shibamoto, T., see Matsuda, Y. (250) 341
Shibata, H., see Mogami, H. (269) 293
Shibata, S., Tanaka, T. and Watanabe, S.
Facilitatory effects of somatostatin on reduced uptake of 2-deoxyglucose in cerebral cortical and hippocampal slices from aged rats (269) 269
Shibata, S., see Satake, N. (251) 1
Shibouta, Y., see Wada, T. (253) 27
Shigenobu, K., see Agata, N. (260) 47
Shih, Y.-H., see MacKenzie, R.G. (266) 79
Shikasho, T., see Chen, X. (267) 175
Shimada, A., Spangler, E.L., London, E.D. and Ingram, D.K.
Spermidine potentiates dizocilpine-induced impairment of learning performance by rats in a 14-unit T-maze (263) 293
Shimada, J., see Kanda, T. (256) 263
Shimada, J., see Nonaka, H. (267) 335
Shimada, J., see Tomaru, A. (264) 91
Shimada, K., see Ikeda, U. (269) 319
Shimada, Y., see Hirabayashi, A. (256) 227
Shimamoto, K., see Okada, M. (259) 339
Shimizu, M., Nishida, A., Fukuda, H., Saito, H. and Yamawaki, S.
Inhibitory effect of imipramine on depolarization-induced increases in intracellular Ca^{2+} of rat cortical neurons (268) 65
Shimoda, S.-I., see Takekoshi, K. (250) 465
Shimomura, A., Itoh, H., Niki, Y., Suga, T., Fujioka, H., Ito, M., Konishi, T., Hollenberg, M.D. and Nakano, T.
Contractile actions of endothelins in rat gastric body: evidence for receptor subtypes and involvement of prostaglandin E_2 (252) 81
Shine, J., see Potter, E.K. (267) 253
Shinohara, T., see Yamanouchi, T. (257) 39
Shinozaki, H., see Bruno, V. (256) 109
Shinozaki, H., see Ishida, M. (268) 267
Shinozaki, H., see Miyamoto, M. (260) 99
Shinozaki, H., see Wilsch, V.W. (262) 287
Shinozuka, K., see Takeuchi, K. (254) 287
Shiotani, T., see Nabeshima, T. (255) 57
Shiozaki, S., see Kanda, T. (256) 263
Shippenberg, T.S., see Spanagel, R. (264) 157
Shirahata, A., see Chu, P.-j. (256) 155
Shirai, Y., see Uchida, W. (264) 285
Shirasaki, H., Adcock, I.M., Kwon, O.J., Nishikawa, M., Mak, J.C. and Barnes, P.J.
Agonist-induced up-regulation of platelet-activating factor receptor messenger RNA in human monocytes (268) 263
Shoaib, M. and Spanagel, R.
Mesolimbic sites mediate the discriminative stimulus effects of morphine (252) 69
Shoei-Yn Lin-Shiau, see Kuei-Sen Hsu, (270) 89
Shreeve, S.M., see Diehl, N.L. (268) 393
Shudo, K., see Oikawa, T. (249) 113
Siegel, M.I., see West, Jr., R.E. (267) 343
Silbaugh, S.A., see Stengel, P.W. (253) 253
Silva, A.R., see Bozza, P.T. (270) 143
Silva, P.M.R., see Altenburg, S.P. (256) 45
Silva, P.M.R., see Bozza, P.T. (270) 143
Silver, P.J., see Dundore, R.L. (249) 293
Silver, P.J., see Krafte, D.S. (266) 245
Sim, M.K. and Radhakrishnan, R.
Effect of pentobarbital and chlordiazepoxide on the central pressor action of angiotensins in normo- and hypertensive rats (253) 171
Sim, M.K. and Radhakrishnan, R.
Novel central action of des-Asp-angiotensin I (257) R1
Sim, M.K., see Radhakrishnan, R. (259) 87
Simon, R.P., see Gaspary, H.L. (262) 197
Simonato, M., Varani, K., Muzzolini, A., Bianchi, C., Beani, L. and Borea, P.A.
Adenosine A_1 receptors in the rat brain in the kindling model of epilepsy (265) 121
Simonazzi, I., see Testa, R. (249) 307
Simonet, S., see Verbeuren, T.J. (270) 27
Simonsson, P., see Larsson, C. (268) 19
Simpson, P.B., Challiss, R.A.J. and Nahorski, S.R.
Potentiation of *N*-methyl-D-aspartate-evoked elevation of intracellular Ca^{2+} concentrations by exogenous glycine in cerebellar granule cells (266) 309
Singh, N.A., see Midgley, L.P. (251) 191
Singh, V.B., Corley, K.C., Krieg, R.J., Phan, T.-H. and Boadle-Biber, M.C.
Sound stress activation of tryptophan hydroxylase blocked by hypophysectomy and intracranial RU 38486 (256) 177
Sipma, H., Den Hertog, A. and Nelemans, A.
The phospholipase C activating P_{2U} purinoceptor also inhibits cyclicAMP formation in DDT_1 MF-2 smooth muscle cells (268) 431
Sirviö, J., see Pitkänen, M. (253) 125
Sitte, B.A., see Kähler, C.M. (249) 281
Sizmann, D., see Marjamäki, A. (267) 117
Skarsfeldt, T.
Comparison of short-term administration of sertindole, clozapine and haloperidol on the inactivation of midbrain dopamine neurons in the rat (254) 291
Skeen, G.A., see Filloux, F.M. (269) 325
Skolnick, P., see Harris, B.D. (267) 269
Skolnick, P., see Long, J.B. (261) 295
Skoogh, B.-E., see Arakawa, H. (252) 313
Skoogh, B.-E., see Arakawa, H. (259) 251
Skorupska, M., see Cervo, L. (253) 139
Slangen, J.L., see Ybema, C.E. (256) 141
Slater, P., see McConnell, S.E. (262) 293
Slatineanu, S., see Brailoiu, E. (250) 489
Slatineanu, S., see Brailoiu, E. (250) 493
Smart, D., see Elliott, J. (268) 447
Smit, J., see Coppes, R.P. (261) 311
Smith, A.J., Patel, S. and Freedman, S.B.
Characterisation of CCK_B receptors on GH_3 pituitary cells: receptor activation is linked to Ca^{2+} mobilisation (267) 215
Smith, A.J., see Patel, S. (253) 237
Smith, D.M., see Veale, P.R. (262) 133
Smith, K.E., see Borden, L.A. (269) 219
Smith, M.T., see Cabot, P.J. (268) 247
Smith, P., see Gilchrist, D. (252) R1
Smith, R., see Fernandez, P. (270) 53
Smith, R.D., see Wong, P.C. (260) 261
Smith, S.D., see Dokita, S. (266) 269
Smith, S.J., see Medhurst, A.D. (256) R5
Smith, T.L., see Knapp, R.J. (269) 133
Smith, T.W., see Oluyomi, A.O. (258) 131
Snyder, Y.M., see Sharp, R.L. (266) R1
Söderpalm, B., see Blomqvist, O. (249) 207
Soejima, O., Katsuragi, T. and Furukawa, T.
Opposite modulation by muscarinic M_1 and M_3 receptors of acetylcholine release from guinea pig ileum as measured directly (249) 1
Sokoll, M.D., see Bhattacharyya, B.J. (254) 97
Sokoloff, P., see Pilon, C. (268) 129

Solomon, T.E., see Varga, G. (250) 37
Soma, G.-I., see Kamei, J. (251) 95
Song, C., see Knuepfer, M.M. (259) 305
Song, D.-K., see Suh, H.-W. (263) 217
Sontrop, A., see Schiereck, P. (249) 317
Sorensen, B.K., see Hancock, A.A. (267) 49
Soria, C., see Fernández-López, A. (262) 283
Sorrentino, L., see Capasso, A. (261) 209
Sorrentino, L., see Cirino, G. (252) 147
Sorrentino, R., see Cirino, G. (252) 147
Sotnikova, T.D., see Gainetdinov, R.R. (261) 327
Soubrié, P., see Emonds-Alt, X. (250) 403
Soudijn, W., see Beukers, M.W. (266) 57
Soudijn, W., see Van Rhee, A.M. (268) 1
Sowa, G. and Przewłocki, R.
cAMP analogues and cholera toxin stimulate the accumulation of nitrite in rat peritoneal macrophage cultures (266) 125
Soyama, M., see Sudo, J.-i. (270) 229
Spada, F., see Ghiggeri, G.M. (270) 195
Spada, M.R., see Hashimoto, K. (266) 67
Spampinato, S., Speroni, E., Govoni, P., Pistacchio, E., Romagnoli, C., Murari, G. and Ferri, S.
Effect of ω-conotoxin and verapamil on antinociceptive, behavioural and thermoregulatory responses to opioids in the rat (254) 229
Spanagel, R., Almeida, O.F.X. and Shippenberg, T.S.
Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes (264) 157
Spanagel, R., Eilbacher, B. and Wilke, R.
Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat – a pharmacokinetic microdialysis study (262) 21
Spanagel, R., see Shoaib, M. (252) 69
Spangler, E.L., see Shimada, A. (263) 293
Spangler, R.S., see Clarke, G.D. (257) 103
Spano, S., see Serra, M. (265) 185
Spear, L.P., see Molina, V.A. (260) 57
Spedding, M., see Lejeune, F. (260) 79
Spedding, M., see Lombet, A. (267) 113
Spedding, M., see Millan, M.J. (260) R3
Sperelakis, N., see Conforti, L. (259) 215
Speroni, E., see Spampinato, S. (254) 229
Spiertz, C., see Lans, M.C. (270) 129
Squadrito, F., Calapai, G., Altavilla, D., Cucinotta, D., Zingarelli, B., Arcoraci, V., Campo, G.M. and Caputi, A.P.
Central serotoninergic system involvement in the anorexia induced by N^G-nitro-L-arginine, an inhibitor of nitric oxide synthase (255) 51
Squadrito, F., see Altavilla, D. (270) 45
Squadrito, F., see Ioculano, M. (264) 143
Squadrito, G., see Ioculano, M. (264) 143
St-Pierre, J.A., see Chaudieu, I. (264) 361
Stachura, J., see Konturek, S.J. (253) 107
Stafford, I., see Zhang, C.L. (252) 299
Stallone, J.N.
Sex differences in nitric oxide-mediated attenuation of vascular reactivity to vasopressin are abolished by gonadectomy (259) 273
Stam, N.J., Vanderheyden, P., Van Alebeek, C., Klomp, J., De Boer, T., Van Delft, A.M.L. and Olijve, W.
Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT_{2C} receptor (269) 339
Stamatakos, C., see Burcher, E. (258) R9
Stancampiano, R., Melis, M.R. and Argiolas, A.
Penile erection and yawning induced by 5-HT_{1C} receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission (261) 149
Stanton, J.A., see Heald, A. (264) 213
Stapf, V., see Thalhammer, T. (270) 213
Stark, G., Dhein, S., Bachernegg, M., Ziskoven, U., Zhao, Y., Klaus, W., Kickenweiz, E., Decrinis, M. and Tritthart, H.A.
Frequency-dependent effects of propafenone decrease with duration of ventricular tachycardia in isolated guinea pig hearts (252) 283
Starr, B.S., see Starr, M.S. (250) 239
Starr, M.S. and Starr, B.S.
Facilitation of dopamine D_1 receptor- but not dopamine D_1/D_2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse (250) 239
Steffen, V., see Vizuete, M.L. (270) 183
Steinberg, R., see Emonds-Alt, X. (250) 403
Stenbäck, F., see Pellinen, P. (270) 35
Stengel, P.W., Bendele, A.M., Cockerham, S.L. and Silbaugh, S.A.
Effect of dexamethasone on A23187-induced airway responses in the guinea pig (253) 253
Stephenson, F.A., see Cik, M. (266) R1
Stephenson, J., see Albinsson, A. (251) 157
Stern, J.E., see Esquifino, A.I. (254) 1
Stillwell, L.I., see Corpus, V.M. (266) 197
Stinus, L., see Gold, L.H. (253) 45
Stjernquist, M., see Bodelsson, G. (249) 299
St. Laurent, D.R., see Schumacher, W.A. (259) 165
Stock, M.J., see Woods, A.J. (264) 125
Stöcker, K., see Felsch, A. (263) 261
Stoessl, A.J.
Dopamine D_1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone (259) 301
Stolz, M., see Denyer, J. (268) 29
Stone, G., see Ng, P.C. (264) 1
Stonesifer, G.Y., see Schneck, K.A. (266) 277
Stoof, J.C., see Vermeulen, R.J. (269) 121
Strada, G., see Testa, R. (249) 307
Strassman, A.M., see Eisenberg, E. (255) 123
Stratton, S.C., Beresford, I.J.M., Harvey, F.J., Turpin, M.P., Hagan, R.M. and Tyers, M.B.
Anxiolytic activity of tachykinin NK_2 receptor antagonists in the mouse light-dark box (250) R11
Strauss, J.D., Bletz, C. and Rüegg, J.C.
The calcium sensitizer EMD 53998 antagonizes phosphate-induced increases in energy cost of isometric tension in cardiac skinned fibres (252) 219
Strichartz, G.R., see Wang, Z.-Y. (260) 121
Stroff, T., Lambrecht, N. and Peskar, B.M.
Nitric oxide as mediator of the gastroprotection by cholecystokinin-8 and pentagastrin (260) R1
Strong, P., see Gardner, C.J. (257) 117
Struthers, L., see Grimwood, S. (266) 43
Stutzmann, J., see Bricca, G. (266) 25
Su, M.-J., Chang, Y.-M., Chi, J.-F. and Lee, S.-S.
Thaliporphine, a positive inotropic agent with a negative chronotropic action (254) 141
Su, T.-P., see Weissman, A.D. (250) 329
Subissi, A., see Catalioto, R.-M. (256) 93
Sudjarwo, S.A., see Karaki, H. (262) 255
Sudo, J.-i., Hayashi, T., Terui, J., Soyama, M., Fukata, M. and Kakuno, K.
Kinetics of Cd^{2+} in plasma, liver and kidneys after single intravenous injection of Cd-metallothionein-II (270) 229
Suga, S.-i., see Hashimoto, Y. (268) 443
Suga, T., see Shimomura, A. (252) 81
Sugden, D.
N-Acyl-3-amino-5-methoxychromans: a new series of non-indolic melatonin analogues (254) 271
Suh, H.-W., Song, D.-K., Kim, Y.-H., Yoo, J.-S. and Tseng, L.F.
Differential antagonism by MK-801 against antinociception in-

duced by opioid receptor agonists administered supraspinally in mice (263) 217
Suhr-Jessen, P., see Pedersen, U.B. (267) 85
Sukamoto, T., see Harada, Y. (256) 321
Sukamoto, T., see Harada, Y. (261) 91
Sultana, M., see Vanderah, T. (252) 133
Suman-Chauhan, N., Grimson, P., Guard, S., Madden, Z., Chung, F.-Z., Watling, K., Pinnock, R. and Woodruff, G.
Characterisation of [^{125}I][MePhe^7]neurokinin B binding to tachykinin NK_3 receptors: evidence for interspecies variance (269) 65
Suman-Chauhan, N., see Pinnock, R.D. (269) 73
Sumii, K., see Conforti, L. (259) 215
Sumner, M.J., see Buchan, K.W. (260) 221
Sumner, M.J., see White, D.G. (257) 307
Sun, J., see Sakamoto, T. (251) 137
Sunter, D., see Kemp, M. (266) 187
Supko, D.E. and Johnston, M.V.
Dexamethasone potentiates NMDA receptor-mediated neuronal injury in the postnatal rat (270) 105
Surber, B.W., see Hancock, A.A. (267) 49
Suthamnatpong, N., see Kanada, A. (250) 59
Suthamnatpong, N., see Maehara, T. (261) 163
Suto, G., see Plourde, V. (256) 125
Sutter, M.C., see Abrahams, Z. (252) 195
Suzdak, P.D., see Thomsen, C. (267) 77
Suzuki, F., see Kanda, T. (256) 263
Suzuki, F., see Nonaka, H. (267) 335
Suzuki, F., see Tomaru, A. (264) 91
Suzuki, H., see Ohno, N. (249) 121
Suzuki, K., see Ishizuka, T. (262) 113
Suzuki, N., Kalso, E. and Rosenberg, P.H.
Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats (249) 247
Suzuki, N., Mizuno, K. and Gomi, Y.
Role of nitric oxide in the peristalsis in the isolated guinea-pig ileum (251) 221
Suzuki, N., see Yoshida, S. (250) 117
Suzuki, T., Mori, T., Funada, M., Misawa, M. and Nagase, H.
Attenuation of the discriminative stimulus properties of cocaine by δ-opioid receptor antagonists (263) 207
Suzuki, T., see Kamei, J. (249) 161
Suzuki, T., see Kamei, J. (251) 95
Suzuki, T., see Kamei, J. (251) 291
Suzuki, T., see Kamei, J. (260) 257
Suzuki, Y., see Ito, M. (263) 245
Suzuki, Y., see Ito, M. (263) 253
Suzuki, Y., see Nagao, T. (259) 233
Suzuki, Y., see Takekoshi, K. (250) 465
Svartengren, J. and Celander, M.
The limbic functional selectivity of amperozide is not mediated by dopamine D_2 receptors as assessed by in vitro and in vivo binding (254) 73
Svartengren, J., see Albinsson, A. (261) 285
Svensson, K., Carlsson, A., Huff, R.M., Kling-Petersen, T. and Waters, N.
Behavioral and neurochemical data suggest functional differences between dopamine D_2 and D_3 receptors (263) 235
Sybertz, E.J., see Vemulapalli, S. (257) 95
Syvälahti, E., see Kuoppamäki, M. (255) 91
Syvälahti, E., see Kuoppamäki, M. (269) 201
Szabó, C., Wu, C.-C., Gross, S.S., Thiemermann, C. and Vane, J.R.
Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo (250) 157
Szallasi, A., Blumberg, P.M., Nilsson, S., Hökfelt, T. and Lundberg, J.M.
Visualization by [^{3}H]resiniferatoxin autoradiography of capsaicin-sensitive neurons in the rat, pig and man (264) 217
Szallasi, A., see Goso, C. (249) 185
Szallasi, A., see Goso, C. (254) 221
Szarek, J.L., see Gruetter, C.A. (257) 275
Szelenyi, I., see Schmidt, J. (260) 247
Szerdahelyi, P., see Tósaki, Á. (264) 455
Szikszay, M., see Horváth, G. (253) 61
Szilvássy, J., see Lonovics, J. (255) 117
Szilvássy, Z., see Lonovics, J. (255) 117
Sziráki, I., Kardos, V., Patthy, M., Pátfalusi, M. and Budai, G.
Methamphetamine protects against MPTP neurotoxicity in C57BL mice (251) 311

Tabrizchi, R. and Triggle, C.R.
Pressor responses to the α_1-adrenoceptor agonist cirazoline: effects of captopril, phenoxybenzamine and nifedipine (251) 15
Tabrizchi, R.
Effects of chronic receptor blockade on excitation-contraction coupling in rat aortic rings (259) 285
Tabuchi, T., see Tsunoda, R. (262) 55
Tabuchi, Y. and Furuhama, K.
Inhibitory effect of DS-4574, a mast cell stabilizer with peptidoleukotriene receptor antagonism, on gastric acid secretion in rats (255) 229
Tabuchi, Y., Kawarabayashi, K., Komada, T. and Furuhama, K.
Protective effect of DS-4574 on gastric mucosal injury induced by acidified ethanol in rats (250) 197
Taché, Y., see Plourde, V. (256) 125
Taddei, C., see Testa, R. (249) 307
Taguchi, T., see Uchida, W. (264) 285
Taira, N., see Murakoshi, H. (268) 451
Taira, N., see Yamagishi, T. (251) 253
Tajima, T., see Akiyama, Y. (263) 181
Takada, K., see Murai, T. (261) 65
Takagi, H., see Ito, C. (257) 203
Takagi, K., see Miyamoto, K.-i. (267) 317
Takagi, M., see Naganobu, K. (251) 307
Takahashi, K., see Miyata, N. (249) 141
Takahashi, K., see Yamaura, H. (260) 269
Takahashi, M., see Ito, C. (257) 203
Takahashi, M., see Uneyama, C. (268) 455
Takahashi, R., see Okada, M. (259) 339
Takahashi, T., see Konno, S.-i. (259) 15
Takai, M., see Yukimura, T. (264) 399
Takaori, K., see Ohta, K. (269) 115
Takasu, T., see Tohda, M. (266) 19
Takayanagi, I., see Satoh, M. (265) 133
Takeda, M., see Nonaka, H. (267) 335
Takeda, Y., see Tohse, N. (249) 231
Takekoshi, K., Kasai, K., Suzuki, Y., Sekiguchi, Y., Banba, N., Nakamura, T. and Shimoda, S.-I.
Effect of N^G-nitro-L-arginine on shock induced by endotoxin and by platelet activating factor in dogs (250) 465
Takemori, A.E., see Vanderah, T. (252) 133
Takenaka, T., see Uchida, W. (264) 285
Takeo, S., see Liu, J.-X. (250) 361
Takeshita, A., see Hirakawa, Y. (252) 267
Takeuchi, A., see Kimura, T. (264) 169
Takeuchi, K., Shinozuka, K., Akimoto, H., Ishii, R. and Hashimoto, T.
Methoxamine-induced release of endogenous ATP from rabbit pulmonary artery (254) 287
Takeuchi, T., see Kanada, A. (250) 59
Takeuchi, T., see Maehara, T. (261) 163
Takeyama, Y., see Ogino, K. (270) 73
Taki, K., see Hirabayashi, A. (256) 227

Takiguchi, Y., see Nishiyama, H. (264) 191
Takizawa, S., Hori, M., Ozaki, H. and Karaki, H.
Effects of isoquinoline derivatives, HA1077 and H-7, on cytosolic Ca^{2+} level and contraction in vascular smooth muscle (250) 431
Takumi, T., see Busch, A.E. (264) 33
Tamargo, J., see Duarte, J. (262) 149
Tamura, S., see Nakamura, J. (254) 83
Tan-No, K., see Sakurada, T. (261) 85
Tanada, S., see Villemagne, V.L. (257) 195
Tanaka, H., see Agata, N. (260) 47
Tanaka, H., see Wakabayashi, I. (255) 111
Tanaka, M., see Chaki, S. (250) 173
Tanaka, M., see Chaki, S. (251) R1
Tanaka, M., see Miyata, N. (249) 141
Tanaka, M., see Yokoo, H. (256) 335
Tanaka, S., see Matsuda, Y. (250) 341
Tanaka, T., see Karaki, H. (262) 255
Tanaka, T., see Shibata, S. (269) 269
Tanaka, T., see Yokoo, H. (256) 335
Tandai, M., see Sakuta, H. (267) 281
Tang, H.-W., see Hu, X.-H. (263) 53
Tang, K.M., Jang, E.K. and Haslam, R.J.
Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors (268) 105
Tang, L., see MacKenzie, R.G. (266) 79
Tang, S.W., see Helmeste, D.M. (266) 327
Tang, S.W., see Helmeste, D.M. (267) 239
Taniyama, K., see Kan, S. (258) 139
Taniyama, K., see Koizumi, S. (259) 195
Taniyama, K., see Matsumoto, Y. (264) 107
Tanonaka, K., see Liu, J.-X. (250) 361
Tao, P.-L., Hwang, C.-L. and Chen, C.-Y.
U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs (256) 281
Tarizzo, G., see Cervo, L. (253) 139
Tarozzo, G., see Delbende, C. (251) 245
Tasker, A.S., see Hancock, A.A. (267) 49
Taskinen, P., Tóth, M. and Ruskoaho, H.
Effects of genistein on cardiac contractile force and atrial natriuretic peptide secretion in the isolated perfused rat heart (256) 251
Tatarczynska, E., see Cervo, L. (263) 187
Tate, S., see Denyer, J. (268) 29
Tattersall, F.D., Rycroft, W., Hargreaves, R.J. and Hill, R.G.
The tachykinin NK_1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret (250) R5
Taveira DaSilva, A.M., see McManigle, J.E. (252) 11
Taverna, F.A. and Hampson, D.R.
Properties of a recombinant kainate receptor expressed in baculovirus-infected insect cells (266) 181
Taverna, F.A., Cameron, B.-R., Hampson, D.L., Wang, L.-Y. and MacDonald, J.F.
Sensitivity of AMPA receptors to pentobarbital (267) R3
Taylor, S.M., Heron, A.E., Cannell, G.R. and Florin, T.H.J.
Pressor effect of ethanol in the isolated perfused human placental lobule (270) 371
Taylor, W.A., see Gardiner, P.J. (258) 95
Tedeschi, D., see Maggio, R. (268) 459
Tedgui, A., see Bernard, C. (270) 115
Tejerina, T., see Del Rio, M. (250) 133
Temma, K., Akera, T., Akihito, C., Ozawa, S. and Kondo, H.
Cellular Ca^{2+} loading and inotropic effects of doxorubicin in atrial muscle preparations isolated from rat or guinea-pig hearts (252) 173
Temma, K., see Jiang, J. (266) 155
Temple, S.D., see Craig, C.G. (269) 79
Teng, C.-M., Guh, J.-H. and Ko, F.-N.
Functional identification of α_1-adrenoceptor subtypes in human prostate: comparison with those in rat vas deferens and spleen (265) 61
Teng, C.-M., see Wang, J.-P. (251) 35
Teng, C.-M., see Yu, S.-M. (252) 29
Teng, C.-M., see Yu, S.-M. (256) 85
Tepper, P.G., see Damsma, G. (249) R9
Terenius, L., see Castel, M.-N. (262) 1
Terry, P., see Izenwasser, S. (263) 277
Terui, J., see Sudo, J.-i. (270) 229
Tessier, C., see Fayard, J.M. (251) 281
Testa, R., Guarneri, L., Ibba, M., Strada, G., Poggesi, E., Taddei, C., Simonazzi, I. and Leonardi, A.
Characterization of α_1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man (249) 307
Teyler, T.J., see Brown, L.M. (254) 307
Thalhammer, T., Stapf, V., Gajdzik, L. and Graf, J.
Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport (270) 213
Tham, C.-S., see Day, J.C. (263) 285
Thastrup, O., see Pedersen, U.B. (267) 85
Thiemermann, C., see McMurdo, L. (259) 51
Thiemermann, C., see Szabó, C. (250) 157
Thierauch, K.-H., see Darius, H. (258) 207
Thomas, D.N., Nutt, D. and Holman, R.B.
Regionally specific changes in extracellular noradrenaline following chronic idazoxan as revealed by in vivo microdialysis (261) 53
Thomas, G., see Browne, I. (265) 125
Thomas, H.A., see Wei, E.T. (263) 319
Thomas, K., see Kalenga, M.K. (268) 231
Thomas, S., see Hancock, A.A. (267) 49
Thomas, Y., see Pellegrini, O. (270) 221
Thompson, A.M., see Gardiner, P.J. (258) 95
Thompson, A.M., see Tudhope, S.R. (264) 317
Thompson, M.A., see Martin, D. (250) 473
Thomsen, C., Boel, E. and Suzdak, P.D.
Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family (267) 77
Thorat, S.N. and Bhargava, H.N.
Evidence for a bidirectional cross-tolerance between morphine and Δ^9-tetrahydrocannabinol in mice (260) 5
Thorat, S.N., see Barjavel, M.J. (258) 173
Thorin-Trescases, N., Hamilton, C.A., Jardine, E. and Reid, J.L.
Signal transduction mechanisms of the vasoconstriction in hypertension (268) 199
Thorn, L., see Bristow, L.J. (264) 353
Thorndike, E.B., see Yasar, S. (259) 243
Tibiriçá, E.V., see Altenburg, S.P. (256) 45
Tiegs, G., see Dimmeler, S. (267) 105
Tielemans, W., see De Kimpe, S.J. (261) 111
Tigley, A., see Ferraz, J.-G.P. (260) 107
Tikkanen, I., see Helin, K. (264) 135
Tilton, R.G., see Hasan, K. (249) 101
Timmerman, H., see Yokoyama, H. (260) 23
Timmermans, P.B.M.W.M., see Wong, P.C. (260) 261
Timmermans, P.B.M.W.M., see Wong, P.C. (262) 185
Tjon, G.H.K., De Vries, T.J., Ronken, E., Hogenboom, F., Wardeh, G., Mulder, A.H. and Schoffelmeer, A.N.M.
Repeated and chronic morphine administration causes differential long-lasting changes in dopaminergic neurotransmission in rat striatum without changing its δ- and κ-opioid receptor regulation (252) 205
Toba, K., see Ishikawa, M. (269) 311
Tobin, J.R., see Clarkson, K. (263) R1
Toda, N., see Okamura, T. (256) 79
Toda, N., see Okamura, T. (263) 85

Todd, R.D., see MacKenzie, R.G. (266) 79
Todt, H., Zojer, N., Raberger, G. and Schütz, W.
Prolongation of the QT interval by dofetilide modulates rate-dependent effects of mexiletine on intraventricular conduction (265) 43
Toews, M.L., see Zhu, J. (268) 279
Toffoleto, O., see Carneiro, R.C.G. (257) 73
Togashi, H., see Hirokami, M. (253) 9
Tohda, C., see Tohda, M. (268) 169
Tohda, M., Takasu, T., Nakamura, J., Morii, N., Narumiya, S. and Nomura, Y.
Inhibitory effects of botulinum toxin on 5-HT_{1C} receptor-induced Cl^- current in *Xenopus* oocytes (266) 19
Tohda, M., Tohda, C., Sakuma, S., Higashida, H. and Nomura, Y.
Distinct induction of c-*fos* mRNA in NG108-15 cells transfected with muscarinic *m1* and *m3* receptors (268) 169
Tohse, N., Takeda, Y. and Kanno, M.
Voltage-dependent modulation of L-type Ca^{2+} current by manidipine in guinea-pig heart cells (249) 231
Tokola, H., Salo, K., Vuolteenaho, O. and Ruskoaho, H.
Basal and acidic fibroblast growth factor-induced atrial natriuretic peptide gene expression and secretion is inhibited by staurosporine (267) 195
Tokuyama, K., see Arakawa, H. (259) 251
Tokuyama, K., see Mochizuki, H. (252) 183
Toll, L., see Morhenn, V.B. (268) 409
Tomaru, A., Ishii, A., Kishibayashi, N., Shimada, J., Suzuki, F. and Karasawa, A.
Possible physiological role of endogenous adenosine in defecation in rats (264) 91
Tomiyama, K., see Murai, T. (261) 65
Toms, N.J. and Roberts, P.J.
NMDA receptor-mediated stimulation of rat cerebellar nitric oxide formation is modulated by cyclic AMP (266) 63
Tonello, C., see Nisoli, E. (259) 181
Tonussi, C.R. and Ferreira, S.H.
Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization (251) 173
Törnwall, M. and Männistö, P.T.
Effects of three types of catechol *O*-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats (250) 77
Torreblanca, A., see Novelli, A. (270) 361
Toru, M., see Ikawa, K. (250) 261
Toru, M., see Ikawa, K. (252) 123
Tósaki, Á., Szerdahelyi, P. and Joó, F.
Treatment with ranitidine of ischemic brain edema (264) 455
Toshima, Y., see Umemura, K. (262) 27
Tóth, M., see Taskinen, P. (256) 251
Traber, J., see De Vry, J. (249) 331
Trabucchi, M., see Barbaccia, M.L. (261) 317
Trabucchi, M., see Pascale, A. (265) 1
Trabucchi, M., see Roscetti, G. (269) 17
Trail, B.K., see Clapham, J.C. (257) 79
Tramontana, M., see Goso, C. (249) 185
Tran, M.-A., see Damase-Michel, C. (258) 277
Tranchand Bunel, D., see Delbende, C. (251) 245
Travagli, R.A., Gillis, R.A. and Kellar, K.J.
S-Adenosyl-L-methionine modulates firing rate of dorsal motor nucleus of the vagus neurones in vitro (264) 385
Traynor, J.R., see Elliott, J. (268) 447
Treiman, M., see Jørgensen, A. (259) 157
Treistman, S.N., see Mullikin-Kilpatrick, D. (270) 17
Trezise, D.J., Bell, N.J., Khakh, B.S., Michel, A.D. and Humphrey, P.P.A.
P_2 purinoceptor antagonist properties of pyridoxal-5-phosphate (259) 295
Trezise, D.J., Drew, G.M., Roach, A.G., Watts, I.S. and Weston, A.H.
Cromakalim does not protect against skeletal muscle fatigue in an anaesthetized rat model of acute hindlimb ischaemia (250) 109
Tricklebank, M.D., see Bristow, L.J. (264) 353
Tricklebank, M.D., see Dawson, G.R. (252) 325
Trifilieff, A., see Lach, E. (269) 87
Triggle, C.R., see Tabrizchi, R. (251) 15
Trillat, A.-C., see Gardier, A.M. (265) 107
Tringali, G., see Montuschi, P. (252) 253
Trist, D., see Cavanni, P. (269) 9
Tritthart, H.A., see Stark, G. (252) 283
Troger, J., see Kähler, C.M. (262) 261
True, T.A. and Mais, D.E.
Localization of [^{125}I]SAP-N_3 binding in the human platelet thromboxane A_2/prostaglandin H_2 receptor by proteolytic cleavage analysis (266) 51
Tsangaris, G.T., see Pellegrini, O. (270) 221
Tschanz, J.A.T., Griffith, K.E., Haracz, J.L. and Rebec, G.V.
Cortical lesions attenuate the opposing effects of amphetamine and haloperidol on neostriatal neurons in freely moving rats (257) 161
Tsen, K., see Bhattacharyya, B.J. (254) 97
Tseng, A., see Potter, E.K. (267) 253
Tseng, C.-J., see Tung, C.-S. (256) 193
Tseng, L.F., Collins, K.A. and Kampine, J.P.
Antisense oligodeoxynucleotide to a δ-opioid receptor selectively blocks the spinal antinociception induced by δ-, but not μ- or κ-opioid receptor agonists in the mouse (258) R1
Tseng, L.F., see Suh, H.-W. (263) 217
Tseng, L.F., see Xu, J.Y. (262) 223
Tsopanoglou, N.E., Pipili-Synetos, E. and Maragoudakis, M.E.
Leukotrienes C_4 and D_4 promote angiogenesis via a receptor-mediated interaction (258) 151
Tsuchida, K., see Miyata, N. (249) 141
Tsuchida, K., see Yamaura, H. (260) 269
Tsuchiya, M., see Kurose, I. (250) 85
Tsuji, T. and Cook, D.A.
Origin of thromboxane-mediated constriction due to neuropeptides in canine basilar artery (264) 77
Tsujimoto, G., see Hirasawa, A. (267) 71
Tsujimoto, G., see Horie, K. (268) 399
Tsukahara, T., see Ito, M. (263) 245
Tsukamoto, S.-i., see Wanibuchi, F. (265) 151
Tsunoda, R., Okumura, K., Ishizaka, H., Matsunaga, T., Tabuchi, T., Yasue, H., Akaike, T., Sato, K. and Maeda, H.
Vasodilator effect of carboxy-2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl in the coronary circulation: in vivo and in vitro studies (262) 55
Tsuzuki, K., see Ito, C. (257) 203
Tu, A.T., see Ohkura, M. (268) R1
Tudhope, S.R., Cuthbert, N.J., Abram, T.S., Jennings, M.A., Maxey, R.J., Thompson, A.M., Norman, P. and Gardiner, P.J.
BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes (264) 317
Tulić, I., see Jovanović, A. (256) 103
Tulić, I., see Jovanović, A. (256) 131
Tulp, M.Th.M., see Ybema, C.E. (256) 141
Tung, C.-S., Wu, W.-H., Tseng, C.-J. and Yin, T.-H.
Effects of amperozide on schedule-induced polydipsia in rats (256) 193
Tung, S.R., see Wang, Z.-Y. (260) 121
Tuominen, R.K., see Rauhala, P. (259) 57
Tuomisto, J., see Unkila, M. (270) 157
Turcaud, S., see Noble, F. (253) 283
Turpin, M.P., see Stratton, S.C. (250) R11
Turski, W.A., see Czuczwar, S.J. (264) 103

Turski, W.A., see Pietrasiewicz, T. (250) 1
Twissell, D., see Bountra, C. (249) R3
Twissell, D.J., see Gardner, C.J. (257) 117
Tyers, M.B., see Stratton, S.C. (250) R11

Uchida, M.K., see Miyauchi, Y. (263) 75
Uchida, T., see Saeki, T. (261) 249
Uchida, W., Hirano, Y., Taguchi, T., Masuda, N., Shirai, Y., Satoh, N. and Takenaka, T.
Cardiovascular effects of YM099, a novel K^+ channel opener, in anesthetized and conscious dogs (264) 285
Uda, T., see Ogino, K. (270) 73
Udvarhelyi, P., see Kemp, M. (266) 187
Ueha, T., see Oyama, Y. (270) 137
Uematsu, T., see Nishiyama, H. (264) 191
Uematsu, T., see Umemura, K. (251) 69
Uhl, G.R., see Kitayama, S. (268) 115
Umemura, K., Toshima, Y. and Nakashima, M.
Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model (262) 27
Umemura, K., Wada, K., Uematsu, T., Mizuno, A. and Nakashima, M.
Effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F, in the rat middle cerebral artery occlusion model (251) 69
Umemura, K., see Nishiyama, H. (264) 191
Umezawa, K., see Agbotounou, W.K. (269) 1
Uneyama, C., Uneyama, H., Takahashi, M. and Akaike, N.
FCCP modulation of Ca^{2+} oscillation in rat megakaryocytes (268) 455
Uneyama, H., see Uneyama, C. (268) 455
Ungerstedt, U., see Morari, M. (256) 23
Unkila, M., Pohjanvirta, R., MacDonald, E. and Tuomisto, J.
Characterization of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-induced brain serotonin metabolism in the rat (270) 157
Unson, D., see Morhenn, V.B. (268) 409
Urbányi, Z., Lakics, V. and Erdő, S.L.
Serum amyloid P component-induced cell death in primary cultures of rat cerebral cortex (270) 375
Usadel, K.H., see Kusterer, K. (259) 265
Ustymowicz, J., see Farbiszewski, R. (270) 263
Usuda, S., see Wanibuchi, F. (265) 151
Utsunomiya, I., Nagai, S. and Oh-ishi, S.
Differential effects of indomethacin and dexamethasone on cytokine production in carrageenin-induced rat pleurisy (252) 213

Vago, T., see Bevilacqua, M. (268) 415
Valentovic, M.A., see Gruetter, C.A. (257) 275
Valet, P., see Bouloumié, A. (269) 95
Valetto, M., see Mazza, E. (254) 17
Vallance, P.J., see White, D.G. (257) 307
Vallebuona, F., see Bonanno, G. (252) 61
Van Alebeek, C., see Stam, N.J. (269) 339
Van Amsterdam, F.Th.M., see Cavanni, P. (269) 9
Van Amsterdam, J.G.C., see Van den Berg, C. (270) 379
Van Amsterdam, J.G.C., see Vleeming, W. (250) 415
Van Andel, A., see Schiereck, P. (249) 317
Van Broeck, D., see Emonds-Alt, X. (250) 403
Van Buren, T., see Kappelle, A.C. (250) 43
Van Delft, A.M.L., see Stam, N.J. (269) 339
Van den Berg, C., Van Amsterdam, J.G.C., Bisschop, A., Piet, J.J., Wemer, J. and De Wildt, D.J.
Septic shock: no correlation between plasma levels of nitric oxide metabolites and hypotension or lethality (270) 379
Vanderah, T., Takemori, A.E., Sultana, M., Portoghese, P.S., Mosberg, H.I., Hruby, V.J., Haaseth, R.C., Matsunaga, T.O. and Porreca, F.
Interaction of [D-Pen^2,D-Pen^5]enkephalin and [D-Ala^2,Glu^4]deltorphin with δ-opioid receptor subtypes in vivo (252) 133
Vander Elst, L., Chatelain, P., Manning, A.S., Laruel, R., Van Haverbeke, Y. and Muller, R.N.
^{31}P nuclear magnetic resonance study of the effects of the calcium ion channel antagonist fantofarone on the rat heart (251) 163
Vanderhaeghen, J.-J., see Mailleux, P. (266) 193
Vanderhaeghen, J.-J., see Mailleux, P. (267) R1
Van der Heijden, M.P.A., see Van Rhee, A.M. (268) 1
Vanderheyden, P., see Stam, N.J. (269) 339
Van der Meer, J., see Boon, J.P. (270) 237
Van der Wenden, E.M., see IJzerman, A.P. (268) 95
Van Dijk, J.P.M., see Zijlstra, F.J. (249) R1
Vane, J.R., see Battistini, B. (252) 341
Vane, J.R., see McMurdo, L. (259) 51
Vane, J.R., see Szabó, C. (250) 157
Vane, J.R., see Warner, T.D. (250) 447
Vane, J.R., see Wellings, R.P. (256) 201
Van Galen, P.J.M., see IJzerman, A.P. (268) 95
Van Haverbeke, Y., see Vander Elst, L. (251) 163
Van Heijst, B., see Schiereck, P. (249) 317
Van Helvoirt, A., see De Boer, T. (253) R5
Van Heuven-Nolsen, D., see De Kimpe, S.J. (261) 111
Vanhoutte, P.M., see De Castro, M. (261) 199
VanLeeuwen, D., see MacKenzie, R.G. (266) 79
Van Meel, J.C.A., see Zhang, J. (262) 247
Van Rhee, A.M., Van der Heijden, M.P.A., Beukers, M.W., IJzerman, A.P., Soudijn, W. and Nickel, P.
Novel competitive antagonists for P_2 purinoceptors (268) 1
Vanscheeuwijck, P., see Fraeyman, N. (267) 63
Van Zwieten, P.A., see Zhang, J. (252) 337
Van Zwieten, P.A., see Zhang, J. (262) 247
Vapaatalo, H., see Riutta, A. (262) 217
Varani, K., see Borea, P.A. (267) 55
Varani, K., see Simonato, M. (265) 121
Vardey, C.J., see Nials, A.T. (251) 127
Varga, C., see László, F. (258) 15
Varga, G., Campbell, D.R., Bussjaeger, L.J. and Solomon, T.E.
Role of gastrin and cholecystokinin receptors in regulation of peptone-stimulated gastric acid secretion in conscious rats (250) 37
Vargaftig, B.B., see Zuany-Amorim, C. (257) 211
Vargiu, P., see Mereu, G. (264) 449
Vassy, R., see Yin, Y. (261) 97
Vaudry, H., see Contesse, V. (265) 27
Vaudry, H., see Delbende, C. (251) 245
Vaughan, P.F.T., see Rana, B. (250) 247
Veale, P.R., Bhogal, R., Morgan, D.G.A., Smith, D.M. and Bloom, S.R.
The presence of islet amyloid polypeptide/calcitonin gene-related peptide/salmon calcitonin binding sites in the rat nucleus accumbens (262) 133
Veilahti, J., see Lindroos, O.F.C. (250) 161
Velasco, C., see Morán, A. (252) 161
Velcich, A., see Jarry, A. (267) 95
Velek, J., see Železná, B. (260) 95
Vemulapalli, S., Chiu, P.J.S., Griscti, K., Brown, A., Kurowski, S. and Sybertz, E.J.
Phosphoramidon does not inhibit endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia in rats (257) 95
Venter, D.P.
Indirectly acting agonists. A model for the functional interaction of released endogenous double agonists (251) 209
Ventura, S. and Pennefather, J.N.
α_2-Adrenoceptor binding sites vary along the length of the male

reproductive tract: a possible basis for the regional variation in response to field stimulation (254) 167
Ventura, S., see Ludbrook, J. (252) 113
Verbeuren, T.J., Simonet, S. and Herman, A.G.
Diet-induced atherosclerosis inhibits release of noradrenaline from sympathetic nerves in rabbit arteries (270) 27
Verde, I., see Campos-Toimil, M. (251) 83
Verdoorn, T.A., Johansen, T.H., Drejer, J. and Nielsen, E.Ø.
Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA receptor antagonist (269) 43
Vermeulen, R.J., Jongenelen, C.A.M., Langeveld, C.H., Wolters, E.Ch., Stoof, J.C. and Drukarch, B.
Dopamine D_1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytes (269) 121
Vernava, A.M., see Deshpande, Y. (256) R1
Versace, P., see Fedele, E. (249) 71
Veselský, L., see Železná, B. (260) 95
Vestereng, M., see Dalen, T. (270) 313
Vetulani, J., see Antkiewicz-Michaluk, L. (254) 9
Vetulani, J., see Papp, M. (261) 141
Vials, A.J. and Burnstock, G.
The effect of suramin on vasodilator responses to ATP and 2-methylthio-ATP in the Sprague-Dawley rat coronary vasculature (251) 299
Vian, J., see Millan, M.J. (260) R3
Viano, I., see Dianzani, C. (263) 223
Vicentini, L.M., see Cattaneo, M.G. (268) 425
Vickers, P.J., see Charleson, S. (267) 275
Vickery-Clark, L.M., see Douglas, S.A. (255) 81
Videbæk, C., Friberg, L., Holm, S., Wammen, S., Foged, C., Andersen, J.V., Dalgaard, L. and Lassen, N.A.
Benzodiazepine receptor equilibrium constants for flumazenil and midazolam determined in humans with the single photon emission computer tomography tracer [^{123}I]iomazenil (249) 43
Vidne, B., see Shany, E. (253) 231
Vieytes, M.R., see Alfonso, A. (267) 289
Vigano', T., see Hernandez, A. (270) 301
Vigé, X., see Carreau, A. (256) 241
Vila, J.M., see Aldasoro, M. (250) 103
Vila, J.M., see Martínez, C. (261) 73
Vilain, P., see Advenier, C. (250) 169
Vilain, P., see Emonds-Alt, X. (250) 403
Villarreal, J.E., see Cruz, S.L. (258) 39
Villarroya, M., see Salas, E. (258) 47
Villemagne, V.L., Frost, J.J., Dannals, R.F., Lever, J.R., Tanada, S., Natarajan, T.K., Wilson, A.A., Ravert, H.T. and Wagner, Jr., H.N.
Comparison of [^{11}C]diprenorphine and [^{11}C]carfentanil in vivo binding to opiate receptors in man using a dual detector system (257) 195
Vincens, M., Li, S.-Y. and Pelletier, G.
Inhibitory effect of 5β-pregnan-3α-ol-20-one on gonadotropin-releasing hormone gene expression in the male rat (260) 157
Vincent, S.R., see Luo, D. (267) 263
Vinet, R., see Montiel, C. (268) 293
Vitorica, J., see Ruano, D. (267) 121
Vizuete, M.L., Steffen, V., Machado, A. and Cano, J.
1-Methyl-4-phenylpyridinium has greater neurotoxic effect after selenium deficiency than after vitamin E deficiency in rat striatum (270) 183
Vleeming, W., Wemer, J., Riezebos, J., Van Amsterdam, J.G.C., De Wildt, D.J. and Porsius, A.J.
Modulation by pertussis toxin of salbutamol- and arecoline-induced effects in the isolated heart and aorta of the rat (250) 415
Vodenlich, A.D., see Hancock, A.A. (267) 49
Voltz, C., Fage, D. and Carter, C.
Synergism between the NMDA receptor antagonistic effects of ifenprodil and the glycine antagonist, 7-chlorokynurenate, in vivo (255) 197
Von Euler, G., see Hillefors-Berglund, M. (261) 179
Von Kügelgen, I., see Allgaier, C. (252) R7
Von Lubitz, D.K.J.E., Lin, R.C.-S., Melman, N., Ji, X.-d., Carter, M.F. and Jacobson, K.A.
Chronic administration of selective adenosine A_1 receptor agonist or antagonist in cerebral ischemia (256) 161
Von Lubitz, D.K.J.E., Lin, R.C.-S., Popik, P., Carter, M.F. and Jacobson, K.A.
Adenosine A_3 receptor stimulation and cerebral ischemia (263) 59
Von Lubitz, D.K.J.E., Paul, I.A., Bartus, R.T. and Jacobson, K.A.
Effects of chronic administration of adenosine A_1 receptor agonist and antagonist on spatial learning and memory (249) 271
Von Lubitz, D.K.J.E., Paul, I.A., Carter, M. and Jacobson, K.A.
Effects of N^6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on *N*-methyl-D-aspartate induced seizures in mice (249) 265
Von Lubitz, D.K.J.E., Paul, I.A., Ji, X.-d., Carter, M. and Jacobson, K.A.
Chronic adenosine A_1 receptor agonist and antagonist: effect on receptor density and *N*-methyl-D-aspartate induced seizures in mice (253) 95
Vorobjev, V.S. and Sharonova, I.N.
Tetrahydroaminoacridine blocks and prolongs NMDA receptor-mediated responses in a voltage-dependent manner (253) 1
Vos, B.G., see Santing, R.E. (257) 145
Vuolteenaho, O., see Tokola, H. (267) 195
Vyskočil, F., see Shakiryanova, D.M. (263) 107

Wachters, A., see Santing, R.E. (254) 49
Wada, K., see Matsui, K. (254) 295
Wada, K., see Umemura, K. (251) 69
Wada, T., Inada, Y., Sanada, T., Ojima, M., Shibouta, Y., Noda, M. and Nishikawa, K.
Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone (253) 27
Wadman, W.J., see Karst, H. (270) 357
Wadsworth, R., see Dalen, T. (270) 313
Wagner, E.J., Moore, K.E. and Lookingland, K.J.
Non-NMDA receptor-mediated regulation of hypothalamic dopaminergic neurons in the rat (254) 105
Wagner, Jr., H.N., see Villemagne, V.L. (257) 195
Wagstaff, J.D., see Midgley, L.P. (251) 191
Wahlestedt, C., see Adner, M. (261) 281
Wahlestedt, C., see Yoo, H. (268) 55
Wakabayashi, I., Sakamoto, K., Hatake, K. and Tanaka, H.
Aclarubicin inhibits phosphatidylinositol hydrolysis and contraction of rat aorta (255) 111
Waldeck, B., see Jeppsson, A.-B. (257) 137
Waldegger, S., see Busch, A.E. (264) 33
Waldegger, S., see Herzer, T. (259) 335
Waldenmeier, M.T., see Hauber, W. (256) 339
Waleh, N.S., see Morhenn, V.B. (268) 409
Walker, J.M., see Leitner, M.L. (259) 65
Walker, M.J.A., see Pugsley, M.K. (261) 303
Wallace, D.R., Muskardin, D.T. and Zahniser, N.R.
Pharmacological characterization of [^{3}H]idazoxan, [^{3}H]RX821002 and *p*-[^{125}I]iodoclonidine binding to α_2-adrenoceptors in rat cerebral cortical membranes (258) 67
Wallace, J.L., Reuter, B., Cicala, C., McKnight, W., Grisham, M. and Cirino, G.
A diclofenac derivative without ulcerogenic properties (257) 249
Wallace, J.L., see Ferraz, J.-G.P. (260) 107
Walland, A., see Schäfer, S. (258) 247
Wallis, D.I., Wu, J. and Wang, X.C.

Is 5-hydroxytryptamine mediating descending inhibition in the neonatal rat spinal cord through different receptor subtypes? (250) 371
Walsh, J.H., see Peskar, B.M. (250) 201
Wammen, S., see Videbæk, C. (249) 43
Wanderley, A.G., see Jurkiewicz, A. (256) 329
Wang, C.-N., Chen, J.-S., Shiao, M.-S. and Wang, C.-T.
Activation of human platelet phospholipases C and A_2 by various oxygenated triterpenes (267) 33
Wang, C.-T., see Wang, C.-N. (267) 33
Wang, H.-R., see Huang, H.-C. (251) 91
Wang, J., see Paik, G.Y. (264) 437
Wang, J.-P., Raung, S.-L., Lin, C.-N. and Teng, C.-M.
Inhibitory effect of norathyriol, a xanthone from *Tripterospermum lanceolatum*, on cutaneous plasma extravasation (251) 35
Wang, J.Q. and Ingenito, A.J.
Cardiovascular responses to intra-hippocampal dynorphin A-(1–8) in spontaneously hypertensive rats (256) 57
Wang, K.-T., see Ho, C.-L. (259) 259
Wang, L.-Y., see Taverna, F.A. (267) R3
Wang, S.-M., see Fu, W.-M. (270) 321
Wang, X.C., see Wallis, D.I. (250) 371
Wang, Y.-L., see Wang, Z.-Y. (260) 121
Wang, Y.-X., Poon, K.S., Randall, D.J. and Pang, C.C.Y.
Endothelium-derived nitric oxide partially mediates salbutamol-induced vasodilatations (250) 335
Wang, Z., see Charleson, S. (267) 275
Wang, Z.-Y., Feng, D.-M., Wang, Y.-L., Tung, S.R., Wong, K., Strichartz, G.R., Folkers, K. and Håkanson, R.
Pharmacological assessment of spantide II analogues (260) 121
Wanibuchi, F., Nishida, T., Yamashita, H., Hidaka, K., Koshiya, K., Tsukamoto, S.-i. and Usuda, S.
Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies (265) 151
Waniewski, R.A. and Martin, D.L.
Acetylcholine receptor agonists stimulate [^{3}H]taurine release from rat sympathetic ganglia (260) 113
Wanner, C., see Galle, J. (265) 111
Ward, K.M., see Zorn, S.H. (269) R1
Ward, P., see Bountra, C. (249) R3
Wardeh, G., see Tjon, G.H.K. (252) 205
Warner, T.D., Battistini, B., Allcock, G.H. and Vane, J.R.
Endothelin ET_A and ET_B receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat (250) 447
Warner, T.D., see Battistini, B. (252) 341
Waszczak, B.L., see Liu, J.-C. (264) 269
Watanabe, A., see Ikawa, K. (250) 261
Watanabe, A., see Ikawa, K. (252) 123
Watanabe, A.M., see Bowling, N. (268) 365
Watanabe, M., see Fujibayashi, K. (261) 133
Watanabe, M., see Yokota, Y. (258) 239
Watanabe, N. and Otsuki, M.
A cholecystokinin receptor antagonist, loxiglumide, stimulates biliary secretion in conscious rats (264) 331
Watanabe, S., see Koizumi, S. (259) 195
Watanabe, S., see Ohno, M. (253) 183
Watanabe, S., see Shibata, S. (269) 269
Watanabe, T., see Kitamura, Y. (253) 297
Watanabe, T., see Yokoyama, H. (260) 23
Watanabe, Y., see Kuroda, Y. (268) R3
Watanabe, Y., see Matsumoto, Y. (264) 107
Watanabe, Y., see Saeki, T. (261) 249
Watano, T., see Inoue, K. (268) 223
Waters, N., Hansson, L., Löfberg, L. and Carlsson, A.
Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo (251) 181
Waters, N., see Svensson, K. (263) 235
Watkins, J., see Kemp, M. (266) 187
Watling, K., see Suman-Chauhan, N. (269) 65
Watts, I.S., see Buchan, K.W. (260) 221
Watts, I.S., see Trezise, D.J. (250) 109
Watts, I.S., see White, D.G. (257) 307
Wead, W.B., see Koch, L.G. (254) 249
Webdale, L., see Pinnock, R.D. (269) 73
Weber, E., see Lutfy, K. (252) 261
Weber, E., see Lutfy, K. (265) 171
Wegelius, K., Honkanen, A. and Korpi, E.R.
Benzodiazepine receptor ligands modulate ethanol drinking in alcohol-preferring rats (263) 141
Wegner, U., see Weigert, N. (264) 337
Wei, E.T. and Thomas, H.A.
Correlation of neuroendocrine and anti-edema activities of alanine-corticotropin-releasing factor analogs (263) 319
Wei, H.-B., Yamamura, H.I. and Roeske, W.R.
Down-regulation and desensitization of the muscarinic M_1 and M_2 receptors in transfected fibroblast B82 cells (268) 381
Weigert, N., Schaffer, K., Wegner, U., Schusdziarra, V., Classen, M. and Schepp, W.
Functional characterization of a muscarinic receptor stimulating gastrin release from rabbit antral G-cells in primary culture (264) 337
Weinmüller, M., see Götz, M.E. (266) 291
Weinshank, R.L., see Borden, L.A. (269) 219
Weir, B., see Zhang, H. (251) 119
Weiss, B., see Qin, Z.-H. (269) 25
Weiss, R.M., see Dokita, S. (266) 269
Weissman, A.D., McCann, D.J., Lorden, J.F. and Su, T.-P.
An absence of changes in σ receptor subtypes in the brains of genetically dystonic (*dt*) rats (250) 329
Weitzberg, E., see Modin, A. (261) 185
Weizman, R., Burgin, R. and Gavish, M.
Modulatory effect of antidepressants on peripheral-type benzodiazepine receptors (250) 289
Wellings, R.P., Corder, R., Doherty, A.M. and Vane, J.R.
Antagonism of renal and systemic responses to endothelin-1 infusion with PD 145065 (256) 201
Welsch, M., see Lippert, K. (253) 207
Wemer, J., see Van den Berg, C. (270) 379
Wemer, J., see Vleeming, W. (250) 415
Werner, P., Mytilineou, C., Cohen, G. and Yahr, M.D.
Impaired oxidation of pyruvate in human embryonic fibroblasts after exposure to L-dopa (263) 157
West, Jr., R.E., Myers, J., Zweig, A., Siegel, M.I., Egan, R.W. and Clark, M.A.
Steroid-sensitivity of agonist binding to pituitary cell line histamine H_3 receptors (267) 343
Westerink, B.H.C., see Damsma, G. (249) R9
Westlind-Danielsson, A., see Johansson, M.H. (269) 149
Weston, A.H., see Trezise, D.J. (250) 109
Wexler, R.R., see Wong, P.C. (260) 261
Wheeler, L.T., see Dundore, R.L. (249) 293
Wheeler, M.A., see Dokita, S. (266) 269
White, D.G., Garratt, H., Mundin, J.W., Sumner, M.J., Vallance, P.J. and Watts, I.S.
Human saphenous vein contains both endothelin ET_A and ET_B contractile receptors (257) 307
White, H.S., see Filloux, F.M. (269) 325
White, I.M. and Rebec, G.V.
Performance on a lever-release, conditioned avoidance response task involves both dopamine D_1 and D_2 receptors (253) 167
White, T.D., see Craig, C.G. (269) 79
Whitebread, S., see Macari, D. (249) 85
Whitebread, S., see Macari, D. (259) 27

Whiting, J.M., see Gard, P.R. (264) 295
Whiting, P.J., see Klein, R.L. (268) 237
Whiting, P.J., see Mihic, S.J. (268) 209
Whittle, B.J.R., see Barrachina, D. (262) 181
Whittle, B.J.R., see László, F. (260) 265
Whittle, B.J.R., see Price, K.J. (263) 199
Wickens, A.P. and Pertwee, R.G.
Δ^9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats (250) 205
Wiedermann, C.J., see Kähler, C.M. (249) 281
Wiedermann, C.J., see Kähler, C.M. (262) 261
Wiesenfeld-Hallin, Z., Luo, L., Xu, X.-J. and Maggi, C.A.
Differential effects of selective tachykinin NK_2 receptor antagonists in rat spinal cord (251) 99
Wiesenfeld-Hallin, Z., see Bedecs, K. (259) 151
Wiesenfeld-Hallin, Z., see Goettl, V.M. (259) 83
Wiklund, C.U., see Persson, M.G. (270) 273
Wikström, H., see Damsma, G. (249) R9
Wilcox, G.L., see Alhaider, A.A. (249) 151
Wilhelm, M., see Barthó, L. (259) 187
Wilke, R., see Spanagel, R. (262) 21
Wilkins, D.G., see Elkins, K.W. (250) 395
Williams, A.R., see Rupniak, N.M.J. (265) 179
Williams, G., see McCarthy, H.D. (265) 99
Williams, R.J. and Kelly, E.
$G_s\alpha$-dependent and -independent desensitisation of prostanoid IP receptor-activated adenylyl cyclase in NG108–15 cells (268) 177
Williams, T.J., see Pons, F. (261) 237
Williams, W., see Hellewell, S.B. (268) 9
Williamson, J.R., see Hasan, K. (249) 101
Willim, K.D., see Doods, H.N. (250) 223
Wilsch, V.W., Pidoplichko, V.I., Opitz, T., Shinozaki, H. and Reymann, K.G.
Metabotropic glutamate receptor agonist DCG-IV as NMDA receptor agonist in immature rat hippocampal neurons (262) 287
Wilson, A.A., see Villemagne, V.L. (257) 195
Wilson, J.H.P., see Zijlstra, F.J. (249) R1
Witkin, J.M., see Izenwasser, S. (263) 277
Wlaź, P., Baran, H. and Löscher, W.
Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice (257) 217
Wolffenbuttel, B.H.R., see Hasan, K. (249) 101
Wolfgang, E.A., see Constantine, J.W. (252) 275
Wolters, E.Ch., see Vermeulen, R.J. (269) 121
Wong, E.H.F., see Bley, K.R. (260) 139
Wong, H.C., see Peskar, B.M. (250) 201
Wong, K., see Wang, Z.-Y. (260) 121
Wong, M., see Balwierczak, J.L. (250) 379
Wong, M., see Denyer, J. (268) 29
Wong, M.G., see Beart, P.M. (269) 193
Wong, P.C., Duncia, J.V., Santella III, J.B., Smith, R.D., Wexler, R.R., Timmermans, P.B.M.W.M. and Chiu, A.T.
EXP597, a nonpeptide angiotensin II receptor antagonist with high affinities for the angiotensin AT_1 and AT_2 receptor subtypes (260) 261
Wong, P.C., Hart, S.D. and Timmermans, P.B.M.W.M.
Effects of nifedipine on phasic and tonic vasoconstrictor responses to Sgd 101/75 in the isolated perfused rabbit ear artery (262) 185
Wong, T.T.L., see Woods, A.J. (264) 125
Woodcock, E.A., see Fitzgerald, M. (268) 275
Woodruff, G., see Suman-Chauhan, N. (269) 65
Woodruff, G.N., see Keegan, K.D. (253) 131
Woodruff, G.N., see Pinnock, R.D. (269) 73
Woodruff, G.N., see Puttick, R.M. (254) 303
Woods, A.J., Stock, M.J., Gupta, A.N., Wong, T.T.L. and Andrews, P.L.R.
Thermoregulatory effects of resiniferatoxin in the rat (264) 125
Woodward, B., see Criddle, D.N. (255) 223
Woodward, R.M., see Lutfy, K. (252) 261
Woody, H.A., see Constantine, J.W. (252) 275
Wotherspoon, G., see Rattray, M. (268) 439
Wu, C.-C., see Szabó, C. (250) 157
Wu, J., see Wallis, D.I. (250) 371
Wu, M.-H. and Yung, B.Y.-M.
Cell cycle phase-dependent cytotoxicity of actinomycin D in HeLa cells (270) 203
Wu, T.-S., see Yu, S.-M. (256) 85
Wu, W.-H., see Tung, C.-S. (256) 193
Wutkiewicz, M., see Remiszewska, M. (250) 355
Wyatt, C.N., see Rana, B. (250) 247
Wyatt, R.J., see Karoum, F. (254) 127

Xia, Y. and Han, C.
Role of K^+ channels in neuropeptide Y-induced vasoconstriction in rabbit cerebral basilar artery (255) 67
Xian, H., Coggan, J.S., Knoper, S.R. and Kreulen, D.L.
The muscarinic receptor agonist oxotremorine methiodide evokes a nicotinic response in mammalian sympathetic neurons (259) 21
Xu, C., see Reith, M.E.A. (253) 175
Xu, J.Y. and Tseng, L.F.
Role of nitric oxide/cyclic GMP in i.c.v. administered β-endorphin- and (+)-*cis*-dioxolane-induced antinociception in the mouse (262) 223
Xu, X.-J., see Bedecs, K. (259) 151
Xu, X.-J., see Goettl, V.M. (259) 83
Xu, X.-J., see Puke, M.J.C. (260) 227
Xu, X.-J., see Wiesenfeld-Hallin, Z. (251) 99

Yabu, H., see Obara, K. (255) 139
Yago, V., see McIntosh, C. (259) 331
Yahr, M.D., see Werner, P. (263) 157
Yakirevich, V., see Shany, E. (253) 231
Yaksh, T.L., see Malmberg, A.B. (256) 205
Yaksh, T.L., see Malmberg, A.B. (260) 283
Yamada, J., see Nakamura, J. (254) 83
Yamada, K., see Nabeshima, T. (255) 57
Yamada, S., Yokoo, H. and Nishi, S.
Effects of *N*-ethylmaleimide on dopamine release in the rat striatum after repeated treatment with methamphetamine (257) 243
Yamada, S., see Yokoo, H. (256) 335
Yamagishi, T., Yanagisawa, T., Satoh, K. and Taira, N.
Relaxant mechanisms of cyclic AMP-increasing agents in porcine coronary artery (251) 253
Yamaguchi, K., see Nonaka, H. (267) 335
Yamaguchi, T., see Ishikawa, M. (269) 311
Yamaguchi, Y. and Kobayashi, H.
Effects of apomorphine, physostigmine and vasoactive intestinal peptide on penile erection and yawning in diabetic rats (254) 91
Yamaguchi, Y., see Matsuda, Y. (250) 341
Yamamoto, B.K., see Gudelsky, G.A. (264) 325
Yamamoto, H., see Miyake, A. (253) 155
Yamamoto, K., see Liu, J.-X. (250) 361
Yamamoto, M., see Fukui, H. (249) 13
Yamamoto, M., see Fukui, H. (250) 281
Yamamoto, M., see Fukui, H. (257) 47
Yamamoto, T., Hosoki, K. and Karasawa, T.
Possible involvement of endothelin in thromboxane A_2 receptor agonist (U-46619)-induced angina in the rat (250) 189
Yamamoto, T., see Isono, T. (260) 163

Yamamoto, T., see Ohno, M. (253) 183
Yamamoto, Y., see Ohno, N. (249) 121
Yamamoto, Y., see Yokota, Y. (258) 239
Yamamura, H., Nabe, T., Kohno, S. and Ohata, K.
Endothelin-1 induces release of histamine and leukotriene C_4 from mouse bone marrow-derived mast cells (257) 235
Yamamura, H., Nabe, T., Kohno, S. and Ohata, K.
Endothelin-1, one of the most potent histamine releasers in mouse peritoneal mast cells (265) 9
Yamamura, H.I., see Knapp, R.J. (269) 133
Yamamura, H.I., see Wei, H.-B. (268) 381
Yamano, M., see Miyata, K. (250) 303
Yamanouchi, T., Moromizato, H., Kojima, S., Shinohara, T., Sekino, N., Minoda, S., Miyashita, H. and Akaoka, I.
Prevention of diabetes by thymic hormone in alloxan-treated rats (257) 39
Yamashita, H., see Wanibuchi, F. (265) 151
Yamashita, M., see Koyama, K. (270) 151
Yamashita, S., see Ogino, K. (270) 73
Yamashita, Y., see Yukimura, T. (264) 399
Yamaura, H., Miyata, N., Takahashi, K., Tsuchida, K. and Otomo, S.
Effects of CD-832, a dihydropyridine derivative with a nitrate ester moiety, on rabbit femoral artery and vein (260) 269
Yamaura, H., see Miyata, N. (249) 141
Yamawaki, I., see Ricciardolo, F.L.M. (261) 127
Yamawaki, S., see Shimizu, M. (268) 65
Yamazaki, S., see Isono, T. (260) 163
Yan, Q.-S., Jobe, P.C. and Dailey, J.W.
Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats (252) 105
Yanagisawa, T., see Yamagishi, T. (251) 253
Yanaihara, N., see Narváez, J.A. (257) 257
Yang, H.-T., see Kohi, M. (250) 95
Yang, S.-N., see Fior, D.R. (262) 271
Yano, M., see Okada, M. (259) 339
Yasar, S., Schindler, C.W., Thorndike, E.B. and Goldberg, S.R.
Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats (259) 243
Yasue, H., see Tsunoda, R. (262) 55
Yasuhara, M., see Hashimoto, Y. (268) 443
Yazawa, H., see Saita, Y. (269) 249
Ybema, C.E., Olivier, B., Mos, J., Tulp, M.Th.M. and Slangen, J.L.
Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT_{1A} receptor agonist flesinoxan (256) 141
Yee, F., see Adner, M. (261) 281
Yehuda, S., Carasso, R.L. and Mostofsky, D.I.
Essential fatty acid preparation (SR-3) raises the seizure threshold in rats (254) 193
Yeulet, S., see Parker, S.G. (265) 17
Yin, T.-H., see Tung, C.-S. (256) 193
Yin, Y., Vassy, R., Nicolas, P., Perret, G.-Y. and Laurent, S.
Antagonism between T_3 and amiodarone on the contractility and the density of β-adrenoceptors of chicken cardiac myocytes (261) 97
Yocca, F.D., see Parker, E.M. (268) 43
Yokoo, H., Yamada, S., Yoshida, M., Tanaka, T., Mizoguchi, K., Emoto, H., Koga, C., Ishii, H., Ishikawa, M., Kurasaki, N., Matsui, M. and Tanaka, M.
Effect of opioid peptides on dopamine release from nucleus accumbens after repeated treatment with methamphetamine (256) 335
Yokoo, H., see Yamada, S. (257) 243
Yokota, Y., Inamura, N., Asano, M., Yamamoto, Y., Nakahara, K., Notsu, Y., Ono, T. and Watanabe, M.
Effect of FR128998, a novel PAF receptor antagonist, on endotoxin-induced disseminated intravascular coagulation (258) 239
Yokoyama, H., Onodera, K., Maeyama, K., Sakurai, E., Iinuma, K., Leurs, R., Timmerman, H. and Watanabe, T.
Clobenpropit (VUF-9153), a new histamine H_3 receptor antagonist, inhibits electrically induced convulsions in mice (260) 23
Yoneda, I., see Sakuta, H. (252) 117
Yoo, H., Fallgren, B., Lindahl, A. and Wahlestedt, C.
Characterization of specific binding sites for α-trinositol (D-*myo*-inositol 1,2,6-trisphosphate) in rat tissues (268) 55
Yoo, J.-S., see Suh, H.-W. (263) 217
Yoshida, K., see Kita, Y. (257) 123
Yoshida, M., see Yokoo, H. (256) 335
Yoshida, S. and Suzuki, N.
Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats (250) 117
Yoshioka, M., see Hirokami, M. (253) 9
Yoshiyama, M., Roppolo, J.R. and De Groat, W.C.
Alteration by urethane of glutamatergic control of micturition (264) 417
Young, G.A., see Haberny, K.A. (261) 1
Young, G.A., see Haberny, K.A. (261) 11
Young, J.M., see Young, K.W. (269) 283
Young, K.W. and Young, J.M.
Potentiation by 1,4-dithiothreitol of histamine-induced inositol phosphate formation in rat cerebral cortex and human HeLa cells (269) 283
Young, L., see Bristow, L.J. (253) 245
Yu, H.-M., see Ho, C.-L. (259) 259
Yu, S.-M., Ko, F.-N., Chueh, S.-C., Chen, J., Chen, S.-C., Chen, C.-C. and Teng, C.-M.
Effects of dicentrine, a novel α_1-adrenoceptor antagonist, on human hyperplastic prostates (252) 29
Yu, S.-M., Ko, F.-N., Wu, T.-S., Lee, J.-Y. and Teng, C.-M.
Cinnamophilin, a novel thromboxane A_2 receptor antagonist, isolated from *Cinnamomum philippinense* (256) 85
Yuan, L.-X., see Fedan, J.S. (256) 51
Yue, T.-L., Mckenna, P.J., Lysko, P.G., Gu, J.-L., Lysko, K.A., Ruffolo, Jr., R.R. and Feuerstein, G.Z.
SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant (251) 237
Yui, Y., see Hattori, R. (267) R1
Yuki, H., see Miyata, K. (250) 303
Yukimura, T., Yamashita, Y., Miura, K., Kim, S., Iwao, H., Takai, M. and Okada, T.
Renal vasodilating and diuretic actions of a selective endothelin ET_B receptor agonist, IRL1620 (264) 399
Yukimura, T., see Ebara, T. (263) 69
Yukimura, T., see Ohta, K. (269) 115
Yung, B.Y.-M., see Wu, M.-H. (270) 203

Zaagsma, J., see Coppes, R.P. (261) 311
Zaagsma, J., see Roffel, A.F. (249) 235
Zaagsma, J., see Roffel, A.F. (250) 267
Zaagsma, J., see Santing, R.E. (254) 49
Zaagsma, J., see Santing, R.E. (257) 145
Zagorodnyuk, V., Santicioli, P. and Maggi, C.A.
Different Ca^{2+} influx pathways mediate tachykinin receptor-induced contraction in circular muscle of guinea-pig colon (255) 9
Zahniser, N.R., see Wallace, D.R. (258) 67
Zalewska, T., see Knapp, R.J. (269) 133
Zappellini, A., see Giraldelo, C.M.M. (257) 87
Zar, M.A., see Iravani, M.M. (250) 193
Zaratin, P. and Clarke, G.D.
Comparative effects of selective κ-opioid receptor agonists on dopamine levels in the dorsal caudate of freely moving rats (264) 151
Zarrindast, M.-R. and Heidari, M.-R.
On the mechanisms by which theophylline changes core body temperature in mice (257) 13

Zarrindast, M.-R. and Shafaghi, B.
Effects of adenosine receptor agonists and antagonists on acquisition of passive avoidance learning (256) 233
Zarrindast, M.-R., see Rezayat, M. (254) 21
Zarzuelo, A., see Duarte, J. (262) 149
Zatz, R., see Giraldelo, C.M.M. (257) 87
Zboinska, J., see Patacchini, R. (250) 311
Zea-Ponce, Y., see Laruelle, M. (263) 39
Zefirov, A.L., see Shakiryanova, D.M. (263) 107
Železná, B., Veselský, L., Velek, J., Zicha, J. and Kuneš, J.
Angiotensin AT_1 receptor blockade by specific antibody prevented two-kidney, one-clip renal hypertension in the rat (260) 95
Zemková, H., see Krůšek, J. (259) 121
Zenkoh, J., see Aramori, I. (269) 277
Zetterström, T., see Pei, Q. (249) 243
Zhang, C.L., De la Lande, I.S., Stafford, I. and Horowitz, J.D.
S-Nitrosothiol modulation of tolerance to glyceryl trinitrate in bovine isolated coronary artery (252) 299
Zhang, G., Franklin, P.H. and Murray, T.F.
Activation of adenosine A_1 receptors underlies anticonvulsant effect of CGS21680 (255) 239
Zhang, H., Inazu, M., Weir, B., Buchanan, M. and Daniel, E.
Cyclopiazonic acid stimulates Ca^{2+} influx through non-specific cation channels in endothelial cells (251) 119
Zhang, J., Pfaffendorf, M., Zhang, J.S. and Van Zwieten, P.A.
A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations (252) 337
Zhang, J., Van Meel, J.C.A., Pfaffendorf, M., Zhang, J. and Van Zwieten, P.A.
Endothelium-dependent, nitric oxide-mediated inhibition of angiotensin II-induced contractions in rabbit aorta (262) 247
Zhang, J., see Bricca, G. (266) 25
Zhang, J., see Zhang, J. (262) 247
Zhang, J.S., see Zhang, J. (252) 337
Zhao, Y., see Stark, G. (252) 283
Zhou, Q., see Satake, N. (251) 1
Zhu, J., Toews, M.L., MacDonald, R.G. and Hexum, T.D.
Neuropeptide Y promotes GTP photo-incorporation into a 55 kDa protein (268) 279
Zhu, M.-Y., see Juorio, A.V. (254) 213
Zicha, J., see Železná, B. (260) 95
Ziegler, H., see Doods, H.N. (253) 275
Zijlstra, F.J., Van Dijk, J.P.M. and Wilson, J.H.P.
Increased platelet activating factor synthesis in experimental colitis after diclofenac and 5-amino-salicylic acid (249) R1
Zingarelli, B., see Altavilla, D. (270) 45
Zingarelli, B., see Squadrito, F. (255) 51
Ziskoven, U., see Stark, G. (252) 283
Zoghbi, S.S., see Laruelle, M. (263) 39
Zojer, N., see Todt, H. (265) 43
Zolotorev, A., see Morhenn, V.B. (268) 409
Zong, R., see Baldessarini, R.J. (254) 199
Zorn, S.H., Jones, S.B., Ward, K.M. and Liston, D.R.
Clozapine is a potent and selective muscarinic M_4 receptor agonist (269) R1
Zuany-Amorim, C., Cordeiro, R.S.B. and Vargaftig, B.B.
Involvement of leukotrienes in allergic inflammation in mice (257) 211
Zuccarello, M., Lewis, A.I. and Rapoport, R.M.
Endothelin ET_A and ET_B receptors in subarachnoid hemorrhage-induced cerebral vasospasm (259) R1
Zvartau, E., see Bespalov, A. (264) 233
Zweig, A., see West, Jr., R.E. (267) 343

ELSEVIER

European Journal of Pharmacology

ejp

Master keyword index to volumes 249–270 (1994)

A23187
Tri-*n*-butyltin; Thymocyte; Ca^{2+} pump; Thapsigargin; Cyclopiazonic acid (Oyama, Y. (270) 137)

A68930
Dopamine D_1 receptor; Astrocyte; Adenylate cyclase; SKF 38393; SKF 81297; (Rat); (Rhesus monkey); (Human) (Vermeulen, R.J. (269) 121)

A77636
Dopamine; Dopamine D_1 receptor; Oral activity (Huang, N.-Y. (253) 163)

[^{3}H]A81988
Angiotensin AT_1 receptor antagonist; [^{125}I][Sar^1-Ile^8]angiotensin-II (Hancock, A.A. (267) 49)

Abecarnil
Diazepam; Chronic treatment; Tolerance; GABAergic transmission; (Mouse) (Serra, M. (259) 1)

$GABA_A$ receptor; Dopamine; Acetylcholine, release (Imperato, A. (261) 205)

Accumbens
Histamine; Stress; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); α-Fluoromethylhistidine; Suprachiasmatic (Fleckenstein, A.E. (264) 163)

Dopamine D_3 receptor; Microdialysis (Rivet, J.-M. (265) 175)

ACEA-1011
Morphine, intrathecal; Clonic seizure-like behavior; NMDA receptor; MK-801; Glycine co-agonist site (Lutfy, K. (252) 261)

Acetaldehyde
Ethanol; Free radical; Reactive oxygen; Oxidative stress (Bondy, S.C. (270) 349)

Acetic acid test
Calcitonin; Analgesia; 5-HT (5-hydroxytryptamine, serotonin); *p*-Chlorophenylalanine; *p*-Chloroamphetamine (Colado, M.I. (252) 291)

Acetylcholine
Opioid receptor; Microdialysis; Adrenal medulla (Hirokami, M. (253) 9)

8-Bromo-cGMP; EDRF (endothelium-derived relaxing factor); Aortic ring, isolated, rat; Atrium, right, isolated, rat; LY-83,583 (6-(phenylamino)-5,8-quinolinedione); Norepinephrine; *N*-Nitro-L-arginine; SIN-1 (3-morpholino-sydnonimine); (Spontaneous rate) (Kennedy, R.H. (255) 149)

Uterine artery; Muscarinic receptor; (Human) (Jovanović, A. (256) 131)

Uterine artery; Pregnancy; Muscarinic receptor; (Guinea-pig) (Jovanović, A. (258) 185)

Adenosine; Angiotensin II; Atrium; Contractility; α-CGRP (calcitonin gene-related peptide); Somatostatin; Ventricle; (Human) (Du, X.Y. (259) 173)

PAF (platelet-activating factor); Mesenteric arterial bed; Spontaneously hypertensive rat (SHR); Desensitization (Kamata, K. (259) 321)

Frontal cortex; Hippocampus; Microdialysis; Dopamine D_1 receptor (Acquas, E. (260) 85)

Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); Neuropeptide Y; Nitroprusside; Milrinone; cAMP; cGMP (Modin, A. (261) 185)

Hippocampus; Medial septal area; Nicotinic acetylcholine receptor; Spatial memory (Decker, M.W. (261) 217)

Nerve terminal current; Cholinomimetic; Anticholinesterase (Shakiryanova, D.M. (263) 107)

d-Amphetamine; Cortex; Dopamine; 6-Hydroxydopamine; Noradrenaline (Day, J.C. (263) 285)

Adrenal catecholamine; Voltage-dependent Ca^{2+} channel, N-type, L-type; ω-Conotoxin GVIA; Nifedipine; Verapamil (Kimura, T. (264) 169)

Hippocampus; 5-HT (5-hydroxytryptamine, serotonin); Fenfluramine (Levkovitz, Y. (264) 279)

Arginine; Bradykinin; cGMP; Gentamicin; Nitric oxide (NO); (Rat) (Rivas-Cabañero, L. (270) 119)

Acetylcholine receptor
Neuromuscular blocking drug; Ammonium compound (Danilov, A.F. (257) 1)

Taurine; Taurine release; Superior cervical ganglion, rat (Waniewski, R.A. (260) 113)

Acetylcholine release
HPLC-ECD system; Cholinergic regulation (presynaptic); Muscarinic receptor agonist; Muscarinic receptor antagonist; Ileum (guinea-pig); Bethanechol; p-F-HHSiD (*p*-fluoro-hexahydro-siladifenidol); AF102B. (Soejima, O. (249) 1)

Dopamine D_1 receptor; Dopamine D_2 receptor; Reserpine; α-Methyl-tyrosine; LY 171555; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor blocker; SCH 23390 (Imperato, A. (251) 271)

Vasoactive intestinal contractor; Endothelin receptor; Ileum, guinea pig; Desensitization (Kan, S. (258) 139)

Abecarnil; $GABA_A$ receptor; Dopamine (Imperato, A. (261) 205)

Neuroleptic; Dopamine release; Dopamine D_1 receptor stimulation; Dopamine D_1 receptor desensitization; (Therapeutic and collateral effect) (Imperato, A. (264) 55)

NMDA receptor; Budipine; Biperiden; Nucleus caudatus; MK-801 binding (Jackisch, R. (264) 207)

Acetylcholinergic neuronal system
σ Receptor ligand; SKF-10,047; DTG (1,3-di-(2-tolyl)guanidine); Benzomorphan-type σ receptor; *p*-Chloroamphetamine; Amnesia; Passive avoidance task; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperizine); (Mouse) (Matsuno, K. (261) 43)

Acetylcholinesterase
E2020; Diisopropylfluorophosphate; Acetylcholinesterase protection; Organophosphate toxicity (Galli, A. (270) 189)

Acetylcholinesterase inhibitor
Galanin; Muscarinic receptor agonist; Cholinomimetic; Hypothermia; ATP-sensitive K^+ channel (Patel, S. (255) 25)

Acetylcholinesterase protection
E2020; Diisopropylfluorophosphate; Acetylcholinesterase; Organophosphate toxicity (Galli, A. (270) 189)

Acetylcholinesterase reactivation
HI-6 ([[[(4-aminocarbonyl)pyridino]-methoxy]methyl]-2-[(hydroxyimino)methyl]-pyridinium dichloride); Soman; Diaphragm, rat; Muscle tension (Adler, M. (270) 9)

Acetylcholine, synthesis and release
Neuroimmunomodulation; Parasympathetic nervous system; Cyclosporine; Lymphoid tissue; Cholinergic innervation; Choline uptake; Sympathetic nervous system; Superior cervical ganglion (Esquifino, A.I. (254) 1)

***N*-Acetylcysteine**
Butylated hydroxyanisole; Metabolite; Cytotoxicity; Hepatocyte, isolated, rat (Nakagawa, Y. (270) 341)

Acetyl-L-carnitine
Protein kinase C; Behavior; (Rat) (Pascale, A. (265) 1)

Acetylsalicylic acid
Proliferative vitreoretinopathy; Fibroblast; Arachidonic acid metabolite, inhibition (Kähler, C.M. (262) 261)

***N*-Acetylserotonin**
Endotoxic shock; Nitric oxide (NO) (Klemm, P. (250) R9)

Acid secretion
Cimetidine; Omeprazole; Gastrin (Ito, M. (263) 253)

Aclarubicin
Phosphatidylinositol; Vasoconstriction; Aorta, rat (Wakabayashi, I. (255) 111)

ACPC (1-aminocyclopropanecarboxylate)
Anxiolytic; Glycine receptor ligand; NMDA (*N*-methyl-D-aspartate); NMDA receptor antagonist; D-Cycloserine (Anthony, E.W. (250) 317)

NMDA (*N*-methyl-D-aspartate); Neuronal injury; Dynorphin A; Glycine (Long, J.B. (261) 295)

***trans*-ACPD (1-aminocyclopentane-*trans*-1,3-dicarboxylic acid)**
Glutamate; Phosphoinositide; cAMP; L-*trans*-2,4-PDC (L-*trans*-2,4-pyrrolidine dicarboxylic acid); Glutamate transport; (+)-α-Methyl-4-carboxyphenylglycine (Miller, S. (269) 235)

(1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate)
Excitatory amino acid receptor (metabotropic); Excitatory amino acid; Convulsion (Klitgaard, H. (250) 9)

Excitatory amino acid; Excitatory amino acid receptor (metabotropic); Convulsion; Scratching (Laudrup, P. (250) 15)

MCPG (α-methyl-4-carboxyphenylglycine); Excitatory amino acid receptor; Presynaptic; cAMP; Glutamate; Receptor; Metabotropic; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

Metabotropic glutamate receptor; Phenylglycine derivative; Phosphoinositide hydrolysis; Cyclic AMP (Thomsen, C. (267) 77)

Metabotropic glutamate receptor; Spinal cord, isolated; cAMP; Phosphoinositide hydrolysis; L-CCG-I((2*S*,1′*S*,2′*S*)-CCG); Cortical cell culture (Ishida, M. (268) 267)

(1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate)
MCPG (α-methyl-4-carboxyphenylglycine); Excitatory amino acid receptor; Presynaptic; cAMP; Glutamate; Receptor; Metabotropic; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

Acquisition
Adenosine; Learning; Passive avoidance learning; (Mouse) (Zarrindast, M.R. (256) 233)

ACTH-(1–24)
Hemorrhagic shock; Dopamine receptor; Haloperidol; *l*-Sulpiride; SCH-23390 (Bazzani, C. (253) 303)

ACTH (adrenocorticotrophic hormone)
Hypothalamo-pituitary-adrenal axis; Stress; Antidepressant; Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); CRF (corticotropin-releasing factor); Corticosterone (Delbende, C. (251) 245)

Ifenprodil; Polyamine; Behavior; NMDA receptor; (Rat) (Genedani, S. (252) 77)

Corticosterone; Dioxadrol; Endocrine; NMDA (*N*-methyl-D-aspartate); Pentazocine; Phencyclidine; σ Receptor; SKF 10,047 (Pechnick, R.N. (263) 115)

WAY100635 (*N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride); Plasma; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); $5\text{-}HT_{1A}$ receptor; (Conscious rat) (Critchley, D.J.P. (264) 95)

ACTH derivative
Melanocortin receptor antagonist; Grooming behavior; α-MSH (α-melanocyte-stimulating hormone) (Adan, R.A.H. (269) 331)

ACTH release
CRF (corticotropin-releasing factor); Anti-edema; (Structure-activity relationship) (Wei, E.T. (263) 319)

Histamine H_3 receptor; AtT-20 cell; [^{3}H]N^{α}-Methylhistamine binding; Steroid effect (West, Jr., R.E. (267) 343)

Actin filament
Ca^{2+} inhibition; Contraction; Smooth muscle; Myometrium; Threshold phenomenon (Miyauchi, Y. (263) 75)

Actinomycin D
Cytotoxicity; Cell cycle; Phase dependency (Wu, M.-H. (270) 203)

Action potential
Apamin; Patch-clamp technique; Delayed rectifier K^+ current; Ventricular myocyte (Koumi, S.-i. (261) 213)

Action potential duration
Mexiletine; Dofetilide; Conduction; QT duration; (Guinea-pig); (In vivo) (Todt, H. (265) 43)

Acute inflammation
EDRF (endothelium-derived relaxing factor); N^{ω}-Nitro-L-arginine methyl ester; Nitric oxide (NO) (Giraldelo, C.M.M. (257) 87)

Acute sound stress
Tryptophan hydroxylase; Hypophysectomy; Hypothalamic deafferentation; RU 38486; Central nucleus of amygdala (Singh, V.B. (256) 177)

Acyl carnitine ester
Coronary vasodilatation; Superior mesenteric vessel (Criddle, D.N. (255) 223)

δ Address
Opioid; Dermenkephalin (binding); Structure-activity study (Charpentier, S. (266) 175)

Adenosine
Xanthine; Memory; Learning; Water maze; (Mouse) (Von Lubitz, D.K.J.E. (249) 271)

Liposome; Smooth muscle, vascular (Brailoiu, E. (250) 489)

Dopamine; Basal ganglion; Dopamine D_1 receptor; Dopamine D_2 receptor; Turning behavior (Morelli, M. (251) 21)

Myocardial infarction; Myocardial ischemia; Purine transport (Poucher, S.M. (252) 19)

Theophylline; Hyperalgesia; NMDA receptor; Noradrenaline; Dopamine (Paalzow, G.H.M. (252) 87)

Brain microdialysis; Cerebral cortex; Tetrodotoxin; NMDA receptor; Muscarinic receptor (Pazzagli, M. (254) 277)

Superior colliculus; Excitation; Glutamate release; Protein kinase (Hirai, H. (256) 65)

Ischemia; Adenosine receptor; Therapy; (Gerbil) (Von Lubitz, D.K.J.E. (256) 161)

Learning; Acquisition; Passive avoidance learning; (Mouse) (Zarrindast, M.R. (256) 233)

GR79236; Antilipolytic; (Rat) (Gardner, C.J. (257) 117)

Nucleoside transporter; Dipyridamole; Nitrobenzylthioinosine; Brain (Jones-Humble, S.A. (257) 311)

Adenosine A_1 receptor; Adenosine A_2 receptor; [^{14}C]2-Deoxyglucose; (Agonist); (Antagonist) (Nehlig, A. (258) 57)

Acetylcholine; Angiotensin II; Atrium; Contractility; α-CGRP (calcitonin gene-related peptide); Somatostatin; Ventricle; (Human) (Du, X.Y. (259) 173)

Defecation, rat; Purinoceptor (Tomaru, A. (264) 91)

S-Adenosyl-L-methionine; Methylation; Brain stem; Vagus motoneuron (Travagli, R.A. (264) 385)

Epilepsy; Kindling; Glutamate binding; Glutamate release (Simonato, M. (265) 121)

ATP-activated channel; PC12 cell; GTP-binding protein (Inoue, K. (268) 223)

Adenosine A_2 receptor; Adenylyl cyclase; Endothelial cells; Heart; Coronary; Capillary; (Guinea pig) (Schiele, J.O. (269) 51)

NMDA; IBMX (3-isobutyl-1-methylxanthine) phosphodiesterase; cAMP; 5′AMP; (*N*-methyl-D-aspartate); (Release) (Craig, C.G. (269) 79)

Adenosine analog
Gastric muscularis mucosae; Smooth muscle; Adenosine receptor; DPCPX (1,3-dipropyl-8-cyclopentylxanthine) (Muller, M.J. (251) 151)

Seizure; NMDA (*N*-methyl-D-aspartate); (Mouse) (Von Lubitz, D.K.J.E. (253) 95)

Adenosine outflow
Idebenone; Inosine outflow; Nucleotide level; Hippocampal slice; Ischemia-like condition (Latini, S. (249) 65)

Adenosine receptor
Gastric muscularis mucosae; Smooth muscle; Adenosine analogue; DPCPX (1,3-dipropyl-8-cyclopentylxanthine) (Muller, M.J. (251) 151)

Vasorelaxation; Aortic baroreceptor; Endothelium; EDRF (endothelium-derived relaxing factor); NECA (5′-*N*-ethylcarboxamidoadenosine); Nitric oxide (NO) (Fahim, M. (254) 183)

Adenosine; Ischemia; Therapy; (Gerbil) (Von Lubitz, D.K.J.E. (256) 161)

Nucleus accumbens; Dopamine release; Midazolam; β-CCE (β-carboline-3-carboxylate ethyl ester); $GABA_A$/benzodiazepine receptor (Murai, T. (261) 65)

Brain ischemia, therapy; Cerebral blood flow; (Gerbil) (Von Lubitz, D.K.J.E. (263) 59)

Priming; Neutrophil, human (Dianzani, C. (263) 223)

Adenosine receptor antagonist; Heart, guinea-pig, perfused; Prostacyclin (Felsch, A. (263) 261)

Molecular modeling; Receptor binding and activation; Bacteriorhodopsin; Histidine residue (IJzerman, A.P. (268) 95)

Adenosine A_1 receptor
Adenosine A_2 receptor; Adenosine A_3 receptor; Pertussis toxin; APNEA (N^6-2-(4-aminophenyl)ethyladenosine) (Carruthers, A.M. (250) 185)

CGS21680; Adenosine A_{2A} receptor; Seizure; Prepiriform cortex; [^{3}H]DPCPX (8-Cyclopentyl-1,3-[^{3}H]dipropylxanthine) (Zhang, G. (255) 239)

Adenosine; Adenosine A_2 receptor; [^{14}C]2-Deoxyglucose; (Agonist); (Antagonist) (Nehlig, A. (258) 57)

Intrinsic activity; Agonists (full and partial); Receptor binding thermodynamics (Borea, P.A. (267) 55)

G_i-protein; Adipocyte; α_2-Adrenoceptor (Larrouy, D. (267) 225)

Adenosine A_2 receptor
Adenosine A_1 receptor; Adenosine A_3 receptor; Pertussis toxin; APNEA (N^6-2-(4-aminophenyl)ethyladenosine) (Carruthers, A.M. (250) 185)

Huntington's disease; (Rat) (Popoli, P. (257) R5)

Adenosine; Adenosine A_1 receptor; [^{14}C]2-Deoxyglucose; (Agonist); (Antagonist) (Nehlig, A. (258) 57)

Adenosine receptor agonist; 2-Hexynyl-NECA (5′-*N*-ethyl-carboxamidoadenosine); Platelet aggregation; [^{111}In]Oxine; Platelet, rabbit (Sandoli, D. (259) 43)

KF17837 ((*E*)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine); Binding assays; cAMP (Nonaka, H. (267) 335)

Adenosine; Adenylyl cyclase; Endothelial cells; Heart; Coronary; Capillary; (Guinea pig) (Schiele, J.O. (269) 51)

Adenosine A_{2A} receptor
CGS21680; Adenosine A_1 receptor; Seizure; Prepiriform cortex; [^{3}H]DPCPX (8-Cyclopentyl-1,3-[^{3}H]dipropylxanthine) (Zhang, G. (255) 239)

Adenosine A_1/A_2 receptor
Dopamine; Striatum; Rotational behavior; (Rat) (Popoli, P. (257) 21)

Adenosine A_3 receptor
Adenosine A_1 receptor; Adenosine A_2 receptor; Pertussis toxin; APNEA (N^6-2-(4-aminophenyl)ethyladenosine) (Carruthers, A.M. (250) 185)

APNEA (N^6-2-(4-aminophenyl)ethyl adenosine); BW-A522 (Fozard, J.R. (252) R5)

Adenosine receptor agonist
Adenosine receptor antagonist; Seizure; NMDA (*N*-methyl-D-aspartate); Protection; (Mouse) (Von Lubitz, D.K.J.E. (249) 265)

Adenosine A_2 receptor; 2-Hexynyl-NECA (5′-*N*-ethyl-carboxamidoadenosine); Platelet aggregation; [^{111}In]Oxine; Platelet, rabbit (Sandoli, D. (259) 43)

Adenosine receptor antagonist
Adenosine receptor agonist; Seizure; NMDA (*N*-methyl-D-aspartate); Protection; (Mouse) (Von Lubitz, D.K.J.E. (249) 265)

Adenosine receptor; Heart, guinea-pig, perfused; Prostacyclin (Felsch, A. (263) 261)

Adenosine A_{2A} receptor antagonist
Catalepsy; Haloperidol; Reserpine; (Mouse) (Kanda, T. (256) 263)

***S*-Adenosyl-L-methionine**
Adenosine; Methylation; Brain stem; Vagus motoneuron (Travagli, R.A. (264) 385)

Adenylate cyclase
5-HT_{1A} receptor; Dorsal raphe nucleus; Nerve impulse flow; (+)-WAY 100 135; SDZ 216-525; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lesopitron; S-20499; Flesinoxan (Lanfumey, L. (249) 25)

Dopamine release; Striatum; Morphine; Opioid receptor (Tjon, G.H.K. (252) 205)

5-HT_{1A} receptor; Autoradiography; Hippocampus; Dorsal raphe nucleus; Firing; Lesopitron; (−)-Tertatolol (Haj-Dahmane, S. (255) 185)

DN-2327; $GABA_B$ receptor; (Agonist) (Ichida, T. (267) 43)

Dopamine D_1 receptor; Astrocyte; SKF 38393; SKF 81297; A 68930; (Rat); (Rhesus monkey); (Human) (Vermeulen, R.J. (269) 121)

Adenylate cyclase activity
SR 57746A (4-(3-trifluoromethylphenyl)-*N*-[2-(naphth-2-yl)ethyl]-1,2,3,6-tetrahydropyridine HCl); 5-HT_{1A} receptor; Forced swimming test; Antidepressant activity (Cervo, L. (253) 139)

Adenylate cyclase inhibition
Morphine treatment (chronic); Desensitization; G-protein (coupling to); Down-regulation (Polastron, J. (266) 139)

Adenylyl cyclase
Metabotropic glutamate receptor; Halothane anesthesia; Glutamate receptor agonist; L-CCG-I ((2*S*,1′*S*,2′*S*)-2-(carboxycyclopropyl)glycine); DCG-IV ((2*S*,1′*R*,2′*R*,3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine) (Miyamoto, M. (260) 99)

G protein; Guanylnucleotide; c-*fos*; Mitogenesis; Phospholipase C; Phorbol ester; Pertussis toxin (Pilon, C. (268) 129)

β-Adrenoceptor; β-Adrenoceptor antagonist; G-protein (G_s); Erythrocyte; Turkey (Götze, K. (268) 151)

Desensitisation; Prostanoid IP receptor; $G_s\alpha$ protein; NG108-15 cell (Williams, R.J. (268) 177)

Morphine withdrawal; Morphine dependence; Locus coeruleus; Amygdala; Thalamus (Matsuoka, I. (268) 215)

Adenosine; Adenosine A_2 receptor; Endothelial cells; Heart; Coronary; Capillary; (Guinea pig) (Schiele, J.O. (269) 51)

Forskolin treatment (chronic); Dopamine D_2 receptor, human; Dopamine; Up-regulation; Supersensitivity (Johansson, M.H. (269) 149)

Galanin; 5-HT (5-hydroxytryptamine, serotonin); 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Forskolin; Hypothalamus; Hippocampus; Brain; Receptor subtype; Peptide fragment (Billecocq, A. (269) 209)

Adenylyl cyclase inhibition
Muscarinic M_2 receptor; Trachea (guinea-pig); Functional antagonism; β-Adrenoceptor agonist (Roffel, A.F. (249) 235)

Adherence
Inflammation; Prostaglandin D_2; Neutrophil; Edema formation; O_2^- production (Pons, F. (261) 237)

Adipocyte
G_i-protein; α_2-Adrenoceptor; Adenosine A_1 receptor (Larrouy, D. (267) 225)

Adrenoceptor; Testosterone; Colocyte; Kidney; Brain; Liver (Bouloumié, A. (269) 95)

Adipose tissue, white
Glucose transport; Brain; Heart (Nagai, K. (260) 29)

Administration, acute and chronic
NMDA receptor; Memory enhancement; Glycine partial agonist (Quartermain, D. (257) 7)

ADP
5-HT (5-hydroxytryptamine, serotonin); Methysergide; Platelet aggregation; Gastric mucosal blood flow; Blood pressure; Blood gas (Cho, C.H. (256) 9)

ADP ribosylation
G protein (low molecular weight); Polyphosphoinositide turnover; Botulinum toxin; 5-HT (5-hydroxytryptamine, serotonin); *Xenopus* oocyte (Tohda, M. (266) 19)

Adrenal catecholamine
Voltage-dependent Ca^{2+} channel, N-type, L-type; ω-Conotoxin GVIA; Nifedipine; Verapamil; Acetylcholine (Kimura, T. (264) 169)

Adrenal chromaffin cell
Staurosporine; Catecholamine release; Ca^{2+} (Maurer, J.A. (253) 115)

Adrenalectomy
5-HT_2 receptor; DOI (1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane); Glucocorticoid; Head shakes (Chaouloff, F. (249) 117)

Angiotensin II; Renin-angiotensin system; Aldosterone; Alcohol drinking; Salt appetite; Saline drinking (Saab, G. (256) 1)

Adrenalectomy / orchidectomy
Neurosteroid; cAMP; Brain cortex, rat; Diazepam binding inhibitor (DBI) receptor, mitochondrial; Protein synthesis inhibitor (Roscetti, G. (269) 17)

Adrenal gland
PAF (platelet-activating factor); Neutrophilia; Catecholamine (Altenburg, S.P. (256) 45)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptor; Benzamide derivative; Azabicycloalkyl benzimidazolone derivative; GR 113808 (Contesse, V. (265) 27)

Adrenal medulla
Acetylcholine; Opioid receptor; Microdialysis (Hirokami, M. (253) 9)

Catecholamine; Neuropeptide Y; [Met^5]Enkephalin; Insulin; Hypoglycemia (Damase-Michel, C. (258) 277)

Adrenergic stimulation
Artery, human; Nitric oxide (NO); Endothelium (Aldasoro, M. (250) 103)

Deferential artery, human; Endothelium (Martínez, C. (261) 73)

Adrenergic transmission
Anococcygeus muscle; Nifedipine; Ca^{2+} channel antagonist (Iravani, M.M. (250) 193)

Adrenoceptor
Aporphine; Antipsychotic; Dopamine receptor; Partial agonist, receptor; 5-HT (5-hydroxytryptamine, serotonin); Stereoisomer (Baldessarini, R.J. (254) 199)

Flesinoxan; Discriminative stimulus; 5-HT receptor; Dopamine receptor; Hypotension (Ybema, C.E. (256) 141)

Prostaglandin $F_{2\alpha}$; Hyperglycemia; Hyperthermia (Nonogaki, K. (262) 177)

Testosterone; Adipocyte; Colocyte; Kidney; Brain; Liver (Bouloumié, A. (269) 95)

α-Adrenoceptor
Brainstem (Human); Clonidine; Imidazoline receptor; GTP; Phenoxybenzamine (Bricca, G. (266) 25)

α_1-Adrenoceptor
HV723 (α-ethyl-3,4,5-trimethoxy-α-(3-((2-(2-methoxyphenoxy)ethyl)-amino)-propyl) benzeneacetonitrile fumarate); Positive inotropic effect; Phosphoinositide hydrolysis; [^{3}H]Prazosin; Ventricular myocardium, rabbit (Kohi, M. (250) 95)

Renal proximal tubule; Prazosin; Adrenoceptor subtype (Gopalakrishnan, S.M. (250) 469)

Cauda epididymis; Vas deferens; α_2-Adrenoceptor; [^{3}H]Rauwolscine; [^{3}H]Prazosin; (Rat) (Ventura, S. (254) 167)

Methoxamine; ATP release; Pulmonary artery, rabbit (Takeuchi, K. (254) 287)

Clozapine; Raphe; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor (Lejeune, F. (260) 79)

5-HT (5-hydroxytryptamine, serotonin); Microdialysis (Rouquier, L. (261) 59)

Angiotensin II; Sympathetic nervous system; Valsartan; PD 123319 (Marano, G. (261) 121)

Paw test; Clozapine; 5-HT_{2A} receptor; Dopamine D_1 receptor (Prinssen, E.P.M. (262) 167)

Ca^{2+} entry blocker; Ear artery, rabbit; Sgd 101/75 (Wong, P.C. (262) 185)

5-HT_{1A} receptor agonist; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Blood pressure; Heart rate; Respiratory rate (Di Francesco, G.F. (262) 205)

Thoracic aorta; β-Escin-skinned fiber; Myosin light chain phosphorylation (Satoh, M. (265) 133)

[^{3}H]Prazosin binding; Phosphoinositide hydrolysis; Phenoxybenzamine; Myocardium (rat) (Sallés, J. (266) 35)

Polymerase chain reaction; mRNA; [^{3}H]Prazosin (Faure, C. (268) 141)

Polymerase chain reaction; Artery, rabbit; Saphenous vein, human (Diehl, N.L. (268) 393)

α_{1B}-Adrenoceptor
CHO (Chinese hamster ovary) cell; Radioligand binding studies; Ca^{2+} concentration, cytosolic (Horie, K. (268) 399)

α_2-Adrenoceptor
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Brain; (Presynaptic α_2-adrenoceptors); (Postsynaptic α_2-adrenoceptors) (Heal, D.J. (249) 37)

Idazoxan; SND 919; B-HT 920; Lisuride; Dopamine D_2 receptor; Behavior (Ferrari, F. (250) 51)

[^{3}H]Rauwolscine; Myometrium; cAMP; Inositol phosphate; (Guinea-pig) (Haynes, J.M. (250) 231)

Receptor autoradiography; Lymph node; Spleen; [^{3}H]Bromoxidine; Immune system (Fernández-López, A. (252) 333)

Dexmedetomidine; Mydriasis; Nociception; Spinal cord (Horváth, G. (253) 61)

Org 3770; 5-HT (5-hydroxytryptamine, serotonin) release (De Boer, T. (253) R5)

SL 84.0418; K^+ channel, ATP-sensitive; Insulin release; Tolbutamide; Imidazoline; (Mouse islet) (Jonas, J.-C. (254) 27)

Cauda epididymis; Vas deferens; α_1-Adrenoceptor; [^{3}H]Rauwolscine; [^{3}H]Prazosin; (Rat) (Ventura, S. (254) 167)

Cortex; Imidazoline; Non-adrenoceptor binding (Wallace, D.R. (258) 67)

Buspirone; 1-PP (1-(2-pyrimidinyl)-piperazine); Clonidine; Antinociception (Cao, B.-J. (259) 75)

Angiotensin II; Angiotensin AT_1 receptor; Nucleus tractus solitarii; Autoradiography; Blood pressure (Fior, D.R. (262) 271)

SL 84.0418; Deriglidole; Insulin release; Imidazoline; K^+ channel, ATP-sensitive; (Mouse islet) (Jonas, J.-C. (264) 81)

Vas deferens, rat; *N*-Ethyl-maleimide; Phenoxybenzamine; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Browne, I. (265) 125)

Recombinant expression; Ligand binding (Marjamäki, A. (267) 117)

G_i-protein; Adipocyte; Adenosine A_1 receptor (Larrouy, D. (267) 225)

Imidazoline receptor; cAMP; Brainstem; Cerebral cortex; Inositol phosphate (Regunathan, S. (269) 273)

β-Adrenoceptor
Pertussis toxin; Salbutamol; Arecoline; Aorta; Langendorff; (Rat) (Vleeming, W. (250) 415)

Autonomic nervous system; Cardiac arrhythmia; Myocardial ischemia; Sudden cardiac death (Avendano, C.E. (255) 99)

cAMP; Glycerol release; Brown adipose tissue; Thermogenesis; Obesity (Nisoli, E. (259) 181)

Amiodarone; Triiodothyronine; Cardiomyocyte; (Chicken) (Yin, Y. (261) 97)

Chronic mild stress; Depression model, rat; Imipramine, chronic; cAMP; Sucrose intake (Papp, M. (261) 141)

$GABA_A$ receptor; $GABA_B$ receptor; Olfactory bulbectomy; Antidepressant; Brain, rat (Dennis, T. (262) 143)

Receptor autoradiography; Lymph node; Spleen; [^{125}I]Cyanopindolol; Immune system; Lymphoid organ (Fernández-López, A. (262) 283)

Salmeterol; cAMP; Thromboxane A_2; Macrophage (Baker, A.J. (264) 301)

Cardiomyocyte, intact; Isoproterenol; Desensitization; cAMP; Forskolin (Murphy, M.G. (268) 121)

β-Adrenoceptor antagonist; G-protein (G_s); Adenylyl cyclase; Erythrocyte; Turkey (Götze, K. (268) 151)

β_1-Adrenoceptor
cAMP; Ca^{2+} concentration, intracellular; Thromboxane A_2; Ca^{2+} sensitivity of contractile elements; Coronary artery (Yamagishi, T. (251) 253)

β_2-Adrenoceptor
Salbutamol; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; Aortic ring; Blood pressure; Endothelium (Wang, Y.-X. (250) 335)

Formoterol; Autoradiography; Lung (Mak, J.C.W. (269) 35)

β_3-Adrenoceptor
Catecholamine; Radioligand binding (Clarkson, K. (263) R1)

β-Adrenoceptor agonist
Muscarinic M_2 receptor; Trachea (guinea-pig); Functional antagonism; Adenylyl cyclase inhibition (Roffel, A.F. (249) 235)

β-Adrenoceptor agonist interaction
Thermodynamics; Lung (rat) (Fraeyman, N. (267) 63)

α-Adrenoceptor antagonist
5-MeO-DMT (5-methoxy-*N*,*N*-dimethyltryptamine); 5-HT receptor; 5-HT receptor agonist; Substance P; Spinal antinociception; GABA (γ-aminobutyric acid) (Alhaider, A.A. (249) 151)

α_1-Adrenoceptor antagonist
α_1-Adrenoceptor subtype; Urethra; Prostate (rat, rabbit, dog, man) (Testa, R. (249) 307)

Dicentrine; Bladder outlet obstruction; Prostatic hyperplasia, benign (Yu, S.-M. (252) 29)

Iminoctadine; Hypotension; Atrium (rat); Vasodilation; (Aorta) (Koyama, K. (270) 151)

α_2-Adrenoceptor antagonist
[^{3}H]RX821002; α_2-Adrenoceptor subtype, human (Devedjian, J.-C. (252) 43)

5-HT (5-hydroxytryptamine, serotonin); Myocardial ischemia (Sargent, C.A. (261) 25)

β-Adrenoceptor antagonist
Antioxidant; Lipid peroxidation; Oxidative stress; Endothelial cell; Cerebellar neuron (Yue, T.-L. (251) 237)

β-Adrenoceptor; G-protein (G_s); Adenylyl cyclase; Erythrocyte; Turkey (Götze, K. (268) 151)

α_2-Adrenoceptor, prejunctional
Imidazolidine compound; Agonist affinity; Agonist efficacy; (Operational model) (Sallés, J. (258) 229)

α_2-Adrenoceptor, presynaptic
Frontal cortex; Hippocampus; Idazoxan, chronic; Microdialysis (Thomas, D.N. (261) 53)

α-Adrenoceptor stimulation
Cl^-; Contractility; Cardiac muscle, rat (Buzzard, S.L. (260) 15)

β-Adrenoceptor stimulation
Indapamide; cAMP; Cardiomyocyte (chick, embryonic); Forskolin; Cholera toxin (Rabkin, S.W. (266) 117)

Aging; $G_{s\alpha}$ protein mRNA; $G_{s\alpha}$ subunit; Inotropic effect; Cardiac ventricle; (Male Wistar rat) (Miyamoto, A. (266) 147)

Adrenoceptor subtype
α_1-Adrenoceptor; Renal proximal tubule; Prazosin (Gopalakrishnan, S.M. (250) 469)

α_1-Adrenoceptor subtype
Urethra; Prostate (rat, rabbit, dog, man); α_1-Adrenoceptor antagonist (Testa, R. (249) 307)

Chloroethylclonidine; Nifedipine; Vas deferens, rat; Spleen, rat; Prostate, human (Teng, C.-M. (265) 61)

[^{3}H]Prazosin; Chloroethylclonidine; Benextramine; Phenoxybenzamine; Cerebral cortex (Sallés, J. (266) 301)

α_2-Adrenoceptor subtype
[^{3}H]Rauwolscine; Ligand binding; Signal transduction; cAMP (Jansson, C.C. (266) 165)

α_2-Adrenoceptor subtype, human
[^{3}H]RX821002; α_2-Adrenoceptor antagonist (Devedjian, J.-C. (252) 43)

α_1-Adrenoceptor, subtypes A, B and C
Spleen, guinea-pig (Eltze, M. (260) 211)

α_1-Adrenoceptor, vascular
Angiotensin-converting enzyme inhibitor; Ca^{2+} channel antagonist; Receptor reserve; Phenoxybenzamine (Tabrizchi, R. (251) 15)

Adrenomedullin
Pulmonary vascular bed; Vasoactive peptide; CGRP (calcitonin gene-related peptide); Pancreatic amylin (DeWitt, B.J. (257) 303)

Adrenomedullin fragment; Vasodilation; Peripheral circulation; Hypotension (Lin, B. (260) 1)

Renal hemodynamics; Renal function (Ebara, T. (263) 69)

Adrenomedullin fragment
Adrenomedullin; Vasodilation; Peripheral circulation; Hypotension (Lin, B. (260) 1)

Aerosol
Phosphodiesterase inhibitor; Eosinophil; Ovalbumin; PAF (platelet-activating factor); (Guinea pig) (Lagente, V. (255) 253)

AF102B
Acetylcholine release; HPLC-ECD system; Cholinergic regulation (presynaptic); Muscarinic receptor agonist; Muscarinic receptor antagonist; Ileum (guinea-pig); Bethanechol; p-F-HHSiD (*p*-fluorohexahydro-siladifenidol) (Soejima, O. (249) 1)

Phosphoinositide; Arachidonic acid; cAMP; Ca^{2+} imaging; G protein (Gurwitz, D. (267) 21)

AF-DX 116
Muscarinic receptor; Ascending reflex; Ileum, guinea-pig; Smooth muscle, intestinal (Doods, H.N. (253) 275)

Afferent nerve stimulation
Capsaicin; Cutaneous hyperemia; Interleukin-1β; Neurogenic inflammation; Nitric oxide (NO) (Herbert, M.K. (260) 89)

Afferent neuron
Capsaicin; Tachykinin; Intestine; Smooth muscle (Barthó, L. (259) 187)

Affinity cross-linking
Bradykinin B_2 receptor; Ileum membrane; (Guinea pig) (Graneß, A. (268) 271)

ω-Agatoxin-IVA
ω-Conotoxin-GVIA; Ca^{2+} channel (voltage sensitive); Autonomic nerve; Neurotransmission; Smooth muscle (Lundy, P.M. (261) 79)

Age
Neuromuscular transmission; Halothane; Voltage clamp (Bhattacharyya, B.J. (254) 97)

Aging
Norepinephrine release; Ca^{2+} channel; Dopamine D_2 receptor; Tail artery, rat (Friedman, D.J. (252) 1)

Macronutrient preference; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Feeding; Protein intake (Lacour, F. (255) 249)

Asthma; Edema; Plasma exudation; Leukotriene; Thromboxane A_2; Airway obstruction; Vascular permeability; Arachidonic acid (Arakawa, H. (259) 251)

$G_{s\alpha}$ protein mRNA; $G_{s\alpha}$ subunit; β-Adrenoceptor stimulation; Inotropic effect; Cardiac ventricle; (Male Wistar rat) (Miyamoto, A. (266) 147)

Somatostatin; Carbachol; 2-Deoxyglucose; Brain slice; Cerebral cortex (Shibata, S. (269) 269)

Agonist affinity
α_2-Adrenoceptor, prejunctional; Imidazolidine compound; Agonist efficacy; (Operational model) (Sallés, J. (258) 229)

Agonist efficacy
α_2-Adrenoceptor, prejunctional; Imidazolidine compound; Agonist affinity; (Operational model) (Sallés, J. (258) 229)

Agonist, full or partial
Adenosine A_1 receptor; Intrinsic activity; Receptor binding thermodynamics (Borea, P.A. (267) 55)

Agonist potency
Morphine; Morphine-6-glucuronide; Ileum, guinea-pig (Schmidt, N. (255) 245)

Airway
BAY x1005; Leukotriene; FLAP (five lipoxygenase activating protein) inhibitor; (Guinea pig) (Gardiner, P.J. (258) 95)

Kinin; Tachykinin; Antigen; Plasma extravasation; Neutral endopeptidase (Ricciardolo, F.L.M. (261) 127)

Airway, guinea-pig
Smooth muscle, airway; VIP (vasoactive intestinal polypeptide) (Iriarte, M.-C.F. (250) 295)

Airway hyperreactivity
Cigarette smoke; Bronchoalveolar lavage; Leukotriene B_4; IdB 1031 (Hernandez, A. (270) 301)

Airway hyperresponsiveness
Platelet activating factor (PAF); Airway inflammation; Plasma protein extravasation; Xanthine; Isbufylline (Manzini, S. (249) 251)

Respiratory viral infection; Airway sensory C fibers; Neurogenic inflammation; Substance P (Kudlacz, E.M. (270) 291)

Airway inflammation
Platelet activating factor (PAF); Airway hyperresponsiveness; Plasma protein extravasation; Xanthine; Isbufylline (Manzini, S. (249) 251)

Allergic reaction, early and late; Bronchial hyperreactivity; Mepyramine; Histamine; (Allergic guinea-pig) (Santing, R.E. (254) 49)

Allergic asthma; Bronchial hyperreactivity; Tracheal smooth muscle function; (Guinea pig model) (Santing, R.E. (257) 145)

Airway microvascular leakage
Sympathetic nerve; Histamine H_3 receptor (Danko, G. (254) 283)

Airway obstruction
Asthma; Edema; Plasma exudation; Aging; Leukotriene; Thromboxane A_2; Vascular permeability; Arachidonic acid (Arakawa, H. (259) 251)

Airway sensory C fibers
Respiratory viral infection; Neurogenic inflammation; Substance P; Airway hyperresponsiveness (Kudlacz, E.M. (270) 291)

Airway, human
Capsaicin; Toluene diisocyanate (Chitano, P. (270) 167)

(+)-AJ76
Microdialysis; Dopamine, release; (+)-UH232; (Rat) (Waters, N. (251) 181)

Alcohol
Nitric oxide (NO); Single breath; Respiratory system; Toxicity; Blood pressure; (Lung); (Pharmacology) (Persson, M.G. (270) 273)

Alcohol drinking
Adrenalectomy; Angiotensin II; Renin-angiotensin system; Aldosterone; Salt appetite; Saline drinking (Saab, G. (256) 1)

Aldose reductase inhibitor
Laser Doppler flowmetry; Motor nerve conduction velocity; Nerve blood flow; Polyol pathway; Streptozotocin-induced diabetes (Calcutt, N.A. (251) 27)

Aldosterone
Angiotensin II receptor antagonist; TCV-116; CV-11974 (Wada, T. (253) 27)

Adrenalectomy; Angiotensin II; Renin-angiotensin system; Alcohol drinking; Salt appetite; Saline drinking (Saab, G. (256) 1)

Allergic asthma
Bronchial hyperreactivity; Tracheal smooth muscle function; Airway inflammation; (Guinea pig model) (Santing, R.E. (257) 145)

Allergic reaction, early and late
Bronchial hyperreactivity; Airway inflammation; Mepyramine; Histamine; (Allergic guinea-pig) (Santing, R.E. (254) 49)

Allergy
Asthma; Anhydride; Cyclosporin A; Glucocorticoid; Sensitization (Arakawa, H. (252) 313)

Allergy and immunology
Muscarinic receptor; Smooth muscle, airway; Bronchodilator agent; (Guinea pig) (Howell, R.E. (265) 67)

Allopurinol
TEI-6720; Xanthine oxidase inhibitor; Uric acid; Hypouricemic effect; (Chimpanzee) (Komoriya, K. (250) 455)

Allosteric interaction
Polyamines; [^{3}H]L-689,560 binding; Glycine; NMDA receptor (Grimwood, S. (266) 43)

Allosteric mechanism
Dopamine D_1 receptor; [^{3}H]SCH 23390; Dissociation kinetics; Striatum (Rat) (Farrell, C.B. (268) 79)

Alloxan
FTS (facteur thymique sérique); Thymic hormone; Thymic immunity (Yamanouchi, T. (257) 39)

***N*-Allylnormetazocine**
DTG (di-*o*-tollylguanidine); SKF10047; σ Receptor; Red nucleus; Movement disorder; Dystonia (Weissman, A.D. (250) 329)

Alprazolam
Imipramine; Propranolol; Forced swimming test, modified; (Rat) (Abel, E.L. (258) 261)

Alzheimer's disease
Serum amyloid P component; Cerebral culture; Cerebral cortex, rat; Cell death (Urbányi, Z. (270) 375)

Ambulation
Methamphetamine; Repeated administration; Sensitization; Haloperidol (Kuribara, H. (256) 295)

Amiloride
Trachea; Epithelium; Smooth muscle; ATP; DIDS (4,4′-diisothiocyano-stilbene-2,2′-disulfonic acid) (Fedan, J.S. (256) 51)

$GABA_B$ receptor; Baclofen; Neocortical slice, rat; Amiloride analog; (Mg^+-free Krebs medium) (Ong, J. (260) 73)

Amiloride analog
$GABA_B$ receptor; Baclofen; Neocortical slice, rat; Amiloride; (Mg^+-free Krebs medium) (Ong, J. (260) 73)

Amino acid
Uptake; Carrier; Glutamate transporter; Proximal tubule; Kidney; In situ hybridization; (Rabbit) (Meister, B. (267) 323)

Aminoglycoside
Loop of Henle; Tubular transport; Micropuncture, in vivo; Microperfusion, in vitro (Kidwell, D.T. (270) 97)

Aminoguanidine
N,*N*′-Diaminoguanidine; Methylguanidine; 1,1-Dimethylguanidine; Nitric oxide (NO); Nitric oxide synthase; N^G-Monomethyl-L-arginine; (L-NMA) (Hasan, K. (249) 101)

Aminopeptidase M
Thrombin; Thrombin receptor; Peptide; (Rabbit) (Godin, D. (253) 225)

L-2-Amino-4-phosphonobutyrate
MCPG (α-methyl-4-carboxyphenylglycine); Excitatory amino acid receptor; Presynaptic; cAMP; Glutamate; Receptor; Metabotropic; (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

2-Amino-3-phosphonopropionate
Metabotropic glutamate receptor; Long-term potentiation; Dentate gyrus; (Anesthetized rat) (Abe, K. (251) 295)

L-2-Amino-3-phosphonopropionate
Neurotoxicity; Cerebellar neurons; Metabotropic glutamate receptor; NMDA receptor (Novelli, A. (270) 361)

Aminophylline
Pentoxifylline; Mesenteric resistance vessel; Endothelium; Nitric oxide (NO); Smooth muscle, vascular; Methylxanthine derivative (Hansen, P.R. (261) 105)

***N*-(3-Aminopropyl)-cyclohexylamine**
Polyamine; NMDA receptor; Seizure (Chu, P.-j. (256) 155)

4-Aminopyridine
Quinine; Morphine; Dopamine release; Behavioural activity; Nucleus accumbens (Pei, Q. (249) 243)

Carbachol; Phenylephrine; Atrium, left; Negative inotropy; $^{86}Rb^+$ efflux; Pertussis toxin (Ray, A. (256) 311)

5-Amino-salicylic acid
Experimental colitis; PAF (platelet activating factor) (Zijlstra, F.J. (249) R1)

21-Aminosteroid (U-74389G)
Antioxidant enzyme; Brain ischemia/reperfusion (Farbiszewski, R. (270) 263)

Amiodarone
Triiodothyronine; β-Adrenoceptor; Cardiomyocyte; (Chicken) (Yin, Y. (261) 97)

Ammonium compound
Neuromuscular blocking drug; Acetylcholine receptor; skeletal muscle (Danilov, A.F. (257) 1)

Amnesia
σ Receptor ligand; SKF-10,047; DTG (1,3-di-(2-tolyl)guanidine); Benzomorphan-type σ receptor; Acetylcholinergic neuronal system; *p*-Chloroamphetamine; Passive avoidance task; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperizine); (Mouse) (Matsuno, K. (261) 43)

5′-AMP
NMDA; IBMX (3-isobutyl-1-methylxanthine) phosphodiesterase; Adenosine; cAMP; (*N*-methyl-D-aspartate); (Release) (Craig, C.G. (269) 79)

cAMP
CD-832; Ca^{2+} channel antagonist; cGMP; Aorta vasodilatation; (Rabbit) (Miyata, N. (249) 141)

[^{3}H]Rauwolscine; α_2-Adrenoceptor; Myometrium; Inositol phosphate; (Guinea-pig) (Haynes, J.M. (250) 231)

Atriopeptin II; Isoproterenol; cGMP; Smooth muscle; Aorta, rat (Jang, E.K. (250) 477)

Aorta, rat; KT2-734 (2-phenyl-8-ethoxycycloheptimidazole); cAMP-phosphodiesterase; Vasorelaxation (Satake, N. (251) 1)

Ca^{2+} concentration, intracellular; β_1-Adrenoceptor; Thromboxane A_2; Ca^{2+} sensitivity of contractile elements; Coronary artery (Yamagishi, T. (251) 253)

Glycerol release; Brown adipose tissue; β-Adrenoceptor; Thermogenesis; Obesity (Nisoli, E. (259) 181)

Chronic mild stress; Depression model, rat; Imipramine, chronic; β-Adrenoceptor; Sucrose intake (Papp, M. (261) 141)

Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); Neuropeptide Y; Nitroprusside; Milrinone; cGMP; Acetylcholine (Modin, A. (261) 185)

β-Adrenoceptor; Salmeterol; Thromboxane A_2; Macrophage (Baker, A.J. (264) 301)

NMDA (*N*-Methyl-D-aspartate); Nitric oxide (NO); Forskolin; Protein kinase A (Toms, N.J. (266) 63)

Indapamide; β-Adrenoceptor stimulation; Cardiomyocyte (chick, embryonic); Forskolin; Cholera toxin (Rabkin, S.W. (266) 117)

α_2-Adrenoceptor subtype; [^{3}H]Rauwolscine; Ligand binding; Signal transduction (Jansson, C.C. (266) 165)

MCPG (α-methyl-4-carboxyphenylglycine); Excitatory amino acid receptor; Presynaptic; Glutamate; Receptor; Metabotropic; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

Phosphoinositide; Arachidonic acid; Ca^{2+} imaging; G protein; AF102B (Gurwitz, D. (267) 21)

Metabotropic glutamate receptor; Phenylglycine derivative; (1*S*,3*R*)-ACPD (1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate; Phosphoinositide hydrolysis (Thomsen, C. (267) 77)

Colonic cell line, human; Mucus secretion; Cytokine regulation; Interferon-γ; MUC2 mucin gene (Jarry, A. (267) 95)

Angiotensin II; mRNA; Ca^{2+} concentration, intracellular; Smooth muscle, vascular; (Down-regulation) (Chen, X. (267) 175)

Adenosine A_2 receptors; KF17837 ((*E*)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine); Binding assays (Nonaka, H. (267) 335)

Photoaffinity labelling; Cyclic GMP-inhibited phosphodiesterase (PDE III); Platelet; Phosphodiesterase inhibitor (Tang, K.M. (268) 105)

Cardiomyocyte, intact; Isoproterenol; β-Adrenoceptor; Desensitization; Forskolin (Murphy, M.G. (268) 121)

Guanosine cyclic monophoshate; NANC (non-adrenergic, non-cholinergic) nerve; Nitric oxide (NO); Urethra; Detrusor (Persson, K. (268) 159)

Metabotropic glutamate receptor; Spinal cord, isolated; Phosphoinositide hydrolysis; ACPD((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); L-CCG-I((2*S*,1′*S*,2′*S*)-CCG); Cortical cell culture (Ishida, M. (268) 267)

Nimesulide; Polymorphonuclear leukocyte; Phosphodiesterase type IV; Superoxide anion; Chemotaxis (Bevilacqua, M. (268) 415)

P_2^U purinoceptor; Protein kinase C; Ca^{2+}; Pertussis toxin; DDT_1 MF-2 cell (Sipma, H. (268) 431)

Metabotropic glutamate receptor; Carboxyphenylglycine (Cavanni, P. (269) 9)

Neurosteroid; Brain cortex, rat; Diazepam binding inhibitor (DBI) receptor, mitochondrial; Protein synthesis inhibitor; Adrenalectomy/orchidectomy (Roscetti, G. (269) 17)

NMDA; IBMX (3-isobutyl-1-methylxanthine) phosphodiesterase; Adenosine; 5′AMP; (*N*-methyl-D-aspartate); (Release) (Craig, C.G. (269) 79)

Galanin; Human cell line; Bowes cell line; Binding; Galantide (Heuillet, E. (269) 139)

Parietal cell (rat); Hydrogen ion production; Radioligand binding; Covalent cross-linking (Schepp, W. (269) 183)

Glutamate; Phosphoinositide; *trans*-ACPD (1-aminocyclopentane-*trans*-1,3-dicarboxylic acid); L-*trans*-2,4-PDC (L-*trans*-2,4-pyrrolidine dicarboxylic acid); Glutamate transport; (+)-α-Methyl-4-carboxyphenylglycine (Miller, S. (269) 235)

Imidazoline receptor; α_2-Adrenoceptor; Brainstem; Cerebral cortex; Inositol phosphate (Regunathan, S. (269) 273)

PTHrP (parathyroid hormone-related protein); Cytosolic free Ca^{2+}; Fura-2; Aortic spiral preparation, rat (Ishikawa, M. (269) 311)

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
NMDA (*N*-methyl-D-aspartate); MK-801 (dizocilpine) (Löscher, W. (259) R3)

Epilepsy; Felbamate; Audiogenic seizure; Glycine/NMDA receptor; (DBA/2 mouse) (De Sarro, G. (262) 11)

Cerebral ischemia; Glutamate; NMDA (*N*-methyl-D-aspartate); Microdialysis; Excitotoxin (Gaspary, H.L. (262) 197)

NMDA (*N*-methyl-D-aspartate); Neurotoxicity; Glucocorticoid; Dexamethasone; Postnatal (Supko, D.E. (270) 105)

cAMP accumulation
Dopamine D_3 receptor; Dopamine D_2 receptor; Receptor binding; Arachidonic acid release; Inositol phosphate (MacKenzie, R.G. (266) 79)

cAMP analog
Nitric oxide (NO); Cholera toxin; Peritoneal macrophage; (Rat) (Sowa, G. (266) 125)

AMPA receptor
Dopamine release; Kainic acid; Neurotoxicity; Glutamic acid; NMDA receptor (Fedele, E. (249) 71)

Haloperidol-induced catalepsy; GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5*H*-2,3-benzodiazepine HCl); CGP 37849 (DL-(*E*)-2-amino-4-methyl-5-phosphono-3-pentenoic acid); NMDA receptor; (Rat) (Hauber, W. (256) 339)

Glutamate; Atrium, rat; Sympathetic neurotransmission (Lorenzo, P.S. (258) 253)

Barbiturate; Glutamate receptor (Taverna, F.A. (267) R3)

AMPA receptor antagonist
NMDA receptor antagonist; BAY k-8644; Seizure (Czuczwar, S.J. (264) 103)

cAMP-dependent protein kinase
8-Br-cGMP; Nitroglycerin; Rp-8-Br-cGMPS; 8-Br-cAMP; Aorta, rabbit; cGMP-dependent protein kinase (Nakazawa, M. (253) 179)

cGMP-dependent protein kinase; Protein kinase C; 5-HT (5-hydroxytryptamine, serotonin) uptake; Imipramine binding (Helmeste, D.M. (267) 239)

Amperozide
Prolactin; 5-HT receptor; (Rat) (Albinsson, A. (251) 157)

Dopamine D_2 receptor; Striatum; Limbic forebrain (Svartengren, J. (254) 73)

Schedule-induced polydipsia; Anxiety (Tung, C.-S. (256) 193)

Amphetamine
Cocaine; Motor activity; δ-Opioid receptor antagonist; Opioid-dopamine interaction (Jones, D.N.C. (249) 167)

5-HT (5-hydroxytryptamine, serotonin); Methamphetamine; Nimodipine; Tryptophan hydroxylase; (Metabolism) (Elkins, K.W. (250) 395)

Behavioral clamping; Cortical lesion; Haloperidol; Neostriatum; Unit activity (Tschanz, J.A.T. (257) 161)

NMDA receptor antagonist, competitive; CGS 19755 (*cis*-4-(phosphonomethyl)piperidine-2-carboxylic acid); Dopamine synthesis; Hyperactivity; (±)-CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Bristow, L.J. (264) 353)

In situ hybridization; 5-HT transporter; Image analysis; 5-HT (5-hydroxytryptamine, serotonin); Uptake site (Rattray, M. (268) 439)

***d*-Amphetamine**
Acetylcholine; Cortex; Dopamine; 6-Hydroxydopamine; Noradrenaline (Day, J.C. (263) 285)

Dopamine; Electrophysiology; Receptor; Antipsychotic; (Rat) (Shepard, P.D. (265) 141)

Amphetamine, protection
Methamphetamine; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Dopaminergic neurotoxicity; MPP^+ (1-methyl-4-phenylpyridinium), uptake inhibition (Sziráki, I. (251) 311)

cAMP-phosphodiesterase
Aorta, rat; KT2-734 (2-phenyl-8-ethoxycycloheptimidazole); cAMP; Vasorelaxation (Satake, N. (251) 1)

cAMP production
Transfected cell; Receptor agonist exposure; Receptor internalization; Phosphatidylinositol hydrolysis; Down-regulation; Muscarinic M_1 receptor; Muscarinic M_2 receptor (Wei, H.-B. (268) 381)

Amygdala
Elevated plus-maze test; Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Mianserin; Eltoprazine; 5-HT_{2C} receptor; Autoradiography; In situ hybridization histochemistry; Limbic system (Rocha, B. (262) 125)

Morphine withdrawal; Morphine dependence; Adenylyl cyclase; Locus coeruleus; Thalamus (Matsuoka, I. (268) 215)

Analgesia
Epibatidine; Nicotinic receptor (Qian, C. (250) R13)

Calcitonin; 5-HT (5-hydroxytryptamine, serotonin); *p*-Chlorophenylalanine; *p*-Chloroamphetamine; Acetic acid test (Colado, M.I. (252) 291)

Morphine, blood level; Dependence; Opiate; Tolerance; Withdrawal (Gold, L.H. (253) 45)

Electroconvulsive shock; Ca^{2+} channel; Apomorphine; Nifedipine; Hyperalgesia; Hot-plate test; Hypermotility; (Rat) (Antkiewicz-Michaluk, L. (254) 9)

Morphinan; Opioid receptor; Receptor conformation (Lemaire, S. (258) 111)

κ-Opioid receptor agonist; U-50,488H; L-Tyrosine; L-Tryptophan; Tail-flick test (Barjavel, M.J. (258) 173)

Antisense oligodeoxyribonucleotide; Opioid receptor second messenger (Raffa, R.B. (258) R5)

Morphine; Δ^9-Tetrahydrocannabinol; Tolerance; Hypothermia; Cross-tolerance; [^{3}H]DAMGO ([^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin), B_{max}, K_d; Brain; Spinal cord (Thorat, S.N. (260) 5)

Indomethacin; Norepinephrine; β-Endorphin; Phentolamine; Naloxone; Pain (Hu, X.-H. (263) 53)

Morphine; Selective breeding; Tail flick assay; Tolerance (Lutfy, K. (265) 171)

Anandamide
Δ^9-Tetrahydrocannabinol; Muscimol; Globus pallidus; Catalepsy; Drug interaction (Wickens, A.P. (250) 205)

Cannabinoid; Δ^9-Tetrahydrocannabinol; Cannabinoid, endogenous; Vas deferens, mouse; Tolerance (Pertwee, R. (259) 115)

Anaphylaxis
Leukotriene; Paw edema; (Mouse) (Zuany-Amorim, C. (257) 211)

Anaphylaxis, mouse
Blood pressure; Histamine; Nitric oxide (NO) (Osada, S. (252) 347)

Anesthesia, theories of
Anesthetic; Synaptic transmission; Spinal cord; Glutamate receptor; NMDA receptor; $GABA_A$ receptor (Kendig, J.J. (264) 427)

Anesthetic
Nitric oxide (NO); N^G-Nitro-L-arginine methylester (L-NAME); Cerebral blood flow; Halothane (Dawson, D.A. (249) 7)

Receptor; Stereoisomer; Isoflurane; (Rat) (Lysko, G.S. (263) 25)

Anesthesia, theories of; Synaptic transmission; Spinal cord; Glutamate receptor; NMDA receptor; $GABA_A$ receptor (Kendig, J.J. (264) 427)

ANF (atrial natriuretic factor)
cGMP; Guanylyl cyclase; ANF receptor antagonist; Hypoxia; Hypoxic coronary vasodilatation; Heart, isolated, guinea pig; Nitric oxide (NO) (Park, K.H. (256) 99)

cGMP; HS-142-1; K^+ channel; Glibenclamide; Y-26763; Cromakalim; *Xenopus* oocyte (Sakuta, H. (267) 281)

ANF receptor antagonist
ANF (atrial natriuretic factor); cGMP; Guanylyl cyclase; Hypoxia; Hypoxic coronary vasodilatation; Heart, isolated, guinea pig; Nitric oxide (NO) (Park, K.H. (256) 99)

Angiogenesis
Leukotriene; Chorioallantoic membrane; (Chick) (Tsopanoglou, N.E. (258) 151)

Angiogenic disorder
Retinoid (synthetic); Cell differentiation modulator; Anti-angiogenic action; Embryonic angiogenesis (Oikawa, T. (249) 113)

Angiotensin
Pentobarbital; Chlordiazepoxide; Blood pressure; (Spontaneously hypertensive rat (SHR)) (Sim, M.K. (253) 171)

Vas deferens; Prostacyclin; Angiotensin AT_1 receptor; (Rabbit) (Catalioto, R.-M. (256) 93)

Angiotensin-(1–7)
Angiotensin II; Angiotensin-(3–8)/angiotensin IV; Vasoconstriction; Pulmonary circulation; Angiotensin AT_1 receptor antagonist; Angiotensin AT_2 receptor antagonist (Cheng, D.Y. (261) 223)

des-Asp-Angiotensin I
Angiotensin III; Spontaneously hypertensive rat (SHR) (Sim, M.K. (257) R1)

Angiotensin II
SR 47436; DuP 753; Smooth muscle cell; Proliferation (Herbert, J.-M. (251) 143)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Kidney (Macari, D. (249) 85)

ANP (atrial natriuretic peptide); Chronotropic effect; (Dog model) (Lambert, C. (252) 245)

Renal artery, rabbit; Losartan; PD123177 (Zhang, J. (252) 337)

Adrenalectomy; Renin-angiotensin system; Aldosterone; Alcohol drinking; Salt appetite; Saline drinking (Saab, G. (256) 1)

Artery, rabbit; Nandrolone; Vascular reactivity; Noradrenaline; 5-HT (5-hydroxytryptamine, serotonin) (Ferrer, M. (258) 103)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Kidney (Macari, D. (259) 27)

Angiotensin III; Spontaneously hypertensive rat (SHR); Losartan (DuP 753); Telemetry (Radhakrishnan, R. (259) 87)

Acetylcholine; Adenosine; Atrium; Contractility; α-CGRP (calcitonin gene-related peptide); Somatostatin; Ventricle; (Human) (Du, X.Y. (259) 173)

Sympathetic nervous system; α_1-Adrenoceptor; Valsartan; PD 123319 (Marano, G. (261) 121)

Angiotensin-(3–8)/angiotensin IV; Angiotensin-(1–7); Vasoconstriction; Pulmonary circulation; Angiotensin AT_1 receptor antagonist; Angiotensin AT_2 receptor antagonist (Cheng, D.Y. (261) 223)

EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Aorta, rabbit; N^G-Monomethyl-L-arginine; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester; Indomethacin (Zhang, J. (262) 247)

Angiotensin AT_1 receptor; α_2-Adrenoceptor; Nucleus tractus solitarii; Autoradiography; Blood pressure (Fior, D.R. (262) 271)

Antidepressive agent; Drinking behavior (Gard, P.R. (264) 295)

mRNA; Ca^{2+} concentration, intracellular; Smooth muscle, vascular; cAMP; (Down-regulation) (Chen, X. (267) 175)

Angiotensin receptor; Human placental lactogen; Pregnancy-specific β_1-glycoprotein; Placenta (Kalenga, M.K. (268) 231)

Xenopus laevis oocyte; Vanadate; Pertussis toxin; Ca^{2+}; Desensitization; LiCl (Sakuta, H. (268) 305)

[^{125}I][Sar^1-Ile^8]Angiotensin-II
Angiotensin AT_1 receptor antagonist; [^{3}H]A-81988 (Hancock, A.A. (267) 49)

Angiotensin III
des-Asp-Angiotensin I; Spontaneously hypertensive rat (SHR) (Sim, M.K. (257) R1)

Angiotensin II; Spontaneously hypertensive rat (SHR); Losartan (DuP 753); Telemetry (Radhakrishnan, R. (259) 87)

Angiotensin-(3–8) / angiotensin IV
Angiotensin II; Angiotensin-(1–7); Vasoconstriction; Pulmonary circulation; Angiotensin AT_1 receptor antagonist; Angiotensin AT_2 receptor antagonist (Cheng, D.Y. (261) 223)

Angiotensin-converting enzyme
Neutral endopeptidase; Captopril; SCH 34826; Heart failure; (Rat) (Helin, K. (264) 135)

Angiotensin-converting enzyme (binding site, active site)
Angiotensin converting enzyme inhibitor (Perich, R.B. (266) 201)

Angiotensin-converting enzyme inhibitor
Endothelium; EDRF (endothelium-derived relaxing factor); Bradykinin; Captopril (Hirano, K. (250) 439)

α_1-Adrenoceptor, vascular; Ca^{2+} channel antagonist; Receptor reserve; Phenoxybenzamine (Tabrizchi, R. (251) 15)

Angiotensin converting enzyme (binding site, active site) (Perich, R.B. (266) 201)

Angiotensin receptor
Angiotensin II; Human placental lactogen; Pregnancy-specific β_1-glycoprotein; Placenta (Kalenga, M.K. (268) 231)

Angiotensin AT_1 receptor
Angiotensin AT_2 receptor; Angiotensin II; Kidney (Macari, D. (249) 85)

Angiotensin; Vas deferens; Prostacyclin; (Rabbit) (Catalioto, R.-M. (256) 93)

Angiotensin AT_2 receptor; Angiotensin II; Kidney (Macari, D. (259) 27)

Blood pressure; Goldblatt hypertension (Železná, B. (260) 95)

Angiotensin II; α_2-Adrenoceptor; Nucleus tractus solitarii; Autoradiography; Blood pressure (Fior, D.R. (262) 271)

Angiotensin AT_2 receptor
Angiotensin AT_1 receptor; Angiotensin II; Kidney (Macari, D. (249) 85)

Angiotensin AT_1 receptor; Angiotensin II; Kidney (Macari, D. (259) 27)

Angiotensin receptor antagonist
Tachykinin NK_3 receptor; Neurokinin B; Brain, rat; Brain, guinea pig (Chrétien, L. (256) 73)

Angiotensin AT_1 receptor antagonist
Angiotensin II; Angiotensin-(3–8)/angiotensin IV; Angiotensin-(1–7); Vasoconstriction; Pulmonary circulation; Angiotensin AT_2 receptor antagonist (Cheng, D.Y. (261) 223)

Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; L158809; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

SR 47436 (BMS-186295); Genetic hypertension; Renal hypertension; (Rat) (Lacour, C. (264) 307)

[^{3}H]A-81988; [^{125}I][Sar^1-Ile^8]angiotensin-II (Hancock, A.A. (267) 49)

Angiotensin AT_2 receptor antagonist
Angiotensin II; Angiotensin-(3–8)/angiotensin IV; Angiotensin-(1–7); Vasoconstriction; Pulmonary circulation; Angiotensin AT_1 receptor antagonist (Cheng, D.Y. (261) 223)

Angiotensin II receptor antagonist
Aldosterone; TCV-116; CV-11974 (Wada, T. (253) 27)

Angiotensin receptor subtype
Losartan; PD 123319; Footshock (Cierco, M. (251) 103)

Angiotensin II receptor subtype
Antihypertensive agent; Losartan; Renin-angiotensin system (Wong, P.C. (260) 261)

Anhedonia
Depression, animal model; MK-801; CGP 37849; CGP 40116; Imipramine; (Rat) (Papp, M. (263) 1)

Anhydride
Asthma; Allergy; Cyclosporin A; Glucocorticoid; Sensitization (Arakawa, H. (252) 313)

Animal model
Anxiety; Benzodiazepine withdrawal; Elevated plus-maze; Valepotriate (Andreatini, R. (260) 233)

Anococcygeus muscle
Nifedipine; Adrenergic transmission; Ca^{2+} channel antagonist (Iravani, M.M. (250) 193)

Anorexia
Nitric oxide (NO); Serotonergic system; Brain; Zucker rat (Squadrito, F. (255) 51)

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; 5-HT (5-hydroxytryptamine, serotonin); Tryptophan; Plasma-free tryptophan; Strain difference; (Brain) (Unkila, M. (270) 157)

Anoxia
Granule cell culture; Glutamate release (Dessi, F. (250) 325)

ANP (atrial natriuretic peptide)
Angiotensin II; Chronotropic effect; (Dog model) (Lambert, C. (252) 245)

Tyrosine kinase; Genistein; Contractile force; Coronary tone; Ca^{2+}, intracellular (Taskinen, P. (256) 251)

Growth factor; aFGF (acidic fibroblast growth factor); Protein kinase C; Staurosporine; Phorbol ester (Tokola, H. (267) 195)

Natriuretic peptide, C-type; Guanylate cyclase; LLC-PK_1 cell (Hashimoto, Y. (268) 443)

Antagonist
Substance P; Septide; Tachykinin NK_1 receptor; Proline, β-substituted (Lavielle, S. (258) 273)

Tachykinin; Neurokinin; CHO (Chinese hamster ovary) cell; Structure-activity; Ca^{2+}; Second messenger; Inositol phosphate; Thapsigargin; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

Anterior thalamus
Melatonin; Limbic system; Receptor autoradiography; Pineal gland (Lindroos, O.F.C. (250) 161)

Antiaggregator
Vasodilator; Furoxan; cGMP; Nitric oxide (NO) (Civelli, M. (255) 17)

Antiallergic agent
Cytokine production, in vitro; Interleukin-2; Interleukin-3; Interleukin-4; Interleukin-5; Peripheral blood leukocyte, human (Konno, S.-i. (264) 265)

Antiallergic drug
Mast cell; Cytology; Drug effect (Konno, S.-i. (259) 15)

Antiangiogenic action
Retinoid (synthetic); Cell differentiation modulator; Embryonic angiogenesis; Angiogenic disorder (Oikawa, T. (249) 113)

Antiangiogenic agent
Titanocene dichloride; Antitumor agent (Bastaki, M. (251) 263)

Antianxiety action
Ca^{2+} channel antagonist; Conflict behavior; (Rat) (Matsumoto, Y. (264) 107)

Antiarrhythmic agent, class III
K^+ channel (Busch, A.E. (264) 33)

Antiarrhythmic / proarrhythmic effect
BRL-38227; Glibenclamide; Myocardial ischemia (Bellemin-Baurreau, J. (256) 115)

Antibody
Endothelin; Cardiac tissue; Endothelin receptor (Shannon, T.R. (267) 233)

Anticancer drug-induced vomiting
5-HT_3 receptor antagonist; Visceral afferent (Fukui, H. (250) 281)

Anticholinesterase
Nerve terminal current; Cholinomimetic; Acetylcholine (Shakiryanova, D.M. (263) 107)

Anticonvulsant
Zonisamide; Brain, neonatal, rat; Hypoxia-ischemia, cerebral; Infarction, cerebral; Hypoxic seizure (Hayakawa, T. (257) 131)

Anticonvulsant effect
Fluoxetine; 5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Genetically epilepsy-prone rat (Yan, Q.-S. (252) 105)

Antidepressant
Imipramine; α-Methyl-*para*-tyrosine; Learned helplessness (De Montis, M.G. (249) 179)

Benzodiazepine receptors, peripheral type; Imipramine; Phenelzine sulfate; [^{3}H]PK 11195 (Weizman, R. (250) 289)

Hypothalamo-pituitary-adrenal axis; Stress; Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); CRF (corticotropin-releasing factor); ACTH (adrenocorticotropin); Corticosterone (Delbende, C. (251) 245)

Chronic variable stress; Morphine; Locomotor activity (Molina, V.A. (260) 57)

Selective serotonin reuptake inhibitor; 5-HT_{1A} autoreceptor; Microdialysis, in vivo; 5-HT (5-hydroxytryptamine, serotonin) release; Central nervous system (Hjorth, S. (260) 251)

$GABA_A$ receptor; $GABA_B$ receptor; β-Adrenoceptor; Olfactory bulbectomy; Brain, rat (Dennis, T. (262) 143)

Hypothalamic-pituitary-adrenal axis; Inflammation; 5-HT (5-hydroxytryptamine, serotonin) (Bianchi, M. (263) 81)

5-HT (5-hydroxytryptamine, serotonin) release; Monoamine oxidase inhibitor; Microdialysis, intracerebral (Ferrer, A. (263) 227)

Angiotensin II; Drinking behavior (Gard, P.R. (264) 295)

Chromaffin cell; Catecholamine; Ca^{2+} channel; Nicotine; Histamine (Firestone, J.A. (269) 177)

Antidepressant activity
SR 57746A (4-(3-trifluoromethylphenyl)-*N*-[2-(naphth-2-yl)ethyl]-1,2,3,6-tetrahydropyridine HCl); 5-HT_{1A} receptor; Adenylate cyclase activity; Forced swimming test (Cervo, L. (253) 139)

Antidepressant (chronic treatment)
Dopamine uptake site; Locomotor activity; Apomorphine; Dopamine receptor (presynaptic) (Allison, K. (249) 125)

Antidepressant effect
Dopamine D_1 receptor agonist; Behavioral despair (D'Aquila, P.S. (262) 107)

Antidiabetic
CS-045; Fructose-2,6-bisphosphate; Hepatocyte; Tolbutamide (Murano, K. (254) 257)

Antiedema
CRF (corticotropin-releasing factor); ACTH (adrenocorticotropin) release; (Structure-activity relationship) (Wei, E.T. (263) 319)

Antiemetic
Tachykinin NK_1 receptor antagonist; CP-99,994 (Tattersall, F.D. (250) R5)

Morphine; Loperamide; 5-HT (5-hydroxytryptamine, serotonin); Nicotine; Vomiting; (*Suncus murinus*) (Selve, N. (256) 287)

Antiendothelin-1 serum
U-46619; Endothelin-1; ST elevation; Radioimmunoassay; (Rat) (Yamamoto, T. (250) 189)

Antiepileptic
CGP 37849; CGP 39551; Seizure (Pietrasiewicz, T. (250) 1)

Antiepileptic effect
Topiramate; Spontaneously epileptic rat (SER); Audiogenic seizure (Nakamura, J. (254) 83)

AntiE-selectin antibody
Selectin, E-; Myocardial ischemia-reperfusion injury; (Rat) (Altavilla, D. (270) 45)

Antiestrogenic activity
Breast cancer; Indole; Yuehchukene (Ng, P.C. (264) 1)

Antiflammin
Phospholipase A_2; Inflammation; Mast cell degranulation; Anti-inflammatory drug (Lloret, S. (264) 379)

Antigen
Kinin; Tachykinin; Plasma extravasation; Airway; Neutral endopeptidase (Ricciardolo, F.L.M. (261) 127)

Antigoitrogenic
Iodolactone; Goiter; Thyroid; Autoregulation (Pisarev, M.A. (258) 33)

Antihistamine
Calcimycin; EDCF (endothelium-derived contracting factor); EDRF (endothelium-derived relaxing factor); Hemoglobin; Iproniazid; Mast cell; Methylene blue; N^G-Methyl-L-arginine (Gruetter, C.A. (257) 275)

Antihypertensive agent
Angiotensin II receptor subtype; Losartan; Renin-angiotensin system (Wong, P.C. (260) 261)

Antihypertensive treatment
Metoprolol; GABA (γ-aminobutyric acid); GABA synthesis and turnover; $GABA_A$ receptor binding (Remiszewska, M. (250) 355)

Anti-inflammatory drug
Avarol; Avarone; Phospholipase A_2; Arachidonic acid metabolism; Superoxide generation; Peritoneal leukocyte (Ferrándiz, M.L. (253) 75)

Antiflammin; Phospholipase A_2; Inflammation; Mast cell degranulation (Lloret, S. (264) 379)

Antilipolytic
GR79236; Adenosine; (Rat) (Gardner, C.J. (257) 117)

Antinociception
Morphine; Morphine-3-glucuronide; Morphine-6-glucuronide; (Intrathecal) (Suzuki, N. (249) 247)

Lipopolysaccharide, *Pantoea agglomerans*; Diabetes; Naltrindole; Nor-binaltorphimine; β-Funaltrexamine; Opioid receptor (Kamei, J. (251) 95)

Opioid; δ-Opioid receptor subtype; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]Deltorphin; (Mouse) (Vanderah, T. (252) 133)

Caerulein; CCK-8 (cholecystokinin octapeptide); Morphine; Tolerance; (Unsulfated CCK-8) (Rezayat, M. (254) 21)

L-Arginine; Diabetes; Naltrindole; Nor-binaltorphimine; β-Funaltrexamine; Opioid receptor (Kamei, J. (254) 113)

Opioid peptide; Behavioral effect; Body temperature; Voltage-dependent Ca^{2+} channel; Verapamil; ω-Conotoxin GVIA (Spampinato, S. (254) 229)

NSAID (non-steroidal anti-inflammatory drug); Nabumetone; Inflammation (Clarke, G.D. (257) 103)

μ-Opioid receptor; κ-Opioid receptor; Visceral pain; Vagal afferent; (Rat) (Diop, L. (257) 181)

Lys-D-Pro-Thr; Lys-D-Pro; Interleukin-1β-(193–195); Tripeptide; Naloxone; Formalin test (Oluyomi, A.O. (258) 131)

Tolerance; *N*-Nitro-L-arginine methyl ester; Morphine; Thyrotropin (TSH); Prolactin; Growth hormone; Hyperthermia (Rauhala, P. (259) 57)

Buspirone; 1-PP (1-(2-pyrimidinyl)-piperazine); Clonidine; α_2-Adrenoceptor (Cao, B.-J. (259) 75)

Substance P, N-terminus; Flexor reflex; Pain (Goettl, V.M. (259) 83)

(+)-*cis*-Dioxolane; β-Endorphin; Tail-flick inhibition; Nitric oxide (NO); cGMP (Xu, J.Y. (262) 223)

$5\text{-}HT_{1A}$ receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Pain transmission; (Rat) (Cervo, L. (263) 187)

Nor-binaltorphimine; Tail-pressure test; Opioid receptor (Spanagel, R. (264) 157)

5-HT (5-hydroxytryptamine, serotonin); Supersensitivity; Spinal cord; 5,7-DHT (5,7-dihydroxytryptamine); (Rat) (Sawynok, J. (264) 249)

Antinociception, intrathecal
S-Flurbiprofen; *R*-Flurbiprofen; Formalin test; Spinal cord; Cyclooxygenase, inhibition (Malmberg, A.B. (256) 205)

S-Flurbiprofen; *R*-Flurbiprofen; Formalin test; Spinal cord; Cyclooxygenase, inhibition (Malmberg, A.B. (260) 283)

Antinociceptive effect
κ-Opioid receptor agonist; R-84760; U-50488; CI-977; Morphine (Fujibayashi, K. (261) 133)

Antioxidant
β-Adrenoceptor antagonist; Lipid peroxidation; Oxidative stress; Endothelial cell; Cerebellar neuron (Yue, T.-L. (251) 237)

Ca^{2+} channel antagonist, T-type; Neuronal ischemic injury; U-92032; Nifedipine; Flunarizine (Ito, C. (257) 203)

Trolox; SIN (3-morpholino sydnonimine); Nitric oxide (NO); cGMP; Prostaglandin; Leukotriene; Leukocyte (Riutta, A. (262) 217)

Antioxidant enzyme
21-Aminosteroid (U-74389G); Brain ischemia/reperfusion (Farbiszewski, R. (270) 263)

Antiproliferative effect
Baicalein; Flavonoid; Smooth muscle cell, vascular (Huang, H.-C. (251) 91)

Baicalein; Esculetin; CEM cell; Transduction signal; Messenger RNA expression (Huang, H.-C. (268) 73)

Antipsychotic
Adrenoceptor; Aporphine; Dopamine receptor; Partial agonist, receptor; 5-HT (5-hydroxytryptamine, serotonin); Stereoisomer (Baldessarini, R.J. (254) 199)

σ Receptor; Brain; Motor system; (Rat) (Leitner, M.L. (259) 65)

DOI ((2,5-dimethoxy-4-iodohenyl)-2-aminopropan); Drug discrimination; MDL 100,907; 5-HT_{2A} receptor (Schreiber, R. (264) 99)

Dopamine; Electrophysiology; Receptor; *d*-Amphetamine; (Rat) (Shepard, P.D. (265) 141)

Antisense oligodeoxynucleotide
κ-Opioid receptor; Opioid analgesia (Chien, C.-C. (253) R7)

δ-Opioid receptor; Tail-flick inhibition (Tseng, L.F. (258) R1)

Endothelin ET_A receptor; Temporal artery, human (Adner, M. (261) 281)

Antisense oligodeoxyribonucleotide
Analgesia; Opioid receptor second messenger (Raffa, R.B. (258) R5)

Antitumor agent
Titanocene dichloride; Antiangiogenic agent (Bastaki, M. (251) 263)

Antitussive effect
Naltrindole; δ-Opioid receptor; κ-Opioid receptor (Kamei, J. (249) 161)

Tachykinin NK_2 receptor; SR 48968; Cough reflex; Citric acid; (Guinea-pig) (Advenier, C. (250) 169)

BNTX (7-benzylidenenaltrexone); Naltriben; δ-Opioid receptor; DPDPE ([D-$Pen^{2,5}$]enkephalin); [D-Ala^2]Deltorphin II (Kamei, J. (251) 291)

[Met^5]Enkephalin-Arg^6-Phe^7; κ-Opioid receptor; (Mouse) (Kamei, J. (253) 293)

Dihydroetorphine; Cough; Opioid receptor; (Mouse) (Kamei, J. (260) 257)

Antiulcer agent
DTG (1,3-di(2-tolyl)guanidine); σ Receptor; Brain membrane; KB-5492; (Guinea-pig) (Harada, Y. (256) 321)

DTG (1,3-di(2-tolyl)guanidine); KB-5492; Mucosa; σ Receptor; SKF 10,047 (*N*-allyl-normetazocine); (Pig) (Harada, Y. (261) 91)

Antral G-cell
Muscarinic receptor subtype; Muscarinic M_3 receptor; Atropine; Hexahydro-sila-difenidol; Pirenzepine; AQ-RA 741 (Weigert, N. (264) 337)

Anxiety
CCK-8 (cholecystokinin octapeptide); GABA (γ-aminobutyric acid); Release; Brain; CCK receptor; (In vitro); (Slice) (Pérez de la Mora, M. (250) 423)

Tachykinin NK_2 receptor antagonist; Behavior (Stratton, S.C. (250) R11)

Amperozide; Schedule-induced polydipsia (Tung, C.-S. (256) 193)

Animal model; Benzodiazepine withdrawal; Elevated plus-maze; Valepotriate (Andreatini, R. (260) 233)

Elevated plus-maze; 5-HT_{1A} receptor; 5-HT_{1A} receptor antagonist; (*S*)-WAY 100135; (Mouse) (Rodgers, R.J. (261) 321)

Elevated plus-maze test; 5-HT (5-hydroxytryptamine, serotonin); Mianserin; Eltoprazine; 5-HT_{2C} receptor; Autoradiography; In situ hybridization histochemistry; Limbic system; Amygdala (Rocha, B. (262) 125)

Anxiolysis
Dorsal raphe nucleus; Hippocampus; 5-HT_{1A} receptor ligand (rat); Ultrasonic vocalization (Schreiber, R. (249) 341)

Anxiolytic
Glycine receptor ligand; NMDA (*N*-methyl-D-aspartate); NMDA receptor antagonist; ACPC (1-aminocyclopropanecarboxylate); D-Cycloserine (Anthony, E.W. (250) 317)

Loreclezole; Flumazenil; CGS 8216; (Rat) (Dawson, G.R. (252) 325)

Aorta
Pertussis toxin; Salbutamol; Arecoline; β-Adrenoceptor; Langendorff; (Rat) (Vleeming, W. (250) 415)

Mg^{2+}; Endothelium; Mineralocorticoid hypertension; (Rat) (Laurant, P. (258) 167)

Vasopressin; EDRF (endothelium-derived relaxing factor); Gonadal steroid hormone; Nitric oxide (NO); Vasoconstriction (Stallone, J.N. (259) 273)

Smooth muscle, vascular; Ca^{2+} channel; Binding; [^{3}H](+)-PN200-110; Spontaneously hypertensive rat (SHR) (Ikeda, S. (264) 223)

Aorta, guinea-pig
Endothelin; Sarafotoxin; BQ-123 (cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu)); Endothelin receptor subtype; Coronary artery (pig); Smooth muscle (vascular) (Schoeffter, P. (249) 199)

Aorta, rabbit
8-Br-cGMP; Nitroglycerin; Rp-8-Br-cGMPS; 8-Br-cAMP; cGMP-dependent protein kinase; cAMP-dependent protein kinase (Nakazawa, M. (253) 179)

Angiotensin II; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); N^G-Monomethyl-L-arginine; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester; Indomethacin (Zhang, J. (262) 247)

Bradykinin B_1 receptor; Smooth muscle cell; Des-Arg^{10}-kallidin (Schneck, K.A. (266) 277)

Atherosclerosis; Pulmonary artery, rabbit; Noradrenaline release; Sympathetic nerve stimulation; Noradrenaline metabolite (Verbeuren, T.J. (270) 27)

Aorta, rat
HA1077; H-7; Ca^{2+} level, cytosolic; Relaxation; Smooth muscle, vascular (Takizawa, S. (250) 431)

Atriopeptin II; Isoproterenol; cGMP; cAMP; Smooth muscle (Jang, E.K. (250) 477)

KT2-734 (2-phenyl-8-ethoxycycloheptimidazole); cAMP-phosphodiesterase; cAMP; Vasorelaxation (Satake, N. (251) 1)

Aclarubicin; Phosphatidylinositol; Vasoconstriction (Wakabayashi, I. (255) 111)

Diabetes mellitus; Noradrenaline; Caffeine; Ca^{2+}, mobilization of intracellular (Hattori, Y. (256) 215)

Quercetin; Staurosporine; Phasic contraction (Duarte, J. (262) 149)

Aorta vasodilatation
CD-832; Ca^{2+} channel antagonist; cGMP; cAMP; (Rabbit) (Miyata, N. (249) 141)

Aortic baroreceptor
Vasorelaxation; Endothelium; Adenosine receptor; EDRF (endothelium-derived relaxing factor); NECA (5′-*N*-ethylcarboxamidoadenosine); Nitric oxide (NO) (Fahim, M. (254) 183)

Aortic endothelial cell
Ca^{2+} concentration, intracellular, free; Cl^-, extracellular; Fura-2; Endothelium-dependent vasodilator (Hosoki, E. (266) 213)

Aortic ring
Salbutamol; Nitric oxide (NO); β_2-Adrenoceptor; N^G-Nitro-L-arginine methyl ester; Blood pressure; Endothelium (Wang, Y.-X. (250) 335)

Aortic ring, isolated, rat
Acetylcholine; 8-Bromo-cGMP; EDRF (endothelium-derived relaxing factor); Atrium, right, isolated, rat; LY-83,583 (6-(phenylamino)-5,8-quinolinedione); Norepinephrine; *N*-Nitro-L-arginine; SIN-1 (3-morpholino-sydnonimine); (Spontaneous rate) (Kennedy, R.H. (255) 149)

Aortic spiral preparation, rat
PTHrP (parathyroid hormone-related protein); Cytosolic free Ca^{2+}; Fura-2; cAMP (Ishikawa, M. (269) 311)

Apamin
Ca^{2+} activated; K^+ current (Dunn, P.M. (252) 189)

Patch-clamp technique; Action potential; Delayed rectifier K^+ current; Ventricular myocyte (Koumi, S.-i. (261) 213)

APNEA (N^6-2-(4-aminophenyl)ethyladenosine)
Adenosine A_1 receptor; Adenosine A_2 receptor; Adenosine A_3 receptor; Pertussis toxin (Carruthers, A.M. (250) 185)

Adenosine A_3 receptor; BW-A522 (Fozard, J.R. (252) R5)

Apneusis
Excitatory amino acid; MK-801 (dizocilpine); NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline); Respiratory activity (McManigle, J.E. (252) 11)

Apomorphine
Antidepressant (chronic treatment); Dopamine uptake site; Locomotor activity; Dopamine receptor (presynaptic) (Allison, K. (249) 125)

Electroconvulsive shock; Ca^{2+} channel; Nifedipine; Analgesia; Hyperalgesia; Hot-plate test; Hypermotility; (Rat) (Antkiewicz-Michaluk, L. (254) 9)

Penile erection; Yawning; Diabetic rat; Physostigmine; VIP (vasoactive intestinal polypeptide) (Yamaguchi, Y. (254) 91)

5-HT receptor agonist; 5-HT receptor antagonist; Oxytocin; Penile erection; Yawning; (Rat) (Stancampiano, R. (261) 149)

Jaw movement; Clozapine; Nucleus accumbens; Striatum; Muscarinic acetylcholine receptor (Kikuchi de Beltrán, K. (262) 49)

Dopamine receptor agonist; Dopamine receptor antagonist; Nicotinic receptor channel; *Xenopus* oocyte; Functional expression (Nakazawa, K. (269) 375)

Aporphine
Adrenoceptor; Antipsychotic; Dopamine receptor; Partial agonist, receptor; 5-HT (5-hydroxytryptamine, serotonin); Stereoisomer (Baldessarini, R.J. (254) 199)

Appetite
Neuropeptide Y; Megestrol acetate; Cancer anorexia; Cachexia; Hypothalamus (McCarthy, H.D. (265) 99)

AQ-RA 741
Antral G-cell; Muscarinic receptor subtype; Muscarinic M_3 receptor; Atropine; Hexahydro-sila-difenidol; Pirenzepine (Weigert, N. (264) 337)

Arachidonic acid
Phospholipase A_2; Uterine cell proliferation (Fayard, J.M. (251) 281)

Asthma; Edema; Plasma exudation; Aging; Leukotriene; Thromboxane A_2; Airway obstruction; Vascular permeability (Arakawa, H. (259) 251)

Phosphoinositide; cAMP; Ca^{2+} imaging; G protein; AF102B (Gurwitz, D. (267) 21)

5-Lipoxygenase-activating protein; 5-Lipoxygenase; Fatty acid; Leukotriene (Charleson, S. (267) 275)

Arachidonic acid metabolism
Avarol; Avarone; Anti-inflammatory drug; Phospholipase A_2; Superoxide generation; Peritoneal leukocyte (Ferrándiz, M.L. (253) 75)

Arachidonic acid metabolite, inhibition
Acetylsalicylic acid; Proliferative vitreoretinopathy; Fibroblast (Kähler, C.M. (262) 261)

Arachidonic acid release
Dopamine D_3 receptor; Dopamine D_2 receptor; Receptor binding; cAMP accumulation; Inositol phosphate (MacKenzie, R.G. (266) 79)

Arcaine
Polyamine; Spermine; Spermidine; 1,10-diaminodecane; Diethylenetriamine; Putrescine; *N*-Methyl-D-aspartate (NMDA); NMDA receptor; Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

Arecoline
Pertussis toxin; Salbutamol; Aorta; β-Adrenoceptor; Langendorff; (Rat) (Vleeming, W. (250) 415)

Arenobufagin
Toad venom; Delayed rectifier K^+ current; Cardiac myocytes (Dos Santos Cruz, J. (266) 317)

Arginine
Acetylcholine; Bradykinin; cGMP; Gentamicin; Nitric oxide (NO); (Rat) (Rivas-Cabañero, L. (270) 119)

L-Arginine
Antinociception; Diabetes; Naltrindole; Nor-binaltorphimine; β-Funaltrexamine; Opioid receptor (Kamei, J. (254) 113)

Uterine artery; Relaxation; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); (Human) (Jovanović, A. (256) 103)

Nitric oxide (NO); Gastric emptying; N^G-Nitro-L-arginine methyl ester; N^G-Monomethyl-L-arginine; Blood pressure (Plourde, V. (256) 125)

Granuloma; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; Macrophage (Iuvone, T. (265) 89)

Arterial reactivity
Interferon-γ; Bradykinin; Nitric oxide (NO) (De Kimpe, S.J. (261) 111)

Arterial smooth muscle relaxation
Cromakalim; K^+ channel, ATP-sensitive; K^+ channel, Ca^{2+}-activated; Spontaneously hypertensive rat (SHR) (Asano, M. (263) 121)

Arteriole
Naftidrofuryl; 5-HT (5-hydroxytryptamine, serotonin); Microcirculation; Cremaster muscle; Vasoconstriction; 5-HT_2 receptor antagonist (Koch, L.G. (254) 249)

Artery, bovine coronary
Glyceryl trinitrate; *S*-Nitroso-*N*-acetylpenicillamine; *S*-Nitroso-*N*-acetylcaptopril; Tolerance, in vitro; *S*-Nitrosothiols (Zhang, C.L. (252) 299)

Artery, human
Nitric oxide (NO); Adrenergic stimulation; Endothelium (Aldasoro, M. (250) 103)

Artery, rabbit
Nandrolone; Vascular reactivity; Noradrenaline; Angiotensin II; 5-HT (5-hydroxytryptamine, serotonin) (Ferrer, M. (258) 103)

Polymerase chain reaction; Saphenous vein, human; α_1-Adrenoceptor (Diehl, N.L. (268) 393)

Artery, rabbit ear, jejunal
ATP; Endothelin-1; Perivascular nerve stimulation; Vasoconstrictor response (La, M. (249) 133)

Ascending reflex
Muscarinic receptor; AF-DX 116; Ileum, guinea-pig; Smooth muscle, intestinal (Doods, H.N. (253) 275)

Aspartate
Riluzole; Glutamate; Hippocampus; Excitatory amino acid; Transmitter release (Martin, D. (250) 473)

Aspartic acid
Glutamic acid; Glycine, uptake, release; Carrier coexistence; Central nervous system; (Rat) (Bonanno, G. (252) 61)

Aspirin-induced mucosal lesion
Morphine; N^G-Nitro-L-arginine; Ethanol-induced mucosal lesion; (Rat) (Gyires, K. (255) 33)

Asthma
Nitric oxide (NO); Bronchoconstriction (Persson, M.G. (249) R7)

Anhydride; Allergy; Cyclosporin A; Glucocorticoid; Sensitization (Arakawa, H. (252) 313)

Corticosteroid; Pulmonary gas trapping; Pulmonary inflammation; Substance P; (Hyperresponsiveness) (Stengel, P.W. (253) 253)

Edema; Plasma exudation; Aging; Leukotriene; Thromboxane A_2; Airway obstruction; Vascular permeability; Arachidonic acid (Arakawa, H. (259) 251)

Astrocyte
Dopamine D_1 receptor; Adenylate cyclase; SKF 38393; SKF 81297; A 68930; (Rat); (Rhesus monkey); (Human) (Vermeulen, R.J. (269) 121)

Astroglia cell
Senile dementia of the Alzheimer type; Nerve growth factor synthesis stimulator; Nerve growth factor; Choline acetyltransferase; Water maze (Nitta, A. (250) 23)

Ataxia
TRH (thyrotropin releasing hormone); TRH analog; Ataxic mutant mouse; Spinocerebellar degeneration (Matsui, K. (254) 295)

Ataxic mutant mouse
TRH (thyrotropin releasing hormone); TRH analog; Ataxia; Spinocerebellar degeneration (Matsui, K. (254) 295)

Atherosclerosis
Histamine H_2 receptor; Hypercholesterolemia; Carotid, artery, common; (Rabbit); (Cannula insertion method) (Fujiwara, T. (258) 195)

Smooth muscle, vascular; Cell proliferation; Dihydropyridine-sensitive Ca^{2+} channel; Voltage-dependent Ca^{2+} channel; Scatchard analysis; Modulated receptor model (Ruiz-Velasco, V. (268) 311)

Nitrite; Interleukin-1; Hypertension (Ikeda, U. (269) 319)

Aorta, rabbit; Pulmonary artery, rabbit; Noradrenaline release; Sympathetic nerve stimulation; Noradrenaline metabolite (Verbeuren, T.J. (270) 27)

ATP
NANC (non-adrenergic non-cholinergic); Inhibitory junction potential; Suramin; Gastric smooth muscle (Ohno, N. (249) 121)

Artery (rabbit ear, jejunal); Endothelin-1; Perivascular nerve stimulation; Vasoconstrictor response (La, M. (249) 133)

Suramin; Ionic conductance; Enteric neuron; Electrophysiology; Purinoceptor; Myenteric plexus (Barajas-López, C. (250) 141)

EDRF (endothelium-dependent relaxing factor); Cotransmission; Ethanol; Purine (Brizzolara, A.L. (254) 175)

Trachea; Epithelium; Smooth muscle; Amiloride; DIDS (4,4′-diisothiocyano-stilbene-2,2′-disulfonic acid) (Fedan, J.S. (256) 51)

Superior cervical ganglion, rat; Uridine 5′-triphosphate; Reactive blue 2; Pyrimidinoceptor; Purinoceptor (Connolly, G.P. (259) 95)

Vas deferens, mouse; Cotransmission; Facilitation; Yohimbine; α_2-Autoinhibition (Karunanithi, S. (261) 17)

NCB-20 cell; Ca^{2+}, intracellular; Bradykinin; Carbachol (Boyd, R.S. (267) 161)

ATP-activated channel
Adenosine; PC12 cell; GTP-binding protein (Inoue, K. (268) 223)

ATPase
Li^+; Chronic; Soleus; Plantaris; Extensor digitorum longus (Adipudi, V. (259) 7)

(Ca^{2+},Mg^{2+})-ATPase
Ca^{2+} channel blocker; Calmodulin binding (Santos, D.L. (267) 307)

(H^+,K^+)-ATPase inhibitor
Histamine H_2 receptor antagonist; Gastric mucin biosynthesis; Organ culture; (Rat) (Ichikawa, T. (251) 107)

ATP release
Methoxamine; α_1-Adrenoceptor; Pulmonary artery, rabbit (Takeuchi, K. (254) 287)

Atriopeptin II
Isoproterenol; cGMP; cAMP; Smooth muscle; Aorta, rat (Jang, E.K. (250) 477)

Atrium
Acetylcholine; Adenosine; Angiotensin II; Contractility; α-CGRP (calcitonin gene-related peptide); Somatostatin; Ventricle; (Human) (Du, X.Y. (259) 173)

Atrium, guinea-pig
αCGRP (calcitonin-gene related peptide), human; αCGRP-(8–37), human; βCGRP-(8–37), human; Vas deferens, rat; SK-N-MC cell (Longmore, J. (265) 53)

Atrium, left
Carbachol; Phenylephrine; Negative inotropy; $^{86}Rb^+$ efflux; Pertussis toxin; 4-Aminopyridine (Ray, A. (256) 311)

Atrium, rat
Glutamate; AMPA receptor; Sympathetic neurotransmission (Lorenzo, P.S. (258) 253)

Diabetes; Endothelin-1; Noradrenaline; Streptozotocin; Sympathetic nerve stimulation (Lieu, A.T. (261) 33)

Atrium (rat)
Iminoctadine; Hypotension; Vasodilation; α_1-Adrenoceptor antagonist; (Aorta) (Koyama, K. (270) 151)

Atrium, right, isolated, rat
Acetylcholine; 8-Bromo-cGMP; EDRF (endothelium-derived relaxing factor); Aortic ring, isolated, rat; LY-83,583 (6-(phenylamino)-5,8-quinolinedione); Norepinephrine; *N*-Nitro-L-arginine; SIN-1 (3-morpholino-sydnonimine); (Spontaneous rate) (Kennedy, R.H. (255) 149)

Atropine
Nitric oxide synthase inhibitor; Mesenteric vascular bed; Endothelium-dependent response; Nitrovasodilator; Vascular tone; (Cat) (Santiago, J.A. (254) 207)

Antral G-cell; Muscarinic receptor subtype; Muscarinic M_3 receptor; Hexahydro-sila-difenidol; Pirenzepine; AQ-RA 741 (Weigert, N. (264) 337)

AtT-20 cell
Histamine H_3 receptor; [^{3}H]N^α-Methylhistamine binding; ACTH (Adrenocorticotropic hormone) release; Steroid effect (West, Jr., R.E. (267) 343)

Atypical antipsychotic
Autoradiography; Choroid plexus; Clozapine; 5-HT_{2C} receptor; Phosphoinositide hydrolysis (Kuoppamäki, M. (269) 201)

Audiogenic seizure
Topiramate; Spontaneously epileptic rat (SER); Antiepileptic effect (Nakamura, J. (254) 83)

Epilepsy; Felbamate; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Glycine/NMDA receptor; (DBA/2 mouse) (De Sarro, G. (262) 11)

α_2-Autoinhibition
Vas deferens, mouse; Cotransmission; ATP; Facilitation; Yohimbine (Karunanithi, S. (261) 17)

Autonomic nerve
ω-Agatoxin-IVA; ω-Conotoxin-GVIA; Ca^{2+} channel (voltage sensitive); Neurotransmission; Smooth muscle (Lundy, P.M. (261) 79)

Autonomic nervous system
PAF (platelet-activating factor, PAF-acether); Hypotension; Renal sympathetic nerve activity, efferent; Renal vascular tone; Baroreflex (Matsuda, Y. (250) 341)

Cardiac arrhythmia; β-Adrenoceptor; Myocardial ischemia; Sudden cardiac death (Avendano, C.E. (255) 99)

Autoradiography
5-HT_{1E}/5-HT receptor; Brain; Lesion (Barone, P. (249) 221)

Ca^{2+} channel; Endothelin; Endothelium; Umbilical artery (human); Endothelin receptor (Bodelsson, G. (249) 299)

$GABA_B$ receptor; Spinal cord; Plasticity; CGP 36742 (3-aminopropyl-*n*-butyl-phosphinic acid); (−)-Baclofen (Malcangio, M. (250) 153)

Pulmonary artery; Dopamine; Dopamine D_1 receptor; (Rabbit) (Kobayashi, Y. (253) 201)

5-HT_1C receptor; Choroid plexus; Clozapine; Receptor reserve; Phosphoinositide hydrolysis (Kuoppamäki, M. (255) 91)

5-HT_{1A} receptor; Hippocampus; Dorsal raphe nucleus; Firing; Adenylate cyclase; Lesopitron; (−)-Tertatolol (Haj-Dahmane, S. (255) 185)

Gastric erosion; Gastric mucosa; Vasopressin; Vasopressin receptor; Vasopressin receptor antagonist (László, F. (258) 15)

5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 6-Hydroxydopamine; mCPP (1-3-(*m*-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Iontophoresis (El Mansari, M. (261) 171)

Pulmonary artery; Dopamine D_2 receptor; Radioligand binding; Catecholamine histofluorescence; Prejunctional receptor (Kobayashi, Y. (261) 229)

Elevated plus-maze test; Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Mianserin; Eltoprazine; 5-HT_{2C} receptor; In situ hybridization histochemistry; Limbic system; Amygdala (Rocha, B. (262) 125)

Angiotensin II; Angiotensin AT_1 receptor; α_2-Adrenoceptor; Nucleus tractus solitarii; Blood pressure (Fior, D.R. (262) 271)

Polyamine; [^{3}H]Spermidine binding; Cerebellar cortex; Brain development, human (McConnell, S.E. (262) 293)

EBOB (4′-ethynyl-4-*n*-propylbicycloorthobenzoate); $GABA_A$ receptor complex; Picrotoxin; Brain, human (Kume, A. (263) 163)

[^{3}H]Resiniferatoxin; Vanilloid receptor; Capsaicin-sensitive neuron; Dorsal root ganglia; Spinal cord (Szallasi, A. (264) 217)

Formoterol; β_2-Adrenoceptor; Lung (Mak, J.C.W. (269) 35)

Atypical antipsychotic; Choroid plexus; Clozapine; 5-HT_{2C} receptor; Phosphoinositide hydrolysis (Kuoppamäki, M. (269) 201)

Autoregulation
Iodolactone; Goiter; Antigoitrogenic; Thyroid (Pisarev, M.A. (258) 33)

Autotomy
Clonidine; Flexor reflex; Guanfacine; Pain; ST-91 (Puke, M.J.C. (260) 227)

Avarol
Avarone; Anti-inflammatory drug; Phospholipase A_2; Arachidonic acid metabolism; Superoxide generation; Peritoneal leukocyte (Ferrándiz, M.L. (253) 75)

Avarone
Avarol; Anti-inflammatory drug; Phospholipase A_2; Arachidonic acid metabolism; Superoxide generation; Peritoneal leukocyte (Ferrándiz, M.L. (253) 75)

Aversive conditioning
Morphine; Opiate withdrawal syndrome; Naloxone; Clonidine (Kosten, T.A. (254) 59)

Avian neurotensin
Neurotensin; Dopamine; Substantia nigra; Neuromedin N; Kinetensin; Electrophysiology (Keegan, K.D. (253) 131

Avoidance response
Endosulfan; Learning; Memory; Escape response; 5-HT (5-hydroxytryptamine, serotonin) (Paul, V. (270) 1)

Azabicycloalkyl benzimidazolone derivative
5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptor; Benzamide derivative; GR 113808; Adrenal gland (Contesse, V. (265) 27)

Azelastine
Smooth muscle cell; Single; Tracheal; Voltage-dependent Ca^{2+} current; K^+ current (Hazama, H. (259) 143)

Baby hamster kidney cell
Dopamine D_{1a} receptor; Dopamine D_{1b} receptor; cDNA; Clonal cell line; Chinese Hamster Ovary cell; Clozapine; Ca^{2+} (Pedersen, U.B. (267) 85)

Baclofen
$GABA_B$ receptor; Neocortical slice, rat; Amiloride; Amiloride analog; (Mg^+-free Krebs medium) (Ong, J. (260) 73)

γ-Guanidinobaclofen; $GABA_B$ receptor agonist; Ileum, guinea-pig, isolated; Neocortical slice, rat; 2-Hydroxysaclofen (Kerr, D.I.B. (262) 189)

(−)-Baclofen
$GABA_B$ receptor; Spinal cord; Plasticity; Autoradiography; CGP 36742 (3-aminopropyl-*n*-butyl-phosphinic acid) (Malcangio, M. (250) 153)

Bacteriorhodopsin
Molecular modeling; Adenosine receptor; Receptor binding and activation; Histidine residue (IJzerman, A.P. (268) 95)

Baculovirus
Epitope-tagged; G-protein coupled receptor; Immunofluorescence (in situ) (Ng, G.YK. (267) 7)

Baicalein
Flavonoid; Antiproliferative effect; Smooth muscle cell, vascular (Huang, H.-C. (251) 91)

Esculetin; Antiproliferative effect; CEM cell; Transduction signal; Messenger RNA expression (Huang, H.-C. (268) 73)

Bai-Hua Qian-Hu
Pd-Ia (3′-angeloyloxy-4′-acetoxy-3′,4′-dihydroseselin); Cardiohemodynamic; Myocardium, stunned; Ca^{2+} channel antagonist (Chang, T.-h. (258) 77)

Balloon angioplasty
Nitric oxide (NO); Endothelin-1; N^{ω}-Nitro-L-arginine methyl ester; Vascular reactivity; Neointima formation (Douglas, S.A. (255) 81)

Balloon denudation
Neointima; Vascular contraction (Antonaccio, M.J. (256) 17)

Barbiturate
Propofol; [^{35}S]TBPS (*t*-[^{35}S]butylbicyclophosphorothionate) binding; GABA (γ-aminobutyric acid); Cl^- channel; Steroid derivative; Benzodiazepine; General anesthetics (Concas, A. (267) 207)

Glutamate receptor; AMPA receptor (Taverna, F.A. (267) R3)

Baroreflex
PAF (platelet-activating factor, PAF-acether); Hypotension; Renal sympathetic nerve activity, efferent; Renal vascular tone; Autonomic nervous system (Matsuda, Y. (250) 341)

Barrel rolling
Endothelin-1; NMDA (*N*-methyl-D-aspartate); Periaqueductal gray area (Maione, S. (250) 209)

Basal ganglion
Adenosine; Dopamine; Dopamine D_1 receptor; Dopamine D_2 receptor; Turning behavior (Morelli, M. (251) 21)

Neurotensin receptor; Brain, guinea-pig; Dopamine; Midbrain; (Non-peptide receptor antagonist) (Azzi, M. (255) 167)

Neuropeptide; Dopamine; Immunohistochemistry; Radioimmunoassay (Castel, M.-N. (262) 1)

Basilar artery
Endothelin; Cromakalim (Zuccarello, M. (259) R1)

Basilar artery, guinea pig
Sumatriptan; Nicotine; 5-HT_1 receptor; Sensory neurotransmission (O'Shaughnessy, C.T. (259) 37)

BAY K 8644
Noradrenaline release; Hexachlorocyclohexane isomer; Nifedipine; DIDS (4,4-diisothiocyanato-stilbene-2,2′-disulfonic acid); W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); Hippocampal slice, rat (Cristòfol, R.M. (252) 305)

Thaliporphine; Positive inotropic action; Ca^{2+} channel; K^+ channel; Cardiomyocyte (Su, M.-J. (254) 141)

Thrombin; Ca^{2+}; Smooth muscle, vascular; TRAP (thrombin receptor-activating peptide) (Antonaccio, M.J. (256) 37)

Dihydropyridine; K^+ contracture; Nifedipine; Skeletal muscle; Twitch response (Kitamura, N. (256) 169)

AMPA receptor antagonist; NMDA receptor antagonist; Seizure (Czuczwar, S.J. (264) 103)

PCA50941; Chromaffin cell; Catecholamine secretion; Dihydropyridine agonist; Ca^{2+} channel; Cytosolic Ca^{2+} (Montiel, C. (268) 293)

BAY u9773
Leukotriene D_4; Leukotriene C_4; Cysteinyl-leukotriene receptor (Tudhope, S.R. (264) 317)

BAY x1005
Leukotriene; FLAP (five lipoxygenase activating protein) inhibitor; Airway; (Guinea pig) (Gardiner, P.J. (258) 95)

BC-264
CCK receptor antagonist; CCK-8; Dopamine; Nomifensine; Depression; L-365,260 (Hernando, F. (261) 257)

Behavior
Idazoxan; SND 919; B-HT 920; Lisuride; Dopamine D_2 receptor; α_2-Adrenoceptor (Ferrari, F. (250) 51)

Tachykinin NK_2 receptor antagonist; Anxiety (Stratton, S.C. (250) R11)

MK-801; NMDA (*N*-methyl-D-aspartate); Phencyclidine; Sensitization; Temperature; Thermoregulation; Tolerance (Pechnick, R.N. (252) 35)

Ifenprodil; Polyamine; ACTH (adrenocorticotropin); NMDA receptor; (Rat) (Genedani, S. (252) 77)

Acetyl-L-carnitine; Protein kinase C; (Rat) (Pascale, A. (265) 1)

Behavioral activity
4-Aminopyridine; Quinine; Morphine; Dopamine release; Nucleus accumbens (Pei, Q. (249) 243)

Behavioral clamping
Amphetamine; Cortical lesion; Haloperidol; Neostriatum; Unit activity (Tschanz, J.A.T. (257) 161)

Behavioral despair
Dopamine D_1 receptor agonist; Antidepressant effect (D'Aquila, P.S. (262) 107)

Behavioral disinhibition
5-HT_4 receptor; Light/dark test; 5-Hydroxytryptophan; SDZ205-557; Tropisetron; Putative anxiolytic (Cheng, C.H.K. (255) 39)

Behavioral effect
Opioid peptide; Body temperature; Antinociception; Voltage-dependent Ca^{2+} channel; Verapamil; ω-Conotoxin GVIA (Spampinato, S. (254) 229)

Behavioral supersensitivity
Dopamine receptor, presynaptic; Dopamine receptor, postsynaptic; Tolerance; γ-Butyrolactone; Drug interaction; Indolylbutylamine (Seyfried, C.A. (257) 67)

Behavioral syndrome
MMAI (5-methoxy-6-methyl-2-aminoindan); Drug discrimination; *p*-Chlorophenylalanine; 5-HT (5-hydroxytryptamine, serotonin) release; (Rat) (Marona-Lewicka, D. (258) 1)

Behavior syndrome
Sexual behavior, male rat; Flat body posture; Forepaw treading; Lower lip retraction; 5-HT_{1A} receptor agonist; 5-HT_2 receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) (Andersson, G. (255) 131)

Benextramine
Neuropeptide Y; Nonpeptide antagonist; Neuropeptide Y receptor subtype; Binding affinity (Melchiorre, C. (265) 93)

α_1-Adrenoceptor subtype; [^{3}H]Prazosin; Chloroethylclonidine; Phenoxybenzamine; Cerebral cortex (Sallés, J. (266) 301)

Benzalkonium chloride
Neuropeptide Y; Neuropeptide Y analog; Pertussis toxin; G-protein; Histamine release; Mast cell; (Rat) (Grundemar, L. (258) 163)

Benzamide
γ-Hydroxybutyrate receptor; Neuroleptic; Dopaminergic activity (Maitre, M. (256) 211)

Dopamine; Dopamine D_2 receptor; SPECT (single photon emission computed tomography); [^{123}I]Iodobenzofuran (Laruelle, M. (263) 39)

Benzamide derivative
5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptor; Azabicycloalkyl benzimidazolone derivative; GR 113808; Adrenal gland (Contesse, V. (265) 27)

Benzimidazolone
BK channel; Maxi-K channel; Smooth muscle cell; Patch-clamp electrophysiology; K^+ channel opener (Olesen, S.-P. (251) 53)

Benzodiazepine
Receptor kinetics; Flumazenil; Midazolam; Radioactive tracer; SPECT (single photon emission computer tomography) (Videbæk, C. (249) 43)

Ethanol drinking; $GABA_A$ receptor; Naloxone; (Selected rat lines) (Wegelius, K. (263) 141)

Propofol; [^{35}S]TBPS (*t*-[^{35}S]butylbicyclophosphorothionate) binding; GABA (γ-aminobutyric acid); Cl^- channel; Barbiturate; Steroid derivative; General anesthetics (Concas, A. (267) 207)

Benzodiazepine binding site, type I
$GABA_A$ receptor complex; [^{3}H]Zolpidem binding; Immunoprecipitation; Photoaffinity labeling; Cortex; (Subunit specific antibodies) (Ruano, D. (267) 121)

Benzodiazepine receptor
GYKI 52466; Spinal reflex; Non-NMDA receptor (Block, F. (256) 149)

Benzodiazepine receptor ligand
Urinary bladder, rat; Skinned urinary bladder; Ca^{2+} channel antagonist (Martí-Cabrera, M. (255) 157)

Benzodiazepine receptor, peripheral type
Imipramine; Phenelzine sulfate; [^{3}H]PK 11195; Antidepressant (Weizman, R. (250) 289)

Benzodiazepine withdrawal
Animal model; Anxiety; Elevated plus-maze; Valepotriate (Andreatini, R. (260) 233)

Benzomorphan-type σ receptor
σ Receptor ligand; SKF-10,047; DTG (1,3-di-(2-tolyl)guanidine); Acetylcholinergic neuronal system; *p*-Chloroamphetamine; Amnesia; Passive avoidance task; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperizine); (Mouse) (Matsuno, K. (261) 43)

7-Benzylidenenaltrexone
Antitussive effect; Naltriben; δ-Opioid receptor; DPDPE ([D-Pen^{2,5}]enkephalin); [D-Ala^2]Deltorphin II (Kamei, J. (251) 291)

Hypovolemia; δ-Opioid receptor; Naltrindole; Hemorrhagic shock; (Rabbit, conscious) (Ludbrook, J. (252) 113)

Cocaine; Drug discrimination; Naltrindole; Naltriben (Suzuki, T. (263) 207)

Bethanechol
Acetylcholine release; HPLC-ECD system; Cholinergic regulation (presynaptic); Muscarinic receptor agonist; Muscarinic receptor antagonist; Ileum (guinea-pig); p-F-HHSiD (*p*-fluoro-hexahydrosiladifenidol); AF102B. (Soejima, O. (249) 1)

Growth hormone; Growth hormone-releasing hormone; Cholinesterase inhibitor (Mazza, E. (254) 17)

B-HT 920
Idazoxan; SND 919; Lisuride; Dopamine D_2 receptor; α_2-Adrenoceptor; Behavior (Ferrari, F. (250) 51)

Big endothelin-1
Endothelin-1; Endothelin converting enzyme; Coronary artery, porcine (Balwierczak, J.L. (250) 379)

Bile flow
CCK receptor antagonist; Loxiglumide; MK-329; Bilirubin secretion (Watanabe, N. (264) 331)

Bile secretion
Liver, rat; P-glycoprotein; Fluorescent dye; Cyclosporin A (Thalhammer, T. (270) 213)

Bilirubin secretion
CCK receptor antagonist; Loxiglumide; MK-329; Bile flow (Watanabe, N. (264) 331)

BIM 23027
Somatostatin; Pertussis toxin; G-protein; Seglitide; SRIF receptor; Vas deferens, mouse (Feniuk, W. (261) 333)

Binding
Brain; Electrophysiology; Gastric acid secretion; Neuropeptide; CCK_B receptor (Bertrand, P. (262) 233)

Smooth muscle, vascular; Ca^{2+} channel; Aorta; [^{3}H](+)-PN200-110; Spontaneously hypertensive rat (SHR) (Ikeda, S. (264) 223)

Tachykinin receptor antagonist; Ca^{2+} channel (Lombet, A. (267) 113)

Ca^{2+} channel antagonist; Heart; SR 33805; Fantofarone; Dihydropyridine (Chatelain, P. (267) 151)

Galanin; Human cell line; Bowes cell line; cAMP; Galantide (Heuillet, E. (269) 139)

Binding affinity
Neuropeptide Y; Benextramine; Nonpeptide antagonist; Neuropeptide Y receptor subtype (Melchiorre, C. (265) 93)

Tripitramine; Methoctramine; Muscarinic receptor subtype; CHO-K1 cell (Maggio, R. (268) 459)

Binding assay
Morphine 6-glucuronide; Intestinal motility; Ileum, guinea-pig (Massi, P. (253) 269)

Adenosine A_2 receptors; KF17837 ((*E*)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine); cAMP (Nonaka, H. (267) 335)

Binding, in vitro
Dopamine carrier, neuronal; Dopamine uptake blocker; *N*-Ethylmaleimide; [^{3}H]GBR 12783; Striatum, rat; (Slow interaction) (Héron, C. (264) 391)

Dopamine carrier (neuronal); Na^+-dependence; N-ethylmaleimide treatment; [^{3}H]GBR 12783; [^{3}H]Cocaine; Striatum; (Rat) (Saadouni, S. (268) 187)

Dopamine neuronal carrier; Thermodynamics; [^{3}H]GBR 12783 (1-[2-{diphenylmethoxy}ethyl]4-{3-phenyl-2-propenyl}-piperazine); BTCP (*N*-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine) derivative; Striatum (Rat) (Billaud, G. (268) 357)

Binding site
α-Trinositol; Inositol phosphate; Heart (Yoo, H. (268) 55)

σ Binding site
FH-510 (5,8-dimethyl-4-(2-di-*n*-propylaminoethyl)carbazol); DTG (1,3-di-*o*-tolylguanidine); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperidine) (Chaki, S. (250) 173)

σ_1 Binding site
σ_2 Binding site; NE-100 (*N*,*N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride) (Chaki, S. (251) R1)

σ_2 Binding site
σ_1 Binding site; NE-100 (*N*,*N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride) (Chaki, S. (251) R1)

Binding study
Muscarinic M_2 receptor; [^{3}H]Quinuclidinyl benzilate; Selective antagonist; Uterus; (Rat) (Pennefather, J.N. (262) 297)

Bioassay
Ileocolonic junction, dog; Nitrergic transmission; Nitric oxide (NO) (Boeckxstaens, G.E. (264) 85)

Biotransformation
PCB (polychlorinated biphenyl); Equilibrium partitioning; (Marine mammals) (Boon, J.P. (270) 237)

Biperiden
NMDA receptor; Acetylcholine release; Budipine; Nucleus caudatus; MK-801 binding (Jackisch, R. (264) 207)

Bisoxonol
Neuroselectivity; K^+ channel (Hunnicutt, Jr., E.J. (261) R1)

BK channel
Maxi-K channel; Smooth muscle cell; Patch-clamp electrophysiology; Benzimidazolone; K^+ channel opener (Olesen, S.-P. (251) 53)

Bladder outlet obstruction
Dicentrine; α_1-Adrenoceptor antagonist; Prostatic hyperplasia, benign (Yu, S.-M. (252) 29)

Bladder voiding
MK-801; Urine storage; Decerebration; Cystometrogram; Sphincter electromyogram; (Rat) (Yoshiyama, M. (264) 417)

Blood-brain barrier
Brain microvessel endothelial cell; Catecholamine; Pinocytosis (Borges, N. (269) 243)

Blood flow
Choroid; Ciliary body; Iris; PACAP (pituitary adenylate cyclase activating polypeptide); Vasodilatation (Nilsson, S.F.E. (253) 17)

Blood gas
5-HT (5-hydroxytryptamine, serotonin); Methysergide; Adenosine diphosphate; Platelet aggregation; Gastric mucosal blood flow; Blood pressure (Cho, C.H. (256) 9)

Blood pressure
Phosphodiesterase inhibitor; Zaprinast; cGMP; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (249) 293)

Salbutamol; Nitric oxide (NO); β_2-Adrenoceptor; N^G-Nitro-L-arginine methyl ester; Aortic ring; Endothelium (Wang, Y.-X. (250) 335)

Cholinomimetic; Muscarinic M_2 receptor; Central nervous system (Özkutlu, U. (250) 349)

Cholinergic neuron; Spinal cord; Medulla oblongata; Heart rate (Feldman, D.S. (250) 483)

NBQX; Non-NMDA receptor antagonist; Sympathetic nerve activity; (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline) (Chen, K. (252) 155)

Anaphylaxis, mouse; Histamine; Nitric oxide (NO) (Osada, S. (252) 347)

Manganese; Nitric oxide (NO); Superoxide dismutase; cGMP (Kasten, T.P. (253) 35)

Pentobarbital; Chlordiazepoxide; Angiotensin; (Spontaneously hypertensive rat (SHR)) (Sim, M.K. (253) 171)

5-HT (5-hydroxytryptamine, serotonin); Methysergide; Adenosine diphosphate; Platelet aggregation; Gastric mucosal blood flow; Blood gas (Cho, C.H. (256) 9)

Hypertension; Hippocampus; Dynorphin; Nor-binaltorphimine; Spontaneously hypertensive rat (SHR) (Wang, J.Q. (256) 57)

Nitric oxide (NO); Gastric emptying; N^G-Nitro-L-arginine methyl ester; N^G-Monomethyl-L-arginine; L-Arginine (Plourde, V. (256) 125)

Galanin; Galanin fragment; Receptor subtype; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Heart rate; Medulla oblongata; (Intracisternal injection) (Narváez, J.A. (257) 257)

Nicotine; Cardiovascular effect; Heart rate; Pentobarbital; Tachyphylaxis (Cruz, S.L. (258) 39)

Angiotensin AT_1 receptor; Goldblatt hypertension (Železná, B. (260) 95)

5-HT_{1A} receptor agonist; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Heart rate; Respiratory rate; α_1-Adrenoceptor (Di Francesco, G.F. (262) 205)

Angiotensin II; Angiotensin AT_1 receptor; α_2-Adrenoceptor; Nucleus tractus solitarii; Autoradiography (Fior, D.R. (262) 271)

Nitric oxide (NO); Single breath; Respiratory system; Alcohol; Toxicity; (Lung); (Pharmacology) (Persson, M.G. (270) 273)

Blood vessel
Phosphodiesterase inhibitor; Pimobendan; Milrinone; UD-CG 212 (Fujimoto, S. (265) 159)

Body temperature
Opioid peptide; Behavioral effect; Antinociception; Voltage-dependent Ca^{2+} channel; Verapamil; ω-Conotoxin GVIA (Spampinato, S. (254) 229)

Bombesin
Neuropeptide release; Synaptosome; Nerve varicosity; Muscarinic receptor; Ileum (Kurjak, M. (257) 169)

MDL-101,562; Gastrin-releasing peptide; Dopaminergic neuron (Manzanares, J. (257) 199)

GRP (gastrin-releasing peptide); Bombesin binding site; Lung, human; GRP-preferring bombesin receptor (Lach, E. (265) 117)

Bombesin binding site
Bombesin; GRP (gastrin-releasing peptide); Lung, human; GRP-preferring bombesin receptor (Lach, E. (265) 117)

Bombesin receptor
Neuromedin C; Glutamate; Nociception; NMDA receptor (Onogi, T. (262) 163)

Bombesin receptor, lung
Guanine nucleotide sensitivity; G-protein; Pertussis toxin; Cholera toxin; (Guinea pig) (Lach, E. (269) 87)

Bone marrow
Neutrophil; Eosinophil; Endotoxin; Lipopolysaccharide; PAF (platelet-activating factor); PAF receptor antagonist (Bozza, P.T. (270) 143)

Bone marrow culture
Vitamin K_2; Osteoclast-like cell formation; 1,25-Dihydroxyvitamin D_3 (Akiyama, Y. (263) 181)

Bosentan
BQ-123; Ro 47-0203; Endothelin ET_A receptor; Endothelin ET_B receptor; Endothelin; Microcirculation; Skin blood flow, rat (Lawrence, E. (260) 103)

Endothelin receptor antagonist; Endothelin-1 binding; Ca^{2+} mobilization; Expression (Adachi, M. (269) 225)

Botulinum toxin
G protein (low molecular weight); Polyphosphoinositide turnover; ADP-ribosylation; 5-HT (5-hydroxytryptamine, serotonin); *Xenopus* oocyte (Tohda, M. (266) 19)

Bovine chromaffin cell
Cell death; Ca^{2+} oscillation; Veratridine; R56865; Flunarizine; Nimodipine; ω-Conotoxin GVIA (Maroto, R. (270) 331)

Bowes cell line
Galanin; Human cell line; Binding; cAMP; Galantide (Heuillet, E. (269) 139)

BQ-123 (cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu))
Endothelin; Sarafotoxin; Endothelin receptor subtype; Aorta (guinea-pig); Coronary artery (pig); Smooth muscle (vascular) (Schoeffter, P. (249) 199)

Endothelin; Endothelin ET_A receptor; Endothelin ET_B receptor; Saphenous vein, human (White, D.G. (257) 307)

Ro 47-0203; Bosentan; Endothelin ET_A receptor; Endothelin ET_B receptor; Endothelin; Microcirculation; Skin blood flow, rat (Lawrence, E. (260) 103)

Endothelin; Pulmonary artery; Ro 46-2005; Sarafotoxin S6c; (Human); (In vitro) (Buchan, K.W. (260) 221)

Bradykinin
Endothelium; EDRF (endothelium-derived relaxing factor); Angiotensin converting enzyme inhibitor; Captopril (Hirano, K. (250) 439)

Bradykinin B_2 receptor; Bronchoconstriction; HOE 140; Microvascular permeability; Vagal stimulation (Sakamoto, T. (251) 137)

Prostaglandin E_1; Prostaglandin E_2; Misoprostol; Enisoprost; Sympathetic nervous system; Plasma extravasation; PAF (platelet activating factor, PAF-acether); Synovial joint (Green, P.G. (252) 127)

Interferon-γ; Arterial reactivity; Nitric oxide (NO) (De Kimpe, S.J. (261) 111)

Substance P; Vasopressin; EDRF (endothelium-derived relaxing factor); Cerebral vasospasm; Subarachnoid hemorrhage (Tsuji, T. (264) 77)

NCB-20 cell; Ca^{2+}, intracellular; ATP; Carbachol (Boyd, R.S. (267) 161)

Acetylcholine; Arginine; cGMP; Gentamicin; Nitric oxide (NO); (Rat) (Rivas-Cabañero, L. (270) 119)

Bradykinin biosynthesis
Bradykinin receptor antagonist; Trachea; Smooth muscle, airway; Captopril; Thiorphan (Farmer, S.G. (259) 309)

Bradykinin B_1 receptor
Aorta (rabbit); Smooth muscle cell; Des-Arg^{10}-kallidin (Schneck, K.A. (266) 277)

Bradykinin B_2 receptor
Bradykinin; Bronchoconstriction; HOE 140; Microvascular permeability; Vagal stimulation (Sakamoto, T. (251) 137)

Affinity cross-linking; Ileum membrane; (Guinea pig) (Graneß, A. (268) 271)

Bradykinin receptor antagonist
Bradykinin biosynthesis; Trachea; Smooth muscle, airway; Captopril; Thiorphan (Farmer, S.G. (259) 309)

Brain
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); α_2-Adrenoceptor; (Presynaptic α_2-adrenoceptors); (Postsynaptic α_2-adrenoceptors) (Heal, D.J. (249) 37)

5-HT_{1E}/5-HT receptor; Autoradiography; Lesion (Barone, P. (249) 221)

CCK-8 (cholecystokinin octapeptide); GABA (γ-aminobutyric acid); Anxiety; Release; CCK receptor; (In vitro); (Slice) (Pérez de la Mora, M. (250) 423)

GBR 12909; GBR 12935; Dopamine uptake; Synaptic vesicle (Reith, M.E.A. (253) 175)

Nitric oxide (NO); Serotonergic system; Anorexia; Zucker rat (Squadrito, F. (255) 51)

Adenosine; Nucleoside transporter; Dipyridamole; Nitrobenzylthioinosine (Jones-Humble, S.A. (257) 311)

Ethanol, chronic voluntary; β-Endorphin; Proopiomelanocortin mRNA, hypothalamic (De Waele, J.-P. (258) 119)

σ Receptor; Motor system; Antipsychotic; (Rat) (Leitner, M.L. (259) 65)

Morphine; Δ^9-Tetrahydrocannabinol; Tolerance; Analgesia; Hypothermia; Cross-tolerance; [^{3}H]DAMGO ([^{3}H][D-Ala^2,$MePhe^4$, Gly-ol^5]enkephalin), B_{max}, K_d; Spinal cord (Thorat, S.N. (260) 5)

Glucose transport; Heart; Adipose tissue, white (Nagai, K. (260) 29)

Binding; Electrophysiology; Gastric acid secretion; Neuropeptide; CCK_B receptor (Bertrand, P. (262) 233)

Galanin receptor; Hypothalamus; (Human) (Lorinet, A.-M. (269) 59)

Adrenoceptor; Testosterone; Adipocyte; Colocyte; Kidney; Liver (Bouloumié, A. (269) 95)

Galanin; 5-HT (5-hydroxytryptamine, serotonin); 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Adenylyl cyclase; Forskolin; Hypothalamus; Hippocampus; Receptor subtype; Peptide fragment (Billecocq, A. (269) 209)

Brain catecholamine
[^{18}F]Fluoro-DOPA; Catechol-*O*-methyl transferase inhibitor; Entacapone; Carbidopa; PET (positron emission tomography) (Pauwels, T. (257) 53)

Brain cortex, rat
Neurosteroid; cAMP; Diazepam binding inhibitor (DBI) receptor, mitochondrial; Protein synthesis inhibitor; Adrenalectomy/orchidectomy (Roscetti, G. (269) 17)

Brain development, human
Polyamine; [^{3}H]Spermidine binding; Autoradiography; Cerebellar cortex (McConnell, S.E. (262) 293)

Brain edema
Magnetic resonance imaging; NMR tomography; Stroke; 5-HT receptor antagonist; Ca^{2+} channel blocker (Elger, B. (254) 65)

Brain, guinea-pig
Neurotensin receptor; Dopamine; Midbrain; Basal ganglia; (Nonpeptide receptor antagonist) (Azzi, M. (255) 167)

Tachykinin NK_3 receptor; Neurokinin B; Angiotensin receptor antagonist; Brain, rat (Chrétien, L. (256) 73)

Brain-gut axis
Gastric acid; Nitric oxide (NO); Gastric distension, 2-Deoxy-D-glucose; Histamine; Pentagastrin (Barrachina, D. (262) 181)

Brain, human
EBOB (4′-ethynyl-4-*n*-propylbicycloorthobenzoate); $GABA_A$ receptor complex; Picrotoxin; Autoradiography (Kume, A. (263) 163)

Imidazoline; Clonidine (Greney, H. (265) R1)

Brain ischemia
Histamine H_2 receptor; Ranitidine; Edema; Na^+; K^+; Ca^{2+}; (Rat) (Tósaki, Á. (264) 455)

Brain ischemia / reperfusion
21-Aminosteroid (U-74389G); Antioxidant enzyme (Farbiszewski, R. (270) 263)

Brain ischemia, therapy
Adenosine receptor; Cerebral blood flow; (Gerbil) (Von Lubitz, D.K.J.E. (263) 59)

Brain membrane
DTG (1,3-di(2-tolyl)guanidine); σ Receptor; KB-5492; Anti-ulcer agent; (Guinea-pig) (Harada, Y. (256) 321)

CCK_B receptor; Gastrin binding; CCK_8 binding; G protein (Lallement, J.-C. (267) 297)

Brain microvessel endothelial cell
Catecholamine; Blood-brain barrier; Pinocytosis (Borges, N. (269) 243)

Brain, mouse
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Diethyldithiocarbamate; Lipoic acid; α-Tocopherol; Coenzyme Q (Götz, M.E. (266) 291)

Brain, neonatal, rat
Zonisamide; Anticonvulsant; Hypoxia-ischemia, cerebral; Infarction, cerebral; Hypoxic seizure (Hayakawa, T. (257) 131)

Brain penetration
CCK_B receptor antagonist; Ex vivo binding; L-365,260; CI988; L-368,935 (Patel, S. (253) 237)

Brain, rat
Tachykinin NK_3 receptor; Neurokinin B; Angiotensin receptor antagonist; Brain, guinea pig (Chrétien, L. (256) 73)

Neurosteroid; Stress; Handling; CO_2 (Barbaccia, M.L. (261) 317)

$GABA_A$ receptor; $GABA_B$ receptor; β-Adrenoceptor; Olfactory bulbectomy; Antidepressant (Dennis, T. (262) 143)

[^{3}H]Ifenprodil binding; Polyamines; NMDA receptor (*N*-Methyl-D-aspartate); σ Receptor (Hashimoto, K. (266) 67)

7-Chlorokynurenate; Polyamine; NMDA receptor antagonist, competitive; Glycine recognition site; NMDA receptor complex (Oblin, A. (266) 103)

σ Receptor; Heterocyclic amino alcohol; Ifenprodil; [^{3}H]3-PPP ([^{3}H]R(+)-3-[3-hydroxyphenyl]-*N*-(1-propyl)piperidine) binding; Molecular modelling (Beart, P.M. (269) 193)

Brain slice
Somatostatin; Aging; Carbachol; 2-Deoxyglucose; Cerebral cortex (Shibata, S. (269) 269)

Brainstem
S-Adenosyl-L-methionine; Adenosine; Methylation; Vagus motoneuron (Travagli, R.A. (264) 385)

Imidazoline receptor; α_2-Adrenoceptor; cAMP; Cerebral cortex; Inositol phosphate (Regunathan, S. (269) 273)

Brainstem, human
Clonidine; Imidazoline receptor; GTP; Phenoxybenzamine; α-Adrenoceptor (Bricca, G. (266) 25)

8-Br-cAMP
8-Br-cGMP; Nitroglycerin; Rp-8-Br-cGMPS; Aorta, rabbit; cGMP-dependent protein kinase; cAMP-dependent protein kinase (Nakazawa, M. (253) 179)

8-Br-cGMP
Nitroglycerin; Rp-8-Br-cGMPS; 8-Br-cAMP; Aorta, rabbit; cGMP-dependent protein kinase; cAMP-dependent protein kinase (Nakazawa, M. (253) 179)

Breast cancer
Anti-estrogenic activity; Indole; Yuehchukene (Ng, P.C. (264) 1)

BRL-38227
Neuropeptide Y; Vasoconstriction; K^+ channel; Diazoxide; Cerebral basilar artery (Xia, Y. (255) 67)

Glibenclamide; Myocardial ischemia; Antiarrhythmic/proarrhythmic effect (Bellemin-Baurreau, J. (256) 115)

BRL-53001
κ-Opioid receptor agonist; Dopamine; Dorsal caudate; Microdialysis (Zaratin, P. (264) 151)

8-Bromo-cGMP
Acetylcholine; EDRF (endothelium-derived relaxing factor); Aortic ring, isolated, rat; Atrium, right, isolated, rat; LY-83,583 (6-(phenylamino)-5,8-quinolinedione); Norepinephrine; *N*-Nitro-L-arginine; SIN-1 (3-morpholino-sydnonimine); (Spontaneous rate) (Kennedy, R.H. (255) 149)

Bromophenacyl bromide
Opsonized zymosan; OX-42; Indomethacin; Dapsone; Prostaglandin E_2 (Klegeris, A. (260) 273)

[^{3}H]Bromoxidine
Receptor autoradiography; α_2-Adrenoceptor; Lymph node; Spleen; Immune system (Fernández-López, A. (252) 333)

Bronchial hyperreactivity
Allergic reaction, early and late; Airway inflammation; Mepyramine; Histamine; (Allergic guinea-pig) (Santing, R.E. (254) 49)

Allergic asthma; Tracheal smooth muscle function; Airway inflammation; (Guinea pig model) (Santing, R.E. (257) 145)

Bronchial hyperresponsiveness
S-1452 (calcium (1*R*,2*S*,3*S*,4*S*)-(5*Z*)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate); Thromboxane A_2; Lung vascular injury (Arimura, A. (260) 201)

Bronchoalveolar lavage
Airway hyperreactivity; Cigarette smoke; Leukotriene B_4; IdB 1031 (Hernandez, A. (270) 301)

Bronchoconstriction
Nitric oxide (NO); Asthma (Persson, M.G. (249) R7)

Bradykinin B_2 receptor; Bradykinin; HOE 140; Microvascular permeability; Vagal stimulation (Sakamoto, T. (251) 137)

Diamide; Sensory nerve; Thromboxane; Hydrogen peroxide; (Guinea pig) (Bannenberg, G. (270) 175)

Bronchodilator
Protein kinase C; Smooth muscle, bovine, tracheal; Smooth muscle, contraction; Ca^{2+}, intracellular (Langlands, J.M. (266) 229)

Bronchodilator agent
Muscarinic receptor; Smooth muscle, airway; Allergy and immunology; (Guinea pig) (Howell, R.E. (265) 67)

Bronchus, human
Okadaic acid (Naline, E. (256) 301)

Loratadine; Histamine H_1 receptor; Ca^{2+}, cytosolic; PAF (platelet activating factor); Macrophage; Leukotriene (Letari, O. (266) 219)

Brown adipose tissue
cAMP; Glycerol release; β-Adrenoceptor; Thermogenesis; Obesity (Nisoli, E. (259) 181)

BTCP (*N*-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine) derivative
Dopamine neuronal carrier; Thermodynamics; [^{3}H]GBR 12783 (1-[2-{diphenylmethoxy}ethyl]4-{3-phenyl-2-propenyl}-piperazine); Binding (in vitro); Striatum (Rat) (Billaud, G. (268) 357)

Budipine
NMDA receptor; Acetylcholine release; Biperiden; Nucleus caudatus; MK-801 binding (Jackisch, R. (264) 207)

Bursting
μ-Opioid receptor; Hippocampal slice; Naloxone; Proconvulsant (Jones, L.S. (264) 39)

Buspirone
Head twitch behavior; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); 5-HT_{1A} receptor; 5-HT_2 receptor; (Mouse) (Kitamura, Y. (253) 297)

1-PP (1-(2-pyrimidinyl)-piperazine); Clonidine; α_2-Adrenoceptor; Antinociception (Cao, B.-J. (259) 75)

Butanol
GABA (γ-aminobutyric acid); Ethanol; Electrophysiology; cDNA; Oocyte (Mihic, S.J. (268) 209)

Butorphanol dependence
κ-Opioid receptor, supraspinal; Nor-binaltorphimine; Naloxone; Withdrawal, precipitated (Jaw, S.P. (257) 153)

Butylated hydroxyanisole
Metabolite; *N*-Acetylcysteine; Cytotoxicity; Hepatocyte, isolated, rat (Nakagawa, Y. (270) 341)

γ-Butyrolactone
Dopamine receptor, presynaptic; Dopamine receptor, postsynaptic; Tolerance; Behavioral supersensitivity; Drug interaction; Indolylbutylamine (Seyfried, C.A. (257) 67)

BW A522
Adenosine A_3 receptor; APNEA (N^6-2-(4-aminophenyl)ethyl adenosine) (Fozard, J.R. (252) R5)

BW 737C89
Catalepsy-associated behavior; R-SKF 38393; SKF 75670; SCH 39166; Haloperidol; SKF 81297; SKF 82958 (Rosenzweig-Lipson, S. (260) 237)

Ca^{2+}
Endothelial cell; Microcirculation; Endothelin; Permeability; Contraction (Kurose, I. (250) 85)

Staurosporine; Adrenal chromaffin cell; Catecholamine release (Maurer, J.A. (253) 115)

Thrombin; Smooth muscle, vascular; TRAP (thrombin receptor-activating peptide); Bay K 8644 (Antonaccio, M.J. (256) 37)

Indapamide; 5-OH-Indapamide; Hydrochlorothiazide; Cicletanine; K^+ (Calder, J.A. (256) 185)

5-HT (5-hydroxytryptamine, serotonin); Carbamylcholine; Trachea (Cox, D.A. (258) 265)

Nitric oxide (NO); Lung (Persson, M.G. (264) 13)

Endothelin; Saponin; Protein kinase C; Positive inotropy; Diacylglycerol; IP_3; Phospholipase (Paik, G.Y. (264) 437)

Brain ischemia; Histamine H_2 receptor; Ranitidine; Edema; Na^+; K^+; (Rat) (Tósaki, Á. (264) 455)

NMDA (*N*-Methyl-D-aspartate); Glycine; Ca^{2+} entry; Cerebellar granule cells; Cell culture (Simpson, P.B. (266) 309)

Dopamine D_{1a} receptor; Dopamine D_{1b} receptor; cDNA; Clonal cell line; Baby Hamster Kidney cells; Chinese Hamster Ovary cell; Clozapine (Pedersen, U.B. (267) 85)

Corticotropin-releasing factor; Ca^{2+} channel; Pertussis toxin; Epithelium (Kiang, J.G. (267) 135)

Xenopus laevis oocyte; Vanadate; Pertussis toxin; Angiotensin II; Desensitization; LiCl (Sakuta, H. (268) 305)

P_2^U purinoceptor; cAMP; Protein kinase C; Pertussis toxin; DDT_1 MF-2 cell (Sipma, H. (268) 431)

Tachykinin; Neurokinin; CHO (Chinese hamster ovary) cell; Antagonist; Structure-activity; Second messenger; Inositol phosphate; Thapsigargin; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

Ca^{2+} activation
K^+ current; Apamin (Dunn, P.M. (252) 189)

Ca^{2+} channel
Autoradiography; Endothelin; Endothelium; Umbilical artery (human); Endothelin receptor (Bodelsson, G. (249) 299)

Norepinephrine release; Aging; Dopamine D_2 receptor; Tail artery, rat (Friedman, D.J. (252) 1)

Ca^{2+} channel antagonist; Smooth muscle, vascular (Hirakawa, Y. (252) 267)

Endothelin; Hypertension (Morel, N. (252) R3)

Electroconvulsive shock; Apomorphine; Nifedipine; Analgesia; Hyperalgesia; Hot-plate test; Hypermotility; (Rat) (Antkiewicz-Michaluk, L. (254) 9)

Thaliporphine; Bay K 8644; Positive inotropic action; K^+ channel; Cardiomyocyte (Su, M.-J. (254) 141)

Vas deferens; Denervation; Dihydropyridine; Isradipine (Jurkiewicz, A. (256) 329)

NMDA receptor; Voltage-clamp, whole-cell; Cortical neuron, cultured; Eliprodil (Biton, B. (257) 297)

Noradrenaline; Ryanodine; G-protein; Protein kinase C; Caffeine; Phenoxybenzamine (Tabrizchi, R. (259) 285)

Smooth muscle, vascular; Aorta; Binding; [^{3}H](+)-PN200-110; Spontaneously hypertensive rat (SHR) (Ikeda, S. (264) 223)

Interleukin; Hippocampus; G-protein; Protein kinase; Patch-clamp; (Guinea pig) (Plata-Salamán, C.R. (266) 1)

Tachykinin receptor antagonist; Binding (Lombet, A. (267) 113)

Ca^{2+}; Corticotropin-releasing factor; Pertussis toxin; Epithelium (Kiang, J.G. (267) 135)

Haloperidol; Hippocampus (Fletcher, E.J. (267) 249)

PCA50941; Bay K 8644; Chromaffin cell; Catecholamine secretion; Dihydropyridine agonist; Cytosolic Ca^{2+} (Montiel, C. (268) 293)

Dihydropyridine; Enantiomer; Vascular myocyte; Patch clamp; Radioligand (Baron, A. (269) 105)

Chromaffin cell; Catecholamine; Antidepressant; Nicotine; Histamine (Firestone, J.A. (269) 177)

Electrophysiology; Permeant ion; Ethanol; PC12; Pheochromocytoma cell (Mullikin-Kilpatrick, D. (270) 17)

Ca^{2+} channel antagonist
CD-832; cGMP; cAMP; Aorta vasodilatation; (Rabbit) (Miyata, N. (249) 141)

Heart cell; Patch-clamp analysis; Ca^{2+} channel (L-type); Manidipine (Tohse, N. (249) 231)

Skinned striated muscle; Tension (maximum); Ca^{2+} sensitivity; Inotropic state (Schiereck, P. (249) 317)

Anococcygeus muscle; Nifedipine; Adrenergic transmission (Iravani, M.M. (250) 193)

Angiotensin-converting enzyme inhibitor; α_1-Adrenoceptor, vascular; Receptor reserve; Phenoxybenzamine (Tabrizchi, R. (251) 15)

Heart, isolated; Fantofarone; Ischemia, ^{31}P NMR spectroscopy (Vander Elst, L. (251) 163)

Ca^{2+} channel; Smooth muscle, vascular (Hirakawa, Y. (252) 267)

CP-96,345; Verapamil; Nifedipine; Smooth muscle, isolated; (Anesthetized dog) (Constantine, J.W. (252) 275)

Magnetic resonance imaging; NMR tomography; Brain edema; Stroke; 5-HT receptor antagonist (Elger, B. (254) 65)

K^+ channel; Glibenclamide; Stereoselectivity; *Xenopus* oocyte; Y-26763 (Sakuta, H. (255) 1)

Urinary bladder, rat; Skinned urinary bladder; Benzodiazepine receptor ligand (Martí-Cabrera, M. (255) 157)

Pd-Ia (3′-angeloyloxy-4′-acetoxy-3′,4′-dihydroseselin); Bai-Hua Qian-Hu; Cardiohemodynamic; Myocardium, stunned (Chang, T.-h. (258) 77)

CD-832; Femoral vein; Femoral artery; (Rabbit) (Yamaura, H. (260) 269)

Heart; L-type Ca^{2+} channel; Voltage clamp; SR33557; SR33805 (Romey, G. (263) 101)

Conflict behavior; Antianxiety action; (Rat) (Matsumoto, Y. (264) 107)

Nicardipine; Ca^{2+} transient; Ca^{2+} concentration, intracellular; Cardiac myocyte, rat (Jiang, J. (266) 155)

Binding; Heart; SR 33805; Fantofarone; Dihydropyridine (Chatelain, P. (267) 151)

(Ca^{2+} + Mg^{2+})-ATPase; Calmodulin binding (Santos, D.L. (267) 307)

Ca^{2+} channel antagonist, inorganic
Imipramine; Ca^{2+} concentration, intracellular; Dihydropyridine; ω-Conotoxin; Cultured neuron (Shimizu, M. (268) 65)

Ca^{2+} channel antagonist, T-type
Neuronal ischemic injury; U-92032; Nifedipine; Flunarizine; Antioxidant (Ito, C. (257) 203)

Ca^{2+} channel antagonist, voltage-dependent
Cinnamophilin; Thromboxane A_2 receptor antagonist; Thoracic aorta; (Rat) (Yu, S.-M. (256) 85)

Ca^{2+} channel, dihydropyridine-sensitive
Smooth muscle, vascular; Cell proliferation; Voltage-dependent Ca^{2+} channel; Scatchard analysis; Modulated receptor model; Atherosclerosis (Ruiz-Velasco, V. (268) 311)

Ca^{2+} channel, L-type
Heart cell; Patch-clamp analysis; Ca^{2+} channel antagonist; Manidipine (Tohse, N. (249) 231)

Oxytocin; Vasopressin; Dihydropyridine; Neurointermediate lobe; (Electrical stimulation) (Jørgensen, A. (259) 157)

Heart; Voltage clamp; Ca^{2+} channel antagonist; SR33557; SR33805 (Romey, G. (263) 101)

Ethanol; Isradipine; Drug discrimination; (Rat) (Colombo, G. (265) 167)

Dihydropyridine; Nitrendipine; MK 801; Ca^{2+} channel, voltage-sensitive; NMDA receptor; Dibenzocycloheptenimine (Filloux, F.M. (269) 325)

Ca^{2+} channel, voltage-dependent
Opioid peptide; Behavioral effect; Body temperature; Antinociception; Verapamil; ω-Conotoxin GVIA (Spampinato, S. (254) 229)

Tachykinin receptor; Sucrose gap; Proximal colon, guinea-pig; Pharmacomechanical coupling; Electromechanical coupling (Zagorodnyuk, V. (255) 9)

Smooth muscle, vascular; Cell proliferation; Dihydropyridine-sensitive Ca^{2+} channel; Scatchard analysis; Modulated receptor model; Atherosclerosis (Ruiz-Velasco, V. (268) 311)

Ca^{2+} channel, voltage-dependent, N-type
ω-Conotoxin MVIIC; ω-Conotoxin GVIA; Ileum, guinea pig; Vas deferens, rat (Boot, J.R. (258) 155)

Ca^{2+} channel, voltage-dependent, N-type, L-type
Adrenal catecholamine; ω-Conotoxin GVIA; Nifedipine; Verapamil; Acetylcholine (Kimura, T. (264) 169)

Ca^{2+} channel, voltage-gated
Endothelin-3; Dopamine; Glutamate; NMDA receptor; Striatal slice (Koizumi, S. (259) 195)

Ca^{2+} channel, voltage-sensitive
ω-Agatoxin-IVA; ω-Conotoxin-GVIA; Autonomic nerve; Neurotransmission; Smooth muscle (Lundy, P.M. (261) 79)

Ca^{2+} channel, L-type; Dihydropyridine; Nitrendipine; MK 801; NMDA receptor; Dibenzocycloheptheneimine (Filloux, F.M. (269) 325)

Cachexia
Neuropeptide Y; Megestrol acetate; Appetite; Cancer anorexia; Hypothalamus (McCarthy, H.D. (265) 99)

Ca^{2+} concentration, cytosolic
α_{1B}-Adrenoceptor; CHO (Chinese hamster ovary) cell; Radioligand binding studies (Horie, K. (268) 399)

Ca^{2+} concentration, intracellular
cAMP; β_1-Adrenoceptor; Thromboxane A_2; Ca^{2+} sensitivity of contractile elements; Coronary artery (Yamagishi, T. (251) 253)

Ca^{2+} channel antagonist; Nicardipine; Ca^{2+} transient; Cardiac myocyte, rat (Jiang, J. (266) 155)

Angiotensin II; mRNA; Smooth muscle, vascular; cAMP; (Down-regulation) (Chen, X. (267) 175)

Imipramine; Dihydropyridine; ω-Conotoxin; Inorganic Ca^{2+} channel blocker; Cultured neuron (Shimizu, M. (268) 65)

Ca^{2+} concentration, intracellular, free
Aortic endothelial cell; Cl^-, extracellular; Fura-2; Endothelium-dependent vasodilator (Hosoki, E. (266) 213)

Ca^{2+} current
Cytochalasin B; Smooth muscle contraction; Myosin phosphorylation; Taenia coli; (Guinea pig) (Obara, K. (255) 139)

Voltage-clamp, whole-cell; Cardiac myocyte; Cl^- channel blocker; Na^+ current; Diphenylamine-2-carboxylate (DPC); Ion channel blocker (Conforti, L. (259) 215)

Philanthotoxin; Hippocampus; Glutamate antagonist; Polyamine; Patch clamp, in situ (Karst, H. (270) 357)

Ca^{2+} current, L-type, I_{Ca}
E4080; Hyperpolarization-activated inward current (I_f); ATP-sensitive K^+ (K^+_{ATP}) channel; Chronotropism; Inotropism; Heart, dog (Sawaki, S. (250) 253)

Ca^{2+} current, voltage-dependent
Smooth muscle cell; Single; Tracheal; Azelastine; K^+ current (Hazama, H. (259) 143)

Ca^{2+}, cytosolic
Loratadine; Histamine H_1 receptor; PAF (platelet activating factor); Macrophage; Leukotriene; Bronchus, human (Letari, O. (266) 219)

Spontaneously hypertensive rat (SHR); Tail artery; [^{3}H]Inositol phosphate (Thorin-Trescases, N. (268) 199)

Ca^{2+} entry
NMDA (*N*-Methyl-D-aspartate); Glycine; Ca^{2+}; Cerebellar granule cells; Cell culture (Simpson, P.B. (266) 309)

Ca^{2+} entry blocker
α_1-Adrenoceptor; Ear artery, rabbit; Sgd 101/75 (Wong, P.C. (262) 185)

Ca^{2+} entry, capacitative
Endothelial cell; Patch clamp; Ca^{2+}, intracellular; Thapsigargin; NPPB (5-Nitro-2-(3-phenylpropylamino)-benzoic acid) (Gericke, M. (269) 381)

Caerulein
CCK-8 (cholecystokinin octapeptide); Morphine; Tolerance; Antinociception; (Unsulfated CCK-8) (Rezayat, M. (254) 21)

Ca^{2+}, extracellular
Myocardium, guinea-pig; Development; Nicardipine; Ryanodine; Isoproterenol (Agata, N. (260) 47)

Caffeine
Ryanodine; Cyclopiazonic acid; Ca^{2+} release; Ca^{2+} influx; Mesenteric resistance vessel; (Rat) (Naganobu, K. (251) 307)

Diabetes mellitus; Noradrenaline; Ca^{2+}, mobilization of intracellular; Aorta, rat (Hattori, Y. (256) 215)

Noradrenaline; Ca^{2+} channel; Ryanodine; G-protein; Protein kinase C; Phenoxybenzamine (Tabrizchi, R. (259) 285)

Quinpirole; *R*(−)-Propylnorapomorphine (NPA); SKF-38393; SKF-77434; Tolerance; Motor activity (Garrett, B.E. (262) 65)

Noradrenaline; Heparin; Ruthenium red; Smooth muscle, vascular (Garcha, R.S. (268) 319)

Ca^{2+} fura2
Polyamine; Spermine; Spermidine; Arcaine; 1,10-diaminodecane; Diethylenetriamine; Putrescine; *N*-Methyl-D-aspartate (NMDA); NMDA receptor (Pritchard, G.A. (266) 107)

Cage leaving
FG5893; 5-HT_{1A} receptor agonist/5-HT_{2A} receptor antagonist; 5-HT receptor; Hypothermia; Head twitch behavior; Passive avoidance; Forced swim test; Ultrasound vocalization; Corticosterone; (Rat) (Albinsson, A. (261) 285)

Ca^{2+} imaging
Phosphoinositide; Arachidonic acid; cAMP; G protein; AF102B (Gurwitz, D. (267) 21)

Ca^{2+} influx
Ryanodine; Cyclopiazonic acid; Caffeine; Ca^{2+} release; Mesenteric resistance vessel; (Rat) (Naganobu, K. (251) 307)

Ryanodine; Verapamil; Femoral artery; Spontaneously hypertensive rat (SHR) (Kojima, M. (254) 159)

P_2 Purinoceptor; P_{2U} Purinoceptor; Ca^{2+} release; Smooth muscle, vascular (Kitajima, S. (266) 263)

Vasorelaxation; 2,2′,2″-Tripyridine; cGMP (Kuei-Sen Hsu, (270) 89)

$^{45}Ca^{2+}$ influx
Hydralazine; Vas deferens (bisected, rat); [^{3}H]Noradrenaline uptake (Campos-Toimil, M. (251) 83)

Ca^{2+} inhibition
Contraction; Smooth muscle; Myometrium; Threshold phenomenon; Actin filament (Miyauchi, Y. (263) 75)

Ca^{2+}, intracellular
Tyrosine kinase; Genistein; Contractile force; Coronary tone; ANP (atrial natriuretic peptide) (Taskinen, P. (256) 251)

Protein kinase C; Smooth muscle, bovine, tracheal; Smooth muscle, contraction; Bronchodilator (Langlands, J.M. (266) 229)

NCB-20 cell; Bradykinin; ATP; Carbachol (Boyd, R.S. (267) 161)

K^+ channel clone; $K_{V1.2}$; Endothelin receptor; *Xenopus* oocyte; Protein kinase C (Murakoshi, H. (268) 451)

PAF (platelet activating factor); Inositol 1,4,5-trisphosphate; Neutrophil (Koike, H. (269) 299)

Endothelial cell; Patch clamp; Thapsigargin; Capacitative Ca^{2+} entry; NPPB (5-Nitro-2-(3-phenylpropylamino)-benzoic acid) (Gericke, M. (269) 381)

Calcimycin
Antihistamine; EDCF (endothelium-derived contracting factor); EDRF (endothelium-derived relaxing factor); Hemoglobin; Iproniazid; Mast cell; Methylene blue; N^G-Methyl-L-arginine (Gruetter, C.A. (257) 275)

Calcitonin
Analgesia; 5-HT (5-hydroxytryptamine, serotonin); *p*-Chlorophenylalanine; *p*-Chloroamphetamine; Acetic acid test (Colado, M.I. (252) 291)

Calcitriol
Psoriasis; Interleukin-8 receptor; Cyclosporine; Dithranol (Kemény, L. (258) 269)

Ca^{2+} level, cytosolic
HA1077; H-7; Relaxation; Aorta, rat; Smooth muscle, vascular (Takizawa, S. (250) 431)

Calmodulin
Nitric oxide (NO); Vasodilator nerve; Cerebral artery; Endothelium (Okamura, T. (256) 79)

Muscarinic acetylcholine receptor; Polyphosphoinositide turnover; c-*fos* expression; Protein kinase C; NG108-15 cell, transfected (Tohda, M. (268) 169)

Calmodulin antagonist
K^+ channel, slow; (Regulation) (Herzer, T. (259) 335)

Calmodulin binding
Ca^{2+} channel blocker; $(Ca^{2+} + Mg^{2+})$-ATPase (Santos, D.L. (267) 307)

Calsequestrin
Myotoxin α; Ca^{2+} releaser (Ohkura, M. (268) R1)

Ca^{2+} mobilization
Rutaecarpine; Vasorelaxant; Endothelium (Chiou, W.-F. (257) 59)

CCK_B receptor; GH_3 cells; Pituitary; Functional coupling; G-protein; L-365,260 (Smith, A.J. (267) 215)

CCK_B receptor; Polymerase chain reaction; Radioligand binding; Fura-2; COS-7 cell; Transient expression; [*N*-methyl-Nle 28,31)]cholecystokinin-(26-33) (Knapp, R.J. (269) 133)

Bosentan; Endothelin receptor antagonist; Endothelin-1 binding; Expression (Adachi, M. (269) 225)

Ca^{2+} mobilization, intracellular
Diabetes mellitus; Noradrenaline; Caffeine; Aorta, rat (Hattori, Y. (256) 215)

YM022; CCK-8 (cholecystokin-8); CCK_B/gastrin receptor antagonist; GH3 cell (Saita, Y. (269) 249)

$^{45}Ca^{2+}$ movement
Indapamide; Conductance vessel; Resistance vessel; (Rabbit); (Sheep) (Del Rio, M. (250) 133)

Cancer anorexia
Neuropeptide Y; Megestrol acetate; Appetite; Cachexia; Hypothalamus (McCarthy, H.D. (265) 99)

Cannabinoid
Δ^9-Tetrahydrocannabinol; Anandamide; Cannabinoid, endogenous; Vas deferens, mouse; Tolerance (Pertwee, R. (259) 115)

Long-term potentiation; Hippocampus (Collins, D.R. (259) R7)

Dystonia; (+)-WIN 55,212-2; GABA (γ-aminobutyric acid); Diazepam; Catalepsy (Richter, A. (264) 371)

Cannabis; Marihuana (Mailleux, P. (267) R1)

Cannabinoid, endogenous
Cannabinoid; Δ^9-Tetrahydrocannabinol; Anandamide; Vas deferens, mouse; Tolerance (Pertwee, R. (259) 115)

Cannabis
δ-9-Tetrahydrocannabinol (THC); Cerebral decortication; MK-801; NMDA receptor; In situ hybridization (Mailleux, P. (266) 193)

Cannabinoid; Marihuana (Mailleux, P. (267) R1)

Ca^{2+} oscillation
FCCP (carbonyl cyanide-*p*-trifluoromethoxyphenyl-hydrazone); Megakaryocyte, rat; Patch-clamp (Uneyama, C. (268) 455)

Cell death; Veratridine; Bovine chromaffin cell; R56865; Flunarizine; Nimodipine; ω-Conotoxin GVIA (Maroto, R. (270) 331)

Capillary
Adenosine; Adenosine A_2 receptor; Adenylyl cyclase; Endothelial cells; Heart; Coronary; (Guinea pig) (Schiele, J.O. (269) 51)

Capsaicin
Experimental colitis; Resiniferatoxin binding; Vanilloid receptor (Goso, C. (249) 185)

CCK (cholecystokinin); Secretin; Gastric emptying; Vagal afferent; Spinal afferent (Raybould, H.E. (250) 165)

CGRP (calcitonin gene-related peptide); Monoclonal anti-CGRP antibody; Immuno-neutralization; Gastric mucosa; Gastric mucosal protection; Gastric mucosal injury (Peskar, B.M. (250) 201)

Gastric hyperemia; Nitric oxide (NO) (Konturek, S.J. (253) 107)

Afferent neuron; Tachykinin; Intestine; Smooth muscle (Barthó, L. (259) 187)

Afferent nerve stimulation; Cutaneous hyperemia; Interleukin-1β; Neurogenic inflammation; Nitric oxide (NO) (Herbert, M.K. (260) 89)

Resiniferatoxin; Hypothermia; Oxygen consumption; Thermoregulation; (Rat) (Woods, A.J. (264) 125)

Airways, human; Toluene diisocyanate (Chitano, P. (270) 167)

Capsaicin-sensitive neuron
[^{3}H]Resiniferatoxin; Autoradiography; Vanilloid receptor; Dorsal root ganglia; Spinal cord (Szallasi, A. (264) 217)

Captopril
Endothelium; EDRF (endothelium-derived relaxing factor); Bradykinin; Angiotensin converting enzyme inhibitor (Hirano, K. (250) 439)

Bradykinin receptor antagonist; Bradykinin biosynthesis; Trachea; Smooth muscle, airway; Thiorphan (Farmer, S.G. (259) 309)

Angiotensin-converting enzyme; Neutral endopeptidase; SCH 34826; Heart failure; (Rat) (Helin, K. (264) 135)

Ca^{2+} pump
Tri-*n*-butyltin; Thymocyte; Thapsigargin; A23187; Cyclopiazonic acid (Oyama, Y. (270) 137)

Carbachol
DS-4574; Mast cell stabilizer; Gastric acid secretion; Histamine leakage; Pentagastrin (Tabuchi, Y. (255) 229)

Phenylephrine; Atrium, left; Negative inotropy; $^{86}Rb^+$ efflux; Pertussis toxin; 4-Aminopyridine (Ray, A. (256) 311)

NCB-20 cell; Ca^{2+}, intracellular; Bradykinin; ATP (Boyd, R.S. (267) 161)

Somatostatin; Aging; 2-Deoxyglucose; Brain slice; Cerebral cortex (Shibata, S. (269) 269)

Carbamylcholine
Ca^{2+}; 5-HT (5-hydroxytryptamine, serotonin); Trachea (Cox, D.A. (258) 265)

Carbidopa
[^{18}F]Fluoro-DOPA; Catechol-*O*-methyl transferase inhibitor; Entacapone; Brain catecholamine; PET (positron emission tomography) (Pauwels, T. (257) 53)

Carboline
Cytochrome *P*450; Steroid (Kühn-Velten, W.N. (250) R1)

β-Carboline
Harman; Norharman; Monoamine oxidase; Pargyline; (Rat) (Rommelspacher, H. (252) 51)

5-Carboxyamidotryptamine
CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Carboxyphenylglycine
Metabotropic glutamate receptor; Adenosine 3′,5′-cyclic phosphate (Cavanni, P. (269) 9)

Carboxy-PTI
PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide); PTI (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl); Radical compound; Coronary vasodilator; Methylene blue (Tsunoda, R. (262) 55)

Cardiac anaphylaxis
Langendorff heart; Staurosporine; Phorbol ester; (Guinea-pig) (Schäfer, S. (258) 247)

Cardiac arrhythmia
Autonomic nervous system; β-Adrenoceptor; Myocardial ischemia; Sudden cardiac death (Avendano, C.E. (255) 99)

Cardiac electrophysiology
Ionic current; Cardiac myocyte, isolated; κ-Opioid receptor agonist; U-50,488H (Pugsley, M.K. (261) 303)

Cardiac hypertrophy
Felodipine; Stroke-prone spontaneously hypertensive rat (SHRSP); Na^+; K^+; Mg^{2+} (Mervaala, E.M.A. (255) 73)

Cardiac muscle, rat
α-Adrenoceptor stimulation; Cl^-; Contractility (Buzzard, S.L. (260) 15)

Cardiac myocyte
Voltage-clamp, whole-cell; Cl^- channel blocker; Na^+ current; Ca^{2+} current; Diphenylamine-2-carboxylate (DPC); Ion channel blocker (Conforti, L. (259) 215)

Arenobufagin; Toad venom; Delayed rectifier K^+ current (Dos Santos Cruz, J. (266) 317)

Cardiac myocyte, isolated
Cardiac electrophysiology; Ionic current; κ-Opioid receptor agonist; U-50,488H (Pugsley, M.K. (261) 303)

Cardiac myocyte, rat
Ca^{2+} channel antagonist; Nicardipine; Ca^{2+} transient; Ca^{2+} concentration, intracellular (Jiang, J. (266) 155)

Cardiac tissue
Endothelin; Endothelin receptor; Antibodies (Shannon, T.R. (267) 233)

Cardiac ventricle
Aging; $G_{s\alpha}$ protein mRNA; $G_{s\alpha}$ subunit; β-Adrenoceptor stimulation; Inotropic effect; (Male Wistar rat) (Miyamoto, A. (266) 147)

Cardiocyte
Keratinocyte; NMDA receptor; [^{3}H]MK-801; mRNA (Morhenn, V.B. (268) 409)

Cardiohemodynamic
Pd-Ia (3′-angeloyloxy-4′-acetoxy-3′,4′-dihydroseselin); Bai-Hua Qian-Hu; Myocardium, stunned; Ca^{2+} channel antagonist (Chang, T.-h. (258) 77)

Cardiomyocyte
Thaliporphine; Bay K 8644; Positive inotropic action; Ca^{2+} channel; K^+ channel (Su, M.-J. (254) 141)

Amiodarone; Triiodothyronine; β-Adrenoceptor; (Chicken) (Yin, Y. (261) 97)

Cardiomyocyte, chick, embryonic
Indapamide; cAMP; β-Adrenoceptor stimulation; Forskolin; Cholera toxin (Rabkin, S.W. (266) 117)

Cardiomyocyte, intact
Isoproterenol; β-Adrenoceptor; Desensitization; cAMP; Forskolin (Murphy, M.G. (268) 121)

Cardioselective
Free radical scavenger; α-Tocopherol analogue; Reperfusion injury; Myocardial ischemia/reperfusion (Petty, M.A. (255) 215)

Cardiovascular
Ropinirole; Dopamine; D_2-like receptor; Spontaneously hypertensive rat (SHR); Tolerance; (Monkey) (Parker, S.G. (265) 17)

Cardiovascular effect
Nicotine; Blood pressure; Heart rate; Pentobarbital; Tachyphylaxis (Cruz, S.L. (258) 39)

Mastoparan B; Structural requirement; Hornet (*Vespa basalis*) venom (Ho, C.-L. (259) 259)

Cardiovascular function
N^G-Nitro-L-arginine; Endotoxin; PAF (platelet activating factor); Shock; (Dog) (Takekoshi, K. (250) 465)

Cardiovascular system
Spontaneously hypertensive rat (SHR); Extracellular matrix; Transforming growth factor β_1; mRNA; Renin-angiotensin system (Ohta, K. (269) 115)

Ca^{2+} release
Ryanodine; Cyclopiazonic acid; Caffeine; Ca^{2+} influx; Mesenteric resistance vessel; (Rat) (Naganobu, K. (251) 307)

P_2 Purinoceptor; P_{2U} Purinoceptor; Ca^{2+} influx; Smooth muscle, vascular (Kitajima, S. (266) 263)

Inositol 1,4,5-trisphosphate; Inositol 1,4,5-trisphosphate receptor; Heart, rat; Neonatal cardiomyocyte (Fitzgerald, M. (268) 275)

Ca^{2+} releaser
Myotoxin α; Calsequestrin (Ohkura, M. (268) R1)

Carotid, artery, common
Atherosclerosis; Histamine H_2 receptor; Hypercholesterolemia; (Rabbit); (Cannula insertion method) (Fujiwara, T. (258) 195)

Carrageenan
Thermal hyperalgesia; Excitatory amino acid; Glutamate receptor; Inflammation; Memantine (Eisenberg, E. (255) 123)

Carrier
Uptake; Amino acid; Glutamate transporter; Proximal tubule; Kidney; In situ hybridization; (Rabbit) (Meister, B. (267) 323)

Carrier coexistence
Glutamic acid; Aspartic acid; Glycine, uptake, release; Central nervous system; (Rat) (Bonanno, G. (252) 61)

Ca^{2+} sensitivity
Ca^{2+} channel antagonist; Skinned striated muscle; Tension (maximum); Inotropic state (Schiereck, P. (249) 317)

Ca^{2+} sensitivity of contractile elements
cAMP; Ca^{2+} concentration, intracellular; β_1-Adrenoceptor; Thromboxane A_2; Coronary artery (Yamagishi, T. (251) 253)

Ca^{2+} sensitizer
Crossbridge kinetics; Skinned cardiac muscle; EMD 53998; Phosphate effect (Strauss, J.D. (252) 219)

Catalepsy
Δ^9-Tetrahydrocannabinol; Anandamide; Muscimol; Globus pallidus; Drug interaction (Wickens, A.P. (250) 205)

Adenosine A_{2A} receptor antagonist; Haloperidol; Reserpine; (Mouse) (Kanda, T. (256) 263)

Glutamate; Dizocilpine; Epilepsy; Glycine receptor (Wlaź, P. (257) 217)

Dystonia; Cannabinoid; (+)-WIN 55,212-2; GABA (γ-aminobutyric acid); Diazepam (Richter, A. (264) 371)

Catalepsy-associated behavior
BW 737C89; R-SKF 38393; SKF 75670; SCH 39166; Haloperidol; SKF 81297; SKF 82958 (Rosenzweig-Lipson, S. (260) 237)

Catecholamine
PAF (platelet-activating factor); Neutrophilia; Adrenal gland (Altenburg, S.P. (256) 45)

Neuropeptide Y; [Met^5]Enkephalin; Adrenal medulla; Insulin; Hypoglycemia (Damase-Michel, C. (258) 277)

β_3-Adrenoceptor; Radioligand binding (Clarkson, K. (263) R1)

Chromaffin cell; Antidepressant; Ca^{2+} channel; Nicotine; Histamine (Firestone, J.A. (269) 177)

Brain microvessel endothelial cell; Blood-brain barrier; Pinocytosis (Borges, N. (269) 243)

Catecholamine histofluorescence
Pulmonary artery; Dopamine D_2 receptor; Radioligand binding; Autoradiography; Prejunctional receptor (Kobayashi, Y. (261) 229)

Catecholamine release
Staurosporine; Adrenal chromaffin cell; Ca^{2+} (Maurer, J.A. (253) 115)

Catecholamine secretion
PCA50941; Bay K 8644; Chromaffin cell; Dihydropyridine agonist; Ca^{2+} channel; Cytosolic Ca^{2+} (Montiel, C. (268) 293)

Catecholamine synthesis rate
Dopamine; Ethanol; Microdialysis (in vivo); Nicotinic acetylcholine receptor; (Rat) (Blomqvist, O. (249) 207)

Catechol *O*-methyltransferase inhibition
6-Hydroxydopamine; Circling behavior; L-DOPA (L-3,4-dihydroxyphenylalanine); Dopamine; Metabolism (Törnwall, M. (250) 77)

Catechol-*O*-methyl transferase inhibitor
[^{18}F]Fluoro-DOPA; Entacapone; Carbidopa; Brain catecholamine; PET (positron emission tomography) (Pauwels, T. (257) 53)

Cation channel, non-specific
Cyclopiazonic acid; Endothelium (Zhang, H. (251) 119)

Ca^{2+} transient
Ca^{2+} channel antagonist; Nicardipine; Ca^{2+} concentration, intracellular; Cardiac myocyte, rat (Jiang, J. (266) 155)

Cauda epididymis
Vas deferens; α_2-Adrenoceptor; α_1-Adrenoceptor; [^{3}H]Rauwolscine; [^{3}H]Prazosin; (Rat) (Ventura, S. (254) 167)

Caudal artery, rat
Muscarine receptor, prejunctional (Shen, A. (252) 167)

Caudate nucleus, pig
[^{3}H]L-694,247 (2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1*H*-indole-3-yl]ethylamine); 5-$HT_{1D\alpha}$/5-$HT_{1D\beta}$ receptor (Heald, A. (264) 213)

Caudate-putamen
Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin); Patch clamp; Substantia nigra; Ventral tegmental area; Nucleus accumbens (Liu, J.-C. (264) 269)

$^{45}Ca^{2+}$ uptake
Hypoxia; Thromboxane; U46619; Coronary artery (Dalen, T. (270) 313)

β-CCE (β-carboline-3-carboxylate ethyl ester)
Nucleus accumbens; Dopamine release; Midazolam; $GABA_A$/benzodiazepine receptor; Adenosine receptor (Murai, T. (261) 65)

L-CCG-I ((2*S*,1′*S*,2′*S*)-2-(carboxycyclopropyl)glycine)
Metabotropic glutamate receptor; Halothane anesthesia; Glutamate receptor agonist; DCG-IV ((2*S*,1′*R*,2′*R*,3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine); Adenylyl cyclase (Miyamoto, M. (260) 99)

Metabotropic glutamate receptor; Spinal cord, isolated; cAMP; Phosphoinositide hydrolysis; ACPD((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); Cortical cell culture (Ishida, M. (268) 267)

CCK-8 binding
Brain membrane; CCK_B receptor; Gastrin binding; G protein (Lallement, J.-C. (267) 297)

CCK (cholecystokinin)
Gastrin; CCK receptor antagonist; Gastric acid secretion (Varga, G. (250) 37)

Secretin; Gastric emptying; Capsaicin; Vagal afferent; Spinal afferent (Raybould, H.E. (250) 165)

Substance P; Clonazepam; Monoamine uptake inhibitor; Panic disorder; Central nervous system, rat (Brodin, K. (263) 175)

CCK-8 (cholecystokinin octapeptide)
GABA (γ-aminobutyric acid); Anxiety; Release; Brain; CCK receptor; (In vitro); (Slice) (Pérez de la Mora, M. (250) 423)

Caerulein; Morphine; Tolerance; Antinociception; (Unsulfated CCK-8) (Rezayat, M. (254) 21)

Pentagastrin; Nitric oxide (NO) (Stroff, T. (260) R1)

CCK receptor antagonist; BC-264; Dopamine; Nomifensine; Depression; L-365,260 (Hernando, F. (261) 257)

YM022; CCK_B/gastrin receptor antagonist; GH3 cell; Ca^{2+} mobilization, intracellular (Saita, Y. (269) 249)

CCK_B/gastrin receptor antagonist
YM022; CCK-8 (cholecystokinin-8); GH3 cell; Ca^{2+} mobilization, intracellular (Saita, Y. (269) 249)

CCK receptor
CCK-8 (cholecystokinin octapeptide); GABA (γ-aminobutyric acid); Anxiety; Release; Brain; (In vitro); (Slice) (Pérez de la Mora, M. (250) 423)

CCK_A receptor
CGRP (calcitonin gene-related peptide), C-terminal fragment; Vasopressin; Somatostatin-28; Iris (monkey) (Almegård, B. (250) 31)

CCK_B receptor
Binding; Brain; Electrophysiology; Gastric acid secretion; Neuropeptide (Bertrand, P. (262) 233)

GH_3 cells; Pituitary; Functional coupling; G-protein; Ca^{2+} mobilisation; L-365,260 (Smith, A.J. (267) 215)

Brain membrane; Gastrin binding; CCK_8 binding; G protein (Lallement, J.-C. (267) 297)

Pharmacology; Cloning; Small cell lung carcinoma; Enterochromaffin-like cell-oma (Denyer, J. (268) 29)

Polymerase chain reaction; Radioligand binding; Calcium mobilization; Fura-2; COS-7 cell; Transient expression; [*N*-methyl-Nle 28,31)]cholecystokinin-(26-33) (Knapp, R.J. (269) 133)

CCK receptor antagonist
Gastrin; CCK (cholecystokinin); Gastric acid secretion (Varga, G. (250) 37)

CCK-8; BC-264; Dopamine; Nomifensine; Depression; L-365,260 (Hernando, F. (261) 257)

Loxiglumide; MK-329; Bile flow; Bilirubin secretion (Watanabe, N. (264) 331)

CCK_B receptor antagonist
Ex vivo binding; L-365,260; CI988; L-368,935; Brain penetration (Patel, S. (253) 237)

CD-832
Ca^{2+} channel antagonist; cGMP; cAMP; Aorta vasodilatation; (Rabbit) (Miyata, N. (249) 141)

Ca^{2+} channel antagonist; Femoral vein; Femoral artery; (Rabbit) (Yamaura, H. (260) 269)

Cd^{2+}
Metallothionein; Heat shock protein; Lymphocyte (Pellegrini, O. (270) 221)

Metallothionein; Nephrotoxicity; Hepatotoxicity; (Rat) (Sudo, J.-i. (270) 229)

293 cell
ICS 205–930; 5-HT_3 receptor antagonist; $GABA_A$ receptor; [^{3}H]Flunitrazepam binding; [^{3}H]Muscimol binding; [^{35}S]TBPS (tert-butylbicyclophosphorothionate) binding; $^{36}Cl^-$ flux; *Xenopus* oocyte (Klein, R.L. (268) 237)

Cell culture
Interleukin-1β; Lipopolysaccharide; Nitric oxide (NO); DL-Propranolol; Smooth muscle, vascular; Spontaneously hypertensive rat (SHR); Wistar Kyoto rat (WKY); (Rat) (De Castro, M. (261) 199)

NMDA (*N*-Methyl-D-aspartate); Glycine; Ca^{2+}; Ca^{2+} entry; Cerebellar granule cells (Simpson, P.B. (266) 309)

Cell cycle
Actinomycin D; Cytotoxicity; Phase dependency (Wu, M.-H. (270) 203)

Cell death
Ca^{2+} oscillation; Veratridine; Bovine chromaffin cell; R56865; Flunarizine; Nimodipine; ω-Conotoxin GVIA (Maroto, R. (270) 331)

Serum amyloid P component; Cerebral culture; Cerebral cortex, rat; Alzheimer's disease (Urbányi, Z. (270) 375)

Cell differentiation modulator
Retinoid (synthetic); Anti-angiogenic action; Embryonic angiogenesis; Angiogenic disorder (Oikawa, T. (249) 113)

Cell nucleus
Vasopressin; Vasopressin receptor; Peptide; Vasopressin receptor antagonist (Phillips, P.A. (259) 325)

Cell proliferation
Smooth muscle, vascular; Dihydropyridine-sensitive Ca^{2+} channel; Voltage-dependent Ca^{2+} channel; Scatchard analysis; Modulated receptor model; Atherosclerosis (Ruiz-Velasco, V. (268) 311)

Fumaric acid; Psoriasis; Keratinocyte; Cytotoxicity (Sebök, B. (270) 79)

β-Cell replication
Glibenclamide; Sulphonylurea; Diabetes; Pancreatic islet (Guiot, Y. (261) 157)

CEM cell
Baicalein; Esculetin; Antiproliferative effect; Transduction signal; Messenger RNA expression (Huang, H.-C. (268) 73)

Central nervous system
Cholinomimetic; Muscarinic M_2 receptor; Blood pressure (Özkutlu, U. (250) 349)

Glutamic acid; Aspartic acid; Glycine, uptake, release; Carrier coexistence; (Rat) (Bonanno, G. (252) 61)

Selective serotonin reuptake inhibitor; 5-HT_{1A} autoreceptor; Antidepressant; Microdialysis, in vivo; 5-HT (5-hydroxytryptamine, serotonin) release (Hjorth, S. (260) 251)

Central nervous system penetration
Tachykinin NK_1 receptor; Chromodacryorrhea; Foot tapping; (Gerbil) (Rupniak, N.M.J. (265) 179)

Central nervous system, rat
CCK (cholecystokinin); Substance P; Clonazepam; Monoamine uptake inhibitor; Panic disorder (Brodin, K. (263) 175)

Central nucleus of amygdala
Tryptophan hydroxylase; Acute sound stress; Hypophysectomy; Hypothalamic deafferentation; RU 38486 (Singh, V.B. (256) 177)

Central respiratory activity
5-HT (5-hydroxytryptamine, serotonin); (Newborn rat); (In vitro) (Monteau, R. (259) 71)

Cerebellar cortex
Polyamine; [^{3}H]Spermidine binding; Autoradiography; Brain development, human (McConnell, S.E. (262) 293)

Cerebellar granule cells
NMDA (*N*-Methyl-D-aspartate); Glycine; Ca^{2+}; Ca^{2+} entry; Cell culture (Simpson, P.B. (266) 309)

Cerebellar neuron
Antioxidant; β-Adrenoceptor antagonist; Lipid peroxidation; Oxidative stress; Endothelial cell (Yue, T.-L. (251) 237)

L-2-Amino-3-phosphonopropionate; Neurotoxicity; Metabotropic glutamate receptor; NMDA receptor (Novelli, A. (270) 361)

Cerebellum
σ-Receptor ligands; DTG (1,3-di(2-tolyl)guanidine); Liver; (Guinea-pig) (Basile, A.S. (252) 139)

Microdialysis; Metalloporphyrins; Nitric oxide synthase; Guanylyl cyclase; cGMP (Luo, D. (267) 263)

Cerebral artery
Nitric oxide (NO); Vasodilator nerve; Calmodulin; Endothelium (Okamura, T. (256) 79)

Cerebral basilar artery
Neuropeptide Y; Vasoconstriction; K^+ channel; BRL38227; Diazoxide (Xia, Y. (255) 67)

Cerebral blood flow
Nitric oxide (NO); N^G-Nitro-L-arginine methylester (L-NAME); Halothane; Anesthetics (Dawson, D.A. (249) 7)

Sympathomimetic anesthesia; Prostaglandin; Lidocaine; Tetrodotoxin; Charybdotoxin; (Neonate) (Albuquerque, M.L.C. (249) 215)

Adenosine receptor; Brain ischemia, therapy; (Gerbil) (Von Lubitz, D.K.J.E. (263) 59)

Cerebral cortex
Adenosine; Brain microdialysis; Tetrodotoxin; NMDA receptor; Muscarinic receptor (Pazzagli, M. (254) 277)

α_1-Adrenoceptor subtype; [^{3}H]Prazosin; Chloroethylclonidine; Benextramine; Phenoxybenzamine (Sallés, J. (266) 301)

Somatostatin; Aging; Carbachol; 2-Deoxyglucose; Brain slice (Shibata, S. (269) 269)

Imidazoline receptor; α_2-Adrenoceptor; cAMP; Brainstem; Inositol phosphate (Regunathan, S. (269) 273)

Cerebral cortex, rat
1,4-Dithiothreitol; Histamine; Inositol phosphate; [^{3}H]Mepyramine; HeLa cell (Young, K.W. (269) 283)

Serum amyloid P component; Cerebral culture; Cell death; Alzheimer's disease (Urbányi, Z. (270) 375)

Cerebral culture
Serum amyloid P component; Cerebral cortex, rat; Cell death; Alzheimer's disease (Urbányi, Z. (270) 375)

Cerebral decortication
Cannabis; δ-9-Tetrahydrocannabinol (THC); MK-801; NMDA receptor; In situ hybridization (Mailleux, P. (266) 193)

Cerebral infarction, focal
Magnetic resonance image; U74006F; Lipid peroxidation; Rose bengal (Umemura, K. (251) 69)

Cerebral ischemia
Glutamate; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Microdialysis; Excitotoxin (Gaspary, H.L. (262) 197)

Cerebral microcirculation
Cocaine; Laser-Doppler; Stroke; (Rat) (Muir, J.K. (249) 287)

Cerebral vasospasm
Bradykinin; Substance P; Vasopressin; EDRF (endothelium-derived relaxing factor); Subarachnoid hemorrhage (Tsuji, T. (264) 77)

Cerebrovascular circulation
Endothelin; Cerebrovascular disease (Patel, T.R. (260) 65)

Cerebrovascular disease
Endothelin; Cerebrovascular circulation (Patel, T.R. (260) 65)

c-*fos*
G protein; Guanylnucleotide; Mitogenesis; Adenylyl cyclase; Phospholipase C; Phorbol ester; Pertussis toxin (Pilon, C. (268) 129)

c-*fos* expression
Neuroblastoma SH-SY5Y cell; Protein kinase C; Muscarinic-receptor-stimulation; Diacylglycerol (Larsson, C. (268) 19)

Muscarinic acetylcholine receptor; Polyphosphoinositide turnover; Calmodulin; Protein kinase C; NG108-15 cell, transfected (Tohda, M. (268) 169)

CFT (WIN 35,428)
Dopamine transporter; GBR 12909; Cocaine; 5-HT (5-hydroxytryptamine, serotonin) transporter; Parkinson's disease (Madras, B.K. (267) 167)

CGP 35348
Neocortex, human; GABA (γ-aminobutyric acid) release; $GABA_B$ autoreceptor; CGP 52432; Phaclofen (Fassio, A. (263) 311)

CGP 37849
Antiepileptic; CGP 39551; Seizure (Pietrasiewicz, T. (250) 1)

Depression, animal model; Anhedonia; MK-801; CGP 40116; Imipramine; (Rat) (Papp, M. (263) 1)

CGP 39551
Antiepileptic; CGP 37849; Seizure (Pietrasiewicz, T. (250) 1)

CGP 40116
Depression, animal model; Anhedonia; MK-801; CGP 37849; Imipramine; (Rat) (Papp, M. (263) 1)

CGP 52432
Neocortex, human; GABA (γ-aminobutyric acid) release; $GABA_B$ autoreceptor; CGP 35348; Phaclofen (Fassio, A. (263) 311)

CGP 36742 (3-aminopropyl-*n*-butyl-phosphinic acid)
$GABA_B$ receptor; Spinal cord; Plasticity; Autoradiography; (−)-Baclofen (Malcangio, M. (250) 153)

CGP 37849 (DL-(*E*)-2-amino-4-methyl-5-phosphono-3-pentenoic acid)
Haloperidol-induced catalepsy; GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5*H*-2,3-benzodiazepine HCl); AMPA receptor; NMDA receptor; (Rat) (Hauber, W. (256) 339)

α-CGRP
Acetylcholine; Adenosine; Angiotensin II; Atrium; Contractility; Somatostatin; Ventricle; (Human) (Du, X.Y. (259) 173)

α-CGRP-(8–37)
Plasma protein extravasation; Dura mater; Tachykinin NK_1 receptor; GR82334 (O'Shaughnessy, C.T. (263) 193)

CGRP (calcitonin gene-related peptide)
Capsaicin; Monoclonal anti-CGRP antibody; Immuno-neutralization; Gastric mucosa; Gastric mucosal protection; Gastric mucosal injury (Peskar, B.M. (250) 201)

Ulcer; Nitric oxide (NO) (Clementi, G. (256) R7)

Pulmonary vascular bed; Vasoactive peptide; Adrenomedullin; Pancreatic amylin (DeWitt, B.J. (257) 303)

IAPP (islet amyloid polypeptide); Salmon calcitonin; Nucleus accumbens (Veale, P.R. (262) 133)

Saphenous artery; Vasodilator nerve; Nitric oxide (NO); Nicotine (Okamura, T. (263) 85)

CGRP, C-terminal fragment
Vasopressin; Somatostatin-28; CCK_A receptor; Iris (monkey) (Almegård, B. (250) 31)

α-CGRP, human
αCGRP-(8–37), human; βCGRP-(8–37), human; Vas deferens, rat; Atrium, guinea-pig; SK-N-MC cell (Longmore, J. (265) 53)

α-CGRP-(8–37), human
αCGRP (calcitonin-gene related peptide), human; βCGRP-(8–37), human; Vas deferens, rat; Atrium, guinea-pig; SK-N-MC cell (Longmore, J. (265) 53)

β-CGRP-(8–37), human
αCGRP (calcitonin-gene related peptide), human; αCGRP-(8–37), human; Vas deferens, rat; Atrium, guinea-pig; SK-N-MC cell (Longmore, J. (265) 53)

CGS 8216
Loreclezole; Anxiolytic; Flumazenil; (Rat) (Dawson, G.R. (252) 325)

CGS 21680
Adenosine A_1 receptor; Adenosine A_{2A} receptor; Seizure; Prepiriform cortex; [^{3}H]DPCPX (8-Cyclopentyl-1,3-[^{3}H]dipropylxanthine) (Zhang, G. (255) 239)

CGS 10746B
Conditioned place preference/aversion; Dopamine; Locomotor activity; (Rat) (Schechter, M.D. (260) 133)

CGS 19755 (*cis*-4-(phosphonomethyl)piperidine-2-carboxylic acid)
NMDA receptor antagonist, competitive; Dopamine synthesis; Hyperactivity; Amphetamine; (±)-CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Bristow, L.J. (264) 353)

Charybdotoxin
Cerebral blood flow; Sympathomimetic anesthesia; Prostaglandin; Lidocaine; Tetrodotoxin; (Neonate) (Albuquerque, M.L.C. (249) 215)

Chemically gated current
Hippocampal neuron, isolated; Concentration jump; Glutamate receptor; NMDA receptor (Wilsch, V.W. (262) 287)

Chemical mediator
Endothelin; Mast cell; Histamine; Leukotriene (Yamamura, H. (257) 235)

Chemotaxis
Nimesulide; Polymorphonuclear leukocyte; Phosphodiesterase type IV; Superoxide anion; cAMP (Bevilacqua, M. (268) 415)

Chimaeric receptor
Muscarinic M_2 receptor; G-protein coupling; (Peptide mimics) (McClue, S.J. (267) 185)

Chloral hydrate, anesthesia
Dopamine neuron; Depolarization inactivation; Haloperidol, chronic; Schizophrenia; (Rat) (Mereu, G. (264) 449)

Chloramine-T
Inwardly rectifying K^+ channel; Ventricular myocyte; Patch-clamp technique; Voltage-dependent inactivation; Inactivation gate; (Guinea pig) (Koumi, S.-i. (258) 281)

Chlordiazepoxide
Pentobarbital; Angiotensin; Blood pressure; (Spontaneously hypertensive rat (SHR)) (Sim, M.K. (253) 171)

***p*-Chloroamphetamine**
Calcitonin; Analgesia; 5-HT (5-hydroxytryptamine, serotonin); *p*-Chlorophenylalanine; Acetic acid test (Colado, M.I. (252) 291)

σ Receptor ligand; SKF-10,047; DTG (1,3-di-(2-tolyl)guanidine); Benzomorphan-type σ receptor; Acetylcholinergic neuronal system; Amnesia; Passive avoidance task; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperizine); (Mouse) (Matsuno, K. (261) 43)

Chloroethylclonidine
α_1-Adrenoceptor subtype; Nifedipine; Vas deferens, rat; Spleen, rat; Prostate, human (Teng, C.-M. (265) 61)

α_1-Adrenoceptor subtype; [^{3}H]Prazosin; Benextramine; Phenoxybenzamine; Cerebral cortex (Sallés, J. (266) 301)

7-Chlorokynurenate
Glycine site; Hippocampus; Working memory; Reference memory (Ohno, M. (253) 183)

NMDA (*N*-methyl-D-aspartate); Glycine; Polyamine; Ifenprodil; (Synergism) (Voltz, C. (255) 197)

Polyamine; NMDA receptor antagonist, competitive; Glycine recognition site; NMDA receptor complex; Brain, rat (Oblin, A. (266) 103)

***p*-Chlorophenylalanine**
Calcitonin; Analgesia; 5-HT (5-hydroxytryptamine, serotonin); *p*-Chloroamphetamine; Acetic acid test (Colado, M.I. (252) 291)

MMAI (5-methoxy-6-methyl-2-aminoindan); Drug discrimination; Behavioral syndrome; 5-HT (5-hydroxytryptamine, serotonin) release; (Rat) (Marona-Lewicka, D. (258) 1)

Food intake; *d*-Fenfluramine; *d*-Norfenfluramine; Microdialysis (Oluyomi, A.O. (264) 111)

***m*-Chlorophenylbiguanide**
5-HT_3 receptor; MDL 72222; Sleep; Wakefulness (Ponzoni, A. (249) 259)

5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

CHO (Chinese hamster ovary) cell
Dopamine D_{1a} receptor; Dopamine D_{1b} receptor; cDNA; Clonal cell line; Baby Hamster Kidney cells; Clozapine; Ca^{2+} (Pedersen, U.B. (267) 85)

α_{1B}-Adrenoceptor; Radioligand binding studies; Ca^{2+} concentration, cytosolic (Horie, K. (268) 399)

Tachykinin; Tachykinin NK_3 receptor; [^{125}I][MePhe^7]neurokinin B binding; Species variation (Suman-Chauhan, N. (269) 65)

Tachykinin; Neurokinin; Antagonist; Structure-activity; Ca^{2+}; Second messenger; Inositol phosphate; Thapsigargin; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

CHO-K1 cell
Tripitramine; Methoctramine; Muscarinic receptor subtype; Binding affinity (Maggio, R. (268) 459)

[*N*-methyl-Nle 28,31)]Cholecystokinin-(26–33)
CCK_B receptor; Polymerase chain reaction; Radioligand binding; Calcium mobilization; Fura-2; COS-7 cell; Transient expression (Knapp, R.J. (269) 133)

Cholera toxin
Indapamide; cAMP; β-Adrenoceptor stimulation; Cardiomyocyte (chick, embryonic); Forskolin (Rabkin, S.W. (266) 117)

Nitric oxide (NO); cAMP analog; Peritoneal macrophage; (Rat) (Sowa, G. (266) 125)

Pertussis toxin; Okadaic acid; Na^+-H^+ antiport; Mast cell; Sodium propionate (Alfonso, A. (267) 289)

Bombesin receptor, lung; Guanine nucleotide sensitivity; G-protein; Pertussis toxin; (Guinea pig) (Lach, E. (269) 87)

Choline acetyltransferase
Senile dementia of the Alzheimer type; Nerve growth factor synthesis stimulator; Nerve growth factor; Water maze; Astroglia cell (Nitta, A. (250) 23)

Cholinergic contraction
Lung strip, guinea pig; Muscarinic M_2 receptor; Trachea, guinea pig; Smooth muscle, human, airway (Roffel, A.F. (250) 267)

Cholinergic innervation
Neuroimmunomodulation; Parasympathetic nervous system; Cyclosporine; Lymphoid tissue; Acetylcholine, synthesis and release; Choline uptake; Sympathetic nervous system; Superior cervical ganglion (Esquifino, A.I. (254) 1)

Cholinergic neuron
Spinal cord; Medulla oblongata; Blood pressure; Heart rate (Feldman, D.S. (250) 483)

Cholinergic regulation, presynaptic
Acetylcholine release; HPLC-ECD system; Muscarinic receptor agonist; Muscarinic receptor antagonist; Ileum (guinea-pig); Bethanechol; p-F-HHSiD (*p*-fluoro-hexahydro-siladifenidol); AF102B. (Soejima, O. (249) 1)

Cholinesterase inhibitor
Growth hormone; Growth hormone-releasing hormone; Bethanechol (Mazza, E. (254) 17)

Choline uptake
Neuroimmunomodulation; Parasympathetic nervous system; Cyclosporine; Lymphoid tissue; Cholinergic innervation; Acetylcholine, synthesis and release; Sympathetic nervous system; Superior cervical ganglion (Esquifino, A.I. (254) 1)

Cholinomimetic
Muscarinic M_2 receptor; Blood pressure; Central nervous system (Özkutlu, U. (250) 349)

Galanin; Muscarinic receptor agonist; Hypothermia; ATP-sensitive K^+ channel; Acetylcholinesterase inhibitor (Patel, S. (255) 25)

Nerve terminal current; Acetylcholine; Anticholinesterase (Shakiryanova, D.M. (263) 107)

Chorioallantoic membrane
Angiogenesis; Leukotriene; (Chick) (Tsopanoglou, N.E. (258) 151)

Choroid
Blood flow; Ciliary body; Iris; PACAP (pituitary adenylate cyclase activating polypeptide); Vasodilatation (Nilsson, S.F.E. (253) 17)

Choroid plexus
5-HT_1C receptor; Clozapine; Receptor reserve; Autoradiography; Phosphoinositide hydrolysis (Kuoppamäki, M. (255) 91)

Atypical antipsychotic; Autoradiography; Clozapine; 5-HT_{2C} receptor; Phosphoinositide hydrolysis (Kuoppamäki, M. (269) 201)

Chromaffin cell
PCA50941; Bay K 8644; Catecholamine secretion; Dihydropyridine agonist; Ca^{2+} channel; Cytosolic Ca^{2+} (Montiel, C. (268) 293)

Catecholamine; Antidepressant; Ca^{2+} channel; Nicotine; Histamine (Firestone, J.A. (269) 177)

Chroman
Melatonin; 2-Iodomelatonin binding; Melanophore; Pigment aggregation; Melatonin receptor (Sugden, D. (254) 271)

Chromodacryorrhea
Tachykinin NK_1 receptor; Hind paw tapping; (Gerbil) (Bristow, L.J. (253) 245)

Tachykinin NK_1 receptor; Foot tapping; CNS (central nervous system) penetration; (Gerbil) (Rupniak, N.M.J. (265) 179)

Chronic
Li^+; ATPase; Soleus; Plantaris; Extensor digitorum longus (Adipudi, V. (259) 7)

Chronic mild stress
Depression model, rat; Imipramine, chronic; cAMP; β-Adrenoceptor; Sucrose intake (Papp, M. (261) 141)

Chronic treatment
Imidazenil; $GABA_A$ receptor, partial agonist; Tolerance (Ghiani, C.A. (254) 299)

Abecarnil; Diazepam; Tolerance; GABAergic transmission; (Mouse) (Serra, M. (259) 1)

Chronic variable stress
Morphine; Locomotor activity; Antidepressant (Molina, V.A. (260) 57)

Chronotropic effect
ANP (atrial natriuretic peptide); Angiotensin II; (Dog model) (Lambert, C. (252) 245)

Chronotropism
E4080; Hyperpolarization-activated inward current (I_f); Ca^{2+} current (L-type, I_{Ca}); ATP-sensitive K^+ (K^+_{ATP}) channel; Inotropism; Heart, dog (Sawaki, S. (250) 253)

CI-977
κ-Opioid receptor agonist; R-84760; U-50488; Morphine; Antinociceptive effect (Fujibayashi, K. (261) 133)

CI-988
CCK_B receptor antagonist; Ex vivo binding; L-365,260; L-368,935; Brain penetration (Patel, S. (253) 237)

Cibacron blue
P_{2X} purinoceptor; iso-PPADS (pyridoxalphosphate-6-azophenyl-2′,5′-disulphonic acid); Suramin (Khakh, B.S. (263) 301)

Cicletanine
Indapamide; 5-OH-Indapamide; Hydrochlorothiazide; K^+; Ca^{2+} (Calder, J.A. (256) 185)

Cigarette smoke
Airway hyperreactivity; Bronchoalveolar lavage; Leukotriene B_4; IdB 1031 (Hernandez, A. (270) 301)

Ciliary body
Blood flow; Choroid; Iris; PACAP (pituitary adenylate cyclase activating polypeptide); Vasodilatation (Nilsson, S.F.E. (253) 17)

Cimetidine
Gastric ulcer; Omeprazole; Gastrin; Gastric acid (Ito, M. (263) 245)

Omeprazole; Acid secretion; Gastrin (Ito, M. (263) 253)

Histamine H_2 receptor antagonist; Hypochlorous acid scavenger (Ching, T.-L. (268) 89)

Cinnamophilin
Thromboxane A_2 receptor antagonist; Ca^{2+} channel blocker, voltage-dependent; Thoracic aorta; (Rat) (Yu, S.-M. (256) 85)

Circling behavior
Catechol *O*-methyltransferase inhibition; 6-Hydroxydopamine; L-DOPA (L-3,4-dihydroxyphenylalanine); Dopamine; Metabolism (Törnwall, M. (250) 77)

Circular muscle
Peristalsis; Nitric oxide (NO); N^G-Nitro-L-arginine; Ileum, guinea-pig (Suzuki, N. (251) 221)

Circulatory shock
Endotoxin shock; Vasodilatation; Vascular hyporeactivity; Cytokine (Szabó, C. (250) 157)

Cisplatin
Emesis; Copper sulfate; Vagal afferent; 5-HT_3 receptor antagonist; (Monkey) (Fukui, H. (249) 13)

Emesis, acute, delayed (Rudd, J.A. (262) R1)

Drug resistance; Excision repair; Ultraviolet (Chao, C.C.-K. (268) 347)

Citalopram
5-HT (5-hydroxytryptamine, serotonin); Microdialysis; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} receptor desensitization (Invernizzi, R. (260) 243)

Citric acid
Tachykinin NK_2 receptor; SR 48968; Antitussive effect; Cough reflex; (Guinea-pig) (Advenier, C. (250) 169)

Cl^-
α-Adrenoceptor stimulation; Contractility; Cardiac muscle, rat (Buzzard, S.L. (260) 15)

Class I antiarrhythmic
Na^+ channel, human; Oocyte; DPI 201-106 (Krafte, D.S. (266) 245)

Cl^- channel
Propofol; [^{35}S]TBPS (*t*-[^{35}S]butylbicyclophosphorothionate) binding; GABA (γ-aminobutyric acid); Barbiturate; Steroid derivative; Benzodiazepine; General anesthetics (Concas, A. (267) 207)

Cl^- channel antagonist
Voltage-clamp, whole-cell; Cardiac myocyte; Na^+ current; Ca^{2+} current; Diphenylamine-2-carboxylate (DPC); Ion channel blocker (Conforti, L. (259) 215)

Cl^-, extracellular
Aortic endothelial cell; Ca^{2+} concentration, intracellular, free; Fura-2; Endothelium-dependent vasodilator (Hosoki, E. (266) 213)

$^{36}Cl^-$ flux
ICS 205–930; 5-HT_3 receptor antagonist; $GABA_A$ receptor; [^{3}H]Flunitrazepam binding; [^{3}H]Muscimol binding; [^{35}S]TBPS (tert-butylbicyclophosphorothionate) binding; 293 cell; *Xenopus* oocyte (Klein, R.L. (268) 237)

Clobenpropit
Histamine H_3 receptor; Imetit; Histidine decarboxylase; Convulsion, electrically induced; Histamine, brain (Yokoyama, H. (260) 23)

Clomipramine
5-HT_{1C} receptor; [^{3}H]Mesulergine; Imipramine; Clorgyline; (Wistar rat) (Hulihan-Giblin, B.A. (263) 213)

Clonal cell line
Dopamine D_{1a} receptor; Dopamine D_{1b} receptor; cDNA; Baby Hamster Kidney cells; Chinese Hamster Ovary cell; Clozapine; Ca^{2+} (Pedersen, U.B. (267) 85)

Clonazepam
CCK (cholecystokinin); Substance P; Monoamine uptake inhibitor; Panic disorder; Central nervous system, rat (Brodin, K. (263) 175)

Clonic seizure-like behavior
Morphine, intrathecal; NMDA receptor; MK-801; Glycine co-agonist site; ACEA-1011 (Lutfy, K. (252) 261)

Clonidine
Morphine; Opiate withdrawal syndrome; Naloxone; Aversive conditioning (Kosten, T.A. (254) 59)

Buspirone; 1-PP (1-(2-pyrimidinyl)-piperazine); α_2-Adrenoceptor; Antinociception (Cao, B.-J. (259) 75)

Autotomy; Flexor reflex; Guanfacine; Pain; ST-91 (Puke, M.J.C. (260) 227)

Imidazoline; Brain, human (Greney, H. (265) R1)

Brainstem (Human); Imidazoline receptor; GTP; Phenoxybenzamine; α-Adrenoceptor (Bricca, G. (266) 25)

Cloning
CCK_B receptor; Pharmacology; Small cell lung carcinoma; Enterochromaffin-like cell-oma (Denyer, J. (268) 29)

Clorgyline
5-HT_{1C} receptor; [^{3}H]Mesulergine; Clomipramine; Imipramine; (Wistar rat) (Hulihan-Giblin, B.A. (263) 213)

Clozapine
Thermoregulation; Dopamine; Dopamine receptor; (Rat) (Salmi, P. (253) 67)

Sertindole; Haloperidol; Short-term treatment; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (254) 291)

5-HT_1C receptor; Choroid plexus; Receptor reserve; Autoradiography; Phosphoinositide hydrolysis (Kuoppamäki, M. (255) 91)

Raphe; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor (Lejeune, F. (260) 79)

Jaw movement; Apomorphine; Nucleus accumbens; Striatum; Muscarinic acetylcholine receptor (Kikuchi de Beltrán, K. (262) 49)

Paw test; α_1-Adrenoceptor; 5-HT_{2A} receptor; Dopamine D_1 receptor (Prinssen, E.P.M. (262) 167)

Haloperidol; Microdialysis; Striatum; Glutamate; GABA (γ-aminobutyric acid) (See, R.E. (263) 269)

Dopamine D_{1a} receptor; Dopamine D_{1b} receptor; cDNA; Clonal cell line; Baby Hamster Kidney cells; Chinese Hamster Ovary cell; Ca^{2+} (Pedersen, U.B. (267) 85)

Atypical antipsychotic; Autoradiography; Choroid plexus; 5-HT_{2C} receptor; Phosphoinositide hydrolysis (Kuoppamäki, M. (269) 201)

Clozaril
Neuroleptic; (Human) (Zorn, S.H. (269) R1)

CO_2
Neurosteroid; Stress; Handling; Brain, rat (Barbaccia, M.L. (261) 317)

Cocaine
Amphetamine; Motor activity; δ-Opioid receptor antagonist; Opioid-dopamine interaction (Jones, D.N.C. (249) 167)

Cerebral microcirculation; Laser-Doppler; Stroke; (Rat) (Muir, J.K. (249) 287)

Deprenyl; Drug discrimination (Yasar, S. (259) 243)

Drug discrimination; Naltrindole; Naltriben; 7-Benzylidenenaltrexone (Suzuki, T. (263) 207)

Dopamine uptake; Dopamine transporter (Izenwasser, S. (263) 277)

Dopamine transporter; GBR 12909; 5-HT (5-hydroxytryptamine, serotonin) transporter; CFT (WIN 35,428); Parkinson's disease (Madras, B.K. (267) 167)

Dopamine transporter; Protein kinase C (Kitayama, S. (268) 115)

Cytochrome P450; Liver, mouse, human; Hepatotoxicity (Pellinen, P. (270) 35)

[^{3}H]Cocaine
Dopamine carrier (neuronal); Na^+-dependence; N-ethylmaleimide treatment; [^{3}H]GBR 12783; Binding in vitro; Striatum; (Rat) (Saadouni, S. (268) 187)

Coenzyme Q
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Diethyldithiocarbamate; Lipoic acid; α-Tocopherol; Brain (mouse) (Götz, M.E. (266) 291)

Cognition
NE-100; σ Receptor; Phencyclidine; Neuroleptic; (Rat) (Ogawa, S.-i. (263) 9)

Colocyte
Adrenoceptor; Testosterone; Adipocyte; Kidney; Brain; Liver (Bouloumié, A. (269) 95)

Colon
VIP (vasoactive intestinal peptide) receptor antagonist; Short-circuit current; Mucosa (Burleigh, D.E. (249) 239)

Skinned muscle; cGMP; NAMC (non-adrenergic, non-cholinergic) inhibition; (Rat) (Maehara, T. (261) 163)

Colon, human
Excitatory nerve; Opioid receptor agonist; Opioid receptor antagonist; Smooth muscle (Chamouard, P. (262) 33)

Colonic cell line, human
Mucus secretion; Cytokine regulation; Interferon-γ; cAMP; MUC2 mucin gene (Jarry, A. (267) 95)

Colon, proximal, guinea-pig
Substance P; CP-96345; SR 48968; WIN 51708; WIN 62577 (Briejer, M.R. (250) 181)

Compound 48/80
Norathyriol; Passive cutaneous anaphylaxis; Neurogenic inflammation; Vascular permeability; Mast cell; (Mouse) (Wang, J.-P. (251) 35)

Mast cell; Endothelin-1; Histamine; Islet-activating protein; Endothelin receptor (Yamamura, H. (265) 9)

Concentration jump
Hippocampal neuron, isolated; Glutamate receptor; NMDA receptor; Chemically gated current (Wilsch, V.W. (262) 287)

Conditioned avoidance response
Eticlopride; SCH-23390 (White, I.M. (253) 167)

Conditioned place preference
Excitatory amino acid; Kynurenic acid; Morphine; Self-stimulation; (Rat) (Bespalov, A. (264) 233)

Conditioned place preference / aversion
CGS 10746B; Dopamine; Locomotor activity; (Rat) (Schechter, M.D. (260) 133)

Conditioned suppression
σ Receptor; Dopaminergic system; Stress (Kamei, H. (260) 39)

Conditioned taste aversion
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; 5-HT receptor subtype; Stimulus property; Drug pre-exposure; (Mouse) (Berendsen, H.H.G. (253) 83)

Conductance vessel
Indapamide; Resistance vessel; $^{45}Ca^{2+}$ movement; (Rabbit); (Sheep) (Del Rio, M. (250) 133)

Conduction
Mexiletine; Dofetilide; Action potential duration; QT duration; (Guinea-pig); (In vivo) (Todt, H. (265) 43)

Conflict behavior
Ca^{2+} channel antagonist; Antianxiety action; (Rat) (Matsumoto, Y. (264) 107)

ω-Conotoxin
Imipramine; Ca^{2+} concentration, intracellular; Dihydropyridine; Inorganic Ca^{2+} channel blocker; Cultured neuron (Shimizu, M. (268) 65)

ω-Conotoxin GVIA
Opioid peptide; Behavioral effect; Body temperature; Antinociception; Voltage-dependent Ca^{2+} channel; Verapamil (Spampinato, S. (254) 229)

ω-Conotoxin MVIIC; N-type voltage-dependent Ca^{2+} channel; Ileum, guinea pig; Vas deferens, rat (Boot, J.R. (258) 155)

ω-Agatoxin-IVA; Ca^{2+} channel (voltage sensitive); Autonomic nerve; Neurotransmission; Smooth muscle (Lundy, P.M. (261) 79)

Adrenal catecholamine; Voltage-dependent Ca^{2+} channel, N-type, L-type; Nifedipine; Verapamil; Acetylcholine (Kimura, T. (264) 169)

Cell death; Ca^{2+} oscillation; Veratridine; Bovine chromaffin cell; R56865; Flunarizine; Nimodipine (Maroto, R. (270) 331)

ω-Conotoxin MVIIC
ω-Conotoxin GVIA; N-type voltage-dependent Ca^{2+} channel; Ileum, guinea pig; Vas deferens, rat (Boot, J.R. (258) 155)

Contractile force
Tyrosine kinase; Genistein; Coronary tone; ANP (atrial natriuretic peptide); Ca^{2+}, intracellular (Taskinen, P. (256) 251)

Contractility
Acetylcholine; Adenosine; Angiotensin II; Atrium; α-CGRP (calcitonin gene-related peptide); Somatostatin; Ventricle; (Human) (Du, X.Y. (259) 173)

α-Adrenoceptor stimulation; Cl^-; Cardiac muscle, rat (Buzzard, S.L. (260) 15)

Contraction
Endothelial cell; Microcirculation; Endothelin; Permeability; Ca^{2+} (Kurose, I. (250) 85)

Ca^{2+} inhibition; Smooth muscle; Myometrium; Threshold phenomenon; Actin filament (Miyauchi, Y. (263) 75)

Convulsion
ACPD (1*S*,3*R*-1-aminocyclopentane-1,3-dicarboxylate); Excitatory amino acid receptor (metabotropic); Excitatory amino acid (Klitgaard, H. (250) 9)

Excitatory amino acid; Excitatory amino acid receptor (metabotropic); ACPD ((1*S*,3*R*)-1-Aminocyclopentane-1,3-dicarboxylic acid); Scratching (Laudrup, P. (250) 15)

Felbamate; Glycine (Coffin, V. (256) R9)

Felbamate; Diazepam; Isoniazid; FG 7142; GABAergic transmission (Serra, M. (265) 185)

Convulsion, electrically induced
Histamine H_3 receptor; Clobenpropit; Imetit; Histidine decarboxylase; Histamine, brain (Yokoyama, H. (260) 23)

Copper sulfate
Emesis; Cisplatin; Vagal afferent; 5-HT_3 receptor antagonist; (Monkey) (Fukui, H. (249) 13)

Vomiting; 5-HT_4 receptor; Visceral afferent fiber (Fukui, H. (257) 47)

Coronary
Adenosine; Adenosine A_2 receptor; Adenylyl cyclase; Endothelial cells; Heart; Capillary; (Guinea pig) (Schiele, J.O. (269) 51)

Coronary artery
cAMP; Ca^{2+} concentration, intracellular; β_1-Adrenoceptor; Thromboxane A_2; Ca^{2+} sensitivity of contractile elements (Yamagishi, T. (251) 253)

Smooth muscle, vascular; Hypoxia; ATP-sensitive K^+ channel; Glibenclamide; Levcromakalim (Mellemkjær, S. (270) 307)

Hypoxia; $^{45}Ca^{2+}$ uptake; Thromboxane; U46619 (Dalen, T. (270) 313)

Coronary artery blood flow
K^+ channel opener; YM099; Levcromakalim; Glibenclamide; Coronary artery vessel diameter; (Dog) (Uchida, W. (264) 285)

Coronary artery, pig
Endothelin; Sarafotoxin; BQ-123 (cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu)); Endothelin receptor subtype; Aorta (guinea-pig); Smooth muscle (vascular) (Schoeffter, P. (249) 199)

Coronary artery, porcine
Big endothelin-1; Endothelin-1; Endothelin converting enzyme (Balwierczak, J.L. (250) 379)

Coronary artery vessel diameter
K^+ channel opener; YM099; Levcromakalim; Glibenclamide; Coronary artery blood flow; (Dog) (Uchida, W. (264) 285)

Coronary tone
Tyrosine kinase; Genistein; Contractile force; ANP (atrial natriuretic peptide); Ca^{2+}, intracellular (Taskinen, P. (256) 251)

Coronary vasculature
Suramin; P_2 purinoceptor (Vials, A.J. (251) 299)

Coronary vasodilatation
Acyl carnitine ester; Superior mesenteric vessel (Criddle, D.N. (255) 223)

Estrogen; 17α-Estradiol (Salas, E. (258) 47)

Coronary vasodilator
PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide); PTI (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl); Carboxy-PTI; Radical compound; Methylene blue (Tsunoda, R. (262) 55)

E4021; Phosphodiesterase type V inhibitor; cGMP; Vasopressin; ST segment elevation (Kodama, K. (263) 93)

Cortex
α_2-Adrenoceptor; Imidazoline; Non-adrenoceptor binding (Wallace, D.R. (258) 67)

Acetylcholine; *d*-Amphetamine; Dopamine; 6-Hydroxydopamine; Noradrenaline (Day, J.C. (263) 285)

$GABA_A$ receptor complex; Benzodiazepine binding site, type I; [^{3}H]Zolpidem binding; Immunoprecipitation; Photoaffinity labeling; (Subunit specific antibodies) (Ruano, D. (267) 121)

Cortical cell culture
Metabotropic glutamate receptor; Spinal cord, isolated; cAMP; Phosphoinositide hydrolysis; ACPD((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); L-CCG-I((2*S*,1′*S*,2′*S*)-CCG) (Ishida, M. (268) 267)

Cortical lesion
Amphetamine; Behavioral clamping; Haloperidol; Neostriatum; Unit activity (Tschanz, J.A.T. (257) 161)

Cortical neuron
DCG-IV ((2*S*,1′*R*,2′*R*,3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine); Excitotoxicity; Metabotropic glutamate receptor (Bruno, V. (256) 109)

Cortical neuron, cultured
NMDA receptor; Ca^{2+} channel; Voltage-clamp, whole-cell; Eliprodil (Biton, B. (257) 297)

Cortical wedge
Glutamate receptor; Myenteric plexus; Homoserine sulfate; Hydroxyproline sulfate; Hydroxypipecolic acid sulfate (Mannaioni, G. (251) 201)

Corticosteroid
Asthma; Pulmonary gas trapping; Pulmonary inflammation; Substance P; (Hyperresponsiveness) (Stengel, P.W. (253) 253)

Interleukin-4; Interleukin-5; Cyclosporin A (Schmidt, J. (260) 247)

Primary neuronal culture; Ventral mesencephalon; κ-Opioid receptor; [^{3}H]Dopamine release; Sensitization (Ronken, E. (263) 149)

Corticosterone
Hypothalamo-pituitary-adrenal axis; Stress; Antidepressant; Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); CRF (corticotropin-releasing factor); ACTH (adrenocorticotropin) (Delbende, C. (251) 245)

FG5893; 5-HT_{1A} receptor agonist/5-HT_{2A} receptor antagonist; 5-HT receptor; Hypothermia; Head twitch behavior; Passive avoidance; Forced swim test; Cage leaving; Ultrasound vocalization; (Rat) (Albinsson, A. (261) 285)

ACTH (adrenocorticotropic hormone); Dioxadrol; Endocrine; NMDA (*N*-methyl-D-aspartate); Pentazocine; Phencyclidine; σ Receptor; SKF 10,047 (Pechnick, R.N. (263) 115)

COS-7 cell
CCK_B receptor; Polymerase chain reaction; Radioligand binding; Calcium mobilization; Fura-2; Transient expression; [*N*-methyl-Nle 28,31)]cholecystokinin-(26-33) (Knapp, R.J. (269) 133)

Cotransmission
EDRF (endothelium-dependent relaxing factor); Ethanol; Purine; ATP (Brizzolara, A.L. (254) 175)

Vas deferens, mouse; ATP; Facilitation; Yohimbine; α_2-Autoinhibition (Karunanithi, S. (261) 17)

Cough
Dihydroetorphine; Antitussive effect; Opioid receptor; (Mouse) (Kamei, J. (260) 257)

Cough reflex
Tachykinin NK_2 receptor; SR 48968; Antitussive effect; Citric acid; (Guinea-pig) (Advenier, C. (250) 169)

Covalent cross-linking
Parietal cell (rat); Hydrogen ion production; Adenosine 3′,5′-cyclic monophosphate; Radioligand binding (Schepp, W. (269) 183)

CP-93,129
5-Carboxyamidotryptamine; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

CP-96,345
Dynorphin; Methamphetamine; Tachykinin NK_1 receptor; Neurotensin; Substance P (Gygi, S.P. (250) 177)

Substance P; SR 48968; WIN 51708; WIN 62577; Colon, proximal, guinea-pig (Briejer, M.R. (250) 181)

CP-96,345
Ca^{2+} channel antagonist; Verapamil; Nifedipine; Smooth muscle, isolated; (Anesthetized dog) (Constantine, J.W. (252) 275)

CP-99,994
Emesis; Neurokinin (Bountra, C. (249) R3)

Tachykinin NK_1 receptor antagonist; Antiemetic (Tattersall, F.D. (250) R5)

(±)-CP-96,345
Tachykinin NK_1 receptor; FK888; RP 67580; IM9 human lymphoblastoma cell; U373 MG human astrocytoma cell (Goso, C. (254) 221)

mCPP (1-(3-chlorophenyl)piperazine)
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 5-HT receptor agonist; 5-HT receptor antagonist; Drug discrimination; (Rat) (Callahan, P.M. (257) 27)

5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 6-Hydroxydopamine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Iontophoresis; Autoradiography (El Mansari, M. (261) 171)

(Rp)-8-pCPT-cGMPS ((Rp)-8-(*para*-chlorophenylthio)guanosine-3′,5′-cyclic monophosphorothioate)
cGMP-dependent protein kinase; Platelet; (Inhibitor) (Butt, E. (269) 265)

Creatine kinase
Disopyramide; Ischemia/reperfusion injury; Propafenone; Na^+ overload; Purine nucleoside; Purine base (Liu, J.-X. (250) 361)

Cremaster muscle
Naftidrofuryl; 5-HT (5-hydroxytryptamine, serotonin); Microcirculation; Arteriole; Vasoconstriction; 5-HT_2 receptor antagonist (Koch, L.G. (254) 249)

Crescentic nephritis
DP-1904; Thromboxane A_2 synthetase inhibitor; Proteinuria (Nagao, T. (259) 233)

CRF (corticotropin-releasing factor)
Hypothalamo-pituitary-adrenal axis; Stress; Antidepressant; Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropin); Corticosterone (Delbende, C. (251) 245)

Anti-edema; ACTH (adrenocorticotropin) release; (Structure-activity relationship) (Wei, E.T. (263) 319)

Ca^{2+}; Ca^{2+} channel; Pertussis toxin; Epithelium (Kiang, J.G. (267) 135)

Cromakalim
K^+ channel opener; Skeletal muscle fatigue; Ischemia (Trezise, D.J. (250) 109)

Diazoxide; ATP-sensitive K^+ channel; Morphine; Naloxone, withdrawal (Robles, L.I. (251) 113)

K^+ channel; Glibenclamide; Y-26763; SKF 525A; Quinacrine; *Xenopus* oocyte; Local anesthetic (Sakuta, H. (252) 117)

Endothelin; Basilar artery (Zuccarello, M. (259) R1)

Arterial smooth muscle relaxation; K^+ channel, ATP-sensitive; K^+ channel, Ca^{2+}-activated; Spontaneously hypertensive rat (SHR) (Asano, M. (263) 121)

Atrial natriuretic factor; cGMP; HS-142-1; K^+ channel; Glibenclamide; Y-26763; *Xenopus* oocyte (Sakuta, H. (267) 281)

K^+ channel; Glibenclamide; *Xenopus* oocyte; Insulin; IGF-1; Phenylarsine oxide; Pertussis toxin; Voltage clamp, 2-electrode (Sakuta, H. (268) 375)

Crossbridge kinetics
Skinned cardiac muscle; EMD 53998; Phosphate effect; Ca^{2+} sensitizer (Strauss, J.D. (252) 219)

Cross-tolerance
Morphine; Δ^9-Tetrahydrocannabinol; Tolerance; Analgesia; Hypothermia; [^{3}H]DAMGO ([^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin), B_{max}, K_d; Brain; Spinal cord (Thorat, S.N. (260) 5)

CS-045
Antidiabetic; Fructose-2,6-bisphosphate; Hepatocyte; Tolbutamide (Murano, K. (254) 257)

Culture
Nicotinic; Muscarinic; Sympathetic ganglion; Electrophysiology; (Guinea pig) (Xian, H. (259) 21)

Cultured neuron
Imipramine; Ca^{2+} concentration, intracellular; Dihydropyridine; ω-Conotoxin; Inorganic Ca^{2+} channel blocker (Shimizu, M. (268) 65)

Cutaneous hyperemia
Afferent nerve stimulation; Capsaicin; Interleukin-1β; Neurogenic inflammation; Nitric oxide (NO) (Herbert, M.K. (260) 89)

CV-11974
Angiotensin II receptor antagonist; Aldosterone; TCV-116 (Wada, T. (253) 27)

CY 208–243 ((−)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenanthyxidine)
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP monkeys; Dopamine D_1 receptor; Dopamine D_2 receptor; SCH-23390; Sulpiride; Dopamine D_1/D_2 interaction; (+)-PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Luquin, M.R. (253) 215)

[^{125}I]Cyanopindolol
Receptor autoradiography; β-Adrenoceptor; Lymph node; Spleen; Immune system; Lymphoid organ (Fernández-López, A. (262) 283)

Cyclic nucleotides
Pulmonary artery; Smooth muscle; Vascular relaxant; Phorbol ester; Protein kinase C; Phosphodiesterase inhibitor (Savineau, J.-P. (249) 191)

Cyclo-oxygenase
Prostaglandin; Inhibitor; Stomach, rat; Smooth muscle, longitudinal and circular (Shimomura, A. (252) 81)

Cyclo-oxygenase, inhibition
S-Flurbiprofen; *R*-Flurbiprofen; Formalin test; Antinociception, intrathecal; Spinal cord (Malmberg, A.B. (256) 205)

S-Flurbiprofen; *R*-Flurbiprofen; Formalin test; Antinociception, intrathecal; Spinal cord (Malmberg, A.B. (260) 283)

Cyclopiazonic acid
Cation channel, non-specific; Endothelium (Zhang, H. (251) 119)

Ryanodine; Caffeine; Ca^{2+} release; Ca^{2+} influx; Mesenteric resistance vessel; (Rat) (Naganobu, K. (251) 307)

Sarcoplasmic reticulum; Thapsigargin; Heart; Excitation-contraction coupling; (Frog) (Bonnet, V. (264) 69)

Tri-*n*-butyltin; Thymocyte; Ca^{2+} pump; Thapsigargin; A23187 (Oyama, Y. (270) 137)

D-Cycloserine
Anxiolytic; Glycine receptor ligand; NMDA (*N*-methyl-D-aspartate); NMDA receptor antagonist; ACPC (1-aminocyclopropanecarboxylate) (Anthony, E.W. (250) 317)

***d*-Cycloserine**
Hippocampus; Granule cell; Field potential; Glycine binding site; NMDA receptor (Pitkänen, M. (253) 125)

Cyclosporin
Nitric oxide (NO); Interleukin 1β; Immunosuppressive drug; Mesangial cell (Mühl, H. (249) 95)

Neuroimmunomodulation; Parasympathetic nervous system; Lymphoid tissue; Cholinergic innervation; Acetylcholine, synthesis and release; Choline uptake; Sympathetic nervous system; Superior cervical ganglion (Esquifino, A.I. (254) 1)

Psoriasis; Interleukin-8 receptor; Calcitriol; Dithranol (Kemény, L. (258) 269)

Cyclosporin A
Asthma; Anhydride; Allergy; Glucocorticoid; Sensitization (Arakawa, H. (252) 313)

Interleukin-4; Interleukin-5; Corticosteroid (Schmidt, J. (260) 247)

Extracellular matrix; Glomerulosclerosis; Mesangial cell (Ghiggeri, G.M. (270) 195)

Liver, rat; Bile secretion; P-glycoprotein; Fluorescent dye (Thalhammer, T. (270) 213)

Cyclothiazide
Glutamate; Receptor desensitization; GYKI 52466 (Sharp, R.L. (266) R1)

Metabotropic glutamate receptor; Receptor desensitization (Sharp, R.L. (269) R5)

Cysteinyl-leukotriene receptor
BAY u9773; Leukotriene D_4; Leukotriene C_4 (Tudhope, S.R. (264) 317)

Cystometrogram
MK-801; Bladder voiding; Urine storage; Decerebration; Sphincter electromyogram; (Rat) (Yoshiyama, M. (264) 417)

[^{3}H]Cytisine
[^{3}H]Nicotine; [^{3}H]Methylcarbamylcholine; Nicotinic acetylcholine receptor, neuronal; (Rat) (Anderson, D.J. (253) 261)

Cytochalasin B
Smooth muscle contraction; Ca^{2+} current; Myosin phosphorylation; Taenia coli; (Guinea pig) (Obara, K. (255) 139)

Cytochrome *P*450
Carboline; Steroid (Kühn-Velten, W.N. (250) R1)

σ Receptor; Pentazocine binding; Piperazine; Phenylalkylamine; 5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor (Cagnotto, A. (266) 131)

Cytochrome P450
Liver, mouse, human; Hepatotoxicity; Cocaine (Pellinen, P. (270) 35)

Cytokine
Endotoxin shock; Vasodilatation; Vascular hyporeactivity; Circulatory shock (Szabó, C. (250) 157)

Endothelin; Endothelin converting enzyme; Hemorrhage; Hypoxia; Interleukin-1β; Phosphoramidon; TNF-α (tumor necrosis factor-α) (Vemulapalli, S. (257) 95)

Cytokine production, in vitro
Anti-allergic agent; Interleukin-2; Interleukin-3; Interleukin-4; Interleukin-5; Peripheral blood leukocyte, human (Konno, S.-i. (264) 265)

Cytokine regulation
Colonic cell line (human); Mucus secretion; Interferon-γ; cAMP; MUC2 mucin gene (Jarry, A. (267) 95)

Cytology
Mast cell; Drug effect; Anti-allergic drug (Konno, S.-i. (259) 15)

Cytoprotection
Nitric oxide (NO); Ulcer; Mucosal blood flow (Ferraz, J.-G.P. (260) 107)

Cytosolic Ca^{2+}
PCA50941; Bay K 8644; Chromaffin cell; Catecholamine secretion; Dihydropyridine agonist; Ca^{2+} channel (Montiel, C. (268) 293)

Cytosolic free Ca^{2+}
PTHrP (parathyroid hormone-related protein); Fura-2; cAMP; Aortic spiral preparation, rat (Ishikawa, M. (269) 311)

Cytotoxicity
Nitric oxide (NO); Glyceraldehyde-3-phosphate dehydrogenase; Endotoxin; Shock (Dimmeler, S. (267) 105)

Fumaric acid; Psoriasis; Keratinocyte; Cell proliferation (Sebök, B. (270) 79)

Actinomycin D; Cell cycle; Phase dependency (Wu, M.-H. (270) 203)

Butylated hydroxyanisole; Metabolite; *N*-Acetylcysteine; Hepatocyte, isolated, rat (Nakagawa, Y. (270) 341)

DAGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin)
Dopamine; Microdialysis; Methamphetamine; Nucleus accumbens; Dynorphin (Yokoo, H. (256) 335)

Somatostatin secretion; β-Funaltrexamine; μ-Opioid receptor (McIntosh, C. (259) 331)

[^{3}H]DAMGO ([^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin), B_{max}, K_d
Morphine; Δ^9-Tetrahydrocannabinol; Tolerance; Analgesia; Hypothermia; Cross-tolerance; Brain; Spinal cord (Thorat, S.N. (260) 5)

Dapsone
Opsonized zymosan; OX-42; Indomethacin; Bromophenacyl bromide; Prostaglandin E_2 (Klegeris, A. (260) 273)

DBA/2J mouse
β-Endorphin fragment; Neocortical spike-and-wave spindling; Electrocorticogram (Capasso, A. (261) 209)

DCG-IV ((2*S*,1′*R*,2′*R*,3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine)
Excitotoxicity; Metabotropic glutamate receptor; Cortical neuron (Bruno, V. (256) 109)

Metabotropic glutamate receptor; Halothane anesthesia; Glutamate receptor agonist; L-CCG-I ((2*S*,1′*S*,2′*S*)-2-(carboxycyclopropyl)glycine); Adenylyl cyclase (Miyamoto, M. (260) 99)

DDT_1 MF-2 cell
Histamine H_1 receptor; [^{3}H]mepyramine; Smooth muscle cell (Dickenson, J.M. (268) 257)

P_2^U purinoceptor; cAMP; Protein kinase C; Ca^{2+}; Pertussis toxin (Sipma, H. (268) 431)

Decerebration
MK-801; Bladder voiding; Urine storage; Cystometrogram; Sphincter electromyogram; (Rat) (Yoshiyama, M. (264) 417)

Defecation, rat
Adenosine; Purinoceptor (Tomaru, A. (264) 91)

Defensive behavior
NAN-190; (−)-Propranolol; Vomiting; 5-HT_{1A} receptor (Lucot, J.B. (253) 53)

Deferential artery, human
Endothelium; Adrenergic stimulation (Martínez, C. (261) 73)

Delayed rectifier K^+ current
Apamin; Patch-clamp technique; Action potential; Ventricular myocyte (Koumi, S.-i. (261) 213)

Arenobufagin; Toad venom; Cardiac myocytes (Dos Santos Cruz, J. (266) 317)

[D-Ala^2,Glu^4]Deltorphin
Opioid; δ-Opioid receptor subtype; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Antinociception; (Mouse) (Vanderah, T. (252) 133)

[D-Ala^2]Deltorphin II
Antitussive effect; BNTX (7-benzylidenenaltrexone); Naltriben; δ-Opioid receptor; DPDPE ([D-Pen^{2,5}]enkephalin) (Kamei, J. (251) 291)

Denervation
Vas deferens; Ca^{2+} channel; Dihydropyridine; Isradipine (Jurkiewicz, A. (256) 329)

Dentate gyrus
Metabotropic glutamate receptor; Long-term potentiation; 2-Amino-3-phosphonopropionate (AP3); (Anesthetized rat) (Abe, K. (251) 295)

2-Deoxy-D-glucose
Gastric acid; Nitric oxide (NO); Gastric distension; Histamine; Pentagastrin; Brain-gut axis (Barrachina, D. (262) 181)

2-Deoxyglucose
Somatostatin; Aging; Carbachol; Brain slice; Cerebral cortex (Shibata, S. (269) 269)

[^{14}C]2-Deoxyglucose
Adenosine; Adenosine A_1 receptor; Adenosine A_2 receptor; (Agonist); (Antagonist) (Nehlig, A. (258) 57)

Dependence
Analgesia; Morphine, blood level; Opiate; Tolerance; Withdrawal (Gold, L.H. (253) 45)

Morphine; U-50,488; Tolerance; (Guinea pig) (Tao, P.-L. (256) 281)

Morphine; MK-801; EEG (electroencephalography); EEG power spectra; (Interaction) (Haberny, K.A. (261) 11)

Depolarization inactivation
Dopamine neuron; Haloperidol, chronic; Schizophrenia; Chloral hydrate, anesthesia; (Rat) (Mereu, G. (264) 449)

Deprenyl
Cocaine; Drug discrimination (Yasar, S. (259) 243)

(−)-Deprenyl
Monoamine oxidase type B; Dopamine; Microdialysis; 2-Phenylethylamine; (Guinea pig) (Juorio, A.V. (254) 213)

Depression
CCK receptor antagonist; CCK-8; BC-264; Dopamine; Nomifensine; L-365,260 (Hernando, F. (261) 257)

Depression model, animal
Anhedonia; MK-801; CGP 37849; CGP 40116; Imipramine; (Rat) (Papp, M. (263) 1)

Depression model, rat
Chronic mild stress; Imipramine, chronic; cAMP; β-Adrenoceptor; Sucrose intake (Papp, M. (261) 141)

Depressor response
R-α-methylhistamine; Histamine H_3 receptor; Histamine; Thioperamide; Pressor response; Tachycardia; (Prejunctional) (Hegde, S.S. (251) 43)

Deriglidole
SL 84.0418; α_2-Adrenoceptor; Insulin release; Imidazoline; K^+ channel, ATP-sensitive; (Mouse islet) (Jonas, J.-C. (264) 81)

Dermenkephalin (binding)
Opioid; Structure-activity study; δ Address (Charpentier, S. (266) 175)

Des-Arg^{10}-kallidin
Bradykinin B_1 receptor; Aorta (rabbit); Smooth muscle cell (Schneck, K.A. (266) 277)

Descending inhibition
5-HT (5-hydroxytryptamine, serotonin); Spinal cord; (Neonatal rat) (Wallis, D.I. (250) 371)

Descending relaxation
5-HT (5-hydroxytryptamine, serotonin); Nitric oxide (NO); Ileum, rat; NANC (non-adrenergic, non-cholinergic) inhibition (Kanada, A. (250) 59)

Desensitization
5-Carboxyamidotryptamine; CP-93,129; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Vasoactive intestinal contractor; Endothelin receptor; Acetylcholine release; Ileum, guinea pig (Kan, S. (258) 139)

Ivermectin; GABA (γ-aminobutyric acid); $GABA_A$ receptor; Hippocampal neurone (mouse) (Krůšek, J. (259) 121)

PAF (platelet-activating factor); Acetylcholine; Mesenteric arterial bed; Spontaneously hypertensive rat (SHR) (Kamata, K. (259) 321)

Morphine treatment (chronic); Adenylate cyclase inhibition; G-protein (coupling to); Down-regulation (Polastron, J. (266) 139)

Cardiomyocyte, intact; Isoproterenol; β-Adrenoceptor; cAMP; Forskolin (Murphy, M.G. (268) 121)

Prostanoid IP receptor; $G_s\alpha$ protein; Adenylyl cyclase; NG108-15 cell (Williams, R.J. (268) 177)

Xenopus laevis oocyte; Vanadate; Pertussis toxin; Ca^{2+}; Angiotensin II; LiCl (Sakuta, H. (268) 305)

Desipramine
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP analog; MPTP derivative; 5-HT (5-hydroxytryptamine, serotonin); Norepinephrine; Fluoxetine (Andrews, A.M. (250) 215)

Tricyclic antidepressant; Imipramine; Patch-clamp; Neuroblastoma; Nicotinic acetylcholine receptor (Rana, B. (250) 247)

Detergent
Immunotoxicology; Respiratory burst; Neutrophil, human; HL-60 cell line; Sodium dodecyl sulfate (SDS) (Kacani, L. (270) 285)

Detrusor
Adenosine cyclic monophoshate; Guanosine cyclic monophoshate; NANC (non-adrenergic, non-cholinergic) nerve; Nitric oxide (NO); Urethra (Persson, K. (268) 159)

Development
Striatum; Dopamine D_1 receptor; Dopamine D_2 receptor; Receptor recovery; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Crawford, C.A. (252) 225)

Myocardium, guinea-pig; Ca^{2+}, extracellular; Nicardipine; Ryanodine; Isoproterenol (Agata, N. (260) 47)

Ethanol; Muscarinic receptor; Phosphoinositide; Fetal alcohol syndrome; (Rat) (Balduini, W. (266) 283)

Developmental change
Staurosporine; Membrane outgrowth; Myocyte, *Xenopus*; Morphological change (Fu, W.-M. (270) 321)

Developmental pharmacology
Nicotine; Peptidergic transmission; Purinergic transmission; NANC (non-adrenergic, non-cholinergic) nerve (Irie, K. (251) 75)

Dexamethasone
Tumor necrosis factor; Interleukin-1; Interleukin-6; Indomethacin; Pleurisy; (Rat) (Utsunomiya, I. (252) 213)

NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate); Neurotoxicity; Glucocorticoid; Postnatal (Supko, D.E. (270) 105)

Dexfenfluramine
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); $5\text{-}HT_{1A}$ autoreceptor; 5-HT (5-hydroxytryptamine, serotonin) release; Frontal cortex; Microdialysis (Gardier, A.M. (265) 107)

Dexmedetomidine
α_2-Adrenoceptor; Mydriasis; Nociception; Spinal cord (Horváth, G. (253) 61)

Dextromethorphan
3-PPP (3-(3-hydroxyphenyl)-*N*-(*n*-propyl)piperidine); Haloperidol; Haloperidol, reduced; (+)-Pentazocine; Receptor down-regulation (Klein, M. (254) 239)

Diabetes
Lipopolysaccharide, *Pantoea agglomerans*; Antinociception; Naltrindole; Nor-binaltorphimine; β-Funaltrexamine; Opioid receptor (Kamei, J. (251) 95)

L-Arginine; Antinociception; Naltrindole; Nor-binaltorphimine; β-Funaltrexamine; Opioid receptor (Kamei, J. (254) 113)

Vanadate; Vanadyl; Glucose homeostasis; Hypoglycemic agent; (Rat) (Becker, D.J. (260) 169)

Atrium, rat; Endothelin-1; Noradrenaline; Streptozotocin; Sympathetic nerve stimulation (Lieu, A.T. (261) 33)

Glibenclamide; Sulphonylurea; β-Cell replication; Pancreatic islet (Guiot, Y. (261) 157)

Diabetes mellitus
Noradrenaline; Caffeine; Ca^{2+}, mobilization of intracellular; Aorta, rat (Hattori, Y. (256) 215)

Diabetic rat
Neuropathy; Nerve blood flow; Vasa nervorum; Nimodipine (Kappelle, A.C. (250) 43)

Penile erection; Yawning; Apomorphine; Physostigmine; VIP (vasoactive intestinal polypeptide) (Yamaguchi, Y. (254) 91)

Diacylglycerol
Endothelin; Saponin; Ca^{2+}; Protein kinase C; Positive inotropy; IP_3; Phospholipase (Paik, G.Y. (264) 437)

Neuroblastoma SH-SY5Y cell; Protein kinase C; c-*fos* expression; Muscarinic-receptor-stimulation (Larsson, C. (268) 19)

Diamide
Sensory nerve; Bronchoconstriction; Thromboxane; Hydrogen peroxide; (Guinea pig) (Bannenberg, G. (270) 175)

1,10-diaminodecane
Polyamine; Spermine; Spermidine; Arcaine; Diethylenetriamine; Putrescine; *N*-Methyl-D-aspartate (NMDA); NMDA receptor; Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

***N,N'*-Diaminoguanidine**
Aminoguanidine; Methylguanidine; 1,1-Dimethylguanidine; Nitric oxide (NO); Nitric oxide synthase; N^G-Monomethyl-L-arginine; (L-NMA) (Hasan, K. (249) 101)

Diaphragm, rat
HI-6 ([[[(4-aminocarbonyl)pyridino]-methoxy]methyl]-2-[(hydroxyimino)methyl]-pyridinium dichloride); Soman; Acetylcholinesterase reactivation; Muscle tension (Adler, M. (270) 9)

Diarrhea
Sodium choleate; Nitric oxide (NO) synthase; Intestinal secretion; Small intestinal transit (Mascolo, N. (264) 21)

Diazepam
Abecarnil; Chronic treatment; Tolerance; GABAergic transmission; (Mouse) (Serra, M. (259) 1)

Dystonia; Cannabinoid; (+)-WIN 55,212-2; GABA (γ-aminobutyric acid); Catalepsy (Richter, A. (264) 371)

Felbamate; Isoniazid; FG 7142; Convulsion; GABAergic transmission (Serra, M. (265) 185)

Diazepam binding inhibitor (DBI) receptor, mitochondrial
Neurosteroid; cAMP; Brain cortex, rat; Protein synthesis inhibitor; Adrenalectomy/orchidectomy (Roscetti, G. (269) 17)

Diazoxide
Cromakalim; ATP-sensitive K^+ channel; Morphine; Naloxone, withdrawal (Robles, L.I. (251) 113)

Neuropeptide Y; Vasoconstriction; K^+ channel; BRL38227; Cerebral basilar artery (Xia, Y. (255) 67)

Levcromakalim; Pinacidil; Glucose tolerance; Glibenclamide; Hypoglycemia (Clapham, J.C. (257) 79)

Dibenzocycloheptheneimine
Ca^{2+} channel, L-type; Dihydropyridine; Nitrendipine; MK 801; Ca^{2+} channel, voltage-sensitive; NMDA receptor (Filloux, F.M. (269) 325)

Dicentrine
α_1-Adrenoceptor antagonist; Bladder outlet obstruction; Prostatic hyperplasia, benign (Yu, S.-M. (252) 29)

1,9-Dideoxy-forskolin
Muscarinic M_1 receptor; Muscarinic M_2 receptor; Mechanistic pathway; LiCl; Forskolin; Phorbol ester; Vas deferens; (Rabbit) (Eltze, M. (263) 31)

DIDS (4,4'-diisothiocyano-stilbene-2,2'-disulfonic acid)
Noradrenaline release; Hexachlorocyclohexane isomer; Bay K 8644; Nifedipine; W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); Hippocampal slice, rat (Cristòfol, R.M. (252) 305)

Trachea; Epithelium; Smooth muscle; ATP; Amiloride (Fedan, J.S. (256) 51)

Diethyldithiocarbamate
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Lipoic acid; α-Tocopherol; Coenzyme Q; Brain (mouse) (Götz, M.E. (266) 291)

Diethylenetriamine
Polyamine; Spermine; Spermidine; Arcaine; 1,10-diaminodecane; Putrescine; *N*-Methyl-D-aspartate (NMDA); NMDA receptor; Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

Differential scanning calorimetry
Tetramethylpyrazine; Membrane fluidity; Phospholipid phase transition; Electron spin resonance; Fluorescence polarization; Drug–lipid interactions (Nie, S.-Q. (266) 11)

Dihydroetorphine
Cough; Antitussive effect; Opioid receptor; (Mouse) (Kamei, J. (260) 257)

Dihydropyridine
Bay K 8644; K^+ contracture; Nifedipine; Skeletal muscle; Twitch response (Kitamura, N. (256) 169)

Vas deferens; Denervation; Ca^{2+} channel; Isradipine (Jurkiewicz, A. (256) 329)

Oxytocin; Vasopressin; Ca^{2+} channel, L-type; Neurointermediate lobe; (Electrical stimulation) (Jørgensen, A. (259) 157)

Ca^{2+} channel antagonist; Binding; Heart; SR 33805; Fantofarone (Chatelain, P. (267) 151)

Imipramine; Ca^{2+} concentration, intracellular; ω-Conotoxin; Inorganic Ca^{2+} channel blocker; Cultured neuron (Shimizu, M. (268) 65)

Ca^{2+} channel; Enantiomer; Vascular myocyte; Patch clamp; Radioligand (Baron, A. (269) 105)

Ca^{2+} channel, L-type; Nitrendipine; MK 801; Ca^{2+} channel, voltage-sensitive; NMDA receptor; Dibenzocycloheptheneimine (Filloux, F.M. (269) 325)

Dihydropyridine agonist
PCA50941; Bay K 8644; Chromaffin cell; Catecholamine secretion; Ca^{2+} channel; Cytosolic Ca^{2+} (Montiel, C. (268) 293)

5,7-Dihydroxytryptamine
5-Carboxyamidotryptamine; CP-93,129; Desensitization; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)-tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

5-HT (5-hydroxytryptamine, serotonin); Supersensitivity; Spinal cord; Antinociception; (Rat) (Sawynok, J. (264) 249)

1,25-Dihydroxyvitamin D_3
Vitamin K_2; Bone marrow culture; Osteoclast-like cell formation (Akiyama, Y. (263) 181)

Diisopropylfluorophosphate
E2020; Acetylcholinesterase; Acetylcholinesterase protection; Organophosphate toxicity (Galli, A. (270) 189)

Dimethindene
K^+ channel; Glibenclamide; *Xenopus* oocyte; Histamine H_1 receptor antagonist; Promethazine (Sakuta, H. (266) 99)

1,1-Dimethylguanidine
Aminoguanidine; *N*,*N'*-Diaminoguanidine; Methylguanidine; Nitric oxide (NO); Nitric oxide synthase; N^G-Monomethyl-L-arginine; (L-NMA) (Hasan, K. (249) 101)

Dioxadrol
ACTH (adrenocorticotropic hormone); Corticosterone; Endocrine; NMDA (*N*-methyl-D-aspartate); Pentazocine; Phencyclidine; σ Receptor; SKF 10,047 (Pechnick, R.N. (263) 115)

(+)-*cis*-Dioxolane
β-Endorphin; Antinociception; Tail-flick inhibition; Nitric oxide (NO); cGMP (Xu, J.Y. (262) 223)

Dioxygenase
Hydroperoxide isomerase; Lipoxygenase inhibitor; Hydroxamic acid (Brodowsky, I.D. (254) 43)

Diphenylamine-2-carboxylate
Voltage-clamp, whole-cell; Cardiac myocyte; Cl^- channel blocker; Na^+ current; Ca^{2+} current; Ion channel blocker (Conforti, L. (259) 215)

Dipsogenicity
VUF 9153 (*S*-[3-(4(5)-imidazolyl)]propyl-*N*-(4-chlorobenzyl)isothiourea); Thioperamide; Histamine H_3 receptor; Ileum, guinea-pig; Radioligand binding (Barnes, J.C. (250) 147)

Dipyridamole
Adenosine; Nucleoside transporter; Nitrobenzylthioinosine; Brain (Jones-Humble, S.A. (257) 311)

Dipyrone
Nitric oxide (NO); Knee joint inflammation; Peripheral analgesia; Nitric oxide synthetase inhibitor (Tonussi, C.R. (251) 173)

Discriminative stimulus
Flesinoxan; 5-HT receptor; Adrenoceptor; Dopamine receptor; Hypotension (Ybema, C.E. (256) 141)

Disopyramide
Ischemia/reperfusion injury; Propafenone; Na^+ overload; Creatine kinase; Purine nucleoside; Purine base (Liu, J.-X. (250) 361)

Disseminated intravascular coagulation
FR128998; PAF (platelet activating factor); Lipopolysaccharide; TNF (tumor necrosis factor) (Yokota, Y. (258) 239)

Dissociation kinetics
Dopamine D_1 receptor; [^{3}H]SCH 23390; Striatum (Rat); Allosteric mechanism (Farrell, C.B. (268) 79)

Dithiothreitol
κ-Opioid receptor; R1.1 Thymoma cell line; Sulfhydryl group; *N*-Ethylmaleimide (Joseph, D.B. (267) 1)

1,4-Dithiothreitol
Histamine; Inositol phosphate; [^{3}H]Mepyramine; Cerebral cortex, rat; HeLa cell (Young, K.W. (269) 283)

Dithranol
Psoriasis; Interleukin-8 receptor; Cyclosporine; Calcitriol (Kemény, L. (258) 269)

Dizocilpine
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline); Neuroprotection; Over-additive effect (Lippert, K. (253) 207)

Glutamate; Epilepsy; Catalepsy; Glycine receptor (Wlaź, P. (257) 217)

NMDA (*N*-methyl-D-aspartate); Glutamate; Glycine; Spermine; Polyamine (Marvizón, J.-C. (269) 165)

DN-2327
$GABA_B$ receptor; Adenylate cyclase; (Agonist) (Ichida, T. (267) 43)

cDNA
Dopamine D_{1a} receptor; Dopamine D_{1b} receptor; Clonal cell line; Baby Hamster Kidney cells; Chinese Hamster Ovary cell; Clozapine; Ca^{2+} (Pedersen, U.B. (267) 85)

GABA (γ-aminobutyric acid); Ethanol; Butanol; Electrophysiology; Oocyte (Mihic, S.J. (268) 209)

Glutamate receptor; Glutamate receptor antagonist (Verdoorn, T.A. (269) 43)

DNA-binding drug
Transcription factor; Epstein-Barr virus (Feriotto, G. (267) 143)

DOCA-salt SHR (deoxycorticosterone acetate-salt spontaneously hypertensive rat)
Endothelin; Endothelin receptor antagonist; Hypertension (Okada, M. (259) 339)

Dofetilide
Mexiletine; Conduction; Action potential duration; QT duration; (Guinea-pig); (In vivo) (Todt, H. (265) 43)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
$5\text{-}HT_2$ receptor; Glucocorticoid; Adrenalectomy; Head shakes (Chaouloff, F. (249) 117)

α-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_2$ receptor; $5\text{-}HT_{1C}$ receptor; (Pithed rat) (Chaouche-Teyara, K. (250) 67)

5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 6-Hydroxydopamine; mCPP (1-3-(*m*-chlorophenyl)piperazine); Iontophoresis; Autoradiography (El Mansari, M. (261) 171)

Antipsychotic; Drug discrimination; MDL 100,907; 5-HT_{2A} receptor (Schreiber, R. (264) 99)

MDMA (3,4-methylenedioxymethamphetamine); 5-MeODMT (5-methoxy-*N*,*N*-dimethyltryptamine); Microdialysis; Neurotoxicity; 5-HT_2 receptor (Gudelsky, G.A. (264) 325)

Maternal aggression; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); TFMPP (1-(3-trifluoromethyl-phenyl)piperazine hydrochloride); Intracerebroventricular; 5-HT receptor agonist (De Almeida, R.M.M. (264) 445)

DOPAC (3,4-dihydroxyphenylacetic acid)
Dopamine; Ethanol; GABA (γ-hydroxybutyric acid); Naloxone; Sleep (Devoto, P. (252) 321)

Dopamine turnover; 3-Methoxytyramine (Karoum, F. (254) 127)

L-DOPA (L-3,4-dihydroxyphenylalanine)
Catechol *O*-methyltransferase inhibition; 6-Hydroxydopamine; Circling behavior; Dopamine; Metabolism (Törnwall, M. (250) 77)

[^{3}H]Mazindol; Dopamine uptake site; Dopamine turnover; α-Methyl-*p*-tyrosine; GBR 12909 (Ikawa, K. (250) 261)

[^{3}H]Mazindol; Dopamine uptake site; Dopamine turnover; α-Methyl-*p*-tyrosine; GBR 12909 (Ikawa, K. (252) 123)

Mitochondrion; Fibroblast; Parkinson's disease; Pyruvate oxidation (Werner, P. (263) 157)

Dopamine
Catecholamine synthesis rate; Ethanol; Microdialysis (in vivo); Nicotinic acetylcholine receptor; (Rat) (Blomqvist, O. (249) 207)

Catechol *O*-methyltransferase inhibition; 6-Hydroxydopamine; Circling behavior; L-DOPA (L-3,4-dihydroxyphenylalanine); Metabolism (Törnwall, M. (250) 77)

Adenosine; Basal ganglion; Dopamine D_1 receptor; Dopamine D_2 receptor; Turning behavior (Morelli, M. (251) 21)

Neuropeptide Y; Striatum; Nucleus accumbens (Midgley, L.P. (251) 191)

Theophylline; Hyperalgesia; NMDA receptor; Noradrenaline; Adenosine (Paalzow, G.H.M. (252) 87)

DOPAC (dihydroxyphenylacetic acid); Ethanol; GABA (γ-hydroxybutyric acid); Naloxone; Sleep (Devoto, P. (252) 321)

Thermoregulation; Dopamine receptor; Clozapine; (Rat) (Salmi, P. (253) 67)

Neurotensin; Substantia nigra; Neuromedin N; Avian neurotensin; Kinetensin; Electrophysiology (Keegan, K.D. (253) 131)

A77636; Dopamine D_1 receptor; Oral activity (Huang, N.-Y. (253) 163)

Pulmonary artery; Dopamine D_1 receptor; Autoradiography; (Rabbit) (Kobayashi, Y. (253) 201)

Monoamine oxidase type B; (−)-Deprenyl; Microdialysis; 2-Phenylethylamine; (Guinea pig) (Juorio, A.V. (254) 213)

[D-Trp^{11}]Neurotensin; Locomotor activity; Nucleus accumbens (Nouel, D. (254) 263)

Neurotensin receptor; Brain, guinea-pig; Midbrain; Basal ganglia; (Non-peptide receptor antagonist) (Azzi, M. (255) 167)

d-Fenfluramine; Food intake; 5-HT (5-hydroxytryptamine, serotonin); *d*-Norfenfluramine; Sex difference (Oluyomi, A.O. (255) 175)

Microdialysis; Methamphetamine; Nucleus accumbens; DAGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); Dynorphin (Yokoo, H. (256) 335)

Adenosine A_1/A_2 receptor; Striatum; Rotational behavior; (Rat) (Popoli, P. (257) 21)

Endothelin-3; Glutamate; NMDA receptor; Striatal slice; Voltage-gated Ca^{2+} channel (Koizumi, S. (259) 195)

Grooming; Opioid; Vacuous chewing movement (Stoessl, A.J. (259) 301)

CGS 10746B; Conditioned place preference/aversion; Locomotor activity; (Rat) (Schechter, M.D. (260) 133)

Abecarnil; $GABA_A$ receptor; Acetylcholine, release (Imperato, A. (261) 205)

CCK receptor antagonist; CCK-8; BC-264; Nomifensine; Depression; L-365,260 (Hernando, F. (261) 257)

Basal ganglion; Neuropeptide; Immunohistochemistry; Radioimmunoassay (Castel, M.-N. (262) 1)

Dopamine D_2 receptor; SPECT (single photon emission computed tomography); Benzamide; [^{123}I]Iodobenzofuran (Laruelle, M. (263) 39)

Acetylcholine; *d*-Amphetamine; Cortex; 6-Hydroxydopamine; Noradrenaline (Day, J.C. (263) 285)

κ-Opioid receptor agonist; Dorsal caudate; Microdialysis; BRL 53001 (Zaratin, P. (264) 151)

GABA (γ-aminobutyric acid); Excitatory amino acid; $GABA_A$ receptor; NMDA (N-methyl-D-aspartate); Tissue culture (Chaudieu, I. (264) 361)

Ropinirole; D_2-like receptor; Spontaneously hypertensive rat (SHR); Cardiovascular; Tolerance; (Monkey) (Parker, S.G. (265) 17)

Electrophysiology; Receptor; *d*-Amphetamine; Antipsychotic; (Rat) (Shepard, P.D. (265) 141)

Protein kinase C; Pituitary; Estradiol; Hyperplasia; (Isoform); (Rat) (Lévy, L. (268) 327)

Forskolin treatment (chronic); Dopamine D_2 receptor, human; Up-regulation; Supersensitivity; Adenylyl cyclase (Johansson, M.H. (269) 149)

Dopamine carrier, neuronal
Dopamine uptake blocker; *N*-Ethylmaleimide; [^{3}H]GBR 12783; Binding, in vitro; Striatum, rat; (Slow interaction) (Héron, C. (264) 391)

Metal ion; [^{3}H]GBR 12783 (in vitro binding); Dopamine uptake; Striatum; (Rat) (Bonnet, J.-J. (266) 87)

Na^+-dependence; N-ethylmaleimide treatment; [^{3}H]GBR 12783; [^{3}H]Cocaine; Binding in vitro; Striatum; (Rat) (Saadouni, S. (268) 187)

Dopamine-glutamate interaction
Reserpine; Dopamine D_1 receptor; Dopamine D_2 receptor; NMDA receptor; Motor activity (Ferré, S. (255) 203)

Dopamine D_1/D_2 interaction
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP monkeys; CY 208–243 ((−)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenanthyxidine); Dopamine D_1 receptor; Dopamine D_2 receptor; SCH-23390; Sulpiride; (+)-PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Luquin, M.R. (253) 215)

Dopamine D_2-like receptor
Ropinirole; Dopamine; Spontaneously hypertensive rat (SHR); Cardiovascular; Tolerance; (Monkey) (Parker, S.G. (265) 17)

Dopamine metabolism
Dopamine release; Dopamine D_2 receptor; Dopamine D_3 receptor; Neuroleptic; Microdialysis (Gainetdinov, R.R. (261) 327)

Dopamine neuron
Depolarization inactivation; Haloperidol, chronic; Schizophrenia; Chloral hydrate, anesthesia; (Rat) (Mereu, G. (264) 449)

Dopamine neuronal carrier
Thermodynamics; [^{3}H]GBR 12783 (1-[2-{diphenylmethoxy}ethyl]4-{3-phenyl-2-propenyl}-piperazine); BTCP (*N*-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine) derivative; Binding (in vitro); Striatum (Rat) (Billaud, G. (268) 357)

Dopamine neuron, central
δ-Opioid receptor; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Naltrindole (Manzanares, J. (249) 107)

Dopamine receptor
Thermoregulation; Dopamine; Clozapine; (Rat) (Salmi, P. (253) 67)

Hemorrhagic shock; ACTH-(1–24); Haloperidol; *l*-Sulpiride; SCH-23390 (Bazzani, C. (253) 303)

Adrenoceptor; Aporphine; Antipsychotic; Partial agonist, receptor; 5-HT (5-hydroxytryptamine, serotonin); Stereoisomer (Baldessarini, R.J. (254) 199)

Flesinoxan; Discriminative stimulus; 5-HT receptor; Adrenoceptor; Hypotension (Ybema, C.E. (256) 141)

Intraocular pressure; Phosphodiesterase inhibitor; Methylxanthine; Pentoxifylline; Trifluperidol; Thiothixene; Fluphenazine; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine); Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

Locomotor activity; Dopamine synthesis; Neostriatum; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); (Rat) (Ahlenius, S. (260) 177)

Dopamine D_1 receptor
Adenosine; Dopamine; Basal ganglion; Dopamine D_2 receptor; Turning behavior (Morelli, M. (251) 21)

Acetylcholine release; Dopamine D_2 receptor; Reserpine; α-Methyl-tyrosine; LY 171555; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor blocker; SCH 23390 (Imperato, A. (251) 271)

Striatum; Dopamine D_2 receptor; Receptor recovery; Development; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Crawford, C.A. (252) 225)

A77636; Dopamine; Oral activity (Huang, N.-Y. (253) 163)

Pulmonary artery; Dopamine; Autoradiography; (Rabbit) (Kobayashi, Y. (253) 201)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP monkeys; CY 208–243 ((−)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenanthyxidine); Dopamine D_2 receptor; SCH-23390; Sulpiride; Dopamine D_1/D_2 interaction; (+)-PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Luquin, M.R. (253) 215)

Reserpine; Dopamine D_2 receptor; NMDA receptor; Motor activity; Dopamine-glutamate interaction (Ferré, S. (255) 203)

Acetylcholine; Frontal cortex; Hippocampus; Microdialysis (Acquas, E. (260) 85)

Paw test; Clozapine; α_1-Adrenoceptor; 5-HT_{2A} receptor (Prinssen, E.P.M. (262) 167)

[^{3}H]SCH 23390; Dissociation kinetics; Striatum (Rat); Allosteric mechanism (Farrell, C.B. (268) 79)

Astrocyte; Adenylate cyclase; SKF 38393; SKF 81297; A 68930; (Rat); (Rhesus monkey); (Human) (Vermeulen, R.J. (269) 121)

Dopamine D_{1a} receptor
Dopamine D_{1b} receptor; cDNA; Clonal cell line; Baby Hamster Kidney cells; Chinese Hamster Ovary cell; Clozapine; Ca^{2+} (Pedersen, U.B. (267) 85)

Dopamine D_{1b} receptor
Dopamine D_{1a} receptor; cDNA; Clonal cell line; Baby Hamster Kidney cells; Chinese Hamster Ovary cell; Clozapine; Ca^{2+} (Pedersen, U.B. (267) 85)

Dopamine D_2 receptor
Dopamine D_3 receptor; Striatal dopamine autoreceptor (Meller, E. (249) R5)

Idazoxan; SND 919; B-HT 920; Lisuride; α_2-Adrenoceptor; Behavior (Ferrari, F. (250) 51)

Adenosine; Dopamine; Basal ganglion; Dopamine D_1 receptor; Turning behavior (Morelli, M. (251) 21)

Acetylcholine release; Dopamine D_1 receptor; Reserpine; α-Methyl-tyrosine; LY 171555; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor blocker; SCH 23390 (Imperato, A. (251) 271)

Norepinephrine release; Aging; Ca^{2+} channel; Tail artery, rat (Friedman, D.J. (252) 1)

Striatum; Dopamine D_1 receptor; Receptor recovery; Development; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Crawford, C.A. (252) 225)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP monkeys; CY 208–243 ((−)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenanthyxidine); Dopamine D_1 receptor; SCH-23390; Sulpiride; Dopamine D_1/D_2 interaction; (+)-PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Luquin, M.R. (253) 215)

Amperozide; Striatum; Limbic forebrain (Svartengren, J. (254) 73)

Reserpine; Dopamine D_1 receptor; NMDA receptor; Motor activity; Dopamine-glutamate interaction (Ferré, S. (255) 203)

Pulmonary artery; Radioligand binding; Autoradiography; Catecholamine histofluorescence; Prejunctional receptor (Kobayashi, Y. (261) 229)

Dopamine release; Dopamine metabolism; Dopamine D_3 receptor; Neuroleptic; Microdialysis (Gainetdinov, R.R. (261) 327)

Dopamine; SPECT (single photon emission computed tomography); Benzamide; [^{123}I]Iodobenzofuran (Laruelle, M. (263) 39)

Dopamine D_3 receptor; Receptor binding; cAMP accumulation; Arachidonic acid release; Inositol phosphate (MacKenzie, R.G. (266) 79)

Dopamine D_3 receptor
Dopamine D_2 receptor; Striatal dopamine autoreceptor (Meller, E. (249) R5)

Hypothermia; 7-OH-DPAT ((+)-7-hydroxy-2-(di-*n*-propylamino)tetralin) (Millan, M.J. (260) R3)

Dopamine release; Dopamine metabolism; Dopamine D_2 receptor; Neuroleptic; Microdialysis (Gainetdinov, R.R. (261) 327)

7-OH-DPAT ((±)-2-dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide); Place conditioning (Mallet, P.E. (261) R5)

Locomotor activity; Dopamine release; Mitogenesis (Svensson, K. (263) 235)

7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin); Patch clamp; Substantia nigra; Ventral tegmental area; Caudate-putamen; Nucleus accumbens (Liu, J.-C. (264) 269)

Microdialysis; Accumbens (Rivet, J.-M. (265) 175)

Dopamine D_2 receptor; Receptor binding; cAMP accumulation; Arachidonic acid release; Inositol phosphate (MacKenzie, R.G. (266) 79)

Dopamine receptor agonist
Ethanol drinking; Nigrostriatal/mesolimbic dopamine; (Inbred mouse) (Ng, G.YK. (269) 365)

Apomorphine; Dopamine receptor antagonist; Nicotinic receptor channel; *Xenopus* oocyte; Functional expression (Nakazawa, K. (269) 375)

Dopamine D_1 receptor agonist
Reserpine; Locomotion; Glutamate receptor antagonist; Dopamine D_2 receptor agonist (Starr, M.S. (250) 239)

Antidepressant effect; Behavioral despair (D'Aquila, P.S. (262) 107)

Dopamine D_2 receptor agonist
Reserpine; Locomotion; Glutamate receptor antagonist; Dopamine D_1 receptor agonist (Starr, M.S. (250) 239)

Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4*H*-thiazolo[4,5-*d*]-azepine); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Chronic treatment); (Common marmoset) (Irifune, M. (264) 117)

Dopamine receptor antagonist
Theophylline; Reserpine; Temperature; (Mouse) (Zarrindast, M.-R. (257) 13)

EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Fluphenazine-*N*-mustard; Substantia nigra; Dopamine D_1 receptor mRNA; Dopamine D_2 receptor mRNA; Glutamic acid decarboxylase mRNA; Gene expression (Qin, Z.-H. (269) 25)

Apomorphine; Dopamine receptor agonist; Nicotinic receptor channel; *Xenopus* oocyte; Functional expression (Nakazawa, K. (269) 375)

Dopamine D_1 receptor antagonist
Acetylcholine release; Dopamine D_1 receptor; Dopamine D_2 receptor; Reserpine; α-Methyl-tyrosine; LY 171555; Dopamine D_2 receptor blocker; SCH 23390 (Imperato, A. (251) 271)

Dopamine D_2 receptor antagonist
Acetylcholine release; Dopamine D_1 receptor; Dopamine D_2 receptor; Reserpine; α-Methyl-tyrosine; LY 171555; Dopamine D_1 receptor antagonist; SCH 23390 (Imperato, A. (251) 271)

Dopamine D_1 receptor desensitization
Neuroleptic; Dopamine release; Acetylcholine release; Dopamine D_1 receptor stimulation; (Therapeutic and collateral effect) (Imperato, A. (264) 55)

Dopamine D_2 receptor, human
Forskolin treatment (chronic); Dopamine; Up-regulation; Supersensitivity; Adenylyl cyclase (Johansson, M.H. (269) 149)

Dopamine D_1/D_2 receptor interaction
Jaw movement; Striatum, dorsal; Dopaminergic/cholinergic interaction; (Rat) (Kikuchi de Beltrán, K. (252) 99)

Dopamine D_1 receptor mRNA
EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Fluphenazine-*N*-mustard; Substantia nigra; Dopamine D_2 receptor mRNA; Glutamic acid decarboxylase mRNA; Gene expression; Dopamine receptor antagonists (Qin, Z.-H. (269) 25)

Dopamine D_2 receptor mRNA
EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Fluphenazine-*N*-mustard; Substantia nigra; Dopamine D_1 receptor mRNA; Glutamic acid decarboxylase mRNA; Gene expression; Dopamine receptor antagonists (Qin, Z.-H. (269) 25)

Dopamine receptor, postsynaptic
Dopamine receptor, presynaptic; Tolerance; γ-Butyrolactone; Behavioral supersensitivity; Drug interaction; Indolylbutylamine (Seyfried, C.A. (257) 67)

Dopamine receptor, presynaptic
Antidepressant (chronic treatment); Dopamine uptake site; Locomotor activity; Apomorphine (Allison, K. (249) 125)

Dopamine receptor, postsynaptic; Tolerance; γ-Butyrolactone; Behavioral supersensitivity; Drug interaction; Indolylbutylamine (Seyfried, C.A. (257) 67)

Dopamine D_1 receptor stimulation
Neuroleptic; Dopamine release; Acetylcholine release; Dopamine D_1 receptor desensitization; (Therapeutic and collateral effect) (Imperato, A. (264) 55)

Dopamine receptor subtype
Ethanol drinking; Nigrostriatal/mesolimbic dopamine; (Inbred mouse) (Ng, G.YK. (269) 349)

Dopamine release
Kainic acid; Neurotoxicity; Glutamic acid; NMDA receptor; AMPA receptor (Fedele, E. (249) 71)

4-Aminopyridine; Quinine; Morphine; Behavioural activity; Nucleus accumbens (Pei, Q. (249) 243)

Enantiomeric selectivity; Yawning (Damsma, G. (249) R9)

Microdialysis; (+)-AJ76; (+)-UH232; (Rat) (Waters, N. (251) 181)

Striatum; Morphine; Adenylate cyclase; Opioid receptor (Tjon, G.H.K. (252) 205)

Receptor antagonist; Neurotensin; Striatum; Mesencephalic cell (Brouard, A. (253) 289)

δ-Opioid receptor; NMDA receptor (Dourmap, N. (253) R9)

N-Ethylmaleimide; Striatum, rat; Forskolin; Methamphetamine (Yamada, S. (257) 243)

Nucleus accumbens; Midazolam; β-CCE (β-carboline-3-carboxylate ethyl ester); $GABA_A$/benzodiazepine receptor; Adenosine receptor (Murai, T. (261) 65)

Dopamine metabolism; Dopamine D_2 receptor; Dopamine D_3 receptor; Neuroleptic; Microdialysis (Gainetdinov, R.R. (261) 327)

Microdialysis; Memantine; Pharmacokinetics; Striatum; Prefrontal cortex (Spanagel, R. (262) 21)

Dopamine D_3 receptor; Locomotor activity; Mitogenesis (Svensson, K. (263) 235)

Neuroleptic; Acetylcholine release; Dopamine D_1 receptor stimulation; Dopamine D_1 receptor desensitization; (Therapeutic and collateral effect) (Imperato, A. (264) 55)

[^{3}H]Dopamine release
Primary neuronal culture; Ventral mesencephalon; κ-Opioid receptor; Sensitization; Corticosteroid (Ronken, E. (263) 149)

Dopaminergic activity
γ-Hydroxybutyrate receptor; Neuroleptic; Benzamide (Maitre, M. (256) 211)

Dopaminergic / cholinergic interaction
Jaw movement; Striatum, dorsal; Dopamine D_1/D_2 receptor interaction; (Rat) (Kikuchi de Beltrán, K. (252) 99)

Dopaminergic neuron
Non-NMDA receptor; Hypothalamus; Striatum (Wagner, E.J. (254) 105)

MDL-101,562; Bombesin; Gastrin-releasing peptide (Manzanares, J. (257) 199)

Dopaminergic neurotoxicity
Methamphetamine; Amphetamine, protection; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPP^+ (1-methyl-4-phenylpyridinium), uptake inhibition (Sziráki, I. (251) 311)

Dopaminergic system
Conditioned suppression; σ Receptor; Stress (Kamei, H. (260) 39)

Dopamine synthesis
Locomotor activity; Neostriatum; Dopamine receptor; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); (Rat) (Ahlenius, S. (260) 177)

NMDA receptor antagonist, competitive; CGS 19755 (*cis*-4-(phosphonomethyl)piperidine-2-carboxylic acid); Hyperactivity; Amphetamine; (±)-CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Bristow, L.J. (264) 353)

Dopamine transporter
Dopamine uptake; Cocaine (Izenwasser, S. (263) 277)

Methylphenidate; *dl-threo*-Methylphenidate; Norepinephrine transporter; Microdialysis; Locomotor activity (Pan, D. (264) 177)

GBR 12909; Cocaine; 5-HT (5-hydroxytryptamine, serotonin) transporter; CFT (WIN 35,428); Parkinson's disease (Madras, B.K. (267) 167)

Protein kinase C; Cocaine (Kitayama, S. (268) 115)

Dopamine turnover
[^{3}H]Mazindol; Dopamine uptake site; L-DOPA (L-3,4-dihydroxyphenylalanine); α-Methyl-*p*-tyrosine; GBR 12909 (Ikawa, K. (250) 261)

[^{3}H]Mazindol; Dopamine uptake site; L-DOPA (L-3,4-dihydroxyphenylalanine); α-Methyl-*p*-tyrosine; GBR 12909 (Ikawa, K. (252) 123)

3-Methoxytyramine; DOPAC (3,4-dihydroxyphenylacetic acid) (Karoum, F. (254) 127)

Dopamine uptake
GBR 12909; GBR 12935; Synaptic vesicle; Brain (Reith, M.E.A. (253) 175)

Cocaine; Dopamine transporter (Izenwasser, S. (263) 277)

Dopamine carrier (neuronal); Metal ion; [^{3}H]GBR 12783 (in vitro binding); Striatum; (Rat) (Bonnet, J.-J. (266) 87)

Dopamine uptake blocker
Dopamine carrier, neuronal; *N*-Ethylmaleimide; [^{3}H]GBR 12783; Binding, in vitro; Striatum, rat; (Slow interaction) (Héron, C. (264) 391)

Dopamine uptake site
Antidepressant (chronic treatment); Locomotor activity; Apomorphine; Dopamine receptor (presynaptic) (Allison, K. (249) 125)

[^{3}H]Mazindol; Dopamine turnover; L-DOPA (L-3,4-dihydroxyphenylalanine); α-Methyl-*p*-tyrosine; GBR 12909 (Ikawa, K. (250) 261)

[^{3}H]Mazindol; Dopamine turnover; L-DOPA (L-3,4-dihydroxyphenylalanine); α-Methyl-*p*-tyrosine; GBR 12909 (Ikawa, K. (252) 123)

Dorsal caudate
κ-Opioid receptor agonist; Dopamine; Microdialysis; BRL 53001 (Zaratin, P. (264) 151)

Dorsal hippocampus
Median raphe nucleus; 5-HT_{1A} receptor; Social interaction; Grooming; (Rat) (Andrews, N. (264) 259)

Dorsal raphe nucleus
5-HT_{1A} receptor; Adenylate cyclase; Nerve impulse flow; (+)-WAY 100 135; SDZ 216-525; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lesopitron; S-20499; Flesinoxan (Lanfumey, L. (249) 25)

Anxiolysis; Hippocampus; 5-HT_{1A} receptor ligand (rat); Ultrasonic vocalization (Schreiber, R. (249) 341)

5-HT_{1A} receptor; Autoradiography; Hippocampus; Firing; Adenylate cyclase; Lesopitron; (−)-Tertatolol (Haj-Dahmane, S. (255) 185)

Lower lip retraction; Median raphe nucleus; 5-HT_{1A} receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-(di-*n*-propylamino)tetralin); (Rat) (Berendsen, H.H.G. (263) 315)

G-protein; 5-HT_{1A} receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Microdialysis; Intracerebral; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (Romero, L. (265) 103)

Dorsal root ganglion
[^{3}H]Resiniferatoxin; Autoradiography; Vanilloid receptor; Capsaicin-sensitive neuron; Spinal cord (Szallasi, A. (264) 217)

Dorsal root ganglion cell
Galanin; Galantide (Puttick, R.M. (254) 303)

Down-regulation
Morphine treatment (chronic); Desensitization; Adenylate cyclase inhibition; G-protein (coupling to) (Polastron, J. (266) 139)

Transfected cell; Receptor agonist exposure; Receptor internalization; Phosphatidylinositol hydrolysis; cAMP production; Muscarinic M_1 receptor; Muscarinic M_2 receptor (Wei, H.-B. (268) 381)

Doxorubicin
Heart muscle preparation, isolated; Inotropic effect; Myocardial Ca^{2+} loading; (Guinea pig); (Rat) (Temma, K. (252) 173)

Ryanodine; Sarcoplasmic reticulum; Receptor, Ca^{2+} release channel (Bowling, N. (268) 365)

DP-1904
Thromboxane A_2 synthetase inhibitor; Crescentic nephritis; Proteinuria (Nagao, T. (259) 233)

[^{3}H]DPCPX
CGS21680; Adenosine A_1 receptor; Adenosine A_{2A} receptor; Seizure; Prepiriform cortex (Zhang, G. (255) 239)

DPCPX (1,3-dipropyl-8-cyclopentylxanthine)
Gastric muscularis mucosae; Smooth muscle; Adenosine receptor; Adenosine analogue (Muller, M.J. (251) 151)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin)
δ-Opioid receptor; Naltrindole; Dopamine neurons (central) (Manzanares, J. (249) 107)

Antitussive effect; BNTX (7-benzylidenenaltrexone); Naltriben; δ-Opioid receptor; [D-Ala^2]Deltorphin II (Kamei, J. (251) 291)

Opioid; δ-Opioid receptor subtype; [D-Ala^2,Glu^4]Deltorphin; Antinociception; (Mouse) (Vanderah, T. (252) 133)

DPI 201-106
Na^+ channel (human); Oocyte; Class I antiarrhythmic (Krafte, D.S. (266) 245)

Draflazine
Nucleoside transporter; Platelet aggregation, (human); Nucleoside transport inhibitor; R75231 (Beukers, M.W. (266) 57)

Drinking behavior
Angiotensin II; Antidepressive agent (Gard, P.R. (264) 295)

Drug discrimination
Morphine; Mesolimbic system; Neuroanatomical mapping; (Rat) (Shoaib, M. (252) 69)

mCPP (*m*-chlorophenylpiperazine); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 5-HT receptor agonist; 5-HT receptor antagonist; (Rat) (Callahan, P.M. (257) 27)

MMAI (5-methoxy-6-methyl-2-aminoindan); *p*-Chlorophenylalanine; Behavioral syndrome; 5-HT (5-hydroxytryptamine, serotonin) release; (Rat) (Marona-Lewicka, D. (258) 1)

Deprenyl; Cocaine (Yasar, S. (259) 243)

Cocaine; Naltrindole; Naltriben; 7-Benzylidenenaltrexone (Suzuki, T. (263) 207)

Antipsychotic; DOI ((2,5-dimethoxy-4-iodohenyl)-2-aminopropan); MDL 100,907; 5-HT_{2A} receptor (Schreiber, R. (264) 99)

Ethanol; Isradipine; L-type Ca^{2+} channel; (Rat) (Colombo, G. (265) 167)

Drug effect
Mast cell; Cytology; Anti-allergic drug (Konno, S.-i. (259) 15)

Drug interaction
Δ^9-Tetrahydrocannabinol; Anandamide; Muscimol; Globus pallidus; Catalepsy (Wickens, A.P. (250) 205)

Dopamine receptor, presynaptic; Dopamine receptor, postsynaptic; Tolerance; γ-Butyrolactone; Behavioral supersensitivity; Indolylbutylamine (Seyfried, C.A. (257) 67)

Drug-lipid interactions
Tetramethylpyrazine; Membrane fluidity; Phospholipid phase transition; Differential scanning calorimetry; Electron spin resonance; Fluorescence polarization (Nie, S.-Q. (266) 11)

Drug pre-exposure
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; 5-HT receptor subtype; Stimulus property; Conditioned taste aversion; (Mouse) (Berendsen, H.H.G. (253) 83)

Drug resistance
Cisplatin; Excision repair; Ultraviolet (Chao, C.C.-K. (268) 347)

DS-4574
Mast cell stabilizer; Peptidoleukotriene; LY171883; Mucosal mast cell; Gastric mucosal injury (Tabuchi, Y. (250) 197)

Mast cell stabilizer; Gastric acid secretion; Histamine leakage; Pentagastrin; Carbachol (Tabuchi, Y. (255) 229)

DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine)
α_2-Adrenoceptor; Brain; (Presynaptic α_2-adrenoceptors); (Postsynaptic α_2-adrenoceptors) (Heal, D.J. (249) 37)

DTG (1,3-di-(2-tolyl)guanidine)
σ Binding site; FH-510 (5,8-dimethyl-4-(2-di-*n*-propylaminoethyl)carbazol); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperidine) (Chaki, S. (250) 173)

SKF10047; σ Receptor; Red nucleus; *N*-Allylnormetazocine; Movement disorder; Dystonia (Weissman, A.D. (250) 329)

σ-Receptor ligands; Cerebellum; Liver; (Guinea-pig) (Basile, A.S. (252) 139)

σ Receptor; Brain membrane; KB-5492; Anti-ulcer agent; (Guinea-pig) (Harada, Y. (256) 321)

σ Receptor ligand; SKF-10,047; Benzomorphan-type σ receptor; Acetylcholinergic neuronal system; *p*-Chloroamphetamine; Amnesia; Passive avoidance task; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperizine); (Mouse) (Matsuno, K. (261) 43)

Anti-ulcer agent; KB-5492; Mucosa; σ Receptor; SKF 10,047 (*N*-allyl-normetazocine); (Pig) (Harada, Y. (261) 91)

Dual detector system
Opiate receptor; Positron emitting tracer (Villemagne, V.L. (257) 195)

DuP 753
SR 47436; Smooth muscle cell; Proliferation; Angiotensin II (Herbert, J.-M. (251) 143)

DuP 714 ester (acetyl-D-phenylalanine-propyl-boroarginine)
Thrombin; Platelet; Hirulog; Heparin; Low molecular weight heparin; PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone); (Rabbit) (Liu, J.T. (264) 183)

Dura mater
Plasma protein extravasation; Tachykinin NK_1 receptor; α-CGRP-(8–37); GR82334 (O'Shaughnessy, C.T. (263) 193)

Dynorphin
CP-96345; Methamphetamine; Tachykinin NK_1 receptor; Neurotensin; Substance P (Gygi, S.P. (250) 177)

Blood pressure; Hypertension; Hippocampus; Nor-binaltorphimine; Spontaneously hypertensive rat (SHR) (Wang, J.Q. (256) 57)

Dopamine; Microdialysis; Methamphetamine; Nucleus accumbens; DAGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin) (Yokoo, H. (256) 335)

Dynorphin A
ACPC (1-aminocyclopropanecarboxylic acid); NMDA (*N*-methyl-D-aspartate); Neuronal injury; Glycine (Long, J.B. (261) 295)

Dyspnoea
Opioid; Lung; Morphine; Naloxone; NANC (Non-adrenergic-non-cholinergic) (Cabot, P.J. (268) 247)

Dystonia
DTG (di-*o*-tollylguanidine); SKF10047; σ Receptor; Red nucleus; *N*-Allylnormetazocine; Movement disorder (Weissman, A.D. (250) 329)

Movement disorder; 5-HT (5-hydroxytryptamine, serotonin); Glutamate (Löscher, W. (255) 235)

Lamotrigine; Glutamate; GABA (γ-aminobutyric acid); Na^+ channel blocker (Richter, A. (264) 345)

Cannabinoid; (+)-WIN 55,212-2; GABA (γ-aminobutyric acid); Diazepam; Catalepsy (Richter, A. (264) 371)

E2020
Diisopropylfluorophosphate; Acetylcholinesterase; Acetylcholinesterase protection; Organophosphate toxicity (Galli, A. (270) 189)

E4021
Phosphodiesterase type V inhibitor; cGMP; Coronary vasodilator; Vasopressin; ST segment elevation (Kodama, K. (263) 93)

E4080
Hyperpolarization-activated inward current (I_f); Ca^{2+} current (L-type, I_{Ca}); ATP-sensitive K^+ (K^+_{ATP}) channel; Chronotropism; Inotropism; Heart, dog (Sawaki, S. (250) 253)

Ear artery, rabbit
α_1-Adrenoceptor; Ca^{2+} entry blocker; Sgd 101/75 (Wong, P.C. (262) 185)

EBOB (4′-ethynyl-4-*n*-propylbicycloorthobenzoate)
$GABA_A$ receptor complex; Picrotoxin; Brain, human; Autoradiography (Kume, A. (263) 163)

Ebselen
Nitric oxide (NO) synthase (Hattori, R. (267) R1)

Ecto-nucleotidase
Radioligand binding; Suramin; P_{2y} purinoceptor; (Antagonist) (Van Rhee, A.M. (268) 1)

EDCF (endothelium-derived contracting factor)
Antihistamine; Calcimycin; EDRF (endothelium-derived relaxing factor); Hemoglobin; Iproniazid; Mast cell; Methylene blue; N^G-Methyl-L-arginine (Gruetter, C.A. (257) 275)

Edema
Asthma; Plasma exudation; Aging; Leukotriene; Thromboxane A_2; Airway obstruction; Vascular permeability; Arachidonic acid (Arakawa, H. (259) 251)

Neuropeptide; Neutrophil; Inflammation; Interleukin-8 (Ahluwalia, A. (264) 407)

Brain ischemia; Histamine H_2 receptor; Ranitidine; Na^+; K^+; Ca^{2+}; (Rat) (Tósaki, Á. (264) 455)

Edema formation
Inflammation; Prostaglandin D_2; Neutrophil; Adherence; O_2^- production (Pons, F. (261) 237)

EDRF (endothelium-dependent relaxing factor)
Cotransmission; Ethanol; Purine; ATP (Brizzolara, A.L. (254) 175)

Protein kinase C; Endothelium; Nitric oxide synthase; Phorbol ester (Davda, R.K. (266) 237)

EDRF (endothelium-derived relaxing factor)
Endothelium; Bradykinin; Angiotensin converting enzyme inhibitor; Captopril (Hirano, K. (250) 439)

Vasorelaxation; Aortic baroreceptor; Endothelium; Adenosine receptor; NECA (5′-*N*-ethylcarboxamidoadenosine); Nitric oxide (NO) (Fahim, M. (254) 183)

Acetylcholine; 8-Bromo-cGMP; Aortic ring, isolated, rat; Atrium, right, isolated, rat; LY-83,583 (6-(phenylamino)-5,8-quinolinedione); Norepinephrine; *N*-Nitro-L-arginine; SIN-1 (3-morpholino-sydnonimine); (Spontaneous rate) (Kennedy, R.H. (255) 149)

Uterine artery; L-Arginine; Relaxation; Nitric oxide (NO); (Human) (Jovanović, A. (256) 103)

N^{ω}-Nitro-L-arginine methyl ester; Acute inflammation; Nitric oxide (NO) (Giraldelo, C.M.M. (257) 87)

Antihistamine; Calcimycin; EDCF (endothelium-derived contracting factor); Hemoglobin; Iproniazid; Mast cell; Methylene blue; N^{G}-Methyl-L-arginine (Gruetter, C.A. (257) 275)

Aorta; Vasopressin; Gonadal steroid hormone; Nitric oxide (NO); Vasoconstriction (Stallone, J.N. (259) 273)

Angiotensin II; Nitric oxide (NO); Aorta, rabbit; N^{G}-Monomethyl-L-arginine; N^{G}-Nitro-L-arginine; N^{G}-Nitro-L-arginine methyl ester; Indomethacin (Zhang, J. (262) 247)

Smooth muscle; Endothelin; Endothelin ET_B receptor; Endothelin ET_B receptor antagonist; RES-701-1 (Karaki, H. (262) 255)

K^+ channel opener; K^+ channel blocker; Hypoxia; Lung; Smooth muscle, vascular (Dumas, J.-P. (263) 17)

Bradykinin; Substance P; Vasopressin; Cerebral vasospasm; Subarachnoid hemorrhage (Tsuji, T. (264) 77)

Endothelin; L-N^{G}-Nitroarginine; Ibuprofen; Renal blood flow; Urine flow rate; Urine osmolality; Glomerular filtration rate; (Dog) (Yukimura, T. (264) 399)

EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline)
Striatum; Dopamine D_1 receptor; Dopamine D_2 receptor; Receptor recovery; Development (Crawford, C.A. (252) 225)

Vas deferens, rat; α_2-Adrenoceptor; *N*-Ethyl-maleimide; Phenoxybenzamine (Browne, I. (265) 125)

Fluphenazine-*N*-mustard; Substantia nigra; Dopamine D_1 receptor mRNA; Dopamine D_2 receptor mRNA; Glutamic acid decarboxylase mRNA; Gene expression; Dopamine receptor antagonists (Qin, Z.-H. (269) 25)

EEG (electroencephalography)
Morphine; MK-801; EEG power spectra; Tolerance; (Interaction) (Haberny, K.A. (261) 1)

Morphine; MK-801; EEG power spectra; Dependence; (Interaction) (Haberny, K.A. (261) 11)

EEG power spectra
Morphine; MK-801; EEG (electroencephalography); Tolerance; (Interaction) (Haberny, K.A. (261) 1)

Morphine; MK-801; EEG (electroencephalography); Dependence; (Interaction) (Haberny, K.A. (261) 11)

EGF (epidermal growth factor, urogastrone)
Prostaglandin; Smooth muscle, relaxation; Protein synthesis inhibitor (Petitclerc, E. (259) 91)

Electrical field stimulation
Nitric oxide (NO); NANC (non-adrenergic non-cholinergic) transmission; Nicotinic receptor; Ileocecal sphincter; (Cat) (Mizhorkova, Z. (265) 77)

Electrical stimulation
Stomach strip, guinea pig; 5-HT_1 receptor; 5-HT_3 receptor; 5-HT_4 receptor (Buchheit, K.-H. (262) 91)

Electroconvulsive shock
Ca^{2+} channel; Apomorphine; Nifedipine; Analgesia; Hyperalgesia; Hot-plate test; Hypermotility; (Rat) (Antkiewicz-Michaluk, L. (254) 9)

Electrocorticogram
β-Endorphin fragment; Neocortical spike-and-wave spindling; DBA/2J mouse (Capasso, A. (261) 209)

Electromechanical coupling
Tachykinin receptor; Sucrose gap; Proximal colon, guinea-pig; Pharmacomechanical coupling; Ca^{2+} channel, voltage-dependent (Zagorodnyuk, V. (255) 9)

Electron spin resonance
Tetramethylpyrazine; Membrane fluidity; Phospholipid phase transition; Differential scanning calorimetry; Fluorescence polarization; Drug–lipid interactions (Nie, S.-Q. (266) 11)

Electrophysiology
Tachykinin NK_1 receptor; Substance P; Smooth muscle; Neuron (Seabrook, G.R. (250) 125)

ATP; Suramin; Ionic conductance; Enteric neuron; Purinoceptor; Myenteric plexus (Barajas-López, C. (250) 141)

Neurotensin; Dopamine; Substantia nigra; Neuromedin N; Avian neurotensin; Kinetensin (Keegan, K.D. (253) 131)

Nicotinic; Muscarinic; Sympathetic ganglion; Culture; (Guinea pig) (Xian, H. (259) 21)

5-HT_2 receptor; Primary olfactory cortex (Marek, G.J. (259) 137)

5-HT (5-hydroxytryptamine, serotonin); Vagus nerve; 5-HT_3 receptor; 5-HT_4 receptor; (Grease-gap) (Bley, K.R. (260) 139)

5-HT (5-hydroxytryptamine, serotonin); Gepirone; Hippocampus; Excitatory synaptic transmission; 5-HT_{1A} receptor; Excitatory postsynaptic potential (Manahan-Vaughan, D. (260) 149)

Binding; Brain; Gastric acid secretion; Neuropeptide; CCK_B receptor (Bertrand, P. (262) 233)

Dopamine; Receptor; *d*-Amphetamine; Antipsychotic; (Rat) (Shepard, P.D. (265) 141)

GABA (γ-aminobutyric acid); Ethanol; Butanol; cDNA; Oocyte (Mihic, S.J. (268) 209)

Ca^{2+} channel; Permeant ion; Ethanol; PC12; Pheochromocytoma cell (Mullikin-Kilpatrick, D. (270) 17)

Elevated plus-maze
Animal model; Anxiety; Benzodiazepine withdrawal; Valepotriate (Andreatini, R. (260) 233)

Anxiety; 5-HT_{1A} receptor; 5-HT_{1A} receptor antagonist; (*S*)-WAY 100135; (Mouse) (Rodgers, R.J. (261) 321)

Elevated plus-maze test
Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Mianserin; Eltoprazine; 5-HT_{2C} receptor; Autoradiography; In situ hybridization histochemistry; Limbic system; Amygdala (Rocha, B. (262) 125)

Eliprodil
NMDA receptor; Ca^{2+} channel; Voltage-clamp, whole-cell; Cortical neuron, cultured (Biton, B. (257) 297)

Eltoprazine
Elevated plus-maze test; Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Mianserin; 5-HT_{2C} receptor; Autoradiography; In situ hybridization histochemistry; Limbic system; Amygdala (Rocha, B. (262) 125)

Embryonic angiogenesis
Retinoid (synthetic); Cell differentiation modulator; Anti-angiogenic action; Angiogenic disorder (Oikawa, T. (249) 113)

EMD 53998
Crossbridge kinetics; Skinned cardiac muscle; Phosphate effect; Ca^{2+} sensitizer (Strauss, J.D. (252) 219)

Emesis
Cisplatin; Copper sulfate; Vagal afferent; 5-HT_3 receptor antagonist; (Monkey) (Fukui, H. (249) 13)

CP-99,994; Neurokinin (Bountra, C. (249) R3)

Emesis, acute, delayed
Cisplatin (Rudd, J.A. (262) R1)

Enantiomer
Ca^{2+} channel; Dihydropyridine; Vascular myocyte; Patch clamp; Radioligand (Baron, A. (269) 105)

Enantiomeric selectivity
Dopamine release; Yawning (Damsma, G. (249) R9)

Endocrine
ACTH (adrenocorticotropic hormone); Corticosterone; Dioxadrol; NMDA (*N*-methyl-D-aspartate); Pentazocine; Phencyclidine; σ Receptor; SKF 10,047 (Pechnick, R.N. (263) 115)

Endo-oligopeptidase
Enkephalin; Morphine withdrawal; Opioid system (Paik, S.H. (253) 101)

β-Endorphin
Ethanol, chronic voluntary; Brain; Proopiomelanocortin mRNA, hypothalamic (De Waele, J.-P. (258) 119)

(+)-*cis*-Dioxolane; Antinociception; Tail-flick inhibition; Nitric oxide (NO); cGMP (Xu, J.Y. (262) 223)

Indomethacin; Analgesia; Norepinephrine; Phentolamine; Naloxone; Pain (Hu, X.-H. (263) 53)

Morphine; MK-801; Tail-flick inhibition; Hot plate inhibition (Suh, H.-W. (263) 217)

β-Endorphin fragment
Neocortical spike-and-wave spindling; Electrocorticogram; DBA/2J mouse (Capasso, A. (261) 209)

Endosulfan
Learning; Memory; Escape response; Avoidance response; 5-HT (5-hydroxytryptamine, serotonin) (Paul, V. (270) 1)

Endothelial cell
Microcirculation; Endothelin; Permeability; Contraction; Ca^{2+} (Kurose, I. (250) 85)

Antioxidant; β-Adrenoceptor antagonist; Lipid peroxidation; Oxidative stress; Cerebellar neuron (Yue, T.-L. (251) 237)

Adenosine; Adenosine A_2 receptor; Adenylyl cyclase; Heart; Coronary; Capillary; (Guinea pig) (Schiele, J.O. (269) 51)

Patch clamp; Ca^{2+}, intracellular; Thapsigargin; Capacitative Ca^{2+} entry; NPPB (5-Nitro-2-(3-phenylpropylamino)-benzoic acid) (Gericke, M. (269) 381)

Endothelial cell, human, vascular
Thromboxane A_2; ICAM-1 (intercellular adhesion molecule-1); Phospholipase A_2 (Ishizuka, T. (262) 113)

Endothelin
Sarafotoxin; BQ-123 (cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu)); Endothelin receptor subtype; Aorta (guinea-pig); Coronary artery (pig); Smooth muscle (vascular) (Schoeffter, P. (249) 199)

Autoradiography; Ca^{2+} channel; Endothelium; Umbilical artery (human); Endothelin receptor (Bodelsson, G. (249) 299)

Endothelial cell; Microcirculation; Permeability; Contraction; Ca^{2+} (Kurose, I. (250) 85)

Sarafotoxin; Prostanoid; Endothelin receptor; PD 145065; Kidney, rat (Warner, T.D. (250) 447)

IRL 1620; PD 145065; Ro 46-2005; Endothelin ET_A/ET_B non-selective receptor antagonist (Battistini, B. (252) 341)

Ca^{2+} channel; Hypertension (Morel, N. (252) R3)

Endothelin receptor antagonist; Renal vasoconstriction; Glomerular filtration rate (Wellings, R.P. (256) 201)

Cytokine; Endothelin converting enzyme; Hemorrhage; Hypoxia; Interleukin-1β; Phosphoramidon; TNF-α (tumor necrosis factor-α) (Vemulapalli, S. (257) 95)

Mast cell; Histamine; Leukotriene; Chemical mediator (Yamamura, H. (257) 235)

BQ123; Endothelin ET_A receptor; Endothelin ET_B receptor; Saphenous vein, human (White, D.G. (257) 307)

Endothelin ET_B receptor; Endothelin ET_A receptor; Prostacyclin (McMurdo, L. (259) 51)

Radioimmunoassay; Spinal cord; Sympathetic nervous system (Knuepfer, M.M. (259) 305)

Endothelin receptor antagonist; Hypertension; DOCA-salt SHR (deoxycorticosterone acetate-salt spontaneously hypertensive rat) (Okada, M. (259) 339)

Basilar artery; Cromakalim (Zuccarello, M. (259) R1)

Cerebrovascular circulation; Cerebrovascular disease (Patel, T.R. (260) 65)

BQ-123; Ro 47-0203; Bosentan; Endothelin ET_A receptor; Endothelin ET_B receptor; Microcirculation; Skin blood flow, rat (Lawrence, E. (260) 103)

BQ123; Pulmonary artery; Ro 46-2005; Sarafotoxin S6c; (Human); (In vitro) (Buchan, K.W. (260) 221)

Smooth muscle; EDRF (endothelium-derived relaxing factor); Endothelin ET_B receptor; Endothelin ET_B receptor antagonist; RES-701-1 (Karaki, H. (262) 255)

L-N^G-Nitroarginine; Ibuprofen; EDRF (endothelium-derived relaxing factor); Renal blood flow; Urine flow rate; Urine osmolality; Glomerular filtration rate; (Dog) (Yukimura, T. (264) 399)

Saponin; Ca^{2+}; Protein kinase C; Positive inotropy; Diacylglycerol; IP_3; Phospholipase (Paik, G.Y. (264) 437)

Cardiac tissue; Endothelin receptor; Antibodies (Shannon, T.R. (267) 233)

Endothelin-1
ATP; Artery (rabbit ear, jejunal); Perivascular nerve stimulation; Vasoconstrictor response (La, M. (249) 133)

U-46619; Anti-endothelin-1 serum; ST elevation; Radioimmunoassay; (Rat) (Yamamoto, T. (250) 189)

NMDA (*N*-methyl-D-aspartate); Barrel rolling; Periaqueductal gray area (Maione, S. (250) 209)

Big endothelin-1; Endothelin converting enzyme; Coronary artery, porcine (Balwierczak, J.L. (250) 379)

Balloon angioplasty; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester; Vascular reactivity; Neointima formation (Douglas, S.A. (255) 81)

Atrium, rat; Diabetes; Noradrenaline; Streptozotocin; Sympathetic nerve stimulation (Lieu, A.T. (261) 33)

Mast cell; Histamine; Compound 48/80; Islet-activating protein; Endothelin receptor (Yamamura, H. (265) 9)

Endothelin-3
Dopamine; Glutamate; NMDA receptor; Striatal slice; Voltage-gated Ca^{2+} channel (Koizumi, S. (259) 195)

Endothelin-1 binding
Bosentan; Endothelin receptor antagonist; Ca^{2+} mobilization; Expression (Adachi, M. (269) 225)

Endothelin converting enzyme
Big endothelin-1; Endothelin-1; Coronary artery, porcine (Balwierczak, J.L. (250) 379)

Cytokine; Endothelin; Hemorrhage; Hypoxia; Interleukin-1β; Phosphoramidon; TNF-α (tumor necrosis factor-α) (Vemulapalli, S. (257) 95)

Endothelin ET_A/ET_B non-selective receptor antagonist
Endothelin; IRL 1620; PD 145065; Ro 46-2005 (Battistini, B. (252) 341)

Endothelin receptor
Autoradiography; Ca^{2+} channel; Endothelin; Endothelium; Umbilical artery (human) (Bodelsson, G. (249) 299)

Endothelin; Sarafotoxin; Prostanoid; PD 145065; Kidney, rat (Warner, T.D. (250) 447)

Vasoactive intestinal contractor; Acetylcholine release; Ileum, guinea pig; Desensitization (Kan, S. (258) 139)

Mast cell; Endothelin-1; Histamine; Compound 48/80; Islet-activating protein (Yamamura, H. (265) 9)

Endothelin; Cardiac tissue; Antibodies (Shannon, T.R. (267) 233)

K^+ channel clone; $K_{V1.2}$; *Xenopus* oocyte; Protein kinase C; Ca^{2+}, intracellular (Murakoshi, H. (268) 451)

Endothelin ET_A receptor
Endothelin; BQ123; Endothelin ET_B receptor; Saphenous vein, human (White, D.G. (257) 307)

Endothelin; Endothelin ET_B receptor; Prostacyclin (McMurdo, L. (259) 51)

BQ-123; Ro 47-0203; Bosentan; Endothelin ET_B receptor; Endothelin; Microcirculation; Skin blood flow, rat (Lawrence, E. (260) 103)

Antisense oligodeoxynucleotide; Temporal artery, human (Adner, M. (261) 281)

Endothelin ET_B receptor
Endothelin; BQ123; Endothelin ET_A receptor; Saphenous vein, human (White, D.G. (257) 307)

Endothelin; Endothelin ET_A receptor; Prostacyclin (McMurdo, L. (259) 51)

BQ-123; Ro 47-0203; Bosentan; Endothelin ET_A receptor; Endothelin; Microcirculation; Skin blood flow, rat (Lawrence, E. (260) 103)

Smooth muscle; EDRF (endothelium-derived relaxing factor); Endothelin; Endothelin ET_B receptor antagonist; RES-701-1 (Karaki, H. (262) 255)

Endothelin receptor antagonist
Endothelin; Renal vasoconstriction; Glomerular filtration rate (Wellings, R.P. (256) 201)

Endothelin; Hypertension; DOCA-salt SHR (deoxycorticosterone acetate-salt spontaneously hypertensive rat) (Okada, M. (259) 339)

Bosentan; Endothelin-1 binding; Ca^{2+} mobilization; Expression (Adachi, M. (269) 225)

Endothelin ET_B receptor antagonist
Smooth muscle; EDRF (endothelium-derived relaxing factor); Endothelin; Endothelin ET_B receptor; RES-701-1 (Karaki, H. (262) 255)

Endothelin receptor subtype
Endothelin; Sarafotoxin; BQ-123 (cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu)); Aorta (guinea-pig); Coronary artery (pig); Smooth muscle (vascular) (Schoeffter, P. (249) 199)

Endothelium
Autoradiography; Ca^{2+} channel; Endothelin; Umbilical artery (human); Endothelin receptor (Bodelsson, G. (249) 299)

Artery, human; Nitric oxide (NO); Adrenergic stimulation (Aldasoro, M. (250) 103)

Salbutamol; Nitric oxide (NO); β_2-Adrenoceptor; N^G-Nitro-L-arginine methyl ester; Aortic ring; Blood pressure (Wang, Y.-X. (250) 335)

Thiol; Nitrovasodilator; Nitrate tolerance; Smooth muscle, vascular (Kojda, G. (250) 385)

EDRF (endothelium-derived relaxing factor); Bradykinin; Angiotensin converting enzyme inhibitor; Captopril (Hirano, K. (250) 439)

Cyclopiazonic acid; Cation channel, non-specific (Zhang, H. (251) 119)

Vascular reactivity; Nitric oxide (NO); cGMP; Nandrolone (Ferrer, M. (252) 233)

Vasorelaxation; Aortic baroreceptor; Adenosine receptor; EDRF (endothelium-derived relaxing factor); NECA (5′-*N*-ethylcarboxamidoadenosine); Nitric oxide (NO) (Fahim, M. (254) 183)

Nitric oxide (NO); Vasodilator nerve; Cerebral artery; Calmodulin (Okamura, T. (256) 79)

Rutaecarpine; Vasorelaxant; Ca^{2+} mobilization (Chiou, W.-F. (257) 59)

Mg^{2+}; Aorta; Mineralocorticoid hypertension; (Rat) (Laurant, P. (258) 167)

Deferential artery, human; Adrenergic stimulation (Martínez, C. (261) 73)

Pentoxifylline; Mesenteric resistance vessel; Aminophylline; Nitric oxide (NO); Smooth muscle, vascular; Methylxanthine derivative (Hansen, P.R. (261) 105)

Interleukin-1β; cGMP; Vascular tone (Schini-Kerth, V. (265) 83)

Lipoprotein; Vasodilation; Nitric oxide (NO) (Galle, J. (265) 111)

Protein kinase C; Nitric oxide synthase; EDRF (endothelium-dependent relaxation factor); Phorbol ester (Davda, R.K. (266) 237)

Endothelium-dependent response
Nitric oxide synthase inhibitor; Mesenteric vascular bed; Nitrovasodilator; Vascular tone; Atropine; (Cat) (Santiago, J.A. (254) 207)

Endothelium-dependent vasodilator
Aortic endothelial cell; Ca^{2+} concentration, intracellular, free; Cl^-, extracellular; Fura-2 (Hosoki, E. (266) 213)

Endotoxic shock
Nitric oxide (NO); *N*-Acetylserotonin (Klemm, P. (250) R9)

Endotoxin
N^G-Nitro-L-arginine; PAF (platelet activating factor); Cardiovascular function; Shock; (Dog) (Takekoshi, K. (250) 465)

Nitric oxide (NO); N^G-Nitro-L-arginine; N^G-Monomethyl-L-arginine; Glucocorticoid (Berrazueta, J.R. (251) 303)

Sepsis; Nitric oxide (NO); Vasopressin; Vasopressin receptor antagonist; Intestinal mucosal injury; Intestinal vascular permeability; N^G-Nitro-L-arginine methyl ester (László, F. (260) 265)

Pancreatitis, acute; PAF (platelet activating factor) (Emanuelli, G. (261) 265)

Lipopolysaccharide; Lung; Nitric oxide (NO); Prostacyclin (Sautebin, L. (262) 193)

Nitric oxide (NO); Glyceraldehyde-3-phosphate dehydrogenase; Cytotoxicity; Shock (Dimmeler, S. (267) 105)

Neutrophil; Eosinophil; Bone marrow; Lipopolysaccharide; PAF (platelet-activating factor); PAF receptor antagonist (Bozza, P.T. (270) 143)

Endotoxin shock
Vasodilatation; Vascular hyporeactivity; Circulatory shock; Cytokine (Szabó, C. (250) 157)

Endplate potential
SK&F 96365; Neostigmine; Nicotinic acetylcholine receptor; Receptor desensitisation (Hong, S.J. (265) 35)

Enisoprost
Prostaglandin E_1; Prostaglandin E_2; Misoprostol; Bradykinin; Sympathetic nervous system; Plasma extravasation; PAF (platelet activating factor, PAF-acether); Synovial joint (Green, P.G. (252) 127)

Enkephalin
Endo-oligopeptidase; Morphine withdrawal; Opioid system (Paik, S.H. (253) 101)

[Met^5]Enkephalin
Catecholamine; Neuropeptide Y; Adrenal medulla; Insulin; Hypoglycemia (Damase-Michel, C. (258) 277)

[Met^5]Enkephalin-Arg^6-Phe^7
Antitussive effect; κ-Opioid receptor; (Mouse) (Kamei, J. (253) 293)

Enkephalin degradation
Neuropathic pain; Mononeuropathic rat; Opioid receptor; Mixed inhibitor (Lee, S.H. (264) 61)

Entacapone
[^{18}F]Fluoro-DOPA; Catechol-*O*-methyl transferase inhibitor; Carbidopa; Brain catecholamine; PET (positron emission tomography) (Pauwels, T. (257) 53)

Enteric neuron
ATP; Suramin; Ionic conductance; Electrophysiology; Purinoceptor; Myenteric plexus (Barajas-López, C. (250) 141)

Enterochromaffin-like cell-oma
CCK_B receptor; Pharmacology; Cloning; Small cell lung carcinoma (Denyer, J. (268) 29)

Eosinophil
Phosphodiesterase inhibitor; Aerosol; Ovalbumin; PAF (platelet-activating factor); (Guinea pig) (Lagente, V. (255) 253)

Neutrophil; Bone marrow; Endotoxin; Lipopolysaccharide; PAF (platelet-activating factor); PAF receptor antagonist (Bozza, P.T. (270) 143)

Epibatidine
Nicotinic receptor; Analgesia (Qian, C. (250) R13)

Epilepsy
Glutamate; Dizocilpine; Catalepsy; Glycine receptor (Wlaź, P. (257) 217)

Felbamate; Audiogenic seizure; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Glycine/NMDA receptor; (DBA/2 mouse) (De Sarro, G. (262) 11)

Adenosine; Kindling; Glutamate binding; Glutamate release (Simonato, M. (265) 121)

Epilepsy, therapy
α-Linolenic acid; Linoleic acid; $\omega 3/\omega 6$ ratio (Yehuda, S. (254) 193)

Epithelium
Trachea; Smooth muscle; ATP; Amiloride; DIDS (4,4′-diisothiocyano-stilbene-2,2′-disulfonic acid) (Fedan, J.S. (256) 51)

Ca^{2+}; Corticotropin-releasing factor; Ca^{2+} channel; Pertussis toxin (Kiang, J.G. (267) 135)

Epitope-tagged
Baculovirus; G-protein coupled receptor; Immunofluorescence (in situ) (Ng, G.YK. (267) 7)

EP_3 receptor
Pithed rat; Prostaglandin E_2; Sulprostone; Presynaptic receptor; Neurogenic vasopressor response (Malinowska, B. (259) 315)

Epstein-Barr virus
DNA-binding drug; Transcription factor (Feriotto, G. (267) 143)

Equilibrium partitioning
PCB (polychlorinated biphenyl); Biotransformation; (Marine mammals) (Boon, J.P. (270) 237)

Erythrocyte
β-Adrenoceptor; β-Adrenoceptor antagonist; G-protein (G_s); Adenylyl cyclase; Turkey (Götze, K. (268) 151)

Escape response
Endosulfan; Learning; Memory; Avoidance response; 5-HT (5-hydroxytryptamine, serotonin) (Paul, V. (270) 1)

β-Escin-skinned fiber
α_1-Adrenoceptor; Thoracic aorta; Myosin light chain phosphorylation (Satoh, M. (265) 133)

Esculetin
Baicalein; Antiproliferative effect; CEM cell; Transduction signal; Messenger RNA expression (Huang, H.-C. (268) 73)

E-selectin
Anti-E-selectin antibody; Myocardial ischemia-reperfusion injury; (Rat) (Altavilla, D. (270) 45)

Estradiol
Protein kinase C; Pituitary; Dopamine; Hyperplasia; (Isoform); (Rat) (Lévy, L. (268) 327)

17α-Estradiol
Estrogen; Coronary vasodilation (Salas, E. (258) 47)

Estrogen
Coronary vasodilation; 17α-Estradiol (Salas, E. (258) 47)

Ethanol
Catecholamine synthesis rate; Dopamine; Microdialysis (in vivo); Nicotinic acetylcholine receptor; (Rat) (Blomqvist, O. (249) 207)

DOPAC (dihydroxyphenylacetic acid); Dopamine; GABA (γ-hydroxybutyric acid); Naloxone; Sleep (Devoto, P. (252) 321)

EDRF (endothelium-dependent relaxing factor); Cotransmission; Purine; ATP (Brizzolara, A.L. (254) 175)

Isradipine; L-type Ca^{2+} channel; Drug discrimination; (Rat) (Colombo, G. (265) 167)

Development; Muscarinic receptor; Phosphoinositide; Fetal alcohol syndrome; (Rat) (Balduini, W. (266) 283)

Zolpidem; $GABA_A$-benzodiazepine type 1 receptor; (α_1 subunit) (Devaud, L.L. (267) 243)

GABA (γ-aminobutyric acid); Butanol; Electrophysiology; cDNA; Oocyte (Mihic, S.J. (268) 209)

Ca^{2+} channel; Electrophysiology; Permeant ion; PC12; Pheochromocytoma cell (Mullikin-Kilpatrick, D. (270) 17)

5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Frontal cortex; Microdialysis (Portas, C.M. (270) 123)

Acetaldehyde; Free radical; Reactive oxygen; Oxidative stress (Bondy, S.C. (270) 349)

Placenta; Fetal artery; Hypertension; Fetal alcohol syndrome; Indomethacin (Taylor, S.M. (270) 371)

Ethanol, chronic voluntary
Brain; β-Endorphin; Proopiomelanocortin mRNA, hypothalamic (De Waele, J.-P. (258) 119)

Ethanol drinking
$GABA_A$ receptor; Benzodiazepine; Naloxone; (Selected rat lines) (Wegelius, K. (263) 141)

Dopamine receptor subtype; Nigrostriatal/mesolimbic dopamine; (Inbred mouse) (Ng, G.YK. (269) 349)

Dopamine receptor agonist; Nigrostriatal/mesolimbic dopamine; (Inbred mouse) (Ng, G.YK. (269) 365)

Ethanol-induced mucosal lesion
Morphine; N^G-Nitro-L-arginine; Aspirin-induced mucosal lesion; (Rat) (Gyires, K. (255) 33)

7-Ethoxyresorufin-*O*-deethylase (EROD)
TCB (3,3′,4,4′-tetrachlorobiphenyl); PCB (polychlorinated biphenyl) metabolism; (Bird); (Mammal); (Fish) (Murk, A. (270) 253)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); (Rat); (Mouse); (Guinea pig); (Hamster) (Håkansson, H. (270) 279)

***N*-Ethylmaleimide**
Dopamine release; Striatum, rat; Forskolin; Methamphetamine (Yamada, S. (257) 243)

Dopamine carrier, neuronal; Dopamine uptake blocker; [^{3}H]GBR 12783; Binding, in vitro; Striatum, rat; (Slow interaction) (Héron, C. (264) 391)

Vas deferens, rat; α_2-Adrenoceptor; Phenoxybenzamine; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Browne, I. (265) 125)

κ-Opioid receptor; R1.1 Thymoma cell line; Sulfhydryl group; Dithiothreitol (Joseph, D.B. (267) 1)

N-Ethylmaleimide treatment
Dopamine carrier (neuronal); Na^+-dependence; [^{3}H]GBR 12783; [^{3}H]Cocaine; Binding in vitro; Striatum; (Rat) (Saadouni, S. (268) 187)

Eticlopride
Conditioned avoidance response; SCH-23390 (White, I.M. (253) 167)

Excision repair
Cisplatin; Drug resistance; Ultraviolet (Chao, C.C.-K. (268) 347)

Excitation
Superior colliculus; Adenosine; Glutamate release; Protein kinase (Hirai, H. (256) 65)

Excitation-contraction coupling
Sarcoplasmic reticulum; Cyclopiazonic acid; Thapsigargin; Heart; (Frog) (Bonnet, V. (264) 69)

Excitatory amino acid
ACPD (1*S*,3*R*-1-aminocyclopentane-1,3-dicarboxylate); Excitatory amino acid receptor (metabotropic); Convulsion (Klitgaard, H. (250) 9)

Excitatory amino acid receptor (metabotropic); ACPD ((1*S*,3*R*)-1-Aminocyclopentane-1,3-dicarboxylic acid); Convulsion; Scratching (Laudrup, P. (250) 15)

Riluzole; Glutamate; Aspartate; Hippocampus; Transmitter release (Martin, D. (250) 473)

Apneusis; MK-801 (dizocilpine); NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline); Respiratory activity (McManigle, J.E. (252) 11)

Thermal hyperalgesia; Glutamate receptor; Inflammation; Memantine; Carrageenan (Eisenberg, E. (255) 123)

Kynurenic acid; Morphine; Conditioned place preference; Self-stimulation; (Rat) (Bespalov, A. (264) 233)

Dopamine; GABA (γ-aminobutyric acid); $GABA_A$ receptor; NMDA (N-methyl-D-aspartate); Tissue culture (Chaudieu, I. (264) 361)

Excitatory amino acid receptor
MCPG (α-methyl-4-carboxyphenylglycine); Presynaptic; cAMP; Glutamate; Receptor; Metabotropic; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

Excitatory amino acid receptor, metabotropic
ACPD (1*S*,3*R*-1-aminocyclopentane-1,3-dicarboxylate); Excitatory amino acid; Convulsion (Klitgaard, H. (250) 9)

Excitatory amino acid; ACPD ((1*S*,3*R*)-1-Aminocyclopentane-1,3-dicarboxylic acid); Convulsion; Scratching (Laudrup, P. (250) 15)

Excitatory nerve
Colon, human; Opioid receptor agonist; Opioid receptor antagonist; Smooth muscle (Chamouard, P. (262) 33)

Excitatory postsynaptic potential
5-HT (5-hydroxytryptamine, serotonin); Gepirone; Hippocampus; Excitatory synaptic transmission; Electrophysiology; $5\text{-}HT_{1A}$ receptor (Manahan-Vaughan, D. (260) 149)

Excitatory response
Opiate; Postsynaptic action, direct; Medial vestibular nucleus, rat (Lin, Y. (262) 99)

Excitatory synaptic transmission
5-HT (5-hydroxytryptamine, serotonin); Gepirone; Hippocampus; Electrophysiology; $5\text{-}HT_{1A}$ receptor; Excitatory postsynaptic potential (Manahan-Vaughan, D. (260) 149)

Excitotoxicity
DCG-IV ((2*S*,1′*R*,2′*R*,3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine); Metabotropic glutamate receptor; Cortical neuron (Bruno, V. (256) 109)

Glutamate Receptor; NMDA receptor (Cik, M. (266) R1)

DL-(Tetrazol-5-yl)glycine; NMDA (*N*-methyl-D-aspartate); *cis*-Methanoglutamate; Neurodegeneration (Schoepp, D.D. (270) 67)

Excitotoxin
Cerebral ischemia; Glutamate; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Microdialysis (Gaspary, H.L. (262) 197)

Exocrine secretion
Pancreas (dog); KRN2391 (*N*-cyano-*N*′-(2-nitroxyethyl)-3-pyridinecarboximidamide monomethanesulfonate); Nitro compound; K^+ channel opener (Iwatsuki, K. (249) 19)

Experimental colitis
Capsaicin; Resiniferatoxin binding; Vanilloid receptor (Goso, C. (249) 185)

PAF (platelet activating factor); 5-Amino-salicylic acid (Zijlstra, F.J. (249) R1)

Expression
Bosentan; Endothelin receptor antagonist; Endothelin-1 binding; Ca^{2+} mobilization (Adachi, M. (269) 225)

Extensor digitorum longus
Li^+; ATPase; Chronic; Soleus; Plantaris (Adipudi, V. (259) 7)

Extracellular matrix
Spontaneously hypertensive rat (SHR); Transforming growth factor β_1; mRNA; Cardiovascular system; Renin-angiotensin system (Ohta, K. (269) 115)

Cyclosporin A; Glomerulosclerosis; Mesangial cell (Ghiggeri, G.M. (270) 195)

Ex vivo binding
CCK_B receptor antagonist; L-365,260; CI988; L-368,935; Brain penetration (Patel, S. (253) 237)

Facilitation
Vas deferens, mouse; Cotransmission; ATP; Yohimbine; α_2-Autoinhibition (Karunanithi, S. (261) 17)

Fantofarone
Ca^{2+} channel antagonist; Heart, isolated; Ischemia, ^{31}P NMR spectroscopy (Vander Elst, L. (251) 163)

Ca^{2+} channel antagonist; Binding; Heart; SR 33805; Dihydropyridine (Chatelain, P. (267) 151)

Fatty acid
5-Lipoxygenase-activating protein; 5-Lipoxygenase; Arachidonic acid; Leukotriene (Charleson, S. (267) 275)

FCCP (carbonyl cyanide-*p*-trifluoromethoxyphenyl-hydrazone)
Ca^{2+} oscillation; Megakaryocyte, rat; Patch-clamp (Uneyama, C. (268) 455)

Feeding
5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY-100135; (Rat) (Hartley, J.E. (252) 329)

Macronutrient preference; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Ageing; Protein intake (Lacour, F. (255) 249)

Felbamate
Glycine; Convulsion (Coffin, V. (256) R9)

Epilepsy; Audiogenic seizure; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Glycine/NMDA receptor; (DBA/2 mouse) (De Sarro, G. (262) 11)

Diazepam; Isoniazid; FG 7142; Convulsion; GABAergic transmission (Serra, M. (265) 185)

Felodipine
Stroke-prone spontaneously hypertensive rat (SHRSP); Cardiac hypertrophy; Na^+; K^+; Mg^{2+} (Mervaala, E.M.A. (255) 73)

Femoral artery
Ryanodine; Ca^{2+} influx; Verapamil; Spontaneously hypertensive rat (SHR) (Kojima, M. (254) 159)

CD-832; Ca^{2+} channel antagonist; Femoral vein; (Rabbit) (Yamaura, H. (260) 269)

Femoral vein
CD-832; Ca^{2+} channel antagonist; Femoral artery; (Rabbit) (Yamaura, H. (260) 269)

Fenfluramine
Hippocampus; 5-HT (5-hydroxytryptamine, serotonin); Acetylcholine (Levkovitz, Y. (264) 279)

***d*-Fenfluramine**
Dopamine; Food intake; 5-HT (5-hydroxytryptamine, serotonin); *d*-Norfenfluramine; Sex difference (Oluyomi, A.O. (255) 175)

Food intake; *d*-Norfenfluramine; Microdialysis; *p*-Chlorophenylalanine (Oluyomi, A.O. (264) 111)

***d*-Fenfluramine therapy**
Non-insulin-dependent diabetes mellitus; Insulin resistance; Liver; (Rat) (Picarel-Blanchot, F. (264) 227)

Fetal alcohol syndrome
Ethanol; Development; Muscarinic receptor; Phosphoinositide; (Rat) (Balduini, W. (266) 283)

Ethanol; Placenta; Fetal artery; Hypertension; Indomethacin (Taylor, S.M. (270) 371)

Fetal artery
Ethanol; Placenta; Hypertension; Fetal alcohol syndrome; Indomethacin (Taylor, S.M. (270) 371)

FG 5893
5-HT_{1A} receptor agonist/5-HT_{2A} receptor antagonist; 5-HT receptor; Hypothermia; Head twitch behavior; Passive avoidance; Forced swim test; Cage leaving; Ultrasound vocalization; Corticosterone; (Rat) (Albinsson, A. (261) 285)

FG 7142
Felbamate; Diazepam; Isoniazid; Convulsion; GABAergic transmission (Serra, M. (265) 185)

aFGF (acidic fibroblast growth factor)
ANP (Atrial natriuretic peptide); Growth factor; Protein kinase C; Staurosporine; Phorbol ester (Tokola, H. (267) 195)

FH-510 (5,8-dimethyl-4-(2-di-*n*-propylaminoethyl)carbazol)
σ Binding site; DTG (1,3-di-*o*-tolylguanidine); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperidine) (Chaki, S. (250) 173)

Fibroblast
Substance P; Migration (Kähler, C.M. (249) 281)

Acetylsalicylic acid; Proliferative vitreoretinopathy; Arachidonic acid metabolite, inhibition (Kähler, C.M. (262) 261)

L-DOPA (3,4-dihydroxyphenylalanine); Mitochondrion; Parkinson's disease; Pyruvate oxidation (Werner, P. (263) 157)

Field potential
Hippocampus; Granule cell; *d*-Cycloserine; Glycine binding site; NMDA receptor (Pitkänen, M. (253) 125)

Field stimulation
Nitric oxide (NO); Sphincter of Oddi; Neural relaxation (Lonovics, J. (255) 117)

Firing
5-HT_{1A} receptor; Autoradiography; Hippocampus; Dorsal raphe nucleus; Adenylate cyclase; Lesopitron; (−)-Tertatolol (Haj-Dahmane, S. (255) 185)

FK409
Isosorbide dinitrate; Nitric oxide (NO) (Kita, Y. (257) 123)

Tolerance; Vasorelaxation; Guanylate cyclase, soluble; Nitric oxide (NO) (Isono, T. (260) 163)

FK888
Tachykinin NK_1 receptor; RP 67580; (±)-CP-96,345; IM9 human lymphoblastoma cell; U373 MG human astrocytoma cell (Goso, C. (254) 221)

FLAP (five lipoxygenase activating protein) inhibitor
BAY x1005; Leukotriene; Airway; (Guinea pig) (Gardiner, P.J. (258) 95)

Flat body posture
Sexual behavior, male rat; Forepaw treading; Lower lip retraction; Behavior syndrome; 5-HT_{1A} receptor agonist; 5-HT_2 receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) (Andersson, G. (255) 131)

Flavonoid
Baicalein; Antiproliferative effect; Smooth muscle cell, vascular (Huang, H.-C. (251) 91)

Flesinoxan
5-HT_{1A} receptor; Adenylate cyclase; Dorsal raphe nucleus; Nerve impulse flow; (+)-WAY 100 135; SDZ 216-525; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lesopitron; S-20499 (Lanfumey, L. (249) 25)

WAY100135 (*N*-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); 5-HT_{1A} receptor; Glucose concentration, plasma; (Conscious rat) (Critchley, D.J.P. (254) 133)

Discriminative stimulus; 5-HT receptor; Adrenoceptor; Dopamine receptor; Hypotension (Ybema, C.E. (256) 141)

Flexor reflex
Neurokinin A; Tachykinin NK_2 receptor; Tachykinin; Nociception; Spinal cord (Wiesenfeld-Hallin, Z. (251) 99)

Substance P, N-terminus; Antinociception; Pain (Goettl, V.M. (259) 83)

Autotomy; Clonidine; Guanfacine; Pain; ST-91 (Puke, M.J.C. (260) 227)

Flosequinan
Smooth muscle; Vascular; Resistance artery; (Human) (Richards, N.T. (257) 189)

Flumazenil
Receptor kinetics; Benzodiazepine; Midazolam; Radioactive tracer; SPECT (single photon emission computer tomography) (Videbæk, C. (249) 43)

Loreclezole; Anxiolytic; CGS 8216; (Rat) (Dawson, G.R. (252) 325)

Flunarizine
Ca^{2+} channel antagonist, T-type; Neuronal ischemic injury; U-92032; Nifedipine; Antioxidant (Ito, C. (257) 203)

Cell death; Ca^{2+} oscillation; Veratridine; Bovine chromaffin cell; R56865; Nimodipine; ω-Conotoxin GVIA (Maroto, R. (270) 331)

Flunitrazepam
Neuroactive steroid; $GABA_A$ receptor; 3α-Hydroxy-5β-pregnan-20-one; 3α-Hydroxy-5α-pregnan-20-one; TBPS (*t*-Butylbicyclophosphorothionate) (Hawkinson, J.E. (269) 157)

[^{3}H]Flunitrazepam binding
ICS 205–930; 5-HT_3 receptor antagonist; $GABA_A$ receptor; [^{3}H]Muscimol binding; [^{35}S]TBPS (tert-butylbicyclophosphorothionate) binding; $^{36}Cl^-$ flux; 293 cell; *Xenopus* oocyte (Klein, R.L. (268) 237)

Fluorescence polarization
Tetramethylpyrazine; Membrane fluidity; Phospholipid phase transition; Differential scanning calorimetry; Electron spin resonance; Drug–lipid interactions (Nie, S.-Q. (266) 11)

Fluorescent dye
Liver, rat; Bile secretion; P-glycoprotein; Cyclosporin A (Thalhammer, T. (270) 213)

[^{18}F]Fluoro-DOPA
Catechol-*O*-methyl transferase inhibitor; Entacapone; Carbidopa; Brain catecholamine; PET (positron emission tomography) (Pauwels, T. (257) 53)

α-Fluoromethylhistidine
Histamine; Stress; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Accumbens; Suprachiasmatic (Fleckenstein, A.E. (264) 163)

Fluoxetine
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP analog; MPTP derivative; 5-HT (5-hydroxytryptamine, serotonin); Norepinephrine; Desipramine (Andrews, A.M. (250) 215)

Frontal cortex; 5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake inhibitor; Single unit recording (Ceci, A. (250) 461)

5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Anticonvulsant effect; Microdialysis; Genetically epilepsy-prone rat (Yan, Q.-S. (252) 105)

Fluphenazine
Intraocular pressure; Dopamine receptor; Phosphodiesterase inhibitor; Methylxanthine; Pentoxifylline; Trifluperidol; Thiothixene; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine); Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

Fluphenazine-*N*-mustard
EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Substantia nigra; Dopamine D_1 receptor mRNA; Dopamine D_2 receptor mRNA; Glutamic acid decarboxylase mRNA; Gene expression; Dopamine receptor antagonists (Qin, Z.-H. (269) 25)

Flurbiprofen
Trachea (guinea-pig); Verapamil; Trifluoperazine (McCaig, D. (249) 53)

***R*-Flurbiprofen**
S-Flurbiprofen; Formalin test; Antinociception, intrathecal; Spinal cord; Cyclooxygenase, inhibition (Malmberg, A.B. (256) 205)

S-Flurbiprofen; Formalin test; Antinociception, intrathecal; Spinal cord; Cyclooxygenase, inhibition (Malmberg, A.B. (260) 283)

***S*-Flurbiprofen**
R-Flurbiprofen; Formalin test; Antinociception, intrathecal; Spinal cord; Cyclooxygenase, inhibition (Malmberg, A.B. (256) 205)

R-Flurbiprofen; Formalin test; Antinociception, intrathecal; Spinal cord; Cyclooxygenase, inhibition (Malmberg, A.B. (260) 283)

Food intake
Dopamine; *d*-Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); *d*-Norfenfluramine; Sex difference (Oluyomi, A.O. (255) 175)

d-Fenfluramine; *d*-Norfenfluramine; Microdialysis; *p*-Chlorophenylalanine (Oluyomi, A.O. (264) 111)

Footshock
Angiotensin receptor subtype; Losartan; PD 123319 (Cierco, M. (251) 103)

Foot tapping
Tachykinin NK_1 receptor; Chromodacryorrhea; CNS (central nervous system) penetration; (Gerbil) (Rupniak, N.M.J. (265) 179)

Forced swimming test
Water temperature; Glucocorticoid; κ-Opioid receptor, selective; Thyroid hormone; Glucose (Jefferys, D. (253) 91)

SR 57746A (4-(3-trifluoromethylphenyl)-*N*-[2-(naphth-2-yl)ethyl]-1,2,3,6-tetrahydropyridine HCl); 5-HT_{1A} receptor; Adenylate cyclase activity; Antidepressant activity (Cervo, L. (253) 139)

FG5893; 5-HT_{1A} receptor agonist/5-HT_{2A} receptor antagonist; 5-HT receptor; Hypothermia; Head twitch behavior; Passive avoidance; Cage leaving; Ultrasound vocalization; Corticosterone; (Rat) (Albinsson, A. (261) 285)

Forced swimming test, modified
Imipramine; Alprazolam; Propranolol; (Rat) (Abel, E.L. (258) 261)

Forepaw treading
Sexual behavior, male rat; Flat body posture; Lower lip retraction; Behavior syndrome; 5-HT_{1A} receptor agonist; 5-HT_2 receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) (Andersson, G. (255) 131)

Formalin test
S-Flurbiprofen; *R*-Flurbiprofen; Antinociception, intrathecal; Spinal cord; Cyclooxygenase, inhibition (Malmberg, A.B. (256) 205)

Lys-D-Pro-Thr; Lys-D-Pro; Interleukin-1β-(193–195); Tripeptide; Naloxone; Antinociception (Oluyomi, A.O. (258) 131)

S-Flurbiprofen; *R*-Flurbiprofen; Antinociception, intrathecal; Spinal cord; Cyclooxygenase, inhibition (Malmberg, A.B. (260) 283)

Formoterol
Salbutamol; Salmeterol; Smooth muscle, airway; Mast cell; (Duration) (Nials, A.T. (251) 127)

Salmeterol; Terbutaline, in vitro; Lung, guinea pig (Jeppsson, A.-B. (257) 137)

β_2-Adrenoceptor; Autoradiography; Lung (Mak, J.C.W. (269) 35)

Forskolin
N-Ethylmaleimide; Dopamine release; Striatum, rat; Methamphetamine (Yamada, S. (257) 243)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; Mechanistic pathway; LiCl; 1,9-Dideoxy-forskolin; Phorbol ester; Vas deferens; (Rabbit) (Eltze, M. (263) 31)

NMDA (*N*-Methyl-D-aspartate); Nitric oxide (NO); Cyclic AMP; Protein kinase A (Toms, N.J. (266) 63)

Indapamide; cAMP; β-Adrenoceptor stimulation; Cardiomyocyte (chick, embryonic); Cholera toxin (Rabkin, S.W. (266) 117)

Cardiomyocyte, intact; Isoproterenol; β-Adrenoceptor; Desensitization; cAMP (Murphy, M.G. (268) 121)

Galanin; 5-HT (5-hydroxytryptamine, serotonin); 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Adenylyl cyclase; Hypothalamus; Hippocampus; Brain; Receptor subtype; Peptide fragment (Billecocq, A. (269) 209)

Forskolin treatment, chronic
Dopamine D_2 receptor, human; Dopamine; Up-regulation; Supersensitivity; Adenylyl cyclase (Johansson, M.H. (269) 149)

FR128998
PAF (platelet activating factor); Disseminated intravascular coagulation; Lipopolysaccharide; TNF (tumor necrosis factor) (Yokota, Y. (258) 239)

Free radical
Ethanol; Acetaldehyde; Reactive oxygen; Oxidative stress (Bondy, S.C. (270) 349)

Free radical scavenger
Cardioselective; α-Tocopherol analogue; Reperfusion injury; Myocardial ischemia/reperfusion (Petty, M.A. (255) 215)

Frequency dependence
Propafenone; QRS duration; Ventricular mapping (Stark, G. (252) 283)

Frontal cortex
Fluoxetine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake inhibitor; Single unit recording (Ceci, A. (250) 461)

5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Acetylcholine; Hippocampus; Microdialysis; Dopamine D_1 receptor (Acquas, E. (260) 85)

Hippocampus; Idazoxan, chronic; Microdialysis; α_2-Adrenoceptor, presynaptic (Thomas, D.N. (261) 53)

Dexfenfluramine; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} autoreceptor; 5-HT (5-hydroxytryptamine, serotonin) release; Microdialysis (Gardier, A.M. (265) 107)

5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Ethanol; Microdialysis (Portas, C.M. (270) 123)

Fructose-2,6-bisphosphate
CS-045; Antidiabetic; Hepatocyte; Tolbutamide (Murano, K. (254) 257)

FTS (facteur thymique sérique)
Thymic hormone; Alloxan; Thymic immunity (Yamanouchi, T. (257) 39)

Fumaric acid
Psoriasis; Keratinocyte; Cell proliferation; Cytotoxicity (Sebök, B. (270) 79)

β-Funaltrexamine
Lipopolysaccharide, *Pantoea agglomerans*; Antinociception; Diabetes; Naltrindole; Nor-binaltorphimine; Opioid receptor (Kamei, J. (251) 95)

L-Arginine; Antinociception; Diabetes; Naltrindole; Nor-binaltorphimine; Opioid receptor (Kamei, J. (254) 113)

Somatostatin secretion; μ-Opioid receptor; DAGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin) (McIntosh, C. (259) 331)

SH-SY5Y human neuroblastoma cell; μ-Opioid receptor subtype; Naloxonazine (Elliott, J. (268) 447)

Functional antagonism
Muscarinic M_2 receptor; Trachea (guinea-pig); β-Adrenoceptor agonist; Adenylyl cyclase inhibition (Roffel, A.F. (249) 235)

Functional coupling
CCK_B receptor; GH_3 cells; Pituitary; G-protein; Ca^{2+} mobilisation; L-365,260 (Smith, A.J. (267) 215)

Functional expression
Apomorphine; Dopamine receptor agonist; Dopamine receptor antagonist; Nicotinic receptor channel; *Xenopus* oocyte (Nakazawa, K. (269) 375)

Functional interaction
Receptor model; Indirect action; Tyramine; Vas deferens, rat (Venter, D.P. (251) 209)

Fura-2
Aortic endothelial cell; Ca^{2+} concentration, intracellular, free; Cl^-, extracellular; Endothelium-dependent vasodilator (Hosoki, E. (266) 213)

CCK_B receptor; Polymerase chain reaction; Radioligand binding; Calcium mobilization; COS-7 cell; Transient expression; [*N*-methyl-Nle 28,31)]cholecystokinin-(26-33) (Knapp, R.J. (269) 133)

PTHrP (parathyroid hormone-related protein); Cytosolic free Ca^{2+}; cAMP; Aortic spiral preparation, rat (Ishikawa, M. (269) 311)

Furoxan
Vasodilator; Antiaggregator; cGMP; Nitric oxide (NO) (Civelli, M. (255) 17)

GABA (γ-aminobutyric acid)
5-MeO-DMT (5-methoxy-*N*,*N*-dimethyltryptamine); 5-HT receptor; 5-HT receptor agonist; α-Adrenoceptor antagonist; Substance P; Spinal antinociception (Alhaider, A.A. (249) 151)

Antihypertensive treatment; Metoprolol; GABA synthesis and turnover; $GABA_A$ receptor binding (Remiszewska, M. (250) 355)

CCK-8 (cholecystokinin octapeptide); Anxiety; Release; Brain; CCK receptor; (In vitro); (Slice) (Pérez de la Mora, M. (250) 423)

Ivermectin; $GABA_A$ receptor; Desensitization; Hippocampal neurone (mouse) (Krůšek, J. (259) 121)

Haloperidol; Clozapine; Microdialysis; Striatum; Glutamate (See, R.E. (263) 269)

Dystonia; Lamotrigine; Glutamate; Na^+ channel blocker (Richter, A. (264) 345)

Dopamine; Excitatory amino acid; $GABA_A$ receptor; NMDA (N-methyl-D-aspartate); Tissue culture (Chaudieu, I. (264) 361)

Dystonia; Cannabinoid; (+)-WIN 55,212-2; Diazepam; Catalepsy (Richter, A. (264) 371)

Propofol; [^{35}S]TBPS (*t*-[^{35}S]butylbicyclophosphorothionate) binding; Cl^- channel; Barbiturate; Steroid derivative; Benzodiazepine; General anesthetics (Concas, A. (267) 207)

Inhalational anesthetics; Muscimol; Stereospecificity; SR 95531 (Harris, B.D. (267) 269)

Ethanol; Butanol; Electrophysiology; cDNA; Oocyte (Mihic, S.J. (268) 209)

GABA transport; Inhibitor; Transporter; (γ-aminobutyric acid); (Lipophilic) (Borden, L.A. (269) 219)

$GABA_B$ autoreceptor
Neocortex, human; GABA (γ-aminobutyric acid) release; CGP 35348; CGP 52432; Phaclofen (Fassio, A. (263) 311)

$GABA_A$ / benzodiazepine receptor
Nucleus accumbens; Dopamine release; Midazolam; β-CCE (β-carboline-3-carboxylate ethyl ester); Adenosine receptor (Murai, T. (261) 65)

$GABA_A$-benzodiazepine type 1 receptor
Ethanol; Zolpidem; (α_1 subunit) (Devaud, L.L. (267) 243)

GABAergic transmission
Abecarnil; Diazepam; Chronic treatment; Tolerance; (Mouse) (Serra, M. (259) 1)

Felbamate; Diazepam; Isoniazid; FG 7142; Convulsion (Serra, M. (265) 185)

$GABA_A$ receptor
Ivermectin; GABA (γ-aminobutyric acid); Desensitization; Hippocampal neurone (mouse) (Krůšek, J. (259) 121)

Abecarnil; Dopamine; Acetylcholine, release (Imperato, A. (261) 205)

$GABA_B$ receptor; β-Adrenoceptor; Olfactory bulbectomy; Antidepressant; Brain, rat (Dennis, T. (262) 143)

Ethanol drinking; Benzodiazepine; Naloxone; (Selected rat lines) (Wegelius, K. (263) 141)

Dopamine; GABA (γ-aminobutyric acid); Excitatory amino acid; NMDA (N-methyl-D-aspartate); Tissue culture (Chaudieu, I. (264) 361)

Anesthetic; Anesthesia, theories of; Synaptic transmission; Spinal cord; Glutamate receptor; NMDA receptor (Kendig, J.J. (264) 427)

ICS 205–930; 5-HT_3 receptor antagonist; [^{3}H]Flunitrazepam binding; [^{3}H]Muscimol binding; [^{35}S]TBPS (tert-butylbicyclophosphorothionate) binding; $^{36}Cl^-$ flux; 293 cell; *Xenopus* oocyte (Klein, R.L. (268) 237)

Neuroactive steroid; 3α-Hydroxy-5β-pregnan-20-one; 3α-Hydroxy-5α-pregnan-20-one; TBPS (*t*-Butylbicyclophosphorothionate); Flunitrazepam (Hawkinson, J.E. (269) 157)

$GABA_B$ receptor
Spinal cord; Plasticity; Autoradiography; CGP 36742 (3-aminopropyl-*n*-butyl-phosphinic acid); (−)-Baclofen (Malcangio, M. (250) 153)

Baclofen; Neocortical slice, rat; Amiloride; Amiloride analog; (Mg^+-free Krebs medium) (Ong, J. (260) 73)

$GABA_A$ receptor; β-Adrenoceptor; Olfactory bulbectomy; Antidepressant; Brain, rat (Dennis, T. (262) 143)

DN-2327; Adenylate cyclase; (Agonist) (Ichida, T. (267) 43)

$GABA_B$ receptor agonist
γ-Guanidinobaclofen; Baclofen; Ileum, guinea-pig, isolated; Neocortical slice, rat; 2-Hydroxysaclofen (Kerr, D.I.B. (262) 189)

$GABA_B$ receptor antagonist
Nitropropane analog, GABA; Nitropropane analog, baclofen; Ileum, isolated, guinea-pig; Neocortex, rat; Spinal cord, cat (Ong, J. (264) 49)

$GABA_A$ receptor binding
Antihypertensive treatment; Metoprolol; GABA (γ-aminobutyric acid); GABA synthesis and turnover (Remiszewska, M. (250) 355)

$GABA_A$ receptor complex
EBOB (4′-ethynyl-4-*n*-propylbicycloorthobenzoate); Picrotoxin; Brain, human; Autoradiography (Kume, A. (263) 163)

Benzodiazepine binding site, type I; [^{3}H]Zolpidem binding; Immunoprecipitation; Photoaffinity labeling; Cortex; (Subunit specific antibodies) (Ruano, D. (267) 121)

$GABA_A$ receptor, partial agonist
Imidazenil; Chronic treatment; Tolerance (Ghiani, C.A. (254) 299)

GABA release
Neocortex, human; $GABA_B$ autoreceptor; CGP 35348; CGP 52432; Phaclofen (Fassio, A. (263) 311)

GABA synthesis and turnover
Antihypertensive treatment; Metoprolol; GABA (γ-aminobutyric acid); $GABA_A$ receptor binding (Remiszewska, M. (250) 355)

GABA transport
GABA; Inhibitor; Transporter; (γ-aminobutyric acid); (Lipophilic) (Borden, L.A. (269) 219)

GABA uptake, synaptosome
Riluzole; Striatum; (Rat) (Mantz, J. (257) R7)

Galanin
Dorsal root ganglion cell; Galantide (Puttick, R.M. (254) 303)

Muscarinic receptor agonist; Cholinomimetic; Hypothermia; ATP-sensitive K^+ channel; Acetylcholinesterase inhibitor (Patel, S. (255) 25)

Galanin fragment; Receptor subtype; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Blood pressure; Heart rate; Medulla oblongata; (Intracisternal injection) (Narváez, J.A. (257) 257)

GMAP (galanin message-associated polypeptide); Insulin secretion; Islet; (In vitro); (Mouse); (Rat) (Gregersen, S. (259) 79)

Preprogalanin; Galanin receptor; Nociception; Spinal cord; Neuropeptide (Bedecs, K. (259) 151)

Galantide; Sexual behavior; (Male rat) (Benelli, A. (260) 279)

Human cell line; Bowes cell line; Binding; cAMP; Galantide (Heuillet, E. (269) 139)

5-HT (5-hydroxytryptamine, serotonin); 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Adenylyl cyclase; Forskolin; Hypothalamus; Hippocampus; Brain; Receptor subtype; Peptide fragment (Billecocq, A. (269) 209)

Galanin fragment
Galanin; Receptor subtype; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Blood pressure; Heart rate; Medulla oblongata; (Intracisternal injection) (Narváez, J.A. (257) 257)

Galanin receptor
Preprogalanin; Galanin; Nociception; Spinal cord; Neuropeptide (Bedecs, K. (259) 151)

Hypothalamus; Brain; (Human) (Lorinet, A.-M. (269) 59)

Galantide
Galanin; Dorsal root ganglion cell (Puttick, R.M. (254) 303)

Galanin; Sexual behavior; (Male rat) (Benelli, A. (260) 279)

Galanin; Human cell line; Bowes cell line; Binding; cAMP (Heuillet, E. (269) 139)

Gastric acid
Nitric oxide (NO); Gastric distension, 2-Deoxy-D-glucose; Histamine; Pentagastrin; Brain-gut axis (Barrachina, D. (262) 181)

Gastric ulcer; Cimetidine; Omeprazole; Gastrin (Ito, M. (263) 245)

Gastric acid secretion
Gastrin; CCK (cholecystokinin); CCK receptor antagonist (Varga, G. (250) 37)

DS-4574; Mast cell stabilizer; Histamine leakage; Pentagastrin; Carbachol (Tabuchi, Y. (255) 229)

Binding; Brain; Electrophysiology; Neuropeptide; CCK_B receptor (Bertrand, P. (262) 233)

Gastric distension
Gastric acid; Nitric oxide (NO); 2-Deoxy-D-glucose; Histamine; Pentagastrin; Brain-gut axis (Barrachina, D. (262) 181)

Gastric emptying
CCK (cholecystokinin); Secretin; Capsaicin; Vagal afferent; Spinal afferent (Raybould, H.E. (250) 165)

Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; N^G-Monomethyl-L-arginine; Blood pressure; L-Arginine (Plourde, V. (256) 125)

Gastric erosion
Gastric mucosa; Vasopressin; Vasopressin receptor; Autoradiography; Vasopressin receptor antagonist (László, F. (258) 15)

Gastric hyperemia
Nitric oxide (NO); Capsaicin (Konturek, S.J. (253) 107)

Gastric motility
Interleukin-1β; TNF (tumor necrosis factor); Leukotriene B_4; Phospholipase A_2; Phospholipase C; 5-Lipoxygenase; Protein kinase C; Phorbol 12-myristate 13-acetate; Stomach, rat (Montuschi, P. (252) 253)

Gastric mucin biosynthesis
Histamine H_2 receptor antagonist; H^+,K^+-ATPase inhibitor; Organ culture; (Rat) (Ichikawa, T. (251) 107)

Gastric mucosa
Capsaicin; CGRP (calcitonin gene-related peptide); Monoclonal anti-CGRP antibody; Immuno-neutralization; Gastric mucosal protection; Gastric mucosal injury (Peskar, B.M. (250) 201)

Gastric erosion; Vasopressin; Vasopressin receptor; Autoradiography; Vasopressin receptor antagonist (László, F. (258) 15)

Nitric oxide (NO); Mucus; Stomach (Price, K.J. (263) 199)

Gastric mucosal blood flow
5-HT (5-hydroxytryptamine, serotonin); Methysergide; Adenosine diphosphate; Platelet aggregation; Blood pressure; Blood gas (Cho, C.H. (256) 9)

Gastric mucosal injury
DS-4574; Mast cell stabilizer; Peptidoleukotriene; LY171883; Mucosal mast cell (Tabuchi, Y. (250) 197)

Capsaicin; CGRP (calcitonin gene-related peptide); Monoclonal anti-CGRP antibody; Immuno-neutralization; Gastric mucosa; Gastric mucosal protection (Peskar, B.M. (250) 201)

Gastric mucosal protection
Capsaicin; CGRP (calcitonin gene-related peptide); Monoclonal anti-CGRP antibody; Immuno-neutralization; Gastric mucosa; Gastric mucosal injury (Peskar, B.M. (250) 201)

Gastric muscularis mucosae
Smooth muscle; Adenosine receptor; Adenosine analogue; DPCPX (1,3-dipropyl-8-cyclopentylxanthine) (Muller, M.J. (251) 151)

Gastric smooth muscle
NANC (non-adrenergic non-cholinergic); Inhibitory junction potential; Suramin; ATP (Ohno, N. (249) 121)

Gastric ulcer
Cimetidine; Omeprazole; Gastrin; Gastric acid (Ito, M. (263) 245)

Gastrin
CCK (cholecystokinin); CCK receptor antagonist; Gastric acid secretion (Varga, G. (250) 37)

Gastric ulcer; Cimetidine; Omeprazole; Gastric acid (Ito, M. (263) 245)

Cimetidine; Omeprazole; Acid secretion (Ito, M. (263) 253)

Gastrin binding
Brain membrane; CCK_B receptor; CCK_8 binding; G protein (Lallement, J.-C. (267) 297)

Gastrin-releasing peptide
MDL-101,562; Bombesin; Dopaminergic neuron (Manzanares, J. (257) 199)

Gastrointestinal hormone
Peptide YY; Neuropeptide Y receptor; [Pro^{34}]peptide YY (Grandt, D. (269) 127)

Gastroprotection
Microvascular permeability; Microcirculation; Octreotide (Kusterer, K. (259) 265)

GBR 12909
[^{3}H]Mazindol; Dopamine uptake site; Dopamine turnover; L-DOPA (L-3,4-dihydroxyphenylalanine); α-Methyl-*p*-tyrosine (Ikawa, K. (250) 261)

[^{3}H]Mazindol; Dopamine uptake site; Dopamine turnover; L-DOPA (L-3,4-dihydroxyphenylalanine); α-Methyl-*p*-tyrosine (Ikawa, K. (252) 123)

GBR 12935; Dopamine uptake; Synaptic vesicle; Brain (Reith, M.E.A. (253) 175)

Dopamine transporter; Cocaine; 5-HT (5-hydroxytryptamine, serotonin) transporter; CFT (WIN 35,428); Parkinson's disease (Madras, B.K. (267) 167)

GBR 12935
GBR 12909; Dopamine uptake; Synaptic vesicle; Brain (Reith, M.E.A. (253) 175)

[^{3}H]GBR 12783 (1-[2-{diphenylmethoxy}ethyl]4-{3-phenyl-2-propenyl}-piperazine)
Dopamine carrier, neuronal; Dopamine uptake blocker; *N*-Ethylmaleimide; Binding, in vitro; Striatum, rat; (Slow interaction) (Héron, C. (264) 391)

Dopamine carrier (neuronal); Na^+-dependence; N-ethylmaleimide treatment; [^{3}H]Cocaine; Binding in vitro; Striatum; (Rat) (Saadouni, S. (268) 187)

Dopamine neuronal carrier; Thermodynamics; BTCP (*N*-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine) derivative; Binding (in vitro); Striatum (Rat) (Billaud, G. (268) 357)

[^{3}H]GBR 12783 (in vitro binding)
Dopamine carrier (neuronal); Metal ion; Dopamine uptake; Striatum; (Rat) (Bonnet, J.-J. (266) 87)

Gene expression
EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Fluphenazine-*N*-mustard; Substantia nigra; Dopamine D_1 receptor mRNA; Dopamine D_2 receptor mRNA; Glutamic acid decarboxylase mRNA; Dopamine receptor antagonists (Qin, Z.-H. (269) 25)

General anesthetic
Propofol; [^{35}S]TBPS (*t*-[^{35}S]butylbicyclophosphorothionate) binding; GABA (γ-aminobutyric acid); Cl^- channel; Barbiturate; Steroid derivative; Benzodiazepine (Concas, A. (267) 207)

Genetically epilepsy-prone rat
Fluoxetine; 5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Anticonvulsant effect; Microdialysis (Yan, Q.-S. (252) 105)

Genetic hypertension
Angiotensin AT_1 receptor antagonist; SR 47436 (BMS-186295); Renal hypertension; (Rat) (Lacour, C. (264) 307)

Genetic instability
T47D cell; TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin) (Fernandez, P. (270) 53)

Genistein
Tyrosine kinase; Contractile force; Coronary tone; ANP (atrial natriuretic peptide); Ca^{2+}, intracellular (Taskinen, P. (256) 251)

Gentamicin
Acetylcholine; Arginine; Bradykinin; cGMP; Nitric oxide (NO); (Rat) (Rivas-Cabañero, L. (270) 119)

Gepirone
5-HT (5-hydroxytryptamine, serotonin); Hippocampus; Excitatory synaptic transmission; Electrophysiology; $5\text{-}HT_{1A}$ receptor; Excitatory postsynaptic potential (Manahan-Vaughan, D. (260) 149)

GHBA (γ-hydroxybutyric acid)
DOPAC (dihydroxyphenylacetic acid); Dopamine; Ethanol; Naloxone; Sleep (Devoto, P. (252) 321)

GH3 cell
CCK_B receptor; Pituitary; Functional coupling; G-protein; Ca^{2+} mobilisation; L-365,260 (Smith, A.J. (267) 215)

YM022; CCK-8 (cholecystokin-8); CCK_B/gastrin receptor antagonist; Ca^{2+} mobilization, intracellular (Saita, Y. (269) 249)

GH (growth hormone)
GHRH (growth hormone-releasing hormone); Somatostatin; Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); (Sheep) (Cataldi, M. (253) 149)

Growth hormone-releasing hormone; Cholinesterase inhibitor; Bethanechol (Mazza, E. (254) 17)

Tolerance; *N*-Nitro-L-arginine methyl ester; Morphine; Thyrotropin (TSH); Prolactin; Antinociception; Hyperthermia (Rauhala, P. (259) 57)

GHRH (growth hormone-releasing hormone)
GH (growth hormone); Somatostatin; Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); (Sheep) (Cataldi, M. (253) 149)

Growth hormone; Cholinesterase inhibitor; Bethanechol (Mazza, E. (254) 17)

Glibenclamide
K^+ channel; Cromakalim; Y-26763; SKF 525A; Quinacrine; *Xenopus* oocyte; Local anesthetic (Sakuta, H. (252) 117)

K^+ channel; Ca^{2+} channel antagonist; Stereoselectivity; *Xenopus* oocyte; Y-26763 (Sakuta, H. (255) 1)

BRL-38227; Myocardial ischemia; Antiarrhythmic/proarrhythmic effect (Bellemin-Baurreau, J. (256) 115)

Levcromakalim; Pinacidil; Diazoxide; Glucose tolerance; Hypoglycemia (Clapham, J.C. (257) 79)

Skeletal muscle; K^+ channel; Lipid bilayer (Light, P.E. (259) 219)

Imidazoline; Imidazolidine; K^+ channel; *Xenopus* oocyte; Y-26763; K^+ channel opener; Structure-activity relationship (Sakuta, H. (259) 223)

Sulphonylurea; β-Cell replication; Diabetes; Pancreatic islet (Guiot, Y. (261) 157)

K^+ channel opener; YM099; Levcromakalim; Coronary artery vessel diameter; Coronary artery blood flow; (Dog) (Uchida, W. (264) 285)

K^+ channel; *Xenopus* oocyte; Histamine H_1 receptor antagonist; Promethazine; Dimethindene (Sakuta, H. (266) 99)

Atrial natriuretic factor; cGMP; HS-142-1; K^+ channel; Y-26763; Cromakalim; *Xenopus* oocyte (Sakuta, H. (267) 281)

K^+ channel; Cromakalim; *Xenopus* oocyte; Insulin; IGF-1; Phenylarsine oxide; Pertussis toxin; Voltage clamp, 2-electrode (Sakuta, H. (268) 375)

Pancreatic β-cell; Sulfonylurea receptor; K^+ channel, ATP-sensitive; MIN 6 cell (Mogami, H. (269) 293)

Coronary artery; Smooth muscle, vascular; Hypoxia; ATP-sensitive K^+ channel; Levcromakalim (Mellemkjær, S. (270) 307)

γ-Globulin, human
K^+ activator/opener; K^+ channel inactivator/closer; Mesenteric portal vein (Abrahams, Z. (252) 195)

Globus pallidus
Δ^9-Tetrahydrocannabinol; Anandamide; Muscimol; Catalepsy; Drug interaction (Wickens, A.P. (250) 205)

Glomerular filtration rate
Endothelin; Endothelin receptor antagonist; Renal vasoconstriction (Wellings, R.P. (256) 201)

Endothelin; L-N^G-Nitroarginine; Ibuprofen; EDRF (endothelium-derived relaxing factor); Renal blood flow; Urine flow rate; Urine osmolality; (Dog) (Yukimura, T. (264) 399)

Glomerulosclerosis
Cyclosporin A; Extracellular matrix; Mesangial cell (Ghiggeri, G.M. (270) 195)

Glucocorticoid
$5\text{-}HT_2$ receptor; DOI (1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane); Adrenalectomy; Head shakes (Chaouloff, F. (249) 117)

Nitric oxide (NO); N^G-Nitro-L-arginine; N^G-Monomethyl-L-arginine; Endotoxin (Berrazueta, J.R. (251) 303)

Asthma; Anhydride; Allergy; Cyclosporin A; Sensitization (Arakawa, H. (252) 313)

Forced swimming test; Water temperature; κ-Opioid receptor, selective; Thyroid hormone; Glucose (Jefferys, D. (253) 91)

NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate); Neurotoxicity; Dexamethasone; Postnatal (Supko, D.E. (270) 105)

Glucocorticoid receptor
Mineralocorticoid receptor; 5-HT (5-hydroxytryptamine, serotonin); Hippocampus; In situ hybridisation; (Rat) (Meijer, O.C. (266) 255)

Glucose
Forced swimming test; Water temperature; Glucocorticoid; κ-Opioid receptor, selective; Thyroid hormone (Jefferys, D. (253) 91)

Mecamylamine; Scopolamine; Spontaneous alternation; Memory (Ragozzino, M.E. (256) 31)

Sulfonylurea; Na^+; Pancreatic islet (Saha, S. (258) 145)

Glucose concentration, plasma
WAY100135 (*N*-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); Flesinoxan; $5\text{-}HT_{1A}$ receptor; (Conscious rat) (Critchley, D.J.P. (254) 133)

Glucose homeostasis
Vanadate; Vanadyl; Diabetes; Hypoglycemic agent; (Rat) (Becker, D.J. (260) 169)

Glucose tolerance
Levcromakalim; Pinacidil; Diazoxide; Glibenclamide; Hypoglycemia (Clapham, J.C. (257) 79)

Glucose transport
Brain; Heart; Adipose tissue, white (Nagai, K. (260) 29)

Glutamate
Riluzole; Aspartate; Hippocampus; Excitatory amino acid; Transmitter release (Martin, D. (250) 473)

Movement disorder; 5-HT (5-hydroxytryptamine, serotonin); Dystonia (Löscher, W. (255) 235)

Dizocilpine; Epilepsy; Catalepsy; Glycine receptor (Wlaź, P. (257) 217)

AMPA receptor; Atrium, rat; Sympathetic neurotransmission (Lorenzo, P.S. (258) 253)

Endothelin-3; Dopamine; NMDA receptor; Striatal slice; Voltage-gated Ca^{2+} channel (Koizumi, S. (259) 195)

Lactate; Microdialysis; Nizofenone; Neuronal damage; Ischemia (Matsumoto, Y. (262) 157)

Neuromedin C; Bombesin receptor; Nociception; NMDA receptor (Onogi, T. (262) 163)

Cerebral ischemia; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Microdialysis; Excitotoxin (Gaspary, H.L. (262) 197)

Haloperidol; Clozapine; Microdialysis; Striatum; GABA (γ-aminobutyric acid) (See, R.E. (263) 269)

Dystonia; Lamotrigine; GABA (γ-aminobutyric acid); Na^+ channel blocker (Richter, A. (264) 345)

MCPG (α-methyl-4-carboxyphenylglycine); Excitatory amino acid receptor; Presynaptic; cAMP; Receptor; Metabotropic; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

Receptor desensitization; Cyclothiazide; GYKI 52466 (Sharp, R.L. (266) R1)

NMDA receptor, recombinant; HEK 293 cell; Ligand affinity; Glycine; MK 801 (Laurie, D.J. (268) 335)

NMDA (*N*-methyl-D-aspartate); Dizocilpine; Glycine; Spermine; Polyamine (Marvizón, J.-C. (269) 165)

Phosphoinositide; cAMP; *trans*-ACPD (1-aminocyclopentane-*trans*-1,3-dicarboxylic acid); L-*trans*-2,4-PDC (L-*trans*-2,4-pyrrolidine dicarboxylic acid); Glutamate transport; (+)-α-Methyl-4-carboxyphenylglycine (Miller, S. (269) 235)

Glutamate antagonist
Philanthotoxin; Ca^{2+} current; Hippocampus; Polyamine; Patch clamp, in situ (Karst, H. (270) 357)

Glutamate binding
Adenosine; Epilepsy; Kindling; Glutamate release (Simonato, M. (265) 121)

Glutamate receptor
Myenteric plexus; Cortical wedge; Homoserine sulfate; Hydroxyproline sulfate; Hydroxypipecolic acid sulfate (Mannaioni, G. (251) 201)

Thermal hyperalgesia; Excitatory amino acid; Inflammation; Memantine; Carrageenan (Eisenberg, E. (255) 123)

Hippocampal neuron, isolated; Concentration jump; NMDA receptor; Chemically gated current (Wilsch, V.W. (262) 287)

Polyamine; Memory; Ion channel (Shimada, A. (263) 293)

Anesthetic; Anesthesia, theories of; Synaptic transmission; Spinal cord; NMDA receptor; $GABA_A$ receptor (Kendig, J.J. (264) 427)

Sf9 cell; Oligosaccharide; Phosphorylation (Taverna, F.A. (266) 181)

NMDA receptor; Excitotoxicity (Cik, M. (266) R1)

Barbiturate; AMPA receptor (Taverna, F.A. (267) R3)

Glutamate receptor antagonist; cDNA (Verdoorn, T.A. (269) 43)

Glutamate receptor agonist
Metabotropic glutamate receptor; Halothane anesthesia; L-CCG-I ((2*S*,1′*S*,2′*S*)-2-(carboxycyclopropyl)glycine); DCG-IV ((2*S*,1′*R*,2′*R*,4-3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine); Adenylyl cyclase (Miyamoto, M. (260) 99)

Glutamate receptor antagonist
Reserpine; Locomotion; Dopamine D_1 receptor agonist; Dopamine D_2 receptor agonist (Starr, M.S. (250) 239)

Glutamate receptor; cDNA (Verdoorn, T.A. (269) 43)

Glutamate release
Anoxia; Granule cell culture (Dessi, F. (250) 325)

Superior colliculus; Adenosine; Excitation; Protein kinase (Hirai, H. (256) 65)

Adenosine; Epilepsy; Kindling; Glutamate binding (Simonato, M. (265) 121)

Glutamate transport
Glutamate; Phosphoinositide; cAMP; *trans*-ACPD (1-aminocyclopentane-*trans*-1,3-dicarboxylic acid); L-*trans*-2,4-PDC (L-*trans*-2,4-pyrrolidine dicarboxylic acid); (+)-α-Methyl-4-carboxyphenylglycine (Miller, S. (269) 235)

Glutamate transporter
Uptake; Amino acid; Carrier; Proximal tubule; Kidney; In situ hybridization; (Rabbit) (Meister, B. (267) 323)

Glutamic acid
Dopamine release; Kainic acid; Neurotoxicity; NMDA receptor; AMPA receptor (Fedele, E. (249) 71)

Aspartic acid; Glycine, uptake, release; Carrier coexistence; Central nervous system; (Rat) (Bonanno, G. (252) 61)

Glutamic acid decarboxylase mRNA
EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Fluphenazine-*N*-mustard; Substantia nigra; Dopamine D_1 receptor mRNA; Dopamine D_2 receptor mRNA; Gene expression; Dopamine receptor antagonists (Qin, Z.-H. (269) 25)

Glybenclamide
Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; L158809; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

Glyceraldehyde-3-phosphate dehydrogenase
Nitric oxide (NO); Endotoxin; Cytotoxicity; Shock (Dimmeler, S. (267) 105)

Glycerol release
cAMP; Brown adipose tissue; β-Adrenoceptor; Thermogenesis; Obesity (Nisoli, E. (259) 181)

Glyceryl trinitrate
S-Nitroso-*N*-acetylpenicillamine; *S*-Nitroso-*N*-acetylcaptopril; Tolerance, in vitro; *S*-Nitrosothiols; Artery, bovine coronary (Zhang, C.L. (252) 299)

Glycine
Neurokinin; Nociception (Seguin, L. (253) R1)

NMDA (*N*-methyl-D-aspartate); Polyamine; 7-Chlorokynurenate; Ifenprodil; (Synergism) (Voltz, C. (255) 197)

Felbamate; Convulsion (Coffin, V. (256) R9)

ACPC (1-aminocyclopropanecarboxylic acid); NMDA (*N*-methyl-D-aspartate); Neuronal injury; Dynorphin A (Long, J.B. (261) 295)

Polyamines; [^{3}H]L-689,560 binding; NMDA receptor; Allosteric interaction (Grimwood, S. (266) 43)

NMDA (*N*-Methyl-D-aspartate); Ca^{2+}; Ca^{2+} entry; Cerebellar granule cells; Cell culture (Simpson, P.B. (266) 309)

NMDA receptor, recombinant; HEK 293 cell; Ligand affinity; Glutamate; MK 801 (Laurie, D.J. (268) 335)

NMDA (*N*-methyl-D-aspartate); Dizocilpine; Glutamate; Spermine; Polyamine (Marvizón, J.-C. (269) 165)

Glycine binding site
Hippocampus; Granule cell; Field potential; *d*-Cycloserine; NMDA receptor (Pitkänen, M. (253) 125)

Glycine co-agonist site
Morphine, intrathecal; Clonic seizure-like behavior; NMDA receptor; MK-801; ACEA-1011 (Lutfy, K. (252) 261)

Glycine / NMDA receptor
Epilepsy; Felbamate; Audiogenic seizure; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); (DBA/2 mouse) (De Sarro, G. (262) 11)

Glycine partial agonist
NMDA receptor; Memory enhancement; Administration, acute and chronic (Quartermain, D. (257) 7)

Glycine receptor
Glutamate; Dizocilpine; Epilepsy; Catalepsy (Wlaź, P. (257) 217)

Glycine receptor ligand
Anxiolytic; NMDA (*N*-methyl-D-aspartate); NMDA receptor antagonist; ACPC (1-aminocyclopropanecarboxylate); D-Cycloserine (Anthony, E.W. (250) 317)

Glycine recognition site
7-Chlorokynurenate; Polyamine; NMDA receptor antagonist, competitive; NMDA receptor complex; Brain, rat (Oblin, A. (266) 103)

Glycine site
7-Chlorokynurenic acid; Hippocampus; Working memory; Reference memory (Ohno, M. (253) 183)

Glycine, uptake, release
Glutamic acid; Aspartic acid; Carrier coexistence; Central nervous system; (Rat) (Bonanno, G. (252) 61)

Glycolysis
Seizure; Lactate (Fornai, F. (254) R1)

GMAP (galanin message-associated polypeptide)
Galanin; Insulin secretion; Islet; (In vitro); (Mouse); (Rat) (Gregersen, S. (259) 79)

cGMP
CD-832; Ca^{2+} channel antagonist; cAMP; Aorta vasodilatation; (Rabbit) (Miyata, N. (249) 141)

Phosphodiesterase inhibitor; Zaprinast; Blood pressure; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (249) 293)

Atriopeptin II; Isoproterenol; cAMP; Smooth muscle; Aorta, rat (Jang, E.K. (250) 477)

Vascular reactivity; Endothelium; Nitric oxide (NO); Nandrolone (Ferrer, M. (252) 233)

Manganese; Nitric oxide (NO); Superoxide dismutase; Blood pressure (Kasten, T.P. (253) 35)

Vasodilator; Antiaggregator; Furoxan; Nitric oxide (NO) (Civelli, M. (255) 17)

ANF (atrial natriuretic factor); Guanylyl cyclase; ANF receptor antagonist; Hypoxia; Hypoxic coronary vasodilatation; Heart, isolated, guinea pig; Nitric oxide (NO) (Park, K.H. (256) 99)

Hyperalgesia; Intrathecal administration (Garry, M.G. (260) 129)

Skinned muscle; Colon; NAMC (non-adrenergic, non-cholinergic) inhibition; (Rat) (Maehara, T. (261) 163)

Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); Neuropeptide Y; Nitroprusside; Milrinone; cAMP; Acetylcholine (Modin, A. (261) 185)

Trolox; Antioxidant; SIN (3-morpholino sydnonimine); Nitric oxide (NO); Prostaglandin; Leukotriene; Leukocyte (Riutta, A. (262) 217)

(+)-*cis*-Dioxolane; β-Endorphin; Antinociception; Tail-flick inhibition; Nitric oxide (NO) (Xu, J.Y. (262) 223)

E4021; Phosphodiesterase type V inhibitor; Coronary vasodilator; Vasopressin; ST segment elevation (Kodama, K. (263) 93)

Interleukin-1β; Endothelium; Vascular tone (Schini-Kerth, V. (265) 83)

Cerebellum; Microdialysis; Metalloporphyrins; Nitric oxide synthase; Guanylyl cyclase (Luo, D. (267) 263)

Atrial natriuretic factor; HS-142-1; K^+ channel; Glibenclamide; Y-26763; Cromakalim; *Xenopus* oocyte (Sakuta, H. (267) 281)

Vasorelaxation; 2,2′,2″-Tripyridine; Ca^{2+} influx (Kuei-Sen Hsu, (270) 89)

Acetylcholine; Arginine; Bradykinin; Gentamicin; Nitric oxide (NO); (Rat) (Rivas-Cabañero, L. (270) 119)

cGMP-dependent protein kinase
8-Br-cGMP; Nitroglycerin; Rp-8-Br-cGMPS; 8-Br-cAMP; Aorta, rabbit; cAMP-dependent protein kinase (Nakazawa, M. (253) 179)

cAMP-dependent protein kinase; Protein kinase C; 5-HT (5-hydroxytryptamine, serotonin) uptake; Imipramine binding (Helmeste, D.M. (267) 239)

(Rp)-8-pCPT-cGMPS ((Rp)-8-(*para*-chlorophenylthio)guanosine-3′,5′-cyclic monophosphorothioate); Platelet; (Inhibitor) (Butt, E. (269) 265)

cGMP-inhibited phosphodiesterase (PDE III)
Photoaffinity labelling; Platelet; Phosphodiesterase inhibitor; Cyclic AMP (Tang, K.M. (268) 105)

GnRH (gonadotropin-releasing hormone) gene expression
5β-Pregnan-3α-ol-20-one; Muscimol; Picrotoxin; Hypothalamus; Hybridization, in situ (Vincens, M. (260) 157)

Goiter
Iodolactone; Antigoitrogenic; Thyroid; Autoregulation (Pisarev, M.A. (258) 33)

Goldblatt hypertension
Blood pressure; Angiotensin AT_1 receptor (Železná, B. (260) 95)

Gonadal steroid hormone
Aorta; Vasopressin; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Vasoconstriction (Stallone, J.N. (259) 273)

gp140^{trk}
Staurosporine; Tyrosine; Phosphorylation; Neurite outgrowth (Rasouly, D. (269) 255)

G-protein
Neuropeptide Y; Neuropeptide Y analog; Pertussis toxin; Benzalkonium chloride; Histamine release; Mast cell; (Rat) (Grundemar, L. (258) 163)

Noradrenaline; Ca^{2+} channel; Ryanodine; Protein kinase C; Caffeine; Phenoxybenzamine (Tabrizchi, R. (259) 285)

Somatostatin; Pertussis toxin; Seglitide; BIM 23027; SRIF receptor; Vas deferens, mouse (Feniuk, W. (261) 333)

Dorsal raphe nucleus; $5\text{-}HT_{1A}$ receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Microdialysis; Intracerebral; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (Romero, L. (265) 103)

Interleukin; Hippocampus; Ca^{2+} channel; Protein kinase; Patch-clamp; (Guinea pig) (Plata-Salamán, C.R. (266) 1)

Phosphoinositide; Arachidonic acid; cAMP; Ca^{2+} imaging; AF102B (Gurwitz, D. (267) 21)

CCK_B receptor; GH_3 cells; Pituitary; Functional coupling; Ca^{2+} mobilisation; L-365,260 (Smith, A.J. (267) 215)

Brain membrane; CCK_B receptor; Gastrin binding; CCK_8 binding (Lallement, J.-C. (267) 297)

5-HT (5-hydroxytryptamine, serotonin); G Protein-Coupled Receptor; Sf9 Cells; (Baculovirus) (Parker, E.M. (268) 43)

Guanylnucleotide; c-*fos*; Mitogenesis; Adenylyl cyclase; Phospholipase C; Phorbol ester; Pertussis toxin (Pilon, C. (268) 129)

Bombesin receptor, lung; Guanine nucleotide sensitivity; Pertussis toxin; Cholera toxin; (Guinea pig) (Lach, E. (269) 87)

G_i-protein
Adipocyte; α_2-Adrenoceptor; Adenosine A_1 receptor (Larrouy, D. (267) 225)

$G_{s\alpha}$-protein
Desensitisation; Prostanoid IP receptor; Adenylyl cyclase; NG108-15 cell (Williams, R.J. (268) 177)

G-protein-coupled receptor
Baculovirus; Epitope-tagged; Immunofluorescence (in situ) (Ng, G.YK. (267) 7)

5-HT (5-hydroxytryptamine, serotonin); G protein; Sf9 Cells; (Baculovirus) (Parker, E.M. (268) 43)

G-protein coupling
Morphine treatment (chronic); Desensitization; Adenylate cyclase inhibition; Down-regulation (Polastron, J. (266) 139)

Muscarinic M_2 receptor; Chimaeric receptor; (Peptide mimics) (McClue, S.J. (267) 185)

$5\text{-}HT_{2C}$ receptor, human; Mesulergine; (Gene) (Stam, N.J. (269) 339)

G-protein (G_s)
β-Adrenoceptor; β-Adrenoceptor antagonist; Adenylyl cyclase; Erythrocyte; Turkey (Götze, K. (268) 151)

$G_{s\alpha}$-protein mRNA
Aging; $G_{s\alpha}$ subunit; β-Adrenoceptor stimulation; Inotropic effect; Cardiac ventricle; (Male Wistar rat) (Miyamoto, A. (266) 147)

G-protein (low molecular weight)
Polyphosphoinositide turnover; Botulinum toxin; ADP-ribosylation; 5-HT (5-hydroxytryptamine, serotonin); *Xenopus* oocyte (Tohda, M. (266) 19)

GR 79236
Adenosine; Antilipolytic; (Rat) (Gardner, C.J. (257) 117)

GR 82334
Plasma protein extravasation; Dura mater; Tachykinin NK_1 receptor; α-CGRP-(8–37) (O'Shaughnessy, C.T. (263) 193)

GR 113808
5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_4$ receptor; Benzamide derivative; Azabicycloalkyl benzimidazolone derivative; Adrenal gland (Contesse, V. (265) 27)

Granule cell
Hippocampus; Field potential; *d*-Cycloserine; Glycine binding site; NMDA receptor (Pitkänen, M. (253) 125)

Granule cell culture
Anoxia; Glutamate release (Dessi, F. (250) 325)

Granuloma
Nitric oxide (NO); L-Arginine; N^G-Nitro-L-arginine methyl ester; Macrophage (Iuvone, T. (265) 89)

Grooming
Dopamine; Opioid; Vacuous chewing movement (Stoessl, A.J. (259) 301)

Median raphe nucleus; Dorsal hippocampus; $5\text{-}HT_{1A}$ receptor; Social interaction; (Rat) (Andrews, N. (264) 259)

Grooming behavior
Melanocortin receptor antagonist; ACTH (adrenocorticotrophic hormone) derivative; α-MSH (α-melanocyte-stimulating hormone) (Adan, R.A.H. (269) 331)

Growth factor
Lung cancer; Polyanionic drug (Favoni, R.E. (264) 199)

ANP (Atrial natriuretic peptide); aFGF (acidic fibroblast growth factor); Protein kinase C; Staurosporine; Phorbol ester (Tokola, H. (267) 195)

GRP (gastrin-releasing peptide)
Bombesin; Bombesin binding site; Lung, human; GRP-preferring bombesin receptor (Lach, E. (265) 117)

GRP-preferring bombesin receptor
Bombesin; GRP (gastrin-releasing peptide); Bombesin binding site; Lung, human (Lach, E. (265) 117)

$G_{s\alpha}$ subunit
Aging; $G_{s\alpha}$ protein mRNA; β-Adrenoceptor stimulation; Inotropic effect; Cardiac ventricle; (Male Wistar rat) (Miyamoto, A. (266) 147)

GTP
Brainstem (Human); Clonidine; Imidazoline receptor; Phenoxybenzamine; α-Adrenoceptor (Bricca, G. (266) 25)

Neuropeptide Y; Photolabeling (Zhu, J. (268) 279)

GTP-binding protein
Mastoparan; Supraspinal analgesia; Opioid (Sánchez-Blázquez, P. (258) 159)

Adenosine; ATP-activated channel; PC12 cell (Inoue, K. (268) 223)

Guanfacine
Autotomy; Clonidine; Flexor reflex; Pain; ST-91 (Puke, M.J.C. (260) 227)

Guanidine
Imidazoline; Imidazoline receptor; Insulin; RIN-5AH cell; Insulinoma; ATP-dependent K^+ channel (Olmos, G. (262) 41)

Guanidinium
Idazoxan; Imidazoline; K^+ channel; Kidney (rabbit) (Corpus, V.M. (266) 197)

γ-Guanidinobaclofen
Baclofen; $GABA_B$ receptor agonist; Ileum, guinea-pig, isolated; Neocortical slice, rat; 2-Hydroxysaclofen (Kerr, D.I.B. (262) 189)

Guanine nucleotide sensitivity
Bombesin receptor, lung; G-protein; Pertussis toxin; Cholera toxin; (Guinea pig) (Lach, E. (269) 87)

Guanosine cyclic monophoshate
Adenosine cyclic monophoshate; NANC (non-adrenergic, non-cholinergic) nerve; Nitric oxide (NO); Urethra; Detrusor (Persson, K. (268) 159)

Guanylate cyclase
ANP (atrial natriuretic peptide); Natriuretic peptide, C-type; LLC-PK_1 cell (Hashimoto, Y. (268) 443)

Guanylate cyclase, soluble
FK409; Tolerance; Vasorelaxation; Nitric oxide (NO) (Isono, T. (260) 163)

Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; L158809; Glybenclamide; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

Guanylnucleotide
G protein; c-*fos*; Mitogenesis; Adenylyl cyclase; Phospholipase C; Phorbol ester; Pertussis toxin (Pilon, C. (268) 129)

Guanylyl cyclase
ANF (atrial natriuretic factor); cGMP; ANF receptor antagonist; Hypoxia; Hypoxic coronary vasodilatation; Heart, isolated, guinea pig; Nitric oxide (NO) (Park, K.H. (256) 99)

Cerebellum; Microdialysis; Metalloporphyrins; Nitric oxide synthase; cGMP (Luo, D. (267) 263)

GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5*H*-2,3-benzodiazepine HCl)
Spinal reflex; Non-NMDA receptor; Benzodiazepine receptor (Block, F. (256) 149)

Haloperidol-induced catalepsy; CGP 37849 (DL-(*E*)-2-amino-4-methyl-5-phosphono-3-pentenoic acid); AMPA receptor; NMDA receptor; (Rat) (Hauber, W. (256) 339)

Glutamate; Receptor desensitization; Cyclothiazide (Sharp, R.L. (266) R1)

H-7
HA1077; Ca^{2+} level, cytosolic; Relaxation; Aorta, rat; Smooth muscle, vascular (Takizawa, S. (250) 431)

HA1077
H-7; Ca^{2+} level, cytosolic; Relaxation; Aorta, rat; Smooth muscle, vascular (Takizawa, S. (250) 431)

Haloperidol
NMDA receptor antagonist; MK-801 ((+)-5-methyl-10,11-dihydro-5*H*-dibenzo[*a*,*d*]cyclohepten-5,10-imine); 6-Hydroxydopamine; Nucleus accumbens; Locomotion; (Rat) (Ouagazzal, A.-m. (251) 229)

Hemorrhagic shock; ACTH-(1–24); Dopamine receptor; *l*-Sulpiride; SCH-23390 (Bazzani, C. (253) 303)

Dextromethorphan; 3-PPP (3-(3-hydroxyphenyl)-*N*-(*n*-propyl)piperidine); Haloperidol, reduced; (+)-Pentazocine; Receptor down-regulation (Klein, M. (254) 239)

Sertindole; Clozapine; Short-term treatment; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (254) 291)

Adenosine A_{2A} receptor antagonist; Catalepsy; Reserpine; (Mouse) (Kanda, T. (256) 263)

Methamphetamine; Repeated administration; Ambulation; Sensitization (Kuribara, H. (256) 295)

Amphetamine; Behavioral clamping; Cortical lesion; Neostriatum; Unit activity (Tschanz, J.A.T. (257) 161)

Sauvagine; Hypothermia; Spiperone (Broccardo, M. (258) 179)

Catalepsy-associated behavior; BW 737C89; R-SKF 38393; SKF 75670; SCH 39166; SKF 81297; SKF 82958 (Rosenzweig-Lipson, S. (260) 237)

7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Remoxipride; *R*(−)-Propylnorapomorphine; Raclopride (Hillefors-Berglund, M. (261) 179)

Clozapine; Microdialysis; Striatum; Glutamate; GABA (γ-aminobutyric acid) (See, R.E. (263) 269)

Ca^{2+} channels; Hippocampus (Fletcher, E.J. (267) 249)

σ Receptor; Liver; Kidney; Pentazocine; Photoaffinity labeling (Hellewell, S.B. (268) 9)

Haloperidol, chronic
Dopamine neuron; Depolarization inactivation; Schizophrenia; Chloral hydrate, anesthesia; (Rat) (Mereu, G. (264) 449)

Haloperidol-induced catalepsy
GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5*H*-2,3-benzodiazepine HCl); CGP 37849 (DL-(*E*)-2-amino-4-methyl-5-phosphono-3-pentenoic acid); AMPA receptor; NMDA receptor; (Rat) (Hauber, W. (256) 339)

Haloperidol, reduced
Dextromethorphan; 3-PPP (3-(3-hydroxyphenyl)-*N*-(*n*-propyl)piperidine); Haloperidol; (+)-Pentazocine; Receptor down-regulation (Klein, M. (254) 239)

Halothane
Nitric oxide (NO); N^G-Nitro-L-arginine methylester (L-NAME); Cerebral blood flow; Anesthetics (Dawson, D.A. (249) 7)

Age; Neuromuscular transmission; Voltage clamp (Bhattacharyya, B.J. (254) 97)

Halothane anesthesia
Metabotropic glutamate receptor; Glutamate receptor agonist; L-CCG-I ((2*S*,1′*S*,2′*S*)-2-(carboxycyclopropyl)glycine); DCG-IV ((2*S*,1′*R*,2′*R*,3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine); Adenylyl cyclase (Miyamoto, M. (260) 99)

Handling
Neurosteroid; Stress; CO_2; Brain, rat (Barbaccia, M.L. (261) 317)

Harman
Norharman; β-Carboline; Monoamine oxidase; Pargyline; (Rat) (Rommelspacher, H. (252) 51)

Head shake
5-HT_2 receptor; DOI (1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane); Glucocorticoid; Adrenalectomy (Chaouloff, F. (249) 117)

Head twitch behavior
Buspirone; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} receptor; 5-HT_2 receptor; (Mouse) (Kitamura, Y. (253) 297)

FG5893; 5-HT_{1A} receptor agonist/5-HT_{2A} receptor antagonist; 5-HT receptor; Hypothermia; Passive avoidance; Forced swim test; Cage leaving; Ultrasound vocalization; Corticosterone; (Rat) (Albinsson, A. (261) 285)

Heart
Glucose transport; Brain; Adipose tissue, white (Nagai, K. (260) 29)

L-type Ca^{2+} channel; Voltage clamp; Ca^{2+} channel antagonist; SR33557; SR33805 (Romey, G. (263) 101)

Sarcoplasmic reticulum; Cyclopiazonic acid; Thapsigargin; Excitation-contraction coupling; (Frog) (Bonnet, V. (264) 69)

Ca^{2+} channel antagonist; Binding; SR 33805; Fantofarone; Dihydropyridine (Chatelain, P. (267) 151)

α-Trinositol; Binding site; Inositol phosphate (Yoo, H. (268) 55)

Adenosine; Adenosine A_2 receptor; Adenylyl cyclase; Endothelial cells; Coronary; Capillary; (Guinea pig) (Schiele, J.O. (269) 51)

Heart cell
Patch-clamp analysis; Ca^{2+} channel (L-type); Ca^{2+} channel antagonist; Manidipine (Tohse, N. (249) 231)

Heart, dog
E4080; Hyperpolarization-activated inward current (I_f); Ca^{2+} current (L-type, I_{Ca}); ATP-sensitive K^+ (K^+_{ATP}) channel; Chronotropism; Inotropism (Sawaki, S. (250) 253)

Heart failure
Angiotensin-converting enzyme; Neutral endopeptidase; Captopril; SCH 34826; (Rat) (Helin, K. (264) 135)

Heart, guinea-pig, perfused
Adenosine receptor; Adenosine receptor antagonist; Prostacyclin (Felsch, A. (263) 261)

Heart, isolated
Ca^{2+} channel antagonist; Fantofarone; Ischemia; ^{31}P NMR spectroscopy (Vander Elst, L. (251) 163)

Heart, isolated, guinea pig
ANF (atrial natriuretic factor); cGMP; Guanylyl cyclase; ANF receptor antagonist; Hypoxia; Hypoxic coronary vasodilatation; Nitric oxide (NO) (Park, K.H. (256) 99)

Heart muscle preparation, isolated
Doxorubicin; Inotropic effect; Myocardial Ca^{2+} loading; (Guinea pig); (Rat) (Temma, K. (252) 173)

Heart, rat
Inositol 1,4,5-trisphosphate; Inositol 1,4,5-trisphosphate receptor; Ca^{2+} release; Neonatal cardiomyocyte (Fitzgerald, M. (268) 275)

Heart rate
Cholinergic neuron; Spinal cord; Medulla oblongata; Blood pressure (Feldman, D.S. (250) 483)

Galanin; Galanin fragment; Receptor subtype; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Blood pressure; Medulla oblongata; (Intracisternal injection) (Narváez, J.A. (257) 257)

Nicotine; Cardiovascular effect; Blood pressure; Pentobarbital; Tachyphylaxis (Cruz, S.L. (258) 39)

5-HT_{1A} receptor agonist; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Blood pressure; Respiratory rate; α_1-Adrenoceptor (Di Francesco, G.F. (262) 205)

Heat shock protein
Cd^{2+}; Metallothionein; Lymphocyte (Pellegrini, O. (270) 221)

HEK 293 cell
NMDA receptor, recombinant; Ligand affinity; Glutamate; Glycine; MK 801 (Laurie, D.J. (268) 335)

HeLa cell
1,4-Dithiothreitol; Histamine; Inositol phosphate; [^{3}H]Mepyramine; Cerebral cortex, rat (Young, K.W. (269) 283)

Hemodynamics
Pirsidomine; Infarct size; (Dog) (Martorana, P.A. (257) 267)

Hemoglobin
Antihistamine; Calcimycin; EDCF (endothelium-derived contracting factor); EDRF (endothelium-derived relaxing factor); Iproniazid; Mast cell; Methylene blue; N^G-Methyl-L-arginine (Gruetter, C.A. (257) 275)

Hemorrhage
Cytokine; Endothelin; Endothelin converting enzyme; Hypoxia; Interleukin-1β; Phosphoramidon; TNF-α (tumor necrosis factor-α) (Vemulapalli, S. (257) 95)

Hemorrhagic shock
Hypovolemia; δ-Opioid receptor; BNTX (7-benzylidenenaltrexone); Naltrindole; (Rabbit, conscious) (Ludbrook, J. (252) 113)

ACTH-(1–24); Dopamine receptor; Haloperidol; *l*-Sulpiride; SCH-23390 (Bazzani, C. (253) 303)

Heparin
Thrombin; Platelet; Hirulog; Low molecular weight heparin; PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone); DuP-714 ester (acetyl-D-phenylalanine-propyl-boroarginine); (Rabbit) (Liu, J.T. (264) 183)

Noradrenaline; Caffeine; Ruthenium red; Smooth muscle, vascular (Garcha, R.S. (268) 319)

Hepatocyte
CS-045; Antidiabetic; Fructose-2,6-bisphosphate; Tolbutamide (Murano, K. (254) 257)

Hepatocyte, isolated, rat
Butylated hydroxyanisole; Metabolite; *N*-Acetylcysteine; Cytotoxicity (Nakagawa, Y. (270) 341)

Hepatotoxicity
Cytochrome P450; Liver, mouse, human; Cocaine (Pellinen, P. (270) 35)

Cd^{2+}; Metallothionein; Nephrotoxicity; (Rat) (Sudo, J.-i. (270) 229)

Heterocyclic amino alcohol
σ Receptor; Ifenprodil; [^{3}H]3-PPP ([^{3}H]R(+)-3-[3-hydroxyphenyl]-*N*-(1-propyl)piperidine) binding; Brain (Rat); Molecular modelling (Beart, P.M. (269) 193)

Hexachlorocyclohexane isomer
Noradrenaline release; Bay K 8644; Nifedipine; DIDS (4,4-diisothiocyanato-stilbene-2,2′-disulfonic acid); W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); Hippocampal slice, rat (Cristòfol, R.M. (252) 305)

Hexahydro-sila-difenidol
Antral G-cell; Muscarinic receptor subtype; Muscarinic M_3 receptor; Atropine; Pirenzepine; AQ-RA 741 (Weigert, N. (264) 337)

2-Hexynyl-NECA (5′-*N*-ethyl-carboxamidoadenosine)
Adenosine receptor agonist; Adenosine A_2 receptor; Platelet aggregation; [^{111}In]Oxine; Platelet, rabbit (Sandoli, D. (259) 43)

p-F-HHSiD (*p*-fluoro-hexahydro-siladifenidol)
Acetylcholine release; HPLC-ECD system; Cholinergic regulation (presynaptic); Muscarinic receptor agonist; Muscarinic receptor antagonist; Ileum (guinea-pig); Bethanechol; AF102B. (Soejima, O. (249) 1)

HI-6 ([[[(4-aminocarbonyl)pyridino]-methoxy]-methyl]-2-[(hydroxyimino)methyl]-pyridinium dichloride)
Soman; Acetylcholinesterase reactivation; Diaphragm, rat; Muscle tension (Adler, M. (270) 9)

Hind paw tapping
Tachykinin NK_1 receptor; Chromodacryorrhea; (Gerbil) (Bristow, L.J. (253) 245)

Hippocampal neuron, isolated
Concentration jump; Glutamate receptor; NMDA receptor; Chemically gated current (Wilsch, V.W. (262) 287)

Hippocampal neuron, mouse
Ivermectin; GABA (γ-aminobutyric acid); $GABA_A$ receptor; Desensitization (Krůšek, J. (259) 121)

Hippocampal slice
Idebenone; Adenosine outflow; Inosine outflow; Nucleotide level; Ischemia-like condition (Latini, S. (249) 65)

μ-Opioid receptor; Naloxone; Proconvulsant; Bursting (Jones, L.S. (264) 39)

Hippocampal slice, rat
Noradrenaline release; Hexachlorocyclohexane isomer; Bay K 8644; Nifedipine; DIDS (4,4-diisothiocyanato-stilbene-2,2′-disulfonic acid); W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide) (Cristòfol, R.M. (252) 305)

Hippocampus
Tolbutamide; NMDA (*N*-methyl-D-aspartate) (Kwiecien, R. (249) 325)

Anxiolysis; Dorsal raphe nucleus; 5-HT_{1A} receptor ligand (rat); Ultrasonic vocalization (Schreiber, R. (249) 341)

Riluzole; Glutamate; Aspartate; Excitatory amino acid; Transmitter release (Martin, D. (250) 473)

Granule cell; Field potential; *d*-Cycloserine; Glycine binding site; NMDA receptor (Pitkänen, M. (253) 125)

Glycine site; 7-Chlorokynurenic acid; Working memory; Reference memory (Ohno, M. (253) 183)

5-HT_{1A} receptor; Autoradiography; Dorsal raphe nucleus; Firing; Adenylate cyclase; Lesopitron; (−)-Tertatolol (Haj-Dahmane, S. (255) 185)

Blood pressure; Hypertension; Dynorphin; Nor-binaltorphimine; Spontaneously hypertensive rat (SHR) (Wang, J.Q. (256) 57)

5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

5-HT (5-hydroxytryptamine, serotonin); Midazolam; Vogel's test; (Rat) (Plaznik, A. (257) 293)

Cannabinoid; Long-term potentiation (Collins, D.R. (259) R7)

Acetylcholine; Frontal cortex; Microdialysis; Dopamine D_1 receptor (Acquas, E. (260) 85)

5-HT (5-hydroxytryptamine, serotonin); Gepirone; Excitatory synaptic transmission; Electrophysiology; 5-HT_{1A} receptor; Excitatory postsynaptic potential (Manahan-Vaughan, D. (260) 149)

Frontal cortex; Idazoxan, chronic; Microdialysis; α_2-Adrenoceptor, presynaptic (Thomas, D.N. (261) 53)

Acetylcholine; Medial septal area; Nicotinic acetylcholine receptor; Spatial memory (Decker, M.W. (261) 217)

5-HT (5-hydroxytryptamine, serotonin); Acetylcholine; Fenfluramine (Levkovitz, Y. (264) 279)

Interleukin; Ca^{2+} channel; G-protein; Protein kinase; Patch-clamp; (Guinea pig) (Plata-Salamán, C.R. (266) 1)

Mineralocorticoid receptor; Glucocorticoid receptor; 5-HT (5-hydroxytryptamine, serotonin); In situ hybridisation; (Rat) (Meijer, O.C. (266) 255)

Haloperidol; Ca^{2+} channels (Fletcher, E.J. (267) 249)

Galanin; 5-HT (5-hydroxytryptamine, serotonin); 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Adenylyl cyclase; Forskolin; Hypothalamus; Brain; Receptor subtype; Peptide fragment (Billecocq, A. (269) 209)

Philanthotoxin; Ca^{2+} current; Glutamate antagonist; Polyamine; Patch clamp, in situ (Karst, H. (270) 357)

Hirulog
Thrombin; Platelet; Heparin; Low molecular weight heparin; PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone); DuP-714 ester (acetyl-D-phenylalanine-propyl-boroarginine); (Rabbit) (Liu, J.T. (264) 183)

Histamine
R-α-methylhistamine; Histamine H_3 receptor; Thioperamide; Depressor response; Pressor response; Tachycardia; (Prejunctional) (Hegde, S.S. (251) 43)

Anaphylaxis, mouse; Blood pressure; Nitric oxide (NO) (Osada, S. (252) 347)

5-HT (5-hydroxytryptamine, serotonin); Mepyramine; Zolantidine; Thioperamide; Metoprine (Fleckenstein, A.E. (254) 35)

Allergic reaction, early and late; Bronchial hyperreactivity; Airway inflammation; Mepyramine; (Allergic guinea-pig) (Santing, R.E. (254) 49)

Endothelin; Mast cell; Leukotriene; Chemical mediator (Yamamura, H. (257) 235)

Gastric acid; Nitric oxide (NO); Gastric distension, 2-Deoxy-D-glucose; Pentagastrin; Brain-gut axis (Barrachina, D. (262) 181)

Stress; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); α-Fluoromethylhistidine; Accumbens; Suprachiasmatic (Fleckenstein, A.E. (264) 163)

Mast cell; Endothelin-1; Compound 48/80; Islet-activating protein; Endothelin receptor (Yamamura, H. (265) 9)

Chromaffin cell; Catecholamine; Antidepressant; Ca^{2+} channel; Nicotine (Firestone, J.A. (269) 177)

1,4-Dithiothreitol; Inositol phosphate; [^{3}H]Mepyramine; Cerebral cortex, rat; HeLa cell (Young, K.W. (269) 283)

Histamine, brain
Histamine H_3 receptor; Clobenpropit; Imetit; Histidine decarboxylase; Convulsion, electrically induced (Yokoyama, H. (260) 23)

Histamine leakage
DS-4574; Mast cell stabilizer; Gastric acid secretion; Pentagastrin; Carbachol (Tabuchi, Y. (255) 229)

Histamine receptor
(*R*)-α-Methylhistamine; Sympathetic-cholinergic response; Nerve stimulation, pre- and postganglionic; Presynaptic inhibition; Sudomotor system (Koss, M.C. (257) 109)

Histamine H_1 receptor
Loratadine; Ca^{2+}, cytosolic; PAF (platelet activating factor); Macrophage; Leukotriene; Bronchus, human (Letari, O. (266) 219)

DDT_1MF-2 cell; [^{3}H]mepyramine; Smooth muscle cell (Dickenson, J.M. (268) 257)

Histamine H_2 receptor
Atherosclerosis; Hypercholesterolemia; Carotid, artery, common; (Rabbit); (Cannula insertion method) (Fujiwara, T. (258) 195)

Brain ischemia; Ranitidine; Edema; Na^+; K^+; Ca^{2+}; (Rat) (Tósaki, Á. (264) 455)

Histamine H_3 receptor
VUF 9153 (*S*-[3-(4(5)-imidazolyl)]propyl-*N*-(4-chlorobenzyl)isothiourea); Thioperamide; Ileum, guinea-pig; Radioligand binding; Dipsogenicity (Barnes, J.C. (250) 147)

R-α-methylhistamine; Histamine; Thioperamide; Depressor response; Pressor response; Tachycardia; (Prejunctional) (Hegde, S.S. (251) 43)

Airway microvascular leakage; Sympathetic nerve (Danko, G. (254) 283)

Locomotor activity; (R)-α-Methylhistamine; Thioperamide; (Mouse); (Stimulant) (Clapham, J. (259) 107)

R-α-Methylhistamine; Species difference; Presynaptic inhibition; Thioperamide (McLeod, R.L. (259) 211)

Clobenpropit; Imetit; Histidine decarboxylase; Convulsion, electrically induced; Histamine, brain (Yokoyama, H. (260) 23)

AtT-20 cell; [^{3}H]N^{α}-Methylhistamine binding; ACTH (Adrenocorticotropic hormone) release; Steroid effect (West, Jr., R.E. (267) 343)

Histamine H_1 receptor antagonist
K^+ channel; Glibenclamide; *Xenopus* oocyte; Promethazine; Dimethindene (Sakuta, H. (266) 99)

Histamine H_2 receptor antagonist
H^+,K^+-ATPase inhibitor; Gastric mucin biosynthesis; Organ culture; (Rat) (Ichikawa, T. (251) 107)

Hypochlorous acid scavenger; Cimetidine (Ching, T.-L. (268) 89)

Histamine release
Neuropeptide Y; Neuropeptide Y analog; Pertussis toxin; Benzalkonium chloride G-protein; Mast cell; (Rat) (Grundemar, L. (258) 163)

Histidine decarboxylase
Histamine H_3 receptor; Clobenpropit; Imetit; Convulsion, electrically induced; Histamine, brain (Yokoyama, H. (260) 23)

Histidine residue
Molecular modeling; Adenosine receptor; Receptor binding and activation; Bacteriorhodopsin (IJzerman, A.P. (268) 95)

Histology
Ischemia; Locomotor activity; Nitric oxide (NO) synthase; N^G-Nitro-L-arginine; (Mongolian gerbil) (Caldwell, M. (260) 191)

HL-60 cell line
Immunotoxicology; Detergent; Respiratory burst; Neutrophil, human; Sodium dodecyl sulfate (SDS) (Kacani, L. (270) 285)

HMG-CoA (3-hydroxy-3-methylglutaryl conenzyme A) reductase inhibitor
Liver mitochondria; Ischemia (Satoh, K. (270) 365)

HOE 140
Bradykinin B_2 receptor; Bradykinin; Bronchoconstriction; Microvascular permeability; Vagal stimulation (Sakamoto, T. (251) 137)

Homoserine sulfate
Glutamate receptor; Myenteric plexus; Cortical wedge; Hydroxyproline sulfate; Hydroxypipecolic acid sulfate (Mannaioni, G. (251) 201)

Hornet (*Vespa basalis*) venom
Mastoparan B; Cardiovascular effect; Structural requirement (Ho, C.-L. (259) 259)

Hot-plate inhibition
β-Endorphin; Morphine; MK-801; Tail-flick inhibition (Suh, H.-W. (263) 217)

Hot-plate test
Electroconvulsive shock; Ca^{2+} channel; Apomorphine; Nifedipine; Analgesia; Hyperalgesia; Hypermotility; (Rat) (Antkiewicz-Michaluk, L. (254) 9)

HPLC-ECD system
Acetylcholine release; Cholinergic regulation (presynaptic); Muscarinic receptor agonist; Muscarinic receptor antagonist; Ileum (guinea-pig); Bethanechol; p-F-HHSiD (*p*-fluoro-hexahydro-siladifenidol); AF102B. (Soejima, O. (249) 1)

HS-142-1
Atrial natriuretic factor; cGMP; K^+ channel; Glibenclamide; Y-26763; Cromakalim; *Xenopus* oocyte (Sakuta, H. (267) 281)

5-HT_{1A} autoreceptor
Selective serotonin reuptake inhibitor; Antidepressant; Microdialysis, in vivo; 5-HT (5-hydroxytryptamine, serotonin) release; Central nervous system (Hjorth, S. (260) 251)

Dexfenfluramine; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin) release; Frontal cortex; Microdialysis (Gardier, A.M. (265) 107)

5-HT_{1C} receptor
Choroid plexus; Clozapine; Receptor reserve; Autoradiography; Phosphoinositide hydrolysis (Kuoppamäki, M. (255) 91)

5-$HT_{1D\alpha}$/5-$HT_{1D\beta}$ receptor
[^{3}H]L-694,247 (2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1*H*-indole-3-yl]ethylamine); Caudate nucleus, pig (Heald, A. (264) 213)

5-HT_{1E}/5-HT receptor
Brain; Autoradiography; Lesion (Barone, P. (249) 221)

5-HT (5-hydroxytryptamine, serotonin)
Ibogaine; Stimulus properties of drugs (Schechter, M.D. (249) 79)

Descending relaxation; Nitric oxide (NO); Ileum, rat; NANC (non-adrenergic, non-cholinergic) inhibition (Kanada, A. (250) 59)

α-Methyl-5-hydroxytryptamine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_2 receptor; 5-HT_{1C} receptor; (Pithed rat) (Chaouche-Teyara, K. (250) 67)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP analog; MPTP derivative; Norepinephrine; Fluoxetine; Desipramine (Andrews, A.M. (250) 215)

Descending inhibition; Spinal cord; (Neonatal rat) (Wallis, D.I. (250) 371)

Amphetamine; Methamphetamine; Nimodipine; Tryptophan hydroxylase; (Metabolism) (Elkins, K.W. (250) 395)

Fluoxetine; Frontal cortex; 5-HT uptake inhibitor; Single unit recording (Ceci, A. (250) 461)

Hypothalamo-pituitary-adrenal axis; Stress; Antidepressant; Tianeptine; CRF (corticotropin-releasing factor); ACTH (adrenocorticotropin); Corticosterone (Delbende, C. (251) 245)

Fluoxetine; 5-Hydroxytryptophan; Anticonvulsant effect; Microdialysis; Genetically epilepsy-prone rat (Yan, Q.-S. (252) 105)

Parasympathetic control; Vagal bradycardia; 5-HT receptor; 5-HT receptor agonist (Morán, A. (252) 161)

Calcitonin; Analgesia; *p*-Chlorophenylalanine; *p*-Chloroamphetamine; Acetic acid test (Colado, M.I. (252) 291)

GH (growth hormone); GHRH (growth hormone-releasing hormone); Somatostatin; Tianeptine; (Sheep) (Cataldi, M. (253) 149)

Histamine; Mepyramine; Zolantidine; Thioperamide; Metoprine (Fleckenstein, A.E. (254) 35)

Adrenoceptor; Aporphine; Antipsychotic; Dopamine receptor; Partial agonist, receptor; Stereoisomer (Baldessarini, R.J. (254) 199)

Naftidrofuryl; Microcirculation; Cremaster muscle; Arteriole; Vasoconstriction; 5-HT_2 receptor antagonist (Koch, L.G. (254) 249)

Sexual behavior, male rat; Flat body posture; Forepaw treading; Lower lip retraction; Behavior syndrome; 5-HT_{1A} receptor agonist; 5-HT_2 receptor antagonist (Andersson, G. (255) 131)

Dopamine; *d*-Fenfluramine; Food intake; *d*-Norfenfluramine; Sex difference (Oluyomi, A.O. (255) 175)

Movement disorder; Dystonia; Glutamate (Löscher, W. (255) 235)

Macronutrient preference; Ageing; Feeding; Protein intake (Lacour, F. (255) 249)

Methysergide; Adenosine diphosphate; Platelet aggregation; Gastric mucosal blood flow; Blood pressure; Blood gas (Cho, C.H. (256) 9)

Norepinephrine; Prostaglandin $F_{2\alpha}$ (Lamb, V.L. (256) 221)

5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Morphine; Loperamide; Anti-emetic; Nicotine; Vomiting; (*Suncus murinus*) (Selve, N. (256) 287)

mCPP (*m*-chlorophenylpiperazine); 5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 5-HT receptor agonist; 5-HT receptor antagonist; Drug discrimination; (Rat) (Callahan, P.M. (257) 27)

Hippocampus; Midazolam; Vogel's test; (Rat) (Plaznik, A. (257) 293)

Artery, rabbit; Nandrolone; Vascular reactivity; Noradrenaline; Angiotensin II (Ferrer, M. (258) 103)

Ca^{2+}; Carbamylcholine; Trachea (Cox, D.A. (258) 265)

Central respiratory activity; (Newborn rat); (In vitro) (Monteau, R. (259) 71)

Clozapine; α_1-Adrenoceptor; Raphe; 5-HT_{1A} receptor (Lejeune, F. (260) 79)

Vagus nerve; Electrophysiology; 5-HT_3 receptor; 5-HT_4 receptor; (Grease-gap) (Bley, K.R. (260) 139)

Gepirone; Hippocampus; Excitatory synaptic transmission; Electrophysiology; 5-HT_{1A} receptor; Excitatory postsynaptic potential (Manahan-Vaughan, D. (260) 149)

Microdialysis; Citalopram; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} receptor desensitization (Invernizzi, R. (260) 243)

α_2-Adrenoceptor antagonist; Myocardial ischemia (Sargent, C.A. (261) 25)

α_1-Adrenoceptor; Microdialysis (Rouquier, L. (261) 59)

Elevated plus-maze test; Anxiety; Mianserin; Eltoprazine; 5-HT_{2C} receptor; Autoradiography; In situ hybridization histochemistry; Limbic system; Amygdala (Rocha, B. (262) 125)

Antidepressant drug; Hypothalamic-pituitary-adrenal axis; Inflammation (Bianchi, M. (263) 81)

Histamine; Stress; 5-HIAA (5-hydroxyindoleacetic acid); α-Fluoromethylhistidine; Accumbens; Suprachiasmatic (Fleckenstein, A.E. (264) 163)

Supersensitivity; Spinal cord; 5,7-DHT (5,7-dihydroxytryptamine); Antinociception; (Rat) (Sawynok, J. (264) 249)

Hippocampus; Acetylcholine; Fenfluramine (Levkovitz, Y. (264) 279)

5-HT_4 receptor; Benzamide derivative; Azabicycloalkyl benzimidazolone derivative; GR 113808; Adrenal gland (Contesse, V. (265) 27)

G protein (low molecular weight); Polyphosphoinositide turnover; Botulinum toxin; ADP-ribosylation; *Xenopus* oocyte (Tohda, M. (266) 19)

Mineralocorticoid receptor; Glucocorticoid receptor; Hippocampus; In situ hybridisation; (Rat) (Meijer, O.C. (266) 255)

Transporter; Imipramine; Lectin (Helmeste, D.M. (266) 327)

G protein; G Protein-Coupled Receptor; Sf9 Cells; (Baculovirus) (Parker, E.M. (268) 43)

5-HT receptor; Small cell lung carcinoma cell; Proliferation (Cattaneo, M.G. (268) 425)

In situ hybridization; 5-HT transporter; Image analysis; Amphetamine; Uptake site (Rattray, M. (268) 439)

Galanin; 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Adenylyl cyclase; Forskolin; Hypothalamus; Hippocampus; Brain; Receptor subtype; Peptide fragment (Billecocq, A. (269) 209)

Endosulfan; Learning; Memory; Escape response; Avoidance response (Paul, V. (270) 1)

5-HT release; Ethanol; Frontal cortex; Microdialysis (Portas, C.M. (270) 123)

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Tryptophan; Plasma-free tryptophan; Anorexia; Strain difference; (Brain) (Unkila, M. (270) 157)

5-HT receptor

5-MeO-DMT (5-methoxy-*N*,*N*-dimethyltryptamine); 5-HT receptor agonist; α-Adrenoceptor antagonist; Substance P; Spinal antinociception; GABA (γ-aminobutyric acid) (Alhaider, A.A. (249) 151)

Amperozide; Prolactin; (Rat) (Albinsson, A. (251) 157)

Parasympathetic control; Vagal bradycardia; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonist (Morán, A. (252) 161)

Flesinoxan; Discriminative stimulus; Adrenoceptor; Dopamine receptor; Hypotension (Ybema, C.E. (256) 141)

FG5893; 5-HT_{1A} receptor agonist/5-HT_{2A} receptor antagonist; Hypothermia; Head twitch behavior; Passive avoidance; Forced swim test; Cage leaving; Ultrasound vocalization; Corticosterone; (Rat) (Albinsson, A. (261) 285)

5-HT, (Serotonin); Small cell lung carcinoma cell; Proliferation (Cattaneo, M.G. (268) 425)

5-HT_1 receptor

Sumatriptan; Nicotine; Sensory neurotransmission; Basilar artery, guinea pig (O'Shaughnessy, C.T. (259) 37)

Stomach strip, guinea pig; 5-HT_3 receptor; 5-HT_4 receptor; Electrical stimulation (Buchheit, K.-H. (262) 91)

5-HT_{1A} receptor

Adenylate cyclase; Dorsal raphe nucleus; Nerve impulse flow; (+)-WAY 100 135; SDZ 216-525; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lesopitron; S-20499; Flesinoxan (Lanfumey, L. (249) 25)

Feeding; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY-100135; (Rat) (Hartley, J.E. (252) 329)

Defensive behavior; NAN-190; (−)-Propranolol; Vomiting (Lucot, J.B. (253) 53)

SR 57746A (4-(3-trifluoromethylphenyl)-*N*-[2-(naphth-2-yl)ethyl]-1,2,3,6-tetrahydropyridine HCl); Adenylate cyclase activity; Forced swimming test; Antidepressant activity (Cervo, L. (253) 139)

Head twitch behavior; Buspirone; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_2 receptor; (Mouse) (Kitamura, Y. (253) 297)

8-OH-DPAT (8-hydroxy-2-(di-*N*-propylamino)tetralin); Phrenic nerve activity (Holtman, Jr., J.R. (253) 307)

WAY100135 (*N*-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); Flesinoxan; Glucose concentration, plasma; (Conscious rat) (Critchley, D.J.P. (254) 133)

Autoradiography; Hippocampus; Dorsal raphe nucleus; Firing; Adenylate cyclase; Lesopitron; (−)-Tertatolol (Haj-Dahmane, S. (255) 185)

Clozapine; α_1-Adrenoceptor; Raphe; 5-HT (5-hydroxytryptamine, serotonin) (Lejeune, F. (260) 79)

5-HT (5-hydroxytryptamine, serotonin); Gepirone; Hippocampus; Excitatory synaptic transmission; Electrophysiology; Excitatory post-synaptic potential (Manahan-Vaughan, D. (260) 149)

Anxiety; Elevated plus-maze; 5-HT_{1A} receptor antagonist; (*S*)-WAY 100135; (Mouse) (Rodgers, R.J. (261) 321)

5-HT_2 receptor; Muscarinic acetylcholine receptor; Medial septum; Passive avoidance (Riekkinen Jr., P. (262) 77)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Pain transmission; Antinociception; (Rat) (Cervo, L. (263) 187)

WAY100635 (*N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride); ACTH (adrenocorticotrophic hormone); Plasma; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); (Conscious rat) (Critchley, D.J.P. (264) 95)

Median raphe nucleus; Dorsal hippocampus; Social interaction; Grooming; (Rat) (Andrews, N. (264) 259)

Dorsal raphe nucleus; G-protein; 5-HT (5-hydroxytryptamine, serotonin) release; Microdialysis; Intracerebral; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (Romero, L. (265) 103)

5-HT_{1B} receptor
mCPP (*m*-chlorophenylpiperazine); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{2A} receptor; 5-HT_{2C} receptor; 5-HT receptor agonist; 5-HT receptor antagonist; Drug discrimination; (Rat) (Callahan, P.M. (257) 27)

5-HT_{2A} receptor; 5-HT_{2C} receptor; 6-Hydroxydopamine; mCPP (1-3-(*m*-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Iontophoresis; Autoradiography (El Mansari, M. (261) 171)

5-HT_{1C} receptor
α-Methyl-5-hydroxytryptamine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor; (Pithed rat) (Chaouche-Teyara, K. (250) 67)

[^{3}H]Mesulergine; Clomipramine; Imipramine; Clorgyline; (Wistar rat) (Hulihan-Giblin, B.A. (263) 213)

5-HT_2 receptor
DOI (1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane); Glucocorticoid; Adrenalectomy; Head shakes (Chaouloff, F. (249) 117)

α-Methyl-5-hydroxytryptamine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1C} receptor; (Pithed rat) (Chaouche-Teyara, K. (250) 67)

Head twitch behavior; Buspirone; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} receptor; (Mouse) (Kitamura, Y. (253) 297)

Electrophysiology; Primary olfactory cortex (Marek, G.J. (259) 137)

5-HT_{1A} receptor; Muscarinic acetylcholine receptor; Medial septum; Passive avoidance (Riekkinen Jr., P. (262) 77)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); MDMA (3,4-methylenedioxymethamphetamine); 5-MeODMT (5-methoxy-*N*,*N*-dimethyltryptamine); Microdialysis; Neurotoxicity (Gudelsky, G.A. (264) 325)

5-HT_{2A} receptor
mCPP (*m*-chlorophenylpiperazine); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; 5-HT_{2C} receptor; 5-HT receptor agonist; 5-HT receptor antagonist; Drug discrimination; (Rat) (Callahan, P.M. (257) 27)

5-HT_{1B} receptor; 5-HT_{2C} receptor; 6-Hydroxydopamine; mCPP (1-3-(*m*-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Iontophoresis; Autoradiography (El Mansari, M. (261) 171)

Paw test; Clozapine; α_1-Adrenoceptor; Dopamine D_1 receptor (Prinssen, E.P.M. (262) 167)

Antipsychotic; DOI ((2,5-dimethoxy-4-iodohenyl)-2-aminopropan); Drug discrimination; MDL 100,907 (Schreiber, R. (264) 99)

5-HT_{2C} receptor
mCPP (*m*-chlorophenylpiperazine); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT receptor agonist; 5-HT receptor antagonist; Drug discrimination; (Rat) (Callahan, P.M. (257) 27)

5-HT_{1B} receptor; 5-HT_{2A} receptor; 6-Hydroxydopamine; mCPP (1-3-(*m*-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Iontophoresis; Autoradiography (El Mansari, M. (261) 171)

Elevated plus-maze test; Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Mianserin; Eltoprazine; Autoradiography; In situ hybridization histochemistry; Limbic system; Amygdala (Rocha, B. (262) 125)

Atypical antipsychotic; Autoradiography; Choroid plexus; Clozapine; Phosphoinositide hydrolysis (Kuoppamäki, M. (269) 201)

5-HT_3 receptor
m-Chlorophenylbiguanide; MDL 72222; Sleep; Wakefulness (Ponzoni, A. (249) 259)

5-HT (5-hydroxytryptamine, serotonin); Vagus nerve; Electrophysiology; 5-HT_4 receptor; (Grease-gap) (Bley, K.R. (260) 139)

Stomach strip, guinea pig; 5-HT_1 receptor; 5-HT_4 receptor; Electrical stimulation (Buchheit, K.-H. (262) 91)

5-HT_4 receptor
Light/dark test; Behavioral disinhibition; 5-Hydroxytryptophan; SDZ205-557; Tropisetron; Putative anxiolytic (Cheng, C.H.K. (255) 39)

Copper sulfate; Vomiting; Visceral afferent fiber (Fukui, H. (257) 47)

5-HT (5-hydroxytryptamine, serotonin); Vagus nerve; Electrophysiology; 5-HT_3 receptor; (Grease-gap) (Bley, K.R. (260) 139)

Stomach strip, guinea pig; 5-HT_1 receptor; 5-HT_3 receptor; Electrical stimulation (Buchheit, K.-H. (262) 91)

5-HT (5-hydroxytryptamine, serotonin); Benzamide derivative; Azabicycloalkyl benzimidazolone derivative; GR 113808; Adrenal gland (Contesse, V. (265) 27)

5-HT receptor agonist
5-MeO-DMT (5-methoxy-*N*,*N*-dimethyltryptamine); 5-HT receptor; α-Adrenoceptor antagonist; Substance P; Spinal antinociception; GABA (γ-aminobutyric acid) (Alhaider, A.A. (249) 151)

Parasympathetic control; Vagal bradycardia; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor (Morán, A. (252) 161)

mCPP (*m*-chlorophenylpiperazine); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 5-HT receptor antagonist; Drug discrimination; (Rat) (Callahan, P.M. (257) 27)

5-HT receptor antagonist; Apomorphine; Oxytocin; Penile erection; Yawning; (Rat) (Stancampiano, R. (261) 149)

Maternal aggression; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); TFMPP (1-(3-trifluoromethyl-phenyl)piperazine hydrochloride); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Intracerebroventricular (De Almeida, R.M.M. (264) 445)

5-HT_{1A} receptor agonist
Sexual behavior, male rat; Flat body posture; Forepaw treading; Lower lip retraction; Behavior syndrome; 5-HT_2 receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) (Andersson, G. (255) 131)

5-HT (5-hydroxytryptamine, serotonin) syndrome; Blood pressure; Heart rate; Respiratory rate; α_1-Adrenoceptor (Di Francesco, G.F. (262) 205)

Lower lip retraction; Dorsal raphe nucleus; Median raphe nucleus; 8-OH-DPAT ((±)-8-hydroxy-(di-*n*-propylamino)tetralin); (Rat) (Berendsen, H.H.G. (263) 315)

5-HT_{1A} receptor agonist / 5-HT_{2A} receptor antagonist
FG5893; 5-HT receptor; Hypothermia; Head twitch behavior; Passive avoidance; Forced swim test; Cage leaving; Ultrasound vocalization; Corticosterone; (Rat) (Albinsson, A. (261) 285)

5-HT receptor antagonist
Magnetic resonance imaging; NMR tomography; Brain edema; Stroke; Ca^{2+} channel blocker (Elger, B. (254) 65)

mCPP (*m*-chlorophenylpiperazine); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 5-HT receptor agonist; Drug discrimination; (Rat) (Callahan, P.M. (257) 27)

5-HT receptor agonist; Apomorphine; Oxytocin; Penile erection; Yawning; (Rat) (Stancampiano, R. (261) 149)

5-HT_{1A} receptor antagonist
Anxiety; Elevated plus-maze; 5-HT_{1A} receptor; (*S*)-WAY 100135; (Mouse) (Rodgers, R.J. (261) 321)

5-HT_2 receptor antagonist
Naftidrofuryl; 5-HT (5-hydroxytryptamine, serotonin); Microcirculation; Cremaster muscle; Arteriole; Vasoconstriction (Koch, L.G. (254) 249)

Sexual behavior, male rat; Flat body posture; Forepaw treading; Lower lip retraction; Behavior syndrome; 5-HT_{1A} receptor agonist; 5-HT (5-hydroxytryptamine, serotonin) (Andersson, G. (255) 131)

5-HT_3 receptor antagonist
Emesis; Cisplatin; Copper sulfate; Vagal afferent; (Monkey) (Fukui, H. (249) 13)

Anticancer drug-induced vomiting; Visceral afferent (Fukui, H. (250) 281)

ICS 205–930; $GABA_A$ receptor; [^{3}H]Flunitrazepam binding; [^{3}H]Muscimol binding; [^{35}S]TBPS (tert-butylbicyclophosphorothionate) binding; $^{36}Cl^-$ flux; 293 cell; *Xenopus* oocyte (Klein, R.L. (268) 237)

5-HT_{1A} receptor desensitization
5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Citalopram; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (Invernizzi, R. (260) 243)

5-HT_{2C} receptor, human
Mesulergine; G protein-coupling; (Gene) (Stam, N.J. (269) 339)

5-HT_{1A} receptor ligand, rat
Anxiolysis; Dorsal raphe nucleus; Hippocampus; Ultrasonic vocalization (Schreiber, R. (249) 341)

5-HT_{1A} receptor, postsynaptic
Isolation-induced aggression; 5-HT uptake inhibitor; (Mouse) (Sánchez, C. (264) 241)

5-HT receptor subtype
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; Stimulus property; Drug pre-exposure; Conditioned taste aversion; (Mouse) (Berendsen, H.H.G. (253) 83)

5-HT release
Org 3770; α_2-Adrenoceptor (De Boer, T. (253) R5)

MMAI (5-methoxy-6-methyl-2-aminoindan); Drug discrimination; *p*-Chlorophenylalanine; Behavioral syndrome; (Rat) (Marona-Lewicka, D. (258) 1)

Selective serotonin reuptake inhibitor; 5-HT_{1A} autoreceptor; Antidepressant; Microdialysis, in vivo; Central nervous system (Hjorth, S. (260) 251)

Monoamine oxidase inhibitor; Antidepressant; Microdialysis, intracerebral (Ferrer, A. (263) 227)

Dorsal raphe nucleus; G-protein; 5-HT_{1A} receptor; Microdialysis; Intracerebral; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (Romero, L. (265) 103)

Dexfenfluramine; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} autoreceptor; Frontal cortex; Microdialysis (Gardier, A.M. (265) 107)

5-HT (5-hydroxytryptamine, serotonin); Ethanol; Frontal cortex; Microdialysis (Portas, C.M. (270) 123)

5-HT reuptake inhibitor
5-HT receptor subtype; Stimulus property; Drug pre-exposure; Conditioned taste aversion; (Mouse) (Berendsen, H.H.G. (253) 83)

5-HT reuptake inhibitor, selective
5-HT_{1A} autoreceptor; Antidepressant; Microdialysis, in vivo; 5-HT (5-hydroxytryptamine, serotonin) release; Central nervous system (Hjorth, S. (260) 251)

5-HT syndrome
5-HT_{1A} receptor agonist; Blood pressure; Heart rate; Respiratory rate; α_1-Adrenoceptor (Di Francesco, G.F. (262) 205)

5-HT transporter
Dopamine transporter; GBR 12909; Cocaine; CFT (WIN 35,428); Parkinson's disease (Madras, B.K. (267) 167)

In situ hybridization; Image analysis; Amphetamine; 5-HT (5-hydroxytryptamine, serotonin); Uptake site (Rattray, M. (268) 439)

Paroxetine binding site; Tianeptine (Kuroda, Y. (268) R3)

5-HT uptake
cAMP-dependent protein kinase; cGMP-dependent protein kinase; Protein kinase C; Imipramine binding (Helmeste, D.M. (267) 239)

5-HT uptake inhibitor
Fluoxetine; Frontal cortex; 5-HT (5-hydroxytryptamine, serotonin); Single unit recording (Ceci, A. (250) 461)

Isolation-induced aggression; 5-HT_{1A} receptor, postsynaptic; (Mouse) (Sánchez, C. (264) 241)

5-HT
σ Receptor; Pentazocine binding; Cytochrome *P*450; Piperazine; Phenylalkylamine (Cagnotto, A. (266) 131)

Human cell line
Galanin; Bowes cell line; Binding; cAMP; Galantide (Heuillet, E. (269) 139)

Huntington's disease
Adenosine A_2 receptor; (Rat) (Popoli, P. (257) R5)

HV723 (α-ethyl-3,4,5-trimethoxy-α-(3-((2-(2-methoxyphenoxy)ethyl)-amino)-propyl) benzeneacetonitrile fumarate)
α_1-Adrenoceptor; Positive inotropic effect; Phosphoinositide hydrolysis; [^{3}H]Prazosin; Ventricular myocardium, rabbit (Kohi, M. (250) 95)

Hybridization, in situ
GnRH (gonadotropin-releasing hormone) gene expression; 5β-Pregnan-3α-ol-20-one; Muscimol; Picrotoxin; Hypothalamus (Vincens, M. (260) 157)

Hydralazine
Vas deferens (bisected, rat); [^{3}H]Noradrenaline uptake; $^{45}Ca^{2+}$ influx (Campos-Toimil, M. (251) 83)

Hydrochlorothiazide
Indapamide; 5-OH-Indapamide; Cicletanine; K^+; Ca^{2+} (Calder, J.A. (256) 185)

Hydrogen ion production
Parietal cell (rat); Adenosine 3′,5′-cyclic monophosphate; Radioligand binding; Covalent cross-linking (Schepp, W. (269) 183)

Hydrogen peroxide
Diamide; Sensory nerve; Bronchoconstriction; Thromboxane; (Guinea pig) (Bannenberg, G. (270) 175)

Hydroperoxide isomerase
Dioxygenase; Lipoxygenase inhibitor; Hydroxamic acid (Brodowsky, I.D. (254) 43)

Hydroxamic acid
Dioxygenase; Hydroperoxide isomerase; Lipoxygenase inhibitor (Brodowsky, I.D. (254) 43)

3α-Hydroxy-5α-pregnan-20-one
Neuroactive steroid; $GABA_A$ receptor; 3α-Hydroxy-5β-pregnan-20-one; TBPS (*t*-Butylbicyclophosphorothionate); Flunitrazepam (Hawkinson, J.E. (269) 157)

3α-Hydroxy-5β-pregnan-20-one
Neuroactive steroid; $GABA_A$ receptor; 3α-Hydroxy-5α-pregnan-20-one; TBPS (*t*-Butylbicyclophosphorothionate); Flunitrazepam (Hawkinson, J.E. (269) 157)

γ-Hydroxybutyrate receptor
Neuroleptic; Benzamide; Dopaminergic activity (Maitre, M. (256) 211)

6-Hydroxydopamine
Catechol *O*-methyltransferase inhibition; Circling behavior; L-DOPA (L-3,4-dihydroxyphenylalanine); Dopamine; Metabolism (Törnwall, M. (250) 77)

NMDA receptor antagonist; MK-801 ((+)-5-methyl-10,11-dihydro-5*H*-dibenzo[*a*,*d*]cyclohepten-5,10-imine); Haloperidol; Nucleus accumbens; Locomotion; (Rat) (Ouagazzal, A.-m. (251) 229)

5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; mCPP (1-3-(*m*-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Iontophoresis; Autoradiography (El Mansari, M. (261) 171)

Acetylcholine; *d*-Amphetamine; Cortex; Dopamine; Noradrenaline (Day, J.C. (263) 285)

12-Hydroxyeicosatetraenoic acid
Tolfenamic acid; Thromboxane B_2; Prostaglandin E_2; (Dog) (McKellar, Q.A. (253) 191)

5-Hydroxyindapamide
Indapamide; Hydrochlorothiazide; Cicletanine; K^+; Ca^{2+} (Calder, J.A. (256) 185)

5-Hydroxyindoleacetic acid
Histamine; Stress; 5-HT (5-hydroxytryptamine, serotonin); α-Fluoromethylhistidine; Accumbens; Suprachiasmatic (Fleckenstein, A.E. (264) 163)

Hydroxylated metabolite
PCB (polychlorinated biphenyl); PCDD (dibenzo-*p*-dioxin); PCDF (dibenzofuran); Thyroxine-binding globulin; Transthyretin (Lans, M.C. (270) 129)

Hydroxyphenyl-*N*-*n*-propylpiperidine
Intraocular pressure; Dopamine receptor; Phosphodiesterase inhibitor; Methylxanthine; Pentoxifylline; Trifluperidol; Thiothixene; Fluphenazine; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine) (Hariton, C. (258) 85)

Hydroxypipecolic acid sulfate
Glutamate receptor; Myenteric plexus; Cortical wedge; Homoserine sulfate; Hydroxyproline sulfate (Mannaioni, G. (251) 201)

Hydroxyproline sulfate
Glutamate receptor; Myenteric plexus; Cortical wedge; Homoserine sulfate; Hydroxypipecolic acid sulfate (Mannaioni, G. (251) 201)

2-Hydroxysaclofen
γ-Guanidinobaclofen; Baclofen; $GABA_B$ receptor agonist; Ileum, guinea-pig, isolated; Neocortical slice, rat (Kerr, D.I.B. (262) 189)

5-Hydroxytryptophan
Fluoxetine; 5-HT (5-hydroxytryptamine, serotonin); Anticonvulsant effect; Microdialysis; Genetically epilepsy-prone rat (Yan, Q.-S. (252) 105)

5-HT_4 receptor; Light/dark test; Behavioral disinhibition; SDZ205-557; Tropisetron; Putative anxiolytic (Cheng, C.H.K. (255) 39)

Hyperactivity
NMDA receptor antagonist, competitive; CGS 19755 (*cis*-4-(phosphonomethyl)piperidine-2-carboxylic acid); Dopamine synthesis; Amphetamine; (±)-CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Bristow, L.J. (264) 353)

Hyperalgesia
Theophylline; NMDA receptor; Noradrenaline; Dopamine; Adenosine (Paalzow, G.H.M. (252) 87)

Electroconvulsive shock; Ca^{2+} channel; Apomorphine; Nifedipine; Analgesia; Hot-plate test; Hypermotility; (Rat) (Antkiewicz-Michaluk, L. (254) 9)

cGMP; Intrathecal administration (Garry, M.G. (260) 129)

Hypercholesterolemia
Atherosclerosis; Histamine H_2 receptor; Carotid, artery, common; (Rabbit); (Cannula insertion method) (Fujiwara, T. (258) 195)

Hyperglycemia
Prostaglandin $F_{2\alpha}$; Adrenoceptor; Hyperthermia (Nonogaki, K. (262) 177)

Prostaglandin $F_{2\alpha}$; Adrenoceptor; Hyperglycemia (Nonogaki, K. (262) 177)

Hypermotility
Electroconvulsive shock; Ca^{2+} channel; Apomorphine; Nifedipine; Analgesia; Hyperalgesia; Hot-plate test; (Rat) (Antkiewicz-Michaluk, L. (254) 9)

Hyperplasia
Protein kinase C; Pituitary; Estradiol; Dopamine; (Isoform); (Rat) (Lévy, L. (268) 327)

Hyperpolarization-activated inward current (I_f)
E4080; Ca^{2+} current (L-type, I_{Ca}); ATP-sensitive K^+ (K^+_{ATP}) channel; Chronotropism; Inotropism; Heart, dog (Sawaki, S. (250) 253)

Hypertension
Ca^{2+} channel; Endothelin (Morel, N. (252) R3)

Blood pressure; Hippocampus; Dynorphin; Nor-binaltorphimine; Spontaneously hypertensive rat (SHR) (Wang, J.Q. (256) 57)

Endothelin; Endothelin receptor antagonist; DOCA-salt SHR (deoxycorticosterone acetate-salt spontaneously hypertensive rat) (Okada, M. (259) 339)

Nitrite; Interleukin-1; Atherosclerosis (Ikeda, U. (269) 319)

Ethanol; Placenta; Fetal artery; Fetal alcohol syndrome; Indomethacin (Taylor, S.M. (270) 371)

Hyperthermia
Tolerance; *N*-Nitro-L-arginine methyl ester; Morphine; Thyrotropin (TSH); Prolactin; Growth hormone; Antinociception (Rauhala, P. (259) 57)

Hypochlorous acid scavenger
Histamine H_2 receptor antagonist; Cimetidine (Ching, T.-L. (268) 89)

Hypoglycemia
Levcromakalim; Pinacidil; Diazoxide; Glucose tolerance; Glibenclamide (Clapham, J.C. (257) 79)

Catecholamine; Neuropeptide Y; [Met^5]Enkephalin; Adrenal medulla; Insulin (Damase-Michel, C. (258) 277)

Hypoglycemic agent
Vanadate; Vanadyl; Diabetes; Glucose homeostasis; (Rat) (Becker, D.J. (260) 169)

Hypophysectomy
Tryptophan hydroxylase; Acute sound stress; Hypothalamic deafferentation; RU 38486; Central nucleus of amygdala (Singh, V.B. (256) 177)

Hypotension
PAF (platelet-activating factor, PAF-acether); Renal sympathetic nerve activity, efferent; Renal vascular tone; Baroreflex; Autonomic nervous system (Matsuda, Y. (250) 341)

Flesinoxan; Discriminative stimulus; 5-HT receptor; Adrenoceptor; Dopamine receptor (Ybema, C.E. (256) 141)

Adrenomedullin; Adrenomedullin fragment; Vasodilation; Peripheral circulation (Lin, B. (260) 1)

Iminoctadine; Atrium (rat); Vasodilation; α_1-Adrenoceptor antagonist; (Aorta) (Koyama, K. (270) 151)

Hypothalamic deafferentation
Tryptophan hydroxylase; Acute sound stress; Hypophysectomy; RU 38486; Central nucleus of amygdala (Singh, V.B. (256) 177)

Hypothalamus-pituitary-adrenal axis
Stress; Antidepressant; Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); CRF (corticotropin-releasing factor); ACTH (adrenocorticotropin); Corticosterone (Delbende, C. (251) 245)

Antidepressant drug; Inflammation; 5-HT (5-hydroxytryptamine, serotonin) (Bianchi, M. (263) 81)

Hypothalamus
Dopaminergic neuron; Non-NMDA receptor; Striatum (Wagner, E.J. (254) 105)

5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

GnRH (gonadotropin-releasing hormone) gene expression; 5β-Pregnan-3α-ol-20-one; Muscimol; Picrotoxin; Hybridization, in situ (Vincens, M. (260) 157)

Neuropeptide Y; Megestrol acetate; Appetite; Cancer anorexia; Cachexia (McCarthy, H.D. (265) 99)

Galanin receptor; Brain; (Human) (Lorinet, A.-M. (269) 59)

Galanin; 5-HT (5-hydroxytryptamine, serotonin); 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Adenylyl cyclase; Forskolin; Hippocampus; Brain; Receptor subtype; Peptide fragment (Billecocq, A. (269) 209)

Hypothermia
Galanin; Muscarinic receptor agonist; Cholinomimetic; ATP-sensitive K^+ channel; Acetylcholinesterase inhibitor (Patel, S. (255) 25)

Sauvagine; Haloperidol; Spiperone (Broccardo, M. (258) 179)

Morphine; Δ^9-Tetrahydrocannabinol; Tolerance; Analgesia; Cross-tolerance; [^{3}H]DAMGO ([^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin), B_{max}, K_d; Brain; Spinal cord (Thorat, S.N. (260) 5)

Dopamine D_3 receptor; 7-OH-DPAT ((+)-7-hydroxy-2-(di-*n*-propylamino)tetralin) (Millan, M.J. (260) R3)

FG5893; 5-HT_{1A} receptor agonist/5-HT_{2A} receptor antagonist; 5-HT receptor; Head twitch behavior; Passive avoidance; Forced swim test; Cage leaving; Ultrasound vocalization; Corticosterone; (Rat) (Albinsson, A. (261) 285)

Resiniferatoxin; Capsaicin; Oxygen consumption; Thermoregulation; (Rat) (Woods, A.J. (264) 125)

Hypouricemic effect
TEI-6720; Allopurinol; Xanthine oxidase inhibitor; Uric acid; (Chimpanzee) (Komoriya, K. (250) 455)

Hypovolemia
δ-Opioid receptor; BNTX (7-benzylidenenaltrexone); Naltrindole; Hemorrhagic shock; (Rabbit, conscious) (Ludbrook, J. (252) 113)

Hypoxia
ANF (atrial natriuretic factor); cGMP; Guanylyl cyclase; ANF receptor antagonist; Hypoxic coronary vasodilatation; Heart, isolated, guinea pig; Nitric oxide (NO) (Park, K.H. (256) 99)

Cytokine; Endothelin; Endothelin converting enzyme; Hemorrhage; Interleukin-1β; Phosphoramidon; TNF-α (tumor necrosis factor-α) (Vemulapalli, S. (257) 95)

EDRF (endothelium-derived relaxing factor); K^+ channel opener; K^+ channel blocker; Lung; Smooth muscle, vascular (Dumas, J.-P. (263) 17)

Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; L158809; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

Coronary artery; Smooth muscle, vascular; ATP-sensitive K^+ channel; Glibenclamide; Levcromakalim (Mellemkjær, S. (270) 307)

$^{45}Ca^{2+}$ uptake; Thromboxane; U46619; Coronary artery (Dalen, T. (270) 313)

Hypoxia-ischemia, cerebral
Zonisamide; Anticonvulsant; Brain, neonatal, rat; Infarction, cerebral; Hypoxic seizure (Hayakawa, T. (257) 131)

Hypoxic coronary vasodilatation
ANF (atrial natriuretic factor); cGMP; Guanylyl cyclase; ANF receptor antagonist; Hypoxia; Heart, isolated, guinea pig; Nitric oxide (NO) (Park, K.H. (256) 99)

Hypoxic pulmonary vasoconstriction
Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; L158809; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

Hypoxic seizure
Zonisamide; Anticonvulsant; Brain, neonatal, rat; Hypoxia-ischemia, cerebral; Infarction, cerebral (Hayakawa, T. (257) 131)

IAPP (islet amyloid polypeptide)
CGRP (calcitonin gene-related peptide); Salmon calcitonin; Nucleus accumbens (Veale, P.R. (262) 133)

IBMX (3-isobutyl-1-methylxanthine) phosphodiesterase
NMDA; Adenosine; cAMP; 5'AMP; (*N*-methyl-D-aspartate); (Release) (Craig, C.G. (269) 79)

Ibogaine
Stimulus properties of drugs; 5-HT (5-hydroxytryptamine, serotonin) (Schechter, M.D. (249) 79)

Ibuprofen
Endothelin; L-N^G-Nitroarginine; EDRF (endothelium-derived relaxing factor); Renal blood flow; Urine flow rate; Urine osmolality; Glomerular filtration rate; (Dog) (Yukimura, T. (264) 399)

ICAM-1 (intercellular adhesion molecule-1)
Endothelial cell, human, vascular; Thromboxane A_2; Phospholipase A_2 (Ishizuka, T. (262) 113)

Myocardial ischemia-reperfusion; Leukocyte accumulation (Ioculano, M. (264) 143)

ICS 205–930
5-HT_3 receptor antagonist; $GABA_A$ receptor; [^{3}H]Flunitrazepam binding; [^{3}H]Muscimol binding; [^{35}S]TBPS (tert-butylbicyclophosphorothionate) binding; $^{36}Cl^-$ flux; 293 cell; *Xenopus* oocyte (Klein, R.L. (268) 237)

Idazoxan
SND 919; B-HT 920; Lisuride; Dopamine D_2 receptor; α_2-Adrenoceptor; Behavior (Ferrari, F. (250) 51)

Imidazoline; Guanidinium; K^+ channel; Kidney (rabbit) (Corpus, V.M. (266) 197)

Idazoxan, chronic
Frontal cortex; Hippocampus; Microdialysis; α_2-Adrenoceptor, presynaptic (Thomas, D.N. (261) 53)

IdB 1031
Airway hyperreactivity; Cigarette smoke; Bronchoalveolar lavage; Leukotriene B_4 (Hernandez, A. (270) 301)

Idebenone
Adenosine outflow; Inosine outflow; Nucleotide level; Hippocampal slice; Ischemia-like condition (Latini, S. (249) 65)

Ifenprodil
Polyamine; ACTH (adrenocorticotropin); Behavior; NMDA receptor; (Rat) (Genedani, S. (252) 77)

NMDA (*N*-methyl-D-aspartate); Glycine; Polyamine; 7-Chlorokynurenate; (Synergism) (Voltz, C. (255) 197)

σ Receptor; Heterocyclic amino alcohol; [^{3}H]3-PPP ([^{3}H]R(+)-3-[3-hydroxyphenyl]-*N*-(1-propyl)piperidine) binding; Brain (Rat); Molecular modelling (Beart, P.M. (269) 193)

[^{3}H]Ifenprodil binding
Polyamines; NMDA receptor (*N*-Methyl-D-aspartate); σ Receptor; Brain (Rat) (Hashimoto, K. (266) 67)

IGF-1
K^+ channel; Glibenclamide; Cromakalim; *Xenopus* oocyte; Insulin; Phenylarsine oxide; Pertussis toxin; Voltage clamp, 2-electrode (Sakuta, H. (268) 375)

Ileal longitudinal muscle, guinea-pig
P_{2X} purinoceptor; P_{2Y} purinoceptor; α,β-Methylene ATP; 2-Methylthio ATP; β,γ-Methylene ATP (Kennedy, I. (261) 273)

Ileocecal sphincter
Nitric oxide (NO); NANC (non-adrenergic non-cholinergic) transmission; Electrical field stimulation; Nicotinic receptor; (Cat) (Mizhorkova, Z. (265) 77)

Ileocolonic junction, dog
Bioassay; Nitrergic transmission; Nitric oxide (NO) (Boeckxstaens, G.E. (264) 85)

Ileum
Neuropeptide release; Synaptosome; Nerve varicosity; Muscarinic receptor; Bombesin (Kurjak, M. (257) 169)

Ileum, guinea-pig
Acetylcholine release; HPLC-ECD system; Cholinergic regulation (presynaptic); Muscarinic receptor agonist; Muscarinic receptor antagonist; Bethanechol; p-F-HHSiD (*p*-fluoro-hexahydro-siladifenidol); AF102B. (Soejima, O. (249) 1)

VUF 9153 (*S*-[3-(4(5)-imidazolyl)]propyl-*N*-(4-chlorobenzyl)isothiourea); Thioperamide; Histamine H_3 receptor; Radioligand binding; Dipsogenicity (Barnes, J.C. (250) 147)

Peristalsis; Nitric oxide (NO); N^G-Nitro-L-arginine; Circular muscle (Suzuki, N. (251) 221)

Morphine 6-glucuronide; Intestinal motility; Binding assay (Massi, P. (253) 269)

Muscarinic receptor; Ascending reflex; AF-DX 116; Smooth muscle, intestinal (Doods, H.N. (253) 275)

Morphine; Morphine-6-glucuronide; Agonist potency (Schmidt, N. (255) 245)

Vasoactive intestinal contractor; Endothelin receptor; Acetylcholine release; Desensitization (Kan, S. (258) 139)

ω-Conotoxin MVIIC; ω-Conotoxin GVIA; N-type voltage-dependent Ca^{2+} channel; Vas deferens, rat (Boot, J.R. (258) 155)

Ileum, isolated, guinea-pig
γ-Guanidinobaclofen; Baclofen; $GABA_B$ receptor agonist; Neocortical slice, rat; 2-Hydroxysaclofen (Kerr, D.I.B. (262) 189)

Nitropropane analog, GABA; Nitropropane analog, baclofen; Neocortex, rat; Spinal cord, cat; $GABA_B$ receptor antagonist (Ong, J. (264) 49)

Ileum membrane
Bradykinin B_2 receptor; Affinity cross-linking; (Guinea pig) (Graneß, A. (268) 271)

Ileum, rat
Descending relaxation; 5-HT (5-hydroxytryptamine, serotonin); Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) inhibition (Kanada, A. (250) 59)

Image analysis
In situ hybridization; 5-HT transporter; Amphetamine; 5-HT (5-hydroxytryptamine, serotonin); Uptake site (Rattray, M. (268) 439)

Imetit
Histamine H_3 receptor; Clobenpropit; Histidine decarboxylase; Convulsion, electrically induced; Histamine, brain (Yokoyama, H. (260) 23)

IM9 human lymphoblastoma cell
Tachykinin NK_1 receptor; FK888; RP 67580; (±)-CP-96,345; U373 MG human astrocytoma cell (Goso, C. (254) 221)

Imidazenil
$GABA_A$ receptor, partial agonist; Chronic treatment; Tolerance (Ghiani, C.A. (254) 299)

Imidazolidine
Imidazoline; Glibenclamide; K^+ channel; *Xenopus* oocyte; Y-26763; K^+ channel opener; Structure-activity relationship (Sakuta, H. (259) 223)

Imidazolidine compound
α_2-Adrenoceptor, prejunctional; Agonist affinity; Agonist efficacy; (Operational model) (Sallés, J. (258) 229)

Imidazoline
SL 84.0418; α_2-Adrenoceptor; K^+ channel, ATP-sensitive; Insulin release; Tolbutamide; (Mouse islet) (Jonas, J.-C. (254) 27)

Oxazoline; Imidazoline site; Insulin secretion, vessel; Pancreas, rat (Berdeu, D. (254) 119)

α_2-Adrenoceptor; Cortex; Non-adrenoceptor binding (Wallace, D.R. (258) 67)

Imidazolidine; Glibenclamide; K^+ channel; *Xenopus* oocyte; Y-26763; K^+ channel opener; Structure-activity relationship (Sakuta, H. (259) 223)

Guanidine; Imidazoline receptor; Insulin; RIN-5AH cell; Insulinoma; ATP-dependent K^+ channel (Olmos, G. (262) 41)

SL 84.0418; Deriglidole; α_2-Adrenoceptor; Insulin release; K^+ channel, ATP-sensitive; (Mouse islet) (Jonas, J.-C. (264) 81)

Clonidine; Brain, human (Greney, H. (265) R1)

Idazoxan; Guanidinium; K^+ channel; Kidney (rabbit) (Corpus, V.M. (266) 197)

Imidazoline receptor
Imidazoline; Guanidine; Insulin; RIN-5AH cell; Insulinoma; ATP-dependent K^+ channel (Olmos, G. (262) 41)

Brainstem (Human); Clonidine; GTP; Phenoxybenzamine; α-Adrenoceptor (Bricca, G. (266) 25)

α_2-Adrenoceptor; cAMP; Brainstem; Cerebral cortex; Inositol phosphate (Regunathan, S. (269) 273)

Imidazoline site
Imidazoline; Oxazoline; Insulin secretion, vessel; Pancreas, rat (Berdeu, D. (254) 119)

Iminoctadine
Hypotension; Atrium (rat); Vasodilation; α_1-Adrenoceptor antagonist; (Aorta) (Koyama, K. (270) 151)

Imipramine
α-Methyl-*para*-tyrosine; Learned helplessness; Antidepressant (De Montis, M.G. (249) 179)

Tricyclic antidepressant; Desipramine; Patch-clamp; Neuroblastoma; Nicotinic acetylcholine receptor (Rana, B. (250) 247)

Benzodiazepine receptors, peripheral type; Phenelzine sulfate; [^{3}H]PK 11195; Antidepressant (Weizman, R. (250) 289)

Alprazolam; Propranolol; Forced swimming test, modified; (Rat) (Abel, E.L. (258) 261)

Depression, animal model; Anhedonia; MK-801; CGP 37849; CGP 40116; (Rat) (Papp, M. (263) 1)

5-HT$_{1C}$ receptor; [^{3}H]Mesulergine; Clomipramine; Clorgyline; (Wistar rat) (Hulihan-Giblin, B.A. (263) 213)

5-HT (5-hydroxytryptamine, serotin); Transporter; Lectin (Helmeste, D.M. (266) 327)

Ca^{2+} concentration, intracellular; Dihydropyridine; ω-Conotoxin; Inorganic Ca^{2+} channel blocker; Cultured neuron (Shimizu, M. (268) 65)

Imipramine binding
cAMP-dependent protein kinase; cGMP-dependent protein kinase; Protein kinase C; 5-HT (5-hydroxytryptamine, serotonin) uptake (Helmeste, D.M. (267) 239)

Imipramine, chronic
Chronic mild stress; Depression model, rat; cAMP; β-Adrenoceptor; Sucrose intake (Papp, M. (261) 141)

Immediate-early gene
Inhibitor of enkephalin-degrading enzyme; Morphine; Nociception; Non-steroidal anti-inflammatory drug; Tolerance (Abbadie, C. (258) 215)

Immune system
Receptor autoradiography; α_2-Adrenoceptor; Lymph node; Spleen; [^{3}H]Bromoxidine (Fernández-López, A. (252) 333)

Receptor autoradiography; β-Adrenoceptor; Lymph node; Spleen; [^{125}I]Cyanopindolol; Lymphoid organ (Fernández-López, A. (262) 283)

Immunofluorescence, in situ
Baculovirus; Epitope-tagged; G-protein coupled receptor (Ng, G.YK. (267) 7)

Immunohistochemistry
Basal ganglion; Neuropeptide; Dopamine; Radioimmunoassay (Castel, M.-N. (262) 1)

Immunoneutralization
Capsaicin; CGRP (calcitonin gene-related peptide); Monoclonal anti-CGRP antibody; Gastric mucosa; Gastric mucosal protection; Gastric mucosal injury (Peskar, B.M. (250) 201)

Immunoprecipitation
$GABA_A$ receptor complex; Benzodiazepine binding site, type I; [^{3}H]Zolpidem binding; Photoaffinity labeling; Cortex; (Subunit specific antibodies) (Ruano, D. (267) 121)

Immunosuppressive drug
Nitric oxide (NO); Interleukin 1β; Cyclosporin; Mesangial cell (Mühl, H. (249) 95)

Immunotoxicology
Detergent; Respiratory burst; Neutrophil, human; HL-60 cell line; Sodium dodecyl sulfate (SDS) (Kacani, L. (270) 285)

Inactivation gate
Inwardly rectifying K^+ channel; Ventricular myocyte; Patch-clamp technique; Voltage-dependent inactivation; Chloramine-T; (Guinea pig) (Koumi, S.-i. (258) 281)

Indapamide
Conductance vessel; Resistance vessel; $^{45}Ca^{2+}$ movement; (Rabbit); (Sheep) (Del Rio, M. (250) 133)

5-OH-Indapamide; Hydrochlorothiazide; Cicletanine; K^+; Ca^{2+} (Calder, J.A. (256) 185)

cAMP; β-Adrenoceptor stimulation; Cardiomyocyte (chick, embryonic); Forskolin; Cholera toxin (Rabkin, S.W. (266) 117)

Indirect action
Receptor model; Functional interaction; Tyramine; Vas deferens, rat (Venter, D.P. (251) 209)

Indole
Anti-estrogenic activity; Breast cancer; Yuehchukene (Ng, P.C. (264) 1)

Indolylbutylamine
Dopamine receptor, presynaptic; Dopamine receptor, postsynaptic; Tolerance; γ-Butyrolactone; Behavioral supersensitivity; Drug interaction (Seyfried, C.A. (257) 67)

Indomethacin
Tumor necrosis factor; Interleukin-1; Interleukin-6; Dexamethasone; Pleurisy; (Rat) (Utsunomiya, I. (252) 213)

Opsonized zymosan; OX-42; Dapsone; Bromophenacyl bromide; Prostaglandin E_2 (Klegeris, A. (260) 273)

Angiotensin II; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Aorta, rabbit; N^G-Monomethyl-L-arginine; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester (Zhang, J. (262) 247)

Analgesia; Norepinephrine; β-Endorphin; Phentolamine; Naloxone; Pain (Hu, X.-H. (263) 53)

Ethanol; Placenta; Fetal artery; Hypertension; Fetal alcohol syndrome (Taylor, S.M. (270) 371)

Infarction, cerebral
Zonisamide; Anticonvulsant; Brain, neonatal, rat; Hypoxia-ischemia, cerebral; Hypoxic seizure (Hayakawa, T. (257) 131)

Infarct size
Pirsidomine; Hemodynamics; (Dog) (Martorana, P.A. (257) 267)

Inflammation
Thermal hyperalgesia; Excitatory amino acid; Glutamate receptor; Memantine; Carrageenan (Eisenberg, E. (255) 123)

NSAID (non-steroidal anti-inflammatory drug); Nabumetone; Antinociception (Clarke, G.D. (257) 103)

Ulcer; NSAID (non-steroidal anti-inflammatory drug); Nitric oxide (NO); Prostaglandin (Wallace, J.L. (257) 249)

Prostaglandin D_2; Neutrophil; Edema formation; Adherence; O_2^- production (Pons, F. (261) 237)

Antidepressant drug; Hypothalamic-pituitary-adrenal axis; 5-HT (5-hydroxytryptamine, serotonin) (Bianchi, M. (263) 81)

Antiflammin; Phospholipase A_2; Mast cell degranulation; Anti-inflammatory drug (Lloret, S. (264) 379)

Neuropeptide; Edema; Neutrophil; Interleukin-8 (Ahluwalia, A. (264) 407)

Inhalational anesthetic
GABA (γ-aminobutyric acid); Muscimol; Stereospecificity; SR 95531 (Harris, B.D. (267) 269)

Inhibitor
Cyclo-oxygenase; Prostaglandin; Stomach, rat; Smooth muscle, longitudinal and circular (Shimomura, A. (252) 81)

GABA; GABA transport; Transporter; (γ-aminobutyric acid); (Lipophilic) (Borden, L.A. (269) 219)

Inhibitor of enkephalin-degrading enzyme
Immediate-early gene; Morphine; Nociception; Non-steroidal anti-inflammatory drug; Tolerance (Abbadie, C. (258) 215)

Inhibitory junction potential
NANC (non-adrenergic non-cholinergic); Suramin; Gastric smooth muscle; ATP (Ohno, N. (249) 121)

Inosine outflow
Idebenone; Adenosine outflow; Nucleotide level; Hippocampal slice; Ischemia-like condition (Latini, S. (249) 65)

Inositol monophosphate
Muscarinic receptor agonists; Phosphatidyl-inositol turnover, in vivo; Oxadiazoles; L-658,903 (Patel, S. (267) 329)

Inositol phosphate
[^{3}H]Rauwolscine; α_2-Adrenoceptor; Myometrium; cAMP; (Guinea-pig) (Haynes, J.M. (250) 231)

Dopamine D_3 receptor; Dopamine D_2 receptor; Receptor binding; cAMP accumulation; Arachidonic acid release (MacKenzie, R.G. (266) 79)

α-Trinositol; Binding site; Heart (Yoo, H. (268) 55)

Tachykinin; Neurokinin; CHO (Chinese hamster ovary) cell; Antagonist; Structure-activity; Ca^{2+}; Second messenger; Thapsigargin; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

Imidazoline receptor; α_2-Adrenoceptor; cAMP; Brainstem; Cerebral cortex (Regunathan, S. (269) 273)

1,4-Dithiothreitol; Histamine; [^{3}H]Mepyramine; Cerebral cortex, rat; HeLa cell (Young, K.W. (269) 283)

[^{3}H]Inositol phosphate
Spontaneously hypertensive rat (SHR); Tail artery; Ca^{2+}, cytosolic (Thorin-Trescases, N. (268) 199)

D-*myo*-Inositol 1,3,4,5-tetrakisphosphate
Liposome; Smooth muscle, aortic; D-*myo*-Inositol 1,4,5-trisphosphate (Brailoiu, E. (250) 493)

Inositol 1,4,5-trisphosphate
Inositol 1,4,5-trisphosphate receptor; Heart, rat; Ca^{2+} release; Neonatal cardiomyocyte (Fitzgerald, M. (268) 275)

PAF (platelet activating factor); Ca^{2+}, intracellular; Neutrophil (Koike, H. (269) 299)

D-*myo*-Inositol 1,4,5-trisphosphate
Liposome; Smooth muscle, aortic; D-*myo*-Inositol 1,3,4,5-tetrakisphosphate (Brailoiu, E. (250) 493)

Inositol 1,4,5-trisphosphate receptor
Inositol 1,4,5-trisphosphate; Heart, rat; Ca^{2+} release; Neonatal cardiomyocyte (Fitzgerald, M. (268) 275)

Inotropic effect
Doxorubicin; Heart muscle preparation, isolated; Myocardial Ca^{2+} loading; (Guinea pig); (Rat) (Temma, K. (252) 173)

Aging; $G_{s\alpha}$ protein mRNA; $G_{s\alpha}$ subunit; β-Adrenoceptor stimulation; Cardiac ventricle; (Male Wistar rat) (Miyamoto, A. (266) 147)

Inotropic state
Ca^{2+} channel antagonist; Skinned striated muscle; Tension (maximum); Ca^{2+} sensitivity (Schiereck, P. (249) 317)

Inotropism
E4080; Hyperpolarization-activated inward current (I_f); Ca^{2+} current (L-type, I_{Ca}); ATP-sensitive K^+ (K^+_{ATP}) channel; Chronotropism; Heart, dog (Sawaki, S. (250) 253)

In situ hybridization
Cannabis; δ-9-Tetrahydrocannabinol (THC); Cerebral decortication; MK-801; NMDA receptor (Mailleux, P. (266) 193)

Mineralocorticoid receptor; Glucocorticoid receptor; 5-HT (5-hydroxytryptamine, serotonin); Hippocampus; (Rat) (Meijer, O.C. (266) 255)

Uptake; Amino acid; Carrier; Glutamate transporter; Proximal tubule; Kidney; (Rabbit) (Meister, B. (267) 323)

5-HT transporter; Image analysis; Amphetamine; 5-HT (5-hydroxytryptamine, serotonin); Uptake site (Rattray, M. (268) 439)

In situ hybridization histochemistry
Elevated plus-maze test; Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Mianserin; Eltoprazine; 5-HT_{2C} receptor; Autoradiography; Limbic system; Amygdala (Rocha, B. (262) 125)

Insulin
Catecholamine; Neuropeptide Y; [Met^5]Enkephalin; Adrenal medulla; Hypoglycemia (Damase-Michel, C. (258) 277)

Imidazoline; Guanidine; Imidazoline receptor; RIN-5AH cell; Insulinoma; ATP-dependent K^+ channel (Olmos, G. (262) 41)

K^+ channel; Glibenclamide; Cromakalim; *Xenopus* oocyte; IGF-1; Phenylarsine oxide; Pertussis toxin; Voltage clamp, 2-electrode (Sakuta, H. (268) 375)

Insulinoma
Imidazoline; Guanidine; Imidazoline receptor; Insulin; RIN-5AH cell; ATP-dependent K^+ channel (Olmos, G. (262) 41)

Insulin release
SL 84.0418; α_2-Adrenoceptor; K^+ channel, ATP-sensitive; Tolbutamide; Imidazoline; (Mouse islet) (Jonas, J.-C. (254) 27)

SL 84.0418; Deriglidole; α_2-Adrenoceptor; Imidazoline; K^+ channel, ATP-sensitive; (Mouse islet) (Jonas, J.-C. (264) 81)

Insulin resistance
Non-insulin-dependent diabetes mellitus; *d*-Fenfluramine therapy; Liver; (Rat) (Picarel-Blanchot, F. (264) 227)

Insulin secretion
GMAP (galanin message-associated polypeptide); Galanin; Islet; (In vitro); (Mouse); (Rat) (Gregersen, S. (259) 79)

Insulin secretion, vessel
Imidazoline; Oxazoline; Imidazoline site; Pancreas, rat (Berdeu, D. (254) 119)

Interferon-γ
Arterial reactivity; Bradykinin; Nitric oxide (NO) (De Kimpe, S.J. (261) 111)

Colonic cell line (human); Mucus secretion; Cytokine regulation; cAMP; MUC2 mucin gene (Jarry, A. (267) 95)

Interleukin
Hippocampus; Ca^{2+} channel; G-protein; Protein kinase; Patch-clamp; (Guinea pig) (Plata-Salamán, C.R. (266) 1)

Interleukin-1
Tumor necrosis factor; Interleukin-6; Indomethacin; Dexamethasone; Pleurisy; (Rat) (Utsunomiya, I. (252) 213)

Nitrite; Atherosclerosis; Hypertension (Ikeda, U. (269) 319)

Interleukin-1β
Nitric oxide (NO); Cyclosporin; Immunosuppressive drug; Mesangial cell (Mühl, H. (249) 95)

TNF (tumor necrosis factor); Leukotriene B_4; Phospholipase A_2; Phospholipase C; 5-Lipoxygenase; Protein kinase C; Phorbol 12-myristate 13-acetate; Stomach, rat; Gastric motility (Montuschi, P. (252) 253)

Cytokine; Endothelin; Endothelin converting enzyme; Hemorrhage; Hypoxia; Phosphoramidon; TNF-α (tumor necrosis factor-α) (Vemulapalli, S. (257) 95)

Afferent nerve stimulation; Capsaicin; Cutaneous hyperemia; Neurogenic inflammation; Nitric oxide (NO) (Herbert, M.K. (260) 89)

Lipopolysaccharide; Nitric oxide (NO); DL-Propranolol; Smooth muscle, vascular; Cell culture; Spontaneously hypertensive rat (SHR); Wistar Kyoto rat (WKY); (Rat) (De Castro, M. (261) 199)

Endothelium; cGMP; Vascular tone (Schini-Kerth, V. (265) 83)

Interleukin-1β-(193–195)
Lys-D-Pro-Thr; Lys-D-Pro; Tripeptide; Naloxone; Antinociception; Formalin test (Oluyomi, A.O. (258) 131)

Interleukin-2
Anti-allergic agent; Cytokine production, in vitro; Interleukin-3; Interleukin-4; Interleukin-5; Peripheral blood leukocyte, human (Konno, S.-i. (264) 265)

Interleukin-3
Anti-allergic agent; Cytokine production, in vitro; Interleukin-2; Interleukin-4; Interleukin-5; Peripheral blood leukocyte, human (Konno, S.-i. (264) 265)

Interleukin-4
Interleukin-5; Corticosteroid; Cyclosporin A (Schmidt, J. (260) 247)

Anti-allergic agent; Cytokine production, in vitro; Interleukin-2; Interleukin-3; Interleukin-5; Peripheral blood leukocyte, human (Konno, S.-i. (264) 265)

Interleukin-5
Interleukin-4; Corticosteroid; Cyclosporin A (Schmidt, J. (260) 247)

Anti-allergic agent; Cytokine production, in vitro; Interleukin-2; Interleukin-3; Interleukin-4; Peripheral blood leukocyte, human (Konno, S.-i. (264) 265)

Interleukin-6
Tumor necrosis factor; Interleukin-1; Indomethacin; Dexamethasone; Pleurisy; (Rat) (Utsunomiya, I. (252) 213)

Interleukin-8
Neuropeptide; Edema; Neutrophil; Inflammation (Ahluwalia, A. (264) 407)

Interleukin-8 receptor
Psoriasis; Cyclosporine; Calcitriol; Dithranol (Kemény, L. (258) 269)

Intestinal motility
Morphine 6-glucuronide; Ileum, guinea-pig; Binding assay (Massi, P. (253) 269)

Intestinal mucosal injury
Endotoxin; Sepsis; Nitric oxide (NO); Vasopressin; Vasopressin receptor antagonist; Intestinal vascular permeability; N^G-Nitro-L-arginine methyl ester (László, F. (260) 265)

Intestinal secretion
Sodium choleate; Nitric oxide (NO) synthase; Diarrhea; Small intestinal transit (Mascolo, N. (264) 21)

Intestinal vascular permeability
Endotoxin; Sepsis; Nitric oxide (NO); Vasopressin; Vasopressin receptor antagonist; Intestinal mucosal injury; N^G-Nitro-L-arginine methyl ester (László, F. (260) 265)

Intestine
Capsaicin; Afferent neuron; Tachykinin; Smooth muscle (Barthó, L. (259) 187)

Intracerebral infusion
Dorsal raphe nucleus; G-protein; 5-HT_{1A} receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Microdialysis; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (Romero, L. (265) 103)

Intracerebroventricular injection
Maternal aggression; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); TFMPP (1-(3-trifluoromethyl-phenyl)piperazine hydrochloride); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT receptor agonist (De Almeida, R.M.M. (264) 445)

Intraocular pressure
Dopamine receptor; Phosphodiesterase inhibitor; Methylxanthine; Pentoxifylline; Trifluperidol; Thiothixene; Fluphenazine; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine); Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

Intrathecal administration
cGMP; Hyperalgesia (Garry, M.G. (260) 129)

Intrathecal injection
Tachykinin receptor antagonist; Spinal cord; (Mouse) (Sakurada, T. (261) 85)

Intrinsic activity
Adenosine A_1 receptor; Agonists (full and partial); Receptor binding thermodynamics (Borea, P.A. (267) 55)

Inwardly rectifying K^+ channel
Ventricular myocyte; Patch-clamp technique; Voltage-dependent inactivation; Chloramine-T; Inactivation gate; (Guinea pig) (Koumi, S.-i. (258) 281)

[^{123}I]Iodobenzofuran
Dopamine; Dopamine D_2 receptor; SPECT (single photon emission computed tomography); Benzamide (Laruelle, M. (263) 39)

Iodolactone
Goiter; Antigoitrogenic; Thyroid; Autoregulation (Pisarev, M.A. (258) 33)

2-Iodomelatonin binding
Melatonin; Melanophore; Pigment aggregation; Melatonin receptor; Chroman (Sugden, D. (254) 271)

Ion channel
Glutamate receptor; Polyamine; Memory (Shimada, A. (263) 293)

Ion channel antagonist
Voltage-clamp, whole-cell; Cardiac myocyte; Cl^- channel blocker; Na^+ current; Ca^{2+} current; Diphenylamine-2-carboxylate (DPC) (Conforti, L. (259) 215)

Ionic conductance
ATP; Suramin; Enteric neuron; Electrophysiology; Purinoceptor; Myenteric plexus (Barajas-López, C. (250) 141)

Ionic current
Cardiac electrophysiology; Cardiac myocyte, isolated; κ-Opioid receptor agonist; U-50,488H (Pugsley, M.K. (261) 303)

Iontophoresis
5-HT_{1B} receptor; 5-HT_{2A} receptor; 5-HT_{2C} receptor; 6-Hydroxydopamine; mCPP (1-3-(*m*-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Autoradiography (El Mansari, M. (261) 171)

IP_3
Endothelin; Saponin; Ca^{2+}; Protein kinase C; Positive inotropy; Diacylglycerol; Phospholipase (Paik, G.Y. (264) 437)

Iproniazid
Antihistamine; Calcimycin; EDCF (endothelium-derived contracting factor); EDRF (endothelium-derived relaxing factor); Hemoglobin; Mast cell; Methylene blue; N^G-Methyl-L-arginine (Gruetter, C.A. (257) 275)

Iris
Blood flow; Choroid; Ciliary body; PACAP (pituitary adenylate cyclase activating polypeptide); Vasodilatation (Nilsson, S.F.E. (253) 17)

Iris, monkey
CGRP (calcitonin gene-related peptide), C-terminal fragment; Vasopressin; Somatostatin-28; CCK_A receptor (Almegård, B. (250) 31)

IRL 1620
Endothelin; PD 145065; Ro 46-2005; Endothelin ET_A/ET_B nonselective receptor antagonist (Battistini, B. (252) 341)

Isbufylline
Platelet activating factor (PAF); Airway hyperresponsiveness; Airway inflammation; Plasma protein extravasation; Xanthine (Manzini, S. (249) 251)

Ischemia
Cromakalim; K^+ channel opener; Skeletal muscle fatigue (Trezise, D.J. (250) 109)

Ca^{2+} channel antagonist; Heart, isolated; Fantofarone; ^{31}P NMR spectroscopy (Vander Elst, L. (251) 163)

Adenosine; Adenosine receptor; Therapy; (Gerbil) (Von Lubitz, D.K.J.E. (256) 161)

Locomotor activity; Nitric oxide (NO) synthase; N^G-Nitro-L-arginine; Histology; (Mongolian gerbil) (Caldwell, M. (260) 191)

Glutamate; Lactate; Microdialysis; Nizofenone; Neuronal damage (Matsumoto, Y. (262) 157)

HMG-CoA (3-hydroxy-3-methylglutaryl conenzyme A) reductase inhibitor; Liver mitochondria (Satoh, K. (270) 365)

Ischemia-like condition
Idebenone; Adenosine outflow; Inosine outflow; Nucleotide level; Hippocampal slice (Latini, S. (249) 65)

Ischemia / reperfusion injury
Disopyramide; Propafenone; Na^+ overload; Creatine kinase; Purine nucleoside; Purine base (Liu, J.-X. (250) 361)

Islet
GMAP (galanin message-associated polypeptide); Galanin; Insulin secretion; (In vitro); (Mouse); (Rat) (Gregersen, S. (259) 79)

Islet-activating protein
Mast cell; Endothelin-1; Histamine; Compound 48/80; Endothelin receptor (Yamamura, H. (265) 9)

Isoflurane
Anesthetic; Receptor; Stereoisomer; (Rat) (Lysko, G.S. (263) 25)

Isolation-induced aggression
5-HT uptake inhibitor; 5-HT_{1A} receptor, postsynaptic; (Mouse) (Sánchez, C. (264) 241)

Isoniazid
Felbamate; Diazepam; FG 7142; Convulsion; GABAergic transmission (Serra, M. (265) 185)

Isoproterenol
Atriopeptin II; cGMP; cAMP; Smooth muscle; Aorta, rat (Jang, E.K. (250) 477)

Myocardium, guinea-pig; Development; Ca^{2+}, extracellular; Nicardipine; Ryanodine (Agata, N. (260) 47)

Cardiomyocyte, intact; β-Adrenoceptor; Desensitization; cAMP; Forskolin (Murphy, M.G. (268) 121)

Isosorbide dinitrate
FK409; Nitric oxide (NO) (Kita, Y. (257) 123)

Isradipine
Vas deferens; Denervation; Ca^{2+} channel; Dihydropyridine (Jurkiewicz, A. (256) 329)

Ethanol; L-type Ca^{2+} channel; Drug discrimination; (Rat) (Colombo, G. (265) 167)

Ivermectin
GABA (γ-aminobutyric acid); $GABA_A$ receptor; Desensitization; Hippocampal neurone (mouse) (Krůšek, J. (259) 121)

Jaw movement
Striatum, dorsal; Dopamine D_1/D_2 receptor interaction; Dopaminergic/cholinergic interaction; (Rat) (Kikuchi de Beltrán, K. (252) 99)

Clozapine; Apomorphine; Nucleus accumbens; Striatum; Muscarinic acetylcholine receptor (Kikuchi de Beltrán, K. (262) 49)

K^+
Felodipine; Stroke-prone spontaneously hypertensive rat (SHRSP); Cardiac hypertrophy; Na^+; Mg^{2+} (Mervaala, E.M.A. (255) 73)

Indapamide; 5-OH-Indapamide; Hydrochlorothiazide; Cicletanine; Ca^{2+} (Calder, J.A. (256) 185)

Brain ischemia; Histamine H_2 receptor; Ranitidine; Edema; Na^+; Ca^{2+}; (Rat) (Tósaki, Á. (264) 455)

$K_{V1.2}$
K^+ channel clone; Endothelin receptor; *Xenopus* oocyte; Protein kinase C; Ca^{2+}, intracellular (Murakoshi, H. (268) 451)

K^+ activator / opener
K^+ channel inactivator/closer; Gamma globulin, human; Mesenteric portal vein (Abrahams, Z. (252) 195)

Kainic acid
Dopamine release; Neurotoxicity; Glutamic acid; NMDA receptor; AMPA receptor (Fedele, E. (249) 71)

KB-5492
DTG (1,3-di(2-tolyl)guanidine); σ Receptor; Brain membrane; Anti-ulcer agent; (Guinea-pig) (Harada, Y. (256) 321)

Anti-ulcer agent; DTG (1,3-di(2-tolyl)guanidine); Mucosa; σ Receptor; SKF 10,047 (*N*-allyl-normetazocine); (Pig) (Harada, Y. (261) 91)

K^+ channel
Glibenclamide; Cromakalim; Y-26763; SKF 525A; Quinacrine; *Xenopus* oocyte; Local anesthetic (Sakuta, H. (252) 117)

Thaliporphine; Bay K 8644; Positive inotropic action; Ca^{2+} channel; Cardiomyocyte (Su, M.-J. (254) 141)

Glibenclamide; Ca^{2+} channel antagonist; Stereoselectivity; *Xenopus* oocyte; Y-26763 (Sakuta, H. (255) 1)

Neuropeptide Y; Vasoconstriction; BRL38227; Diazoxide; Cerebral basilar artery (Xia, Y. (255) 67)

Smooth muscle; NANC (non-adrenergic, non-cholinergic) relaxation; Penile erection; Nicotinic receptor (Alaranta, S. (259) 203)

Glibenclamide; Skeletal muscle; Lipid bilayer (Light, P.E. (259) 219)

Imidazoline; Imidazolidine; Glibenclamide; *Xenopus* oocyte; Y-26763; K^+ channel opener; Structure-activity relationship (Sakuta, H. (259) 223)

Bisoxonol; Neuroselectivity (Hunnicutt, Jr., E.J. (261) R1)

Antiarrhythmic agent, class III (Busch, A.E. (264) 33)

Glibenclamide; *Xenopus* oocyte; Histamine H_1 receptor antagonist; Promethazine; Dimethindene (Sakuta, H. (266) 99)

Idazoxan; Imidazoline; Guanidinium; Kidney (rabbit) (Corpus, V.M. (266) 197)

Atrial natriuretic factor; cGMP; HS-142-1; Glibenclamide; Y-26763; Cromakalim; *Xenopus* oocyte (Sakuta, H. (267) 281)

Glibenclamide; Cromakalim; *Xenopus* oocyte; Insulin; IGF-1; Phenylarsine oxide; Pertussis toxin; Voltage clamp, 2-electrode (Sakuta, H. (268) 375)

K^+ channel, ATP-dependent
Imidazoline; Guanidine; Imidazoline receptor; Insulin; RIN-5AH cell; Insulinoma (Olmos, G. (262) 41)

K^+ channel, ATP-sensitive
E4080; Hyperpolarization-activated inward current (I_f); Ca^{2+} current (L-type, I_{Ca}); Chronotropism; Inotropism; Heart, dog (Sawaki, S. (250) 253)

Cromakalim; Diazoxide; Morphine; Naloxone, withdrawal (Robles, L.I. (251) 113)

SL 84.0418; α_2-Adrenoceptor; Insulin release; Tolbutamide; Imidazoline; (Mouse islet) (Jonas, J.-C. (254) 27)

Galanin; Muscarinic receptor agonist; Cholinomimetic; Hypothermia; Acetylcholinesterase inhibitor (Patel, S. (255) 25)

Cromakalim; Arterial smooth muscle relaxation; K^+ channel, Ca^{2+}-activated; Spontaneously hypertensive rat (SHR) (Asano, M. (263) 121)

Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; L158809; Glybenclamide; Guanylate cyclase, soluble; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

SL 84.0418; Deriglidole; α_2-Adrenoceptor; Insulin release; Imidazoline; (Mouse islet) (Jonas, J.-C. (264) 81)

Pancreatic β-cell; Sulfonylurea receptor; Glibenclamide; MIN 6 cell (Mogami, H. (269) 293)

Coronary artery; Smooth muscle, vascular; Hypoxia; Glibenclamide; Levcromakalim (Mellemkjær, S. (270) 307)

K^+ channel antagonist
EDRF (endothelium-derived relaxing factor); K^+ channel opener; Hypoxia; Lung; Smooth muscle, vascular (Dumas, J.-P. (263) 17)

K^+ channel, Ca^{2+}-activated
Cromakalim; Arterial smooth muscle relaxation; K^+ channel, ATP-sensitive; Spontaneously hypertensive rat (SHR) (Asano, M. (263) 121)

K^+ channel clone
$K_{V1.2}$; Endothelin receptor; *Xenopus* oocyte; Protein kinase C; Ca^{2+}, intracellular (Murakoshi, H. (268) 451)

K^+ channel inactivator / closer
K^+ activator/opener; Gamma globulin, human; Mesenteric portal vein (Abrahams, Z. (252) 195)

K^+ channel opener
Pancreas (dog); Exocrine secretion; KRN2391 (*N*-cyano-*N'*-(2-nitroxyethyl)-3-pyridinecarboximidamide monomethanesulfonate); Nitro compound (Iwatsuki, K. (249) 19)

Cromakalim; Skeletal muscle fatigue; Ischemia (Trezise, D.J. (250) 109)

BK channel; Maxi-K channel; Smooth muscle cell; Patch-clamp electrophysiology; Benzimidazolone (Olesen, S.-P. (251) 53)

Imidazoline; Imidazolidine; Glibenclamide; K^+ channel; *Xenopus* oocyte; Y-26763; Structure-activity relationship (Sakuta, H. (259) 223)

EDRF (endothelium-derived relaxing factor); K^+ channel blocker; Hypoxia; Lung; Smooth muscle, vascular (Dumas, J.-P. (263) 17)

YM099; Levcromakalim; Glibenclamide; Coronary artery vessel diameter; Coronary artery blood flow; (Dog) (Uchida, W. (264) 285)

K^+ channel, slow
Calmodulin antagonist; (Regulation) (Herzer, T. (259) 335)

K^+ contracture
Bay K 8644; Dihydropyridine; Nifedipine; Skeletal muscle; Twitch response (Kitamura, N. (256) 169)

K^+ current
Ca^{2+} activated; Apamin (Dunn, P.M. (252) 189)

Smooth muscle cell; Single; Tracheal; Azelastine; Voltage-dependent Ca^{2+} current (Hazama, H. (259) 143)

Keratinocyte
Cardiocyte; NMDA receptor; [^{3}H]MK-801; mRNA (Morhenn, V.B. (268) 409)

Fumaric acid; Psoriasis; Cell proliferation; Cytotoxicity (Sebök, B. (270) 79)

KF17837 ((*E*)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine)
Adenosine A_2 receptors; Binding assays; cAMP (Nonaka, H. (267) 335)

Kidney
Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Angiotensin II (Macari, D. (249) 85)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Angiotensin II (Macari, D. (259) 27)

Uptake; Amino acid; Carrier; Glutamate transporter; Proximal tubule; In situ hybridization; (Rabbit) (Meister, B. (267) 323)

σ Receptor; Liver; Haloperidol; Pentazocine; Photoaffinity labeling (Hellewell, S.B. (268) 9)

Adrenoceptor; Testosterone; Adipocyte; Colocyte; Brain; Liver (Bouloumié, A. (269) 95)

Kidney, rabbit
Idazoxan; Imidazoline; Guanidinium; K^+ channel (Corpus, V.M. (266) 197)

Kidney, rat
Endothelin; Sarafotoxin; Prostanoid; Endothelin receptor; PD 145065 (Warner, T.D. (250) 447)

Kindling
Adenosine; Epilepsy; Glutamate binding; Glutamate release (Simonato, M. (265) 121)

Kinetensin
Neurotensin; Dopamine; Substantia nigra; Neuromedin N; Avian neurotensin; Electrophysiology (Keegan, K.D. (253) 131)

Kinin
Tachykinin; Antigen; Plasma extravasation; Airway; Neutral endopeptidase (Ricciardolo, F.L.M. (261) 127)

Knee joint inflammation
Nitric oxide (NO); Peripheral analgesia; Dipyrone; Nitric oxide synthetase inhibitor (Tonussi, C.R. (251) 173)

KRN2391 (*N*-cyano-*N'*-(2-nitroxyethyl)-3-pyridinecarboximidamide monomethanesulfonate)
Pancreas (dog); Exocrine secretion; Nitro compound; K^+ channel opener (Iwatsuki, K. (249) 19)

KT2-734 (2-phenyl-8-ethoxycycloheptimidazole)
Aorta, rat; cAMP-phosphodiesterase; cAMP; Vasorelaxation (Satake, N. (251) 1)

Kynurenic acid
Excitatory amino acid; Morphine; Conditioned place preference; Self-stimulation; (Rat) (Bespalov, A. (264) 233)

L158,809
Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

L-365,260
CCK_B receptor antagonist; Ex vivo binding; CI988; L-368,935; Brain penetration (Patel, S. (253) 237)

CCK receptor antagonist; CCK-8; BC-264; Dopamine; Nomifensine; Depression (Hernando, F. (261) 257)

CCK_B receptor; GH_3 cells; Pituitary; Functional coupling; G-protein; Ca^{2+} mobilisation (Smith, A.J. (267) 215)

L-368,935
CCK_B receptor antagonist; Ex vivo binding; L-365,260; CI988; Brain penetration (Patel, S. (253) 237)

L-658,903
Muscarinic receptor agonists; Inositol monophosphates; Phosphatidyl-inositol turnover, in vivo; Oxadiazoles (Patel, S. (267) 329)

[^{3}H]L-689,560 binding
Polyamines; Glycine; NMDA receptor; Allosteric interaction (Grimwood, S. (266) 43)

Lactate
Seizure; Glycolysis (Fornai, F. (254) R1)

Glutamate; Microdialysis; Nizofenone; Neuronal damage; Ischemia (Matsumoto, Y. (262) 157)

Lamotrigine
Dystonia; Glutamate; GABA (γ-aminobutyric acid); Na^+ channel blocker (Richter, A. (264) 345)

Langendorff
Pertussis toxin; Salbutamol; Arecoline; Aorta; β-Adrenoceptor; (Rat) (Vleeming, W. (250) 415)

Langendorff heart
Cardiac anaphylaxis; Staurosporine; Phorbol ester; (Guinea-pig) (Schäfer, S. (258) 247)

Laser-Doppler
Cocaine; Cerebral microcirculation; Stroke; (Rat) (Muir, J.K. (249) 287)

Laser-Doppler flowmetry
Aldose reductase inhibitor; Motor nerve conduction velocity; Nerve blood flow; Polyol pathway; Streptozotocin-induced diabetes (Calcutt, N.A. (251) 27)

Lavendustin A and C6
$pp60^{F527}$; Tyrosine phosphorylation; Tyrosine kinase inhibitors (Agbotounou, W.K. (269) 1)

Learned helplessness
Imipramine; α-Methyl-*para*-tyrosine; Antidepressant (De Montis, M.G. (249) 179)

Learning
Adenosine; Xanthine; Memory; Water maze; (Mouse) (Von Lubitz, D.K.J.E. (249) 271)

Adenosine; Acquisition; Passive avoidance learning; (Mouse) (Zarrindast, M.R. (256) 233)

Endosulfan; Memory; Escape response; Avoidance response; 5-HT (5-hydroxytryptamine, serotonin) (Paul, V. (270) 1)

Learning behavior
Muscarinic acetylcholine receptor agonist; YM796; Muscarinic M_1 receptor; Muscarinic M_2 receptor (Wanibuchi, F. (265) 151)

Learning, latent
Nefiracetam (DM-9384); Water finding test; Nootropic (Nabeshima, T. (255) 57)

Lectin
5-HT (5-hydroxytryptamine, serotin); Transporter; Imipramine (Helmeste, D.M. (266) 327)

Lesion
$5\text{-}HT_{1E}$/5-HT receptor; Brain; Autoradiography (Barone, P. (249) 221)

Lesopitron
$5\text{-}HT_{1A}$ receptor; Adenylate cyclase; Dorsal raphe nucleus; Nerve impulse flow; (+)-WAY 100 135; SDZ 216-525; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); S-20499; Flesinoxan (Lanfumey, L. (249) 25)

$5\text{-}HT_{1A}$ receptor; Autoradiography; Hippocampus; Dorsal raphe nucleus; Firing; Adenylate cyclase; (−)-Tertatolol (Haj-Dahmane, S. (255) 185)

Leukocyte
Trolox; Antioxidant; SIN (3-morpholino sydnonimine); Nitric oxide (NO); cGMP; Prostaglandin; Leukotriene (Riutta, A. (262) 217)

Reocclusion after thrombolysis; Recombinant tissue-type plasminogen activator (rt-PA); Thromboxane A_2; Thrombin; (Guinea pig) (Nishiyama, H. (264) 191)

Leukocyte accumulation
Myocardial ischemia-reperfusion; ICAM-1 (intercellular adhesion molecule) (Ioculano, M. (264) 143)

Leukotriene
Anaphylaxis; Paw edema; (Mouse) (Zuany-Amorim, C. (257) 211)

Endothelin; Mast cell; Histamine; Chemical mediator (Yamamura, H. (257) 235)

ZD2138; ZM230487; MK-886; Zileuton; 5-Lipoxygenase (Kusner, E.J. (257) 285)

BAY x1005; FLAP (five lipoxygenase activating protein) inhibitor; Airway; (Guinea pig) (Gardiner, P.J. (258) 95)

Angiogenesis; Chorioallantoic membrane; (Chick) (Tsopanoglou, N.E. (258) 151)

Asthma; Edema; Plasma exudation; Aging; Thromboxane A_2; Airway obstruction; Vascular permeability; Arachidonic acid (Arakawa, H. (259) 251)

Trolox; Antioxidant; SIN (3-morpholino sydnonimine); Nitric oxide (NO); cGMP; Prostaglandin; Leukocyte (Riutta, A. (262) 217)

Loratadine; Histamine H_1 receptor; Ca^{2+}, cytosolic; PAF (platelet activating factor); Macrophage; Bronchus, human (Letari, O. (266) 219)

5-Lipoxygenase-activating protein; 5-Lipoxygenase; Arachidonic acid; Fatty acid (Charleson, S. (267) 275)

Leukotriene B_4
Interleukin-1β; TNF (tumor necrosis factor); Phospholipase A_2; Phospholipase C; 5-Lipoxygenase; Protein kinase C; Phorbol 12-myristate 13-acetate; Stomach, rat; Gastric motility (Montuschi, P. (252) 253)

Airway hyperreactivity; Cigarette smoke; Bronchoalveolar lavage; IdB 1031 (Hernandez, A. (270) 301)

Leukotriene C_4
BAY u9773; Leukotriene D_4; Cysteinyl-leukotriene receptor (Tudhope, S.R. (264) 317)

Leukotriene D_4
BAY u9773; Leukotriene C_4; Cysteinyl-leukotriene receptor (Tudhope, S.R. (264) 317)

Levcromakalim
Pinacidil; Diazoxide; Glucose tolerance; Glibenclamide; Hypoglycemia (Clapham, J.C. (257) 79)

K^+ channel opener; YM099; Glibenclamide; Coronary artery vessel diameter; Coronary artery blood flow; (Dog) (Uchida, W. (264) 285)

Coronary artery; Smooth muscle, vascular; Hypoxia; ATP-sensitive K^+ channel; Glibenclamide (Mellemkjær, S. (270) 307)

Li^+
ATPase; Chronic; Soleus; Plantaris; Extensor digitorum longus (Adipudi, V. (259) 7)

LiCl
Muscarinic M_1 receptor; Muscarinic M_2 receptor; Mechanistic pathway; Forskolin; 1,9-Dideoxy-forskolin; Phorbol ester; Vas deferens; (Rabbit) (Eltze, M. (263) 31)

Xenopus laevis oocyte; Vanadate; Pertussis toxin; Ca^{2+}; Angiotensin II; Desensitization (Sakuta, H. (268) 305)

Lidocaine
Cerebral blood flow; Sympathomimetic anesthesia; Prostaglandin; Tetrodotoxin; Charybdotoxin; (Neonate) (Albuquerque, M.L.C. (249) 215)

Ligand affinity
NMDA receptor, recombinant; HEK 293 cell; Glutamate; Glycine; MK 801 (Laurie, D.J. (268) 335)

Ligand binding
α_2-Adrenoceptor subtype; [^{3}H]Rauwolscine; Signal transduction; cAMP (Jansson, C.C. (266) 165)

Recombinant expression; α_2-Adrenoceptor (Marjamäki, A. (267) 117)

Light / dark test
5-HT_4 receptor; Behavioral disinhibition; 5-Hydroxytryptophan; SDZ205-557; Tropisetron; Putative anxiolytic (Cheng, C.H.K. (255) 39)

Limbic forebrain
Amperozide; Dopamine D_2 receptor; Striatum (Svartengren, J. (254) 73)

Limbic system
Melatonin; Anterior thalamus; Receptor autoradiography; Pineal gland (Lindroos, O.F.C. (250) 161)

Elevated plus-maze test; Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Mianserin; Eltoprazine; 5-HT_{2C} receptor; Autoradiography; In situ hybridization histochemistry; Amygdala (Rocha, B. (262) 125)

Linoleic acid
Epilepsy, therapy; α-Linolenic acid; $\omega 3/\omega 6$ ratio (Yehuda, S. (254) 193)

α-Linolenic acid
Epilepsy, therapy; Linoleic acid; $\omega 3/\omega 6$ ratio (Yehuda, S. (254) 193)

Lipid bilayer
Glibenclamide; Skeletal muscle; K^+ channel (Light, P.E. (259) 219)

Lipid peroxidation
Magnetic resonance image; Cerebral infarction, focal; U74006F; Rose bengal (Umemura, K. (251) 69)

Antioxidant; β-Adrenoceptor antagonist; Oxidative stress; Endothelial cell; Cerebellar neuron (Yue, T.-L. (251) 237)

Lipoic acid
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Diethyldithiocarbamate; α-Tocopherol; Coenzyme Q; Brain (mouse) (Götz, M.E. (266) 291)

Lipopolysaccharide
FR128998; PAF (platelet activating factor); Disseminated intravascular coagulation; TNF (tumor necrosis factor) (Yokota, Y. (258) 239)

Interleukin-1β; Nitric oxide (NO); DL-Propranolol; Smooth muscle, vascular; Cell culture; Spontaneously hypertensive rat (SHR); Wistar Kyoto rat (WKY); (Rat) (De Castro, M. (261) 199)

Endotoxin; Lung; Nitric oxide (NO); Prostacyclin (Sautebin, L. (262) 193)

Neutrophil; Eosinophil; Bone marrow; Endotoxin; PAF (platelet-activating factor); PAF receptor antagonist (Bozza, P.T. (270) 143)

Septic shock; Nitric oxide (NO); Inducible nitric oxide synthase (Van den Berg, C. (270) 379)

Lipopolysaccharide, *Pantoea agglomerans*
Antinociception; Diabetes; Naltrindole; Nor-binaltorphimine; β-Funaltrexamine; Opioid receptor (Kamei, J. (251) 95)

Lipoprotein
Vasodilation; Nitric oxide (NO); Endothelium (Galle, J. (265) 111)

Liposome
Adenosine; Smooth muscle, vascular (Brailoiu, E. (250) 489)

Smooth muscle, aortic; D-*myo*-Inositol 1,4,5-trisphosphate; D-*myo*-Inositol 1,3,4,5-tetrakisphosphate (Brailoiu, E. (250) 493)

5-Lipoxygenase
Interleukin-1β; TNF (tumor necrosis factor); Leukotriene B_4; Phospholipase A_2; Phospholipase C; Protein kinase C; Phorbol 12-myristate 13-acetate; Stomach, rat; Gastric motility (Montuschi, P. (252) 253)

ZD2138; ZM230487; MK-886; Zileuton; Leukotriene (Kusner, E.J. (257) 285)

5-Lipoxygenase-activating protein; Arachidonic acid; Fatty acid; Leukotriene (Charleson, S. (267) 275)

5-Lipoxygenase-activating protein
5-Lipoxygenase; Arachidonic acid; Fatty acid; Leukotriene (Charleson, S. (267) 275)

Lipoxygenase inhibitor
Dioxygenase; Hydroperoxide isomerase; Hydroxamic acid (Brodowsky, I.D. (254) 43)

Lisuride
Idazoxan; SND 919; B-HT 920; Dopamine D_2 receptor; α_2-Adrenoceptor; Behavior (Ferrari, F. (250) 51)

Liver
σ-Receptor ligands; DTG (1,3-di(2-tolyl)guanidine); Cerebellum; (Guinea-pig) (Basile, A.S. (252) 139)

Non-insulin-dependent diabetes mellitus; *d*-Fenfluramine therapy; Insulin resistance; (Rat) (Picarel-Blanchot, F. (264) 227)

σ Receptor; Kidney; Haloperidol; Pentazocine; Photoaffinity labeling (Hellewell, S.B. (268) 9)

Adrenoceptor; Testosterone; Adipocyte; Colocyte; Kidney; Brain (Bouloumié, A. (269) 95)

Liver mitochondria
HMG-CoA (3-hydroxy-3-methylglutaryl conenzyme A) reductase inhibitor; Ischemia (Satoh, K. (270) 365)

Liver, mouse, human
Cytochrome P450; Hepatotoxicity; Cocaine (Pellinen, P. (270) 35)

Liver, rat
Bile secretion; P-glycoprotein; Fluorescent dye; Cyclosporin A (Thalhammer, T. (270) 213)

LLC-PK$_1$ cell
ANP (atrial natriuretic peptide); Natriuretic peptide, C-type; Guanylate cyclase (Hashimoto, Y. (268) 443)

[^{3}H]L-694,247 (2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1*H*-indole-3-yl]ethylamine)
Caudate nucleus, pig; 5-HT$_{1D\alpha}$/5-HT$_{1D\beta}$ receptor (Heald, A. (264) 213)

Local anesthetic
K^+ channel; Glibenclamide; Cromakalim; Y-26763; SKF 525A; Quinacrine; *Xenopus* oocyte (Sakuta, H. (252) 117)

Locomotion
Reserpine; Glutamate receptor antagonist; Dopamine D_1 receptor agonist; Dopamine D_2 receptor agonist (Starr, M.S. (250) 239)

NMDA receptor antagonist; MK-801 ((+)-5-methyl-10,11-dihydro-5*H*-dibenzo[*a*,*d*]cyclohepten-5,10-imine); 6-Hydroxydopamine; Haloperidol; Nucleus accumbens; (Rat) (Ouagazzal, A.-m. (251) 229)

Locomotor activity
Antidepressant (chronic treatment); Dopamine uptake site; Apomorphine; Dopamine receptor (presynaptic) (Allison, K. (249) 125)

[D-Trp^{11}]Neurotensin; Dopamine; Nucleus accumbens (Nouel, D. (254) 263)

Histamine H_3 receptor; (R)-α-Methylhistamine; Thioperamide; (Mouse); (Stimulant) (Clapham, J. (259) 107)

Chronic variable stress; Morphine; Antidepressant (Molina, V.A. (260) 57)

CGS 10746B; Conditioned place preference/aversion; Dopamine; (Rat) (Schechter, M.D. (260) 133)

Dopamine synthesis; Neostriatum; Dopamine receptor; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); (Rat) (Ahlenius, S. (260) 177)

Ischemia; Nitric oxide (NO) synthase; N^G-Nitro-L-arginine; Histology; (Mongolian gerbil) (Caldwell, M. (260) 191)

Dopamine D_3 receptor; Dopamine release; Mitogenesis (Svensson, K. (263) 235)

Methylphenidate; *dl-threo*-Methylphenidate; Dopamine transporter; Norepinephrine transporter; Microdialysis (Pan, D. (264) 177)

Locus coeruleus
Morphine withdrawal; Morphine dependence; Adenylyl cyclase; Amygdala; Thalamus (Matsuoka, I. (268) 215)

Long-term potentiation
Metabotropic glutamate receptor; Dentate gyrus; 2-Amino-3-phosphonopropionate (AP3); (Anesthetized rat) (Abe, K. (251) 295)

Cannabinoid; Hippocampus (Collins, D.R. (259) R7)

Redox; NMDA receptor (Gozlan, H. (262) R3)

Loop of Henle
Aminoglycoside; Tubular transport; Micropuncture, in vivo; Microperfusion, in vitro (Kidwell, D.T. (270) 97)

Loperamide
Morphine; Anti-emetic; 5-HT (5-hydroxytryptamine, serotonin); Nicotine; Vomiting; (*Suncus murinus*) (Selve, N. (256) 287)

Loratadine
Histamine H_1 receptor; Ca^{2+}, cytosolic; PAF (platelet activating factor); Macrophage; Leukotriene; Bronchus, human (Letari, O. (266) 219)

Loreclezole
Anxiolytic; Flumazenil; CGS 8216; (Rat) (Dawson, G.R. (252) 325)

Losartan
Angiotensin receptor subtype; PD 123319; Footshock (Cierco, M. (251) 103)

Renal artery, rabbit; Angiotensin II; PD123177 (Zhang, J. (252) 337)

Angiotensin II receptor subtype; Antihypertensive agent; Renin-angiotensin system (Wong, P.C. (260) 261)

Losartan (DuP 753)
Angiotensin II; Angiotensin III; Spontaneously hypertensive rat (SHR); Telemetry (Radhakrishnan, R. (259) 87)

Lower lip retraction
Sexual behavior, male rat; Flat body posture; Forepaw treading; Behavior syndrome; 5-HT$_{1A}$ receptor agonist; 5-HT$_2$ receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) (Andersson, G. (255) 131)

Dorsal raphe nucleus; Median raphe nucleus; 5-HT$_{1A}$ receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-(di-*n*-propylamino)tetralin); (Rat) (Berendsen, H.H.G. (263) 315)

Low molecular weight heparin
Thrombin; Platelet; Hirulog; Heparin; PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone); DuP-714 ester (acetyl-D-phenylalanine-propyl-boroarginine); (Rabbit) (Liu, J.T. (264) 183)

Loxiglumide
CCK receptor antagonist; MK-329; Bile flow; Bilirubin secretion (Watanabe, N. (264) 331)

Lung
Endotoxin; Lipopolysaccharide; Nitric oxide (NO); Prostacyclin (Sautebin, L. (262) 193)

EDRF (endothelium-derived relaxing factor); K^+ channel opener; K^+ channel blocker; Hypoxia; Smooth muscle, vascular (Dumas, J.-P. (263) 17)

Nitric oxide (NO); Ca^{2+} (Persson, M.G. (264) 13)

Opioid; Dyspnoea; Morphine; Naloxone; NANC (Non-adrenergic-non-cholinergic) (Cabot, P.J. (268) 247)

Formoterol; β_2-Adrenoceptor; Autoradiography (Mak, J.C.W. (269) 35)

Lung cancer
Growth factor; Polyanionic drug (Favoni, R.E. (264) 199)

Lung, guinea pig
Formoterol; Salmeterol; Terbutaline, in vitro (Jeppsson, A.-B. (257) 137)

Lung, human
Bombesin; GRP (gastrin-releasing peptide); Bombesin binding site; GRP-preferring bombesin receptor (Lach, E. (265) 117)

Lung (rat)
Thermodynamics; β-Adrenoceptor agonist interaction (Fraeyman, N. (267) 63)

Lung strip, guinea pig
Cholinergic contraction; Muscarinic M_2 receptor; Trachea, guinea pig; Smooth muscle, human, airway (Roffel, A.F. (250) 267)

Lung vascular injury
S-1452 (calcium (1*R*,2*S*,3*S*,4*S*)-(5*Z*)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate); Thromboxane A_2; Bronchial hyperresponsiveness (Arimura, A. (260) 201)

LY83583
Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; L158809; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

LY 171555
Acetylcholine release; Dopamine D_1 receptor; Dopamine D_2 receptor; Reserpine; α-Methyl-tyrosine; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor blocker; SCH 23390 (Imperato, A. (251) 271)

LY171883
DS-4574; Mast cell stabilizer; Peptidoleukotriene; Mucosal mast cell; Gastric mucosal injury (Tabuchi, Y. (250) 197)

Lymph node
Receptor autoradiography; α_2-Adrenoceptor; Spleen; [^{3}H]Bromoxidine; Immune system (Fernández-López, A. (252) 333)

Receptor autoradiography; β-Adrenoceptor; Spleen; [^{125}I]Cyanopindolol; Immune system; Lymphoid organ (Fernández-López, A. (262) 283)

Lymphocyte
Cd^{2+}; Metallothionein; Heat shock protein (Pellegrini, O. (270) 221)

Lymphoid organ
Receptor autoradiography; β-Adrenoceptor; Lymph node; Spleen; [^{125}I]Cyanopindolol; Immune system (Fernández-López, A. (262) 283)

Lymphoid tissue
Neuroimmunomodulation; Parasympathetic nervous system; Cyclosporine; Cholinergic innervation; Acetylcholine, synthesis and release; Choline uptake; Sympathetic nervous system; Superior cervical ganglion (Esquifino, A.I. (254) 1)

LY-83583 (6-(phenylamino)-5,8-quinolinedione)
Acetylcholine; 8-Bromo-cGMP; EDRF (endothelium-derived relaxing factor); Aortic ring, isolated, rat; Atrium, right, isolated, rat; Norepinephrine; *N*-Nitro-L-arginine; SIN-1 (3-morpholino-sydnonimine); (Spontaneous rate) (Kennedy, R.H. (255) 149)

Lys-D-Pro
Lys-D-Pro-Thr; Interleukin-1β-(193–195); Tripeptide; Naloxone; Antinociception; Formalin test (Oluyomi, A.O. (258) 131)

Lys-D-Pro-Thr
Lys-D-Pro; Interleukin-1β-(193–195); Tripeptide; Naloxone; Antinociception; Formalin test (Oluyomi, A.O. (258) 131)

Macronutrient preference
5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Ageing; Feeding; Protein intake (Lacour, F. (255) 249)

Macrophage
β-Adrenoceptor; Salmeterol; cAMP; Thromboxane A_2 (Baker, A.J. (264) 301)

Granuloma; Nitric oxide (NO); L-Arginine; N^G-Nitro-L-arginine methyl ester (Iuvone, T. (265) 89)

Loratadine; Histamine H_1 receptor; Ca^{2+}, cytosolic; PAF (platelet activating factor); Leukotriene; Bronchus, human (Letari, O. (266) 219)

Temperature; Nitric oxide (NO) (Bernard, C. (270) 115)

Magnetic resonance imaging
Cerebral infarction, focal; U74006F; Lipid peroxidation; Rose bengal (Umemura, K. (251) 69)

NMR tomography; Brain edema; Stroke; 5-HT receptor antagonist; Ca^{2+} channel blocker (Elger, B. (254) 65)

Manganese
Nitric oxide (NO); Superoxide dismutase; cGMP; Blood pressure (Kasten, T.P. (253) 35)

Manidipine
Heart cell; Patch-clamp analysis; Ca^{2+} channel (L-type); Ca^{2+} channel antagonist (Tohse, N. (249) 231)

Marihuana
Cannabis; Cannabinoid (Mailleux, P. (267) R1)

Mast cell
Norathyriol; Passive cutaneous anaphylaxis; Neurogenic inflammation; Vascular permeability; Compound 48/80; (Mouse) (Wang, J.-P. (251) 35)

Formoterol; Salbutamol; Salmeterol; Smooth muscle, airway; (Duration) (Nials, A.T. (251) 127)

Endothelin; Histamine; Leukotriene; Chemical mediator (Yamamura, H. (257) 235)

Antihistamine; Calcimycin; EDCF (endothelium-derived contracting factor); EDRF (endothelium-derived relaxing factor); Hemoglobin; Iproniazid; Methylene blue; N^G-Methyl-L-arginine (Gruetter, C.A. (257) 275)

Neuropeptide Y; Neuropeptide Y analog; Pertussis toxin; Benzalkonium chloride G-protein; Histamine release; (Rat) (Grundemar, L. (258) 163)

Cytology; Drug effect; Anti-allergic drug (Konno, S.-i. (259) 15)

Endothelin-1; Histamine; Compound 48/80; Islet-activating protein; Endothelin receptor (Yamamura, H. (265) 9)

Pertussis toxin; Cholera toxin; Okadaic acid; Na^+-H^+ antiport; Sodium propionate (Alfonso, A. (267) 289)

Mast cell degranulation
Antiflammin; Phospholipase A_2; Inflammation; Anti-inflammatory drug (Lloret, S. (264) 379)

Mast cell stabilizer
DS-4574; Peptidoleukotriene; LY171883; Mucosal mast cell; Gastric mucosal injury (Tabuchi, Y. (250) 197)

DS-4574; Gastric acid secretion; Histamine leakage; Pentagastrin; Carbachol (Tabuchi, Y. (255) 229)

Mastoparan
GTP-binding protein; Supraspinal analgesia; Opioid (Sánchez-Blázquez, P. (258) 159)

Mastoparan B
Cardiovascular effect; Structural requirement; Hornet (*Vespa basalis*) venom (Ho, C.-L. (259) 259)

Maternal aggression
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); TFMPP (1-(3-trifluoromethyl-phenyl)piperazine hydrochloride); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Intracerebroventricular; 5-HT receptor agonist (De Almeida, R.M.M. (264) 445)

Maxi-K channel
BK channel; Smooth muscle cell; Patch-clamp electrophysiology; Benzimidazolone; K^+ channel opener (Olesen, S.-P. (251) 53)

[^{3}H]Mazindol
Dopamine uptake site; Dopamine turnover; L-DOPA (L-3,4-dihydroxyphenylalanine); α-Methyl-*p*-tyrosine; GBR 12909 (Ikawa, K. (250) 261)

Dopamine uptake site; Dopamine turnover; L-DOPA (L-3,4-dihydroxyphenylalanine); α-Methyl-*p*-tyrosine; GBR 12909 (Ikawa, K. (252) 123)

m4 binding site
Muscarinic receptor; Smooth muscle, uterus; Muscarinic M_2 receptor (Doods, H.N. (250) 223)

McN-A-343
Muscarinic receptor subtype; Smooth muscle, ileal; Pirenzepine analog (Barocelli, E. (254) 151)

MCPG (α-methyl-4-carboxyphenylglycine)
Excitatory amino acid receptor; Presynaptic; cAMP; Glutamate; Receptor; Metabotropic; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

MDL 72,222
5-HT_3 receptor; *m*-Chlorophenylbiguanide; Sleep; Wakefulness (Ponzoni, A. (249) 259)

MDL 100,907
Antipsychotic; DOI ((2,5-dimethoxy-4-iodohenyl)-2-aminopropan); Drug discrimination; 5-HT_{2A} receptor (Schreiber, R. (264) 99)

MDL 101,562
Bombesin; Gastrin-releasing peptide; Dopaminergic neuron (Manzanares, J. (257) 199)

MDMA (3,4-methylenedioxymethamphetamine)
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-MeODMT (5-methoxy-*N*,*N*-dimethyltryptamine); Microdialysis; Neurotoxicity; 5-HT_2 receptor (Gudelsky, G.A. (264) 325)

Mecamylamine
Glucose; Scopolamine; Spontaneous alternation; Memory (Ragozzino, M.E. (256) 31)

Mechanistic pathway
Muscarinic M_1 receptor; Muscarinic M_2 receptor; LiCl; Forskolin; 1,9-Dideoxy-forskolin; Phorbol ester; Vas deferens; (Rabbit) (Eltze, M. (263) 31)

Medial septal area
Acetylcholine; Hippocampus; Nicotinic acetylcholine receptor; Spatial memory (Decker, M.W. (261) 217)

Medial septum
5-HT_{1A} receptor; 5-HT_2 receptor; Muscarinic acetylcholine receptor; Passive avoidance (Riekkinen Jr., P. (262) 77)

Medial vestibular nucleus, rat
Opiate; Excitatory response; Postsynaptic action, direct (Lin, Y. (262) 99)

Median raphe nucleus
Lower lip retraction; Dorsal raphe nucleus; 5-HT_{1A} receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-(di-*n*-propylamino)tetralin); (Rat) (Berendsen, H.H.G. (263) 315)

Dorsal hippocampus; 5-HT_{1A} receptor; Social interaction; Grooming; (Rat) (Andrews, N. (264) 259)

Medulla oblongata
Cholinergic neuron; Spinal cord; Blood pressure; Heart rate (Feldman, D.S. (250) 483)

Galanin; Galanin fragment; Receptor subtype; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Blood pressure; Heart rate; (Intracisternal injection) (Narváez, J.A. (257) 257)

Megakaryocyte, rat
FCCP (carbonyl cyanide-*p*-trifluoromethoxyphenyl-hydrazone); Ca^{2+} oscillation; Patch-clamp (Uneyama, C. (268) 455)

Megestrol acetate
Neuropeptide Y; Appetite; Cancer anorexia; Cachexia; Hypothalamus (McCarthy, H.D. (265) 99)

Melanocortin receptor antagonist
Grooming behavior; ACTH (adrenocorticotrophic hormone) derivative; α-MSH (α-melanocyte-stimulating hormone) (Adan, R.A.H. (269) 331)

Melanophore
Melatonin; 2-Iodomelatonin binding; Pigment aggregation; Melatonin receptor; Chroman (Sugden, D. (254) 271)

Melatonin
Anterior thalamus; Limbic system; Receptor autoradiography; Pineal gland (Lindroos, O.F.C. (250) 161)

2-Iodomelatonin binding; Melanophore; Pigment aggregation; Melatonin receptor; Chroman (Sugden, D. (254) 271)

Sympathetic neurotransmission; Vas deferens; Nicotinic receptor; Protein synthesis (Carneiro, R.C.G. (257) 73)

Melatonin receptor
Melatonin; 2-Iodomelatonin binding; Melanophore; Pigment aggregation; Chroman (Sugden, D. (254) 271)

Memantine
Thermal hyperalgesia; Excitatory amino acid; Glutamate receptor; Inflammation; Carrageenan (Eisenberg, E. (255) 123)

Microdialysis; Dopamine release; Pharmacokinetics; Striatum; Prefrontal cortex (Spanagel, R. (262) 21)

Membrane fluidity
Tetramethylpyrazine; Phospholipid phase transition; Differential scanning calorimetry; Electron spin resonance; Fluorescence polarization; Drug–lipid interactions (Nie, S.-Q. (266) 11)

Membrane outgrowth
Staurosporine; Myocyte, *Xenopus*; Morphological change; Developmental change (Fu, W.-M. (270) 321)

Memory
Adenosine; Xanthine; Learning; Water maze; (Mouse) (Von Lubitz, D.K.J.E. (249) 271)

Glucose; Mecamylamine; Scopolamine; Spontaneous alternation (Ragozzino, M.E. (256) 31)

Glutamate receptor; Polyamine; Ion channel (Shimada, A. (263) 293)

Endosulfan; Learning; Escape response; Avoidance response; 5-HT (5-hydroxytryptamine, serotonin) (Paul, V. (270) 1)

Memory enhancement
NMDA receptor; Glycine partial agonist; Administration, acute and chronic (Quartermain, D. (257) 7)

5-MeO-DMT (5-methoxy-*N*,*N*-dimethyltryptamine)
5-HT receptor; 5-HT receptor agonist; α-Adrenoceptor antagonist; Substance P; Spinal antinociception; GABA (γ-aminobutyric acid) (Alhaider, A.A. (249) 151)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); MDMA (3,4-methylenedioxymethamphetamine); Microdialysis; Neurotoxicity; 5-HT_2 receptor (Gudelsky, G.A. (264) 325)

Mepyramine
Histamine; 5-HT (5-hydroxytryptamine, serotonin); Zolantidine; Thioperamide; Metoprine (Fleckenstein, A.E. (254) 35)

Allergic reaction, early and late; Bronchial hyperreactivity; Airway inflammation; Histamine; (Allergic guinea-pig) (Santing, R.E. (254) 49)

[^{3}H]Mepyramine
DDT_1MF-2 cell; Histamine H_1 receptor; Smooth muscle cell (Dickenson, J.M. (268) 257)

1,4-Dithiothreitol; Histamine; Inositol phosphate; Cerebral cortex, rat; HeLa cell (Young, K.W. (269) 283)

Mesangial cell
Nitric oxide (NO); Interleukin 1β; Cyclosporin; Immunosuppressive drug (Mühl, H. (249) 95)

Cyclosporin A; Extracellular matrix; Glomerulosclerosis (Ghiggeri, G.M. (270) 195)

Mesencephalic cell
Receptor antagonist; Neurotensin; Dopamine release; Striatum (Brouard, A. (253) 289)

Mesenteric arterial bed
PAF (platelet-activating factor); Acetylcholine; Spontaneously hypertensive rat (SHR); Desensitization (Kamata, K. (259) 321)

Mesenteric portal vein
K^+ activator/opener; K^+ channel inactivator/closer; Gamma globulin, human (Abrahams, Z. (252) 195)

Mesenteric resistance vessel
Ryanodine; Cyclopiazonic acid; Caffeine; Ca^{2+} release; Ca^{2+} influx; (Rat) (Naganobu, K. (251) 307)

Pentoxifylline; Aminophylline; Endothelium; Nitric oxide (NO); Smooth muscle, vascular; Methylxanthine derivative (Hansen, P.R. (261) 105)

Mesenteric vascular bed
Nitric oxide synthase inhibitor; Endothelium-dependent response; Nitrovasodilator; Vascular tone; Atropine; (Cat) (Santiago, J.A. (254) 207)

Mesolimbic dopamine system
Tachykinin NK_1 receptor; (Guinea-pig) (Rupniak, N.M.J. (262) 171)

Mesolimbic system
Morphine; Drug discrimination; Neuroanatomical mapping; (Rat) (Shoaib, M. (252) 69)

Messenger RNA expression
Baicalein; Esculetin; Antiproliferative effect; CEM cell; Transduction signal (Huang, H.-C. (268) 73)

Mesulergine
5-HT_{2C} receptor, human; G protein-coupling; (Gene) (Stam, N.J. (269) 339)

[^{3}H]Mesulergine
5-HT_{1C} receptor; Clomipramine; Imipramine; Clorgyline; (Wistar rat) (Hulihan-Giblin, B.A. (263) 213)

Metabolism
Catechol *O*-methyltransferase inhibition; 6-Hydroxydopamine; Circling behavior; L-DOPA (L-3,4-dihydroxyphenylalanine); Dopamine (Törnwall, M. (250) 77)

Metabolite
Butylated hydroxyanisole; *N*-Acetylcysteine; Cytotoxicity; Hepatocyte, isolated, rat (Nakagawa, Y. (270) 341)

Metabotropic
MCPG (α-methyl-4-carboxyphenylglycine); Excitatory amino acid receptor; Presynaptic; cAMP; Glutamate; Receptor; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

Metabotropic glutamate receptor
Long-term potentiation; Dentate gyrus; 2-Amino-3-phosphonopropionate (AP3); (Anesthetized rat) (Abe, K. (251) 295)

DCG-IV ((2*S*,1′*R*,2′*R*,3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine); Excitotoxicity; Cortical neuron (Bruno, V. (256) 109)

Halothane anesthesia; Glutamate receptor agonist; L-CCG-I ((2*S*,1′*S*,2′*S*)-2-(carboxycyclopropyl)glycine); DCG-IV ((2*S*,1′*R*,2′*R*,3′*R*)-2-(2,3-dicarboxycyclopropyl)glycine); Adenylyl cyclase (Miyamoto, M. (260) 99)

Phenylglycine derivative; (1*S*,3*R*)-ACPD (1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate; Phosphoinositide hydrolysis; Cyclic AMP (Thomsen, C. (267) 77)

Spinal cord, isolated; cAMP; Phosphoinositide hydrolysis; ACPD((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); L-CCG-I((2*S*,1′*S*,2′*S*)-CCG); Cortical cell culture (Ishida, M. (268) 267)

Carboxyphenylglycine; Adenosine 3′,5′-cyclic phosphate (Cavanni, P. (269) 9)

Receptor desensitization; Cyclothiazide (Sharp, R.L. (269) R5)

L-2-Amino-3-phosphonopropionate; Neurotoxicity; Cerebellar neurons; NMDA receptor (Novelli, A. (270) 361)

Metal ion
Ryanodine; Muscle contracture (Liu, S.-H. (251) 61)

Dopamine carrier (neuronal); [^{3}H]GBR 12783 (in vitro binding); Dopamine uptake; Striatum; (Rat) (Bonnet, J.-J. (266) 87)

Metalloporphyrins
Cerebellum; Microdialysis; Nitric oxide synthase; Guanylyl cyclase; cGMP (Luo, D. (267) 263)

Metallothionein
Cd^{2+}; Heat shock protein; Lymphocyte (Pellegrini, O. (270) 221)

Cd^{2+}; Nephrotoxicity; Hepatotoxicity; (Rat) (Sudo, J.-i. (270) 229)

Methamphetamine
CP-96345; Dynorphin; Tachykinin NK_1 receptor; Neurotensin; Substance P (Gygi, S.P. (250) 177)

Amphetamine; 5-HT (5-hydroxytryptamine, serotonin); Nimodipine; Tryptophan hydroxylase; (Metabolism) (Elkins, K.W. (250) 395)

Amphetamine, protection; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Dopaminergic neurotoxicity; MPP^+ (1-methyl-4-phenylpyridinium), uptake inhibition (Sziráki, I. (251) 311)

Repeated administration; Ambulation; Sensitization; Haloperidol (Kuribara, H. (256) 295)

Dopamine; Microdialysis; Nucleus accumbens; DAGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); Dynorphin (Yokoo, H. (256) 335)

N-Ethylmaleimide; Dopamine release; Striatum, rat; Forskolin (Yamada, S. (257) 243)

***cis*-Methanoglutamate**
DL-(Tetrazol-5-yl)glycine; NMDA (*N*-methyl-D-aspartate); Excitotoxicity; Neurodegeneration (Schoepp, D.D. (270) 67)

Methoctramine
Tripitramine; Muscarinic receptor subtype; Binding affinity; CHO-K1 cell (Maggio, R. (268) 459)

Methoxamine
ATP release; α_1-Adrenoceptor; Pulmonary artery, rabbit (Takeuchi, K. (254) 287)

3-Methoxytyramine
Dopamine turnover; DOPAC (3,4-dihydroxyphenylacetic acid) (Karoum, F. (254) 127)

N^G-Methyl-L-arginine
Antihistamine; Calcimycin; EDCF (endothelium-derived contracting factor); EDRF (endothelium-derived relaxing factor); Hemoglobin; Iproniazid; Mast cell; Methylene blue (Gruetter, C.A. (257) 275)

Methylation
S-Adenosyl-L-methionine; Adenosine; Brain stem; Vagus motoneuron (Travagli, R.A. (264) 385)

[^{3}H]Methylcarbamylcholine
[^{3}H]Cytisine; [^{3}H]Nicotine; Nicotinic acetylcholine receptor, neuronal; (Rat) (Anderson, D.J. (253) 261)

(+)-α-Methyl-4-carboxyphenylglycine
Glutamate; Phosphoinositide; cAMP; *trans*-ACPD (1-aminocyclopentane-*trans*-1,3-dicarboxylic acid); L-*trans*-2,4-PDC (L-*trans*-2,4-pyrrolidine dicarboxylic acid); Glutamate transport (Miller, S. (269) 235)

α,β-Methylene ATP
Pyridoxal-5-phosphate; Vagus nerve, rat; Vas deferens, rat; P_2 purinoceptor (Trezise, D.J. (259) 295)

Ileal longitudinal muscle, guinea pig; P_{2X} purinoceptor; P_{2Y} purinoceptor; 2-Methylthio ATP; β,γ-Methylene ATP (Kennedy, I. (261) 273)

β,γ-Methylene ATP
Ileal longitudinal muscle, guinea pig; P_{2X} purinoceptor; P_{2Y} purinoceptor; α,β-Methylene ATP; 2-Methylthio ATP (Kennedy, I. (261) 273)

Methylene blue
Antihistamine; Calcimycin; EDCF (endothelium-derived contracting factor); EDRF (endothelium-derived relaxing factor); Hemoglobin; Iproniazid; Mast cell; N^G-Methyl-L-arginine (Gruetter, C.A. (257) 275)

PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide); PTI (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl); Carboxy-PTI; Radical compound; Coronary vasodilator (Tsunoda, R. (262) 55)

Methylguanidine
Aminoguanidine; *N*,*N*′-Diaminoguanidine; 1,1-Dimethylguanidine; Nitric oxide (NO); Nitric oxide synthase; N^G-Monomethyl-L-arginine; (L-NMA) (Hasan, K. (249) 101)

(*R*)-α-Methylhistamine
Histamine H_3 receptor; Histamine; Thioperamide; Depressor response; Pressor response; Tachycardia; (Prejunctional) (Hegde, S.S. (251) 43)

Sympathetic-cholinergic response; Histamine receptor; Nerve stimulation, pre- and postganglionic; Presynaptic inhibition; Sudomotor system (Koss, M.C. (257) 109)

Histamine H_3 receptor; Locomotor activity; Thioperamide; (Mouse); (Stimulant) (Clapham, J. (259) 107)

Histamine H_3 receptor; Species difference; Presynaptic inhibition; Thioperamide (McLeod, R.L. (259) 211)

[^{3}H]N^{α}-Methylhistamine binding
Histamine H_3 receptor; AtT-20 cell; ACTH (Adrenocorticotropic hormone) release; Steroid effect (West, Jr., R.E. (267) 343)

2-Methyl-5-HT (2-methyl-5-hydroxytryptamine)
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor; 5-HT_{1C} receptor; (Pithed rat) (Chaouche-Teyara, K. (250) 67)

5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Methylphenidate
dl-threo-Methylphenidate; Dopamine transporter; Norepinephrine transporter; Microdialysis; Locomotor activity (Pan, D. (264) 177)

***dl-threo*-Methylphenidate**
Methylphenidate; Dopamine transporter; Norepinephrine transporter; Microdialysis; Locomotor activity (Pan, D. (264) 177)

1-Methyl-4-phenylpyridinium
Striatum; Selenium; Vitamin E; Monoamine; (Rat) (Vizuete, M.L. (270) 183)

2-Methylthio ATP
Ileal longitudinal muscle, guinea pig; P_{2X} purinoceptor; P_{2Y} purinoceptor; α,β-Methylene ATP; β,γ-Methylene ATP (Kennedy, I. (261) 273)

α-Methyl-*p*-tyrosine
Imipramine; Learned helplessness; Antidepressant (De Montis, M.G. (249) 179)

[^{3}H]Mazindol; Dopamine uptake site; Dopamine turnover; L-DOPA (L-3,4-dihydroxyphenylalanine); GBR 12909 (Ikawa, K. (250) 261)

Acetylcholine release; Dopamine D_1 receptor; Dopamine D_2 receptor; Reserpine; LY 171555; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor blocker; SCH 23390 (Imperato, A. (251) 271)

[^{3}H]Mazindol; Dopamine uptake site; Dopamine turnover; L-DOPA (L-3,4-dihydroxyphenylalanine); GBR 12909 (Ikawa, K. (252) 123)

Methylxanthine
Intraocular pressure; Dopamine receptor; Phosphodiesterase inhibitor; Pentoxifylline; Trifluperidol; Thiothixene; Fluphenazine; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine); Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

Methylxanthine derivative
Pentoxifylline; Mesenteric resistance vessel; Aminophylline; Endothelium; Nitric oxide (NO); Smooth muscle, vascular (Hansen, P.R. (261) 105)

Methysergide
5-HT (5-hydroxytryptamine, serotonin); Adenosine diphosphate; Platelet aggregation; Gastric mucosal blood flow; Blood pressure; Blood gas (Cho, C.H. (256) 9)

Metoprine
Histamine; 5-HT (5-hydroxytryptamine, serotonin); Mepyramine; Zolantidine; Thioperamide (Fleckenstein, A.E. (254) 35)

Metoprolol
Antihypertensive treatment; GABA (γ-aminobutyric acid); GABA synthesis and turnover; $GABA_A$ receptor binding (Remiszewska, M. (250) 355)

Mexiletine
Dofetilide; Conduction; Action potential duration; QT duration; (Guinea-pig); (In vivo) (Todt, H. (265) 43)

Mg^{2+}
Felodipine; Stroke-prone spontaneously hypertensive rat (SHRSP); Cardiac hypertrophy; Na^+; K^+ (Mervaala, E.M.A. (255) 73)

Endothelium; Aorta; Mineralocorticoid hypertension; (Rat) (Laurant, P. (258) 167)

Mianserin
Elevated plus-maze test; Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Eltoprazine; 5-HT_{2C} receptor; Autoradiography; In situ hybridization histochemistry; Limbic system; Amygdala (Rocha, B. (262) 125)

Microcirculation
Endothelial cell; Endothelin; Permeability; Contraction; Ca^{2+} (Kurose, I. (250) 85)

Naftidrofuryl; 5-HT (5-hydroxytryptamine, serotonin); Cremaster muscle; Arteriole; Vasoconstriction; 5-HT_2 receptor antagonist (Koch, L.G. (254) 249)

Microvascular permeability; Gastroprotection; Octreotide (Kusterer, K. (259) 265)

BQ-123; Ro 47-0203; Bosentan; Endothelin ET_A receptor; Endothelin ET_B receptor; Endothelin; Skin blood flow, rat (Lawrence, E. (260) 103)

Microdialysis
Dopamine, release; (+)-AJ76; (+)-UH232; (Rat) (Waters, N. (251) 181)

Fluoxetine; 5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Anticonvulsant effect; Genetically epilepsy-prone rat (Yan, Q.-S. (252) 105)

Acetylcholine; Opioid receptor; Adrenal medulla (Hirokami, M. (253) 9)

Monoamine oxidase type B; (−)-Deprenyl; Dopamine; 2-Phenylethylamine; (Guinea pig) (Juorio, A.V. (254) 213)

NMDA (*N*-methyl-D-aspartate); SCH 23390; Raclopride; Striatum; (Neurotransmitter release) (Morari, M. (256) 23)

Dopamine; Methamphetamine; Nucleus accumbens; DAGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); Dynorphin (Yokoo, H. (256) 335)

Acetylcholine; Frontal cortex; Hippocampus; Dopamine D_1 receptor (Acquas, E. (260) 85)

5-HT (5-hydroxytryptamine, serotonin); Citalopram; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} receptor desensitization (Invernizzi, R. (260) 243)

Frontal cortex; Hippocampus; Idazoxan, chronic; α_2-Adrenoceptor, presynaptic (Thomas, D.N. (261) 53)

α_1-Adrenoceptor; 5-HT (5-hydroxytryptamine, serotonin) (Rouquier, L. (261) 59)

Dopamine release; Dopamine metabolism; Dopamine D_2 receptor; Dopamine D_3 receptor; Neuroleptic (Gainetdinov, R.R. (261) 327)

Dopamine release; Memantine; Pharmacokinetics; Striatum; Prefrontal cortex (Spanagel, R. (262) 21)

Glutamate; Lactate; Nizofenone; Neuronal damage; Ischemia (Matsumoto, Y. (262) 157)

Cerebral ischemia; Glutamate; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Excitotoxin (Gaspary, H.L. (262) 197)

Haloperidol; Clozapine; Striatum; Glutamate; GABA (γ-aminobutyric acid) (See, R.E. (263) 269)

Food intake; *d*-Fenfluramine; *d*-Norfenfluramine; *p*-Chlorophenylalanine (Oluyomi, A.O. (264) 111)

κ-Opioid receptor agonist; Dopamine; Dorsal caudate; BRL 53001 (Zaratin, P. (264) 151)

Methylphenidate; *dl-threo*-Methylphenidate; Dopamine transporter; Norepinephrine transporter; Locomotor activity (Pan, D. (264) 177)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); MDMA (3,4-methylenedioxymethamphetamine); 5-MeODMT (5-methoxy-*N*,*N*-dimethyltryptamine); Neurotoxicity; 5-HT_2 receptor (Gudelsky, G.A. (264) 325)

Dorsal raphe nucleus; G-protein; 5-HT_{1A} receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Intracerebral; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (Romero, L. (265) 103)

Dexfenfluramine; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} autoreceptor; 5-HT (5-hydroxytryptamine, serotonin) release; Frontal cortex (Gardier, A.M. (265) 107)

Dopamine D_3 receptor; Accumbens (Rivet, J.-M. (265) 175)

Cerebellum; Metalloporphyrins; Nitric oxide synthase; Guanylyl cyclase; cGMP (Luo, D. (267) 263)

5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Ethanol; Frontal cortex (Portas, C.M. (270) 123)

Microdialysis, brain
Adenosine; Cerebral cortex; Tetrodotoxin; NMDA receptor; Muscarinic receptor (Pazzagli, M. (254) 277)

Microdialysis, intracerebral
5-HT (5-hydroxytryptamine, serotonin) release; Monoamine oxidase inhibitor; Antidepressant (Ferrer, A. (263) 227)

Microdialysis, in vivo
Catecholamine synthesis rate; Dopamine; Ethanol; Nicotinic acetylcholine receptor; (Rat) (Blomqvist, O. (249) 207)

Selective serotonin reuptake inhibitor; 5-HT_{1A} autoreceptor; Antidepressant; 5-HT (5-hydroxytryptamine, serotonin) release; Central nervous system (Hjorth, S. (260) 251)

Microperfusion, in vitro
Aminoglycoside; Loop of Henle; Tubular transport; Micropuncture, in vivo (Kidwell, D.T. (270) 97)

Micropuncture, in vivo
Aminoglycoside; Loop of Henle; Tubular transport; Microperfusion, in vitro (Kidwell, D.T. (270) 97)

Microvascular permeability
Bradykinin B_2 receptor; Bradykinin; Bronchoconstriction; HOE 140; Vagal stimulation (Sakamoto, T. (251) 137)

Gastroprotection; Microcirculation; Octreotide (Kusterer, K. (259) 265)

Micturition
Tachykinin receptor antagonist; Tachykinin receptor; Spinal cord (Lecci, A. (259) 129)

Midazolam
Receptor kinetics; Benzodiazepine; Flumazenil; Radioactive tracer; SPECT (single photon emission computer tomography) (Videbæk, C. (249) 43)

Hippocampus; 5-HT (5-hydroxytryptamine, serotonin); Vogel's test; (Rat) (Plaznik, A. (257) 293)

Nucleus accumbens; Dopamine release; β-CCE (β-carboline-3-carboxylate ethyl ester); $GABA_A$/benzodiazepine receptor; Adenosine receptor (Murai, T. (261) 65)

Midbrain
Neurotensin receptor; Brain, guinea-pig; Dopamine; Basal ganglia; (Non-peptide receptor antagonist) (Azzi, M. (255) 167)

Middle cerebral artery
Nitric oxide (NO) synthase; Neuroprotection; N^{ω}-Nitro-L-arginine (Carreau, A. (256) 241)

Middle cerebral artery thrombosis
Photochemically induced thrombosis; Tissue-type plasminogen activator; SUN9216; (Rat) (Umemura, K. (262) 27)

Migration
Substance P; Fibroblast (Kähler, C.M. (249) 281)

Milrinone
Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); Neuropeptide Y; Nitroprusside; cAMP; cGMP; Acetylcholine (Modin, A. (261) 185)

Blood vessel; Phosphodiesterase inhibitor; Pimobendan; UD-CG 212 (Fujimoto, S. (265) 159)

MIN 6 cell
Pancreatic β-cell; Sulfonylurea receptor; K^+ channel, ATP-sensitive; Glibenclamide (Mogami, H. (269) 293)

Mineralocorticoid hypertension
Mg^{2+}; Endothelium; Aorta; (Rat) (Laurant, P. (258) 167)

Mineralocorticoid receptor
Glucocorticoid receptor; 5-HT (5-hydroxytryptamine, serotonin); Hippocampus; In situ hybridisation; (Rat) (Meijer, O.C. (266) 255)

Misoprostol
Prostaglandin E_1; Prostaglandin E_2; Enisoprost; Bradykinin; Sympathetic nervous system; Plasma extravasation; PAF (platelet activating factor, PAF-acether); Synovial joint (Green, P.G. (252) 127)

Mitochondrion
L-DOPA (3,4-dihydroxyphenylalanine); Fibroblast; Parkinson's disease; Pyruvate oxidation (Werner, P. (263) 157)

Mitogenesis
Dopamine D_3 receptor; Locomotor activity; Dopamine release (Svensson, K. (263) 235)

G protein; Guanylnucleotide; c-*fos*; Adenylyl cyclase; Phospholipase C; Phorbol ester; Pertussis toxin (Pilon, C. (268) 129)

Mixed inhibitor
Neuropathic pain; Mononeuropathic rat; Opioid receptor; Enkephalin degradation (Lee, S.H. (264) 61)

MK-329
CCK receptor antagonist; Loxiglumide; Bile flow; Bilirubin secretion (Watanabe, N. (264) 331)

[^{3}H]MK-801
Keratinocyte; Cardiocyte; NMDA receptor; mRNA (Morhenn, V.B. (268) 409)

MK-801 binding
NMDA receptor; Acetylcholine release; Budipine; Biperiden; Nucleus caudatus (Jackisch, R. (264) 207)

MK-801 (dizocilpine)
NMDA receptor antagonist; 6-Hydroxydopamine; Haloperidol; Nucleus accumbens; Locomotion; (Rat) (Ouagazzal, A.-m. (251) 229)

Excitatory amino acid; Apneusis; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline); Respiratory activity (McManigle, J.E. (252) 11)

Behavior; NMDA (*N*-methyl-D-aspartate); Phencyclidine; Sensitization; Temperature; Thermoregulation; Tolerance (Pechnick, R.N. (252) 35)

Morphine, intrathecal; Clonic seizure-like behavior; NMDA receptor; Glycine co-agonist site; ACEA-1011 (Lutfy, K. (252) 261)

NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) (Löscher, W. (259) R3)

Morphine; EEG (electroencephalography); EEG power spectra; Tolerance; (Interaction) (Haberny, K.A. (261) 1)

Morphine; EEG (electroencephalography); EEG power spectra; Dependence; (Interaction) (Haberny, K.A. (261) 11)

Depression, animal model; Anhedonia; CGP 37849; CGP 40116; Imipramine; (Rat) (Papp, M. (263) 1)

β-Endorphin; Morphine; Tail-flick inhibition; Hot plate inhibition (Suh, H.-W. (263) 217)

Bladder voiding; Urine storage; Decerebration; Cystometrogram; Sphincter electromyogram; (Rat) (Yoshiyama, M. (264) 417)

Cannabis; δ-9-Tetrahydrocannabinol (THC); Cerebral decortication; NMDA receptor; In situ hybridization (Mailleux, P. (266) 193)

NMDA receptor, recombinant; HEK 293 cell; Ligand affinity; Glutamate; Glycine (Laurie, D.J. (268) 335)

Ca^{2+} channel, L-type; Dihydropyridine; Nitrendipine; Ca^{2+} channel, voltage-sensitive; NMDA receptor; Dibenzocycloheptenimine (Filloux, F.M. (269) 325)

MK-886
ZD2138; ZM230487; Zileuton; 5-Lipoxygenase; Leukotriene (Kusner, E.J. (257) 285)

MMAI (5-methoxy-6-methyl-2-aminoindan)
Drug discrimination; *p*-Chlorophenylalanine; Behavioral syndrome; 5-HT (5-hydroxytryptamine, serotonin) release; (Rat) (Marona-Lewicka, D. (258) 1)

Modulated receptor model
Smooth muscle, vascular; Cell proliferation; Dihydropyridine-sensitive Ca^{2+} channel; Voltage-dependent Ca^{2+} channel; Scatchard analysis; Atherosclerosis (Ruiz-Velasco, V. (268) 311)

Molecular modeling
Adenosine receptor; Receptor binding and activation; Bacteriorhodopsin; Histidine residue (IJzerman, A.P. (268) 95)

σ Receptor; Heterocyclic amino alcohol; Ifenprodil; [^{3}H]3-PPP ([^{3}H]R(+)-3-[3-hydroxyphenyl]-*N*-(1-propyl)piperidine) binding; Brain (Rat) (Beart, P.M. (269) 193)

Monoamine
Striatum; 1-Methyl-4-phenylpyridinium; Selenium; Vitamin E; (Rat) (Vizuete, M.L. (270) 183)

Monoamine oxidase
Harman; Norharman; β-Carboline; Pargyline; (Rat) (Rommelspacher, H. (252) 51)

Monoamine oxidase inhibitor
5-HT (5-hydroxytryptamine, serotonin) release; Antidepressant; Microdialysis, intracerebral (Ferrer, A. (263) 227)

Monoamine oxidase type B
(−)-Deprenyl; Dopamine; Microdialysis; 2-Phenylethylamine; (Guinea pig) (Juorio, A.V. (254) 213)

Monoamine uptake inhibitor
CCK (cholecystokinin); Substance P; Clonazepam; Panic disorder; Central nervous system, rat (Brodin, K. (263) 175)

Monoclonal anti-CGRP antibody
Capsaicin; CGRP (calcitonin gene-related peptide); Immuno-neutralization; Gastric mucosa; Gastric mucosal protection; Gastric mucosal injury (Peskar, B.M. (250) 201)

Monocyte
PAF (platelet activating factor) receptor; PAF receptor antagonist; (Receptor expression) (Shirasaki, H. (268) 263)

N^G-Monomethyl-L-arginine
Aminoguanidine; *N*,*N*′-Diaminoguanidine; Methylguanidine; 1,1-Dimethylguanidine; Nitric oxide (NO); Nitric oxide synthase; (L-NMA) (Hasan, K. (249) 101)

Nitric oxide (NO); N^G-Nitro-L-arginine; Glucocorticoid; Endotoxin (Berrazueta, J.R. (251) 303)

Nitric oxide (NO); Gastric emptying; N^G-Nitro-L-arginine methyl ester; Blood pressure; L-Arginine (Plourde, V. (256) 125)

Angiotensin II; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Aorta, rabbit; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester; Indomethacin (Zhang, J. (262) 247)

Mononeuropathic rat
Neuropathic pain; Opioid receptor; Enkephalin degradation; Mixed inhibitor (Lee, S.H. (264) 61)

Moricizine hydrochloride
Na^+ current; Ventricular myocyte, single, feline; Voltage clamp, whole cell (Saeki, T. (261) 249)

Morphinan
Opioid receptor; Receptor conformation; Analgesia (Lemaire, S. (258) 111)

Morphine
4-Aminopyridine; Quinine; Dopamine release; Behavioural activity; Nucleus accumbens (Pei, Q. (249) 243)

Morphine-3-glucuronide; Morphine-6-glucuronide; Antinociception; (Intrathecal) (Suzuki, N. (249) 247)

Cromakalim; Diazoxide; ATP-sensitive K^+ channel; Naloxone, withdrawal (Robles, L.I. (251) 113)

Mesolimbic system; Drug discrimination; Neuroanatomical mapping; (Rat) (Shoaib, M. (252) 69)

Dopamine release; Striatum; Adenylate cyclase; Opioid receptor (Tjon, G.H.K. (252) 205)

RB 101 (mixed inhibitor of enkephalin-degrading enzymes); Naloxone; Physical dependence; (Intravenous perfusion) (Noble, F. (253) 283)

Caerulein; CCK-8 (cholecystokinin octapeptide); Tolerance; Antinociception; (Unsulfated CCK-8) (Rezayat, M. (254) 21)

Opiate withdrawal syndrome; Naloxone; Clonidine; Aversive conditioning (Kosten, T.A. (254) 59)

N^G-Nitro-L-arginine; Ethanol-induced mucosal lesion; Aspirin-induced mucosal lesion; (Rat) (Gyires, K. (255) 33)

Morphine-6-glucuronide; Agonist potency; Ileum, guinea-pig (Schmidt, N. (255) 245)

U-50,488; Tolerance; Dependence; (Guinea pig) (Tao, P.-L. (256) 281)

Loperamide; Anti-emetic; 5-HT (5-hydroxytryptamine, serotonin); Nicotine; Vomiting; (*Suncus murinus*) (Selve, N. (256) 287)

Immediate-early gene; Inhibitor of enkephalin-degrading enzyme; Nociception; Non-steroidal anti-inflammatory drug; Tolerance (Abbadie, C. (258) 215)

Tolerance; *N*-Nitro-L-arginine methyl ester; Thyrotropin (TSH); Prolactin; Growth hormone; Antinociception; Hyperthermia (Rauhala, P. (259) 57)

Δ^9-Tetrahydrocannabinol; Tolerance; Analgesia; Hypothermia; Cross-tolerance; [^{3}H]DAMGO ([^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin), B_{max}, K_d; Brain; Spinal cord (Thorat, S.N. (260) 5)

Chronic variable stress; Locomotor activity; Antidepressant (Molina, V.A. (260) 57)

MK-801; EEG (electroencephalography); EEG power spectra; Tolerance; (Interaction) (Haberny, K.A. (261) 1)

MK-801; EEG (electroencephalography); EEG power spectra; Dependence; (Interaction) (Haberny, K.A. (261) 11)

κ-Opioid receptor agonist; R-84760; U-50488; CI-977; Antinociceptive effect (Fujibayashi, K. (261) 133)

Straub tail; μ_2-Opioid receptor (Nath, C. (263) 203)

β-Endorphin; MK-801; Tail-flick inhibition; Hot plate inhibition (Suh, H.-W. (263) 217)

Excitatory amino acid; Kynurenic acid; Conditioned place preference; Self-stimulation; (Rat) (Bespalov, A. (264) 233)

Analgesia; Selective breeding; Tail flick assay; Tolerance (Lutfy, K. (265) 171)

Opioid; Lung; Dyspnoea; Naloxone; NANC (Non-adrenergic-non-cholinergic) (Cabot, P.J. (268) 247)

Morphine, blood level
Analgesia; Dependence; Opiate; Tolerance; Withdrawal (Gold, L.H. (253) 45)

Morphine dependence
Morphine withdrawal; Adenylyl cyclase; Locus coeruleus; Amygdala; Thalamus (Matsuoka, I. (268) 215)

Morphine-3-glucuronide
Morphine; Morphine-6-glucuronide; Antinociception; (Intrathecal) (Suzuki, N. (249) 247)

Morphine-6-glucuronide
Morphine; Morphine-3-glucuronide; Antinociception; (Intrathecal) (Suzuki, N. (249) 247)

Intestinal motility; Ileum, guinea-pig; Binding assay (Massi, P. (253) 269)

Morphine; Agonist potency; Ileum, guinea-pig (Schmidt, N. (255) 245)

Morphine, intrathecal
Clonic seizure-like behavior; NMDA receptor; MK-801; Glycine co-agonist site; ACEA-1011 (Lutfy, K. (252) 261)

Morphine treatment, chronic
Desensitization; Adenylate cyclase inhibition; G-protein (coupling to); Down-regulation (Polastron, J. (266) 139)

Morphine withdrawal
Endo-oligopeptidase; Enkephalin; Opioid system (Paik, S.H. (253) 101)

Morphine dependence; Adenylyl cyclase; Locus coeruleus; Amygdala; Thalamus (Matsuoka, I. (268) 215)

Morphological change
Staurosporine; Membrane outgrowth; Myocyte, *Xenopus*; Developmental change (Fu, W.-M. (270) 321)

Motoneuron
Tachykinin NK_2 receptor; Tackykinin NK_1 receptor; Spinal cord (Lepre, M. (258) 23)

Motor activity
Amphetamine; Cocaine; δ-Opioid receptor antagonist; Opioid-dopamine interaction (Jones, D.N.C. (249) 167)

Reserpine; Dopamine D_1 receptor; Dopamine D_2 receptor; NMDA receptor; Dopamine-glutamate interaction (Ferré, S. (255) 203)

Caffeine; Quinpirole; *R*(−)-Propylnorapomorphine (NPA); SKF-38393; SKF-77434; Tolerance (Garrett, B.E. (262) 65)

Motor nerve conduction velocity
Aldose reductase inhibitor; Laser Doppler flowmetry; Nerve blood flow; Polyol pathway; Streptozotocin-induced diabetes (Calcutt, N.A. (251) 27)

Motor system
σ Receptor; Brain; Antipsychotic; (Rat) (Leitner, M.L. (259) 65)

Movement disorder
DTG (di-*o*-tollylguanidine); SKF10047; σ Receptor; Red nucleus; *N*-Allylnormetazocine; Dystonia (Weissman, A.D. (250) 329)

5-HT (5-hydroxytryptamine, serotonin); Dystonia; Glutamate (Löscher, W. (255) 235)

MPP^+ (1-methyl-4-phenylpyridinium), uptake inhibition
Methamphetamine; Amphetamine, protection; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Dopaminergic neurotoxicity (Sziráki, I. (251) 311)

MPTP analog
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP derivative; 5-HT (5-hydroxytryptamine, serotonin); Norepinephrine; Fluoxetine; Desipramine (Andrews, A.M. (250) 215)

MPTP derivative
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP analog; 5-HT (5-hydroxytryptamine, serotonin); Norepinephrine; Fluoxetine; Desipramine (Andrews, A.M. (250) 215)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
MPTP analog; MPTP derivative; 5-HT (5-hydroxytryptamine, serotonin); Norepinephrine; Fluoxetine; Desipramine (Andrews, A.M. (250) 215)

Methamphetamine; Amphetamine, protection; Dopaminergic neurotoxicity; MPP^+ (1-methyl-4-phenylpyridinium), uptake inhibition (Sziráki, I. (251) 311)

MPTP monkeys; CY 208–243 ((−)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenanthyxidine); Dopamine D_1 receptor; Dopamine D_2 receptor; SCH-23390; Sulpiride; Dopamine D_1/D_2 interaction; (+)-PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Luquin, M.R. (253) 215)

Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4*H*-thiazolo[4,5-*d*]-azepine); Dopamine D_2 receptor agonist; Parkinson's disease; (Chronic treatment); (Common marmoset) (Irifune, M. (264) 117)

Diethyldithiocarbamate; Lipoic acid; α-Tocopherol; Coenzyme Q; Brain (mouse) (Götz, M.E. (266) 291)

MPTP monkey
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); CY 208–243 ((−)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenanthyxidine); Dopamine D_1 receptor; Dopamine D_2 receptor; SCH-23390; Sulpiride; Dopamine D_1/D_2 interaction; (+)-PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Luquin, M.R. (253) 215)

α-MSH (α-melanocyte-stimulating hormone)
Melanocortin receptor antagonist; Grooming behavior; ACTH (adrenocorticotrophic hormone) derivative (Adan, R.A.H. (269) 331)

MUC2 mucin gene
Colonic cell line (human); Mucus secretion; Cytokine regulation; Interferon-γ; cAMP (Jarry, A. (267) 95)

Mucosa
VIP (vasoactive intestinal peptide) receptor antagonist; Short-circuit current; Colon (Burleigh, D.E. (249) 239)

Anti-ulcer agent; DTG (1,3-di(2-tolyl)guanidine); KB-5492; σ Receptor; SKF 10,047 (*N*-allyl-normetazocine); (Pig) (Harada, Y. (261) 91)

Mucosal blood flow
Nitric oxide (NO); Ulcer; Cytoprotection (Ferraz, J.-G.P. (260) 107)

Mucosal mast cell
DS-4574; Mast cell stabilizer; Peptidoleukotriene; LY171883; Gastric mucosal injury (Tabuchi, Y. (250) 197)

Mucus
Nitric oxide (NO); Gastric mucosa; Stomach (Price, K.J. (263) 199)

Mucus secretion
Colonic cell line (human); Cytokine regulation; Interferon-γ; cAMP; MUC2 mucin gene (Jarry, A. (267) 95)

Muscarinic
Nicotinic; Sympathetic ganglion; Culture; Electrophysiology; (Guinea pig) (Xian, H. (259) 21)

Muscarinic acetylcholine receptor
Jaw movement; Clozapine; Apomorphine; Nucleus accumbens; Striatum (Kikuchi de Beltrán, K. (262) 49)

$5\text{-}HT_{1A}$ receptor; $5\text{-}HT_2$ receptor; Medial septum; Passive avoidance (Riekkinen Jr., P. (262) 77)

Myocyte; Nicotinic acetylcholine receptor; Oxotremorine methiodide; Patch clamping; (Single channel) (Reitstetter, R. (264) 27)

Polyphosphoinositide turnover; c-*fos* expression; Calmodulin; Protein kinase C; NG108-15 cell, transfected (Tohda, M. (268) 169)

Muscarinic acetylcholine receptor agonist
YM796; Muscarinic M_1 receptor; Muscarinic M_2 receptor; Learning behavior (Wanibuchi, F. (265) 151)

Muscarinic receptor
Smooth muscle, uterus; Muscarinic M_2 receptor; m4 binding site (Doods, H.N. (250) 223)

Muscarinic receptor antagonist; SPECT (single-photon emission computed tomography) imaging; Radioligand (Baumgold, J. (251) 315)

Ascending reflex; AF-DX 116; Ileum, guinea-pig; Smooth muscle, intestinal (Doods, H.N. (253) 275)

Adenosine; Brain microdialysis; Cerebral cortex; Tetrodotoxin; NMDA receptor (Pazzagli, M. (254) 277)

Uterine artery; Acetylcholine; (Human) (Jovanović, A. (256) 131)

Neuropeptide release; Synaptosome; Nerve varicosity; Ileum; Bombesin (Kurjak, M. (257) 169)

Uterine artery; Pregnancy; Acetylcholine; (Guinea-pig) (Jovanović, A. (258) 185)

Smooth muscle, airway; Bronchodilator agent; Allergy and immunology; (Guinea pig) (Howell, R.E. (265) 67)

Ethanol; Development; Phosphoinositide; Fetal alcohol syndrome; (Rat) (Balduini, W. (266) 283)

Muscarinic M_1 receptor
Muscarinic M_2 receptor; Mechanistic pathway; LiCl; Forskolin; 1,9-Dideoxy-forskolin; Phorbol ester; Vas deferens; (Rabbit) (Eltze, M. (263) 31)

Muscarinic acetylcholine receptor agonist; YM796; Muscarinic M_2 receptor; Learning behavior (Wanibuchi, F. (265) 151)

Transfected cell; Receptor agonist exposure; Receptor internalization; Phosphatidylinositol hydrolysis; cAMP production; Down-regulation; Muscarinic M_2 receptor (Wei, H.-B. (268) 381)

Muscarinic M_2 receptor
Trachea (guinea-pig); Functional antagonism; β-Adrenoceptor agonist; Adenylyl cyclase inhibition (Roffel, A.F. (249) 235)

Muscarinic receptor; Smooth muscle, uterus; m4 binding site (Doods, H.N. (250) 223)

Lung strip, guinea pig; Cholinergic contraction; Trachea, guinea pig; Smooth muscle, human, airway (Roffel, A.F. (250) 267)

Cholinomimetic; Blood pressure; Central nervous system (Özkutlu, U. (250) 349)

Binding study; [^{3}H]Quinuclidinyl benzilate; Selective antagonist; Uterus; (Rat) (Pennefather, J.N. (262) 297)

Muscarinic M_1 receptor; Mechanistic pathway; LiCl; Forskolin; 1,9-Dideoxy-forskolin; Phorbol ester; Vas deferens; (Rabbit) (Eltze, M. (263) 31)

Muscarinic acetylcholine receptor agonist; YM796; Muscarinic M_1 receptor; Learning behavior (Wanibuchi, F. (265) 151)

G-protein coupling; Chimaeric receptor; (Peptide mimics) (McClue, S.J. (267) 185)

Transfected cell; Receptor agonist exposure; Receptor internalization; Phosphatidylinositol hydrolysis; cAMP production; Down-regulation; Muscarinic M_1 receptor (Wei, H.-B. (268) 381)

Muscarinic M_3 receptor
Antral G-cell; Muscarinic receptor subtype; Atropine; Hexahydro-sila-difenidol; Pirenzepine; AQ-RA 741 (Weigert, N. (264) 337)

Muscarinic receptor agonist
Acetylcholine release; HPLC-ECD system; Cholinergic regulation (presynaptic); Muscarinic receptor antagonist; Ileum (guinea-pig); Bethanechol; p-F-HHSiD (*p*-fluoro-hexahydro-siladifenidol); AF102B. (Soejima, O. (249) 1)

Galanin; Cholinomimetic; Hypothermia; ATP-sensitive K^+ channel; Acetylcholinesterase inhibitor (Patel, S. (255) 25)

Muscarinic receptor agonists
Inositol monophosphates; Phosphatidyl-inositol turnover, in vivo; Oxadiazoles; L-658,903 (Patel, S. (267) 329)

Muscarinic receptor antagonist
Acetylcholine release; HPLC-ECD system; Cholinergic regulation (presynaptic); Muscarinic receptor agonist; Ileum (guinea-pig); Bethanechol; p-F-HHSiD (*p*-fluoro-hexahydro-siladifenidol); AF102B. (Soejima, O. (249) 1)

Muscarinic receptor; SPECT (single-photon emission computed tomography) imaging; Radioligand (Baumgold, J. (251) 315)

Nitric oxide (NO); Opioid; Small intestine; Substance P; VIP (vasoactive intestinal peptide) (Gustafsson, B.I. (257) 227)

Muscarinic receptor, prejunctional
Caudal artery, rat (Shen, A. (252) 167)

Muscarinic receptor stimulation
Neuroblastoma SH-SY5Y cell; Protein kinase C; c-*fos* expression; Diacylglycerol (Larsson, C. (268) 19)

Muscarinic receptor subtype
Smooth muscle, ileal; Pirenzepine analog; McN-A-343 (Barocelli, E. (254) 151)

Antral G-cell; Muscarinic M_3 receptor; Atropine; Hexahydro-siladifenidol; Pirenzepine; AQ-RA 741 (Weigert, N. (264) 337)

Tripitramine; Methoctramine; Binding affinity; CHO-K1 cell (Maggio, R. (268) 459)

Muscimol
Δ^9-Tetrahydrocannabinol; Anandamide; Globus pallidus; Catalepsy; Drug interaction (Wickens, A.P. (250) 205)

GnRH (gonadotropin-releasing hormone) gene expression; 5β-Pregnan-3α-ol-20-one; Picrotoxin; Hypothalamus; Hybridization, in situ (Vincens, M. (260) 157)

GABA (γ-aminobutyric acid); Inhalational anesthetics; Stereospecificity; SR 95531 (Harris, B.D. (267) 269)

[^{3}H]Muscimol binding
ICS 205–930; 5-HT_3 receptor antagonist; $GABA_A$ receptor; [^{3}H]Flunitrazepam binding; [^{35}S]TBPS (tert-butylbicyclophosphorothionate) binding; $^{36}Cl^-$ flux; 293 cell; *Xenopus* oocyte (Klein, R.L. (268) 237)

Muscle contracture
Ryanodine; Metal ion (Liu, S.-H. (251) 61)

Muscle strip, human
Peripheral benzodiazepine; Ro 5-4864; PK 11195 (Shany, E. (253) 231)

Muscle tension
HI-6 ([[[(4-aminocarbonyl)pyridino]-methoxy]methyl]-2-[(hydroxyimino)methyl]-pyridinium dichloride); Soman; Acetylcholinesterase reactivation; Diaphragm, rat (Adler, M. (270) 9)

Mydriasis
α_2-Adrenoceptor; Dexmedetomidine; Nociception; Spinal cord (Horváth, G. (253) 61)

Myenteric plexus
ATP; Suramin; Ionic conductance; Enteric neuron; Electrophysiology; Purinoceptor (Barajas-López, C. (250) 141)

Glutamate receptor; Cortical wedge; Homoserine sulfate; Hydroxyproline sulfate; Hydroxypipecolic acid sulfate (Mannaioni, G. (251) 201)

Tachykinin receptor; Septide (Burcher, E. (258) R9)

Myocardial Ca^{2+} loading
Doxorubicin; Heart muscle preparation, isolated; Inotropic effect; (Guinea pig); (Rat) (Temma, K. (252) 173)

Myocardial infarction
Myocardial ischemia; Adenosine; Purine transport (Poucher, S.M. (252) 19)

Myocardial ischemia
Myocardial infarction; Adenosine; Purine transport (Poucher, S.M. (252) 19)

Autonomic nervous system; Cardiac arrhythmia; β-Adrenoceptor; Sudden cardiac death (Avendano, C.E. (255) 99)

BRL-38227; Glibenclamide; Antiarrhythmic/proarrhythmic effect (Bellemin-Baurreau, J. (256) 115)

Tilisolol; Propranolol; Myocardial metabolism; (Dog) (Hayase, N. (260) 183)

α_2-Adrenoceptor antagonist; 5-HT (5-hydroxytryptamine, serctonin) (Sargent, C.A. (261) 25)

Myocardial ischemia / reperfusion
Cardioselective; Free radical scavenger; α-Tocopherol analogue; Reperfusion injury (Petty, M.A. (255) 215)

Myocardial ischemia-reperfusion
ICAM-1 (intercellular adhesion molecule); Leukocyte accumulation (Ioculano, M. (264) 143)

Myocardial ischemia-reperfusion injury
Selectin, E-; Anti-E-selectin antibody; (Rat) (Altavilla, D. (270) 45)

Myocardial metabolism
Tilisolol; Propranolol; Myocardial ischemia; (Dog) (Hayase, N. (260) 183)

Myocardium, guinea-pig
Development; Ca^{2+}, extracellular; Nicardipine; Ryanodine; Isoproterenol (Agata, N. (260) 47)

Myocardium, rat
α_1-Adrenoceptor; [^{3}H]Prazosin binding; Phosphoinositide hydrolysis; Phenoxybenzamine (Sallés, J. (266) 35)

Myocardium, stunned
Pd-Ia (3′-angeloyloxy-4′-acetoxy-3′,4′-dihydroseselin); Bai-Hua Qian-Hu; Cardiohemodynamic; Ca^{2+} channel antagonist (Chang, T.-h. (258) 77)

Myocyte
Muscarinic acetylcholine receptor; Nicotinic acetylcholine receptor; Oxotremorine methiodide; Patch clamping; (Single channel) (Reitstetter, R. (264) 27)

Myocyte, *Xenopus*
Staurosporine; Membrane outgrowth; Morphological change; Developmental change (Fu, W.-M. (270) 321)

Myometrium
[^{3}H]Rauwolscine; α_2-Adrenoceptor; cAMP; Inositol phosphate; (Guinea-pig) (Haynes, J.M. (250) 231)

Ca^{2+} inhibition; Contraction; Smooth muscle; Threshold phenomenon; Actin filament (Miyauchi, Y. (263) 75)

Myosin light chain phosphorylation
α_1-Adrenoceptor; Thoracic aorta; β-Escin-skinned fiber (Satoh, M. (265) 133)

Myosin phosphorylation
Cytochalasin B; Smooth muscle contraction; Ca^{2+} current; Taenia coli; (Guinea pig) (Obara, K. (255) 139)

Myotoxin α
Ca^{2+} releaser; Calsequestrin (Ohkura, M. (268) R1)

Na^+
Felodipine; Stroke-prone spontaneously hypertensive rat (SHRSP); Cardiac hypertrophy; K^+; Mg^{2+} (Mervaala, E.M.A. (255) 73)

Sulfonylurea; Glucose; Pancreatic islet (Saha, S. (258) 145)

Brain ischemia; Histamine H_2 receptor; Ranitidine; Edema; K^+; Ca^{2+}; (Rat) (Tósaki, Á. (264) 455)

Nabumetone
NSAID (non-steroidal anti-inflammatory drug); Inflammation; Antinociception (Clarke, G.D. (257) 103)

Na^+ channel antagonist
Dystonia; Lamotrigine; Glutamate; GABA (γ-aminobutyric acid) (Richter, A. (264) 345)

Na^+ channel, human
Oocyte; Class I antiarrhythmic; DPI 201-106 (Krafte, D.S. (266) 245)

Na^+ current
Voltage-clamp, whole-cell; Cardiac myocyte; Cl^- channel blocker; Ca^{2+} current; Diphenylamine-2-carboxylate (DPC); Ion channel blocker (Conforti, L. (259) 215)

Moricizine hydrochloride; Ventricular myocyte, single, feline; Voltage clamp, whole cell (Saeki, T. (261) 249)

Na^+ dependence
Dopamine carrier (neuronal); N-ethylmaleimide treatment; [^{3}H]GBR 12783; [^{3}H]Cocaine; Binding in vitro; Striatum; (Rat) (Saadouni, S. (268) 187)

Naftidrofuryl
5-HT (5-hydroxytryptamine, serotonin); Microcirculation; Cremaster muscle; Arteriole; Vasoconstriction; 5-HT_2 receptor antagonist (Koch, L.G. (254) 249)

Na^+-H^+ antiport
Pertussis toxin; Cholera toxin; Okadaic acid; Mast cell; Sodium propionate (Alfonso, A. (267) 289)

Naloxonazine
SH-SY5Y human neuroblastoma cell; μ-Opioid receptor subtype; β-Funaltrexamine (Elliott, J. (268) 447)

Naloxone
DOPAC (dihydroxyphenylacetic acid); Dopamine; Ethanol; GABA (γ-hydroxybutyric acid); Sleep (Devoto, P. (252) 321)

RB 101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Physical dependence; (Intravenous perfusion) (Noble, F. (253) 283)

Morphine; Opiate withdrawal syndrome; Clonidine; Aversive conditioning (Kosten, T.A. (254) 59)

κ-Opioid receptor, supraspinal; Butorphanol dependence; Nor-binaltorphimine; Withdrawal, precipitated (Jaw, S.P. (257) 153)

Lys-D-Pro-Thr; Lys-D-Pro; Interleukin-1β-(193–195); Tripeptide; Antinociception; Formalin test (Oluyomi, A.O. (258) 131)

Indomethacin; Analgesia; Norepinephrine; β-Endorphin; Phentolamine; Pain (Hu, X.-H. (263) 53)

Ethanol drinking; $GABA_A$ receptor; Benzodiazepine; (Selected rat lines) (Wegelius, K. (263) 141)

μ-Opioid receptor; Hippocampal slice; Proconvulsant; Bursting (Jones, L.S. (264) 39)

Opioid; Lung; Dyspnoea; Morphine; NANC (Non-adrenergic-non-cholinergic) (Cabot, P.J. (268) 247)

Naloxone, withdrawal
Cromakalim; Diazoxide; ATP-sensitive K^+ channel; Morphine (Robles, L.I. (251) 113)

Naltriben
Antitussive effect; BNTX (7-benzylidenenaltrexone); δ-Opioid receptor; DPDPE ([D-$Pen^{2,5}$]enkephalin); [D-Ala^2]Deltorphin II (Kamei, J. (251) 291)

Cocaine; Drug discrimination; Naltrindole; 7-Benzylidenenaltrexone (Suzuki, T. (263) 207)

Naltrindole
δ-Opioid receptor; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Dopamine neurons (central) (Manzanares, J. (249) 107)

δ-Opioid receptor; κ-Opioid receptor; Antitussive effect (Kamei, J. (249) 161)

Lipopolysaccharide, *Pantoea agglomerans*; Antinociception; Diabetes; Nor-binaltorphimine; β-Funaltrexamine; Opioid receptor (Kamei, J. (251) 95)

Hypovolemia; δ-Opioid receptor; BNTX (7-benzylidenenaltrexone); Hemorrhagic shock; (Rabbit, conscious) (Ludbrook, J. (252) 113)

L-Arginine; Antinociception; Diabetes; Nor-binaltorphimine; β-Funaltrexamine; Opioid receptor (Kamei, J. (254) 113)

Cocaine; Drug discrimination; Naltriben; 7-Benzylidenenaltrexone (Suzuki, T. (263) 207)

NAN-190
Defensive behavior; (−)-Propranolol; Vomiting; 5-HT_{1A} receptor (Lucot, J.B. (253) 53)

NANC (non-adrenergic non-cholinergic)
Inhibitory junction potential; Suramin; Gastric smooth muscle; ATP (Ohno, N. (249) 121)

Opioid; Lung; Dyspnoea; Morphine; Naloxone (Cabot, P.J. (268) 247)

NANC inhibition
Descending relaxation; 5-HT (5-hydroxytryptamine, serotonin); Nitric oxide (NO); Ileum, rat (Kanada, A. (250) 59)

Skinned muscle; cGMP; Colon; (Rat) (Maehara, T. (261) 163)

NANC nerve
Nicotine; Peptidergic transmission; Purinergic transmission; Developmental pharmacology (Irie, K. (251) 75)

Adenosine cyclic monophoshate; Guanosine cyclic monophoshate; Nitric oxide (NO); Urethra; Detrusor (Persson, K. (268) 159)

NANC neurotransmission
Small intestine, rat; Nitric oxide (NO); Nitric oxide (NO)-induced contraction (Barthó, L. (259) 101)

NANC relaxation
K^+ channel; Smooth muscle; Penile erection; Nicotinic receptor (Alaranta, S. (259) 203)

Urethra (rabbit); Nitric oxide synthase; Nitric oxide synthase inhibitor (Dokita, S. (266) 269)

NANC transmission
Nitric oxide (NO); Electrical field stimulation; Nicotinic receptor; Ileocecal sphincter; (Cat) (Mizhorkova, Z. (265) 77)

Nandrolone
Vascular reactivity; Endothelium; Nitric oxide (NO); cGMP (Ferrer, M. (252) 233)

Artery, rabbit; Vascular reactivity; Noradrenaline; Angiotensin II; 5-HT (5-hydroxytryptamine, serotonin) (Ferrer, M. (258) 103)

Na^+ overload
Disopyramide; Ischemia/reperfusion injury; Propafenone; Creatine kinase; Purine nucleoside; Purine base (Liu, J.-X. (250) 361)

Natriuretic peptide, C-type
ANP (atrial natriuretic peptide); Guanylate cyclase; LLC-PK_1 cell (Hashimoto, Y. (268) 443)

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline)
Excitatory amino acid; Apneusis; MK-801 (dizocilpine); Respiratory activity (McManigle, J.E. (252) 11)

Non-NMDA receptor antagonist; Sympathetic nerve activity; Blood pressure; (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline) (Chen, K. (252) 155)

Dizocilpine; Neuroprotection; Over-additive effect (Lippert, K. (253) 207)

NCB-20 cell
Ca^{2+}, intracellular; Bradykinin; ATP; Carbachol (Boyd, R.S. (267) 161)

NE-100
σ Receptor; Phencyclidine; Cognition; Neuroleptic; (Rat) (Ogawa, S.-i. (263) 9)

NECA (5′-*N*-ethylcarboxamidoadenosine)
Vasorelaxation; Aortic baroreceptor; Endothelium; Adenosine receptor; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO) (Fahim, M. (254) 183)

Nefiracetam (DM-9384)
Learning, latent; Water finding test; Nootropic (Nabeshima, T. (255) 57)

Negative inotropy
Carbachol; Phenylephrine; Atrium, left; $^{86}Rb^+$ efflux; Pertussis toxin; 4-Aminopyridine (Ray, A. (256) 311)

NE-100 (*N*,*N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride)
σ_1 Binding site; σ_2 Binding site (Chaki, S. (251) R1)

Neocortex, human
GABA (γ-aminobutyric acid) release; $GABA_B$ autoreceptor; CGP 35348; CGP 52432; Phaclofen (Fassio, A. (263) 311)

Neocortex, rat
Nitropropane analog, GABA; Nitropropane analog, baclofen; Ileum, isolated, guinea-pig; Spinal cord, cat; $GABA_B$ receptor antagonist (Ong, J. (264) 49)

Neocortical slice, rat
$GABA_B$ receptor; Baclofen; Amiloride; Amiloride analog; (Mg^+-free Krebs medium) (Ong, J. (260) 73)

γ-Guanidinobaclofen; Baclofen; $GABA_B$ receptor agonist; Ileum, guinea-pig, isolated; 2-Hydroxysaclofen (Kerr, D.I.B. (262) 189)

Neocortical spike-and-wave spindling
β-Endorphin fragment; Electrocorticogram; DBA/2J mouse (Capasso, A. (261) 209)

Neointima
Balloon denudation; Vascular contraction (Antonaccio, M.J. (256) 17)

Neointima formation
Balloon angioplasty; Nitric oxide (NO); Endothelin-1; N^{ω}-Nitro-L-arginine methyl ester; Vascular reactivity (Douglas, S.A. (255) 81)

Neonatal cardiomyocyte
Inositol 1,4,5-trisphosphate; Inositol 1,4,5-trisphosphate receptor; Heart, rat; Ca^{2+} release (Fitzgerald, M. (268) 275)

Neostigmine
SK&F 96365; Endplate potential; Nicotinic acetylcholine receptor; Receptor desensitisation (Hong, S.J. (265) 35)

Neostriatum
Amphetamine; Behavioral clamping; Cortical lesion; Haloperidol; Unit activity (Tschanz, J.A.T. (257) 161)

Locomotor activity; Dopamine synthesis; Dopamine receptor; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin); (Rat) (Ahlenius, S. (260) 177)

Nephrotoxicity
Cd^{2+}; Metallothionein; Hepatotoxicity; (Rat) (Sudo, J.-i. (270) 229)

Nerve blood flow
Neuropathy; Diabetic rat; Vasa nervorum; Nimodipine (Kappelle, A.C. (250) 43)

Aldose reductase inhibitor; Laser Doppler flowmetry; Motor nerve conduction velocity; Polyol pathway; Streptozotocin-induced diabetes (Calcutt, N.A. (251) 27)

Nerve growth factor
Senile dementia of the Alzheimer type; Nerve growth factor synthesis stimulator; Choline acetyltransferase; Water maze; Astroglia cell (Nitta, A. (250) 23)

Nerve growth factor synthesis stimulator
Senile dementia of the Alzheimer type; Nerve growth factor; Choline acetyltransferase; Water maze; Astroglia cell (Nitta, A. (250) 23)

Nerve impulse flow
$5\text{-}HT_{1A}$ receptor; Adenylate cyclase; Dorsal raphe nucleus; (+)-WAY 100 135; SDZ 216-525; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lesopitron; S-20499; Flesinoxan (Lanfumey, L. (249) 25)

Nerve stimulation, pre- and postganglionic
(*R*)-α-Methylhistamine; Sympathetic-cholinergic response; Histamine receptor; Presynaptic inhibition; Sudomotor system (Koss, M.C. (257) 109)

Nerve terminal current
Cholinomimetic; Acetylcholine; Anticholinesterase (Shakiryanova, D.M. (263) 107)

Nerve varicosity
Neuropeptide release; Synaptosome; Muscarinic receptor; Ileum; Bombesin (Kurjak, M. (257) 169)

Neural relaxation
Nitric oxide (NO); Sphincter of Oddi; Field stimulation (Lonovics, J. (255) 117)

Neurite outgrowth
Staurosporine; $gp140^{trk}$; Tyrosine; Phosphorylation (Rasouly, D. (269) 255)

Neuroactive steroid
$GABA_A$ receptor; 3α-Hydroxy-5β-pregnan-20-one; 3α-Hydroxy-5α-pregnan-20-one; TBPS (*t*-Butylbicyclophosphorothionate); Flunitrazepam (Hawkinson, J.E. (269) 157)

Neuroanatomical mapping
Morphine; Mesolimbic system; Drug discrimination; (Rat) (Shoaib, M. (252) 69)

Neuroblastoma
Tricyclic antidepressant; Imipramine; Desipramine; Patch-clamp; Nicotinic acetylcholine receptor (Rana, B. (250) 247)

Neuroblastoma SH-SY5Y cell
Protein kinase C; c-*fos* expression; Muscarinic-receptor-stimulation; Diacylglycerol (Larsson, C. (268) 19)

Neurodegeneration
DL-(Tetrazol-5-yl)glycine; NMDA (*N*-methyl-D-aspartate); *cis*-Methanoglutamate; Excitotoxicity (Schoepp, D.D. (270) 67)

Neurogenic inflammation
Norathyriol; Passive cutaneous anaphylaxis; Vascular permeability; Compound 48/80; Mast cell; (Mouse) (Wang, J.-P. (251) 35)

Afferent nerve stimulation; Capsaicin; Cutaneous hyperemia; Interleukin-1β; Nitric oxide (NO) (Herbert, M.K. (260) 89)

Respiratory viral infection; Airway sensory C fibers; Substance P; Airway hyperresponsiveness (Kudlacz, E.M. (270) 291)

Neurogenic vasopressor response
Pithed rat; EP_3 receptor; Prostaglandin E_2; Sulprostone; Presynaptic receptor (Malinowska, B. (259) 315)

Neuroimmunomodulation
Parasympathetic nervous system; Cyclosporine; Lymphoid tissue; Cholinergic innervation; Acetylcholine, synthesis and release; Choline uptake; Sympathetic nervous system; Superior cervical ganglion (Esquifino, A.I. (254) 1)

Neurointermediate lobe
Oxytocin; Vasopressin; Ca^{2+} channel, L-type; Dihydropyridine; (Electrical stimulation) (Jørgensen, A. (259) 157)

Neurokinin
CP-99,994; Emesis (Bountra, C. (249) R3)

Glycine; Nociception (Seguin, L. (253) R1)

Tachykinin; CHO (Chinese hamster ovary) cell; Antagonist; Structure-activity; Ca^{2+}; Second messenger; Inositol phosphate; Thapsigargin; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

Neurokinin A
Tachykinin NK_2 receptor; Tachykinin; Nociception; Spinal cord; Flexor reflex (Wiesenfeld-Hallin, Z. (251) 99)

Pulmonary edema, neurotransmitter; Neuropeptide Y (Hirabayashi, A. (256) 227)

Neurokinin B
Tachykinin NK_3 receptor; Angiotensin receptor antagonist; Brain, rat; Brain, guinea pig (Chrétien, L. (256) 73)

[^{125}I][MePhe^7]Neurokinin B binding
Tachykinin; Tachykinin NK_3 receptor; CHO (Chinese hamster ovary) cell; Species variation (Suman-Chauhan, N. (269) 65)

Neuroleptic
γ-Hydroxybutyrate receptor; Benzamide; Dopaminergic activity (Maitre, M. (256) 211)

Dopamine release; Dopamine metabolism; Dopamine D_2 receptor; Dopamine D_3 receptor; Microdialysis (Gainetdinov, R.R. (261) 327)

NE-100; σ Receptor; Phencyclidine; Cognition; (Rat) (Ogawa, S.-i. (263) 9)

Dopamine release; Acetylcholine release; Dopamine D_1 receptor stimulation; Dopamine D_1 receptor desensitization; (Therapeutic and collateral effect) (Imperato, A. (264) 55)

Clozaril; (Human) (Zorn, S.H. (269) R1)

Neuromedin C
Bombesin receptor; Glutamate; Nociception; NMDA receptor (Onogi, T. (262) 163)

Neuromedin N
Neurotensin; Dopamine; Substantia nigra; Avian neurotensin; Kinetensin; Electrophysiology (Keegan, K.D. (253) 131)

Neuromuscular blocking drug
Ammonium compound; Acetylcholine receptor; Skeletal muscle (Danilov, A.F. (257) 1)

Neuromuscular transmission
Age; Halothane; Voltage clamp (Bhattacharyya, B.J. (254) 97)

Neuron
Tachykinin NK_1 receptor; Substance P; Smooth muscle; Electrophysiology (Seabrook, G.R. (250) 125)

Neuronal damage
Glutamate; Lactate; Microdialysis; Nizofenone; Ischemia (Matsumoto, Y. (262) 157)

Neuronal injury
ACPC (1-aminocyclopropanecarboxylic acid); NMDA (*N*-methyl-D-aspartate); Dynorphin A; Glycine (Long, J.B. (261) 295)

Neuronal ischemic injury
Ca^{2+} channel antagonist, T-type; U-92032; Nifedipine; Flunarizine; Antioxidant (Ito, C. (257) 203)

Neuronal rescue
Selegiline; Trophic factor (Koutsilieri, E. (269) R3)

Neuropathic pain
Mononeuropathic rat; Opioid receptor; Enkephalin degradation; Mixed inhibitor (Lee, S.H. (264) 61)

Neuropathy
Diabetic rat; Nerve blood flow; Vasa nervorum; Nimodipine (Kappelle, A.C. (250) 43)

Neuropeptide
Preprogalanin; Galanin; Galanin receptor; Nociception; Spinal cord (Bedecs, K. (259) 151)

Basal ganglion; Dopamine; Immunohistochemistry; Radioimmunoassay (Castel, M.-N. (262) 1)

Binding; Brain; Electrophysiology; Gastric acid secretion; CCK_B receptor (Bertrand, P. (262) 233)

Edema; Neutrophil; Inflammation; Interleukin-8 (Ahluwalia, A. (264) 407)

Neuropeptide release
Synaptosome; Nerve varicosity; Muscarinic receptor; Ileum; Bombesin (Kurjak, M. (257) 169)

Neuropeptide Y
Dopamine; Striatum; Nucleus accumbens (Midgley, L.P. (251) 191)

Vasoconstriction; K^+ channel; BRL38227; Diazoxide; Cerebral basilar artery (Xia, Y. (255) 67)

Pulmonary edema, neurotransmitter; Neurokinin A (Hirabayashi, A. (256) 227)

Neuropeptide Y analog; Pertussis toxin; Benzalkonium chloride G-protein; Histamine release; Mast cell; (Rat) (Grundemar, L. (258) 163)

Catecholamine; [Met^5]Enkephalin; Adrenal medulla; Insulin; Hypoglycemia (Damase-Michel, C. (258) 277)

Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); Nitroprusside; Milrinone; cAMP; cGMP; Acetylcholine (Modin, A. (261) 185)

Prejunctional receptor; Noradrenaline overflow, evoked; [Leu^{31}, Pro^{34}]Neuropeptide Y; Neuropeptide Y-(18–36); Portal vein; (Freely moving rat) (Coppes, R.P. (261) 311)

Benextramine; Nonpeptide antagonist; Neuropeptide Y receptor subtype; Binding affinity (Melchiorre, C. (265) 93)

Megestrol acetate; Appetite; Cancer anorexia; Cachexia; Hypothalamus (McCarthy, H.D. (265) 99)

Neuropeptide Y Y_2 receptor agonist; Vagus nerve (Potter, E.K. (267) 253)

GTP; Photolabeling (Zhu, J. (268) 279)

[Leu^{31},Pro^{34}]Neuropeptide Y
Prejunctional receptor; Noradrenaline overflow, evoked; Neuropeptide Y; Neuropeptide Y-(18–36); Portal vein; (Freely moving rat) (Coppes, R.P. (261) 311)

Neuropeptide Y-(18–36)
Prejunctional receptor; Noradrenaline overflow, evoked; Neuropeptide Y; [Leu^{31},Pro^{34}]Neuropeptide Y; Portal vein; (Freely moving rat) (Coppes, R.P. (261) 311)

Neuropeptide Y analog
Neuropeptide Y; Pertussis toxin; Benzalkonium chloride G-protein; Histamine release; Mast cell; (Rat) (Grundemar, L. (258) 163)

Neuropeptide Y receptor
Peptide YY; [Pro^{34}]peptide YY; Gastrointestinal hormone (Grandt, D. (269) 127)

Neuropeptide Y receptor subtype
Neuropeptide Y; Benextramine; Nonpeptide antagonist; Binding affinity (Melchiorre, C. (265) 93)

Neuropeptide Y Y_2 receptor agonist
Neuropeptide Y; Vagus nerve (Potter, E.K. (267) 253)

Neuroprotection
Dizocilpine; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)-quinoxaline); Over-additive effect (Lippert, K. (253) 207)

Nitric oxide (NO) synthase; Middle cerebral artery; N^{ω}-Nitro-L-arginine (Carreau, A. (256) 241)

Neuroselectivity
Bisoxonol; K^+ channel (Hunnicutt, Jr., E.J. (261) R1)

Neurosteroid
Stress; Handling; CO_2; Brain, rat (Barbaccia, M.L. (261) 317)

cAMP; Brain cortex, rat; Diazepam binding inhibitor (DBI) receptor, mitochondrial; Protein synthesis inhibitor; Adrenalectomy/orchidectomy (Roscetti, G. (269) 17)

Neurotensin
CP-96345; Dynorphin; Methamphetamine; Tachykinin NK_1 receptor; Substance P (Gygi, S.P. (250) 177)

Dopamine; Substantia nigra; Neuromedin N; Avian neurotensin; Kinetensin; Electrophysiology (Keegan, K.D. (253) 131)

Receptor antagonist; Dopamine release; Striatum; Mesencephalic cell (Brouard, A. (253) 289)

[D-Trp^{11}]Neurotensin
Locomotor activity; Dopamine; Nucleus accumbens (Nouel, D. (254) 263)

Neurotensin receptor
Brain, guinea-pig; Dopamine; Midbrain; Basal ganglia; (Non-peptide receptor antagonist) (Azzi, M. (255) 167)

Neurotoxicity
Dopamine release; Kainic acid; Glutamic acid; NMDA receptor; AMPA receptor (Fedele, E. (249) 71)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); MDMA (3,4-methylenedioxymethamphetamine); 5-MeODMT (5-methoxy-*N*,*N*-dimethyltryptamine); Microdialysis; 5-HT_2 receptor (Gudelsky, G.A. (264) 325)

NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate); Glucocorticoid; Dexamethasone; Postnatal (Supko, D.E. (270) 105)

L-2-Amino-3-phosphonopropionate; Cerebellar neurons; Metabotropic glutamate receptor; NMDA receptor (Novelli, A. (270) 361)

Neurotransmission
ω-Agatoxin-IVA; ω-Conotoxin-GVIA; Ca^{2+} channel (voltage sensitive); Autonomic nerve; Smooth muscle (Lundy, P.M. (261) 79)

Neutral endopeptidase
Kinin; Tachykinin; Antigen; Plasma extravasation; Airway (Ricciardolo, F.L.M. (261) 127)

Angiotensin-converting enzyme; Captopril; SCH 34826; Heart failure; (Rat) (Helin, K. (264) 135)

Neutrophil
Inflammation; Prostaglandin D_2; Edema formation; Adherence; O_2^- production (Pons, F. (261) 237)

Neuropeptide; Edema; Inflammation; Interleukin-8 (Ahluwalia, A. (264) 407)

PAF (platelet activating factor); Ca^{2+}, intracellular; Inositol 1,4,5-trisphosphate (Koike, H. (269) 299)

Eosinophil; Bone marrow; Endotoxin; Lipopolysaccharide; PAF (platelet-activating factor); PAF receptor antagonist (Bozza, P.T. (270) 143)

Neutrophil, human
Priming; Adenosine receptor (Dianzani, C. (263) 223)

Immunotoxicology; Detergent; Respiratory burst; HL-60 cell line; Sodium dodecyl sulfate (SDS) (Kacani, L. (270) 285)

Neutrophilia
PAF (platelet-activating factor); Catecholamine; Adrenal gland (Altenburg, S.P. (256) 45)

Neutrophil, rat
Zinc hydroxide; Respiratory burst; Phagocytosis (Ogino, K. (270) 73)

NG108-15 cell
Desensitisation; Prostanoid IP receptor; $G_s\alpha$ protein; Adenylyl cyclase (Williams, R.J. (268) 177)

NG108-15 cell, transfected
Muscarinic acetylcholine receptor; Polyphosphoinositide turnover; c-*fos* expression; Calmodulin; Protein kinase C (Tohda, M. (268) 169)

Nicardipine
Myocardium, guinea-pig; Development; Ca^{2+}, extracellular; Ryanodine; Isoproterenol (Agata, N. (260) 47)

Ca^{2+} channel antagonist; Ca^{2+} transient; Ca^{2+} concentration, intracellular; Cardiac myocyte, rat (Jiang, J. (266) 155)

Nicotine
Peptidergic transmission; Purinergic transmission; NANC (non-adrenergic, non-cholinergic) nerve; Developmental pharmacology (Irie, K. (251) 75)

Morphine; Loperamide; Anti-emetic; 5-HT (5-hydroxytryptamine, serotonin); Vomiting; (*Suncus murinus*) (Selve, N. (256) 287)

Cardiovascular effect; Blood pressure; Heart rate; Pentobarbital; Tachyphylaxis (Cruz, S.L. (258) 39)

Sumatriptan; 5-HT_1 receptor; Sensory neurotransmission; Basilar artery, guinea pig (O'Shaughnessy, C.T. (259) 37)

Saphenous artery; Vasodilator nerve; Nitric oxide (NO); CGRP (calcitonin gene-related peptide) (Okamura, T. (263) 85)

Chromaffin cell; Catecholamine; Antidepressant; Ca^{2+} channel; Histamine (Firestone, J.A. (269) 177)

[^{3}H]Nicotine
[^{3}H]Cytisine; [^{3}H]Methylcarbamylcholine; Nicotinic acetylcholine receptor, neuronal; (Rat) (Anderson, D.J. (253) 261)

Nicotinic
Muscarinic; Sympathetic ganglion; Culture; Electrophysiology; (Guinea pig) (Xian, H. (259) 21)

Nicotinic acetylcholine receptor
Catecholamine synthesis rate; Dopamine; Ethanol; Microdialysis (in vivo); (Rat) (Blomqvist, O. (249) 207)

Tricyclic antidepressant; Imipramine; Desipramine; Patch-clamp; Neuroblastoma (Rana, B. (250) 247)

Acetylcholine; Hippocampus; Medial septal area; Spatial memory (Decker, M.W. (261) 217)

Muscarinic acetylcholine receptor; Myocyte; Oxotremorine methiodide; Patch clamping; (Single channel) (Reitstetter, R. (264) 27)

SK&F 96365; Neostigmine; Endplate potential; Receptor desensitisation (Hong, S.J. (265) 35)

Nicotinic acetylcholine receptor, neuronal
[^{3}H]Cytisine; [^{3}H]Nicotine; [^{3}H]Methylcarbamylcholine; (Rat) (Anderson, D.J. (253) 261)

Nicotinic receptor
Epibatidine; Analgesia (Qian, C. (250) R13)

Melatonin; Sympathetic neurotransmission; Vas deferens; Protein synthesis (Carneiro, R.C.G. (257) 73)

K^+ channel; Smooth muscle; NANC (non-adrenergic, non-cholinergic) relaxation; Penile erection (Alaranta, S. (259) 203)

Nitric oxide (NO); NANC (non-adrenergic non-cholinergic) transmission; Electrical field stimulation; Ileocecal sphincter; (Cat) (Mizhorkova, Z. (265) 77)

Nicotinic receptor channel
Apomorphine; Dopamine receptor agonist; Dopamine receptor antagonist; *Xenopus* oocyte; Functional expression (Nakazawa, K. (269) 375)

Nifedipine
Anococcygeus muscle; Adrenergic transmission; Ca^{2+} channel antagonist (Iravani, M.M. (250) 193)

CP-96,345; Ca^{2+} channel antagonist; Verapamil; Smooth muscle, isolated; (Anesthetized dog) (Constantine, J.W. (252) 275)

Noradrenaline release; Hexachlorocyclohexane isomer; Bay K 8644; DIDS (4,4-diisothiocyanato-stilbene-2,2′-disulfonic acid); W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); Hippocampal slice, rat (Cristòfol, R.M. (252) 305)

Electroconvulsive shock; Ca^{2+} channel; Apomorphine; Analgesia; Hyperalgesia; Hot-plate test; Hypermotility; (Rat) (Antkiewicz-Michaluk, L. (254) 9)

Bay K 8644; Dihydropyridine; K^+ contracture; Skeletal muscle; Twitch response (Kitamura, N. (256) 169)

Ca^{2+} channel antagonist, T-type; Neuronal ischemic injury; U-92032; Flunarizine; Antioxidant (Ito, C. (257) 203)

Adrenal catecholamine; Voltage-dependent Ca^{2+} channel, N-type, L-type; ω-Conotoxin GVIA; Verapamil; Acetylcholine (Kimura, T. (264) 169)

α_1-Adrenoceptor subtype; Chloroethylclonidine; Vas deferens, rat; Spleen, rat; Prostate, human (Teng, C.-M. (265) 61)

Nigrostriatal / mesolimbic dopamine
Dopamine receptor subtype; Ethanol drinking; (Inbred mouse) (Ng, G.YK. (269) 349)

Dopamine receptor agonist; Ethanol drinking; (Inbred mouse) (Ng, G.YK. (269) 365)

NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1*H*-cyclopenta(*b*)-quinoline monohydrate hydrochloride)
Tacrine; Physostigmine; Scopolamine-induced amnesia; Side-effect (central); Side-effect (peripheral) (Yoshida, S. (250) 117)

Nimesulide
Polymorphonuclear leukocyte; Phosphodiesterase type IV; Superoxide anion; cAMP; Chemotaxis (Bevilacqua, M. (268) 415)

Nimodipine
Neuropathy; Diabetic rat; Nerve blood flow; Vasa nervorum (Kappelle, A.C. (250) 43)

Amphetamine; 5-HT (5-hydroxytryptamine, serotonin); Methamphetamine; Tryptophan hydroxylase; (Metabolism) (Elkins, K.W. (250) 395)

Cell death; Ca^{2+} oscillation; Veratridine; Bovine chromaffin cell; R56865; Flunarizine; ω-Conotoxin GVIA (Maroto, R. (270) 331)

Nitrate tolerance
Thiol; Nitrovasodilator; Smooth muscle, vascular; Endothelium (Kojda, G. (250) 385)

Nitrendipine
Ca^{2+} channel, L-type; Dihydropyridine; MK 801; Ca^{2+} channel, voltage-sensitive; NMDA receptor; Dibenzocycloheptenimine (Filloux, F.M. (269) 325)

Nitrergic transmission
Bioassay; Ileocolonic junction, dog; Nitric oxide (NO) (Boeckxstaens, G.E. (264) 85)

Nitric oxide (NO)
N^G-Nitro-L-arginine methylester (L-NAME); Cerebral blood flow; Halothane; Anesthetics (Dawson, D.A. (249) 7)

Interleukin 1β; Cyclosporin; Immunosuppressive drug; Mesangial cell (Mühl, H. (249) 95)

Aminoguanidine; *N*,*N*′-Diaminoguanidine; Methylguanidine; 1,1-Dimethylguanidine; Nitric oxide synthase; N^G-Monomethyl-L-arginine; (L-NMA) (Hasan, K. (249) 101)

Asthma; Bronchoconstriction (Persson, M.G. (249) R7)

Descending relaxation; 5-HT (5-hydroxytryptamine, serotonin); Ileum, rat; NANC (non-adrenergic, non-cholinergic) inhibition (Kanada, A. (250) 59)

Artery, human; Adrenergic stimulation; Endothelium (Aldasoro, M. (250) 103)

Salbutamol; β_2-Adrenoceptor; N^G-Nitro-L-arginine methyl ester; Aortic ring; Blood pressure; Endothelium (Wang, Y.-X. (250) 335)

Endotoxic shock; *N*-Acetylserotonin (Klemm, P. (250) R9)

Knee joint inflammation; Peripheral analgesia; Dipyrone; Nitric oxide synthetase inhibitor (Tonussi, C.R. (251) 173)

Peristalsis; N^G-Nitro-L-arginine; Circular muscle; Ileum, guinea-pig (Suzuki, N. (251) 221)

N^G-Nitro-L-arginine; N^G-Monomethyl-L-arginine; Glucocorticoid; Endotoxin (Berrazueta, J.R. (251) 303)

Vascular reactivity; Endothelium; cGMP; Nandrolone (Ferrer, M. (252) 233)

Anaphylaxis, mouse; Blood pressure; Histamine (Osada, S. (252) 347)

Manganese; Superoxide dismutase; cGMP; Blood pressure (Kasten, T.P. (253) 35)

Gastric hyperemia; Capsaicin (Konturek, S.J. (253) 107)

Vasorelaxation; Aortic baroreceptor; Endothelium; Adenosine receptor; EDRF (endothelium-derived relaxing factor); NECA (5′-*N*-ethylcarboxamidoadenosine) (Fahim, M. (254) 183)

Vasodilator; Antiaggregator; Furoxan; cGMP (Civelli, M. (255) 17)

Serotonergic system; Brain; Anorexia; Zucker rat (Squadrito, F. (255) 51)

Balloon angioplasty; Endothelin-1; N^ω-Nitro-L-arginine methyl ester; Vascular reactivity; Neointima formation (Douglas, S.A. (255) 81)

Sphincter of Oddi; Field stimulation; Neural relaxation (Lonovics, J. (255) 117)

Vasodilator nerve; Cerebral artery; Calmodulin; Endothelium (Okamura, T. (256) 79)

ANF (atrial natriuretic factor); cGMP; Guanylyl cyclase; ANF receptor antagonist; Hypoxia; Hypoxic coronary vasodilatation; Heart, isolated, guinea pig (Park, K.H. (256) 99)

Uterine artery; L-Arginine; Relaxation; EDRF (endothelium-derived relaxing factor); (Human) (Jovanović, A. (256) 103)

Gastric emptying; N^G-Nitro-L-arginine methyl ester; N^G-Monomethyl-L-arginine; Blood pressure; L-Arginine (Plourde, V. (256) 125)

CGRP (calcitonin gene-related peptide); Ulcer (Clementi, G. (256) R7)

EDRF (endothelium-derived relaxing factor); N^ω-Nitro-L-arginine methyl ester; Acute inflammation (Giraldelo, C.M.M. (257) 87)

FK409; Isosorbide dinitrate (Kita, Y. (257) 123)

Muscarinic receptor antagonist; Opioid; Small intestine; Substance P; VIP (vasoactive intestinal peptide) (Gustafsson, B.I. (257) 227)

Ulcer; NSAID (non-steroidal anti-inflammatory drug); Inflammation; Prostaglandin (Wallace, J.L. (257) 249)

Small intestine, rat; NANC (non-adrenergic, non-cholinergic) neurotransmission; Nitric oxide (NO)-induced contraction (Barthó, L. (259) 101)

Aorta; Vasopressin; EDRF (endothelium-derived relaxing factor); Gonadal steroid hormone; Vasoconstriction (Stallone, J.N. (259) 273)

Afferent nerve stimulation; Capsaicin; Cutaneous hyperemia; Interleukin-1β; Neurogenic inflammation (Herbert, M.K. (260) 89)

Ulcer; Cytoprotection; Mucosal blood flow (Ferraz, J.-G.P. (260) 107)

FK409; Tolerance; Vasorelaxation; Guanylate cyclase, soluble (Isono, T. (260) 163)

Endotoxin; Sepsis; Vasopressin; Vasopressin receptor antagonist; Intestinal mucosal injury; Intestinal vascular permeability; N^G-Nitro-L-arginine methyl ester (László, F. (260) 265)

Cholecystokinin-8; Pentagastrin (Stroff, T. (260) R1)

Pentoxifylline; Mesenteric resistance vessel; Aminophylline; Endothelium; Smooth muscle, vascular; Methylxanthine derivative (Hansen, P.R. (261) 105)

Interferon-γ; Arterial reactivity; Bradykinin (De Kimpe, S.J. (261) 111)

VIP (vasoactive intestinal polypeptide); Neuropeptide Y; Nitroprusside; Milrinone; cAMP; cGMP; Acetylcholine (Modin, A. (261) 185)

Interleukin-1β; Lipopolysaccharide; DL-Propranolol; Smooth muscle, vascular; Cell culture; Spontaneously hypertensive rat (SHR); Wistar Kyoto rat (WKY); (Rat) (De Castro, M. (261) 199)

Gastric acid; Gastric distension; 2-Deoxy-D-glucose; Histamine; Pentagastrin; Brain-gut axis (Barrachina, D. (262) 181)

Endotoxin; Lipopolysaccharide; Lung; Prostacyclin (Sautebin, L. (262) 193)

Trolox; Antioxidant; SIN (3-morpholino sydnonimine); cGMP; Prostaglandin; Leukotriene; Leukocyte (Riutta, A. (262) 217)

(+)-*cis*-Dioxolane; β-Endorphin; Antinociception; Tail-flick inhibition; cGMP (Xu, J.Y. (262) 223)

Angiotensin II; EDRF (endothelium-derived relaxing factor); Aorta, rabbit; N^G-Monomethyl-L-arginine; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester; Indomethacin (Zhang, J. (262) 247)

Saphenous artery; Vasodilator nerve; CGRP (calcitonin gene-related peptide); Nicotine (Okamura, T. (263) 85)

Gastric mucosa; Mucus; Stomach (Price, K.J. (263) 199)

Lung; Ca^{2+} (Persson, M.G. (264) 13)

Bioassay; Ileocolonic junction, dog; Nitrergic transmission (Boeckxstaens, G.E. (264) 85)

NANC (non-adrenergic non-cholinergic) transmission; Electrical field stimulation; Nicotinic receptor; Ileocecal sphincter; (Cat) (Mizhorkova, Z. (265) 77)

Granuloma; L-Arginine; N^G-Nitro-L-arginine methyl ester; Macrophage (Iuvone, T. (265) 89)

Lipoprotein; Vasodilation; Endothelium (Galle, J. (265) 111)

NMDA (*N*-Methyl-D-aspartate); Cyclic AMP; Forskolin; Protein kinase A (Toms, N.J. (266) 63)

cAMP analog; Cholera toxin; Peritoneal macrophage; (Rat) (Sowa, G. (266) 125)

Glyceraldehyde-3-phosphate dehydrogenase; Endotoxin; Cytotoxicity; Shock (Dimmeler, S. (267) 105)

Adenosine cyclic monophoshate; Guanosine cyclic monophoshate; NANC (non-adrenergic, non-cholinergic) nerve; Urethra; Detrusor (Persson, K. (268) 159)

Macrophage; Temperature (Bernard, C. (270) 115)

Acetylcholine; Arginine; Bradykinin; cGMP; Gentamicin; (Rat) (Rivas-Cabañero, L. (270) 119)

Single breath; Respiratory system; Alcohol; Toxicity; Blood pressure; (Lung); (Pharmacology) (Persson, M.G. (270) 273)

Lipopolysaccharide; Septic shock; Inducible nitric oxide synthase (Van den Berg, C. (270) 379)

Nitric oxide (NO)-induced contraction
Small intestine, rat; Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) neurotransmission (Barthó, L. (259) 101)

Nitric oxide (NO) synthase
Aminoguanidine; *N*,*N*′-Diaminoguanidine; Methylguanidine; 1,1-Dimethylguanidine; Nitric oxide (NO); N^G-Monomethyl-L-arginine; (L-NMA) (Hasan, K. (249) 101)

Middle cerebral artery; Neuroprotection; N^ω-Nitro-L-arginine (Carreau, A. (256) 241)

Ischemia; Locomotor activity; N^G-Nitro-L-arginine; Histology; (Mongolian gerbil) (Caldwell, M. (260) 191)

Sodium choleate; Diarrhea; Intestinal secretion; Small intestinal transit (Mascolo, N. (264) 21)

Protein kinase C; Endothelium; EDRF (endothelium-dependent relaxation factor); Phorbol ester (Davda, R.K. (266) 237)

Urethra (rabbit); Non-adrenergic, non-cholinergic (NANC) relaxation; Nitric oxide synthase inhibitor (Dokita, S. (266) 269)

Cerebellum; Microdialysis; Metalloporphyrins; Guanylyl cyclase; cGMP (Luo, D. (267) 263)

Ebselen (Hattori, R. (267) R1)

Nitric oxide (NO) synthase, inducible
Lipopolysaccharide; Septic shock; Nitric oxide (NO) (Van den Berg, C. (270) 379)

Nitric oxide (NO) synthase inhibitor
Nitric oxide (NO); Knee joint inflammation; Peripheral analgesia; Dipyrone (Tonussi, C.R. (251) 173)

Mesenteric vascular bed; Endothelium-dependent response; Nitrovasodilator; Vascular tone; Atropine; (Cat) (Santiago, J.A. (254) 207)

Urethra (rabbit); Non-adrenergic, non-cholinergic (NANC) relaxation; Nitric oxide synthase (Dokita, S. (266) 269)

Nitric oxide (NO) synthesis
N^ω-Nitro-L-arginine methyl ester; LY83583; L158809; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

Nitrite
Interleukin-1; Atherosclerosis; Hypertension (Ikeda, U. (269) 319)

***N*-Nitro-L-arginine**
Acetylcholine; 8-Bromo-cGMP; EDRF (endothelium-derived relaxing factor); Aortic ring, isolated, rat; Atrium, right, isolated, rat; LY-83,583 (6-(phenylamino)-5,8-quinolinedione); Norepinephrine; SIN-1 (3-morpholino-sydnonimine); (Spontaneous rate) (Kennedy, R.H. (255) 149)

N^G-Nitro-L-arginine
Endotoxin; PAF (platelet activating factor); Cardiovascular function; Shock; (Dog) (Takekoshi, K. (250) 465)

Peristalsis; Nitric oxide (NO); Circular muscle; Ileum, guinea-pig (Suzuki, N. (251) 221)

Nitric oxide (NO); N^G-Monomethyl-L-arginine; Glucocorticoid; Endotoxin (Berrazueta, J.R. (251) 303)

Morphine; Ethanol-induced mucosal lesion; Aspirin-induced mucosal lesion; (Rat) (Gyires, K. (255) 33)

Ischemia; Locomotor activity; Nitric oxide (NO) synthase; Histology; (Mongolian gerbil) (Caldwell, M. (260) 191)

Angiotensin II; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Aorta, rabbit; N^G-Monomethyl-L-arginine; N^G-Nitro-L-arginine methyl ester; Indomethacin (Zhang, J. (262) 247)

Endothelin; Ibuprofen; EDRF (endothelium-derived relaxing factor); Renal blood flow; Urine flow rate; Urine osmolality; Glomerular filtration rate; (Dog) (Yukimura, T. (264) 399)

N^ω-Nitro-L-arginine
Nitric oxide (NO) synthase; Middle cerebral artery; Neuroprotection (Carreau, A. (256) 241)

***N*-Nitro-L-arginine methyl ester**
Tolerance; Morphine; Thyrotropin (TSH); Prolactin; Growth hormone; Antinociception; Hyperthermia (Rauhala, P. (259) 57)

N^G-Nitro-L-arginine methyl ester
Nitric oxide (NO); Cerebral blood flow; Halothane; Anesthetics (Dawson, D.A. (249) 7)

Salbutamol; Nitric oxide (NO); β_2-Adrenoceptor; Aortic ring; Blood pressure; Endothelium (Wang, Y.-X. (250) 335)

Nitric oxide (NO); Gastric emptying; N^G-Monomethyl-L-arginine; Blood pressure; L-Arginine (Plourde, V. (256) 125)

Endotoxin; Sepsis; Nitric oxide (NO); Vasopressin; Vasopressin receptor antagonist; Intestinal mucosal injury; Intestinal vascular permeability (László, F. (260) 265)

Angiotensin II; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Aorta, rabbit; N^G-Monomethyl-L-arginine; N^G-Nitro-L-arginine; Indomethacin (Zhang, J. (262) 247)

Granuloma; Nitric oxide (NO); L-Arginine; Macrophage (Iuvone, T. (265) 89)

N^ω-Nitro-L-arginine methyl ester
Balloon angioplasty; Nitric oxide (NO); Endothelin-1; Vascular reactivity; Neointima formation (Douglas, S.A. (255) 81)

EDRF (endothelium-derived relaxing factor); Acute inflammation; Nitric oxide (NO) (Giraldelo, C.M.M. (257) 87)

Nitric oxide (NO) synthesis; LY83583; L158809; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

Nitrobenzylthioinosine
Adenosine; Nucleoside transporter; Dipyridamole; Brain (Jones-Humble, S.A. (257) 311)

Nitro compound
Pancreas (dog); Exocrine secretion; KRN2391 (*N*-cyano-*N'*-(2-nitroxyethyl)-3-pyridinecarboximidamide monomethanesulfonate); K^+ channel opener (Iwatsuki, K. (249) 19)

Nitroglycerin
8-Br-cGMP; Rp-8-Br-cGMPS; 8-Br-cAMP; Aorta, rabbit; cGMP-dependent protein kinase; cAMP-dependent protein kinase (Nakazawa, M. (253) 179)

6-Nitroindazole
7-Nitroindazole; Smooth muscle relaxation (Medhurst, A.D. (256) R5)

7-Nitroindazole
Smooth muscle relaxation; 6-Nitroindazole (Medhurst, A.D. (256) R5)

Nitropropane analog, baclofen
Nitropropane analog, GABA; Ileum, isolated, guinea-pig; Neocortex, rat; Spinal cord, cat; $GABA_B$ receptor antagonist (Ong, J. (264) 49)

Nitropropane analog, GABA
Nitropropane analog, baclofen; Ileum, isolated, guinea-pig; Neocortex, rat; Spinal cord, cat; $GABA_B$ receptor antagonist (Ong, J. (264) 49)

Nitroprusside
Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); Neuropeptide Y; Milrinone; cAMP; cGMP; Acetylcholine (Modin, A. (261) 185)

***S*-Nitroso-*N*-acetylcaptopril**
Glyceryl trinitrate; *S*-Nitroso-*N*-acetylpenicillamine; Tolerance, in vitro; *S*-Nitrosothiols; Artery, bovine coronary (Zhang, C.L. (252) 299)

***S*-Nitroso-*N*-acetylpenicillamine**
Glyceryl trinitrate; *S*-Nitroso-*N*-acetylcaptopril; Tolerance, in vitro; *S*-Nitrosothiols; Artery, bovine coronary (Zhang, C.L. (252) 299)

***S*-Nitrosothiols**
Glyceryl trinitrate; *S*-Nitroso-*N*-acetylpenicillamine; *S*-Nitroso-*N*-acetylcaptopril; Tolerance, in vitro; Artery, bovine coronary (Zhang, C.L. (252) 299)

Nitrovasodilator
Thiol; Nitrate tolerance; Smooth muscle, vascular; Endothelium (Kojda, G. (250) 385)

Nitric oxide synthase inhibitor; Mesenteric vascular bed; Endothelium-dependent response; Vascular tone; Atropine; (Cat) (Santiago, J.A. (254) 207)

Nizofenone
Glutamate; Lactate; Microdialysis; Neuronal damage; Ischemia (Matsumoto, Y. (262) 157)

NMDA (*N*-methyl-D-aspartate)
Adenosine receptor agonist; Adenosine receptor antagonist; Seizure; Protection; (Mouse) (Von Lubitz, D.K.J.E. (249) 265)

Tolbutamide; Hippocampus (Kwiecien, R. (249) 325)

Endothelin-1; Barrel rolling; Periaqueductal gray area (Maione, S. (250) 209)

Anxiolytic; Glycine receptor ligand; NMDA receptor antagonist; ACPC (1-aminocyclopropanecarboxylate); D-Cycloserine (Anthony, E.W. (250) 317)

Behavior; MK-801; Phencyclidine; Sensitization; Temperature; Thermoregulation; Tolerance (Pechnick, R.N. (252) 35)

1,2,3,4-Tetrahydro-9-aminoacridine; Tacrine; Voltage-clamp experiment; Open-channel block (Vorobjev, V.S. (253) 1)

Adenosine analog; Seizure; (Mouse) (Von Lubitz, D.K.J.E. (253) 95)

Phenytoin; Phenobarbital; Valproic acid; Norepinephrine efflux (Brown, L.M. (254) 307)

Glycine; Polyamine; 7-Chlorokynurenate; Ifenprodil; (Synergism) (Voltz, C. (255) 197)

SCH 23390; Raclopride; Striatum; Microdialysis; (Neurotransmitter release) (Morari, M. (256) 23)

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); MK-801 (dizocilpine) (Löscher, W. (259) R3)

ACPC (1-aminocyclopropanecarboxylic acid); Neuronal injury; Dynorphin A; Glycine (Long, J.B. (261) 295)

Cerebral ischemia; Glutamate; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Microdialysis; Excitotoxin (Gaspary, H.L. (262) 197)

Dopamine; GABA (γ-aminobutyric acid); Excitatory amino acid; $GABA_A$ receptor; Tissue culture (Chaudieu, I. (264) 361)

Nitric oxide (NO); Cyclic AMP; Forskolin; Protein kinase A (Toms, N.J. (266) 63)

Polyamine; Spermine; Spermidine; Arcaine; 1,10-diaminodecane; Diethylenetriamine; Putrescine; NMDA receptor; Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

Glycine; Ca^{2+}; Ca^{2+} entry; Cerebellar granule cells; Cell culture (Simpson, P.B. (266) 309)

IBMX (3-isobutyl-1-methylxanthine) phosphodiesterase; Adenosine; cAMP; 5'AMP; (*N*-methyl-D-aspartate); (Release) (Craig, C.G. (269) 79)

ACTH (adrenocorticotropic hormone); Corticosterone; Dioxadrol; Endocrine; Pentazocine; Phencyclidine; σ Receptor; SKF 10,047 (Pechnick, R.N. (263) 115)

Dizocilpine; Glutamate; Glycine; Spermine; Polyamine (Marvizón, J.-C. (269) 165)

DL-(Tetrazol-5-yl)glycine; *cis*-Methanoglutamate; Excitotoxicity; Neurodegeneration (Schoepp, D.D. (270) 67)

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate); Neurotoxicity; Glucocorticoid; Dexamethasone; Postnatal (Supko, D.E. (270) 105)

NMDA receptor

Dopamine release; Kainic acid; Neurotoxicity; Glutamic acid; AMPA receptor (Fedele, E. (249) 71)

Ifenprodil; Polyamine; ACTH (adrenocorticotropin); Behavior; (Rat) (Genedani, S. (252) 77)

Theophylline; Hyperalgesia; Noradrenaline; Dopamine; Adenosine (Paalzow, G.H.M. (252) 87)

Morphine, intrathecal; Clonic seizure-like behavior; MK-801; Glycine co-agonist site; ACEA-1011 (Lutfy, K. (252) 261)

Hippocampus; Granule cell; Field potential; *d*-Cycloserine; Glycine binding site (Pitkänen, M. (253) 125)

Dopamine release; δ-Opioid receptor (Dourmap, N. (253) R9)

Adenosine; Brain microdialysis; Cerebral cortex; Tetrodotoxin; Muscarinic receptor (Pazzagli, M. (254) 277)

Reserpine; Dopamine D_1 receptor; Dopamine D_2 receptor; Motor activity; Dopamine-glutamate interaction (Ferré, S. (255) 203)

Polyamine; Seizure; *N*-(3-Aminopropyl)-cyclohexylamine (Chu, P.-j. (256) 155)

Haloperidol-induced catalepsy; GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5*H*-2,3-benzodiazepine HCl); CGP 37849 (DL-(*E*)-2-amino-4-methyl-5-phosphono-3-pentenoic acid); AMPA receptor; (Rat) (Hauber, W. (256) 339)

Memory enhancement; Glycine partial agonist; Administration, acute and chronic (Quartermain, D. (257) 7)

Ca^{2+} channel; Voltage-clamp, whole-cell; Cortical neuron, cultured; Eliprodil (Biton, B. (257) 297)

Endothelin-3; Dopamine; Glutamate; Striatal slice; Voltage-gated Ca^{2+} channel (Koizumi, S. (259) 195)

Neuromedin C; Bombesin receptor; Glutamate; Nociception (Onogi, T. (262) 163)

Hippocampal neuron, isolated; Concentration jump; Glutamate receptor; Chemically gated current (Wilsch, V.W. (262) 287)

Redox; Long-term potentiation (Gozlan, H. (262) R3)

Acetylcholine release; Budipine; Biperiden; Nucleus caudatus; MK-801 binding (Jackisch, R. (264) 207)

Anesthetic; Anesthesia, theories of; Synaptic transmission; Spinal cord; Glutamate receptor; $GABA_A$ receptor (Kendig, J.J. (264) 427)

Polyamines; [^{3}H]L-689,560 binding; Glycine; Allosteric interaction (Grimwood, S. (266) 43)

[^{3}H]Ifenprodil binding; Polyamines; σ Receptor; Brain, rat (Hashimoto, K. (266) 67)

Polyamine; Spermine; Spermidine; Arcaine; 1,10-diaminodecane; Diethylenetriamine; Putrescine; *N*-Methyl-D-aspartate (NMDA); Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

Cannabis; δ-9-Tetrahydrocannabinol (THC); Cerebral decortication; MK-801; In situ hybridization (Mailleux, P. (266) 193)

Glutamate Receptor; Excitotoxicity (Cik, M. (266) R1)

Keratinocyte; Cardiocyte; [^{3}H]MK-801; mRNA (Morhenn, V.B. (268) 409)

Ca^{2+} channel, L-type; Dihydropyridine; Nitrendipine; MK 801; Ca^{2+} channel, voltage-sensitive; Dibenzocycloheptenеimine (Filloux, F.M. (269) 325)

L-2-Amino-3-phosphonopropionate; Neurotoxicity; Cerebellar neurons; Metabotropic glutamate receptor (Novelli, A. (270) 361)

NMDA receptor antagonist
Anxiolytic; Glycine receptor ligand; NMDA (*N*-methyl-D-aspartate); ACPC (1-aminocyclopropanecarboxylate); D-Cycloserine (Anthony, E.W. (250) 317)

MK-801 ((+)-5-methyl-10,11-dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5,10-imine); 6-Hydroxydopamine; Haloperidol; Nucleus accumbens; Locomotion; (Rat) (Ouagazzal, A.-m. (251) 229)

Vestibular compensation; Org 2766 (Gilchrist, D. (252) R1)

AMPA receptor antagonist; BAY k-8644; Seizure (Czuczwar, S.J. (264) 103)

NMDA receptor antagonist, competitive
CGS 19755 (*cis*-4-(phosphonomethyl)piperidine-2-carboxylic acid); Dopamine synthesis; Hyperactivity; Amphetamine; (±)-CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Bristow, L.J. (264) 353)

7-Chlorokynurenate; Polyamine; Glycine recognition site; NMDA receptor complex; Brain, rat (Oblin, A. (266) 103)

NMDA receptor complex
7-Chlorokynurenate; Polyamine; NMDA receptor antagonist, competitive; Glycine recognition site; Brain, rat (Oblin, A. (266) 103)

NMDA receptor, recombinant
HEK 293 cell; Ligand affinity; Glutamate; Glycine; MK 801 (Laurie, D.J. (268) 335)

^{31}P NMR spectroscopy
Ca^{2+} channel antagonist; Heart, isolated; Fantofarone; Ischemia (Vander Elst, L. (251) 163)

NMR tomography
Magnetic resonance imaging; Brain edema; Stroke; 5-HT receptor antagonist; Ca^{2+} channel blocker (Elger, B. (254) 65)

Nociception
Neurokinin A; Tachykinin NK_2 receptor; Tachykinin; Spinal cord; Flexor reflex (Wiesenfeld-Hallin, Z. (251) 99)

α_2-Adrenoceptor; Dexmedetomidine; Mydriasis; Spinal cord (Horváth, G. (253) 61)

Glycine; Neurokinin (Seguin, L. (253) R1)

Immediate-early gene; Inhibitor of enkephalin-degrading enzyme; Morphine; Non-steroidal anti-inflammatory drug; Tolerance (Abbadie, C. (258) 215)

Preprogalanin; Galanin; Galanin receptor; Spinal cord; Neuropeptide (Bedecs, K. (259) 151)

Neuromedin C; Bombesin receptor; Glutamate; NMDA receptor (Onogi, T. (262) 163)

Nomifensine
CCK receptor antagonist; CCK-8; BC-264; Dopamine; Depression; L-365,260 (Hernando, F. (261) 257)

Non-adrenoceptor binding
α_2-Adrenoceptor; Cortex; Imidazoline (Wallace, D.R. (258) 67)

Non-insulin-dependent diabetes mellitus
d-Fenfluramine therapy; Insulin resistance; Liver; (Rat) (Picarel-Blanchot, F. (264) 227)

Non-NMDA receptor
Dopaminergic neuron; Hypothalamus; Striatum (Wagner, E.J. (254) 105)

GYKI 52466; Spinal reflex; Benzodiazepine receptor (Block, F. (256) 149)

Non-NMDA receptor antagonist
NBQX; Sympathetic nerve activity; Blood pressure; (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline) (Chen, K. (252) 155)

Non-peptide antagonist
Neuropeptide Y; Benextramine; Neuropeptide Y receptor subtype; Binding affinity (Melchiorre, C. (265) 93)

Non-steroidal anti-inflammatory drug
Tracheal epithelial cell; Short circuit current (Mochizuki, H. (252) 183)

Nabumetone; Inflammation; Antinociception (Clarke, G.D. (257) 103)

Ulcer; Nitric oxide (NO); Inflammation; Prostaglandin (Wallace, J.L. (257) 249)

Immediate-early gene; Inhibitor of enkephalin-degrading enzyme; Morphine; Nociception; Tolerance (Abbadie, C. (258) 215)

Nootropic
Learning, latent; Nefiracetam (DM-9384); Water finding test (Nabeshima, T. (255) 57)

Noradrenaline
Theophylline; Hyperalgesia; NMDA receptor; Dopamine; Adenosine (Paalzow, G.H.M. (252) 87)

Diabetes mellitus; Caffeine; Ca^{2+}, mobilization of intracellular; Aorta, rat (Hattori, Y. (256) 215)

Artery, rabbit; Nandrolone; Vascular reactivity; Angiotensin II; 5-HT (5-hydroxytryptamine, serotonin) (Ferrer, M. (258) 103)

Ca^{2+} channel; Ryanodine; G-protein; Protein kinase C; Caffeine; Phenoxybenzamine (Tabrizchi, R. (259) 285)

Atrium, rat; Diabetes; Endothelin-1; Streptozotocin; Sympathetic nerve stimulation (Lieu, A.T. (261) 33)

Acetylcholine; *d*-Amphetamine; Cortex; Dopamine; 6-Hydroxydopamine (Day, J.C. (263) 285)

Caffeine; Heparin; Ruthenium red; Smooth muscle, vascular (Garcha, R.S. (268) 319)

Noradrenaline metabolite
Atherosclerosis; Aorta, rabbit; Pulmonary artery, rabbit; Noradrenaline release; Sympathetic nerve stimulation (Verbeuren, T.J. (270) 27)

Noradrenaline overflow, evoked
Prejunctional receptor; Neuropeptide Y; [Leu^{31},Pro^{34}]Neuropeptide Y; Neuropeptide Y-(18–36); Portal vein; (Freely moving rat) (Coppes, R.P. (261) 311)

Noradrenaline release
Hexachlorocyclohexane isomer; Bay K 8644; Nifedipine; DIDS (4,4-diisothiocyanato-stilbene-2,2′-disulfonic acid); W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); Hippocampal slice, rat (Cristòfol, R.M. (252) 305)

P_2 purinoceptor; Sympathetic neuron (Allgaier, C. (252) R7)

Atherosclerosis; Aorta, rabbit; Pulmonary artery, rabbit; Sympathetic nerve stimulation; Noradrenaline metabolite (Verbeuren, T.J. (270) 27)

[^{3}H]Noradrenaline uptake
Hydralazine; Vas deferens (bisected, rat); $^{45}Ca^{2+}$ influx (Campos-Toimil, M. (251) 83)

Norathyriol
Passive cutaneous anaphylaxis; Neurogenic inflammation; Vascular permeability; Compound 48/80; Mast cell; (Mouse) (Wang, J.-P. (251) 35)

Nor-binaltorphimine
Lipopolysaccharide, *Pantoea agglomerans*; Antinociception; Diabetes; Naltrindole; β-Funaltrexamine; Opioid receptor (Kamei, J. (251) 95)

L-Arginine; Antinociception; Diabetes; Naltrindole; β-Funaltrexamine; Opioid receptor (Kamei, J. (254) 113)

Blood pressure; Hypertension; Hippocampus; Dynorphin; Spontaneously hypertensive rat (SHR) (Wang, J.Q. (256) 57)

κ-Opioid receptor, supraspinal; Butorphanol dependence; Naloxone; Withdrawal, precipitated (Jaw, S.P. (257) 153)

Tail-pressure test; Antinociception; Opioid receptor (Spanagel, R. (264) 157)

Norepinephrine
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP analog; MPTP derivative; 5-HT (5-hydroxytryptamine, serotonin); Fluoxetine; Desipramine (Andrews, A.M. (250) 215)

Acetylcholine; 8-Bromo-cGMP; EDRF (endothelium-derived relaxing factor); Aortic ring, isolated, rat; Atrium, right, isolated, rat; LY-83,583 (6-(phenylamino)-5,8-quinolinedione); *N*-Nitro-L-arginine; SIN-1 (3-morpholino-sydnonimine); (Spontaneous rate) (Kennedy, R.H. (255) 149)

5-HT (5-hydroxytryptamine, serotonin); Prostaglandin $F_{2\alpha}$ (Lamb, V.L. (256) 221)

Indomethacin; Analgesia; β-Endorphin; Phentolamine; Naloxone; Pain (Hu, X.-H. (263) 53)

Norepinephrine efflux
Phenytoin; Phenobarbital; Valproic acid; NMDA (*N*-methyl-D-aspartate) (Brown, L.M. (254) 307)

Norepinephrine release
Aging; Ca^{2+} channel; Dopamine D_2 receptor; Tail artery, rat (Friedman, D.J. (252) 1)

Norepinephrine transporter
Methylphenidate; *dl-threo*-Methylphenidate; Dopamine transporter; Microdialysis; Locomotor activity (Pan, D. (264) 177)

***d*-Norfenfluramine**
Dopamine; *d*-Fenfluramine; Food intake; 5-HT (5-hydroxytryptamine, serotonin); Sex difference (Oluyomi, A.O. (255) 175)

Food intake; *d*-Fenfluramine; Microdialysis; *p*-Chlorophenylalanine (Oluyomi, A.O. (264) 111)

Norharman
Harman; β-Carboline; Monoamine oxidase; Pargyline; (Rat) (Rommelspacher, H. (252) 51)

NPPB (5-nitro-2-(3-phenylpropylamino)-benzoic acid)
Endothelial cell; Patch clamp; Ca^{2+}, intracellular; Thapsigargin; Capacitative Ca^{2+} entry (Gericke, M. (269) 381)

Nucleoside transporter
Adenosine; Dipyridamole; Nitrobenzylthioinosine; Brain (Jones-Humble, S.A. (257) 311)

Platelet aggregation, (human); Nucleoside transport inhibitor; R75231; Draflazine (Beukers, M.W. (266) 57)

Nucleoside transport inhibitor
Nucleoside transporter; Platelet aggregation, (human); R75231; Draflazine (Beukers, M.W. (266) 57)

Nucleotide level
Idebenone; Adenosine outflow; Inosine outflow; Hippocampal slice; Ischemia-like condition (Latini, S. (249) 65)

Nucleus accumbens
4-Aminopyridine; Quinine; Morphine; Dopamine release; Behavioural activity (Pei, Q. (249) 243)

Neuropeptide Y; Dopamine; Striatum (Midgley, L.P. (251) 191)

NMDA receptor antagonist; MK-801 ((+)-5-methyl-10,11-dihydro-5*H*-dibenzo[*a*,*d*]cyclohepten-5,10-imine); 6-Hydroxydopamine; Haloperidol; Locomotion; (Rat) (Ouagazzal, A.-m. (251) 229)

[D-Trp^{11}]Neurotensin; Locomotor activity; Dopamine (Nouel, D. (254) 263)

Dopamine; Microdialysis; Methamphetamine; DAGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); Dynorphin (Yokoo, H. (256) 335)

Dopamine release; Midazolam; β-CCE (β-carboline-3-carboxylate ethyl ester); $GABA_A$/benzodiazepine receptor; Adenosine receptor (Murai, T. (261) 65)

Jaw movement; Clozapine; Apomorphine; Striatum; Muscarinic acetylcholine receptor (Kikuchi de Beltrán, K. (262) 49)

IAPP (islet amyloid polypeptide); CGRP (calcitonin gene-related peptide); Salmon calcitonin (Veale, P.R. (262) 133)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin); Patch clamp; Substantia nigra; Ventral tegmental area; Caudate-putamen (Liu, J.-C. (264) 269)

Nucleus caudatus
NMDA receptor; Acetylcholine release; Budipine; Biperiden; MK-801 binding (Jackisch, R. (264) 207)

Nucleus tractus solitarii
Angiotensin II; Angiotensin AT_1 receptor; α_2-Adrenoceptor; Autoradiography; Blood pressure (Fior, D.R. (262) 271)

Obesity
cAMP; Glycerol release; Brown adipose tissue; β-Adrenoceptor; Thermogenesis (Nisoli, E. (259) 181)

Octreotide
Microvascular permeability; Gastroprotection; Microcirculation (Kusterer, K. (259) 265)

7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin)
Locomotor activity; Dopamine synthesis; Neostriatum; Dopamine receptor; (Rat) (Ahlenius, S. (260) 177)

Dopamine D_3 receptor; Hypothermia (Millan, M.J. (260) R3)

Remoxipride; *R*(−)-Propylnorapomorphine; Raclopride; Haloperidol (Hillefors-Berglund, M. (261) 179)

Place conditioning; Dopamine D_3 receptor (Mallet, P.E. (261) R5)

Dopamine D_3 receptor; Patch clamp; Substantia nigra; Ventral tegmental area; Caudate-putamen; Nucleus accumbens (Liu, J.-C. (264) 269)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)
5-HT_{1A} receptor; Adenylate cyclase; Dorsal raphe nucleus; Nerve impulse flow; (+)-WAY 100 135; SDZ 216-525; Lesopitron; S-20499; Flesinoxan (Lanfumey, L. (249) 25)

Feeding; 5-HT_{1A} receptor; WAY-100135; (Rat) (Hartley, J.E. (252) 329)

Head twitch behavior; Buspirone; 5-HT_{1A} receptor; 5-HT_2 receptor; (Mouse) (Kitamura, Y. (253) 297)

Phrenic nerve activity; 5-HT_{1A} receptor (Holtman, Jr., J.R. (253) 307)

WAY100135 (*N*-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide); Flesinoxan; 5-HT_{1A} receptor; Glucose concentration, plasma; (Conscious rat) (Critchley, D.J.P. (254) 133)

Macronutrient preference; 5-HT (5-hydroxytryptamine, serotonin); Aging; Feeding; Protein intake (Lacour, F. (255) 249)

5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Galanin; Galanin fragment; Receptor subtype; Blood pressure; Heart rate; Medulla oblongata; (Intracisternal injection) (Narváez, J.A. (257) 257)

5-HT (5-hydroxytryptamine, serotonin); Microdialysis; 5-HT_{1A} receptor desensitization; Citalopram (Invernizzi, R. (260) 243

5-HT_{1A} receptor; Pain transmission; Antinociception; (Rat) (Cervo, L. (263) 187)

Lower lip retraction; Dorsal raphe nucleus; Median raphe nucleus; 5-HT_{1A} receptor agonist; (Rat) (Berendsen, H.H.G. (263) 315)

WAY100635 (*N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride); ACTH (adrenocorticotrophic hormone); Plasma; 5-HT_{1A} receptor; (Conscious rat) (Critchley, D.J.P. (264) 95)

Maternal aggression; TFMPP (1-(3-trifluoromethyl-phenyl)piperazine hydrochloride); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Intracerebroventricular; 5-HT receptor agonist (De Almeida, R.M.M. (264) 445)

Dorsal raphe nucleus; G-protein; 5-HT_{1A} receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Microdialysis; Intracerebral (Romero, L. (265) 103)

Dexfenfluramine; 5-HT_{1A} autoreceptor; 5-HT (5-hydroxytryptamine, serotonin) release; Frontal cortex; Microdialysis (Gardier, A.M. (265) 107)

Galanin; 5-HT (5-hydroxytryptamine, serotonin); Adenylyl cyclase; Forskolin; Hypothalamus; Hippocampus; Brain; Receptor subtype; Peptide fragment (Billecocq, A. (269) 209)

Okadaic acid
Bronchus, human (Naline, E. (256) 301)

Pertussis toxin; Cholera toxin; Na^+-H^+ antiport; Mast cell; Sodium propionate (Alfonso, A. (267) 289)

Olfactory bulbectomy
$GABA_A$ receptor; $GABA_B$ receptor; β-Adrenoceptor; Antidepressant; Brain, rat (Dennis, T. (262) 143)

Oligosaccharide
Glutamate receptor; Sf9 cell; Phosphorylation (Taverna, F.A. (266) 181)

Omeprazole
Gastric ulcer; Cimetidine; Gastrin; Gastric acid (Ito, M. (263) 245)

Cimetidine; Acid secretion; Gastrin (Ito, M. (263) 253)

Ondansetron
5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Oocyte
Na^+ channel (human); DPI 201-106 (Krafte, D.S. (266) 245)

GABA (γ-aminobutyric acid); Ethanol; Butanol; Electrophysiology; cDNA (Mihic, S.J. (268) 209)

Open-channel block
N-Methyl-D-aspartate (NMDA); 1,2,3,4-Tetrahydro-9-aminoacridine; Tacrine; Voltage-clamp experiment (Vorobjev, V.S. (253) 1)

Opiate
Analgesia; Morphine, blood level; Dependence; Tolerance; Withdrawal (Gold, L.H. (253) 45)

Excitatory response; Postsynaptic action, direct; Medial vestibular nucleus, rat (Lin, Y. (262) 99)

Opiate receptor
Positron emitting tracer; Dual detector system (Villemagne, V.L. (257) 195)

Opiate withdrawal syndrome
Morphine; Naloxone; Clonidine; Aversive conditioning (Kosten, T.A. (254) 59)

Opioid
δ-Opioid receptor subtype; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]Deltorphin; Antinociception; (Mouse) (Vanderah, T. (252) 133)

Muscarinic receptor antagonist; Nitric oxide (NO); Small intestine; Substance P; VIP (vasoactive intestinal peptide) (Gustafsson, B.I. (257) 227)

Mastoparan; GTP-binding protein; Supraspinal analgesia (Sánchez-Blázquez, P. (258) 159)

Dopamine; Grooming; Vacuous chewing movement (Stoessl, A.J. (259) 301)

Dermenkephalin (binding); Structure-activity study; δ Address (Charpentier, S. (266) 175)

Lung; Dyspnoea; Morphine; Naloxone; NANC (Non-adrenergic-non-cholinergic) (Cabot, P.J. (268) 247)

Opioid analgesia
Antisense oligodeoxynucleotide; κ-Opioid receptor (Chien, C.-C. (253) R7)

Opioid-dopamine interaction
Amphetamine; Cocaine; Motor activity; δ-Opioid receptor antagonist (Jones, D.N.C. (249) 167)

Opioid peptide
Behavioral effect; Body temperature; Antinociception; Voltage-dependent Ca^{2+} channel; Verapamil; ω-Conotoxin GVIA (Spampinato, S. (254) 229)

Opioid receptor
σ Receptor; σ Receptor antagonist (Chien, C.C. (250) R7)

Lipopolysaccharide, *Pantoea agglomerans*; Antinociception; Diabetes; Naltrindole; Nor-binaltorphimine; β-Funaltrexamine (Kamei, J. (251) 95)

Dopamine release; Striatum; Morphine; Adenylate cyclase (Tjon, G.H.K. (252) 205)

Acetylcholine; Microdialysis; Adrenal medulla (Hirokami, M. (253) 9)

L-Arginine; Antinociception; Diabetes; Naltrindole; Nor-binaltorphimine; β-Funaltrexamine (Kamei, J. (254) 113)

Morphinan; Receptor conformation; Analgesia (Lemaire, S. (258) 111)

Dihydroetorphine; Cough; Antitussive effect; (Mouse) (Kamei, J. (260) 257)

Neuropathic pain; Mononeuropathic rat; Enkephalin degradation; Mixed inhibitor (Lee, S.H. (264) 61)

Nor-binaltorphimine; Tail-pressure test; Antinociception (Spanagel, R. (264) 157)

δ-Opioid receptor
DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Naltrindole; Dopamine neurons (central) (Manzanares, J. (249) 107)

Naltrindole; κ-Opioid receptor; Antitussive effect (Kamei, J. (249) 161)

Antitussive effect; BNTX (7-benzylidenenaltrexone); Naltriben; DPDPE ([D-Pen^{2,5}]enkephalin); [D-Ala^2]Deltorphin II (Kamei, J. (251) 291)

Hypovolemia; BNTX (7-benzylidenenaltrexone); Naltrindole; Hemorrhagic shock; (Rabbit, conscious) (Ludbrook, J. (252) 113)

Dopamine release; NMDA receptor (Dourmap, N. (253) R9)

Antisense oligodeoxynucleotide; Tail-flick inhibition (Tseng, L.F. (258) R1)

κ-Opioid receptor
Naltrindole; δ-Opioid receptor; Antitussive effect (Kamei, J. (249) 161)

[Met^5]Enkephalin-Arg^6-Phe^7; Antitussive effect; (Mouse) (Kamei, J. (253) 293)

Antisense oligodeoxynucleotide; Opioid analgesia (Chien, C.-C. (253) R7)

μ-Opioid receptor; Antinociception; Visceral pain; Vagal afferent; (Rat) (Diop, L. (257) 181)

Primary neuronal culture; Ventral mesencephalon; [^{3}H]Dopamine release; Sensitization; Corticosteroid (Ronken, E. (263) 149)

R1.1 Thymoma cell line; Sulfhydryl group; *N*-Ethylmaleimide; Dithiothreitol (Joseph, D.B. (267) 1)

μ-Opioid receptor
κ-Opioid receptor; Antinociception; Visceral pain; Vagal afferent; (Rat) (Diop, L. (257) 181)

Somatostatin secretion; β-Funaltrexamine; DAGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin) (McIntosh, C. (259) 331)

Hippocampal slice; Naloxone; Proconvulsant; Bursting (Jones, L.S. (264) 39)

μ_2-Opioid receptor
Morphine; Straub tail (Nath, C. (263) 203)

Opioid receptor agonist
Excitatory nerve; Colon, human; Opioid receptor antagonist; Smooth muscle (Chamouard, P. (262) 33)

κ-Opioid receptor agonist
U-50,488H; L-Tyrosine; L-Tryptophan; Analgesia; Tail-flick test (Barjavel, M.J. (258) 173)

R-84760; U-50488; CI-977; Morphine; Antinociceptive effect (Fujibayashi, K. (261) 133)

Cardiac electrophysiology; Ionic current; Cardiac myocyte, isolated; U-50,488H (Pugsley, M.K. (261) 303)

Dopamine; Dorsal caudate; Microdialysis; BRL 53001 (Zaratin, P. (264) 151)

Opioid receptor antagonist
Excitatory nerve; Colon, human; Opioid receptor agonist; Smooth muscle (Chamouard, P. (262) 33)

δ-Opioid receptor antagonist
Amphetamine; Cocaine; Motor activity; Opioid-dopamine interaction (Jones, D.N.C. (249) 167)

Opioid receptor second messenger
Antisense oligodeoxyribonucleotide; Analgesia (Raffa, R.B. (258) R5)

κ-Opioid receptor, selective
Forced swimming test; Water temperature; Glucocorticoid; Thyroid hormone; Glucose (Jefferys, D. (253) 91)

δ-Opioid receptor subtype
Opioid; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); [D-Ala^2,Glu^4]Deltorphin; Antinociception; (Mouse) (Vanderah, T. (252) 133)

μ-Opioid receptor subtype
SH-SY5Y human neuroblastoma cell; Naloxonazine; β-Funaltrexamine (Elliott, J. (268) 447)

κ-Opioid receptor, supraspinal
Butorphanol dependence; Nor-binaltorphimine; Naloxone; Withdrawal, precipitated (Jaw, S.P. (257) 153)

Opioid system
Endo-oligopeptidase; Enkephalin; Morphine withdrawal (Paik, S.H. (253) 101)

O_2^- production
Inflammation; Prostaglandin D_2; Neutrophil; Edema formation; Adherence (Pons, F. (261) 237)

Opsonized zymosan
OX-42; Indomethacin; Dapsone; Bromophenacyl bromide; Prostaglandin E_2 (Klegeris, A. (260) 273)

Oral activity
A77636; Dopamine; Dopamine D_1 receptor (Huang, N.-Y. (253) 163)

Org 2766
Vestibular compensation; NMDA receptor antagonist (Gilchrist, D. (252) R1)

Org 3770
α_2-Adrenoceptor; 5-HT (5-hydroxytryptamine, serotonin) release (De Boer, T. (253) R5)

Organ culture
Histamine H_2 receptor antagonist; H^+,K^+-ATPase inhibitor; Gastric mucin biosynthesis; (Rat) (Ichikawa, T. (251) 107)

Organophosphate toxicity
E2020; Diisopropylfluorophosphate; Acetylcholinesterase; Acetylcholinesterase protection (Galli, A. (270) 189)

Osteoclast-like cell formation
Vitamin K_2; Bone marrow culture; 1,25-Dihydroxyvitamin D_3 (Akiyama, Y. (263) 181)

Ovalbumin
Phosphodiesterase inhibitor; Eosinophil; Aerosol; PAF (platelet-activating factor); (Guinea pig) (Lagente, V. (255) 253)

Over-additive effect
Dizocilpine; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)-quinoxaline); Neuroprotection (Lippert, K. (253) 207)

OX-42
Opsonized zymosan; Indomethacin; Dapsone; Bromophenacyl bromide; Prostaglandin E_2 (Klegeris, A. (260) 273)

Oxadiazoles
Muscarinic receptor agonists; Inositol monophosphates; Phosphatidyl-inositol turnover, in vivo; L-658,903 (Patel, S. (267) 329)

Oxazoline
Imidazoline; Imidazoline site; Insulin secretion, vessel; Pancreas, rat (Berdeu, D. (254) 119)

Oxidative stress
Antioxidant; β-Adrenoceptor antagonist; Lipid peroxidation; Endothelial cell; Cerebellar neuron (Yue, T.-L. (251) 237)

Ethanol; Acetaldehyde; Free radical; Reactive oxygen (Bondy, S.C. (270) 349)

[^{111}In]Oxine
Adenosine receptor agonist; Adenosine A_2 receptor; 2-Hexynyl-NECA (5′-*N*-ethyl-carboxamidoadenosine); Platelet aggregation; Platelet, rabbit (Sandoli, D. (259) 43)

Oxotremorine methiodide
Muscarinic acetylcholine receptor; Myocyte; Nicotinic acetylcholine receptor; Patch clamping; (Single channel) (Reitstetter, R. (264) 27)

Oxygenated triterpenes
Phospholipase C; Phospholipase A_2; Platelets, Human (Wang, C.-N. (267) 33)

Oxygen consumption
Resiniferatoxin; Capsaicin; Hypothermia; Thermoregulation; (Rat) (Woods, A.J. (264) 125)

Oxytocin
Vasopressin; Ca^{2+} channel, L-type; Dihydropyridine; Neurointermediate lobe; (Electrical stimulation) (Jørgensen, A. (259) 157)

5-HT receptor agonist; 5-HT receptor antagonist; Apomorphine; Penile erection; Yawning; (Rat) (Stancampiano, R. (261) 149)

PACAP (pituitary adenylate cyclase activating polypeptide)
Blood flow; Choroid; Ciliary body; Iris; Vasodilatation (Nilsson, S.F.E. (253) 17)

PAF (platelet-activating factor)
Airway hyperresponsiveness; Airway inflammation; Plasma protein extravasation; Xanthine; Isbufylline (Manzini, S. (249) 251)

Experimental colitis; 5-Amino-salicylic acid (Zijlstra, F.J. (249) R1)

Hypotension; Renal sympathetic nerve activity, efferent; Renal vascular tone; Baroreflex; Autonomic nervous system (Matsuda, Y. (250) 341)

N^G-Nitro-L-arginine; Endotoxin; Cardiovascular function; Shock; (Dog) (Takekoshi, K. (250) 465)

Prostaglandin E_1; Prostaglandin E_2; Misoprostol; Enisoprost; Bradykinin; Sympathetic nervous system; Plasma extravasation; Synovial joint (Green, P.G. (252) 127)

Phosphodiesterase inhibitor; Eosinophil; Aerosol; Ovalbumin; (Guinea pig) (Lagente, V. (255) 253)

Neutrophilia; Catecholamine; Adrenal gland (Altenburg, S.P. (256) 45)

VIP (vasoactive intestinal peptide); Substance P (Deshpande, Y. (256) R1)

FR128998; Disseminated intravascular coagulation; Lipopolysaccharide; TNF (tumor necrosis factor) (Yokota, Y. (258) 239)

Acetylcholine; Mesenteric arterial bed; Spontaneously hypertensive rat (SHR); Desensitization (Kamata, K. (259) 321)

Pancreatitis, acute; Endotoxin (Emanuelli, G. (261) 265)

Loratadine; Histamine H_1 receptor; Ca^{2+}, cytosolic; Macrophage; Leukotriene; Bronchus, human (Letari, O. (266) 219)

Ca^{2+}, intracellular; Inositol 1,4,5-trisphosphate; Neutrophil (Koike, H. (269) 299)

Neutrophil; Eosinophil; Bone marrow; Endotoxin; Lipopolysaccharide; PAF receptor antagonist (Bozza, P.T. (270) 143)

PAF receptor
Monocyte; PAF receptor antagonist; (Receptor expression) (Shirasaki, H. (268) 263)

PAF receptor antagonist
PAF (platelet activating factor) receptor; Monocyte; (Receptor expression) (Shirasaki, H. (268) 263)

Neutrophil; Eosinophil; Bone marrow; Endotoxin; Lipopolysaccharide; PAF (platelet-activating factor) (Bozza, P.T. (270) 143)

Pain
Substance P, N-terminus; Flexor reflex; Antinociception (Goettl, V.M. (259) 83)

Autotomy; Clonidine; Flexor reflex; Guanfacine; ST-91 (Puke, M.J.C. (260) 227)

Indomethacin; Analgesia; Norepinephrine; β-Endorphin; Phentolamine; Naloxone (Hu, X.-H. (263) 53)

Pain transmission
$5\text{-}HT_{1A}$ receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Antinociception; (Rat) (Cervo, L. (263) 187)

Pancreas, dog
Exocrine secretion; KRN2391 (*N*-cyano-*N'*-(2-nitroxyethyl)-3-pyridinecarboximidamide monomethanesulfonate); Nitro compound; K^+ channel opener (Iwatsuki, K. (249) 19)

Pancreas, rat
Imidazoline; Oxazoline; Imidazoline site; Insulin secretion, vessel (Berdeu, D. (254) 119)

Pancreatic amylin
Pulmonary vascular bed; Vasoactive peptide; Adrenomedullin; CGRP (calcitonin gene-related peptide) (DeWitt, B.J. (257) 303)

Pancreatic β-cell
Sulfonylurea receptor; K^+ channel, ATP-sensitive; Glibenclamide; MIN 6 cell (Mogami, H. (269) 293)

Pancreatic islet
Sulfonylurea; Glucose; Na^+ (Saha, S. (258) 145)

Glibenclamide; Sulphonylurea; β-Cell replication; Diabetes (Guiot, Y. (261) 157)

Pancreatitis, acute
Endotoxin; PAF (platelet activating factor) (Emanuelli, G. (261) 265)

Panic disorder
CCK (cholecystokinin); Substance P; Clonazepam; Monoamine uptake inhibitor; Central nervous system, rat (Brodin, K. (263) 175)

Parasympathetic control
Vagal bradycardia; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor; 5-HT receptor agonist (Morán, A. (252) 161)

Parasympathetic nervous system
Neuroimmunomodulation; Cyclosporine; Lymphoid tissue; Cholinergic innervation; Acetylcholine, synthesis and release; Choline uptake; Sympathetic nervous system; Superior cervical ganglion (Esquifino, A.I. (254) 1)

Pargyline
Harman; Norharman; β-Carboline; Monoamine oxidase; (Rat) (Rommelspacher, H. (252) 51)

Parietal cell (rat)
Hydrogen ion production; Adenosine 3',5'-cyclic monophosphate; Radioligand binding; Covalent cross-linking (Schepp, W. (269) 183)

Parkinson's disease
L-DOPA (3,4-dihydroxyphenylalanine); Mitochondrion; Fibroblast; Pyruvate oxidation (Werner, P. (263) 157)

Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4*H*-thiazolo[4,5-*d*]-azepine); Dopamine D_2 receptor agonist; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); (Chronic treatment); (Common marmoset) (Irifune, M. (264) 117)

Dopamine transporter; GBR 12909; Cocaine; 5-HT (5-hydroxytryptamine, serotonin) transporter; CFT (WIN 35,428) (Madras, B.K. (267) 167)

Paroxetine
5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Paroxetine binding site
5-HT (5-hydroxytryptamine, serotonin) transporter; Tianeptine (Kuroda, Y. (268) R3)

Partial agonist, receptor
Adrenoceptor; Aporphine; Antipsychotic; Dopamine receptor; 5-HT (5-hydroxytryptamine, serotonin); Stereoisomer (Baldessarini, R.J. (254) 199)

Passive avoidance
FG5893; $5\text{-}HT_{1A}$ receptor agonist/$5\text{-}HT_{2A}$ receptor antagonist; 5-HT receptor; Hypothermia; Head twitch behavior; Forced swim test; Cage leaving; Ultrasound vocalization; Corticosterone; (Rat) (Albinsson, A. (261) 285)

$5\text{-}HT_{1A}$ receptor; $5\text{-}HT_2$ receptor; Muscarinic acetylcholine receptor; Medial septum (Riekkinen Jr., P. (262) 77)

Passive avoidance learning
Adenosine; Learning; Acquisition; (Mouse) (Zarrindast, M.R. (256) 233)

Passive avoidance task
σ Receptor ligand; SKF-10,047; DTG (1,3-di-(2-tolyl)guanidine); Benzomorphan-type σ receptor; Acetylcholinergic neuronal system; *p*-Chloroamphetamine; Amnesia; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperizine); (Mouse) (Matsuno, K. (261) 43)

Passive cutaneous anaphylaxis
Norathyriol; Neurogenic inflammation; Vascular permeability; Compound 48/80; Mast cell; (Mouse) (Wang, J.-P. (251) 35)

Patch-clamp
Tricyclic antidepressant; Imipramine; Desipramine; Neuroblastoma; Nicotinic acetylcholine receptor (Rana, B. (250) 247)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin); Substantia nigra; Ventral tegmental area; Caudate-putamen; Nucleus accumbens (Liu, J.-C. (264) 269)

Interleukin; Hippocampus; Ca^{2+} channel; G-protein; Protein kinase; (Guinea pig) (Plata-Salamán, C.R. (266) 1)

FCCP (carbonyl cyanide-*p*-trifluoromethoxyphenyl-hydrazone); Ca^{2+} oscillation; Megakaryocyte, rat (Uneyama, C. (268) 455)

Ca^{2+} channel; Dihydropyridine; Enantiomer; Vascular myocyte; Radioligand (Baron, A. (269) 105)

Endothelial cell; Ca^{2+}, intracellular; Thapsigargin; Capacitative Ca^{2+} entry; NPPB (5-Nitro-2-(3-phenylpropylamino)-benzoic acid) (Gericke, M. (269) 381)

Patch-clamp analysis
Heart cell; Ca^{2+} channel (L-type); Ca^{2+} channel antagonist; Manidipine (Tohse, N. (249) 231)

Patch-clamp electrophysiology
BK channel; Maxi-K channel; Smooth muscle cell; Benzimidazolone; K^+ channel opener (Olesen, S.-P. (251) 53)

Patch-clamping
Muscarinic acetylcholine receptor; Myocyte; Nicotinic acetylcholine receptor; Oxotremorine methiodide; (Single channel) (Reitstetter, R. (264) 27)

Patch-clamp, in situ
Philanthotoxin; Ca^{2+} current; Hippocampus; Glutamate antagonist; Polyamine (Karst, H. (270) 357)

Patch-clamp technique
Inwardly rectifying K^+ channel; Ventricular myocyte; Voltage-dependent inactivation; Chloramine-T; Inactivation gate; (Guinea pig) (Koumi, S.-i. (258) 281)

Apamin; Action potential; Delayed rectifier K^+ current; Ventricular myocyte (Koumi, S.-i. (261) 213)

Paw edema
Leukotriene; Anaphylaxis; (Mouse) (Zuany-Amorim, C. (257) 211)

Paw test
Clozapine; α_1-Adrenoceptor; $5\text{-}HT_{2A}$ receptor; Dopamine D_1 receptor (Prinssen, E.P.M. (262) 167)

PC12
Ca^{2+} channel; Electrophysiology; Permeant ion; Ethanol; Pheochromocytoma cell (Mullikin-Kilpatrick, D. (270) 17)

PCA50941
Bay K 8644; Chromaffin cell; Catecholamine secretion; Dihydropyridine agonist; Ca^{2+} channel; Cytosolic Ca^{2+} (Montiel, C. (268) 293)

PCB (polychlorinated biphenyl)
PCDD (dibenzo-*p*-dioxin); PCDF (dibenzofuran); Hydroxylated metabolite; Thyroxine-binding globulin; Transthyretin (Lans, M.C. (270) 129)

Equilibrium partitioning; Biotransformation; (Marine mammals) (Boon, J.P. (270) 237)

PCB metabolism
TCB (3,3′,4,4′-tetrachlorobiphenyl); Ethoxyresorufin-*O*-deethylase (EROD); (Bird); (Mammal); (Fish) (Murk, A. (270) 253)

PC12 cell
Adenosine; ATP-activated channel; GTP-binding protein (Inoue, K. (268) 223)

PCDD (dibenzo-*p*-dioxin)
PCB (polychlorinated biphenyl); PCDF (dibenzofuran); Hydroxylated metabolite; Thyroxine-binding globulin; Transthyretin (Lans, M.C. (270) 129)

PCDF (dibenzofuran)
PCB (polychlorinated biphenyl); PCDD (dibenzo-*p*-dioxin); Hydroxylated metabolite; Thyroxine-binding globulin; Transthyretin (Lans, M.C. (270) 129)

PCR (polymerase chain reaction)
Vasopressin receptor; mRNA; (Rat) (Hirasawa, A. (267) 71)

PD 123177
Renal artery, rabbit; Angiotensin II; Losartan (Zhang, J. (252) 337)

PD 123319
Angiotensin receptor subtype; Losartan; Footshock (Cierco, M. (251) 103)

Angiotensin II; Sympathetic nervous system; α_1-Adrenoceptor; Valsartan (Marano, G. (261) 121)

PD 145065
Endothelin; Sarafotoxin; Prostanoid; Endothelin receptor; Kidney, rat (Warner, T.D. (250) 447)

Endothelin; IRL 1620; Ro 46-2005; Endothelin ET_A/ET_B non-selective receptor antagonist (Battistini, B. (252) 341)

L-*trans*-2,4-PDC (L-*trans*-2,4-pyrrolidine dicarboxylic acid)
Glutamate; Phosphoinositide; cAMP; *trans*-ACPD (1-aminocyclopentane-*trans*-1,3-dicarboxylic acid); Glutamate transport; (+)-α-Methyl-4-carboxyphenylglycine (Miller, S. (269) 235)

Pd-Ia (3′-angeloyloxy-4′-acetoxy-3′,4′-dihydroseselin)
Bai-Hua Qian-Hu; Cardiohemodynamic; Myocardium, stunned; Ca^{2+} channel antagonist (Chang, T.-h. (258) 77)

Penile erection
Yawning; Diabetic rat; Apomorphine; Physostigmine; VIP (vasoactive intestinal polypeptide) (Yamaguchi, Y. (254) 91)

K^+ channel; Smooth muscle; NANC (non-adrenergic, non-cholinergic) relaxation; Nicotinic receptor (Alaranta, S. (259) 203)

5-HT receptor agonist; 5-HT receptor antagonist; Apomorphine; Oxytocin; Yawning; (Rat) (Stancampiano, R. (261) 149)

Pentagastrin
DS-4574; Mast cell stabilizer; Gastric acid secretion; Histamine leakage; Carbachol (Tabuchi, Y. (255) 229)

Cholecystokinin-8; Nitric oxide (NO) (Stroff, T. (260) R1)

Gastric acid; Nitric oxide (NO); Gastric distension; 2-Deoxy-D-glucose; Histamine; Brain-gut axis (Barrachina, D. (262) 181)

Pentazocine
ACTH (adrenocorticotropic hormone); Corticosterone; Dioxadrol; Endocrine; NMDA (*N*-methyl-D-aspartate); Phencyclidine; σ Receptor; SKF 10,047 (Pechnick, R.N. (263) 115)

σ Receptor; Liver; Kidney; Haloperidol; Photoaffinity labeling (Hellewell, S.B. (268) 9)

(+)-Pentazocine
Dextromethorphan; 3-PPP (3-(3-hydroxyphenyl)-*N*-(*n*-propyl)piperidine); Haloperidol; Haloperidol, reduced; Receptor down-regulation (Klein, M. (254) 239)

Pentazocine binding
σ Receptor; Cytochrome *P*450; Piperazine; Phenylalkylamine; 5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor (Cagnotto, A. (266) 131)

Pentobarbital
Chlordiazepoxide; Angiotensin; Blood pressure; (Spontaneously hypertensive rat (SHR)) (Sim, M.K. (253) 171)

Nicotine; Cardiovascular effect; Blood pressure; Heart rate; Tachyphylaxis (Cruz, S.L. (258) 39)

Pentoxifylline
Intraocular pressure; Dopamine receptor; Phosphodiesterase inhibitor; Methylxanthine; Trifluperidol; Thiothixene; Fluphenazine; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine); Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

Mesenteric resistance vessel; Aminophylline; Endothelium; Nitric oxide (NO); Smooth muscle, vascular; Methylxanthine derivative (Hansen, P.R. (261) 105)

Peptide
Thrombin; Thrombin receptor; Aminopeptidase M; (Rabbit) (Godin, D. (253) 225)

Vasopressin; Vasopressin receptor; Cell nucleus; Vasopressin receptor antagonist (Phillips, P.A. (259) 325)

Peptide fragment
Galanin; 5-HT (5-hydroxytryptamine, serotonin); 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Adenylyl cyclase; Forskolin; Hypothalamus; Hippocampus; Brain; Receptor subtype (Billecocq, A. (269) 209)

Peptidergic transmission
Nicotine; Purinergic transmission; NANC (non-adrenergic, non-cholinergic) nerve; Developmental pharmacology (Irie, K. (251) 75)

Peptide YY
Neuropeptide Y receptor; [Pro^{34}]peptide YY; Gastrointestinal hormone (Grandt, D. (269) 127)

[Pro^{34}]Peptide YY
Peptide YY; Neuropeptide Y receptor; Gastrointestinal hormone (Grandt, D. (269) 127)

Peptidoleukotriene
DS-4574; Mast cell stabilizer; LY171883; Mucosal mast cell; Gastric mucosal injury (Tabuchi, Y. (250) 197)

Periaqueductal grey area
Endothelin-1; NMDA (*N*-methyl-D-aspartate); Barrel rolling (Maione, S. (250) 209)

Peripheral analgesia
Nitric oxide (NO); Knee joint inflammation; Dipyrone; Nitric oxide synthetase inhibitor (Tonussi, C.R. (251) 173)

Peripheral benzodiazepine
Muscle strip, human; Ro 5-4864; PK 11195 (Shany, E. (253) 231)

Peripheral blood leukocyte, human
Anti-allergic agent; Cytokine production, in vitro; Interleukin-2; Interleukin-3; Interleukin-4; Interleukin-5 (Konno, S.-i. (264) 265)

Peripheral circulation
Adrenomedullin; Adrenomedullin fragment; Vasodilation; Hypotension (Lin, B. (260) 1)

Peristalsis
Nitric oxide (NO); N^G-Nitro-L-arginine; Circular muscle; Ileum, guinea-pig (Suzuki, N. (251) 221)

Peritoneal leukocyte
Avarol; Avarone; Anti-inflammatory drug; Phospholipase A_2; Arachidonic acid metabolism; Superoxide generation (Ferrándiz, M.L. (253) 75)

Peritoneal macrophage
Nitric oxide (NO); cAMP analog; Cholera toxin; (Rat) (Sowa, G. (266) 125)

Perivascular nerve stimulation
ATP; Artery (rabbit ear, jejunal); Endothelin-1; Vasoconstrictor response (La, M. (249) 133)

Permeability
Endothelial cell; Microcirculation; Endothelin; Contraction; Ca^{2+} (Kurose, I. (250) 85)

Permeant ion
Ca^{2+} channel; Electrophysiology; Ethanol; PC12; Pheochromocytoma cell (Mullikin-Kilpatrick, D. (270) 17)

Pertussis toxin
Adenosine A_1 receptor; Adenosine A_2 receptor; Adenosine A_3 receptor; APNEA (N^6-2-(4-aminophenyl)ethyladenosine) (Carruthers, A.M. (250) 185)

Salbutamol; Arecoline; Aorta; β-Adrenoceptor; Langendorff; (Rat) (Vleeming, W. (250) 415)

Carbachol; Phenylephrine; Atrium, left; Negative inotropy; $^{86}Rb^+$ efflux; 4-Aminopyridine (Ray, A. (256) 311)

Neuropeptide Y; Neuropeptide Y analog; Benzalkonium chloride G-protein; Histamine release; Mast cell; (Rat) (Grundemar, L. (258) 163)

Somatostatin; G-protein; Seglitide; BIM 23027; SRIF receptor; Vas deferens, mouse (Feniuk, W. (261) 333)

Ca^{2+}; Corticotropin-releasing factor; Ca^{2+} channel; Epithelium (Kiang, J.G. (267) 135)

Cholera toxin; Okadaic acid; Na^+-H^+ antiport; Mast cell; Sodium propionate (Alfonso, A. (267) 289)

G protein; Guanylnucleotide; c-*fos*; Mitogenesis; Adenylyl cyclase; Phospholipase C; Phorbol ester (Pilon, C. (268) 129)

Xenopus laevis oocyte; Vanadate; Ca^{2+}; Angiotensin II; Desensitization; LiCl (Sakuta, H. (268) 305)

K^+ channel; Glibenclamide; Cromakalim; *Xenopus* oocyte; Insulin; IGF-1; Phenylarsine oxide; Voltage clamp, 2-electrode (Sakuta, H. (268) 375)

P_2^U purinoceptor; cAMP; Protein kinase C; Ca^{2+}; DDT_1 MF-2 cell (Sipma, H. (268) 431)

Bombesin receptor, lung; Guanine nucleotide sensitivity; G-protein; Cholera toxin; (Guinea pig) (Lach, E. (269) 87)

PET (positron emission tomography)
[^{18}F]Fluoro-DOPA; Catechol-*O*-methyl transferase inhibitor; Entacapone; Carbidopa; Brain catecholamine (Pauwels, T. (257) 53)

P-glycoprotein
Liver, rat; Bile secretion; Fluorescent dye; Cyclosporin A (Thalhammer, T. (270) 213)

Phaclofen
Neocortex, human; GABA (γ-aminobutyric acid) release; $GABA_B$ autoreceptor; CGP 35348; CGP 52432 (Fassio, A. (263) 311)

Phagocytosis
Zinc hydroxide; Respiratory burst; Neutrophil, rat (Ogino, K. (270) 73)

Pharmacokinetics
Microdialysis; Dopamine release; Memantine; Striatum; Prefrontal cortex (Spanagel, R. (262) 21)

Pharmacology
CCK_B receptor; Cloning; Small cell lung carcinoma; Enterochromaffin-like cell-oma (Denyer, J. (268) 29)

Pharmacomechanical coupling
Tachykinin receptor; Sucrose gap; Proximal colon, guinea-pig; Electromechanical coupling; Ca^{2+} channel, voltage-dependent (Zagorodnyuk, V. (255) 9)

Phase dependency
Actinomycin D; Cytotoxicity; Cell cycle (Wu, M.-H. (270) 203)

Phasic contraction
Quercetin; Staurosporine; Aorta, rat (Duarte, J. (262) 149)

Phencyclidine
Behavior; MK-801; NMDA (*N*-methyl-D-aspartate); Sensitization; Temperature; Thermoregulation; Tolerance (Pechnick, R.N. (252) 35)

NE-100; σ Receptor; Cognition; Neuroleptic; (Rat) (Ogawa, S.-i. (263) 9)

ACTH (adrenocorticotropic hormone); Corticosterone; Dioxadrol; Endocrine; NMDA (*N*-methyl-D-aspartate); Pentazocine; σ Receptor; SKF 10,047 (Pechnick, R.N. (263) 115)

Phenelzine sulfate
Benzodiazepine receptors, peripheral type; Imipramine; [^{3}H]PK 11195; Antidepressant (Weizman, R. (250) 289)

Phenobarbital
Phenytoin; Valproic acid; NMDA (*N*-methyl-D-aspartate); Norepinephrine efflux (Brown, L.M. (254) 307)

Phenoxybenzamine
Angiotensin-converting enzyme inhibitor; α_1-Adrenoceptor, vascular; Ca^{2+} channel antagonist; Receptor reserve (Tabrizchi, R. (251) 15)

Noradrenaline; Ca^{2+} channel; Ryanodine; G-protein; Protein kinase C; Caffeine (Tabrizchi, R. (259) 285)

Vas deferens, rat; α_2-Adrenoceptor; *N*-Ethyl-maleimide; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Browne, I. (265) 125)

Brainstem (Human); Clonidine; Imidazoline receptor; GTP; α-Adrenoceptor (Bricca, G. (266) 25)

α_1-Adrenoceptor; [^{3}H]Prazosin binding; Phosphoinositide hydrolysis; Myocardium (rat) (Sallés, J. (266) 35)

α_1-Adrenoceptor subtype; [^{3}H]Prazosin; Chloroethylclonidine; Benextramine; Cerebral cortex (Sallés, J. (266) 301)

Phentolamine
Indomethacin; Analgesia; Norepinephrine; β-Endorphin; Naloxone; Pain (Hu, X.-H. (263) 53)

Phenylalkylamine
σ Receptor; Pentazocine binding; Cytochrome *P*450; Piperazine; 5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor (Cagnotto, A. (266) 131)

Phenylarsine oxide
K^+ channel; Glibenclamide; Cromakalim; *Xenopus* oocyte; Insulin; IGF-1; Pertussis toxin; Voltage clamp, 2-electrode (Sakuta, H. (268) 375)

Phenylephrine
Carbachol; Atrium, left; Negative inotropy; $^{86}Rb^+$ efflux; Pertussis toxin; 4-Aminopyridine (Ray, A. (256) 311)

2-Phenylethylamine
Monoamine oxidase type B; (−)-Deprenyl; Dopamine; Microdialysis; (Guinea pig) (Juorio, A.V. (254) 213)

Phenylglycine derivative
Metabotropic glutamate receptor; (1*S*,3*R*)-ACPD (1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate; Phosphoinositide hydrolysis; Cyclic AMP (Thomsen, C. (267) 77)

Phenytoin
Phenobarbital; Valproic acid; NMDA (*N*-methyl-D-aspartate); Norepinephrine efflux (Brown, L.M. (254) 307)

Pheochromocytoma cell
Ca^{2+} channel; Electrophysiology; Permeant ion; Ethanol; PC12 (Mullikin-Kilpatrick, D. (270) 17)

Philanthotoxin
Ca^{2+} current; Hippocampus; Glutamate antagonist; Polyamine; Patch clamp, in situ (Karst, H. (270) 357)

Phorbol ester
Pulmonary artery; Smooth muscle; Vascular relaxant; Protein kinase C; Phosphodiesterase inhibitor; Cyclic nucleotides (Savineau, J.-P. (249) 191)

Cardiac anaphylaxis; Langendorff heart; Staurosporine; (Guinea-pig) (Schäfer, S. (258) 247)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; Mechanistic pathway; LiCl; Forskolin; 1,9-Dideoxy-forskolin; Vas deferens; (Rabbit) (Eltze, M. (263) 31)

Protein kinase C; Endothelium; Nitric oxide synthase; EDRF (endothelium-dependent relaxation factor) (Davda, R.K. (266) 237)

ANP (Atrial natriuretic peptide); Growth factor; aFGF (acidic fibroblast growth factor); Protein kinase C; Staurosporine (Tokola, H. (267) 195)

G protein; Guanylnucleotide; c-*fos*; Mitogenesis; Adenylyl cyclase; Phospholipase C; Pertussis toxin (Pilon, C. (268) 129)

Phorbol 12-myristate 13-acetate
Interleukin-1β; TNF (tumor necrosis factor); Leukotriene B_4; Phospholipase A_2; Phospholipase C; 5-Lipoxygenase; Protein kinase C; Stomach, rat; Gastric motility (Montuschi, P. (252) 253)

Phosphate effect
Crossbridge kinetics; Skinned cardiac muscle; EMD 53998; Ca^{2+} sensitizer (Strauss, J.D. (252) 219)

Phosphatidylinositol
Aclarubicin; Vasoconstriction; Aorta, rat (Wakabayashi, I. (255) 111)

Phosphatidylinositol hydrolysis
Transfected cell; Receptor agonist exposure; Receptor internalization; cAMP production; Down-regulation; Muscarinic M_1 receptor; Muscarinic M_2 receptor (Wei, H.-B. (268) 381)

Phosphatidylinositol turnover, in vivo
Muscarinic receptor agonists; Inositol monophosphates; Oxadiazoles; L-658,903 (Patel, S. (267) 329)

Phosphodiesterase
Xanthine derivative; Tracheal relaxation; Structure-activity relationship (Miyamoto, K.-i. (267) 317)

Phosphodiesterase inhibitor
Pulmonary artery; Smooth muscle; Vascular relaxant; Phorbol ester; Protein kinase C; Cyclic nucleotides (Savineau, J.-P. (249) 191)

Zaprinast; cGMP; Blood pressure; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (249) 293)

Eosinophil; Aerosol; Ovalbumin; PAF (platelet-activating factor); (Guinea pig) (Lagente, V. (255) 253)

Intraocular pressure; Dopamine receptor; Methylxanthine; Pentoxifylline; Trifluperidol; Thiothixene; Fluphenazine; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine); Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

Blood vessel; Pimobendan; Milrinone; UD-CG 212 (Fujimoto, S. (265) 159)

Photoaffinity labelling; Cyclic GMP-inhibited phosphodiesterase (PDE III); Platelet; Cyclic AMP (Tang, K.M. (268) 105)

Phosphodiesterase type IV
Nimesulide; Polymorphonuclear leukocyte; Superoxide anion; cAMP; Chemotaxis (Bevilacqua, M. (268) 415)

Phosphodiesterase type V inhibitor
E4021; cGMP; Coronary vasodilator; Vasopressin; ST segment elevation (Kodama, K. (263) 93)

Phosphoinositide
Ethanol; Development; Muscarinic receptor; Fetal alcohol syndrome; (Rat) (Balduini, W. (266) 283)

Arachidonic acid; cAMP; Ca^{2+} imaging; G protein; AF102B (Gurwitz, D. (267) 21)

Glutamate; cAMP; *trans*-ACPD (1-aminocyclopentane-*trans*-1,3-dicarboxylic acid); L-*trans*-2,4-PDC (L-*trans*-2,4-pyrrolidine dicarboxylic acid); Glutamate transport; (+)-α-Methyl-4-carboxyphenylglycine (Miller, S. (269) 235)

Phosphoinositide hydrolysis
HV723 (α-ethyl-3,4,5-trimethoxy-α-(3-((2-(2-methoxyphenoxy)ethyl)-amino)-propyl) benzeneacetonitrile fumarate); α_1-Adrenoceptor; Positive inotropic effect; [^{3}H]Prazosin; Ventricular myocardium, rabbit (Kohi, M. (250) 95)

5-HT_1C receptor; Choroid plexus; Clozapine; Receptor reserve; Autoradiography (Kuoppamäki, M. (255) 91)

α_1-Adrenoceptor; [^{3}H]Prazosin binding; Phenoxybenzamine; Myocardium (rat) (Sallés, J. (266) 35)

Metabotropic glutamate receptor; Phenylglycine derivative; (1*S*,3*R*)-ACPD (1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate; Cyclic AMP (Thomsen, C. (267) 77)

Metabotropic glutamate receptor; Spinal cord, isolated; cAMP; ACPD((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); L-CCG-I((2*S*,1′*S*,2′*S*)-CCG); Cortical cell culture (Ishida, M. (268) 267)

Atypical antipsychotic; Autoradiography; Choroid plexus; Clozapine; 5-HT_{2C} receptor (Kuoppamäki, M. (269) 201)

Phospholipase
Endothelin; Saponin; Ca^{2+}; Protein kinase C; Positive inotropy; Diacylglycerol; IP_3 (Paik, G.Y. (264) 437)

Phospholipase A_2
Arachidonic acid; Uterine cell proliferation (Fayard, J.M. (251) 281)

Interleukin-1β; TNF (tumor necrosis factor); Leukotriene B_4; Phospholipase C; 5-Lipoxygenase; Protein kinase C; Phorbol 12-myristate 13-acetate; Stomach, rat; Gastric motility (Montuschi, P. (252) 253)

Avarol; Avarone; Anti-inflammatory drug; Arachidonic acid metabolism; Superoxide generation; Peritoneal leukocyte (Ferrándiz, M.L. (253) 75)

YM-26734; Prostaglandin E_2 (Miyake, A. (253) 155)

Endothelial cell, human, vascular; Thromboxane A_2; ICAM-1 (intercellular adhesion molecule-1) (Ishizuka, T. (262) 113)

Antiflammin; Inflammation; Mast cell degranulation; Anti-inflammatory drug (Lloret, S. (264) 379)

Oxygenated triterpenes; Phospholipase C; Platelets, Human (Wang, C.-N. (267) 33)

Phospholipase A_2, snake
Platelet aggregation; Recombinant phospholipase A_2, human; Platelet accumulation (Cirino, G. (252) 147)

Phospholipase C
Interleukin-1β; TNF (tumor necrosis factor); Leukotriene B_4; Phospholipase A_2; 5-Lipoxygenase; Protein kinase C; Phorbol 12-myristate 13-acetate; Stomach, rat; Gastric motility (Montuschi, P. (252) 253)

Oxygenated triterpenes; Phospholipase A_2; Platelets, Human (Wang, C.-N. (267) 33)

G protein; Guanylnucleotide; c-*fos*; Mitogenesis; Adenylyl cyclase; Phorbol ester; Pertussis toxin (Pilon, C. (268) 129)

Phospholipid phase transition
Tetramethylpyrazine; Membrane fluidity; Differential scanning calorimetry; Electron spin resonance; Fluorescence polarization; Drug–lipid interactions (Nie, S.-Q. (266) 11)

Phosphoramidon
Cytokine; Endothelin; Endothelin converting enzyme; Hemorrhage; Hypoxia; Interleukin-1β; TNF-α (tumor necrosis factor-α) (Vemulapalli, S. (257) 95)

Phosphorylation
Glutamate receptor; Sf9 cell; Oligosaccharide (Taverna, F.A. (266) 181)

Staurosporine; $gp140^{trk}$; Tyrosine; Neurite outgrowth (Rasouly, D. (269) 255)

Photoaffinity labeling
Thromboxane A_2 receptor; (Receptors) (True, T.A. (266) 51)

$GABA_A$ receptor complex; Benzodiazepine binding site, type I; [^{3}H]Zolpidem binding; Immunoprecipitation; Cortex; (Subunit specific antibodies) (Ruano, D. (267) 121)

σ Receptor; Liver; Kidney; Haloperidol; Pentazocine (Hellewell, S.B. (268) 9)

Cyclic GMP-inhibited phosphodiesterase (PDE III); Platelet; Phosphodiesterase inhibitor; Cyclic AMP (Tang, K.M. (268) 105)

Photochemically induced thrombosis
Tissue-type plasminogen activator; Middle cerebral artery thrombosis; SUN9216; (Rat) (Umemura, K. (262) 27)

Photolabeling
Neuropeptide Y; GTP (Zhu, J. (268) 279)

Phrenic nerve activity
8-OH-DPAT (8-hydroxy-2-(di-*N*-propylamino)tetralin); $5\text{-}HT_{1A}$ receptor (Holtman, Jr., J.R. (253) 307)

Physical dependence
RB 101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Naloxone; (Intravenous perfusion) (Noble, F. (253) 283)

Physostigmine
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1*H*-cyclopenta(*b*)-quinoline monohydrate hydrochloride); Tacrine; Scopolamine-induced amnesia; Side-effect (central); Side-effect (peripheral) (Yoshida, S. (250) 117)

Penile erection; Yawning; Diabetic rat; Apomorphine; VIP (vasoactive intestinal polypeptide) (Yamaguchi, Y. (254) 91)

Picrotoxin
GnRH (gonadotropin-releasing hormone) gene expression; 5β-Pregnan-3α-ol-20-one; Muscimol; Hypothalamus; Hybridization, in situ (Vincens, M. (260) 157)

EBOB (4′-ethynyl-4-*n*-propylbicycloorthobenzoate); $GABA_A$ receptor complex; Brain, human; Autoradiography (Kume, A. (263) 163)

Pigment aggregation
Melatonin; 2-Iodomelatonin binding; Melanophore; Melatonin receptor; Chroman (Sugden, D. (254) 271)

Pimobendan
Blood vessel; Phosphodiesterase inhibitor; Milrinone; UD-CG 212 (Fujimoto, S. (265) 159)

Pinacidil
Levcromakalim; Diazoxide; Glucose tolerance; Glibenclamide; Hypoglycemia (Clapham, J.C. (257) 79)

Pineal gland
Melatonin; Anterior thalamus; Limbic system; Receptor autoradiography (Lindroos, O.F.C. (250) 161)

Pinocytosis
Brain microvessel endothelial cell; Catecholamine; Blood-brain barrier (Borges, N. (269) 243)

Piperazine
σ Receptor; Pentazocine binding; Cytochrome *P*450; Phenylalkylamine; 5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor (Cagnotto, A. (266) 131)

Pirenzepine
Antral G-cell; Muscarinic receptor subtype; Muscarinic M_3 receptor; Atropine; Hexahydro-sila-difenidol; AQ-RA 741 (Weigert, N. (264) 337)

Pirenzepine analog
Muscarinic receptor subtype; Smooth muscle, ileal; McN-A-343 (Barocelli, E. (254) 151)

Pirsidomine
Infarct size; Hemodynamics; (Dog) (Martorana, P.A. (257) 267)

Pithed rat
EP_3 receptor; Prostaglandin E_2; Sulprostone; Presynaptic receptor; Neurogenic vasopressor response (Malinowska, B. (259) 315)

Pituitary
CCK_B receptor; GH_3 cells; Functional coupling; G-protein; Ca^{2+} mobilisation; L-365,260 (Smith, A.J. (267) 215)

Protein kinase C; Estradiol; Dopamine; Hyperplasia; (Isoform); (Rat) (Lévy, L. (268) 327)

PK 11195
Peripheral benzodiazepine; Muscle strip, human; Ro 5-4864 (Shany, E. (253) 231)

[^{3}H]PK 11195
Benzodiazepine receptors, peripheral type; Imipramine; Phenelzine sulfate; Antidepressant (Weizman, R. (250) 289)

Place conditioning
7-OH-DPAT ((±)-2-dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide); Dopamine D_3 receptor (Mallet, P.E. (261) R5)

Placenta
Angiotensin II; Angiotensin receptor; Human placental lactogen; Pregnancy-specific β_1-glycoprotein (Kalenga, M.K. (268) 231)

Ethanol; Fetal artery; Hypertension; Fetal alcohol syndrome; Indomethacin (Taylor, S.M. (270) 371)

Placental lactogen, human
Angiotensin II; Angiotensin receptor; Pregnancy-specific β_1-glycoprotein; Placenta (Kalenga, M.K. (268) 231)

Plantaris
Li^+; ATPase; Chronic; Soleus; Extensor digitorum longus (Adipudi, V. (259) 7)

Plasma
WAY100635 (*N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride); ACTH (adrenocorticotrophic hormone); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} receptor; (Conscious rat) (Critchley, D.J.P. (264) 95)

Plasma extravasation
Substance P; Septide; Tachykinin NK_1 receptor antagonist; Urinary bladder contraction; (Rat) (Montier, F. (251) 9)

Prostaglandin E_1; Prostaglandin E_2; Misoprostol; Enisoprost; Bradykinin; Sympathetic nervous system; PAF (platelet activating factor, PAF-acether); Synovial joint (Green, P.G. (252) 127)

Kinin; Tachykinin; Antigen; Airway; Neutral endopeptidase (Ricciardolo, F.L.M. (261) 127)

Plasma exudation
Asthma; Edema; Aging; Leukotriene; Thromboxane A_2; Airway obstruction; Vascular permeability; Arachidonic acid (Arakawa, H. (259) 251)

Plasma-free tryptophan
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; 5-HT (5-hydroxytryptamine, serotonin); Tryptophan; Anorexia; Strain difference; (Brain) (Unkila, M. (270) 157)

Plasma protein extravasation
Platelet activating factor (PAF); Airway hyperresponsiveness; Airway inflammation; Xanthine; Isbufylline (Manzini, S. (249) 251)

Dura mater; Tachykinin NK_1 receptor; α-CGRP-(8–37); GR82334 (O'Shaughnessy, C.T. (263) 193)

Plasticity
$GABA_B$ receptor; Spinal cord; Autoradiography; CGP 36742 (3-aminopropyl-*n*-butyl-phosphinic acid); (−)-Baclofen (Malcangio, M. (250) 153)

Platelet
Polymorphonuclear neutrophil; Prostaglandin D_2; ZK 118.182 (Darius, H. (258) 207)

Thrombin; Hirulog; Heparin; Low molecular weight heparin; PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone); DuP-714 ester (acetyl-D-phenylalanine-propyl-boroarginine); (Rabbit) (Liu, J.T. (264) 183)

Photoaffinity labelling; Cyclic GMP-inhibited phosphodiesterase (PDE III); Phosphodiesterase inhibitor; Cyclic AMP (Tang, K.M. (268) 105)

(Rp)-8-pCPT-cGMPS ((Rp)-8-(*para*-chlorophenylthio)guanosine-3′,5′-cyclic monophosphorothioate); cGMP-dependent protein kinase; (Inhibitor) (Butt, E. (269) 265)

Platelet accumulation
Platelet aggregation; Recombinant phospholipase A_2, human; Phospholipase A_2, snake (Cirino, G. (252) 147)

Platelet aggregation
Recombinant phospholipase A_2, human; Phospholipase A_2, snake; Platelet accumulation (Cirino, G. (252) 147)

5-HT (5-hydroxytryptamine, serotonin); Methysergide; Adenosine diphosphate; Gastric mucosal blood flow; Blood pressure; Blood gas (Cho, C.H. (256) 9)

Adenosine receptor agonist; Adenosine A_2 receptor; 2-Hexynyl-NECA (5′-*N*-ethyl-carboxamidoadenosine); [^{111}In]Oxine; Platelet, rabbit (Sandoli, D. (259) 43)

Platelet aggregation, human
Nucleoside transporter; Nucleoside transport inhibitor; R75231; Draflazine (Beukers, M.W. (266) 57)

Platelet, rabbit
Adenosine receptor agonist; Adenosine A_2 receptor; 2-Hexynyl-NECA (5′-*N*-ethyl-carboxamidoadenosine); Platelet aggregation; [^{111}In]Oxine (Sandoli, D. (259) 43)

Platelet, human
Oxygenated triterpenes; Phospholipase C; Phospholipase A_2 (Wang, C.-N. (267) 33)

Pleurisy
Tumor necrosis factor; Interleukin-1; Interleukin-6; Indomethacin; Dexamethasone; (Rat) (Utsunomiya, I. (252) 213)

[^{3}H](+)-PN200-110
Smooth muscle, vascular; Ca^{2+} channel; Aorta; Binding; Spontaneously hypertensive rat (SHR) (Ikeda, S. (264) 223)

Polyamine
Ifenprodil; ACTH (adrenocorticotropin); Behavior; NMDA receptor; (Rat) (Genedani, S. (252) 77)

NMDA (*N*-methyl-D-aspartate); Glycine; 7-Chlorokynurenate; Ifenprodil; (Synergism) (Voltz, C. (255) 197)

NMDA receptor; Seizure; *N*-(3-Aminopropyl)-cyclohexylamine (Chu, P.-j. (256) 155)

[^{3}H]Spermidine binding; Autoradiography; Cerebellar cortex; Brain development, human (McConnell, S.E. (262) 293)

Glutamate receptor; Memory; Ion channel (Shimada, A. (263) 293)

[^{3}H]L-689,560 binding; Glycine; NMDA receptor; Allosteric interaction (Grimwood, S. (266) 43)

[^{3}H]Ifenprodil binding; NMDA receptor (*N*-Methyl-D-aspartate); σ Receptor; Brain, rat (Hashimoto, K. (266) 67)

7-Chlorokynurenate; NMDA receptor antagonist, competitive; Glycine recognition site; NMDA receptor complex; Brain, rat (Oblin, A. (266) 103)

Spermine; Spermidine; Arcaine; 1,10-diaminodecane; Diethylenetriamine; Putrescine; *N*-Methyl-D-aspartate (NMDA); NMDA receptor; Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

NMDA (*N*-methyl-D-aspartate); Dizocilpine; Glutamate; Glycine; Spermine (Marvizón, J.-C. (269) 165)

Philanthotoxin; Ca^{2+} current; Hippocampus; Glutamate antagonist; Patch clamp, in situ (Karst, H. (270) 357)

Polyanionic drug
Lung cancer; Growth factor (Favoni, R.E. (264) 199)

Polymerase chain reaction
α_1-Adrenoceptor; mRNA; [^{3}H]Prazosin (Faure, C. (268) 141)

Artery, rabbit; Saphenous vein, human; α_1-Adrenoceptor (Diehl, N.L. (268) 393)

CCK_B receptor; Radioligand binding; Calcium mobilization; Fura-2; COS-7 cell; Transient expression; [*N*-methyl-Nle 28,31)]cholecystokinin-(26-33) (Knapp, R.J. (269) 133)

Polymorphonuclear leukocyte
Nimesulide; Phosphodiesterase type IV; Superoxide anion; cAMP; Chemotaxis (Bevilacqua, M. (268) 415)

Polymorphonuclear neutrophil
Platelet; Prostaglandin D_2; ZK 118.182 (Darius, H. (258) 207)

Polyol pathway
Aldose reductase inhibitor; Laser Doppler flowmetry; Motor nerve conduction velocity; Nerve blood flow; Streptozotocin-induced diabetes (Calcutt, N.A. (251) 27)

Polyphosphoinositide turnover
G protein (low molecular weight); Botulinum toxin; ADP-ribosylation; 5-HT (5-hydroxytryptamine, serotonin); *Xenopus* oocyte (Tohda, M. (266) 19)

Muscarinic acetylcholine receptor; c-*fos* expression; Calmodulin; Protein kinase C; NG108-15 cell, transfected (Tohda, M. (268) 169)

Portal vein
Prejunctional receptor; Noradrenaline overflow, evoked; Neuropeptide Y; [Leu^{31},Pro^{34}]Neuropeptide Y; Neuropeptide Y-(18–36); (Freely moving rat) (Coppes, R.P. (261) 311)

Positive inotropic action
Thaliporphine; Bay K 8644; Ca^{2+} channel; K^+ channel; Cardiomyocyte (Su, M.-J. (254) 141)

Positive inotropic effect
HV723 (α-ethyl-3,4,5-trimethoxy-α-(3-((2-(2-methoxyphenoxy)ethyl)-amino)-propyl) benzeneacetonitrile fumarate); α_1-Adrenoceptor; Phosphoinositide hydrolysis; [^{3}H]Prazosin; Ventricular myocardium, rabbit (Kohi, M. (250) 95)

Positive inotropy
Endothelin; Saponin; Ca^{2+}; Protein kinase C; Diacylglycerol; IP_3; Phospholipase (Paik, G.Y. (264) 437)

Positron emitting tracer
Opiate receptor; Dual detector system (Villemagne, V.L. (257) 195)

Postnatal
NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate); Neurotoxicity; Glucocorticoid; Dexamethasone (Supko, D.E. (270) 105)

Postsynaptic action, direct
Opiate; Excitatory response; Medial vestibular nucleus, rat (Lin, Y. (262) 99)

pp60^{F527}
Tyrosine phosphorylation; Lavendustin A and C6; Tyrosine kinase inhibitors (Agbotounou, W.K. (269) 1)

PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone)
Thrombin; Platelet; Hirulog; Heparin; Low molecular weight heparin; DuP-714 ester (acetyl-D-phenylalanine-propyl-boroarginine); (Rabbit) (Liu, J.T. (264) 183)

iso-PPADS (pyridoxalphosphate-6-azophenyl-2′,5′-disulphonic acid)
P_{2X} purinoceptor; Suramin; Cibacron blue (Khakh, B.S. (263) 301)

1-PP (1-(2-pyrimidinyl)-piperazine)
Buspirone; Clonidine; α_2-Adrenoceptor; Antinociception (Cao, B.-J. (259) 75)

[^{3}H]3-PPP binding
σ Receptor; Heterocyclic amino alcohol; Ifenprodil; Brain (Rat); Molecular modelling (Beart, P.M. (269) 193)

3-PPP (3-(3-hydroxyphenyl)-*N*-(*n*-propyl)piperidine)
Dextromethorphan; Haloperidol; Haloperidol, reduced; (+)-Pentazocine; Receptor down-regulation (Klein, M. (254) 239)

Intraocular pressure; Dopamine receptor; Phosphodiesterase inhibitor; Methylxanthine; Pentoxifylline; Trifluperidol; Thiothixene; Fluphenazine; Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

P_2 purinoceptor
Suramin; Coronary vasculature (Vials, A.J. (251) 299)

Noradrenaline release; Sympathetic neuron (Allgaier, C. (252) R7)

Pyridoxal-5-phosphate; α,β-Methylene ATP; Vagus nerve, rat; Vas deferens, rat (Trezise, D.J. (259) 295)

P_{2U} purinoceptor; Ca^{2+} release; Ca^{2+} influx; Smooth muscle, vascular (Kitajima, S. (266) 263)

P_{2U} purinoceptor
P_2 Purinoceptor; Ca^{2+} release; Ca^{2+} influx; Smooth muscle, vascular (Kitajima, S. (266) 263)

cAMP; Protein kinase C; Ca^{2+}; Pertussis toxin; DDT_1 MF-2 cell (Sipma, H. (268) 431)

P_{2X} purinoceptor
Ileal longitudinal muscle, guinea pig; P_{2Y} purinoceptor; α,β-Methylene ATP; 2-Methylthio ATP; β,γ-Methylene ATP (Kennedy, I. (261) 273)

iso-PPADS (pyridoxalphosphate-6-azophenyl-2′,5′-disulphonic acid); Suramin; Cibacron blue (Khakh, B.S. (263) 301)

P_{2Y} purinoceptor
Ileal longitudinal muscle, guinea pig; P_{2X} purinoceptor; α,β-Methylene ATP; 2-Methylthio ATP; β,γ-Methylene ATP (Kennedy, I. (261) 273)

Radioligand binding; Suramin; Ecto-nucleotidase; (Antagonist) (Van Rhee, A.M. (268) 1)

Prazosin
α_1-Adrenoceptor; Renal proximal tubule; Adrenoceptor subtype (Gopalakrishnan, S.M. (250) 469)

[^{3}H]Prazosin
HV723 (α-ethyl-3,4,5-trimethoxy-α-(3-((2-(2-methoxyphenoxy)ethyl)-amino)-propyl) benzeneacetonitrile fumarate); α_1-Adrenoceptor; Positive inotropic effect; Phosphoinositide hydrolysis; Ventricular myocardium, rabbit (Kohi, M. (250) 95)

Cauda epididymis; Vas deferens; α_2-Adrenoceptor; α_1-Adrenoceptor; [^{3}H]Rauwolscine; (Rat) (Ventura, S. (254) 167)

α_1-Adrenoceptor subtype; Chloroethylclonidine; Benextramine; Phenoxybenzamine; Cerebral cortex (Sallés, J. (266) 301)

α_1-Adrenoceptor; Polymerase chain reaction; mRNA (Faure, C. (268) 141)

[^{3}H]Prazosin binding
α_1-Adrenoceptor; Phosphoinositide hydrolysis; Phenoxybenzamine; Myocardium (rat) (Sallés, J. (266) 35)

Prefrontal cortex
Microdialysis; Dopamine release; Memantine; Pharmacokinetics; Striatum (Spanagel, R. (262) 21)

5β-Pregnan-3α-ol-20-one
GnRH (gonadotropin-releasing hormone) gene expression; Muscimol; Picrotoxin; Hypothalamus; Hybridization, in situ (Vincens, M. (260) 157)

Pregnancy
Uterine artery; Muscarinic receptor; Acetylcholine; (Guinea-pig) (Jovanović, A. (258) 185)

Pregnancy-specific β_1-glycoprotein
Angiotensin II; Angiotensin receptor; Human placental lactogen; Placenta (Kalenga, M.K. (268) 231)

Prejunctional receptor
Pulmonary artery; Dopamine D_2 receptor; Radioligand binding; Autoradiography; Catecholamine histofluorescence (Kobayashi, Y. (261) 229)

Noradrenaline overflow, evoked; Neuropeptide Y; [Leu^{31},Pro^{34}]Neuropeptide Y; Neuropeptide Y-(18–36); Portal vein; (Freely moving rat) (Coppes, R.P. (261) 311)

Prepiriform cortex
CGS21680; Adenosine A_1 receptor; Adenosine A_{2A} receptor; Seizure; [^{3}H]DPCPX (8-Cyclopentyl-1,3-[^{3}H]dipropylxanthine) (Zhang, G. (255) 239)

Preprogalanin
Galanin; Galanin receptor; Nociception; Spinal cord; Neuropeptide (Bedecs, K. (259) 151)

Pressor response
R-α-methylhistamine; Histamine H_3 receptor; Histamine; Thioperamide; Depressor response; Tachycardia; (Prejunctional) (Hegde, S.S. (251) 43)

Presynaptic
MCPG (α-methyl-4-carboxyphenylglycine); Excitatory amino acid receptor; cAMP; Glutamate; Receptor; Metabotropic; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-amino-cyclopentane-1,3-dicarboxylate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-amino-cyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

Presynaptic inhibition
(*R*)-α-Methylhistamine; Sympathetic-cholinergic response; Histamine receptor; Nerve stimulation, pre- and postganglionic; Sudomotor system (Koss, M.C. (257) 109)

Histamine H_3 receptor; *R*-α-Methylhistamine; Species difference; Thioperamide (McLeod, R.L. (259) 211)

Presynaptic modulation
5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; (*S*)-Zacopride (Mongeau, R. (256) 269)

Presynaptic receptor
Pithed rat; EP_3 receptor; Prostaglandin E_2; Sulprostone; Neurogenic vasopressor response (Malinowska, B. (259) 315)

Primary neuronal culture
Ventral mesencephalon; κ-Opioid receptor; [^{3}H]Dopamine release; Sensitization; Corticosteroid (Ronken, E. (263) 149)

Primary olfactory cortex
5-HT_2 receptor; Electrophysiology (Marek, G.J. (259) 137)

Priming
Adenosine receptor; Neutrophil, human (Dianzani, C. (263) 223)

Proconvulsant
μ-Opioid receptor; Hippocampal slice; Naloxone; Bursting (Jones, L.S. (264) 39)

Prolactin
Amperozide; 5-HT receptor; (Rat) (Albinsson, A. (251) 157)

Tolerance; *N*-Nitro-L-arginine methyl ester; Morphine; Thyrotropin (TSH); Growth hormone; Antinociception; Hyperthermia (Rauhala, P. (259) 57)

Proliferation
SR 47436; DuP 753; Smooth muscle cell; Angiotensin II (Herbert, J.-M. (251) 143)

5-HT, (Serotonin); 5-HT receptor; Small cell lung carcinoma cell (Cattaneo, M.G. (268) 425)

Proliferative vitreoretinopathy
Acetylsalicylic acid; Fibroblast; Arachidonic acid metabolite, inhibition (Kähler, C.M. (262) 261)

Proline, β-substituted
Antagonist; Substance P; Septide; Tachykinin NK_1 receptor (Lavielle, S. (258) 273)

Promethazine
K^+ channel; Glibenclamide; *Xenopus* oocyte; Histamine H_1 receptor antagonist; Dimethindene (Sakuta, H. (266) 99)

Proopiomelanocortin mRNA, hypothalamic
Ethanol, chronic voluntary; Brain; β-Endorphin (De Waele, J.-P. (258) 119)

Propafenone
Disopyramide; Ischemia/reperfusion injury; Na^+ overload; Creatine kinase; Purine nucleoside; Purine base (Liu, J.-X. (250) 361)

Frequency dependence; QRS duration; Ventricular mapping (Stark, G. (252) 283)

Propofol
[^{35}S]TBPS (*t*-[^{35}S]butylbicyclophosphorothionate) binding; GABA (γ-aminobutyric acid); Cl^- channel; Barbiturate; Steroid derivative; Benzodiazepine; General anesthetics (Concas, A. (267) 207)

(−)-Propranolol
Defensive behavior; NAN-190; Vomiting; 5-HT_{1A} receptor (Lucot, J.B. (253) 53)

Propranolol
Imipramine; Alprazolam; Forced swimming test, modified; (Rat) (Abel, E.L. (258) 261)

Tilisolol; Myocardial ischemia; Myocardial metabolism; (Dog) (Hayase, N. (260) 183)

DL-Propranolol
Interleukin-1β; Lipopolysaccharide; Nitric oxide (NO); Smooth muscle, vascular; Cell culture; Spontaneously hypertensive rat (SHR); Wistar Kyoto rat (WKY); (Rat) (De Castro, M. (261) 199)

***R*(−)-Propylnorapomorphine**
7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Remoxipride; Raclopride; Haloperidol (Hillefors-Berglund, M. (261) 179)

Caffeine; Quinpirole; SKF-38393; SKF-77434; Tolerance; Motor activity (Garrett, B.E. (262) 65)

Prostacyclin
Angiotensin; Vas deferens; Angiotensin AT_1 receptor; (Rabbit) (Catalioto, R.-M. (256) 93)

Endothelin; Endothelin ET_B receptor; Endothelin ET_A receptor (McMurdo, L. (259) 51)

Endotoxin; Lipopolysaccharide; Lung; Nitric oxide (NO) (Sautebin, L. (262) 193)

Adenosine receptor; Adenosine receptor antagonist; Heart, guinea-pig, perfused (Felsch, A. (263) 261)

Prostaglandin
Cerebral blood flow; Sympathomimetic anesthesia; Lidocaine; Tetrodotoxin; Charybdotoxin; (Neonate) (Albuquerque, M.L.C. (249) 215)

Cyclo-oxygenase; Inhibitor; Stomach, rat; Smooth muscle, longitudinal and circular (Shimomura, A. (252) 81)

Ulcer; NSAID (non-steroidal anti-inflammatory drug); Nitric oxide (NO); Inflammation (Wallace, J.L. (257) 249)

EGF (epidermal growth factor, urogastrone); Smooth muscle, relaxation; Protein synthesis inhibitor (Petitclerc, E. (259) 91)

Trolox; Antioxidant; SIN (3-morpholino sydnonimine); Nitric oxide (NO); cGMP; Leukotriene; Leukocyte (Riutta, A. (262) 217)

Prostaglandin D_2
Platelet; Polymorphonuclear neutrophil; ZK 118.182 (Darius, H. (258) 207)

Inflammation; Neutrophil; Edema formation; Adherence; O_2^- production (Pons, F. (261) 237)

Prostaglandin E_1
Prostaglandin E_2; Misoprostol; Enisoprost; Bradykinin; Sympathetic nervous system; Plasma extravasation; PAF (platelet activating factor, PAF-acether); Synovial joint (Green, P.G. (252) 127)

Prostaglandin E_2
Prostaglandin E_1; Misoprostol; Enisoprost; Bradykinin; Sympathetic nervous system; Plasma extravasation; PAF (platelet activating factor, PAF-acether); Synovial joint (Green, P.G. (252) 127)

YM-26734; Phospholipase A_2 (Miyake, A. (253) 155)

Tolfenamic acid; Thromboxane B_2; 12-Hydroxyeicosatetraenoic acid; (Dog) (McKellar, Q.A. (253) 191)

Pithed rat; EP_3 receptor; Sulprostone; Presynaptic receptor; Neurogenic vasopressor response (Malinowska, B. (259) 315)

Opsonized zymosan; OX-42; Indomethacin; Dapsone; Bromophenacyl bromide (Klegeris, A. (260) 273)

Prostaglandin $F_{2\alpha}$
Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin) (Lamb, V.L. (256) 221)

Adrenoceptor; Hyperglycemia; Hyperthermia (Nonogaki, K. (262) 177)

Prostanoid
Endothelin; Sarafotoxin; Endothelin receptor; PD 145065; Kidney, rat (Warner, T.D. (250) 447)

Prostanoid IP receptor
Desensitisation; $G_s\alpha$ protein; Adenylyl cyclase; NG108-15 cell (Williams, R.J. (268) 177)

Prostate, human
α_1-Adrenoceptor subtype; Chloroethylclonidine; Nifedipine; Vas deferens, rat; Spleen, rat (Teng, C.-M. (265) 61)

Prostate, rat, rabbit, dog, human
α_1-Adrenoceptor subtype; Urethra; α_1-Adrenoceptor antagonist (Testa, R. (249) 307)

Prostatic hyperplasia, benign
Dicentrine; α_1-Adrenoceptor antagonist; Bladder outlet obstruction (Yu, S.-M. (252) 29)

Protection
Adenosine receptor agonist; Adenosine receptor antagonist; Seizure; NMDA (*N*-methyl-D-aspartate); (Mouse) (Von Lubitz, D.K.J.E. (249) 265)

Protein intake
Macronutrient preference; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Ageing; Feeding (Lacour, F. (255) 249)

Protein kinase
Superior colliculus; Adenosine; Excitation; Glutamate release (Hirai, H. (256) 65)

Interleukin; Hippocampus; Ca^{2+} channel; G-protein; Patch-clamp; (Guinea pig) (Plata-Salamán, C.R. (266) 1)

Protein kinase A
NMDA (*N*-Methyl-D-aspartate); Nitric oxide (NO); Cyclic AMP; Forskolin (Toms, N.J. (266) 63)

Protein kinase C
Pulmonary artery; Smooth muscle; Vascular relaxant; Phorbol ester; Phosphodiesterase inhibitor; Cyclic nucleotides (Savineau, J.-P. (249) 191)

Interleukin-1β; TNF (tumor necrosis factor); Leukotriene B_4; Phospholipase A_2; Phospholipase C; 5-Lipoxygenase; Phorbol 12-myristate 13-acetate; Stomach, rat; Gastric motility (Montuschi, P. (252) 253)

Noradrenaline; Ca^{2+} channel; Ryanodine; G-protein; Caffeine; Phenoxybenzamine (Tabrizchi, R. (259) 285)

Endothelin; Saponin; Ca^{2+}; Positive inotropy; Diacylglycerol; IP_3; Phospholipase (Paik, G.Y. (264) 437)

Acetyl-L-carnitine; Behavior; (Rat) (Pascale, A. (265) 1)

Smooth muscle, bovine, tracheal; Smooth muscle, contraction; Ca^{2+}, intracellular; Bronchodilator (Langlands, J.M. (266) 229)

Endothelium; Nitric oxide synthase; EDRF (endothelium-dependent relaxation factor); Phorbol ester (Davda, R.K. (266) 237)

ANP (Atrial natriuretic peptide); Growth factor; aFGF (acidic fibroblast growth factor); Staurosporine; Phorbol ester (Tokola, H. (267) 195)

cAMP-dependent protein kinase; cGMP-dependent protein kinase; 5-HT (5-hydroxytryptamine, serotonin) uptake; Imipramine binding (Helmeste, D.M. (267) 239)

Neuroblastoma SH-SY5Y cell; c-*fos* expression; Muscarinic-receptor-stimulation; Diacylglycerol (Larsson, C. (268) 19)

Dopamine transporter; Cocaine (Kitayama, S. (268) 115)

Muscarinic acetylcholine receptor; Polyphosphoinositide turnover; c-*fos* expression; Calmodulin; NG108-15 cell, transfected (Tohda, M. (268) 169)

Pituitary; Estradiol; Dopamine; Hyperplasia; (Isoform); (Rat) (Lévy, L. (268) 327)

P_2^U purinoceptor; cAMP; Ca^{2+}; Pertussis toxin; DDT_1 MF-2 cell (Sipma, H. (268) 431)

K^+ channel clone; $K_{V1.2}$; Endothelin receptor; *Xenopus* oocyte; Ca^{2+}, intracellular (Murakoshi, H. (268) 451)

Protein synthesis
Melatonin; Sympathetic neurotransmission; Vas deferens; Nicotinic receptor (Carneiro, R.C.G. (257) 73)

Protein synthesis inhibitor
EGF (epidermal growth factor, urogastrone); Prostaglandin; Smooth muscle, relaxation (Petitclerc, E. (259) 91)

Neurosteroid; cAMP; Brain cortex, rat; Diazepam binding inhibitor (DBI) receptor, mitochondrial; Adrenalectomy/orchidectomy (Roscetti, G. (269) 17)

Proteinuria
DP-1904; Thromboxane A_2 synthetase inhibitor; Crescentic nephritis (Nagao, T. (259) 233)

Proximal colon, guinea-pig
Tachykinin receptor; Sucrose gap; Pharmacomechanical coupling; Electromechanical coupling; Ca^{2+} channel, voltage-dependent (Zagorodnyuk, V. (255) 9)

Proximal tubule
Uptake; Amino acid; Carrier; Glutamate transporter; Kidney; In situ hybridization; (Rabbit) (Meister, B. (267) 323)

Psoriasis
Interleukin-8 receptor; Cyclosporine; Calcitriol; Dithranol (Kemény, L. (258) 269)

Fumaric acid; Keratinocyte; Cell proliferation; Cytotoxicity (Sebök, B. (270) 79)

PTHrP (parathyroid hormone-related protein)
Cytosolic free Ca^{2+}; Fura-2; cAMP; Aortic spiral preparation, rat (Ishikawa, M. (269) 311)

PTI (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl)
PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide); Carboxy-PTI; Radical compound; Coronary vasodilator; Methylene blue (Tsunoda, R. (262) 55)

PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide)
PTI (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl); Carboxy-PTI; Radical compound; Coronary vasodilator; Methylene blue (Tsunoda, R. (262) 55)

Pulmonary artery
Smooth muscle; Vascular relaxant; Phorbol ester; Protein kinase C; Phosphodiesterase inhibitor; Cyclic nucleotides (Savineau, J.-P. (249) 191)

Dopamine; Dopamine D_1 receptor; Autoradiography; (Rabbit) (Kobayashi, Y. (253) 201)

BQ123; Endothelin; Ro 46-2005; Sarafotoxin S6c; (Human); (In vitro) (Buchan, K.W. (260) 221)

Dopamine D_2 receptor; Radioligand binding; Autoradiography; Catecholamine histofluorescence; Prejunctional receptor (Kobayashi, Y. (261) 229)

Pulmonary artery, rabbit
Methoxamine; ATP release; α_1-Adrenoceptor (Takeuchi, K. (254) 287)

Atherosclerosis; Aorta, rabbit; Noradrenaline release; Sympathetic nerve stimulation; Noradrenaline metabolite (Verbeuren, T.J. (270) 27)

Pulmonary circulation
Angiotensin II; Angiotensin-(3–8)/angiotensin IV; Angiotensin-(1–7); Vasoconstriction; Angiotensin AT_1 receptor antagonist; Angiotensin AT_2 receptor antagonist (Cheng, D.Y. (261) 223)

Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; L158809; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Hypoxic pulmonary vasoconstriction; Pulmonary vascular bed, rat (Feng, C.J. (263) 133)

Pulmonary edema, neurotransmitter
Neuropeptide Y; Neurokinin A (Hirabayashi, A. (256) 227)

Pulmonary gas trapping
Asthma; Corticosteroid; Pulmonary inflammation; Substance P; (Hyperresponsiveness) (Stengel, P.W. (253) 253)

Pulmonary inflammation
Asthma; Corticosteroid; Pulmonary gas trapping; Substance P; (Hyperresponsiveness) (Stengel, P.W. (253) 253)

Pulmonary vascular bed
Vasoactive peptide; Adrenomedullin; CGRP (calcitonin gene-related peptide); Pancreatic amylin (DeWitt, B.J. (257) 303)

Pulmonary vascular bed, rat
Nitric oxide (NO) synthesis; N^{ω}-Nitro-L-arginine methyl ester; LY83583; L158809; Glybenclamide; Guanylate cyclase, soluble; K^+ channel, ATP-sensitive; Angiotensin AT_1 receptor antagonist; Hypoxia; Pulmonary circulation; Hypoxic pulmonary vasoconstriction (Feng, C.J. (263) 133)

Purine
EDRF (endothelium-dependent relaxing factor); Cotransmission; Ethanol; ATP (Brizzolara, A.L. (254) 175)

Purine base
Disopyramide; Ischemia/reperfusion injury; Propafenone; Na^+ overload; Creatine kinase; Purine nucleoside (Liu, J.-X. (250) 361)

Purine nucleoside
Disopyramide; Ischemia/reperfusion injury; Propafenone; Na^+ overload; Creatine kinase; Purine base (Liu, J.-X. (250) 361)

Purinergic transmission
Nicotine; Peptidergic transmission; NANC (non-adrenergic, non-cholinergic) nerve; Developmental pharmacology (Irie, K. (251) 75)

Purine transport
Myocardial infarction; Myocardial ischemia; Adenosine (Poucher, S.M. (252) 19)

Purinoceptor
ATP; Suramin; Ionic conductance; Enteric neuron; Electrophysiology; Myenteric plexus (Barajas-López, C. (250) 141)

Superior cervical ganglion, rat; Uridine 5′-triphosphate; Adenosine 5′-triphosphate; Reactive blue 2; Pyrimidinoceptor (Connolly, G.P. (259) 95)

Adenosine; Defecation, rat (Tomaru, A. (264) 91)

Putative anxiolytic
$5\text{-}HT_4$ receptor; Light/dark test; Behavioral disinhibition; 5-Hydroxytryptophan; SDZ205-557; Tropisetron (Cheng, C.H.K. (255) 39)

Putrescine
Polyamine; Spermine; Spermidine; Arcaine; 1,10-diaminodecane; Diethylenetriamine; *N*-Methyl-D-aspartate (NMDA); NMDA receptor; Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

Pyridoxal-5-phosphate
α,β-Methylene ATP; Vagus nerve, rat; Vas deferens, rat; P_2 purinoceptor (Trezise, D.J. (259) 295)

Pyrimidinoceptor
Superior cervical ganglion, rat; Uridine 5′-triphosphate; Adenosine 5′-triphosphate; Reactive blue 2; Purinoceptor (Connolly, G.P. (259) 95)

Pyruvate oxidation
L-DOPA (3,4-dihydroxyphenylalanine); Mitochondrion; Fibroblast; Parkinson's disease (Werner, P. (263) 157)

QRS duration
Propafenone; Frequency dependence; Ventricular mapping (Stark, G. (252) 283)

QT duration
Mexiletine; Dofetilide; Conduction; Action potential duration; (Guinea-pig); (In vivo) (Todt, H. (265) 43)

Quercetin
Staurosporine; Phasic contraction; Aorta, rat (Duarte, J. (262) 149)

Quinacrine
K^+ channel; Glibenclamide; Cromakalim; Y-26763; SKF 525A; *Xenopus* oocyte; Local anesthetic (Sakuta, H. (252) 117)

Quinine
4-Aminopyridine; Morphine; Dopamine release; Behavioural activity; Nucleus accumbens (Pei, Q. (249) 243)

Quinpirole
Caffeine; *R*(−)-Propylnorapomorphine (NPA); SKF-38393; SKF-77434; Tolerance; Motor activity (Garrett, B.E. (262) 65)

[^{3}H]Quinuclidinyl benzilate
Binding study; Muscarinic M_2 receptor; Selective antagonist; Uterus; (Rat) (Pennefather, J.N. (262) 297)

R56865
Cell death; Ca^{2+} oscillation; Veratridine; Bovine chromaffin cell; Flunarizine; Nimodipine; ω-Conotoxin GVIA (Maroto, R. (270) 331)

R75231
Nucleoside transporter; Platelet aggregation, (human); Nucleoside transport inhibitor; Draflazine (Beukers, M.W. (266) 57)

R84760
κ-Opioid receptor agonist; U-50488; CI-977; Morphine; Antinociceptive effect (Fujibayashi, K. (261) 133)

Raclopride
NMDA (*N*-methyl-D-aspartate); SCH 23390; Striatum; Microdialysis; (Neurotransmitter release) (Morari, M. (256) 23)

7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Remoxipride; *R*(−)-Propylnorapomorphine; Haloperidol (Hillefors-Berglund, M. (261) 179)

Radical compound
PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide); PTI (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl); Carboxy-PTI; Coronary vasodilator; Methylene blue (Tsunoda, R. (262) 55)

Radioactive tracer
Receptor kinetics; Benzodiazepine; Flumazenil; Midazolam; SPECT (single photon emission computer tomography) (Videbæk, C. (249) 43)

Radioimmunoassay
U-46619; Endothelin-1; Anti-endothelin-1 serum; ST elevation; (Rat) (Yamamoto, T. (250) 189)

Endothelin; Spinal cord; Sympathetic nervous system (Knuepfer, M.M. (259) 305)

Basal ganglion; Neuropeptide; Dopamine; Immunohistochemistry (Castel, M.-N. (262) 1)

Radioligand
Muscarinic receptor; Muscarinic receptor antagonist; SPECT (single-photon emission computed tomography) imaging (Baumgold, J. (251) 315)

Ca^{2+} channel; Dihydropyridine; Enantiomer; Vascular myocyte; Patch clamp (Baron, A. (269) 105)

Radioligand binding
VUF 9153 (*S*-[3-(4(5)-imidazolyl)]propyl-*N*-(4-chlorobenzyl)isothiourea); Thioperamide; Histamine H_3 receptor; Ileum, guinea-pig; Dipsogenicity (Barnes, J.C. (250) 147)

Pulmonary artery; Dopamine D_2 receptor; Autoradiography; Catecholamine histofluorescence; Prejunctional receptor (Kobayashi, Y. (261) 229)

β_3-Adrenoceptor; Catecholamine (Clarkson, K. (263) R1)

Suramin; P_{2y} purinoceptor; Ecto-nucleotidase; (Antagonist) (Van Rhee, A.M. (268) 1)

CCK_B receptor; Polymerase chain reaction; Calcium mobilization; Fura-2; COS-7 cell; Transient expression; [*N*-methyl-Nle 28,31)]cholecystokinin-(26-33) (Knapp, R.J. (269) 133)

Parietal cell (rat); Hydrogen ion production; Adenosine 3′,5′-cyclic monophosphate; Covalent cross-linking (Schepp, W. (269) 183)

Radioligand binding studies
α_{1B}-Adrenoceptor; CHO (Chinese hamster ovary) cell; Ca^{2+} concentration, cytosolic (Horie, K. (268) 399)

Ranitidine
Brain ischemia; Histamine H_2 receptor; Edema; Na^+; K^+; Ca^{2+}; (Rat) (Tósaki, Á. (264) 455)

Raphe
Clozapine; α_1-Adrenoceptor; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor (Lejeune, F. (260) 79)

$\omega 3 / \omega 6$ Ratio
Epilepsy, therapy; α-Linolenic acid; Linoleic acid (Yehuda, S. (254) 193)

[^{3}H]Rauwolscine
α_2-Adrenoceptor; Myometrium; cAMP; Inositol phosphate; (Guinea-pig) (Haynes, J.M. (250) 231)

Cauda epididymis; Vas deferens; α_2-Adrenoceptor; α_1-Adrenoceptor; [^{3}H]Prazosin; (Rat) (Ventura, S. (254) 167)

α_2-Adrenoceptor subtype; Ligand binding; Signal transduction; cAMP (Jansson, C.C. (266) 165)

$^{86}Rb^+$ efflux
Carbachol; Phenylephrine; Atrium, left; Negative inotropy; Pertussis toxin; 4-Aminopyridine (Ray, A. (256) 311)

RB 101 (mixed inhibitor of enkephalin-degrading enzymes)
Morphine; Naloxone; Physical dependence; (Intravenous perfusion) (Noble, F. (253) 283)

Reactive blue 2
Superior cervical ganglion, rat; Uridine 5′-triphosphate; Adenosine 5′-triphosphate; Pyrimidinoceptor; Purinoceptor (Connolly, G.P. (259) 95)

Reactive oxygen
Ethanol; Acetaldehyde; Free radical; Oxidative stress (Bondy, S.C. (270) 349)

Receptor
Anesthetic; Stereoisomer; Isoflurane; (Rat) (Lysko, G.S. (263) 25)

Dopamine; Electrophysiology; *d*-Amphetamine; Antipsychotic; (Rat) (Shepard, P.D. (265) 141)

MCPG (α-methyl-4-carboxyphenylglycine); Excitatory amino acid receptor; Presynaptic; cAMP; Glutamate; Metabotropic; L-AP4 (L-2-amino-4-phosphonobutyrate); (1*S*,3*R*)-ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); (1*S*,3*S*)-ACPD ((1*S*,3*S*)-1-aminocyclopentane-1,3-dicarboxylate) (Kemp, M. (266) 187)

σ Receptor
DTG (di-*o*-tollylguanidine); SKF10047; Red nucleus; *N*-Allylnormetazocine; Movement disorder; Dystonia (Weissman, A.D. (250) 329)

Opioid receptor; σ Receptor antagonist (Chien, C.C. (250) R7)

DTG (1,3-di(2-tolyl)guanidine); Brain membrane; KB-5492; Anti-ulcer agent; (Guinea-pig) (Harada, Y. (256) 321)

Brain; Motor system; Antipsychotic; (Rat) (Leitner, M.L. (259) 65)

Conditioned suppression; Dopaminergic system; Stress (Kamei, H. (260) 39)

Anti-ulcer agent; DTG (1,3-di(2-tolyl)guanidine); KB-5492; Mucosa; SKF 10,047 (*N*-allyl-normetazocine); (Pig) (Harada, Y. (261) 91)

NE-100; Phencyclidine; Cognition; Neuroleptic; (Rat) (Ogawa, S.-i. (263) 9)

ACTH (adrenocorticotropic hormone); Corticosterone; Dioxadrol; Endocrine; NMDA (*N*-methyl-D-aspartate); Pentazocine; Phencyclidine; SKF 10,047 (Pechnick, R.N. (263) 115)

[^{3}H]Ifenprodil binding; Polyamine; NMDA receptor; Brain, rat (Hashimoto, K. (266) 67)

Pentazocine binding; Cytochrome *P*450; Piperazine; Phenylalkylamine; 5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor (Cagnotto, A. (266) 131)

Liver; Kidney; Haloperidol; Pentazocine; Photoaffinity labeling (Hellewell, S.B. (268) 9)

Heterocyclic amino alcohol; Ifenprodil; [^{3}H]3-PPP ([^{3}H]R(+)-3-[3-hydroxyphenyl]-*N*-(1-propyl)piperidine) binding; Brain (Rat); Molecular modelling (Beart, P.M. (269) 193)

Receptor agonist exposure
Transfected cell; Receptor internalization; Phosphatidylinositol hydrolysis; cAMP production; Down-regulation; Muscarinic M_1 receptor; Muscarinic M_2 receptor (Wei, H.-B. (268) 381)

Receptor antagonist
Neurotensin; Dopamine release; Striatum; Mesencephalic cell (Brouard, A. (253) 289)

σ Receptor antagonist
Opioid receptor; σ Receptor (Chien, C.C. (250) R7)

Receptor autoradiography
Melatonin; Anterior thalamus; Limbic system; Pineal gland (Lindroos, O.F.C. (250) 161)

α_2-Adrenoceptor; Lymph node; Spleen; [^{3}H]Bromoxidine; Immune system (Fernández-López, A. (252) 333)

β-Adrenoceptor; Lymph node; Spleen; [^{125}I]Cyanopindolol; Immune system; Lymphoid organ (Fernández-López, A. (262) 283)

Receptor binding
Dopamine D_3 receptor; Dopamine D_2 receptor; cAMP accumulation; Arachidonic acid release; Inositol phosphate (MacKenzie, R.G. (266) 79)

Receptor binding and activation
Molecular modeling; Adenosine receptor; Bacteriorhodopsin; Histidine residue (IJzerman, A.P. (268) 95)

Receptor binding thermodynamics
Adenosine A_1 receptor; Intrinsic activity; Agonists (full and partial) (Borea, P.A. (267) 55)

Receptor, Ca^{2+} release channel
Ryanodine; Sarcoplasmic reticulum; Doxorubicin (Bowling, N. (268) 365)

Receptor conformation
Morphinan; Opioid receptor; Analgesia (Lemaire, S. (258) 111)

Receptor desensitization
SK&F 96365; Neostigmine; Endplate potential; Nicotinic acetylcholine receptor (Hong, S.J. (265) 35)

Glutamate; Cyclothiazide; GYKI 52466 (Sharp, R.L. (266) R1)

Metabotropic glutamate receptor; Cyclothiazide (Sharp, R.L. (269) R5)

Receptor down-regulation
Dextromethorphan; 3-PPP (3-(3-hydroxyphenyl)-*N*-(*n*-propyl)piperidine); Haloperidol; Haloperidol, reduced; (+)-Pentazocine (Klein, M. (254) 239)

Receptor internalization
Transfected cell; Receptor agonist exposure; Phosphatidylinositol hydrolysis; cAMP production; Down-regulation; Muscarinic M_1 receptor; Muscarinic M_2 receptor (Wei, H.-B. (268) 381)

Receptor kinetics
Benzodiazepine; Flumazenil; Midazolam; Radioactive tracer; SPECT (single photon emission computer tomography) (Videbæk, C. (249) 43)

σ Receptor ligand
DTG (1,3-di(2-tolyl)guanidine); Cerebellum; Liver; (Guinea-pig) (Basile, A.S. (252) 139)

SKF-10,047; DTG (1,3-di-(2-tolyl)guanidine); Benzomorphan-type σ receptor; Acetylcholinergic neuronal system; *p*-Chloroamphetamine; Amnesia; Passive avoidance task; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperizine); (Mouse) (Matsuno, K. (261) 43)

Receptor model
Functional interaction; Indirect action; Tyramine; Vas deferens, rat (Venter, D.P. (251) 209)

Receptor recovery
Striatum; Dopamine D_1 receptor; Dopamine D_2 receptor; Development; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Crawford, C.A. (252) 225)

Receptor reserve
Angiotensin-converting enzyme inhibitor; α_1-Adrenoceptor, vascular; Ca^{2+} channel antagonist; Phenoxybenzamine (Tabrizchi, R. (251) 15)

5-HT_1C receptor; Choroid plexus; Clozapine; Autoradiography; Phosphoinositide hydrolysis (Kuoppamäki, M. (255) 91)

Receptor subtype
Galanin; Galanin fragment; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Blood pressure; Heart rate; Medulla oblongata; (Intracisternal injection) (Narváez, J.A. (257) 257)

Galanin; 5-HT (5-hydroxytryptamine, serotonin); 8-OD-DPAT (8-OH-2-(di-*n*-propylamino)-tetralin); Adenylyl cyclase; Forskolin; Hypothalamus; Hippocampus; Brain; Peptide fragment (Billecocq, A. (269) 209)

Recombinant expression
α_2-Adrenoceptor; Ligand binding (Marjamäki, A. (267) 117)

Recombinant phospholipase A_2, human
Platelet aggregation; Phospholipase A_2, snake; Platelet accumulation (Cirino, G. (252) 147)

Recombinant tissue-type plasminogen activator (rt-PA)
Reocclusion after thrombolysis; Thromboxane A_2; Leucocyte; Thrombin; (Guinea pig) (Nishiyama, H. (264) 191)

Red nucleus
DTG (di-*o*-tollylguanidine); SKF10047; σ Receptor; *N*-Allylnormetazocine; Movement disorder; Dystonia (Weissman, A.D. (250) 329)

Redox
NMDA receptor; Long-term potentiation (Gozlan, H. (262) R3)

Reference memory
Glycine site; 7-Chlorokynurenic acid; Hippocampus; Working memory (Ohno, M. (253) 183)

Relaxation
HA1077; H-7; Ca^{2+} level, cytosolic; Aorta, rat; Smooth muscle, vascular (Takizawa, S. (250) 431)

Uterine artery; L-Arginine; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); (Human) (Jovanović, A. (256) 103)

Release
CCK-8 (cholecystokinin octapeptide); GABA (γ-aminobutyric acid); Anxiety; Brain; CCK receptor; (In vitro); (Slice) (Pérez de la Mora, M. (250) 423)

Remoxipride
7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); *R*(−)-Propylnorapomorphine; Raclopride; Haloperidol (Hillefors-Berglund, M. (261) 179)

Renal artery, rabbit
Angiotensin II; Losartan; PD123177 (Zhang, J. (252) 337)

Renal blood flow
Endothelin; L-N^G-Nitroarginine; Ibuprofen; EDRF (endothelium-derived relaxing factor); Urine flow rate; Urine osmolality; Glomerular filtration rate; (Dog) (Yukimura, T. (264) 399)

Renal function
Adrenomedullin; Renal hemodynamics (Ebara, T. (263) 69)

Renal hemodynamics
Adrenomedullin; Renal function (Ebara, T. (263) 69)

Renal hypertension
Angiotensin AT_1 receptor antagonist; SR 47436 (BMS-186295); Genetic hypertension; (Rat) (Lacour, C. (264) 307)

Renal proximal tubule
α_1-Adrenoceptor; Prazosin; Adrenoceptor subtype (Gopalakrishnan, S.M. (250) 469)

Renal sympathetic nerve activity, efferent
PAF (platelet-activating factor, PAF-acether); Hypotension; Renal vascular tone; Baroreflex; Autonomic nervous system (Matsuda, Y. (250) 341)

Renal vascular tone
PAF (platelet-activating factor, PAF-acether); Hypotension; Renal sympathetic nerve activity, efferent; Baroreflex; Autonomic nervous system (Matsuda, Y. (250) 341)

Renal vasoconstriction
Endothelin; Endothelin receptor antagonist; Glomerular filtration rate (Wellings, R.P. (256) 201)

Renin-angiotensin system
Adrenalectomy; Angiotensin II; Aldosterone; Alcohol drinking; Salt appetite; Saline drinking (Saab, G. (256) 1)

Angiotensin II receptor subtype; Antihypertensive agent; Losartan (Wong, P.C. (260) 261)

Spontaneously hypertensive rat (SHR); Extracellular matrix; Transforming growth factor β_1; mRNA; Cardiovascular system (Ohta, K. (269) 115)

Reocclusion after thrombolysis
Recombinant tissue-type plasminogen activator (rt-PA); Thromboxane A_2; Leucocyte; Thrombin; (Guinea pig) (Nishiyama, H. (264) 191)

Repeated administration
Methamphetamine; Ambulation; Sensitization; Haloperidol (Kuribara, H. (256) 295)

Reperfusion injury
Cardioselective; Free radical scavenger; α-Tocopherol analogue; Myocardial ischemia/reperfusion (Petty, M.A. (255) 215)

RES-701-1
Smooth muscle; EDRF (endothelium-derived relaxing factor); Endothelin; Endothelin ET_B receptor; Endothelin ET_B receptor antagonist (Karaki, H. (262) 255)

Reserpine
Locomotion; Glutamate receptor antagonist; Dopamine D_1 receptor agonist; Dopamine D_2 receptor agonist (Starr, M.S. (250) 239)

Acetylcholine release; Dopamine D_1 receptor; Dopamine D_2 receptor; α-Methyl-tyrosine; LY 171555; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor blocker; SCH 23390 (Imperato, A. (251) 271)

Dopamine D_1 receptor; Dopamine D_2 receptor; NMDA receptor; Motor activity; Dopamine-glutamate interaction (Ferré, S. (255) 203)

Adenosine A_{2A} receptor antagonist; Catalepsy; Haloperidol; (Mouse) (Kanda, T. (256) 263)

Theophylline; Dopamine receptor antagonist; Temperature; (Mouse) (Zarrindast, M.-R. (257) 13)

Resiniferatoxin
Capsaicin; Hypothermia; Oxygen consumption; Thermoregulation; (Rat) (Woods, A.J. (264) 125)

[^{3}H]Resiniferatoxin
Autoradiography; Vanilloid receptor; Capsaicin-sensitive neuron; Dorsal root ganglia; Spinal cord (Szallasi, A. (264) 217)

Resiniferatoxin binding
Experimental colitis; Capsaicin; Vanilloid receptor (Goso, C. (249) 185)

Resistance artery
Flosequinan; Smooth muscle; Vascular; (Human) (Richards, N.T. (257) 189)

Resistance vessel
Indapamide; Conductance vessel; $^{45}Ca^{2+}$ movement; (Rabbit); (Sheep) (Del Rio, M. (250) 133)

Respiratory activity
Excitatory amino acid; Apneusis; MK-801 (dizocilpine); NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline) (McManigle, J.E. (252) 11)

Respiratory burst
Zinc hydroxide; Neutrophil, rat; Phagocytosis (Ogino, K. (270) 73)

Immunotoxicology; Detergent; Neutrophil, human; HL-60 cell line; Sodium dodecyl sulfate (SDS) (Kacani, L. (270) 285)

Respiratory rate
5-HT_{1A} receptor agonist; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Blood pressure; Heart rate; α_1-Adrenoceptor (Di Francesco, G.F. (262) 205)

Respiratory system
Nitric oxide (NO); Single breath; Alcohol; Toxicity; Blood pressure; (Lung); (Pharmacology) (Persson, M.G. (270) 273)

Respiratory viral infection
Airway sensory C fibers; Neurogenic inflammation; Substance P; Airway hyperresponsiveness (Kudlacz, E.M. (270) 291)

Retinoid (synthetic)
Cell differentiation modulator; Anti-angiogenic action; Embryonic angiogenesis; Angiogenic disorder (Oikawa, T. (249) 113)

Riluzole
Glutamate; Aspartate; Hippocampus; Excitatory amino acid; Transmitter release (Martin, D. (250) 473)

GABA uptake, synaptosomes; Striatum; (Rat) (Mantz, J. (257) R7)

RIN-5AH cell
Imidazoline; Guanidine; Imidazoline receptor; Insulin; Insulinoma; ATP-dependent K^+ channel (Olmos, G. (262) 41)

mRNA
Vasopressin receptor; PCR (polymerase chain reaction); (Rat) (Hirasawa, A. (267) 71)

Angiotensin II; Ca^{2+} concentration, intracellular; Smooth muscle, vascular; cAMP; (Down-regulation) (Chen, X. (267) 175)

α_1-Adrenoceptor; Polymerase chain reaction; [^{3}H]Prazosin (Faure, C. (268) 141)

Keratinocyte; Cardiocyte; NMDA receptor; [^{3}H]MK-801 (Morhenn, V.B. (268) 409)

Spontaneously hypertensive rat (SHR); Extracellular matrix; Transforming growth factor β_1; Cardiovascular system; Renin-angiotensin system (Ohta, K. (269) 115)

Ro 5-4864
Peripheral benzodiazepine; Muscle strip, human; PK 11195 (Shany, E. (253) 231)

Ro 46-2005
Endothelin; IRL 1620; PD 145065; Endothelin ET_A/ET_B non-selective receptor antagonist (Battistini, B. (252) 341)

BQ123; Endothelin; Pulmonary artery; Sarafotoxin S6c; (Human); (In vitro) (Buchan, K.W. (260) 221)

Ro 47-0203
BQ-123; Bosentan; Endothelin ET_A receptor; Endothelin ET_B receptor; Endothelin; Microcirculation; Skin blood flow, rat (Lawrence, E. (260) 103)

Ropinirole
Dopamine; D_2-like receptor; Spontaneously hypertensive rat (SHR); Cardiovascular; Tolerance; (Monkey) (Parker, S.G. (265) 17)

Rose bengal
Magnetic resonance image; Cerebral infarction, focal; U74006F; Lipid peroxidation (Umemura, K. (251) 69)

Rotational behavior
Adenosine A_1/A_2 receptor; Dopamine; Striatum; (Rat) (Popoli, P. (257) 21)

RP 67580
Tachykinin NK_1 receptor; FK888; (±)-CP-96,345; IM9 human lymphoblastoma cell; U373 MG human astrocytoma cell (Goso, C. (254) 221)

Rp-8-Br-cGMPS
8-Br-cGMP; Nitroglycerin; 8-Br-cAMP; Aorta, rabbit; cGMP-dependent protein kinase; cAMP-dependent protein kinase (Nakazawa, M. (253) 179)

R1.1 Thymoma cell line
κ-Opioid receptor; Sulfhydryl group; *N*-Ethylmaleimide; Dithiothreitol (Joseph, D.B. (267) 1)

RU 38486
Tryptophan hydroxylase; Acute sound stress; Hypophysectomy; Hypothalamic deafferentation; Central nucleus of amygdala (Singh, V.B. (256) 177)

Rutaecarpine
Vasorelaxant; Endothelium; Ca^{2+} mobilization (Chiou, W.-F. (257) 59)

Ruthenium red
Noradrenaline; Caffeine; Heparin; Smooth muscle, vascular (Garcha, R.S. (268) 319)

[^{3}H]RX821002
α_2-Adrenoceptor antagonist; α_2-Adrenoceptor subtype, human (Devedjian, J.-C. (252) 43)

Ryanodine
Metal ion; Muscle contracture (Liu, S.-H. (251) 61)

Cyclopiazonic acid; Caffeine; Ca^{2+} release; Ca^{2+} influx; Mesenteric resistance vessel; (Rat) (Naganobu, K. (251) 307)

Ca^{2+} influx; Verapamil; Femoral artery; Spontaneously hypertensive rat (SHR) (Kojima, M. (254) 159)

Noradrenaline; Ca^{2+} channel; G-protein; Protein kinase C; Caffeine; Phenoxybenzamine (Tabrizchi, R. (259) 285)

Myocardium, guinea-pig; Development; Ca^{2+}, extracellular; Nicardipine; Isoproterenol (Agata, N. (260) 47)

Sarcoplasmic reticulum; Receptor, Ca^{2+} release channel; Doxorubicin (Bowling, N. (268) 365)

Tachykinin; Neurokinin; CHO (Chinese hamster ovary) cell; Antagonist; Structure-activity; Ca^{2+}; Second messenger; Inositol phosphate; Thapsigargin; U73122 (Pinnock, R.D. (269) 73)

S-1452 (calcium (1*R*,2*S*,3*S*,4*S*)-(5*Z*)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate)
Thromboxane A_2; Bronchial hyperresponsiveness; Lung vascular injury (Arimura, A. (260) 201)

S-20499
5-HT_{1A} receptor; Adenylate cyclase; Dorsal raphe nucleus; Nerve impulse flow; (+)-WAY 100 135; SDZ 216-525; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lesopitron; Flesinoxan (Lanfumey, L. (249) 25)

Salbutamol
Nitric oxide (NO); β_2-Adrenoceptor; N^G-Nitro-L-arginine methyl ester; Aortic ring; Blood pressure; Endothelium (Wang, Y.-X. (250) 335)

Pertussis toxin; Arecoline; Aorta; β-Adrenoceptor; Langendorff; (Rat) (Vleeming, W. (250) 415)

Formoterol; Salmeterol; Smooth muscle, airway; Mast cell; (Duration) (Nials, A.T. (251) 127)

Saline drinking
Adrenalectomy; Angiotensin II; Renin-angiotensin system; Aldosterone; Alcohol drinking; Salt appetite (Saab, G. (256) 1)

Salmeterol
Formoterol; Salbutamol; Smooth muscle, airway; Mast cell; (Duration) (Nials, A.T. (251) 127)

Formoterol; Terbutaline, in vitro; Lung, guinea pig (Jeppsson, A.-B. (257) 137)

β-Adrenoceptor; cAMP; Thromboxane A_2; Macrophage (Baker, A.J. (264) 301)

Salmon calcitonin
IAPP (islet amyloid polypeptide); CGRP (calcitonin gene-related peptide); Nucleus accumbens (Veale, P.R. (262) 133)

Salt appetite
Adrenalectomy; Angiotensin II; Renin-angiotensin system; Aldosterone; Alcohol drinking; Saline drinking (Saab, G. (256) 1)

Saphenous artery
Vasodilator nerve; Nitric oxide (NO); CGRP (calcitonin gene-related peptide); Nicotine (Okamura, T. (263) 85)

Saphenous vein, human
Endothelin; BQ123; Endothelin ET_A receptor; Endothelin ET_B receptor (White, D.G. (257) 307)

Polymerase chain reaction; Artery, rabbit; α_1-Adrenoceptor (Diehl, N.L. (268) 393)

Saponin
Endothelin; Ca^{2+}; Protein kinase C; Positive inotropy; Diacylglycerol; IP_3; Phospholipase (Paik, G.Y. (264) 437)

Sarafotoxin
Endothelin; BQ-123 (cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu)); Endothelin receptor subtype; Aorta (guinea-pig); Coronary artery (pig); Smooth muscle (vascular) (Schoeffter, P. (249) 199)

Endothelin; Prostanoid; Endothelin receptor; PD 145065; Kidney, rat (Warner, T.D. (250) 447)

Sarafotoxin S6c
BQ123; Endothelin; Pulmonary artery; Ro 46-2005; (Human); (In vitro) (Buchan, K.W. (260) 221)

Sarcoplasmic reticulum
Cyclopiazonic acid; Thapsigargin; Heart; Excitation-contraction coupling; (Frog) (Bonnet, V. (264) 69)

Ryanodine; Receptor, Ca^{2+} release channel; Doxorubicin (Bowling, N. (268) 365)

Sauvagine
Hypothermia; Haloperidol; Spiperone (Broccardo, M. (258) 179)

Scatchard analysis
Smooth muscle, vascular; Cell proliferation; Dihydropyridine-sensitive Ca^{2+} channel; Voltage-dependent Ca^{2+} channel; Modulated receptor model; Atherosclerosis (Ruiz-Velasco, V. (268) 311)

SCH 23390
Acetylcholine release; Dopamine D_1 receptor; Dopamine D_2 receptor; Reserpine; α-Methyl-tyrosine; LY 171555; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor blocker (Imperato, A. (251) 271)

Conditioned avoidance response; Eticlopride (White, I.M. (253) 167)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP monkeys; CY 208–243 ((−)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenanthyxidine); Dopamine D_1 receptor; Dopamine D_2 receptor; Sulpiride; Dopamine D_1/D_2 interaction; (+)-PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Luquin, M.R. (253) 215)

Hemorrhagic shock; ACTH-(1–24); Dopamine receptor; Haloperidol; *l*-Sulpiride (Bazzani, C. (253) 303)

NMDA (*N*-methyl-D-aspartate); Raclopride; Striatum; Microdialysis; (Neurotransmitter release) (Morari, M. (256) 23)

SCH 34826
Angiotensin-converting enzyme; Neutral endopeptidase; Captopril; Heart failure; (Rat) (Helin, K. (264) 135)

SCH 39166
Catalepsy-associated behavior; BW 737C89; R-SKF 38393; SKF 75670; Haloperidol; SKF 81297; SKF 82958 (Rosenzweig-Lipson, S. (260) 237)

[^{3}H]SCH 23390
Dopamine D_1 receptor; Dissociation kinetics; Striatum (Rat); Allosteric mechanism (Farrell, C.B. (268) 79)

Schedule-induced polydipsia
Amperozide; Anxiety (Tung, C.-S. (256) 193)

Schizophrenia
Dopamine neuron; Depolarization inactivation; Haloperidol, chronic; Chloral hydrate, anesthesia; (Rat) (Mereu, G. (264) 449)

Scopolamine
Glucose; Mecamylamine; Spontaneous alternation; Memory (Ragozzino, M.E. (256) 31)

Scopolamine-induced amnesia
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1*H*-cyclopenta(*b*)-quinoline monohydrate hydrochloride); Tacrine; Physostigmine; Side-effect (central); Side-effect (peripheral) (Yoshida, S. (250) 117)

Scratching
Excitatory amino acid; Excitatory amino acid receptor (metabotropic); ACPD ((1*S*,3*R*)-1-Aminocyclopentane-1,3-dicarboxylic acid); Convulsion (Laudrup, P. (250) 15)

Scyliorhinin I
Tachykinin receptor; Tachykinin receptor agonist (Patacchini, R. (250) 311)

SDZ 205-557
5-HT_4 receptor; Light/dark test; Behavioral disinhibition; 5-Hydroxytryptophan; Tropisetron; Putative anxiolytic (Cheng, C.H.K. (255) 39)

SDZ 216-525
5-HT_{1A} receptor; Adenylate cyclase; Dorsal raphe nucleus; Nerve impulse flow; (+)-WAY 100 135; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lesopitron; S-20499; Flesinoxan (Lanfumey, L. (249) 25)

Second messenger
Tachykinin; Neurokinin; CHO (Chinese hamster ovary) cell; Antagonist; Structure-activity; Ca^{2+}; Inositol phosphate; Thapsigargin; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

Tachykinin receptor antagonist; Tachykinin receptor; Transfection; (Binding); (Subtype- and species-selectivity) (Aramori, I. (269) 277)

Secretin
CCK (cholecystokinin); Gastric emptying; Capsaicin; Vagal afferent; Spinal afferent (Raybould, H.E. (250) 165)

Seglitide
Somatostatin; Pertussis toxin; G-protein; BIM 23027; SRIF receptor; Vas deferens, mouse (Feniuk, W. (261) 333)

Seizure
Adenosine receptor agonist; Adenosine receptor antagonist; NMDA (*N*-methyl-D-aspartate); Protection; (Mouse) (Von Lubitz, D.K.J.E. (249) 265)

Antiepileptic; CGP 37849; CGP 39551 (Pietrasiewicz, T. (250) 1)

Adenosine analog; NMDA (*N*-methyl-D-aspartate); (Mouse) (Von Lubitz, D.K.J.E. (253) 95)

Glycolysis; Lactate (Fornai, F. (254) R1)

CGS21680; Adenosine A_1 receptor; Adenosine A_{2A} receptor; Prepiriform cortex; [^{3}H]DPCPX (8-Cyclopentyl-1,3-[^{3}H]dipropylxanthine) (Zhang, G. (255) 239)

Polyamine; NMDA receptor; *N*-(3-Aminopropyl)-cyclohexylamine (Chu, P.-j. (256) 155)

AMPA receptor antagonist; NMDA receptor antagonist; BAY k-8644 (Czuczwar, S.J. (264) 103)

Selective antagonist
Binding study; Muscarinic M_2 receptor; [^{3}H]Quinuclidinyl benzilate; Uterus; (Rat) (Pennefather, J.N. (262) 297)

Selective breeding
Analgesia; Morphine; Tail flick assay; Tolerance (Lutfy, K. (265) 171)

Selegiline
Neuronal rescue; Trophic factor (Koutsilieri, E. (269) R3)

Selenium
Striatum; 1-Methyl-4-phenylpyridinium; Vitamin E; Monoamine; (Rat) (Vizuete, M.L. (270) 183)

Self-stimulation
Excitatory amino acid; Kynurenic acid; Morphine; Conditioned place preference; (Rat) (Bespalov, A. (264) 233)

Senile dementia of the Alzheimer type
Nerve growth factor synthesis stimulator; Nerve growth factor; Choline acetyltransferase; Water maze; Astroglia cell (Nitta, A. (250) 23)

Sensitization
Behavior; MK-801; NMDA (*N*-methyl-D-aspartate); Phencyclidine; Temperature; Thermoregulation; Tolerance (Pechnick, R.N. (252) 35)

Asthma; Anhydride; Allergy; Cyclosporin A; Glucocorticoid (Arakawa, H. (252) 313)

Methamphetamine; Repeated administration; Ambulation; Haloperidol (Kuribara, H. (256) 295)

Primary neuronal culture; Ventral mesencephalon; κ-Opioid receptor; [^{3}H]Dopamine release; Corticosteroid (Ronken, E. (263) 149)

Sensory nerve
Diamide; Bronchoconstriction; Thromboxane; Hydrogen peroxide; (Guinea pig) (Bannenberg, G. (270) 175)

Sensory neurotransmission
Sumatriptan; Nicotine; 5-HT_1 receptor; Basilar artery, guinea pig (O'Shaughnessy, C.T. (259) 37)

Sepsis
Endotoxin; Nitric oxide (NO); Vasopressin; Vasopressin receptor antagonist; Intestinal mucosal injury; Intestinal vascular permeability; N^G-Nitro-L-arginine methyl ester (László, F. (260) 265)

Septic shock
Lipopolysaccharide; Nitric oxide (NO); Inducible nitric oxide synthase (Van den Berg, C. (270) 379)

Septide
Substance P; Tachykinin NK_1 receptor antagonist; Urinary bladder contraction; Plasma extravasation; (Rat) (Montier, F. (251) 9)

Antagonist; Substance P; Tachykinin NK_1 receptor; Proline, β-substituted (Lavielle, S. (258) 273)

Tachykinin receptor; Myenteric plexus (Burcher, E. (258) R9)

Serotonergic system
Nitric oxide (NO); Brain; Anorexia; Zucker rat (Squadrito, F. (255) 51)

Sertindole
Haloperidol; Clozapine; Short-term treatment; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (254) 291)

Serum amyloid P component
Cerebral culture; Cerebral cortex, rat; Cell death; Alzheimer's disease (Urbányi, Z. (270) 375)

Sex difference
Dopamine; *d*-Fenfluramine; Food intake; 5-HT (5-hydroxytryptamine, serotonin); *d*-Norfenfluramine (Oluyomi, A.O. (255) 175)

Sexual behavior
Galantide; Galanin; (Male rat) (Benelli, A. (260) 279)

Sexual behavior, male rat
Flat body posture; Forepaw treading; Lower lip retraction; Behavior syndrome; 5-HT_{1A} receptor agonist; 5-HT_2 receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) (Andersson, G. (255) 131)

Sf9 cell
Glutamate receptor; Oligosaccharide; Phosphorylation (Taverna, F.A. (266) 181)

5-HT (5-hydroxytryptamine, serotonin); G protein; G Protein-Coupled Receptor; (Baculovirus) (Parker, E.M. (268) 43)

Sgd 101/75
α_1-Adrenoceptor; Ca^{2+} entry blocker; Ear artery, rabbit (Wong, P.C. (262) 185)

Shock
N^G-Nitro-L-arginine; Endotoxin; PAF (platelet activating factor); Cardiovascular function; (Dog) (Takekoshi, K. (250) 465)

Nitric oxide (NO); Glyceraldehyde-3-phosphate dehydrogenase; Endotoxin; Cytotoxicity (Dimmeler, S. (267) 105)

Short-circuit current
VIP (vasoactive intestinal peptide) receptor antagonist; Mucosa; Colon (Burleigh, D.E. (249) 239)

Tracheal epithelial cell; Non-steroidal anti-inflammatory drug (Mochizuki, H. (252) 183)

Short-term treatment
Sertindole; Haloperidol; Clozapine; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (254) 291)

SH-SY5Y human neuroblastoma cell
μ-Opioid receptor subtype; Naloxonazine; β-Funaltrexamine (Elliott, J. (268) 447)

Side-effect (central)
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1*H*-cyclopenta(*b*)-quinoline monohydrate hydrochloride); Tacrine; Physostigmine; Scopolamine-induced amnesia; Side-effect (peripheral) (Yoshida, S. (250) 117)

Side-effect (peripheral)
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1*H*-cyclopenta(*b*)-quinoline monohydrate hydrochloride); Tacrine; Physostigmine; Scopolamine-induced amnesia; Side-effect (central) (Yoshida, S. (250) 117)

Signal transduction
α_2-Adrenoceptor subtype; [^{3}H]Rauwolscine; Ligand binding; cAMP (Jansson, C.C. (266) 165)

Single
Smooth muscle cell; Tracheal; Azelastine; Voltage-dependent Ca^{2+} current; K^+ current (Hazama, H. (259) 143)

Single breath
Nitric oxide (NO); Respiratory system; Alcohol; Toxicity; Blood pressure; (Lung); (Pharmacology) (Persson, M.G. (270) 273)

Single unit recording
Fluoxetine; Frontal cortex; 5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake inhibitor (Ceci, A. (250) 461)

SIN-1 (3-morpholino-sydnonimine)
Acetylcholine; 8-Bromo-cGMP; EDRF (endothelium-derived relaxing factor); Aortic ring, isolated, rat; Atrium, right, isolated, rat; LY-83,583 (6-(phenylamino)-5,8-quinolinedione); Norepinephrine; *N*-Nitro-L-arginine; (Spontaneous rate) (Kennedy, R.H. (255) 149)

Trolox; Antioxidant; Nitric oxide (NO); cGMP; Prostaglandin; Leukotriene; Leukocyte (Riutta, A. (262) 217)

Skeletal muscle
Bay K 8644; Dihydropyridine; K^+ contracture; Nifedipine; Twitch response (Kitamura, N. (256) 169)

Neuromuscular blocking drug; Ammonium compound; Acetylcholine receptor (Danilov, A.F. (257) 1)

Glibenclamide; K^+ channel; Lipid bilayer (Light, P.E. (259) 219)

Skeletal muscle fatigue
Cromakalim; K^+ channel opener; Ischemia (Trezise, D.J. (250) 109)

SKF-525A
K^+ channel; Glibenclamide; Cromakalim; Y-26763; Quinacrine; *Xenopus* oocyte; Local anesthetic (Sakuta, H. (252) 117)

SKF-10,047
DTG (di-*o*-tollylguanidine); σ Receptor; Red nucleus; *N*-Allylnormetazocine; Movement disorder; Dystonia (Weissman, A.D. (250) 329)

σ Receptor ligand; DTG (1,3-di-(2-tolyl)guanidine); Benzomorphan-type σ receptor; Acetylcholinergic neuronal system; *p*-Chloroamphetamine; Amnesia; Passive avoidance task; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperizine); (Mouse) (Matsuno, K. (261) 43)

Anti-ulcer agent; DTG (1,3-di(2-tolyl)guanidine); KB-5492; Mucosa; σ Receptor; (Pig) (Harada, Y. (261) 91)

ACTH (adrenocorticotropic hormone); Corticosterone; Dioxadrol; Endocrine; NMDA (*N*-methyl-D-aspartate); Pentazocine; Phencyclidine; σ Receptor (Pechnick, R.N. (263) 115)

SKF-38393
Caffeine; Quinpirole; *R*(−)-Propylnorapomorphine (NPA); SKF-77434; Tolerance; Motor activity (Garrett, B.E. (262) 65)

Dopamine D_1 receptor; Astrocyte; Adenylate cyclase; SKF 81297; A 68930; (Rat); (Rhesus monkey); (Human) (Vermeulen, R.J. (269) 121)

***R*-SKF-38393**
Catalepsy-associated behavior; BW 737C89; SKF 75670; SCH 39166; Haloperidol; SKF 81297; SKF 82958 (Rosenzweig-Lipson, S. (260) 237)

SKF-75670
Catalepsy-associated behavior; BW 737C89; R-SKF 38393; SCH 39166; Haloperidol; SKF 81297; SKF 82958 (Rosenzweig-Lipson, S. (260) 237)

SKF-77434
Caffeine; Quinpirole; *R*(−)-Propylnorapomorphine (NPA); SKF-38393; Tolerance; Motor activity (Garrett, B.E. (262) 65)

SKF-81297
Catalepsy-associated behavior; BW 737C89; R-SKF 38393; SKF 75670; SCH 39166; Haloperidol; SKF 82958 (Rosenzweig-Lipson, S. (260) 237)

Dopamine D_1 receptor; Astrocyte; Adenylate cyclase; SKF 38393; A 68930; (Rat); (Rhesus monkey); (Human) (Vermeulen, R.J. (269) 121)

SKF-82958
Catalepsy-associated behavior; BW 737C89; R-SKF 38393; SKF 75670; SCH 39166; Haloperidol; SKF 81297 (Rosenzweig-Lipson, S. (260) 237)

SKF-96365
Neostigmine; Endplate potential; Nicotinic acetylcholine receptor; Receptor desensitisation (Hong, S.J. (265) 35)

Skin blood flow, rat
BQ-123; Ro 47-0203; Bosentan; Endothelin ET_A receptor; Endothelin ET_B receptor; Endothelin; Microcirculation (Lawrence, E. (260) 103)

Skinned cardiac muscle
Crossbridge kinetics; EMD 53998; Phosphate effect; Ca^{2+} sensitizer (Strauss, J.D. (252) 219)

Skinned muscle
cGMP; Colon; NAMC (non-adrenergic, non-cholinergic) inhibition; (Rat) (Maehara, T. (261) 163)

Skinned striated muscle
Ca^{2+} channel antagonist; Tension (maximum); Ca^{2+} sensitivity; Inotropic state (Schiereck, P. (249) 317)

Skinned urinary bladder
Urinary bladder, rat; Ca^{2+} channel antagonist; Benzodiazepine receptor ligand (Martí-Cabrera, M. (255) 157)

SK-N-MC cell
αCGRP (calcitonin-gene related peptide), human; αCGRP-(8–37), human; βCGRP-(8–37), human; Vas deferens, rat; Atrium, guinea-pig (Longmore, J. (265) 53)

SL 84.0418
α_2-Adrenoceptor; K^+ channel, ATP-sensitive; Insulin release; Tolbutamide; Imidazoline; (Mouse islet) (Jonas, J.-C. (254) 27)

Deriglidole; α_2-Adrenoceptor; Insulin release; Imidazoline; K^+ channel, ATP-sensitive; (Mouse islet) (Jonas, J.-C. (264) 81)

Sleep
5-HT_3 receptor; *m*-Chlorophenylbiguanide; MDL 72222; Wakefulness (Ponzoni, A. (249) 259)

DOPAC (dihydroxyphenylacetic acid); Dopamine; Ethanol; GABA (γ-hydroxybutyric acid); Naloxone (Devoto, P. (252) 321)

Small cell lung carcinoma
CCK_B receptor; Pharmacology; Cloning; Enterochromaffin-like cell-oma (Denyer, J. (268) 29)

Small cell lung carcinoma cell
5-HT, (Serotonin); 5-HT receptor; Proliferation (Cattaneo, M.G. (268) 425)

Small intestinal transit
Sodium choleate; Nitric oxide (NO) synthase; Diarrhea; Intestinal secretion (Mascolo, N. (264) 21)

Small intestine
Muscarinic receptor antagonist; Nitric oxide (NO); Opioid; Substance P; VIP (vasoactive intestinal peptide) (Gustafsson, B.I. (257) 227)

Small intestine, rat
Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) neurotransmission; Nitric oxide (NO)-induced contraction (Barthó, L. (259) 101)

Smooth muscle
Pulmonary artery; Vascular relaxant; Phorbol ester; Protein kinase C; Phosphodiesterase inhibitor; Cyclic nucleotides (Savineau, J.-P. (249) 191)

Tachykinin NK_1 receptor; Substance P; Neuron; Electrophysiology (Seabrook, G.R. (250) 125)

Atriopeptin II; Isoproterenol; cGMP; cAMP; Aorta, rat (Jang, E.K. (250) 477)

Gastric muscularis mucosae; Adenosine receptor; Adenosine analogue; DPCPX (1,3-dipropyl-8-cyclopentylxanthine) (Muller, M.J. (251) 151)

Trachea; Epithelium; ATP; Amiloride; DIDS (4,4′-diisothiocyanostilbene-2,2′-disulfonic acid) (Fedan, J.S. (256) 51)

Flosequinan; Vascular; Resistance artery; (Human) (Richards, N.T. (257) 189)

Capsaicin; Afferent neuron; Tachykinin; Intestine (Barthó, L. (259) 187)

K^+ channel; NANC (non-adrenergic, non-cholinergic) relaxation; Penile erection; Nicotinic receptor (Alaranta, S. (259) 203)

ω-Agatoxin-IVA; ω-Conotoxin-GVIA; Ca^{2+} channel (voltage sensitive); Autonomic nerve; Neurotransmission (Lundy, P.M. (261) 79)

Excitatory nerve; Colon, human; Opioid receptor agonist; Opioid receptor antagonist (Chamouard, P. (262) 33)

EDRF (endothelium-derived relaxing factor); Endothelin; Endothelin ET_B receptor; Endothelin ET_B receptor antagonist; RES-701-1 (Karaki, H. (262) 255)

Ca^{2+} inhibition; Contraction; Myometrium; Threshold phenomenon; Actin filament (Miyauchi, Y. (263) 75)

Smooth muscle, airway
Airway, guinea-pig; VIP (vasoactive intestinal polypeptide) (Iriarte, M.-C.F. (250) 295)

Formoterol; Salbutamol; Salmeterol; Mast cell; (Duration) (Nials, A.T. (251) 127)

Bradykinin receptor antagonist; Bradykinin biosynthesis; Trachea; Captopril; Thiorphan (Farmer, S.G. (259) 309)

Muscarinic receptor; Bronchodilator agent; Allergy and immunology; (Guinea pig) (Howell, R.E. (265) 67)

Smooth muscle, aortic
Liposome; D-*myo*-Inositol 1,4,5-trisphosphate; D-*myo*-Inositol 1,3,4,5-tetrakisphosphate (Brailoiu, E. (250) 493)

Smooth muscle, bovine, tracheal
Protein kinase C; Smooth muscle, contraction; Ca^{2+}, intracellular; Bronchodilator (Langlands, J.M. (266) 229)

Smooth muscle cell
BK channel; Maxi-K channel; Patch-clamp electrophysiology; Benzimidazolone; K^+ channel opener (Olesen, S.-P. (251) 53)

SR 47436; DuP 753; Proliferation; Angiotensin II (Herbert, J.-M. (251) 143)

Single; Tracheal; Azelastine; Voltage-dependent Ca^{2+} current; K^+ current (Hazama, H. (259) 143)

Bradykinin B_1 receptor; Aorta (rabbit); Des-Arg^{10}-kallidin (Schneck, K.A. (266) 277)

DDT_1MF-2 cell; Histamine H_1 receptor; [^{3}H]mepyramine (Dickenson, J.M. (268) 257)

Smooth muscle cell, vascular
Baicalein; Flavonoid; Antiproliferative effect (Huang, H.-C. (251) 91)

Smooth muscle, contraction
Cytochalasin B; Ca^{2+} current; Myosin phosphorylation; Taenia coli; (Guinea pig) (Obara, K. (255) 139)

Protein kinase C; Smooth muscle, bovine, tracheal; Ca^{2+}, intracellular; Bronchodilator (Langlands, J.M. (266) 229)

Smooth muscle, human, airway
Lung strip, guinea pig; Cholinergic contraction; Muscarinic M_2 receptor; Trachea, guinea pig (Roffel, A.F. (250) 267)

Smooth muscle, ileal
Muscarinic receptor subtype; Pirenzepine analog; McN-A-343 (Barocelli, E. (254) 151)

Smooth muscle, intestinal
Muscarinic receptor; Ascending reflex; AF-DX 116; Ileum, guinea-pig (Doods, H.N. (253) 275)

Smooth muscle, isolated
CP-96,345; Ca^{2+} channel antagonist; Verapamil; Nifedipine; (Anesthetized dog) (Constantine, J.W. (252) 275)

Smooth muscle, longitudinal and circular
Cyclo-oxygenase; Prostaglandin; Inhibitor; Stomach, rat (Shimomura, A. (252) 81)

Smooth muscle, relaxation
7-Nitroindazole; 6-Nitroindazole (Medhurst, A.D. (256) R5)

EGF (epidermal growth factor, urogastrone); Prostaglandin; Protein synthesis inhibitor (Petitclerc, E. (259) 91)

Smooth muscle, uterus
Muscarinic receptor; Muscarinic M_2 receptor; m4 binding site (Doods, H.N. (250) 223)

Smooth muscle, vascular
Endothelin; Sarafotoxin; BQ-123 (cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu)); Endothelin receptor subtype; Aorta (guinea-pig); Coronary artery (pig) (Schoeffter, P. (249) 199)

Thiol; Nitrovasodilator; Nitrate tolerance; Endothelium (Kojda, G. (250) 385)

HA1077; H-7; Ca^{2+} level, cytosolic; Relaxation; Aorta, rat (Takizawa, S. (250) 431)

Liposome; Adenosine (Brailoiu, E. (250) 489)

Ca^{2+} channel antagonist; Ca^{2+} channel (Hirakawa, Y. (252) 267)

Thrombin; Ca^{2+}; TRAP (thrombin receptor-activating peptide); Bay K 8644 (Antonaccio, M.J. (256) 37)

Pentoxifylline; Mesenteric resistance vessel; Aminophylline; Endothelium; Nitric oxide (NO); Methylxanthine derivative (Hansen, P.R. (261) 105)

Interleukin-1β; Lipopolysaccharide; Nitric oxide (NO); DL-Propranolol; Cell culture; Spontaneously hypertensive rat (SHR); Wistar Kyoto rat (WKY); (Rat) (De Castro, M. (261) 199)

EDRF (endothelium-derived relaxing factor); K^+ channel opener; K^+ channel blocker; Hypoxia; Lung (Dumas, J.-P. (263) 17)

Ca^{2+} channel; Aorta; Binding; [^{3}H](+)-PN200-110; Spontaneously hypertensive rat (SHR) (Ikeda, S. (264) 223)

P_2 Purinoceptor; P_{2U} Purinoceptor; Ca^{2+} release; Ca^{2+} influx (Kitajima, S. (266) 263)

Angiotensin II; mRNA; Ca^{2+} concentration, intracellular; cAMP; (Down-regulation) (Chen, X. (267) 175)

Cell proliferation; Dihydropyridine-sensitive Ca^{2+} channel; Voltage-dependent Ca^{2+} channel; Scatchard analysis; Modulated receptor model; Atherosclerosis (Ruiz-Velasco, V. (268) 311)

Noradrenaline; Caffeine; Heparin; Ruthenium red (Garcha, R.S. (268) 319)

Coronary artery; Hypoxia; ATP-sensitive K^+ channel; Glibenclamide; Levcromakalim (Mellemkjær, S. (270) 307)

SND 919
Idazoxan; B-HT 920; Lisuride; Dopamine D_2 receptor; α_2-Adrenoceptor; Behavior (Ferrari, F. (250) 51)

Social interaction
Median raphe nucleus; Dorsal hippocampus; 5-HT_{1A} receptor; Grooming; (Rat) (Andrews, N. (264) 259)

Sodium choleate
Nitric oxide (NO) synthase; Diarrhea; Intestinal secretion; Small intestinal transit (Mascolo, N. (264) 21)

Sodium dodecyl sulfate (SDS)
Immunotoxicology; Detergent; Respiratory burst; Neutrophil, human; HL-60 cell line (Kacani, L. (270) 285)

Sodium propionate
Pertussis toxin; Cholera toxin; Okadaic acid; Na^+-H^+ antiport; Mast cell (Alfonso, A. (267) 289)

Soleus
Li^+; ATPase; Chronic; Plantaris; Extensor digitorum longus (Adipudi, V. (259) 7)

Soman
HI-6 ([[[(4-aminocarbonyl)pyridino]-methoxy]methyl]-2-[(hydroxyimino)methyl]-pyridinium dichloride); Acetylcholinesterase reactivation; Diaphragm, rat; Muscle tension (Adler, M. (270) 9)

Somatostatin
GH (growth hormone); GHRH (growth hormone-releasing hormone); Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); (Sheep) (Cataldi, M. (253) 149)

Acetylcholine; Adenosine; Angiotensin II; Atrium; Contractility; α-CGRP (calcitonin gene-related peptide); Ventricle; (Human) (Du, X.Y. (259) 173)

Pertussis toxin; G-protein; Seglitide; BIM 23027; SRIF receptor; Vas deferens, mouse (Feniuk, W. (261) 333)

Aging; Carbachol; 2-Deoxyglucose; Brain slice; Cerebral cortex (Shibata, S. (269) 269)

Somatostatin-28
CGRP (calcitonin gene-related peptide), C-terminal fragment; Vasopressin; CCK_A receptor; Iris (monkey) (Almegård, B. (250) 31)

Somatostatin secretion
DAGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin); β-Funaltrexamine; μ-Opioid receptor (McIntosh, C. (259) 331)

Spantide II
Tachykinin receptor antagonist; Structure-activity relationship (Wang, Z.-Y. (260) 121)

Spatial memory
Acetylcholine; Hippocampus; Medial septal area; Nicotinic acetylcholine receptor (Decker, M.W. (261) 217)

Species difference
Histamine H_3 receptor; *R*-α-Methylhistamine; Presynaptic inhibition; Thioperamide (McLeod, R.L. (259) 211)

Species variation
Tachykinin; Tachykinin NK_3 receptor; CHO (Chinese hamster ovary) cell; [^{125}I][MePhe^7]neurokinin B binding (Suman-Chauhan, N. (269) 65)

SPECT imaging
Muscarinic receptor; Muscarinic receptor antagonist; Radioligand (Baumgold, J. (251) 315)

SPECT (single photon emission computed tomography)
Receptor kinetics; Benzodiazepine; Flumazenil; Midazolam; Radioactive tracer (Videbæk, C. (249) 43)

Dopamine; Dopamine D_2 receptor; Benzamide; [^{123}I]Iodobenzofuran (Laruelle, M. (263) 39)

Spermidine
Polyamine; Spermine; Arcaine; 1,10-diaminodecane; Diethylenetriamine; Putrescine; *N*-Methyl-D-aspartate (NMDA); NMDA receptor; Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

[^{3}H]Spermidine binding
Polyamine; Autoradiography; Cerebellar cortex; Brain development, human (McConnell, S.E. (262) 293)

Spermine
Polyamine; Spermidine; Arcaine; 1,10-diaminodecane; Diethylenetriamine; Putrescine; *N*-Methyl-D-aspartate (NMDA); NMDA receptor; Ca^{2+} Fura2 (Pritchard, G.A. (266) 107)

NMDA (*N*-methyl-D-aspartate); Dizocilpine; Glutamate; Glycine; Polyamine (Marvizón, J.-C. (269) 165)

Sphincter electromyogram
MK-801; Bladder voiding; Urine storage; Decerebration; Cystometrogram; (Rat) (Yoshiyama, M. (264) 417)

Sphincter of Oddi
Nitric oxide (NO); Field stimulation; Neural relaxation (Lonovics, J. (255) 117)

Spinal afferent
CCK (cholecystokinin); Secretin; Gastric emptying; Capsaicin; Vagal afferent (Raybould, H.E. (250) 165)

Spinal antinociception
5-MeO-DMT (5-methoxy-*N*,*N*-dimethyltryptamine); 5-HT receptor; 5-HT receptor agonist; α-Adrenoceptor antagonist; Substance P; GABA (γ-aminobutyric acid) (Alhaider, A.A. (249) 151)

Spinal cord
$GABA_B$ receptor; Plasticity; Autoradiography; CGP 36742 (3-aminopropyl-*n*-butyl-phosphinic acid); (−)-Baclofen (Malcangio, M. (250) 153)

5-HT (5-hydroxytryptamine, serotonin); Descending inhibition; (Neonatal rat) (Wallis, D.I. (250) 371)

Cholinergic neuron; Medulla oblongata; Blood pressure; Heart rate (Feldman, D.S. (250) 483)

Neurokinin A; Tachykinin NK_2 receptor; Tachykinin; Nociception; Flexor reflex (Wiesenfeld-Hallin, Z. (251) 99)

α_2-Adrenoceptor; Dexmedetomidine; Mydriasis; Nociception (Horváth, G. (253) 61)

S-Flurbiprofen; *R*-Flurbiprofen; Formalin test; Antinociception, intrathecal; Cyclooxygenase, inhibition (Malmberg, A.B. (256) 205)

Tachykinin NK_2 receptor; Tackykinin NK_1 receptor; Motoneurone (Lepre, M. (258) 23)

Micturition; Tachykinin receptor antagonist; Tachykinin receptor (Lecci, A. (259) 129)

Preprogalanin; Galanin; Galanin receptor; Nociception; Neuropeptide (Bedecs, K. (259) 151)

Endothelin; Radioimmunoassay; Sympathetic nervous system (Knuepfer, M.M. (259) 305)

Morphine; Δ^9-Tetrahydrocannabinol; Tolerance; Analgesia; Hypothermia; Cross-tolerance; [^{3}H]DAMGO ([^{3}H][D-Ala^2,MePhe^4, Gly-ol^5]enkephalin), B_{max}, K_d; Brain (Thorat, S.N. (260) 5)

S-Flurbiprofen; *R*-Flurbiprofen; Formalin test; Antinociception, intrathecal; Cyclooxygenase, inhibition (Malmberg, A.B. (260) 283)

Tachykinin receptor antagonist; Intrathecal injection; (Mouse) (Sakurada, T. (261) 85)

[^{3}H]Resiniferatoxin; Autoradiography; Vanilloid receptor; Capsaicin-sensitive neuron; Dorsal root ganglia (Szallasi, A. (264) 217)

5-HT (5-hydroxytryptamine, serotonin); Supersensitivity; 5,7-DHT (5,7-dihydroxytryptamine); Antinociception; (Rat) (Sawynok, J. (264) 249)

Anesthetic; Anesthesia, theories of; Synaptic transmission; Glutamate receptor; NMDA receptor; $GABA_A$ receptor (Kendig, J.J. (264) 427)

Spinal cord, cat
Nitropropane analog, GABA; Nitropropane analog, baclofen; Ileum, isolated, guinea-pig; Neocortex, rat; $GABA_B$ receptor antagonist (Ong, J. (264) 49)

Spinal cord, isolated
Metabotropic glutamate receptor; cAMP; Phosphoinositide hydrolysis; ACPD((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylate); L-CCG-I((2*S*,1′*S*,2′*S*)-CCG); Cortical cell culture (Ishida, M. (268) 267)

Spinal reflex
GYKI 52466; Non-NMDA receptor; Benzodiazepine receptor (Block, F. (256) 149)

Spinocerebellar degeneration
TRH (thyrotropin releasing hormone); TRH analog; Ataxic mutant mouse; Ataxia (Matsui, K. (254) 295)

Spiperone
Sauvagine; Hypothermia; Haloperidol (Broccardo, M. (258) 179)

Spleen
Receptor autoradiography; α_2-Adrenoceptor; Lymph node; [^{3}H]Bromoxidine; Immune system (Fernández-López, A. (252) 333)

Receptor autoradiography; β-Adrenoceptor; Lymph node; [^{125}I]Cyanopindolol; Immune system; Lymphoid organ (Fernández-López, A. (262) 283)

Spleen, guinea-pig
α_1-Adrenoceptor, subtypes A, B and C (Eltze, M. (260) 211)

Spleen, rat
α_1-Adrenoceptor subtype; Chloroethylclonidine; Nifedipine; Vas deferens, rat; Prostate, human (Teng, C.-M. (265) 61)

Spontaneous alternation
Glucose; Mecamylamine; Scopolamine; Memory (Ragozzino, M.E. (256) 31)

Spontaneously epileptic rat (SER)
Topiramate; Antiepileptic effect; Audiogenic seizure (Nakamura, J. (254) 83)

Spontaneously hypertensive rat (SHR)
Phosphodiesterase inhibitor; Zaprinast; cGMP; Blood pressure (Dundore, R.L. (249) 293)

Ryanodine; Ca^{2+} influx; Verapamil; Femoral artery (Kojima, M. (254) 159)

Blood pressure; Hypertension; Hippocampus; Dynorphin; Nor-binaltorphimine (Wang, J.Q. (256) 57)

des-Asp-Angiotensin I; Angiotensin III (Sim, M.K. (257) R1)

Angiotensin II; Angiotensin III; Losartan (DuP 753); Telemetry (Radhakrishnan, R. (259) 87)

PAF (platelet-activating factor); Acetylcholine; Mesenteric arterial bed; Desensitization (Kamata, K. (259) 321)

Interleukin-1β; Lipopolysaccharide; Nitric oxide (NO); DL-Propranolol; Smooth muscle, vascular; Cell culture; Wistar Kyoto rat (WKY); (Rat) (De Castro, M. (261) 199)

Cromakalim; Arterial smooth muscle relaxation; K^+ channel, ATP-sensitive; K^+ channel, Ca^{2+}-activated (Asano, M. (263) 121)

Smooth muscle, vascular; Ca^{2+} channel; Aorta; Binding; [^{3}H](+)-PN200-110 (Ikeda, S. (264) 223)

Ropinirole; Dopamine; D_2-like receptor; Cardiovascular; Tolerance; (Monkey) (Parker, S.G. (265) 17)

Tail artery; Ca^{2+}, cytosolic; [^{3}H]Inositol phosphate (Thorin-Trescases, N. (268) 199)

Extracellular matrix; Transforming growth factor β_1; mRNA; Cardiovascular system; Renin-angiotensin system (Ohta, K. (269) 115)

SR 33557
Heart; L-type Ca^{2+} channel; Voltage clamp; Ca^{2+} channel antagonist; SR33805 (Romey, G. (263) 101)

SR 33805
Heart; L-type Ca^{2+} channel; Voltage clamp; Ca^{2+} channel antagonist; SR33557 (Romey, G. (263) 101)

Ca^{2+} channel antagonist; Binding; Heart; Fantofarone; Dihydropyridine (Chatelain, P. (267) 151)

SR 47436
DuP 753; Smooth muscle cell; Proliferation; Angiotensin II (Herbert, J.-M. (251) 143)

SR 47436 (BMS-186295)
Angiotensin AT_1 receptor antagonist; Genetic hypertension; Renal hypertension; (Rat) (Lacour, C. (264) 307)

SR 48968
Tachykinin NK_2 receptor; Antitussive effect; Cough reflex; Citric acid; (Guinea-pig) (Advenier, C. (250) 169)

Substance P; CP-96345; WIN 51708; WIN 62577; Colon, proximal, guinea-pig (Briejer, M.R. (250) 181)

SR 57746A (4-(3-trifluoromethylphenyl)-*N*-[2-(naphth-2-yl)ethyl]-1,2,3,6-tetrahydropyridine HCl)
5-HT_{1A} receptor; Adenylate cyclase activity; Forced swimming test; Antidepressant activity (Cervo, L. (253) 139)

SR 95531
GABA (γ-aminobutyric acid); Inhalational anesthetics; Muscimol; Stereospecificity (Harris, B.D. (267) 269)

SR 140333
Tachykinin NK_1 receptor; Substance P; (Non-peptide receptor antagonist) (Emonds-Alt, X. (250) 403)

SRIF receptor
Somatostatin; Pertussis toxin; G-protein; Seglitide; BIM 23027; Vas deferens, mouse (Feniuk, W. (261) 333)

ST-91
Autotomy; Clonidine; Flexor reflex; Guanfacine; Pain (Puke, M.J.C. (260) 227)

Staurosporine
Adrenal chromaffin cell; Catecholamine release; Ca^{2+} (Maurer, J.A. (253) 115)

Cardiac anaphylaxis; Langendorff heart; Phorbol ester; (Guinea-pig) (Schäfer, S. (258) 247)

Quercetin; Phasic contraction; Aorta, rat (Duarte, J. (262) 149)

ANP (Atrial natriuretic peptide); Growth factor; aFGF (acidic fibroblast growth factor); Protein kinase C; Phorbol ester (Tokola, H. (267) 195)

gp140^{trk}; Tyrosine; Phosphorylation; Neurite outgrowth (Rasouly, D. (269) 255)

Membrane outgrowth; Myocyte, *Xenopus*; Morphological change; Developmental change (Fu, W.-M. (270) 321)

ST elevation
U-46619; Endothelin-1; Anti-endothelin-1 serum; Radioimmunoassay; (Rat) (Yamamoto, T. (250) 189)

Stereoisomer
Adrenoceptor; Aporphine; Antipsychotic; Dopamine receptor; Partial agonist, receptor; 5-HT (5-hydroxytryptamine, serotonin) (Baldessarini, R.J. (254) 199)

Anesthetic; Receptor; Isoflurane; (Rat) (Lysko, G.S. (263) 25)

Stereoselectivity
K^+ channel; Glibenclamide; Ca^{2+} channel antagonist; *Xenopus* oocyte; Y-26763 (Sakuta, H. (255) 1)

Stereospecificity
GABA (γ-aminobutyric acid); Inhalational anesthetics; Muscimol; SR 95531 (Harris, B.D. (267) 269)

Steroid
Carboline; Cytochrome *P*450 (Kühn-Velten, W.N. (250) R1)

Steroid derivative
Propofol; [^{35}S]TBPS (*t*-[^{35}S]butylbicyclophosphorothionate) binding; GABA (γ-aminobutyric acid); Cl^- channel; Barbiturate; Benzodiazepine; General anesthetics (Concas, A. (267) 207)

Steroid effect
Histamine H_3 receptor; AtT-20 cell; [^{3}H]N^α-Methylhistamine binding; ACTH (Adrenocorticotropic hormone) release (West, Jr., R.E. (267) 343)

Stimulus property
Ibogaine; 5-HT (5-hydroxytryptamine, serotonin) (Schechter, M.D. (249) 79)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; 5-HT receptor subtype; Drug pre-exposure; Conditioned taste aversion; (Mouse) (Berendsen, H.H.G. (253) 83)

Stomach
Nitric oxide (NO); Gastric mucosa; Mucus (Price, K.J. (263) 199)

Stomach, rat
Cyclo-oxygenase; Prostaglandin; Inhibitor; Smooth muscle, longitudinal and circular (Shimomura, A. (252) 81)

Interleukin-1β; TNF (tumor necrosis factor); Leukotriene B_4; Phospholipase A_2; Phospholipase C; 5-Lipoxygenase; Protein kinase C; Phorbol 12-myristate 13-acetate; Gastric motility (Montuschi, P. (252) 253)

Stomach strip, guinea pig
5-HT_1 receptor; 5-HT_3 receptor; 5-HT_4 receptor; Electrical stimulation (Buchheit, K.-H. (262) 91)

Strain difference
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; 5-HT (5-hydroxytryptamine, serotonin); Tryptophan; Plasma-free tryptophan; Anorexia; (Brain) (Unkila, M. (270) 157)

Straub tail
Morphine; μ_2-Opioid receptor (Nath, C. (263) 203)

Streptozotocin
Atrium, rat; Diabetes; Endothelin-1; Noradrenaline; Sympathetic nerve stimulation (Lieu, A.T. (261) 33)

Streptozotocin-induced diabetes
Aldose reductase inhibitor; Laser Doppler flowmetry; Motor nerve conduction velocity; Nerve blood flow; Polyol pathway (Calcutt, N.A. (251) 27)

Stress
Hypothalamo-pituitary-adrenal axis; Antidepressant; Tianeptine; 5-HT (5-hydroxytryptamine, serotonin); CRF (corticotropin-releasing factor); ACTH (adrenocorticotropin); Corticosterone (Delbende, C. (251) 245)

Conditioned suppression; σ Receptor; Dopaminergic system (Kamei, H. (260) 39)

Neurosteroid; Handling; CO_2; Brain, rat (Barbaccia, M.L. (261) 317)

Histamine; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); α-Fluoromethylhistidine; Accumbens; Suprachiasmatic (Fleckenstein, A.E. (264) 163)

Striatal dopamine autoreceptor
Dopamine D_3 receptor; Dopamine D_2 receptor (Meller, E. (249) R5)

Striatal slice
Endothelin-3; Dopamine; Glutamate; NMDA receptor; Voltage-gated Ca^{2+} channel (Koizumi, S. (259) 195)

Striatum
Neuropeptide Y; Dopamine; Nucleus accumbens (Midgley, L.P. (251) 191)

Dopamine release; Morphine; Adenylate cyclase; Opioid receptor (Tjon, G.H.K. (252) 205)

Dopamine D_1 receptor; Dopamine D_2 receptor; Receptor recovery; Development; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Crawford, C.A. (252) 225)

Receptor antagonist; Neurotensin; Dopamine release; Mesencephalic cell (Brouard, A. (253) 289)

Amperozide; Dopamine D_2 receptor; Limbic forebrain (Svartengren, J. (254) 73)

Dopaminergic neuron; Non-NMDA receptor; Hypothalamus (Wagner, E.J. (254) 105)

NMDA (*N*-methyl-D-aspartate); SCH 23390; Raclopride; Microdialysis; (Neurotransmitter release) (Morari, M. (256) 23)

Adenosine A_1/A_2 receptor; Dopamine; Rotational behavior; (Rat) (Popoli, P. (257) 21)

Riluzole; GABA uptake, synaptosomes; (Rat) (Mantz, J. (257) R7)

Microdialysis; Dopamine release; Memantine; Pharmacokinetics; Prefrontal cortex (Spanagel, R. (262) 21)

Jaw movement; Clozapine; Apomorphine; Nucleus accumbens; Muscarinic acetylcholine receptor (Kikuchi de Beltrán, K. (262) 49)

Haloperidol; Clozapine; Microdialysis; Glutamate; GABA (γ-aminobutyric acid) (See, R.E. (263) 269)

Dopamine carrier (neuronal); Metal ion; [^{3}H]GBR 12783 (in vitro binding); Dopamine uptake; (Rat) (Bonnet, J.-J. (266) 87)

Dopamine carrier (neuronal); Na^+-dependence; N-ethylmaleimide treatment; [^{3}H]GBR 12783; [^{3}H]Cocaine; Binding in vitro; (Rat) (Saadouni, S. (268) 187)

1-Methyl-4-phenylpyridinium; Selenium; Vitamin E; Monoamine; (Rat) (Vizuete, M.L. (270) 183)

Striatum, dorsal
Jaw movement; Dopamine D_1/D_2 receptor interaction; Dopaminergic/cholinergic interaction; (Rat) (Kikuchi de Beltrán, K. (252) 99)

Striatum, rat
N-Ethylmaleimide; Dopamine release; Forskolin; Methamphetamine (Yamada, S. (257) 243)

Dopamine carrier, neuronal; Dopamine uptake blocker; *N*-Ethylmaleimide; [^{3}H]GBR 12783; Binding, in vitro; (Slow interaction) (Héron, C. (264) 391)

Dopamine D_1 receptor; [^{3}H]SCH 23390; Dissociation kinetics; Allosteric mechanism (Farrell, C.B. (268) 79)

Dopamine neuronal carrier; Thermodynamics; [^{3}H]GBR 12783 (1-[2-{diphenylmethoxy}ethyl]4-{3-phenyl-2-propenyl}-piperazine); BTCP (*N*-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine) derivative; Binding (in vitro) (Billaud, G. (268) 357)

Stroke
Cocaine; Cerebral microcirculation; Laser-Doppler; (Rat) (Muir, J.K. (249) 287)

Magnetic resonance imaging; NMR tomography; Brain edema; 5-HT receptor antagonist; Ca^{2+} channel blocker (Elger, B. (254) 65)

Stroke-prone spontaneously hypertensive rat (SHRSP)
Felodipine; Cardiac hypertrophy; Na^+; K^+; Mg^{2+} (Mervaala, E.M.A. (255) 73)

Structural requirement
Mastoparan B; Cardiovascular effect; Hornet (*Vespa basalis*) venom (Ho, C.-L. (259) 259)

Structure-activity relationship
Imidazoline; Imidazolidine; Glibenclamide; K^+ channel; *Xenopus* oocyte; Y-26763; K^+ channel opener (Sakuta, H. (259) 223)

Spantide II; Tachykinin receptor antagonist (Wang, Z.-Y. (260) 121)

Xanthine derivative; Tracheal relaxation; Phosphodiesterase (Miyamoto, K.-i. (267) 317)

Tachykinin; Neurokinin; CHO (Chinese hamster ovary) cell; Antagonist; Ca^{2+}; Second messenger; Inositol phosphate; Thapsigargin; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

Structure-activity study
Opioid; Dermenkephalin (binding); δ Address (Charpentier, S. (266) 175)

ST segment elevation
E4021; Phosphodiesterase type V inhibitor; cGMP; Coronary vasodilator; Vasopressin (Kodama, K. (263) 93)

Subarachnoid hemorrhage
Bradykinin; Substance P; Vasopressin; EDRF (endothelium-derived relaxing factor); Cerebral vasospasm (Tsuji, T. (264) 77)

Substance P
5-MeO-DMT (5-methoxy-*N*,*N*-dimethyltryptamine); 5-HT receptor; 5-HT receptor agonist; α-Adrenoceptor antagonist; Spinal antinociception; GABA (γ-aminobutyric acid) (Alhaider, A.A. (249) 151)

Fibroblast; Migration (Kähler, C.M. (249) 281)

Tachykinin NK_1 receptor; Smooth muscle; Neuron; Electrophysiology (Seabrook, G.R. (250) 125)

CP-96345; Dynorphin; Methamphetamine; Tachykinin NK_1 receptor; Neurotensin (Gygi, S.P. (250) 177)

CP-96345; SR 48968; WIN 51708; WIN 62577; Colon, proximal, guinea-pig (Briejer, M.R. (250) 181)

SR140333; Tachykinin NK_1 receptor; (Non-peptide receptor antagonist) (Emonds-Alt, X. (250) 403)

Septide; Tachykinin NK_1 receptor antagonist; Urinary bladder contraction; Plasma extravasation; (Rat) (Montier, F. (251) 9)

Asthma; Corticosteroid; Pulmonary gas trapping; Pulmonary inflammation; (Hyperresponsiveness) (Stengel, P.W. (253) 253)

PAF (platelet-activating factor); VIP (vasoactive intestinal peptide) (Deshpande, Y. (256) R1)

Muscarinic receptor antagonist; Nitric oxide (NO); Opioid; Small intestine; VIP (vasoactive intestinal peptide) (Gustafsson, B.I. (257) 227)

Antagonist; Septide; Tachykinin NK_1 receptor; Proline, β-substituted (Lavielle, S. (258) 273)

CCK (cholecystokinin); Clonazepam; Monoamine uptake inhibitor; Panic disorder; Central nervous system, rat (Brodin, K. (263) 175)

Bradykinin; Vasopressin; EDRF (endothelium-derived relaxing factor); Cerebral vasospasm; Subarachnoid hemorrhage (Tsuji, T. (264) 77)

Respiratory viral infection; Airway sensory C fibers; Neurogenic inflammation; Airway hyperresponsiveness (Kudlacz, E.M. (270) 291)

Substance P, *N*-terminus
Flexor reflex; Antinociception; Pain (Goettl, V.M. (259) 83)

Substantia nigra
Neurotensin; Dopamine; Neuromedin N; Avian neurotensin; Kinetensin; Electrophysiology (Keegan, K.D. (253) 131)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin); Patch clamp; Ventral tegmental area; Caudate-putamen; Nucleus accumbens (Liu, J.-C. (264) 269)

EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Fluphenazine-*N*-mustard; Dopamine D_1 receptor mRNA; Dopamine D_2 receptor mRNA; Glutamic acid decarboxylase mRNA; Gene expression; Dopamine receptor antagonists (Qin, Z.-H. (269) 25)

Substantia nigra pars compacta
Sertindole; Haloperidol; Clozapine; Short-term treatment; Ventral tegmental area; (Rat) (Skarsfeldt, T. (254) 291)

Sucrose gap
Tachykinin receptor; Proximal colon, guinea-pig; Pharmacomechanical coupling; Electromechanical coupling; Ca^{2+} channel, voltage-dependent (Zagorodnyuk, V. (255) 9)

Sucrose intake
Chronic mild stress; Depression model, rat; Imipramine, chronic; cAMP; β-Adrenoceptor (Papp, M. (261) 141)

Sudden cardiac death
Autonomic nervous system; Cardiac arrhythmia; β-Adrenoceptor; Myocardial ischemia (Avendano, C.E. (255) 99)

Sudomotor system
(*R*)-α-Methylhistamine; Sympathetic-cholinergic response; Histamine receptor; Nerve stimulation, pre- and postganglionic; Presynaptic inhibition (Koss, M.C. (257) 109)

Sulfhydryl group
κ-Opioid receptor; R1.1 Thymoma cell line; *N*-Ethylmaleimide; Dithiothreitol (Joseph, D.B. (267) 1)

Sulfonylurea
Glucose; Na^+; Pancreatic islet (Saha, S. (258) 145)

Glibenclamide; β-Cell replication; Diabetes; Pancreatic islet (Guiot, Y. (261) 157)

Sulfonylurea receptor
Pancreatic β-cell; K^+ channel, ATP-sensitive; Glibenclamide; MIN 6 cell (Mogami, H. (269) 293)

Sulpiride
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); MPTP monkeys; CY 208–243 ((−)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenanthyxidine); Dopamine D_1 receptor; Dopamine D_2 receptor; SCH-23390; Dopamine D_1/D_2 interaction; (+)-PHNO ((+)-4-propyl-9-hydroxynaphthoxazine) (Luquin, M.R. (253) 215)

***l*-Sulpiride**
Hemorrhagic shock; ACTH-(1–24); Dopamine receptor; Haloperidol; SCH-23390 (Bazzani, C. (253) 303)

Sulprostone
Pithed rat; EP_3 receptor; Prostaglandin E_2; Presynaptic receptor; Neurogenic vasopressor response (Malinowska, B. (259) 315)

Sumatriptan
Nicotine; 5-HT_1 receptor; Sensory neurotransmission; Basilar artery, guinea pig (O'Shaughnessy, C.T. (259) 37)

SUN9216
Photochemically induced thrombosis; Tissue-type plasminogen activator; Middle cerebral artery thrombosis; (Rat) (Umemura, K. (262) 27)

Superior cervical ganglion
Neuroimmunomodulation; Parasympathetic nervous system; Cyclosporine; Lymphoid tissue; Cholinergic innervation; Acetylcholine, synthesis and release; Choline uptake; Sympathetic nervous system (Esquifino, A.I. (254) 1)

Superior cervical ganglion, rat
Uridine 5′-triphosphate; Adenosine 5′-triphosphate; Reactive blue 2; Pyrimidinoceptor; Purinoceptor (Connolly, G.P. (259) 95)

Taurine; Taurine release; Acetylcholine receptor (Waniewski, R.A. (260) 113)

Superior colliculus
Adenosine; Excitation; Glutamate release; Protein kinase (Hirai, H. (256) 65)

Superior mesenteric vessel
Coronary vasodilatation; Acyl carnitine ester (Criddle, D.N. (255) 223)

Superoxide anion
Nimesulide; Polymorphonuclear leukocyte; Phosphodiesterase type IV; cAMP; Chemotaxis (Bevilacqua, M. (268) 415)

Superoxide dismutase
Manganese; Nitric oxide (NO); cGMP; Blood pressure (Kasten, T.P. (253) 35)

Superoxide generation
Avarol; Avarone; Anti-inflammatory drug; Phospholipase A_2; Arachidonic acid metabolism; Peritoneal leukocyte (Ferrándiz, M.L. (253) 75)

Supersensitivity
5-HT (5-hydroxytryptamine, serotonin); Spinal cord; 5,7-DHT (5,7-dihydroxytryptamine); Antinociception; (Rat) (Sawynok, J. (264) 249)

Forskolin treatment (chronic); Dopamine D_2 receptor, human; Dopamine; Up-regulation; Adenylyl cyclase (Johansson, M.H. (269) 149)

Suprachiasmatic
Histamine; Stress; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); α-Fluoromethylhistidine; Accumbens (Fleckenstein, A.E. (264) 163)

Supraspinal analgesia
Mastoparan; GTP-binding protein; Opioid (Sánchez-Blázquez, P. (258) 159)

Suramin
NANC (non-adrenergic non-cholinergic); Inhibitory junction potential; Gastric smooth muscle; ATP (Ohno, N. (249) 121)

ATP; Ionic conductance; Enteric neuron; Electrophysiology; Purinoceptor; Myenteric plexus (Barajas-López, C. (250) 141)

Coronary vasculature; P_2 purinoceptor (Vials, A.J. (251) 299)

P_{2X} purinoceptor; iso-PPADS (pyridoxalphosphate-6-azophenyl-2′,5′-disulphonic acid); Cibacron blue (Khakh, B.S. (263) 301)

Radioligand binding; P_{2y} purinoceptor; Ecto-nucleotidase; (Antagonist) (Van Rhee, A.M. (268) 1)

Sympathetic-cholinergic response
(*R*)-α-Methylhistamine; Histamine receptor; Nerve stimulation, pre- and postganglionic; Presynaptic inhibition; Sudomotor system (Koss, M.C. (257) 109)

Sympathetic ganglion
Nicotinic; Muscarinic; Culture; Electrophysiology; (Guinea pig) (Xian, H. (259) 21)

Sympathetic nerve
Airway microvascular leakage; Histamine H_3 receptor (Danko, G. (254) 283)

Sympathetic nerve activity
NBQX; Non-NMDA receptor antagonist; Blood pressure; (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline) (Chen, K. (252) 155)

Sympathetic nerve stimulation
Atrium, rat; Diabetes; Endothelin-1; Noradrenaline; Streptozotocin (Lieu, A.T. (261) 33)

Atherosclerosis; Aorta, rabbit; Pulmonary artery, rabbit; Noradrenaline release; Noradrenaline metabolite (Verbeuren, T.J. (270) 27)

Sympathetic nervous system
Prostaglandin E_1; Prostaglandin E_2; Misoprostol; Enisoprost; Bradykinin; Plasma extravasation; PAF (platelet activating factor, PAF-acether); Synovial joint (Green, P.G. (252) 127)

Neuroimmunomodulation; Parasympathetic nervous system; Cyclosporine; Lymphoid tissue; Cholinergic innervation; Acetylcholine, synthesis and release; Choline uptake; Superior cervical ganglion (Esquifino, A.I. (254) 1)

Endothelin; Radioimmunoassay; Spinal cord (Knuepfer, M.M. (259) 305)

Angiotensin II; α_1-Adrenoceptor; Valsartan; PD 123319 (Marano, G. (261) 121)

Sympathetic neuron
P_2 purinoceptor; Noradrenaline release (Allgaier, C. (252) R7)

Sympathetic neurotransmission
Melatonin; Vas deferens; Nicotinic receptor; Protein synthesis (Carneiro, R.C.G. (257) 73)

Glutamate; AMPA receptor; Atrium, rat (Lorenzo, P.S. (258) 253)

Sympathomimetic anesthesia
Cerebral blood flow; Prostaglandin; Lidocaine; Tetrodotoxin; Charybdotoxin; (Neonate) (Albuquerque, M.L.C. (249) 215)

Synaptic transmission
Anesthetic; Anesthesia, theories of; Spinal cord; Glutamate receptor; NMDA receptor; $GABA_A$ receptor (Kendig, J.J. (264) 427)

Synaptic vesicle
GBR 12909; GBR 12935; Dopamine uptake; Brain (Reith, M.E.A. (253) 175)

Synaptosome
Neuropeptide release; Nerve varicosity; Muscarinic receptor; Ileum; Bombesin (Kurjak, M. (257) 169)

Synovial joint
Prostaglandin E_1; Prostaglandin E_2; Misoprostol; Enisoprost; Bradykinin; Sympathetic nervous system; Plasma extravasation; PAF (platelet activating factor, PAF-acether) (Green, P.G. (252) 127)

Tachycardia
R-α-methylhistamine; Histamine H_3 receptor; Histamine; Thioperamide; Depressor response; Pressor response; (Prejunctional) (Hegde, S.S. (251) 43)

Tachykinin
Neurokinin A; Tachykinin NK_2 receptor; Nociception; Spinal cord; Flexor reflex (Wiesenfeld-Hallin, Z. (251) 99)

Capsaicin; Afferent neuron; Intestine; Smooth muscle (Barthó, L. (259) 187)

Kinin; Antigen; Plasma extravasation; Airway; Neutral endopeptidase (Ricciardolo, F.L.M. (261) 127)

Tachykinin NK_3 receptor; CHO (Chinese hamster ovary) cell; [^{125}I][MePhe^7]neurokinin B binding; Species variation (Suman-Chauhan, N. (269) 65)

Neurokinin; CHO (Chinese hamster ovary) cell; Antagonist; Structure-activity; Ca^{2+}; Second messenger; Inositol phosphate; Thapsigargin; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

Tachykinin receptor
Scyliorhinin I; Tachykinin receptor agonist (Patacchini, R. (250) 311)

Sucrose gap; Proximal colon, guinea-pig; Pharmacomechanical coupling; Electromechanical coupling; Ca^{2+} channel, voltage-dependent (Zagorodnyuk, V. (255) 9)

Septide; Myenteric plexus (Burcher, E. (258) R9)

Micturition; Tachykinin receptor antagonist; Spinal cord (Lecci, A. (259) 129)

Tachykinin receptor antagonist; Transfection; Second messenger; (Binding); (Subtype- and species-selectivity) (Aramori, I. (269) 277)

Tachykinin NK_1 receptor
Substance P; Smooth muscle; Neuron; Electrophysiology (Seabrook, G.R. (250) 125)

CP-96345; Dynorphin; Methamphetamine; Neurotensin; Substance P (Gygi, S.P. (250) 177)

SR140333; Substance P; (Non-peptide receptor antagonist) (Emonds-Alt, X. (250) 403)

Chromodacryorrhea; Hind paw tapping; (Gerbil) (Bristow, L.J. (253) 245)

FK888; RP 67580; (±)-CP-96,345; IM9 human lymphoblastoma cell; U373 MG human astrocytoma cell (Goso, C. (254) 221)

Tachykinin NK_2 receptor; Spinal cord; Motoneurone (Lepre, M. (258) 23)

Antagonist; Substance P; Septide; Proline, β-substituted (Lavielle, S. (258) 273)

Mesolimbic dopamine system; (Guinea-pig) (Rupniak, N.M.J. (262) 171)

Plasma protein extravasation; Dura mater; α-CGRP-(8–37); GR82334 (O'Shaughnessy, C.T. (263) 193)

Chromodacryorrhea; Foot tapping; CNS (central nervous system) penetration; (Gerbil) (Rupniak, N.M.J. (265) 179)

Tachykinin NK_2 receptor
SR 48968; Antitussive effect; Cough reflex; Citric acid; (Guinea-pig) (Advenier, C. (250) 169)

Neurokinin A; Tachykinin; Nociception; Spinal cord; Flexor reflex (Wiesenfeld-Hallin, Z. (251) 99)

Tackykinin NK_1 receptor; Spinal cord; Motoneurone (Lepre, M. (258) 23)

Tachykinin NK_3 receptor
Neurokinin B; Angiotensin receptor antagonist; Brain, rat; Brain, guinea pig (Chrétien, L. (256) 73)

Tachykinin; CHO (Chinese hamster ovary) cell; [^{125}I][MePhe^7]neurokinin B binding; Species variation (Suman-Chauhan, N. (269) 65)

Tachykinin receptor agonist
Scyliorhinin I; Tachykinin receptor (Patacchini, R. (250) 311)

Tachykinin receptor antagonist
Micturition; Tachykinin receptor; Spinal cord (Lecci, A. (259) 129)

Spantide II; Structure-activity relationship (Wang, Z.-Y. (260) 121)

Spinal cord; Intrathecal injection; (Mouse) (Sakurada, T. (261) 85)

Ca^{2+} channel; Binding (Lombet, A. (267) 113)

Tachykinin receptor; Transfection; Second messenger; (Binding); (Subtype- and species-selectivity) (Aramori, I. (269) 277)

Tachykinin NK_1 receptor antagonist
Antiemetic; CP-99,994 (Tattersall, F.D. (250) R5)

Substance P; Septide; Urinary bladder contraction; Plasma extravasation; (Rat) (Montier, F. (251) 9)

Tachykinin NK_2 receptor antagonist
Behavior; Anxiety (Stratton, S.C. (250) R11)

Tachyphylaxis
Nicotine; Cardiovascular effect; Blood pressure; Heart rate; Pentobarbital (Cruz, S.L. (258) 39)

Tacrine
NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1*H*-cyclopenta(*b*)-quinoline monohydrate hydrochloride); Physostigmine; Scopolamine-induced amnesia; Side-effect (central); Side-effect (peripheral) (Yoshida, S. (250) 117)

N-Methyl-D-aspartate (NMDA); 1,2,3,4-Tetrahydro-9-aminoacridine; Voltage-clamp experiment; Open-channel block (Vorobjev, V.S. (253) 1)

Taenia coli
Cytochalasin B; Smooth muscle contraction; Ca^{2+} current; Myosin phosphorylation; (Guinea pig) (Obara, K. (255) 139)

Tail artery
Spontaneously hypertensive rat (SHR); Ca^{2+}, cytosolic; [^{3}H]Inositol phosphate (Thorin-Trescases, N. (268) 199)

Tail artery, rat
Norepinephrine release; Aging; Ca^{2+} channel; Dopamine D_2 receptor (Friedman, D.J. (252) 1)

Tail-flick assay
Analgesia; Morphine; Selective breeding; Tolerance (Lutfy, K. (265) 171)

Tail-flick inhibition
Antisense oligodeoxynucleotide; δ-Opioid receptor (Tseng, L.F. (258) R1)

(+)-*cis*-Dioxolane; β-Endorphin; Antinociception; Nitric oxide (NO); cGMP (Xu, J.Y. (262) 223)

β-Endorphin; Morphine; MK-801; Hot plate inhibition (Suh, H.-W. (263) 217)

Tail-flick test
κ-Opioid receptor agonist; U-50,488H; L-Tyrosine; L-Tryptophan; Analgesia (Barjavel, M.J. (258) 173)

Tail-pressure test
Nor-binaltorphimine; Antinociception; Opioid receptor (Spanagel, R. (264) 157)

Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4*H*-thiazolo[4,5-*d*]-azepine)
Dopamine D_2 receptor agonist; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Chronic treatment); (Common marmoset) (Irifune, M. (264) 117)

Taurine
Taurine release; Superior cervical ganglion, rat; Acetylcholine receptor (Waniewski, R.A. (260) 113)

Taurine release
Taurine; Superior cervical ganglion, rat; Acetylcholine receptor (Waniewski, R.A. (260) 113)

TBPS (*t*-butylbicyclophosphorothionate)
Neuroactive steroid; $GABA_A$ receptor; 3α-Hydroxy-5β-pregnan-20-one; 3α-Hydroxy-5α-pregnan-20-one; Flunitrazepam (Hawkinson, J.E. (269) 157)

[^{35}S]TBPS binding
ICS 205–930; 5-HT_3 receptor antagonist; $GABA_A$ receptor; [^{3}H]Flunitrazepam binding; [^{3}H]Muscimol binding; $^{36}Cl^-$ flux; 293 cell; *Xenopus* oocyte (Klein, R.L. (268) 237)

Propofol; GABA (γ-aminobutyric acid); Cl^- channel; Barbiturate; Steroid derivative; Benzodiazepine; General anesthetics (Concas, A. (267) 207)

TCB (3,3′,4,4′-tetrachlorobiphenyl)
PCB (polychlorinated biphenyl) metabolism; Ethoxyresorufin-*O*-deethylase (EROD); (Bird); (Mammal); (Fish) (Murk, A. (270) 253)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin)
T47D cell; Genetic instability (Fernandez, P. (270) 53)

7-Ethoxyresorufin *O*-deethylase (EROD); (Rat); (Mouse); (Guinea pig); (Hamster) (Håkansson, H. (270) 279)

TCV-116
Angiotensin II receptor antagonist; Aldosterone; CV-11974 (Wada, T. (253) 27)

T47D cell
Genetic instability; TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin) (Fernandez, P. (270) 53)

TEI-6720
Allopurinol; Xanthine oxidase inhibitor; Uric acid; Hypouricemic effect; (Chimpanzee) (Komoriya, K. (250) 455)

Telemetry
Angiotensin II; Angiotensin III; Spontaneously hypertensive rat (SHR); Losartan (DuP 753) (Radhakrishnan, R. (259) 87)

Temperature
Behavior; MK-801; NMDA (*N*-methyl-D-aspartate); Phencyclidine; Sensitization; Thermoregulation; Tolerance (Pechnick, R.N. (252) 35)

Theophylline; Dopamine receptor antagonist; Reserpine; (Mouse) (Zarrindast, M.-R. (257) 13)

Macrophage; Nitric oxide (NO) (Bernard, C. (270) 115)

Temporal artery, human
Antisense oligodeoxynucleotide; Endothelin ET_A receptor (Adner, M. (261) 281)

Tension, maximum
Ca^{2+} channel antagonist; Skinned striated muscle; Ca^{2+} sensitivity; Inotropic state (Schiereck, P. (249) 317)

Terbutaline, in vitro
Formoterol; Salmeterol; Lung, guinea pig (Jeppsson, A.-B. (257) 137)

(−)-Tertatolol
5-HT_{1A} receptor; Autoradiography; Hippocampus; Dorsal raphe nucleus; Firing; Adenylate cyclase; Lesopitron (Haj-Dahmane, S. (255) 185)

Testosterone
Adrenoceptor; Adipocyte; Colocyte; Kidney; Brain; Liver (Bouloumié, A. (269) 95)

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
5-HT (5-hydroxytryptamine, serotonin); Tryptophan; Plasma-free tryptophan; Anorexia; Strain difference; (Brain) (Unkila, M. (270) 157)

1,2,3,4-Tetrahydro-9-aminoacridine
N-Methyl-D-aspartate (NMDA); Tacrine; Voltage-clamp experiment; Open-channel block (Vorobjev, V.S. (253) 1)

Δ^9-Tetrahydrocannabinol
Anandamide; Muscimol; Globus pallidus; Catalepsy; Drug interaction (Wickens, A.P. (250) 205)

Cannabinoid; Anandamide; Cannabinoid, endogenous; Vas deferens, mouse; Tolerance (Pertwee, R. (259) 115)

Morphine; Tolerance; Analgesia; Hypothermia; Cross-tolerance; [^{3}H]DAMGO ([^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin), B_{max}, K_d; Brain; Spinal cord (Thorat, S.N. (260) 5)

Cannabis; Cerebral decortication; MK-801; NMDA receptor; In situ hybridization (Mailleux, P. (266) 193)

Tetramethylpyrazine
Membrane fluidity; Phospholipid phase transition; Differential scanning calorimetry; Electron spin resonance; Fluorescence polarization; Drug–lipid interactions (Nie, S.-Q. (266) 11)

DL-(Tetrazol-5-yl)glycine
NMDA (*N*-methyl-D-aspartate); *cis*-Methanoglutamate; Excitotoxicity; Neurodegeneration (Schoepp, D.D. (270) 67)

Tetrodotoxin
Cerebral blood flow; Sympathomimetic anesthesia; Prostaglandin; Lidocaine; Charybdotoxin; (Neonate) (Albuquerque, M.L.C. (249) 215)

Adenosine; Brain microdialysis; Cerebral cortex; NMDA receptor; Muscarinic receptor (Pazzagli, M. (254) 277)

TFMPP (1-(3-trifluoromethyl-phenyl)piperazine hydrochloride)
Maternal aggression; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)-tetralin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Intracerebroventricular; 5-HT receptor agonist (De Almeida, R.M.M. (264) 445)

Thalamus
Morphine withdrawal; Morphine dependence; Adenylyl cyclase; Locus coeruleus; Amygdala (Matsuoka, I. (268) 215)

Thaliporphine
Bay K 8644; Positive inotropic action; Ca^{2+} channel; K^+ channel; Cardiomyocyte (Su, M.-J. (254) 141)

Thapsigargin
Sarcoplasmic reticulum; Cyclopiazonic acid; Heart; Excitation-contraction coupling; (Frog) (Bonnet, V. (264) 69)

Tachykinin; Neurokinin; CHO (Chinese hamster ovary) cell; Antagonist; Structure-activity; Ca^{2+}; Second messenger; Inositol phosphate; Ryanodine; U73122 (Pinnock, R.D. (269) 73)

Endothelial cell; Patch clamp; Ca^{2+}, intracellular; Capacitative Ca^{2+} entry; NPPB (5-Nitro-2-(3-phenylpropylamino)-benzoic acid) (Gericke, M. (269) 381)

Tri-*n*-butyltin; Thymocyte; Ca^{2+} pump; A23187; Cyclopiazonic acid (Oyama, Y. (270) 137)

Theophylline
Hyperalgesia; NMDA receptor; Noradrenaline; Dopamine; Adenosine (Paalzow, G.H.M. (252) 87)

Dopamine receptor antagonist; Reserpine; Temperature; (Mouse) (Zarrindast, M.-R. (257) 13)

Therapy
Adenosine; Ischemia; Adenosine receptor; (Gerbil) (Von Lubitz, D.K.J.E. (256) 161)

Thermal hyperalgesia
Excitatory amino acid; Glutamate receptor; Inflammation; Memantine; Carrageenan (Eisenberg, E. (255) 123)

Thermodynamics
β-Adrenoceptor agonist interaction; Lung (rat) (Fraeyman, N. (267) 63)

Dopamine neuronal carrier; [^{3}H]GBR 12783 (1-[2-{diphenylmethoxy}ethyl]4-{3-phenyl-2-propenyl}-piperazine); BTCP (*N*-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine) derivative; Binding (in vitro); Striatum (Rat) (Billaud, G. (268) 357)

Thermogenesis
cAMP; Glycerol release; Brown adipose tissue; β-Adrenoceptor; Obesity (Nisoli, E. (259) 181)

Thermoregulation
Behavior; MK-801; NMDA (*N*-methyl-D-aspartate); Phencyclidine; Sensitization; Temperature; Tolerance (Pechnick, R.N. (252) 35)

Dopamine; Dopamine receptor; Clozapine; (Rat) (Salmi, P. (253) 67)

Resiniferatoxin; Capsaicin; Hypothermia; Oxygen consumption; (Rat) (Woods, A.J. (264) 125)

Thiol
Nitrovasodilator; Nitrate tolerance; Smooth muscle, vascular; Endothelium (Kojda, G. (250) 385)

Thioperamide
VUF 9153 (*S*-[3-(4(5)-imidazolyl)]propyl-*N*-(4-chlorobenzyl)isothiourea); Histamine H_3 receptor; Ileum, guinea-pig; Radioligand binding; Dipsogenicity (Barnes, J.C. (250) 147)

R-α-methylhistamine; Histamine H_3 receptor; Histamine; Depressor response; Pressor response; Tachycardia; (Prejunctional) (Hegde, S.S. (251) 43)

Histamine; 5-HT (5-hydroxytryptamine, serotonin); Mepyramine; Zolantidine; Metoprine (Fleckenstein, A.E. (254) 35)

Histamine H_3 receptor; Locomotor activity; (R)-α-Methylhistamine; (Mouse); (Stimulant) (Clapham, J. (259) 107)

Histamine H_3 receptor; *R*-α-Methylhistamine; Species difference; Presynaptic inhibition (McLeod, R.L. (259) 211)

Thiorphan
Bradykinin receptor antagonist; Bradykinin biosynthesis; Trachea; Smooth muscle, airway; Captopril (Farmer, S.G. (259) 309)

Thiothixene
Intraocular pressure; Dopamine receptor; Phosphodiesterase inhibitor; Methylxanthine; Pentoxifylline; Trifluperidol; Fluphenazine; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine); Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

Thoracic aorta
Cinnamophilin; Thromboxane A_2 receptor antagonist; Ca^{2+} channel blocker, voltage-dependent; (Rat) (Yu, S.-M. (256) 85)

α_1-Adrenoceptor; β-Escin-skinned fiber; Myosin light chain phosphorylation (Satoh, M. (265) 133)

Threshold phenomenon
Ca^{2+} inhibition; Contraction; Smooth muscle; Myometrium; Actin filament (Miyauchi, Y. (263) 75)

Thrombin
Thrombin receptor; Aminopeptidase M; Peptide; (Rabbit) (Godin, D. (253) 225)

Ca^{2+}; Smooth muscle, vascular; TRAP (thrombin receptor-activating peptide); Bay K 8644 (Antonaccio, M.J. (256) 37)

Platelet; Hirulog; Heparin; Low molecular weight heparin; PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone); DuP-714 ester (acetyl-D-phenylalanine-propyl-boroarginine); (Rabbit) (Liu, J.T. (264) 183)

Reocclusion after thrombolysis; Recombinant tissue-type plasminogen activator (rt-PA); Thromboxane A_2; Leucocyte; (Guinea pig) (Nishiyama, H. (264) 191)

Thrombin inhibitor
Thrombosis, arterial; Thrombosis, venous; Thrombocytopenia; (Rat) (Schumacher, W.A. (259) 165)

Thrombin receptor
Thrombin; Aminopeptidase M; Peptide; (Rabbit) (Godin, D. (253) 225)

Thrombocytopenia
Thrombosis, arterial; Thrombosis, venous; Thrombin inhibitor; (Rat) (Schumacher, W.A. (259) 165)

Thrombosis, arterial
Thrombosis, venous; Thrombin inhibitor; Thrombocytopenia; (Rat) (Schumacher, W.A. (259) 165)

Thrombosis, venous
Thrombosis, arterial; Thrombin inhibitor; Thrombocytopenia; (Rat) (Schumacher, W.A. (259) 165)

Thromboxane
Diamide; Sensory nerve; Bronchoconstriction; Hydrogen peroxide; (Guinea pig) (Bannenberg, G. (270) 175)

Hypoxia; $^{45}Ca^{2+}$ uptake; U46619; Coronary artery (Dalen, T. (270) 313)

Thromboxane A_2
cAMP; Ca^{2+} concentration, intracellular; β_1-Adrenoceptor; Ca^{2+} sensitivity of contractile elements; Coronary artery (Yamagishi, T. (251) 253)

Asthma; Edema; Plasma exudation; Aging; Leukotriene; Airway obstruction; Vascular permeability; Arachidonic acid (Arakawa, H. (259) 251)

S-1452 (calcium (1*R*,2*S*,3*S*,4*S*)-(5*Z*)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate); Bronchial hyperresponsiveness; Lung vascular injury (Arimura, A. (260) 201)

Endothelial cell, human, vascular; ICAM-1 (intercellular adhesion molecule-1); Phospholipase A_2 (Ishizuka, T. (262) 113)

Reocclusion after thrombolysis; Recombinant tissue-type plasminogen activator (rt-PA); Leucocyte; Thrombin; (Guinea pig) (Nishiyama, H. (264) 191)

β-Adrenoceptor; Salmeterol; cAMP; Macrophage (Baker, A.J. (264) 301)

Thromboxane A_2 receptor
Photoaffinity labelling; (Receptor) (True, T.A. (266) 51)

Thromboxane A_2 receptor antagonist
Cinnamophilin; Ca^{2+} channel blocker, voltage-dependent; Thoracic aorta; (Rat) (Yu, S.-M. (256) 85)

Thromboxane A_2 synthetase inhibitor
DP-1904; Crescentic nephritis; Proteinuria (Nagao, T. (259) 233)

Thromboxane B_2
Tolfenamic acid; Prostaglandin E_2; 12-Hydroxyeicosatetraenoic acid; (Dog) (McKellar, Q.A. (253) 191)

Thymic hormone
FTS (facteur thymique sérique); Alloxan; Thymic immunity (Yamanouchi, T. (257) 39)

Thymic immunity
FTS (facteur thymique sérique); Thymic hormone; Alloxan (Yamanouchi, T. (257) 39)

Thymocyte
Tri-*n*-butyltin; Ca^{2+} pump; Thapsigargin; A23187; Cyclopiazonic acid (Oyama, Y. (270) 137)

Thyroid
Iodolactone; Goiter; Antigoitrogenic; Autoregulation (Pisarev, M.A. (258) 33)

Thyroid hormone
Forced swimming test; Water temperature; Glucocorticoid; κ-Opioid receptor, selective; Glucose (Jefferys, D. (253) 91)

Thyrotropin (TSH)
Tolerance; *N*-Nitro-L-arginine methyl ester; Morphine; Prolactin; Growth hormone; Antinociception; Hyperthermia (Rauhala, P. (259) 57)

Thyroxine-binding globulin
PCB (polychlorinated biphenyl); PCDD (dibenzo-*p*-dioxin); PCDF (dibenzofuran); Hydroxylated metabolite; Transthyretin (Lans, M.C. (270) 129)

Tianeptine
Hypothalamo-pituitary-adrenal axis; Stress; Antidepressant; 5-HT (5-hydroxytryptamine, serotonin); CRF (corticotropin-releasing factor); ACTH (adrenocorticotropin); Corticosterone (Delbende, C. (251) 245)

GH (growth hormone); GHRH (growth hormone-releasing hormone); Somatostatin; 5-HT (5-hydroxytryptamine, serotonin); (Sheep) (Cataldi, M. (253) 149)

5-HT (5-hydroxytryptamine, serotonin) transporter; Paroxetine binding site (Kuroda, Y. (268) R3)

Tilisolol
Propranolol; Myocardial ischemia; Myocardial metabolism; (Dog) (Hayase, N. (260) 183)

Tissue culture
Dopamine; GABA (γ-aminobutyric acid); Excitatory amino acid; $GABA_A$ receptor; NMDA (N-methyl-D-aspartate) (Chaudieu, I. (264) 361)

Tissue-type plasminogen activator
Photochemically induced thrombosis; Middle cerebral artery thrombosis; SUN9216; (Rat) (Umemura, K. (262) 27)

Titanocene dichloride
Antitumor agent; Antiangiogenic agent (Bastaki, M. (251) 263)

TNF (tumor necrosis factor)
Interleukin-1; Interleukin-6; Indomethacin; Dexamethasone; Pleurisy; (Rat) (Utsunomiya, I. (252) 213)

Interleukin-1β; Leukotriene B_4; Phospholipase A_2; Phospholipase C; 5-Lipoxygenase; Protein kinase C; Phorbol 12-myristate 13-acetate; Stomach, rat; Gastric motility (Montuschi, P. (252) 253)

FR128998; PAF (platelet activating factor); Disseminated intravascular coagulation; Lipopolysaccharide (Yokota, Y. (258) 239)

TNF-α (tumor necrosis factor-α)
Cytokine; Endothelin; Endothelin converting enzyme; Hemorrhage; Hypoxia; Interleukin-1β; Phosphoramidon (Vemulapalli, S. (257) 95)

Toad venom
Arenobufagin; Delayed rectifier K^+ current; Cardiac myocytes (Dos Santos Cruz, J. (266) 317)

α-Tocopherol
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Diethyldithiocarbamate; Lipoic acid; Coenzyme Q; Brain (mouse) (Götz, M.E. (266) 291)

α-Tocopherol analog
Cardioselective; Free radical scavenger; Reperfusion injury; Myocardial ischemia/reperfusion (Petty, M.A. (255) 215)

Tolbutamide
NMDA (*N*-methyl-D-aspartate); Hippocampus (Kwiecien, R. (249) 325)

SL 84.0418; α_2-Adrenoceptor; K^+ channel, ATP-sensitive; Insulin release; Imidazoline; (Mouse islet) (Jonas, J.-C. (254) 27)

CS-045; Antidiabetic; Fructose-2,6-bisphosphate; Hepatocyte (Murano, K. (254) 257)

Tolerance
Behavior; MK-801; NMDA (*N*-methyl-D-aspartate); Phencyclidine; Sensitization; Temperature; Thermoregulation (Pechnick, R.N. (252) 35)

Analgesia; Morphine, blood level; Dependence; Opiate; Withdrawal (Gold, L.H. (253) 45)

Caerulein; CCK-8 (cholecystokinin octapeptide); Morphine; Antinociception; (Unsulfated CCK-8) (Rezayat, M. (254) 21)

Imidazenil; $GABA_A$ receptor, partial agonist; Chronic treatment (Ghiani, C.A. (254) 299)

Morphine; U-50,488; Dependence; (Guinea pig) (Tao, P.-L. (256) 281)

Dopamine receptor, presynaptic; Dopamine receptor, postsynaptic; γ-Butyrolactone; Behavioral supersensitivity; Drug interaction; Indolylbutylamine (Seyfried, C.A. (257) 67)

Immediate-early gene; Inhibitor of enkephalin-degrading enzyme; Morphine; Nociception; Non-steroidal anti-inflammatory drug (Abbadie, C. (258) 215)

Abecarnil; Diazepam; Chronic treatment; GABAergic transmission; (Mouse) (Serra, M. (259) 1)

N-Nitro-L-arginine methyl ester; Morphine; Thyrotropin (TSH); Prolactin; Growth hormone; Antinociception; Hyperthermia (Rauhala, P. (259) 57)

Cannabinoid; Δ^9-Tetrahydrocannabinol; Anandamide; Cannabinoid, endogenous; Vas deferens, mouse (Pertwee, R. (259) 115)

Morphine; Δ^9-Tetrahydrocannabinol; Analgesia; Hypothermia; Cross-tolerance; [^{3}H]DAMGO ([^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin), B_{max}, K_d; Brain; Spinal cord (Thorat, S.N. (260) 5)

FK409; Vasorelaxation; Guanylate cyclase, soluble; Nitric oxide (NO) (Isono, T. (260) 163)

Morphine; MK-801; EEG (electroencephalography); EEG power spectra; (Interaction) (Haberny, K.A. (261) 1)

Caffeine; Quinpirole; *R*(−)-Propylnorapomorphine (NPA); SKF-38393; SKF-77434; Motor activity (Garrett, B.E. (262) 65)

Ropinirole; Dopamine; D_2-like receptor; Spontaneously hypertensive rat (SHR); Cardiovascular; (Monkey) (Parker, S.G. (265) 17)

Analgesia; Morphine; Selective breeding; Tail flick assay (Lutfy, K. (265) 171)

Tolerance, in vitro
Glyceryl trinitrate; *S*-Nitroso-*N*-acetylpenicillamine; *S*-Nitroso-*N*-acetylcaptopril; *S*-Nitrosothiols; Artery, bovine coronary (Zhang, C.L. (252) 299)

Tolfenamic acid
Thromboxane B_2; Prostaglandin E_2; 12-Hydroxyeicosatetraenoic acid; (Dog) (McKellar, Q.A. (253) 191)

Toluene diisocyanate
Capsaicin; Airways, human (Chitano, P. (270) 167)

Topiramate
Spontaneously epileptic rat (SER); Antiepileptic effect; Audiogenic seizure (Nakamura, J. (254) 83)

Toxicity
Nitric oxide (NO); Single breath; Respiratory system; Alcohol; Blood pressure; (Lung); (Pharmacology) (Persson, M.G. (270) 273)

Trachea
Epithelium; Smooth muscle; ATP; Amiloride; DIDS (4,4′-diisothiocyano-stilbene-2,2′-disulfonic acid) (Fedan, J.S. (256) 51)

Ca^{2+}; 5-HT (5-hydroxytryptamine, serotonin); Carbamylcholine (Cox, D.A. (258) 265)

Bradykinin receptor antagonist; Bradykinin biosynthesis; Smooth muscle, airway; Captopril; Thiorphan (Farmer, S.G. (259) 309)

Trachea, guinea-pig
Verapamil; Trifluoperazine; Flurbiprofen (McCaig, D. (249) 53)

Muscarinic M_2 receptor; Functional antagonism; β-Adrenoceptor agonist; Adenylyl cyclase inhibition (Roffel, A.F. (249) 235)

Lung strip, guinea pig; Cholinergic contraction; Muscarinic M_2 receptor; Smooth muscle, human, airway (Roffel, A.F. (250) 267)

Tracheal
Smooth muscle cell; Single; Azelastine; Voltage-dependent Ca^{2+} current; K^+ current (Hazama, H. (259) 143)

Tracheal epithelial cell
Non-steroidal anti-inflammatory drug; Short circuit current (Mochizuki, H. (252) 183)

Tracheal relaxation
Xanthine derivative; Phosphodiesterase; Structure-activity relationship (Miyamoto, K.-i. (267) 317)

Tracheal smooth muscle function
Allergic asthma; Bronchial hyperreactivity; Airway inflammation; (Guinea pig model) (Santing, R.E. (257) 145)

Transcription factor
DNA-binding drug; Epstein-Barr virus (Feriotto, G. (267) 143)

Transduction signal
Baicalein; Esculetin; Antiproliferative effect; CEM cell; Messenger RNA expression (Huang, H.-C. (268) 73)

Transfected cell
Receptor agonist exposure; Receptor internalization; Phosphatidylinositol hydrolysis; cAMP production; Down-regulation; Muscarinic M_1 receptor; Muscarinic M_2 receptor (Wei, H.-B. (268) 381)

Transfection
Tachykinin receptor antagonist; Tachykinin receptor; Second messenger; (Binding); (Subtype- and species-selectivity) (Aramori, I. (269) 277)

Transforming growth factor β_1
Spontaneously hypertensive rat (SHR); Extracellular matrix; mRNA; Cardiovascular system; Renin-angiotensin system (Ohta, K. (269) 115)

Transient expression
CCK_B receptor; Polymerase chain reaction; Radioligand binding; Calcium mobilization; Fura-2; COS-7 cell; [*N*-methyl-Nle 28,31)]cholecystokinin-(26-33) (Knapp, R.J. (269) 133)

Transmitter release
Riluzole; Glutamate; Aspartate; Hippocampus; Excitatory amino acid (Martin, D. (250) 473)

Transporter
5-HT (5-hydroxytryptamine, serotin); Imipramine; Lectin (Helmeste, D.M. (266) 327)

GABA; GABA transport; Inhibitor; (γ-aminobutyric acid); (Lipophilic) (Borden, L.A. (269) 219)

Transthyretin
PCB (polychlorinated biphenyl); PCDD (dibenzo-*p*-dioxin); PCDF (dibenzofuran); Hydroxylated metabolite; Thyroxine-binding globulin (Lans, M.C. (270) 129)

TRAP (thrombin receptor-activating peptide)
Thrombin; Ca^{2+}; Smooth muscle, vascular; Bay K 8644 (Antonaccio, M.J. (256) 37)

TRH analog
TRH (thyrotropin releasing hormone); Ataxic mutant mouse; Ataxia; Spinocerebellar degeneration (Matsui, K. (254) 295)

TRH (thyrotropin-releasing hormone)
TRH analog; Ataxic mutant mouse; Ataxia; Spinocerebellar degeneration (Matsui, K. (254) 295)

Tricyclic antidepressant
Imipramine; Desipramine; Patch-clamp; Neuroblastoma; Nicotinic acetylcholine receptor (Rana, B. (250) 247)

Trifluoperazine
Trachea (guinea-pig); Verapamil; Flurbiprofen (McCaig, D. (249) 53)

Trifluperidol
Intraocular pressure; Dopamine receptor; Phosphodiesterase inhibitor; Methylxanthine; Pentoxifylline; Thiothixene; Fluphenazine; 3-PPP (3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine); Hydroxyphenyl-*N*-*n*-propylpiperidine (Hariton, C. (258) 85)

Triiodothyronine
Amiodarone; β-Adrenoceptor; Cardiomyocyte; (Chicken) (Yin, Y. (261) 97)

Tri-*n*-butyltin
Thymocyte; Ca^{2+} pump; Thapsigargin; A23187; Cyclopiazonic acid (Oyama, Y. (270) 137)

α-Trinositol
Binding site; Inositol phosphate; Heart (Yoo, H. (268) 55)

Tripeptide
Lys-D-Pro-Thr; Lys-D-Pro; Interleukin-1β-(193–195); Naloxone; Antinociception; Formalin test (Oluyomi, A.O. (258) 131)

Tripitramine
Methoctramine; Muscarinic receptor subtype; Binding affinity; CHO-K1 cell (Maggio, R. (268) 459)

2,2′,2″-Tripyridine
Vasorelaxation; Ca^{2+} influx; cGMP (Kuei-Sen Hsu, (270) 89)

Trolox
Antioxidant; SIN (3-morpholino sydnonimine); Nitric oxide (NO); cGMP; Prostaglandin; Leukotriene; Leukocyte (Riutta, A. (262) 217)

Trophic factor
Selegiline; Neuronal rescue (Koutsilieri, E. (269) R3)

Tropisetron
5-HT_4 receptor; Light/dark test; Behavioral disinhibition; 5-Hydroxytryptophan; SDZ205-557; Putative anxiolytic (Cheng, C.H.K. (255) 39)

5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation; (*S*)-Zacopride (Mongeau, R. (256) 269)

Tryptophan
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; 5-HT (5-hydroxytryptamine, serotonin); Plasma-free tryptophan; Anorexia; Strain difference; (Brain) (Unkila, M. (270) 157)

L-Tryptophan
κ-Opioid receptor agonist; U-50,488H; L-Tyrosine; Analgesia; Tail-flick test (Barjavel, M.J. (258) 173)

Tryptophan hydroxylase
Amphetamine; 5-HT (5-hydroxytryptamine, serotonin); Methamphetamine; Nimodipine; (Metabolism) (Elkins, K.W. (250) 395)

Acute sound stress; Hypophysectomy; Hypothalamic deafferentation; RU 38486; Central nucleus of amygdala (Singh, V.B. (256) 177)

Tubular transport
Aminoglycoside; Loop of Henle; Micropuncture, in vivo; Microperfusion, in vitro (Kidwell, D.T. (270) 97)

Turkey
β-Adrenoceptor; β-Adrenoceptor antagonist; G-protein (G_s); Adenylyl cyclase; Erythrocyte (Götze, K. (268) 151)

Turning behavior
Adenosine; Dopamine; Basal ganglion; Dopamine D_1 receptor; Dopamine D_2 receptor (Morelli, M. (251) 21)

Twitch response
Bay K 8644; Dihydropyridine; K^+ contracture; Nifedipine; Skeletal muscle (Kitamura, N. (256) 169)

Tyramine
Receptor model; Functional interaction; Indirect action; Vas deferens, rat (Venter, D.P. (251) 209)

Tyrosine
Staurosporine; $gp140^{trk}$; Phosphorylation; Neurite outgrowth (Rasouly, D. (269) 255)

L-Tyrosine
κ-Opioid receptor agonist; U-50,488H; L-Tryptophan; Analgesia; Tail-flick test (Barjavel, M.J. (258) 173)

Tyrosine kinase
Genistein; Contractile force; Coronary tone; ANP (atrial natriuretic peptide); Ca^{2+}, intracellular (Taskinen, P. (256) 251)

Tyrosine kinase inhibitors
$pp60^{F527}$; Tyrosine phosphorylation; Lavendustin A and C6 (Agbotounou, W.K. (269) 1)

Tyrosine phosphorylation
$pp60^{F527}$; Lavendustin A and C6; Tyrosine kinase inhibitors (Agbotounou, W.K. (269) 1)

U-46619
Endothelin-1; Anti-endothelin-1 serum; ST elevation; Radioimmunoassay; (Rat) (Yamamoto, T. (250) 189)

Hypoxia; $^{45}Ca^{2+}$ uptake; Thromboxane; Coronary artery (Dalen, T. (270) 313)

U-50,488
Morphine; Tolerance; Dependence; (Guinea pig) (Tao, P.-L. (256) 281)

κ-Opioid receptor agonist; L-Tyrosine; L-Tryptophan; Analgesia; Tail-flick test (Barjavel, M.J. (258) 173)

κ-Opioid receptor agonist; R-84760; CI-977; Morphine; Antinociceptive effect (Fujibayashi, K. (261) 133)

U-50,488H
Cardiac electrophysiology; Ionic current; Cardiac myocyte, isolated; κ-Opioid receptor agonist (Pugsley, M.K. (261) 303)

U-73122
Tachykinin; Neurokinin; CHO (Chinese hamster ovary) cell; Antagonist; Structure-activity; Ca^{2+}; Second messenger; Inositol phosphate; Thapsigargin; Ryanodine (Pinnock, R.D. (269) 73)

U-74006F
Magnetic resonance image; Cerebral infarction, focal; Lipid peroxidation; Rose bengal (Umemura, K. (251) 69)

UD-CG 212
Blood vessel; Phosphodiesterase inhibitor; Pimobendan; Milrinone (Fujimoto, S. (265) 159)

U-92032
Ca^{2+} channel antagonist, T-type; Neuronal ischemic injury; Nifedipine; Flunarizine; Antioxidant (Ito, C. (257) 203)

(+)-UH232
Microdialysis; Dopamine, release; (+)-AJ76; (Rat) (Waters, N. (251) 181)

Ulcer
CGRP (calcitonin gene-related peptide); Nitric oxide (NO) (Clementi, G. (256) R7)

NSAID (non-steroidal anti-inflammatory drug); Nitric oxide (NO); Inflammation; Prostaglandin (Wallace, J.L. (257) 249)

Nitric oxide (NO); Cytoprotection; Mucosal blood flow (Ferraz, J.-G.P. (260) 107)

Ultrasonic vocalization
Anxiolysis; Dorsal raphe nucleus; Hippocampus; 5-HT_{1A} receptor ligand (rat) (Schreiber, R. (249) 341)

Ultrasound vocalization
FG5893; 5-HT_{1A} receptor agonist/5-HT_{2A} receptor antagonist; 5-HT receptor; Hypothermia; Head twitch behavior; Passive avoidance; Forced swim test; Cage leaving; Corticosterone; (Rat) (Albinsson, A. (261) 285)

Ultraviolet
Cisplatin; Drug resistance; Excision repair (Chao, C.C.-K. (268) 347)

Umbilical artery (human)
Autoradiography; Ca^{2+} channel; Endothelin; Endothelium; Endothelin receptor (Bodelsson, G. (249) 299)

U373 MG human astrocytoma cell
Tachykinin NK_1 receptor; FK888; RP 67580; (±)-CP-96,345; IM9 human lymphoblastoma cell (Goso, C. (254) 221)

Unit activity
Amphetamine; Behavioral clamping; Cortical lesion; Haloperidol; Neostriatum (Tschanz, J.A.T. (257) 161)

Up-regulation
Forskolin treatment (chronic); Dopamine D_2 receptor, human; Dopamine; Supersensitivity; Adenylyl cyclase (Johansson, M.H. (269) 149)

Uptake
Amino acid; Carrier; Glutamate transporter; Proximal tubule; Kidney; In situ hybridization; (Rabbit) (Meister, B. (267) 323)

Uptake site
In situ hybridization; 5-HT transporter; Image analysis; Amphetamine; 5-HT (5-hydroxytryptamine, serotonin) (Rattray, M. (268) 439)

Urethra
α_1-Adrenoceptor subtype; Prostate (rat, rabbit, dog, man); α_1-Adrenoceptor antagonist (Testa, R. (249) 307)

Adenosine cyclic monophoshate; Guanosine cyclic monophoshate; NANC (non-adrenergic, non-cholinergic) nerve; Nitric oxide (NO); Detrusor (Persson, K. (268) 159)

Urethra, rabbit
Non-adrenergic, non-cholinergic (NANC) relaxation; Nitric oxide synthase; Nitric oxide synthase inhibitor (Dokita, S. (266) 269)

Uric acid
TEI-6720; Allopurinol; Xanthine oxidase inhibitor; Hypouricemic effect; (Chimpanzee) (Komoriya, K. (250) 455)

Uridine 5′-triphosphate
Superior cervical ganglion, rat; Adenosine 5′-triphosphate; Reactive blue 2; Pyrimidinoceptor; Purinoceptor (Connolly, G.P. (259) 95)

Urinary bladder contraction
Substance P; Septide; Tachykinin NK_1 receptor antagonist; Plasma extravasation; (Rat) (Montier, F. (251) 9)

Urinary bladder, rat
Skinned urinary bladder; Ca^{2+} channel antagonist; Benzodiazepine receptor ligand (Martí-Cabrera, M. (255) 157)

Urine flow rate
Endothelin; L-N^G-Nitroarginine; Ibuprofen; EDRF (endothelium-derived relaxing factor); Renal blood flow; Urine osmolality; Glomerular filtration rate; (Dog) (Yukimura, T. (264) 399)

Urine osmolality
Endothelin; L-N^G-Nitroarginine; Ibuprofen; EDRF (endothelium-derived relaxing factor); Renal blood flow; Urine flow rate; Glomerular filtration rate; (Dog) (Yukimura, T. (264) 399)

Urine storage
MK-801; Bladder voiding; Decerebration; Cystometrogram; Sphincter electromyogram; (Rat) (Yoshiyama, M. (264) 417)

Uterine artery
L-Arginine; Relaxation; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); (Human) (Jovanović, A. (256) 103)

Acetylcholine; Muscarinic receptor; (Human) (Jovanović, A. (256) 131)

Pregnancy; Muscarinic receptor; Acetylcholine; (Guinea-pig) (Jovanović, A. (258) 185)

Uterine cell proliferation
Phospholipase A_2; Arachidonic acid (Fayard, J.M. (251) 281)

Uterus
Binding study; Muscarinic M_2 receptor; [^{3}H]Quinuclidinyl benzilate; Selective antagonist; (Rat) (Pennefather, J.N. (262) 297)

Vacuous chewing movement
Dopamine; Grooming; Opioid (Stoessl, A.J. (259) 301)

Vagal afferent
Emesis; Cisplatin; Copper sulfate; 5-HT_3 receptor antagonist; (Monkey) (Fukui, H. (249) 13)

CCK (cholecystokinin); Secretin; Gastric emptying; Capsaicin; Spinal afferent (Raybould, H.E. (250) 165)

μ-Opioid receptor; κ-Opioid receptor; Antinociception; Visceral pain; (Rat) (Diop, L. (257) 181)

Vagal bradycardia
Parasympathetic control; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor; 5-HT receptor agonist (Morán, A. (252) 161)

Vagal stimulation
Bradykinin B_2 receptor; Bradykinin; Bronchoconstriction; HOE 140; Microvascular permeability (Sakamoto, T. (251) 137)

Vagus motoneuron
S-Adenosyl-L-methionine; Adenosine; Methylation; Brain stem (Travagli, R.A. (264) 385)

Vagus nerve
5-HT (5-hydroxytryptamine, serotonin); Electrophysiology 5-HT_3 receptor; 5-HT_4 receptor; (Grease-gap) (Bley, K.R. (260) 139)

Neuropeptide Y; Neuropeptide Y Y_2 receptor agonist (Potter, E.K. (267) 253)

Vagus nerve, rat
Pyridoxal-5-phosphate; α,β-Methylene ATP; Vas deferens, rat; P_2 purinoceptor (Trezise, D.J. (259) 295)

Valepotriate
Animal model; Anxiety; Benzodiazepine withdrawal; Elevated plus-maze (Andreatini, R. (260) 233)

Valproic acid
Phenytoin; Phenobarbital; NMDA (*N*-methyl-D-aspartate); Norepinephrine efflux (Brown, L.M. (254) 307)

Valsartan
Angiotensin II; Sympathetic nervous system; α_1-Adrenoceptor; PD 123319 (Marano, G. (261) 121)

Vanadate
Vanadyl; Diabetes; Glucose homeostasis; Hypoglycemic agent; (Rat) (Becker, D.J. (260) 169)

Xenopus laevis oocyte; Pertussis toxin; Ca^{2+}; Angiotensin II; Desensitization; LiCl (Sakuta, H. (268) 305)

Vanadyl
Vanadate; Diabetes; Glucose homeostasis; Hypoglycemic agent; (Rat) (Becker, D.J. (260) 169)

Vanilloid receptor
Experimental colitis; Capsaicin; Resiniferatoxin binding (Goso, C. (249) 185)

[^{3}H]Resiniferatoxin; Autoradiography; Capsaicin-sensitive neuron; Dorsal root ganglia; Spinal cord (Szallasi, A. (264) 217)

Vasa nervorum
Neuropathy; Diabetic rat; Nerve blood flow; Nimodipine (Kappelle, A.C. (250) 43)

Vascular
Flosequinan; Smooth muscle; Resistance artery; (Human) (Richards, N.T. (257) 189)

Vascular contraction
Balloon denudation; Neointima (Antonaccio, M.J. (256) 17)

Vascular hyporeactivity
Endotoxin shock; Vasodilatation; Circulatory shock; Cytokine (Szabó, C. (250) 157)

Vascular myocyte
Ca^{2+} channel; Dihydropyridine; Enantiomer; Patch clamp; Radioligand (Baron, A. (269) 105)

Vascular permeability
Norathyriol; Passive cutaneous anaphylaxis; Neurogenic inflammation; Compound 48/80; Mast cell; (Mouse) (Wang, J.-P. (251) 35)

Asthma; Edema; Plasma exudation; Aging; Leukotriene; Thromboxane A_2; Airway obstruction; Arachidonic acid (Arakawa, H. (259) 251)

Vascular reactivity
Endothelium; Nitric oxide (NO); cGMP; Nandrolone (Ferrer, M. (252) 233)

Balloon angioplasty; Nitric oxide (NO); Endothelin-1; N^{ω}-Nitro-L-arginine methyl ester; Neointima formation (Douglas, S.A. (255) 81)

Artery, rabbit; Nandrolone; Noradrenaline; Angiotensin II; 5-HT (5-hydroxytryptamine, serotonin) (Ferrer, M. (258) 103)

Vascular relaxant
Pulmonary artery; Smooth muscle; Phorbol ester; Protein kinase C; Phosphodiesterase inhibitor; Cyclic nucleotides (Savineau, J.-P. (249) 191)

Vascular tone
Nitric oxide synthase inhibitor; Mesenteric vascular bed; Endothelium-dependent response; Nitrovasodilator; Atropine; (Cat) (Santiago, J.A. (254) 207)

Interleukin-1β; Endothelium; cGMP (Schini-Kerth, V. (265) 83)

Vas deferens
Cauda epididymis; α_2-Adrenoceptor; α_1-Adrenoceptor; [^{3}H]Rauwolscine; [^{3}H]Prazosin; (Rat) (Ventura, S. (254) 167)

Angiotensin; Prostacyclin; Angiotensin AT_1 receptor; (Rabbit) (Catalioto, R.-M. (256) 93)

Denervation; Ca^{2+} channel; Dihydropyridine; Isradipine (Jurkiewicz, A. (256) 329)

Melatonin; Sympathetic neurotransmission; Nicotinic receptor; Protein synthesis (Carneiro, R.C.G. (257) 73)

Muscarinic M_1 receptor; Muscarinic M_2 receptor; Mechanistic pathway; LiCl; Forskolin; 1,9-Dideoxy-forskolin; Phorbol ester; (Rabbit) (Eltze, M. (263) 31)

Vas deferens, bisected, rat
Hydralazine; [^{3}H]Noradrenaline uptake; $^{45}Ca^{2+}$ influx (Campos-Toimil, M. (251) 83)

Vas deferens, mouse
Cannabinoid; Δ^9-Tetrahydrocannabinol; Anandamide; Cannabinoid, endogenous; Tolerance (Pertwee, R. (259) 115)

Cotransmission; ATP; Facilitation; Yohimbine; α_2-Autoinhibition (Karunanithi, S. (261) 17)

Somatostatin; Pertussis toxin; G-protein; Seglitide; BIM 23027; SRIF receptor (Feniuk, W. (261) 333)

Vas deferens, rat
Receptor model; Functional interaction; Indirect action; Tyramine (Venter, D.P. (251) 209)

ω-Conotoxin MVIIC; ω-Conotoxin GVIA; N-type voltage-dependent Ca^{2+} channel; Ileum, guinea pig (Boot, J.R. (258) 155)

Pyridoxal-5-phosphate; α,β-Methylene ATP; Vagus nerve, rat; P_2 purinoceptor (Trezise, D.J. (259) 295)

αCGRP (calcitonin-gene related peptide), human; αCGRP-(8–37), human; βCGRP-(8–37), human; Atrium, guinea-pig; SK-N-MC cell (Longmore, J. (265) 53)

α_1-Adrenoceptor subtype; Chloroethylclonidine; Nifedipine; Spleen, rat; Prostate, human (Teng, C.-M. (265) 61)

α_2-Adrenoceptor; *N*-Ethyl-maleimide; Phenoxybenzamine; EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) (Browne, I. (265) 125)

Vasoactive intestinal contractor
Endothelin receptor; Acetylcholine release; Ileum, guinea pig; Desensitization (Kan, S. (258) 139)

Vasoactive peptide
Pulmonary vascular bed; Adrenomedullin; CGRP (calcitonin gene-related peptide); Pancreatic amylin (DeWitt, B.J. (257) 303)

Vasoconstriction
Naftidrofuryl; 5-HT (5-hydroxytryptamine, serotonin); Microcirculation; Cremaster muscle; Arteriole; 5-HT_2 receptor antagonist (Koch, L.G. (254) 249)

Neuropeptide Y; K^+ channel; BRL38227; Diazoxide; Cerebral basilar artery (Xia, Y. (255) 67)

Aclarubicin; Phosphatidylinositol; Aorta, rat (Wakabayashi, I. (255) 111)

Aorta; Vasopressin; EDRF (endothelium-derived relaxing factor); Gonadal steroid hormone; Nitric oxide (NO) (Stallone, J.N. (259) 273)

Angiotensin II; Angiotensin-(3–8)/angiotensin IV; Angiotensin-(1–7); Pulmonary circulation; Angiotensin AT_1 receptor antagonist; Angiotensin AT_2 receptor antagonist (Cheng, D.Y. (261) 223)

Vasoconstrictor response
ATP; Artery (rabbit ear, jejunal); Endothelin-1; Perivascular nerve stimulation (La, M. (249) 133)

Vasodilatation
Endotoxin shock; Vascular hyporeactivity; Circulatory shock; Cytokine (Szabó, C. (250) 157)

Blood flow; Choroid; Ciliary body; Iris; PACAP (pituitary adenylate cyclase activating polypeptide) (Nilsson, S.F.E. (253) 17)

Adrenomedullin; Adrenomedullin fragment; Peripheral circulation; Hypotension (Lin, B. (260) 1)

Lipoprotein; Nitric oxide (NO); Endothelium (Galle, J. (265) 111)

Iminoctadine; Hypotension; Atrium (rat); α_1-Adrenoceptor antagonist; (Aorta) (Koyama, K. (270) 151)

Vasodilator
Antiaggregator; Furoxan; cGMP; Nitric oxide (NO) (Civelli, M. (255) 17)

Vasodilator nerve
Nitric oxide (NO); Cerebral artery; Calmodulin; Endothelium (Okamura, T. (256) 79)

Saphenous artery; Nitric oxide (NO); CGRP (calcitonin gene-related peptide); Nicotine (Okamura, T. (263) 85)

Vasopressin
CGRP (calcitonin gene-related peptide), C-terminal fragment; Somatostatin-28; CCK_A receptor; Iris (monkey) (Almegård, B. (250) 31)

Gastric erosion; Gastric mucosa; Vasopressin receptor; Autoradiography; Vasopressin receptor antagonist (László, F. (258) 15)

Oxytocin; Ca^{2+} channel, L-type; Dihydropyridine; Neurointermediate lobe; (Electrical stimulation) (Jørgensen, A. (259) 157)

Aorta; EDRF (endothelium-derived relaxing factor); Gonadal steroid hormone; Nitric oxide (NO); Vasoconstriction (Stallone, J.N. (259) 273)

Vasopressin receptor; Cell nucleus; Peptide; Vasopressin receptor antagonist (Phillips, P.A. (259) 325)

Endotoxin; Sepsis; Nitric oxide (NO); Vasopressin receptor antagonist; Intestinal mucosal injury; Intestinal vascular permeability; N^G-Nitro-L-arginine methyl ester (László, F. (260) 265)

E4021; Phosphodiesterase type V inhibitor; cGMP; Coronary vasodilator; ST segment elevation (Kodama, K. (263) 93)

Bradykinin; Substance P; EDRF (endothelium-derived relaxing factor); Cerebral vasospasm; Subarachnoid hemorrhage (Tsuji, T. (264) 77)

Vasopressin receptor
Gastric erosion; Gastric mucosa; Vasopressin; Autoradiography; Vasopressin receptor antagonist (László, F. (258) 15)

Vasopressin; Cell nucleus; Peptide; Vasopressin receptor antagonist (Phillips, P.A. (259) 325)

mRNA; PCR (polymerase chain reaction); (Rat) (Hirasawa, A. (267) 71)

Vasopressin receptor antagonist
Gastric erosion; Gastric mucosa; Vasopressin; Vasopressin receptor; Autoradiography (László, F. (258) 15)

Vasopressin; Vasopressin receptor; Cell nucleus; Peptide (Phillips, P.A. (259) 325)

Endotoxin; Sepsis; Nitric oxide (NO); Vasopressin; Intestinal mucosal injury; Intestinal vascular permeability; N^G-Nitro-L-arginine methyl ester (László, F. (260) 265)

Vasorelaxant
Rutaecarpine; Endothelium; Ca^{2+} mobilization (Chiou, W.-F. (257) 59)

Vasorelaxation
Aorta, rat; KT2-734 (2-phenyl-8-ethoxycycloheptimidazole); cAMP-phosphodiesterase; cAMP (Satake, N. (251) 1)

Aortic baroreceptor; Endothelium; Adenosine receptor; EDRF (endothelium-derived relaxing factor); NECA (5′-*N*-ethylcarboxamidoadenosine); Nitric oxide (NO) (Fahim, M. (254) 183)

FK409; Tolerance; Guanylate cyclase, soluble; Nitric oxide (NO) (Isono, T. (260) 163)

2,2′,2″-Tripyridine; Ca^{2+} influx; cGMP (Kuei-Sen Hsu, (270) 89)

Ventral mesencephalon
Primary neuronal culture; κ-Opioid receptor; [^{3}H]Dopamine release; Sensitization; Corticosteroid (Ronken, E. (263) 149)

Ventral tegmental area
Sertindole; Haloperidol; Clozapine; Short-term treatment; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (254) 291)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin); Patch clamp; Substantia nigra; Caudate-putamen; Nucleus accumbens (Liu, J.-C. (264) 269)

Ventricle
Acetylcholine; Adenosine; Angiotensin II; Atrium; Contractility; α-CGRP (calcitonin gene-related peptide); Somatostatin; (Human) (Du, X.Y. (259) 173)

Ventricular mapping
Propafenone; Frequency dependence; QRS duration (Stark, G. (252) 283)

Ventricular myocardium, rabbit
HV723 (α-ethyl-3,4,5-trimethoxy-α-(3-((2-(2-methoxyphenoxy)ethyl)-amino)-propyl) benzeneacetonitrile fumarate); α_1-Adrenoceptor; Positive inotropic effect; Phosphoinositide hydrolysis; [^{3}H]Prazosin (Kohi, M. (250) 95)

Ventricular myocyte
Inwardly rectifying K^+ channel; Patch-clamp technique; Voltage-dependent inactivation; Chloramine-T; Inactivation gate; (Guinea pig) (Koumi, S.-i. (258) 281)

Apamin; Patch-clamp technique; Action potential; Delayed rectifier K^+ current (Koumi, S.-i. (261) 213)

Ventricular myocyte, single, feline
Na^+ current; Moricizine hydrochloride; Voltage clamp, whole cell (Saeki, T. (261) 249)

Verapamil
Trachea (guinea-pig); Trifluoperazine; Flurbiprofen (McCaig, D. (249) 53)

CP-96,345; Ca^{2+} channel antagonist; Nifedipine; Smooth muscle, isolated; (Anesthetized dog) (Constantine, J.W. (252) 275)

Ryanodine; Ca^{2+} influx; Femoral artery; Spontaneously hypertensive rat (SHR) (Kojima, M. (254) 159)

Opioid peptide; Behavioral effect; Body temperature; Antinociception; Voltage-dependent Ca^{2+} channel; ω-Conotoxin GVIA (Spampinato, S. (254) 229)

Adrenal catecholamine; Voltage-dependent Ca^{2+} channel, N-type, L-type; ω-Conotoxin GVIA; Nifedipine; Acetylcholine (Kimura, T. (264) 169)

Veratridine
Cell death; Ca^{2+} oscillation; Bovine chromaffin cell; R56865; Flunarizine; Nimodipine; ω-Conotoxin GVIA (Maroto, R. (270) 331)

Vestibular compensation
Org 2766; NMDA receptor antagonist (Gilchrist, D. (252) R1)

VIP receptor antagonist
Short-circuit current; Mucosa; Colon (Burleigh, D.E. (249) 239)

VIP (vasoactive intestinal polypeptide)
Smooth muscle, airway; Airway, guinea-pig (Iriarte, M.-C.F. (250) 295)

Penile erection; Yawning; Diabetic rat; Apomorphine; Physostigmine (Yamaguchi, Y. (254) 91)

PAF (platelet-activating factor); Substance P (Deshpande, Y. (256) R1)

Muscarinic receptor antagonist; Nitric oxide (NO); Opioid; Small intestine; Substance P (Gustafsson, B.I. (257) 227)

Nitric oxide (NO); Neuropeptide Y; Nitroprusside; Milrinone; cAMP; cGMP; Acetylcholine (Modin, A. (261) 185)

Visceral afferent
Anticancer drug-induced vomiting; 5-HT_3 receptor antagonist (Fukui, H. (250) 281)

Visceral afferent fiber
Copper sulfate; Vomiting; 5-HT_4 receptor (Fukui, H. (257) 47)

Visceral pain
μ-Opioid receptor; κ-Opioid receptor; Antinociception; Vagal afferent; (Rat) (Diop, L. (257) 181)

Vitamin E
Striatum; 1-Methyl-4-phenylpyridinium; Selenium; Monoamine; (Rat) (Vizuete, M.L. (270) 183)

Vitamin K_2
Bone marrow culture; Osteoclast-like cell formation; 1,25-Dihydroxyvitamin D_3 (Akiyama, Y. (263) 181)

Vogel's test
Hippocampus; 5-HT (5-hydroxytryptamine, serotonin); Midazolam; (Rat) (Plaznik, A. (257) 293)

Voltage clamp
Age; Neuromuscular transmission; Halothane (Bhattacharyya, B.J. (254) 97)

Heart; L-type Ca^{2+} channel; Ca^{2+} channel antagonist; SR33557; SR33805 (Romey, G. (263) 101)

Voltage clamp, 2-electrode
K^+ channel; Glibenclamide; Cromakalim; *Xenopus* oocyte; Insulin; IGF-1; Phenylarsine oxide; Pertussis toxin (Sakuta, H. (268) 375)

Voltage-clamp experiment
N-Methyl-D-aspartate (NMDA); 1,2,3,4-Tetrahydro-9-aminoacridine; Tacrine; Open-channel block (Vorobjev, V.S. (253) 1)

Voltage-clamp, whole-cell
NMDA receptor; Ca^{2+} channel; Cortical neuron, cultured; Eliprodil (Biton, B. (257) 297)

Cardiac myocyte; Cl^- channel blocker; Na^+ current; Ca^{2+} current; Diphenylamine-2-carboxylate (DPC); Ion channel blocker (Conforti, L. (259) 215)

Na^+ current; Moricizine hydrochloride; Ventricular myocyte, single, feline (Saeki, T. (261) 249)

Voltage-dependent inactivation
Inwardly rectifying K^+ channel; Ventricular myocyte; Patch-clamp technique; Chloramine-T; Inactivation gate; (Guinea pig) (Koumi, S.-i. (258) 281)

Vomiting
Defensive behavior; NAN-190; (−)-Propranolol; 5-HT_{1A} receptor (Lucot, J.B. (253) 53)

Morphine; Loperamide; Anti-emetic; 5-HT (5-hydroxytryptamine, serotonin); Nicotine; (*Suncus murinus*) (Selve, N. (256) 287)

Copper sulfate; 5-HT_4 receptor; Visceral afferent fiber (Fukui, H. (257) 47)

VUF 9153 (*S*-[3-(4(5)-imidazolyl)]propyl-*N*-(4-chlorobenzyl)isothiourea)
Thioperamide; Histamine H_3 receptor; Ileum, guinea-pig; Radioligand binding; Dipsogenicity (Barnes, J.C. (250) 147)

Wakefulness
5-HT_3 receptor; *m*-Chlorophenylbiguanide; MDL 72222; Sleep (Ponzoni, A. (249) 259)

Water finding test
Learning, latent; Nefiracetam (DM-9384); Nootropic (Nabeshima, T. (255) 57)

Water maze
Adenosine; Xanthine; Memory; Learning; (Mouse) (Von Lubitz, D.K.J.E. (249) 271)

Senile dementia of the Alzheimer type; Nerve growth factor synthesis stimulator; Nerve growth factor; Choline acetyltransferase; Astroglia cell (Nitta, A. (250) 23)

Water temperature
Forced swimming test; Glucocorticoid; κ-Opioid receptor, selective; Thyroid hormone; Glucose (Jefferys, D. (253) 91)

(+)-WAY100135
5-HT_{1A} receptor; Adenylate cyclase; Dorsal raphe nucleus; Nerve impulse flow; SDZ 216-525; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lesopitron; S-20499; Flesinoxan (Lanfumey, L. (249) 25)

(*S*)-WAY100135
Anxiety; Elevated plus-maze; 5-HT_{1A} receptor; 5-HT_{1A} receptor antagonist; (Mouse) (Rodgers, R.J. (261) 321)

WAY100635 (*N*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*N*-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride)
ACTH (adrenocorticotrophic hormone); Plasma; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT_{1A} receptor; (Conscious rat) (Critchley, D.J.P. (264) 95)

WAY100135 (*N*-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide)
Feeding; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); (Rat) (Hartley, J.E. (252) 329)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Flesinoxan; 5-HT_{1A} receptor; Glucose concentration, plasma; (Conscious rat) (Critchley, D.J.P. (254) 133)

WIN 51708
Substance P; CP-96345; SR 48968; WIN 62577; Colon, proximal, guinea-pig (Briejer, M.R. (250) 181)

WIN 62577
Substance P; CP-96345; SR 48968; WIN 51708; Colon, proximal, guinea-pig (Briejer, M.R. (250) 181)

(+)-WIN 55,212-2
Dystonia; Cannabinoid; GABA (γ-aminobutyric acid); Diazepam; Catalepsy (Richter, A. (264) 371)

Wistar Kyoto rat (WKY)
Interleukin-1β; Lipopolysaccharide; Nitric oxide (NO); DL-Propranolol; Smooth muscle, vascular; Cell culture; Spontaneously hypertensive rat (SHR); (Rat) (De Castro, M. (261) 199)

Withdrawal
Analgesia; Morphine, blood level; Dependence; Opiate; Tolerance (Gold, L.H. (253) 45)

Withdrawal, precipitated
κ-Opioid receptor, supraspinal; Butorphanol dependence; Nor-binaltorphimine; Naloxone (Jaw, S.P. (257) 153)

W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide)
Noradrenaline release; Hexachlorocyclohexane isomer; Bay K 8644; Nifedipine; DIDS (4,4-diisothiocyanato-stilbene-2,2′-disulfonic acid); Hippocampal slice, rat (Cristòfol, R.M. (252) 305)

Working memory
Glycine site; 7-Chlorokynurenic acid; Hippocampus; Reference memory (Ohno, M. (253) 183)

Xanthine
Platelet activating factor (PAF); Airway hyperresponsiveness; Airway inflammation; Plasma protein extravasation; Isbufylline (Manzini, S. (249) 251)

Adenosine; Memory; Learning; Water maze; (Mouse) (Von Lubitz, D.K.J.E. (249) 271)

Xanthine derivative
Tracheal relaxation; Phosphodiesterase; Structure-activity relationship (Miyamoto, K.-i. (267) 317)

Xanthine oxidase inhibitor
TEI-6720; Allopurinol; Uric acid; Hypouricemic effect; (Chimpanzee) (Komoriya, K. (250) 455)

***Xenopus* oocyte**
K^+ channel; Glibenclamide; Cromakalim; Y-26763; SKF 525A; Quinacrine; Local anesthetic (Sakuta, H. (252) 117)

K^+ channel; Glibenclamide; Ca^{2+} channel antagonist; Stereoselectivity; Y-26763 (Sakuta, H. (255) 1)

Imidazoline; Imidazolidine; Glibenclamide; K^+ channel; Y-26763; K^+ channel opener; Structure-activity relationship (Sakuta, H. (259) 223)

G protein (low molecular weight); Polyphosphoinositide turnover; Botulinum toxin; ADP-ribosylation; 5-HT (5-hydroxytryptamine, serotonin) (Tohda, M. (266) 19)

K^+ channel; Glibenclamide; Histamine H_1 receptor antagonist; Promethazine; Dimethindene (Sakuta, H. (266) 99)

Atrial natriuretic factor; cGMP; HS-142-1; K^+ channel; Glibenclamide; Y-26763; Cromakalim (Sakuta, H. (267) 281)

ICS 205–930; 5-HT_3 receptor antagonist; $GABA_A$ receptor; [^{3}H]Flunitrazepam binding; [^{3}H]Muscimol binding; [^{35}S]TBPS (tert-butylbicyclophosphorothionate) binding; $^{36}Cl^-$ flux; 293 cell (Klein, R.L. (268) 237)

Vanadate; Pertussis toxin; Ca^{2+}; Angiotensin II; Desensitization; LiCl (Sakuta, H. (268) 305)

K^+ channel; Glibenclamide; Cromakalim; Insulin; IGF-1; Phenylarsine oxide; Pertussis toxin; Voltage clamp, 2-electrode (Sakuta, H. (268) 375)

K^+ channel clone; $K_{V1.2}$; Endothelin receptor; Protein kinase C; Ca^{2+}, intracellular (Murakoshi, H. (268) 451)

Apomorphine; Dopamine receptor agonist; Dopamine receptor antagonist; Nicotinic receptor channel; Functional expression (Nakazawa, K. (269) 375)

Y-26763
K^+ channel; Glibenclamide; Cromakalim; SKF 525A; Quinacrine; *Xenopus* oocyte; Local anesthetic (Sakuta, H. (252) 117)

K^+ channel; Glibenclamide; Ca^{2+} channel antagonist; Stereoselectivity; *Xenopus* oocyte (Sakuta, H. (255) 1)

Imidazoline; Imidazolidine; Glibenclamide; K^+ channel; *Xenopus* oocyte; K^+ channel opener; Structure-activity relationship (Sakuta, H. (259) 223)

Atrial natriuretic factor; cGMP; HS-142-1; K^+ channel; Glibenclamide; Cromakalim; *Xenopus* oocyte (Sakuta, H. (267) 281)

Yawning
Enantiomeric selectivity; Dopamine release (Damsma, G. (249) R9)

Penile erection; Diabetic rat; Apomorphine; Physostigmine; VIP (vasoactive intestinal polypeptide) (Yamaguchi, Y. (254) 91)

5-HT receptor agonist; 5-HT receptor antagonist; Apomorphine; Oxytocin; Penile erection; (Rat) (Stancampiano, R. (261) 149)

YM022
CCK-8 (cholecystokin-8); CCK_B/gastrin receptor antagonist; GH3 cell; Ca^{2+} mobilization, intracellular (Saita, Y. (269) 249)

YM099
K^+ channel opener; Levcromakalim; Glibenclamide; Coronary artery vessel diameter; Coronary artery blood flow; (Dog) (Uchida, W. (264) 285)

YM796
Muscarinic acetylcholine receptor agonist; Muscarinic M_1 receptor; Muscarinic M_2 receptor; Learning behavior (Wanibuchi, F. (265) 151)

YM26734
Phospholipase A_2; Prostaglandin E_2 (Miyake, A. (253) 155)

Yohimbine
Vas deferens, mouse; Cotransmission; ATP; Facilitation; α_2-Autoinhibition (Karunanithi, S. (261) 17)

Yuehchukene
Anti-estrogenic activity; Breast cancer; Indole (Ng, P.C. (264) 1)

(*S*)-Zacopride
5-Carboxyamidotryptamine; CP-93,129; Desensitization; 5,7-Dihydroxytryptamine; Hippocampus; Hypothalamus; Frontal cortex; Tropisetron; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2(di-*n*-propylamino)tetralin); 2-Methyl-5-HT; *m*-Chlorophenylbiguanide; Ondansetron; Paroxetine; Presynaptic modulation (Mongeau, R. (256) 269)

Zaprinast
Phosphodiesterase inhibitor; cGMP; Blood pressure; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (249) 293)

ZD2138
ZM230487; MK-886; Zileuton; 5-Lipoxygenase; Leukotriene (Kusner, E.J. (257) 285)

Zileuton
ZD2138; ZM230487; MK-886; 5-Lipoxygenase; Leukotriene (Kusner, E.J. (257) 285)

Zinc hydroxide
Respiratory burst; Neutrophil, rat; Phagocytosis (Ogino, K. (270) 73)

ZK 118.182
Platelet; Polymorphonuclear neutrophil; Prostaglandin D_2 (Darius, H. (258) 207)

ZM230487
ZD2138; MK-886; Zileuton; 5-Lipoxygenase; Leukotriene (Kusner, E.J. (257) 285)

Zolantidine
Histamine; 5-HT (5-hydroxytryptamine, serotonin); Mepyramine; Thioperamide; Metoprine (Fleckenstein, A.E. (254) 35)

Zolpidem
Ethanol; $GABA_A$-benzodiazepine type 1 receptor; (α_1 subunit) (Devaud, L.L. (267) 243)

[^{3}H]Zolpidem binding
$GABA_A$ receptor complex; Benzodiazepine binding site, type I; Immunoprecipitation; Photoaffinity labeling; Cortex; (Subunit specific antibodies) (Ruano, D. (267) 121)

Zonisamide
Anticonvulsant; Brain, neonatal, rat; Hypoxia-ischemia, cerebral; Infarction, cerebral; Hypoxic seizure (Hayakawa, T. (257) 131)

Zucker rat
Nitric oxide (NO); Serotonergic system; Brain; Anorexia (Squadrito, F. (255) 51)

European Journal of Pharmacology

GENERAL INSTRUCTIONS

Authors should consult the extensive 'Notice to authors' (see Vol. 272, No. 1, p. v) when preparing a manuscript for submission.
The original and 3 copies, complete with 4 sets of figures and tables should be sent to:

The Editorial Office, European Journal of Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands (Tel.: +31.30.538833, Fax: +31.30.539033).

The preferred medium of final submission to the accepting editor is on disk with the accompanying reviewed and revised manuscript (see 'Electronic manuscripts' below). Manuscripts submitted by facsimile transmission will not be considered. Manuscripts should be typewritten or printed with double spacing (at least 6 mm between lines) and with wide margins (not more than 26 lines per page). The possibility that accepted manuscripts will be processed by electronic scanning makes it essential that the typing/printing be of the highest quality. A laser-type or similar quality printer or a high-quality typewriter with a black carbon ribbon should be used to ensure proper contrast for the original. A standard, at least 12-point (0.0138 inch), type face, neither distorted nor reduced or enlarged, is to be used. Manuscripts printed with low-quality printers will be returned for retyping with an acceptable type face. Manuscripts should be written in English. On their acceptance, manuscripts will, if necessary, be corrected for English style and language. Should the changes be extensive, the manuscripts will be returned to the authors for retyping. Submission of a fully language-corrected paper will, therefore, shorten publication time considerably.

1. Rapid communications

(a) Reports on exciting new results within the scope of the journal can be submitted for publication in the rapid communications section.
(b) A rapid communication should not exceed 700 words and should contain no or only one simple table or figure of not more than 8.4 cm=1 column width.
(c) A maximum of 8 references may be used.
(d) The rapid communication should be typewritten, lines double spaced, with wide margins, without any subheadings, and preferably accompanied by a floppy disk (see section 6). The manuscript should be arranged in the following order: title (not exceeding 85 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done (all on 1 page); abstract (max. 75 words) and keywords (indexing terms, max. 3 items); text; acknowledgement(s); references; figure legend and figure; table (colour figures will delay publication). Name, full postal address, telephone and telefax numbers of author to whom correspondence is to be sent should be mentioned on the title page.
(e) Rapid communications have priority at the editorial office and publisher.
(f) All proofreading will be done by the editorial staff of the publisher; no proofs will be sent to the author(s).
(g) Upon acceptance of a rapid communication a reprint order form will be sent to the author(s).

2. Full length manuscripts

(a) The manuscript should be arranged in the following order: title (not exceeding 85 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done; name, full postal address, telephone and telefax numbers of author to whom proofs and other correspondence should be sent (all on 1 page); abstract and keywords (indexing terms: normally 3–6 items); the following sections: 1. Introduction; 2. Materials and methods; 3. Results; 4. Discussion; Acknowledgements; References; figure legends and figures; tables. Subdivisions of a section should also be numbered within that section (2.1., 2.2., 2.3. etc.).
(b) Abstract and keywords: an abstract not exceeding 150 words and stating what was done, what was found, and what was concluded should be typed on a separate sheet. It will appear at the beginning of the article. Below the abstract, type 3–6 keywords or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, keywords should be selected from *Index Medicus* or *Excerpta Medica Index*. First category keywords (e.g. Hyperphagia; G-Strophantidin; Fiber shortening) will all be listed and cross-indexed. Second category keywords (e.g. Rat, Cold, Metabolite) will only be listed under the index entry for the first category keywords. If the editors feel that keywords should be adjusted to the standards of the journal this will be done without consultation of the author(s).
(c) Standard nomenclature should be used throughout. Unnecessary abbreviations and symbols are to be avoided. For essential details concerning the use of abbrevations, see extensive 'Notice to authors' (Vol. 272, No. 1, p. v). Words at the end of a line should not be divided. Use of hyphens, capital letters, numbers written or spelled out (e.g. 8 or eight) should be consistent throughout the manuscript.
(d) Legends of illustrations and footnotes should be typed on separate sheets, lines double spaced. Footnotes, to be numbered consecutively in superscript throughout the text, should be used as little as possible.
(e) Drugs: generic names should be used. Trade names may be mentioned in parentheses the first time the name of the drug appears in the text. The form of the drug used should be indicated.

3. Short communications should be prepared as described under 2, except for the following:

(a) The average length of a short communication should be between 2000 and 2300 words, which is about 6 double-spaced typewritten pages with a maximum of 2 illustrations (figures and tables).
(b) An abstract of not more than 100 words should be provided and 3–6 keywords should be listed immediately below the abstract.
(c) All proofreading will be done by the editorial staff of the publisher; no proofs will be sent to the author(s).
(d) Short communications should not contain more than 15 references.
(e) Upon acceptance of a short communication a reprint order form will be sent to the author(s).

4. References

References in the text to literature cited should be given by the name of the author(s), followed by the year of publication in parentheses, e.g.: Downie and Larsson (1990) or (Hicks et al., 1988, 1989; Seeman et al., 1990; Stoof and Kebabian, 1991a,b,c). For three or more authors the name of the first author followed by et al. should be used. Journal names should be abbreviated according to the *List of Serial Title Word Abbreviations* (available from the International Serials Data System, 20 Rue Bachaumont, 75002 Paris, France; ISBN 2-904938-02-8). References should be listed alphabetically. Citations of the literature in the list of references should include the full title of the article referred to. Personal communications and unpublished data should not appear in the list of references. Sample references:

Periodicals:

Harrison, J.K., W.R. Pearson and K.R. Lynch, 1991, Molecular characterization of α_1- and α_2-adrenoceptors, Trends Pharmacol. Sci. 12, 62.

Books:

De Graan, P.N.E., P. Schotman and D.H.G. Versteeg, 1990, Neural mechanisms of action of neuropeptides: macromolecules and neurotransmitters, in: Neuropeptides: Basics and Perspectives, ed. D. De Wied (Elsevier, Amsterdam) p. 139.

Appenzeller, O., 1990, The Autonomic Nervous System (Elsevier, Amsterdam) p. 419.

5. Illustrations, graphs and tables (for explicit instructions see Notice to authors, Vol. 272, No. 1, p. v)

(a) Either the original drawings plus 3 good photographs, 4 good photographs of the drawings (on glossy paper and unmounted) or 4 high-quality computer printouts should be submitted. Illustrations may be submitted in electronic format as well, but must always be accompanied by reproducible paper printouts. Photocopies may not be used instead of originals. The photographs should be of adequate definition and contrast. The number of illustrations should be limited to the essential.

(b) It is important to allow for reduction to fit a single column, 8.4 cm wide, or at most a double column, maximally 17.6 cm wide. Illustrations, especially photomicrographs, should be submitted in their final size (single or double column). When possible, all key symbols should be explained in the figures. The following symbols can be typeset and explained (as well as all lettering) in the legends: + × ◹ ◩ ◹ ◪ ⬠ ⬡ ◧ ◒ ⊖ ■ □ ● ▲ ▼ ◀ ▶ ○ ◇ △ ▽ ▷ ◁. All letters and numerals appearing in a particular illustration should be of the same size (approximately 1.4–2 mm height when reduced to 8.4 cm width).

(c) Graphs, electrocardiograms and oscillograms should be prepared by a skilled photographer so that the dark, cross-hatched background is eliminated, the faint portions of the graphs intensified, and a sharp print obtained. This process may be avoided by using blue-ruled instead of black-ruled recording paper for the originals. Kymograph records on sooted paper should be reversed photographically to ensure graphs in black on a white background.

(d) Drawings of complicated chemical structures should be prepared in the same way as graphs.

(e) A calibration bar should be drawn on the micrographs instead of giving a magnification rate in the figure legend.

(f) All illustrations should be referred to as figures and numbered in Arabic numerals (Fig. 1, 2 etc.).

(g) Legends to figures should make these comprehensible without reference to the text.

(h) Tables should be numbered separately in Arabic numerals (Table 1, 2 etc.).

(i) Colour reproduction of illustrations is available at cost. Original high-quality illustrations (preferably slides) should be well protected against possible damage during shipment. Detailed information regarding the use of colour may be obtained from the publisher, at the time of submission of the manuscript to the editors.

6. Electronic manuscripts

Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. The preferred storage medium is a $5\frac{1}{4}$ or $3\frac{1}{2}$ inch disk in MS-DOS format, although other systems are welcome, e.g., NEC and Macintosh (in this case, save your file in the usual manner, do not use the option 'save in MS-DOS format'). Please do not split the article into separate files (title page as one file, text as another, etc.). Ensure that the letter 'l' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your wordprocessor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter α). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your wordprocessor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the wordprocessor format. If your wordprocessor features the option to save files 'in flat ASCII', please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and wordprocessing package used and label the disk with your name and the name of the file on the disk. After final acceptance, your disk plus one, final, printed and exactly matching version (as a printout) should be submitted together to the accepting editor. It is important that the file on disk and the printout are identical. Both will then be forwarded by the editor to Elsevier. Further information may be obtained from the Publisher.

7. Proofs

One set of galley proofs will be sent to the author named on the title page (see 2.). Proofs will usually be drawn on lower quality paper. Only printer's errors may be corrected; no changes in, or additions to, the edited manuscript will be allowed. Proofs should be returned within 48 hours to Elsevier Science B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands, preferably by telefax (31-20-485.3271). If this period is exceeded no reminders will be sent, the manuscript will be read by the editorial staff of the publisher only and printed without the author's corrections. Authors of short an rapid communications will not receive galley proofs.

8. Page charges and reprints

There will be no page charge. Authors of a full length paper will receive, together with the galley proofs, a reprint order form which must be completed and returned to the publisher with the proofs. Authors of short and rapid communications will receive a reprint order form but no proofs: this order form should be mailed to the publisher by return post. Reprints ordered after the journal has been printed will cost considerably more than those ordered immediately.

9. Publication information

European Journal of Pharmacology (ISSN 0014-2999). For 1995 volumes 271–293 are scheduled for publication, including *Molecular Pharmacology Section* (volumes 288–291), and *Environmental Toxicology and Pharmacology Section* (volumes 292–293). Volumes 271, 288 No. 1, and 292 No. 1 appeared in 1994 but remain the first volumes of the 1995 subscription year.

Subscription prices are available upon request from the publisher. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where air delivery via SAL mail is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request.

Claims for missing issues must be made within six months of our publication (mailing) date.

Please address all your requests regarding orders and subscription queries to: Elsevier Science B.V., Journal Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands. Tel.: 31-20-485.3642, Fax: 31-20-485.3598.

All questions arising after acceptance of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publisher, Elsevier Science B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands (Fax: 31-20-485.3271). Address for courier service: Molenwerf 1, 1014 AG Amsterdam, The Netherlands.

In the U.S.A. and Canada: for further information and personal subscriptions, contact Elsevier Science Inc., Journal Information Center, 655 Avenue of the Americas, New York, NY 10010, U.S.A. (Tel.: 212-633.3750; Fax: 212-633.3990; Telex: 420.643 AEP UI).

Advertising information: Advertising orders and enquiries can be sent to the Advertising Department, Elsevier Science B.V., P.O. Box 211, 1000 AE Amsterdam, The Netherlands. Tel.: 31 (20) 485.3796; Fax: 31 (20) 485.3810. Courier shipments to street address: Molenwerf 1, 1014 AG Amsterdam, The Netherlands. For Great Britain: T.G. Scott & Son Ltd., Vanessa Bird, Portland House, 21, Narborough Road, Cosby, Leicestershire LE9 5TA. Tel.: (0116) 2750.521/2753.333; Fax: (0116) 2750.522. For USA & Canada: Weston Media Associates, Daniel Lipner, P.O. Box 1110, Greens Farms, CT 06436-1110. Tel.: (203) 261.2500; Fax: (203) 261.0101.

© 1995 Elsevier Science B.V. All rights reserved

Printed in The Netherlands *Library of Congress Catalog Card Number 68-26539* Published 3 times/month

EUROPEAN JOURNAL OF PHARMACOLOGY

EJP Molecular Pharmacology Section, Volumes 266–269, and EJP Environmental Toxicology and Pharmacology Section, Volume 270, incorporated

Cited in: Biological Abstracts – Chemical Abstracts – Current Contents/Life Sciences – Excerpta Medica (EMBASE) – Index Medicus – Pascal M – Reference Update – Unlisted Drugs – Current Awareness in Biological Sciences (CABS)

CONTENTS

Master author index to volumes 249–270 (1994) 1

Master keyword index to volumes 249–270 (1994) 57

0014-2999(1994)249/270*;1-Y